Edited by Todd Leff and James G. Granneman Adipose Tissue in Health and Disease
Related Titles G. Williams, G. Fruhbe...
69 downloads
1181 Views
4MB Size
Report
This content was uploaded by our users and we assume good faith they have the permission to share this book. If you own the copyright to this book and it is wrongfully on our website, we offer a simple DMCA procedure to remove your content from our site. Start by pressing the button below!
Report copyright / DMCA form
Edited by Todd Leff and James G. Granneman Adipose Tissue in Health and Disease
Related Titles G. Williams, G. Fruhbeck (Eds.)
Obesity Science to Practice 2009 ISBN: 978-0-470-01911-5
J. Östman, M. Britton, E. Jonsson (Eds.)
Treating and Preventing Obesity An Evidence Based Review 2004 ISBN: 978-3-527-30818-7
Novartis Foundation
Fatty Acid and Lipotoxicity in Obesity and Diabetes 2008 ISBN: 978-0-470-05764-3
M. Bader (Ed.)
Cardiovascular Hormone Systems From Molecular Mechanisms to Novel Therapeutics 2008 ISBN: 978-3-527-31920-6
R. Brigelius-Flohé, H.-G. Joost (Eds.)
Nutritional Genomics Impact on Health and Disease 2006 ISBN: 978-3-527-31294-8
Edited by Todd Leff and James G. Granneman
Adipose Tissue in Health and Disease
The Editors Todd Leff Wayne State University Department of Pathology 540 E. Canfield Detroit, MI 48201 USA
All books published by Wiley-VCH are carefully produced. Nevertheless, authors, editors, and publisher do not warrant the information contained in these books, including this book, to be free of errors. Readers are advised to keep in mind that statements, data, illustrations, procedural details or other items may inadvertently be inaccurate. Library of Congress Card No.: applied for
James G. Granneman Wayne State University Department of Psychiatry 550 E. Canfield Detroit, MI 48201 USA Cover Whole mount micrograph of brown adipose tissue. Capillaries (red) were labeled with Griffonia simplicifolia I-B4 isolectin and brown adiipocytes were labeled with antibodies to perilipin (green). The image is a 3D projection of numerous confocal optical slices. Printed with kind permission by J. Granneman.
British Library Cataloguing-in-Publication Data A catalogue record for this book is available from the British Library. Bibliographic information published by the Deutsche Nationalbibliothek The Deutsche Nationalbibliothek lists this publication in the Deutsche Nationalbibliografie; detailed bibliographic data are available on the Internet at http://dnb.d-nb.de. # 2010 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim All rights reserved (including those of translation into other languages). No part of this book may be reproduced in any form – by photoprinting, microfilm, or any other means – nor transmitted or translated into a machine language without written permission from the publishers. Registered names, trademarks, etc. used in this book, even when not specifically marked as such, are not to be considered unprotected by law. Cover Design Adam Design, Weinheim Typesetting Thomson Digital, Noida, India Printing and Binding betz-druck GmbH, Darmstadt Printed in the Federal Republic of Germany Printed on acid-free paper ISBN: 978-3-527-31857-5
V
Contents Preface XIX List of Contributors
XXI
Part One Adipose Tissue Development and Morphology 1 1 1.1 1.2 1.2.1 1.2.2 1.2.3 1.2.4 1.2.5 1.2.6 1.3 1.3.1 1.3.2 1.3.3 1.3.4 1.3.5
2
2.1 2.1.1 2.1.2 2.1.3 2.1.4 2.2
Transcriptional Control of Adipogenesis and Fat Cell Gene Expression Ursula A. White and Jacqueline M. Stephens Introduction 3 Transcriptional Control of Adipogenesis 4 AP-1 Transcription Factors 4 Signal Transducers and Activators of Transcription 5 Krüppel-Like Factors 6 SREBPs 7 C/EBP 7 PPAR-c 8 Identification of Adipocyte Transcription Factor Target Genes 9 C/EBP Target Genes 9 SREBP-1 Target Genes 10 PPAR-c Target Genes 11 STAT-5 Target Genes 12 Summary 13 References 14 Cellular and Molecular Basis of Functional Differences among Fat Depots 21 Thomas Thomou, Tamara Tchkonia, and James L. Kirkland Introduction 21 Fat Tissue Function 21 Diversity in Fat Distribution 23 Regional Differences in Fat Tissue Growth 24 Disease Associations 26 Physiology 27
3
VI
Contents
2.2.1 2.2.2 2.2.3 2.2.4 2.2.5 2.2.6 2.2.7 2.3
3 3.1 3.2 3.3 3.3.1 3.3.2 3.4 3.5 3.6 3.6.1 3.6.2 3.6.3
3.6.4 3.7
4 4.1 4.2 4.3 4.3.1 4.4 4.4.1
Contribution of Inherent Cell Dynamic Mechanisms to Regional Differences 28 Preadipocyte Function 29 Preadipocyte Replication 29 Differences in Adipogenesis among Depots 30 Regional Variation in Susceptibility to Apoptosis 32 Differences in Preadipocyte Subpopulations among Fat Depots 32 Differences in Preadipocyte Gene Expression Profiles among Depots 33 Conclusions 35 References 36 Plasticity of the Adipose Organ 49 Saverio Cinti Introduction 49 Gross Anatomy Demonstrates that WAT and BAT are Mixed Together in the Adipose Organ 50 Light and Electron Microscopy show that White and Brown Adipocytes have a Well-Defined and Distinct Morphology 51 WAT 51 BAT 52 WAT and BAT have a Different Vascular and Nerve Supply 53 WAT and BAT have a Different Physiology 54 Phenotype of the Adipose Organ is Variable: Plasticity of the Adipose Organ 55 Transformation of the Phenotype: Cold and Warm Exposure and Acclimatization 55 Transformation of the Phenotype: Pregnancy and Lactation 58 Transformation of the Phenotype: Hypertrophy and Hyperplasia (Positive Energy Balance: Overweight and Obesity) 59 Transformation of the Phenotype: Hypoplasia (Negative Energy Balance: Caloric Restriction and Fasting) 60 Adipose Organ of Humans 61 References 63 Biology of Adipose Tissue Stem Cells 69 Jeffrey M. Gimble, Bruce A. Bunnell, and Farshid Guilak Introduction 69 In Situ Localization and Embryology 69 Isolation Methods 70 Yield, Proliferation Rate, Depot, and Aging Influences Characterization 71 Immunophenotype 71
70
Contents
4.4.2 4.4.3 4.4.4 4.4.5 4.5 4.5.1 4.5.2 4.6
Immunogenicity 71 Proteomic and Transcriptomic Analysis 72 Cytokine Profile 72 Clonality 72 Differentiation and Potential Utility for Regenerative Medicine Mesodermal Lineages 73 Endodermal and Ectodermal Lineages 73 Conclusions 74 References 74
Part Two Metabolic Functions of Adipose Tissue 5 5.1 5.2 5.2.1 5.2.2 5.2.2.1 5.2.2.2 5.2.2.3 5.2.2.4 5.3 5.3.1 5.3.2 5.3.3 5.3.4 5.3.5 5.3.6 5.4
6
6.1 6.2 6.3 6.4 6.5 6.6
81
Molecular Mechanisms of Adipocyte Lipolysis 83 James G. Granneman and Hsiao-Ping H. Moore Introduction 83 Key Players in Adipocyte Lipolysis 83 Lipid Droplets and Droplet Scaffold Proteins 84 Lipases 86 HSL 86 Adipose Triglyceride Lipase 87 CGI-58 87 Other Lipases and the Biological Significance of HSL versus ATGL 88 Lipolytic Protein Trafficking 88 PLIN Subcellular Targeting 88 Interactions with CGI-58 88 Interactions with HSL 89 Interactions with ATGL 89 Disruption and Dispersion of Lipid Droplets Following PKA Activation 90 Additional Interactions 90 Working Model and Unresolved Issues 91 References 93 New Developments in the Lipolytic Processing of Triglyceride-Rich Lipoproteins 97 André Bensadoun, Anne P. Beigneux, Loren G. Fong, and Stephen G. Young Introduction 97 LPL 98 Functional Domains of LPL 99 Regulation of LPL Activity by Angiopoietin-Like Proteins Role of GPIHBP1 in the Lipolysis of Triglyceride-Rich Lipoproteins 101 Role of Apo-AV in Lipolysis 103
100
73
VII
VIII
Contents
6.7
Newly Discovered Regulators of LPL Activity and their Physiological Significance 104 References 105
7
Intracellular Fatty Acid Transport, Activation, and Trafficking 109 Doug Mashek Introduction 109 Fatty Acid-Binding Protein Family 109 Function and Regulation of FABP-4 110 Function and Regulation of FABP-5 112 Fatty Acid Activation and Channeling: Role of Long-Chain Acyl-CoA Synthetases and Fatty Acid Transport Proteins 113 Role of Acyl-CoA-Binding Protein in Acyl-CoA Metabolism 116 Regulation and Function of Distinct Fatty Acid and Acyl-CoA Pools 117 Contribution of Fatty Acid and Acyl-CoA Metabolism to Metabolic Diseases 119 Conclusions 121 References 121
7.1 7.2 7.2.1 7.2.2 7.3 7.4 7.5 7.6 7.7
8
8.1 8.2 8.3 8.3.1 8.3.2 8.3.3 8.3.4
8.4 8.4.1 8.4.2 8.5 8.6 8.7
Aquaporins and Adipose Tissue: Lesson from Discovery to Physiopathology and to the Clinic of Aquaporin Adipose (AQP7) 129 Ken Kishida Introduction 129 Characteristics of Adipocytes and Gycerol Metabolism in the Mammalian Body 130 Adipose Glycerol Channel: AQP7 132 AQP7: A Putative Adipose-Specific Glycerol Channel 132 Function and Regulation of AQP7 in Adipocytes 134 Human AQP7 Genetic Mutation 137 Adipose-Derived Glycerol and Gluconeogenesis through AQP7 – Lessons from AQP7-Deficient Mice and Cells 139 Hepatic Glycerol Channel: AQP9 141 AQP9: A Putative Hepatic-Specific Glycerol Channel 141 Gluconeogenesis through AQP9 – Lessons from AQP9-Deficient Mice 142 Coordination of Adipose Glycerol Channel, AQP7, and Hepatic Glycerol Channel, AQP9 143 Dysregulation of AQP7 and AQP9 in Obesity with Insulin Resistance 143 Conclusions 144 References 144
Contents
9
9.1 9.2 9.2.1 9.2.2 9.3 9.4 9.5 9.6 9.6.1 9.6.2 9.6.3 9.6.4 9.7 9.7.1 9.7.2 9.7.3 9.7.4 9.8
Signaling Pathways Controlling Lipolysis and Lipid Mobilization in Humans 149 Max Lafontan Introduction 149 Role of Lipases in the Regulation of Hydrolysis of Fat Cell Triacylglycerols 151 Hormone-Sensitive Lipase 151 Adipose Tissue Triglyceride Lipase 151 Adrenergic Control of cAMP Production, Lipolysis and Lipid Mobilization 152 Control of cAMP Production by Adenylyl Cyclase Inhibitors – Inhibition of Lipolysis 157 Insulin: A Major Antilipolytic Agent Controlling cAMP Degradation 158 Natriuretic Peptides Control cGMP Production, Lipolysis, and Lipid Mobilization in Humans 159 Natriuretic Peptides 159 Lipolytic Effect of Natriuretic Peptides 160 Induction of Lipid Mobilization by Administration of Pharmacological Doses of ANP 162 Contribution of ANP to the Physiological Control of Lipid Mobilization in Humans 162 Other Lipolytic Pathways 163 Growth Hormone 163 IL-6 164 TNF-a 165 Other Lipolytic Peptides 166 Future Trends and Pharmacological Prospects 167 References 168
Part Three Endocrine Functions of Adipose Tissue 181 10 10.1 10.2 10.2.1 10.2.2 10.2.3 10.3 10.4 10.5 10.6 10.6.1 10.6.2
Leptin Secretion and Action 183 Robert V. Considine Introduction 183 Leptin Synthesis 184 Gender and Body Fat Distribution Determine Serum Leptin 184 Caloric Intake, Insulin, and Glucose Influence Serum Leptin 185 Transcriptional Regulation of Leptin Synthesis in Adipocytes 186 Leptin Receptors 187 Leptin Action in the Central Nervous System 187 Leptin Resistance in Obesity 189 Metabolic Complications of Hyperleptinemia in Obesity 190 Leptin and Obesity-Related Hypertension 190 Other Possible Pathologic Effects of Leptin 191
IX
X
Contents
10.7 10.7.1 10.7.2 10.7.3 10.7.4 10.8
Leptin Therapy in Humans 192 Leptin, Weight Loss, and Human Obesity Congenital Leptin Deficiency 192 Lipodystrophic Leptin Deficiency 193 Hypothalamic Amenorrhea 193 Conclusions 194 References 194
11
Adiponectin 201 Jonathan P. Whitehead and Ayanthi A. Richards Introduction 201 Adiponectin Structure and Post-Translational Modifications 202 Significance and Bioactivity of Adiponectin Multimers 204 Adiponectin and Liver 205 Adiponectin and Skeletal Muscle 206 Adiponectin and the Vasculature 206 Adiponectin and the Brain 207 Adiponectin Expression and Secretion 208 Adiponectin Secretion 209 Ectopic Adiponectin Expression 211 Regulation of Expression and Secretion 212 Oxidative stress 212 Activators of PPARc – TZDs and Fish Oils 213 Weight Loss 213 Other Agents 214 Adiponectin Clearance 214 Adiponectin Receptors and Downstream Effectors 215 Adiponectin Signaling 216 Conclusions 217 References 218
11.1 11.2 11.3 11.4 11.5 11.6 11.7 11.8 11.9 11.10 11.11 11.11.1 11.11.2 11.11.3 11.11.4 11.12 11.13 11.14 11.15
12
12.1 12.2 12.3 12.4 12.5 12.6 12.7 12.8
192
Preadipocyte factor-1 and Adipose Tissue-Specific Secretory Factor/Resistin – Two Secreted Factors from Adipose Tissue: Role in Adipogenesis and Insulin Resistance 231 Hei Sook Sul, Yuhui Wang, and Carolyn Hudak Introduction 231 Pref-1 Structure 232 Pref-1 Inhibition of Adipocyte Differentiation 233 Mechanism for Pref-1 Function 234 In Vivo Effect of Pref-1 on Adipogenesis and Glucose/Insulin Homeostasis 235 ADSF/Resistin: Identification and Structure 236 ADSF/Resistin Expression and Function 237 Conclusions 239 References 240
Contents
13 13.1 13.2 13.2.1 13.2.2 13.2.3 13.2.4 13.2.5 13.2.6 13.2.7 13.2.8 13.3 13.3.1 13.3.2 13.4
14 14.1 14.2 14.3 14.4 14.5 14.5.1 14.5.2 14.6 14.7 14.8
Adipose Tissue and Blood Pressure Regulation 245 Lisa A. Cassis and Sara B. Police Introduction 245 Adipose Tissue Changes with Obesity: Relation to Blood Pressure Control 245 Adipocyte RAS in Obesity-Related Hypertension 247 Leptin in Obesity-Related Hypertension 249 Adiponectin in Obesity-Related Hypertension 250 Insulin and Obesity-Related Hypertension 251 Plasminogen Activator Inhibitor-1 and Obesity-Related Hypertension 252 Free Fatty Acids and Obesity-Related Hypertension 252 Resistin and Obesity-Related Hypertension 253 11b-HSD-1 and Obesity-Related Hypertension 254 Regional Adipose Deposition and Blood Pressure Regulation 254 Changes in Visceral Adipose Tissue in Obesity-Related Hypertension 255 Potential Role for Perivascular Adipose Tissue in Obesity-Related Hypertension 255 Conclusions 256 References 257 Adipokines, Inflammation, and Obesity 265 Karine Clément Introduction 265 Contribution of Adipose Tissue in Systemic Inflammation during Obesity 266 Adipose Tissue Depots and Adipokine Production 268 Adipokines and Adipose Tissue Cell Types 269 Adipokines, Macrophages, and the Biology of Adipocytes 270 Chemoattraction 271 Paracrine Cross-Talk in the Adipose Tissue via Adipokines 272 Adipokines and Complications of Obesity 274 Adipokines and Weight Loss 275 Conclusions 276 References 276
Part Four Adipose Tissue and Disease 15
15.1 15.2
283
Depot-Specific Biology of Adipose Tissues: Links to Fat Distribution and Metabolic Risk 285 Mi-Jeong Lee and Susan K. Fried Introduction 285 Adipose Depots: Definitions 286
XI
XII
Contents
15.3 15.3.1 15.3.2 15.4 15.4.1 15.4.2 15.4.3 15.5
15.6 15.7 15.8 15.9 15.10
16
16.1 16.2 16.2.1 16.2.2 16.2.3 16.2.4 16.2.4.1 16.2.4.2 16.2.4.3 16.2.4.4 16.2.4.5 16.3 16.4 16.5 16.6 16.7 16.8 16.9
Physiological and Anatomical Differences among Depots may Drive Functional Heterogeneity 286 Depot Differences in Cellular Composition 286 Definition of Visceral Fat Depots 287 Heterogeneity in Adipocyte Function among Adipose Depots 288 Lipolysis 288 Triglyceride Deposition 289 Glucose Uptake and Insulin Action 290 Regional Differences in Adipose Tissue Gene Expression and Protein Production: Relationship to the Metabolic Syndrome 291 Search for Novel Adipokines with Depot-Specific Expression that Link Regional Adiposity to Metabolic Risk 291 Importance of Adipose Tissue Macrophages and other Immunocytes in Regional Adipose Tissue Dysfunction 293 Gene Expression Profiles are Providing New Insights on Regional Adipose Growth and Function 295 Depot Differences in Cell Proliferation and Differentiation Capacity 296 Conclusions and Future Directions 297 References 298 Viral Induction of Obesity and Adipogenesis 307 Magdalena Pasarica, Rohan N. Dhurandhar, Nazar Mashtalir, and Nikhil V. Dhurandhar Introduction 307 Viruses 313 Canine Distemper Virus 313 Rous-Associated Virus-7 314 Borna Disease Virus 314 Adenoviruses 315 SMAM-1 315 Ad-36 316 Ad-5 319 Ad-37 319 Adipogenic Potential of other Adenoviruses 319 Chlamydia pneumoniae 320 Gut Microbiota 320 Gut Parasites 321 Scrapie Agents 322 Interaction of Pathogens and Adipose Tissue 323 Adipogenic Pathogens and Humans 324 Conclusions 324 References 325
Contents
17 17.1 17.2 17.3 17.4 17.5 17.6 17.7 17.8
18 18.1 18.2 18.3 18.4 18.4.1 18.4.2 18.4.3 18.5 18.5.1 18.5.1.1 18.5.2 18.5.2.1 18.5.2.2 18.5.2.3 18.6 18.6.1 18.6.1.1 18.6.1.2 18.6.2 18.6.2.1 18.7 18.8
Adipose Tissue Cachexia 333 Michael John Tisdale 333 Introduction 333 Changes in Adipose Tissue in Cachexia 333 Energy Expenditure in Cancer Patients 335 Factors Governing Adipose Tissue Mass 336 Mechanism of Loss of Adipose Tissue in Cachexia 337 Requirements of Tumor-Bearing Animals for Lipids 338 Fat-Mobilizing Substances in Cancer Cachexia 338 Conclusion 340 References 342 Obesity and Diabetes: Lipotoxicity 347 Christopher J. Lelliott, Matej Ore4si4c, and Antonio J. Vidal-Puig Introduction 347 White Adipose Tissue at the Center of Lipid Homeostasis and Delivery 348 Insulin Resistance in Adipocytes Disrupts the Balance between Lipid Storage and Secretion 348 Scenarios that may Result in Ectopic Fat Deposition 348 Altered Plasticity of the Adipose Tissue: A Shift in Expansion Towards Hypertrophy 349 Impaired Fat Deposition Capacity in Adipose Tissue 350 Inappropriate Balance of Substrate Uptake and Oxidative Capacity in Peripheral Tissue 353 Mechanisms Contributing to the Lipotoxicity in the Peripheral Organs 355 Lipotoxicity in Skeletal Muscle 355 Randle Hypothesis and its Successors 355 Molecular Mechanisms for the Generation of Muscle Lipotoxicity 356 Type of Lipids is More Important than the Amount of Fat Deposited 356 Diacylglycerols and Insulin Resistance 358 Ceramides and Insulin Resistance 358 Impaired Oxidation as a Trigger for Lipotoxicity 360 Adipocytokines Proinflammatory Activity Contributes to Lipotoxicty in Skeletal Muscle 361 Adipose Tissue Macrophages as Key Players for Lipotoxicity 361 Signaling Effector Pathways in Lipotoxicty 361 Lipotoxicity and Insulin Resistance Affecting Liver Metabolism 362 Hepatic Lipotoxicity 362 Pancreatic b-Cell as a Target for Lipotoxicity 363 New Analytical and Computational Methods to Identify Lipotoxicity-Related Metabolic Networks 363
XIII
XIV
Contents
18.9
Lessons from Lipotoxicity – Potential Antilipotoxic Therapeutic Strategies 365 References 365
19
Obesity and Cancer 369 Andrew G. Renehan Introduction 369 Epidemiology 369 Excess Body Weight and Cancer Risk 369 Excess Body Weight and Cancer Mortality 370 Biological Mechanisms 371 Candidate Mechanisms 371 Insulin and IGFs 372 Insulin-Cancer Hypothesis 372 Insulin and C-Peptide 372 IGFs 376 Sex Steroids 376 Estrogen and Breast Cancer 376 Androgens and Breast Cancer 377 Sex Steroids and Endometrial Cancer 377 Adipokines 378 Overview 378 Leptin and Cancer in Humans 378 Adiponectin and Cancer Risk in Humans 379 Adipokines, Animal Models, and Cancer Risk 380 Other Biological Candidates 380 Obesity-Related Inflammatory Markers 380 Nuclear Factor-kB System 381 Oxidative Stresses 381 Mechanical Mechanisms 381 New Research Areas 382 References 382
19.1 19.2 19.2.1 19.2.2 19.3 19.3.1 19.3.2 19.3.2.1 19.3.2.2 19.3.2.3 19.3.3 19.3.3.1 19.3.3.2 19.3.3.3 19.3.4 19.3.4.1 19.3.4.2 19.3.4.3 19.3.4.4 19.4 19.4.1 19.4.2 19.4.3 19.5 19.6
20 20.1 20.2 20.2.1 20.2.1.1 20.2.1.2 20.2.2 20.2.2.1 20.2.2.2 20.3
Overview of Acquired and Genetic Lipodystrophies 385 Tisha Joy and Robert A. Hegele Introduction 385 Congenital Lipodystrophies 386 Congenital Generalized Lipodystrophy (Berardinelli–Seip Syndrome) 386 Clinical Features 386 Molecular Genetics 390 Familial Partial Lipodystrophy 390 Clinical Features 390 Molecular Genetics 391 Acquired Lipodystrophies with a Possible Genetic Component 393
Contents
20.3.1 20.3.1.1 20.3.1.2 20.3.2 20.3.2.1 20.3.2.2 20.3.3 20.4 20.4.1 20.4.1.1 20.4.1.2 20.4.2 20.4.2.1 20.4.2.2 20.4.3 20.4.3.1 20.4.3.2 20.4.4 20.4.4.1 20.4.4.2 20.4.5 20.4.5.1 20.4.5.2 20.5
Acquired Generalized Lipodystrophy 393 Clinical Features 393 Molecular Genetics 393 Acquired Partial Lipodystrophy (Barraquer–Simons Syndrome) 393 Clinical Features 393 Molecular Genetics 394 HIV-Related Lipodystrophy 394 Lipodystrophy Associated with other Syndromes 395 Mandibuloacral Dysplasia 395 Clinical Features 395 Molecular Genetics 395 SHORT Syndrome 396 Clinical Features 396 Molecular Genetics 396 Neonatal Progeroid Syndrome 396 Clinical Features 396 Molecular Genetics 396 Hutchinson–Gilford Progeria Syndrome 396 Clinical Features 396 Molecular Genetics 397 Werner Syndrome 397 Clinical Features 397 Molecular Genetics 397 Conclusions 397 References 398
21
Mouse Models of Lipodystrophy 403 Jimmy Donkor and Karen Reue Introduction 403 Physiological Mechanisms of Lipodystrophy in Mouse Models 403 Lipodystrophic Models with Impaired Adipogenesis 407 A-ZIP/F1 Transgenic Mouse 408 aP2- SREBP-1c Transgenic Mouse 408 Mouse Models with Altered PPAR-c Levels 409 C/EBPa-Deficient Mouse 410 Zmpste24-Deficient Mice 410 Lipodystrophic Models with Impaired Triacylglycerol Biosynthesis 411 GPAT1-Deficient Mouse 411 AGPAT6-Deficient Mouse 412 DGAT1-Deficient Mouse 412 Lipin-1-Deficient Mouse 412 Lipodystrophic Models with Enhanced Energy Expenditure 414 Leptin Transgenic Mouse 414 PPAR-d Transgenic Mouse 415
21.1 21.2 21.3 21.3.1 21.3.2 21.3.3 21.3.4 21.3.5 21.4 21.4.1 21.4.2 21.4.3 21.4.4 21.5 21.5.1 21.5.2
XV
XVI
Contents
21.5.3 21.6 21.6.1 21.6.2 21.6.3 21.6.4 21.6.5 21.7
22 22.1 22.2 22.3 22.4 22.5 22.6 22.7 22.8 22.8.1 22.8.2 22.8.3 22.8.4 22.9 22.9.1 22.9.2 22.10 22.11
23
23.1 23.2 23.2.1 23.2.2 23.3 23.3.1 23.3.2 23.4 23.5
FOXC2 Transgenic Mouse 415 Mouse Models with Acquired or Conditional Lipodystrophy 416 aP2-DTA Transgenic Mouse 416 FAT-ATTAC Transgenic Mouse 416 RSK2 Deficient Mouse 417 Drug-Induced Lipoatrophy 417 Diet-Induced Lipoatrophy 417 Conclusions 418 References 419 Caloric Restriction, Longevity, and Adiposity 423 Leanne M. Redman and Eric Ravussin Introduction 423 Physiological Changes with Aging 424 Aging and Caloric Restriction 424 Energy Restriction may Alter the ‘‘Rate of Living’’ 425 CR and Oxidative Stress 426 CR and Cardiovascular Disease 427 CR and Insulin Resistance/Type 2 Diabetes Mellitus 427 What is Known from Humans? 427 Centenarians from Okinawa 427 Vallejo Study 428 Unexpected CR in Biosphere 2 428 Randomized Controlled Trials of Prolonged CR in Humans 429 Could CR Increase Longevity in Humans? 431 How Much CR? 432 How Long is CR Required? 432 CR Mimetics 433 Conclusions 434 References 434 Peroxisome Proliferator-Activated Receptor-c: A Key Regulator of Adipose Tissue Formation, Remodeling, and Metabolism 441 Olga Astapova and Todd Leff Introduction 441 Molecular Biology of PPAR-c 442 PPAR-c Structure and DNA Binding 442 Transcriptional Regulation by PPAR-c 444 PPAR-c is a Master Regulator of Adipose Tissue Development 447 Role of PPAR-c in Adipogenesis – Cell Culture Studies 447 PPAR-c is Required for Adipose Tissue Development In Vivo 448 Metabolic Functions of PPAR-c 449 White versus Brown Fat-Specific Functions of PPAR-c 450
Contents
23.6 23.7
24 24.1 24.2 24.3 24.3.1 24.3.2 24.4 24.4.1 24.4.2 24.4.3 24.5 24.5.1 24.5.2 24.5.3 24.6 24.6.1 24.6.2
25 25.1 25.2 25.3 25.3.1 25.3.2 25.3.3 25.4 25.5 25.6 25.7
PPAR-c Function in Adipose Tissue Maintenance and Remodeling 452 Conclusions 454 References 454 Early-Life Programming of Adipogenesis and Adiposity 459 Roselle L. Cripps and Susan E. Ozanne Introduction 459 Theories for the Developmental Origins of Obesity 460 Evidence for the Developmental Origins of Obesity 460 Data from Humans 461 Data from Animal Models 461 Adipogenesis 462 Adipogenesis In Vitro 462 Control of Adipogenesis 463 Developmental Alterations to Adipogenesis 464 Potential Mechanisms? 465 Glucocorticoids 465 Leptin 465 Epigenetic Alterations 467 Future Perspectives 467 Optimizing Early Life Nutrition? 467 Interventions? 467 References 468 Evolutionary Aspects of Obesity and Adipose Tissue Function 473 Jonathan C. K. Wells Introduction 473 Thrifty Genotype and Phenotype Hypotheses 474 Ethological Approach 476 Ontogeny 477 Fitness Value 478 Evolutionary History 480 Significance of Agriculture 482 Significance of Colonizing 483 Significance of Social Inequality 485 New Obesogenic Environment 486 References 487 Index
491
XVII
XIX
Preface We are in the midst of a world-wide epidemic of obesity. The causes of this epidemic are complex and multifaceted, and reflect an unintended synergy between our evolutionary legacy and the current postindustrial environment we have collectively created. Despite these complexities, one thing is clear: the wide-spread prevalence of obesity has contributed directly and fundamentally to several chronic diseases, foremost of which is diabetes. The nature of the connection between adiposity and disease is incompletely understood. However, experience with human and animal lipodystrophies (abnormalities of adipose tissue quantity and distribution), indicates that the relationship between obesity and diabetes is not due to the magnitude of fat accumulation per se, but rather the functioning of the adipose organ. Thus, the aim of this collection is to outline our current understanding of the basic metabolic, endocrine and immune functions of adipose tissues, and how dysregulation of adipose tissue physiology contributes to disease. The collection is organized along four interrelated topics. Part 1 addresses aspects of the molecular and cellular development of adipocytes, and morphology of adipose tissue. A theme developed in these chapters concerns the remarkable heterogeneity and plasticity of the adipose tissue organ. Indeed, growing evidence demonstrates that various fat depots have distinct developmental origins, cellular composition, and unique endocrine and metabolic profiles that differentially contribute to health and disease. Part 2 focuses on metabolic functions that are classically associated with adipose tissue, such as lipid storage and mobilization. Here, too, recent work has identified novel and unexpected complexities in the transmembrane and intracellular mechanisms by which the balance of lipid storage and mobilization is maintained. Adipose tissue secretes a diverse set of hormones and cytokines, collectively known as adipokines, that greatly impact both local and systemic metabolism. Part 3 addresses recent developments in our understanding of the now ‘‘classic’’ endocrine functions of adipocytes (i.e., leptin and adiponectin), and touches upon the potentially important relationships between the production of inflammatory cytokines in adipose tissue during hypertrophic obesity and systemic insulin sensitivity.
XX
Preface
Lastly, nearly half of the collection is devoted to the topic of adipose tissue in health and disease. Chapters in Part 4 explore the developmental, evolutionary and social origins of human obesity. In addition, these chapters address the physiological consequences of exceeding adipose tissue capacity, as occurs in both obese and lipodystrophic states, as well as the specific risks to health conferred by obesity and potential mechanisms involved. Finally, this section touches upon adipose tissue as a therapeutic target for approaches to promote health and longevity. Detroit, January 2010
Todd Leff and James G. Granneman
XXI
List of Contributors Olga Astapova Wayne State University School of Medicine Department of Pathology 540 E. Canfield Detroit, MI 48201 USA Anne P. Beigneux University of California David Geffen School of Medicine Department of Medicine Division of Cardiology 650 Charles E. Young Drive South A2-237 CHS Bldg. Los Angeles, CA 90095 USA André Bensadoun Cornell University Division of Nutritional Sciences 321 Savage Hall Ithaca, NY 14853 USA Bruce A. Bunnell Tulane Center for Gene Therapy Tulane University Health Sciences Center J. Bennett Johnston Building 1324 Tulane Avenue, SL-99 New Orleans, LA 70112-2699 USA
Lisa A. Cassis University of Kentucky Graduate Center for Nutritional Sciences Lexington, KY 40536 USA Saverio Cinti University of Ancona Department of Molecular Pathology and Innovative Therapies-Anatomy via Tronto 10/a 60020 Ancona Italy Karine Clément Hôpital Pitié-Salpêtrière INSERM, Cordelier Research Center Endocrinology and Nutrition department Batiment Husson Mourrier Boulevard de lhôpital 75013 Paris France Robert V. Considine Indiana University School of Medicine Division of Endocrinology 541 N. Clinical Drive Indianapolis, IN 46202 USA
XXII
List of Contributors
Roselle L. Cripps University of Cambridge Metabolic Research Laboratories Level 4, Institute of Metabolic Science Box 289, Addenbrookes Hospital Cambridge CB2 OQQ UK Nikhil V. Dhurandhar Louisiana State University System Pennington Biomedical Research Center Department of Infection and Obesity 6400 Perkins Road Baton Rouge, LA 70808 USA Rohan N. Dhurandhar Louisiana State University System Pennington Biomedical Research Center Department of Infection and Obesity 6400 Perkins Road Baton Rouge, LA 70808 USA Jimmy Donkor University of California David Geffen School of Medicine Departments of Human Genetics and Medicine 695 Charles E. Young Drive South Los Angeles, CA 90095 USA Loren G. Fong University of California David Geffen School of Medicine Department of Medicine Division of Cardiology 695 Charles E. Young Drive South Gonda Bldg., Rm4524 Los Angeles, CA 90095 USA
Susan K. Fried University of Maryland School of Medicine Department of Medicine Division of Endocrinology, Diabetes and Nutrition 660 W. Redwood Street Baltimore, MD 21201 USA and Baltimore Veterans Affairs Medical Center Geriatric Research Education and Clinical Center 10 N. Greene Street Baltimore, MD 21201 USA Jeffrey M. Gimble Louisiana State University System Pennington Biomedical Research Center 6400 Perkins Road Baton Rouge, LA 70808 USA James G. Granneman Wayne State University School of Medicine Center for Integrative Metabolic and Endocrine Research Detroit, MI 48201 USA Farshid Guilak Duke University Medical Center Department of Surgery Division of Orthopedics MSRB Rm 375, Box 3093 Durham, NC 27710 USA
List of Contributors
Robert A. Hegele University of Western Ontario Schulich School of Medicine and Dentistry 100 Perth Drive London, Ontario N6A 5K8 Canada
Max Lafontan Institut de Médecine Moléculaire de Rangueil INSERM Unit 858 BP 84225 31432 Toulouse Cedex 4 France
Carolyn Hudak University of California Department of Nutritional Science and Toxicology Morgan Hall Berkeley, CA 94720 USA
Mi-Jeong Lee University of Maryland School of Medicine Department of Medicine Division of Endocrinology, Diabetes and Nutrition 660 W. Redwood Street Baltimore, MD 21201 USA
Tisha Joy University of Western Ontario Division of Endocrinology 100 Perth Drive London, Ontario N6A 5K8 Canada James L. Kirkland Mayo Clinic Robert and Arlene Kogod Center on Aging 200 First St., S.W. Rochester, MN 55905 USA Ken Kishida Osaka University Graduate School of Medicine Department of Metabolic Medicine 2-2-B5 Yamada-oka, Suita Osaka 565-0871 Japan
Todd Leff Wayne State University School of Medicine Department of Pathology Detroit, MI 00000 USA Christopher J. Lelliott AstraZeneca R&D Cardiovascular/Gastrointestinal Research Area Department of Biosciences Pepparedsleden 1 43183 Mölndal Sweden Doug Mashek University of Minnesota Department of Food Science and Nutrition 1334 Eckles Avenue St. Paul, MN 55108 USA
XXIII
XXIV
List of Contributors
Nazar Mashtalir Louisiana State University System Pennington Biomedical Research Center Department of Infection and Obesity 6400 Perkins Road Baton Rouge, LA 70808 USA
Eric Ravussin Louisiana State University System Pennington Biomedical Research Center Department of Human Physiology 6400 Perkins Road Baton Rouge, LA 70808 USA
Hsiao-Ping H. Moore Lawrence Technological University College of Arts and Sciences Southfield, MI 48075 USA
Leanne M. Redman Louisiana State University System Pennington Biomedical Research Center Department of Human Physiology 6400 Perkins Road Baton Rouge, LA 70808 USA
Matej Ore4si4c VTT Technical Research Center of Finland Tietotie 2 02044 Espoo Finland Susan E. Ozanne University of Cambridge Metabolic Research Laboratories Level 4, Institute of Metabolic Science Box 289, Addenbrookes Hospital Cambridge CB2 OQQ UK Magdalena Pasarica Louisiana State University System Pennington Biomedical Research Center Department of Infection and Obesity 6400 Perkins Road Baton Rouge, LA 70808 USA Sara B. Police University of Kentucky Graduate Center for Nutritional Sciences Lexington, KY 40536 USA
Andrew G. Renehan University of Manchester School of Cancer, Enabling Sciences and Technology Manchester Academic Health Science Center The Christie NHS Foundation Trust Wilmslow Road Manchester M20 4BX UK Karen Reue University of California David Geffen School of Medicine Departments of Human Genetics and Medicine 695 Charles E. Young Drive South Los Angeles, CA 90095 USA Ayanthi A. Richards University of Queensland Princess Alexandra Hospital Diamantina Institute for Immunology, Cancer and Metabolic Medicine Brisbane Queensland, QLD 4102 Australia
List of Contributors
Jacqueline M. Stephens Louisiana State University Department of Biological Sciences 202 Life Sciences Building Baton Rouge, LA 70803 USA Hei Sook Sul University of California Department of Nutritional Science and Toxicology Morgan Hall Berkeley, CA 94720 USA Tamara Tchkonia Mayo Clinic Robert and Arlene Kogod Center on Aging 200 First St., S.W. Rochester, MN 55905 USA Thomas Thomou Mayo Clinic Robert and Arlene Kogod Center on Aging 200 First St., S.W. Rochester, MN 55905 USA Michael John Tisdale Aston University School of Life and Health Sciences Nutritional Biomedicine Birmingham B4 7ET UK Antonio J. Vidal-Puig University of Cambridge Addenbrookes Hospital Department of Clinical Biochemistry Hills Road Cambridge CB2 2QR UK
Yuhui Wang University of California Department of Nutritional Science and Toxicology Morgan Hall Berkeley, CA 94720 USA Jonathan C.K. Wells UCL Institute of Child Health Childhood Nutrition Research Centre 30 Guilford Street London WC1N 1EH UK Ursula A. White Louisiana State University Department of Biological Sciences 202 Life Sciences Building Baton Rouge, LA 70803 USA Jonathan P. Whitehead University of Queensland Princess Alexandra Hospital Diamantina Institute for Immunology, Cancer and Metabolic Medicine Brisbane Queensland, QLD 4102 Australia Stephen G. Young University of California David Geffen School of Medicine Department of Medicine Division of Cardiology 650 Charles E. Young Drive South A2-237 CHS Bldg. Los Angeles, CA 90095 USA
XXV
Part One Adipose Tissue Development and Morphology
j3
1 Transcriptional Control of Adipogenesis and Fat Cell Gene Expression Ursula A. White and Jacqueline M. Stephens 1.1 Introduction
Adipocytes are highly specialized cells that play a major role in energy homeostasis in vertebrate organisms. Excess adipocyte size or number is a hallmark of obesity, which is currently a global epidemic. Obesity is not only the primary disease of fat cells, but a major risk factor for the development of non-insulin-dependent diabetes mellitus, cardiovascular disease, and hypertension. Obesity and its related disorders result in dysregulation of the mechanisms that control the expression of metabolic genes in adipocytes. Therefore, understanding adipocyte differentiation is relevant not only for understanding the pathogenesis of metabolic diseases, but also for identifying proteins or pathways that might be appropriate targets for pharmacological interventions. In the last 15 years, significant advances towards an understanding of the regulatory processes involved in adipocyte differentiation have largely been made by the identification of transcription factors that regulate the differentiation of fat cells and/or are involved in the induction and maintenance of adipocyte gene expression. Interestingly, the majority of studies that have identified transcriptional regulators of adipogenesis have been performed in vitro. These studies have been primarily conducted in the 3T3-L1 or 3T3-F442A preadipocyte cell lines that were originally generated in the laboratory of Howard Green at Harvard University [1, 2]. In the last 32 years, these cells lines have been used by thousands of investigators worldwide. In vivo, adipocytes have three primary characteristics, which include lipid storage, insulin sensitivity, and endocrine properties. The 3T3-L1 cells have all three of these notable characteristics of fat cells. In addition, many adipocyte specific genes have been identified using this cell line. Many cell types cannot be adequately studied in vitro because the cultured cells do not have all the properties that the cells have in vivo. However, the preadipocyte cell lines that were developed by Green have been an extremely useful model system for adipocyte biologists and the data obtained in these cells has been validated from less mechanistic in vivo studies in the last decade.
j 1 Transcriptional Control of Adipogenesis and Fat Cell Gene Expression
4
In the late 1980s, a commentary by Steven McKnight and Dan Lane indicated that CAAAT/enhancer-binding protein (C/EBP)-a was a key metabolic regulator of energy metabolism [3]. Numerous studies have since confirmed the role of C/EBP-a and other C/EBP family members in energy balance, and defined roles for these transcription factors in adipocyte differentiation (reviewed in [4]). In 1994, two prominent laboratories independently identified peroxisome proliferator-activated receptor-c (PPAR)-c as an important modulator of adipocyte differentiation. Studies by Mitch Lazars group observed the induction of PPAR-c during adipogenesis [5], and experiments by Bruce Speigelmans laboratory revealed that PPAR-c was a transcriptional factor that bound to an enhancer element in the fatty acid-binding protein, aP2, promoter and conferred its fat-specific expression [6]. The early 1990s was the time that Brown and Goldstein identified sterol regulatory element-binding protein (SREBP)-1 [7], also termed adipocyte differentiation and determination factor (ADD)-1, whose expression was observed to play a role in adipocyte determination by the Spiegelman laboratory [8]. Since this time, several other transcription factors have been found to play an important role in adipocyte differentiation. Section 1.2 focuses on the transcription factors mentioned above and other important transcription factors that are regulated during adipocyte differentiation and are known to contribute to this process. Section 1.3 focuses on target genes that have been shown to be modulated by several of these transcription factors in both differentiating and mature adipocytes.
1.2 Transcriptional Control of Adipogenesis
Studies of the aP2 gene or use of its regulatory sequences have led to significant discoveries in adipocyte biology and metabolic diseases. aP2 is an abundantly expressed adipocyte gene that was first discovered in 1984 [9]. One of the earliest studies on PPAR-c identified it as a transcription factor that bound to an enhancer element in the aP2 promoter and conferred its fat-specific expression [8]. Since its discovery, the aP2 promoter has been used by hundreds of laboratories to construct transgenes to have fat-specific expression. One lesser known fact is that c-Fos was also shown to bind to the aP2 promoter just 124 bp upstream of the transcriptional start site [10]. As a means of introduction, this was the first study to propose that activating protein (AP)-1 proteins were regulators of adipocyte gene expression. 1.2.1 AP-1 Transcription Factors
Members of the AP-1 family of transcription factors are well-known regulators of cellular proliferation and differentiation. AP-1 is a collective term referring to dimeric transcription factors composed of c-Jun, JunB, JunD and c-Fos, FosB, Fra-1, or Fra-2 subunits that bind to a common DNA site – the AP-1-binding site (reviewed in [11]). As indicated above, studies by the Spiegelman laboratory indicated that c-Fos was
1.2 Transcriptional Control of Adipogenesis
involved in the modulation of aP2 expression [10]. Several years later, it was shown that the expression of c-Jun, c-Fos, Jun-B, Fos-B, and Fra-1 was induced immediately after the induction of adipocyte differentiation [12, 13]. Although the role of individual AP-1 family members in adipogenesis has not been elucidated, there is strong evidence to indicate these transcription factors are important in vivo. Transgenic mice were generated that express a dominant-negative protein that prevents the DNA binding of B-ZIP transcription factors of both the C/EBP and Jun families under the control of the adipose-specific aP2 enhancer/promoter. These mice have no white fat tissue throughout life [14]. Collectively, these studies suggest that the induction and expression of AP-1 transcription factors are important in fat cell differentiation. 1.2.2 Signal Transducers and Activators of Transcription
In the last 10 years, several groups have studied the modulation and function of signal transducers and activators of transcription (STAT) proteins during adipogenesis and in mature fat cells. The STAT family of mammalian transcription factors is comprised of seven proteins (STAT-1, -2, -3, -4, -5A, -5B, and -6) that, in response to stimulation of various receptors, mainly those for cytokines, are phosphorylated on tyrosine residues causing their translocation to the nucleus. Each STAT family member shows a distinct pattern of activation by cytokines and upon nuclear translocation can regulate the transcription of particular genes [15]. STATs have been shown to bind distinct DNA sequences and this binding regulates the transcription of specific genes [15, 16]. Since the tissue distribution and function of each STAT is unique, the regulation of tissue-specific genes appears to be a physiological role for these proteins [17]. This hypothesis is supported by numerous reports that demonstrate that specific STATs are activated differently by growth factors and cytokines, and STAT activation can be cell-type dependent. In addition, transgenic knockout experiments have revealed crucial roles for each known mammalian STAT [15] and cell-specific functions for STAT family members have been identified [18]. The first studies on STATexpression in 3T3-L1 cells revealed that STAT-1, -5A, and 5B were highly induced during murine adipogenesis [19]. Similar results were observed during the in vitro differentiation of human preadipocytes [20]. In addition, the ectopic expression of C/EBP-b and -d in nonprecursor cells results in an induction of adipogenesis [21] that is accompanied by an induction in STAT-5A and -5B protein levels [22]. These two STATproteins are also coordinately regulated with both PPAR-c and C/EBP-a in differentiating 3T3-L1 cells under a variety of different conditions [23]. In 3T3-F442A preadipocytes, the ability of growth hormone to modulate adipogenesis was attenuated by STAT-5 antisense oligonucleotides [24]. Also, constitutively active STAT-5 is capable of replacing the requirement for growth hormone in adipogenesis of these cells [25]. Moreover, ectopic expression of STAT-5A has been shown to confer adipogenesis in 3T3-L1 preadipocytes [26] and in two different nonprecursor cell lines [27]. Interestingly, STAT-5B was not capable of conferring adipogenesis in nonprecursor cells [27]. Transgenic deletion of STAT-5A, STAT-5B, or
j5
j 1 Transcriptional Control of Adipogenesis and Fat Cell Gene Expression
6
AP 1 (fos, jun, etc.) STAT 5 phosphorylaon C/EBP and C/EBP KLF15 SREBP 1/ADD1 PPAR C/EBP STAT5A and STAT 5B
Figure 1.1 Induction of transcription factors during adipogenesis.
both STAT-5 genes in mice resulted in significantly reduced fat pad sizes compared to wild-type mice [28]. Also, in primary cultures of adipose tissue from these animals, growth hormone did not stimulate lipolysis as it did in adipocytes from wild-type animals [29], suggesting that some of the effects of growth hormone on fat metabolism are dependent on STAT-5 proteins. It should be noted that the increased expression of STAT-5 proteins is not typically observed until after the induction of C/ EBP-a and PPAR-c (refer to Figure 1.1), yet the activation of STAT-5 proteins in preadipocytes occurs prior to the induction in expression of PPAR-c in 3T3-L1 cells [27]. In fact, both STAT-5 proteins are tyrosine phosphorylated and translocate to the nucleus within 15 min after the induction of adipogenesis of preadipocytes [27, 30]. Coupled with the observations in STAT-5 null mice, which have fat pads one-fifth normal size [28], the data suggest that activation of STAT-5 proteins may be an important driver of adipogenesis both in vitro and in vivo. This hypothesis is also supported by work indicating that one of the PPAR-c promoters can be modulated by STAT-5 [31], suggesting that STAT-5 activation might drive adipogenesis by inducing PPAR-c expression. In summary, work by a variety of laboratories has demonstrated that STAT-5 proteins, particularly STAT-5A, are activated and induced during adipogenesis, and play an important role in adipose tissue development. 1.2.3 Kr€ uppel-Like Factors
Kr€ uppel-like zinc finger transcription factors (KLFs) are known to play diverse roles in cell differentiation and development in mammals. One protein in the KLF family, KLF-15, was shown to be highly induced during the differentiation of 3T3-L1 preadipocytes into adipocytes [32]. Inhibition of KLF-15 function or expression with a dominant-negative mutant or via RNA interference results in an inhibition of adipogenesis in 3T3-L1 cells [32]. These studies also revealed that KLF-15 could confer adipogenesis in nonprecursor cells and result in the induction of PPAR-c expression. Similar to KLF-15, KLF-5 expression is also highly induced during adipocyte differentiation in 3T3-L1 cells and embryonic fibroblasts obtained from heterozygote KLF-5 mice exhibit reduced adipogenesis [33]. Another member of this family, KLF-2, has been shown to be a negative regulator of adipogenesis and has the ability to attenuate PPAR-c expression [34]. KLF-s are not only involved in lipid accumulation, but also appear to play a role in the ability of the adipocyte to
1.2 Transcriptional Control of Adipogenesis
be insulin-sensitive, as indicated by studies showing that KLF-15 is important in the expression of glucose transporter 4 (GLUT4) [35]. 1.2.4 SREBPs
In 1993, studies by the Spiegelman group identified a basic helix–loop–helix transcription factor that was expressed in adipocytes and whose expression was increased during adipogenesis [8]. The protein was called ADD-1. Two months later, this protein was labeled SREBP-1 by the Brown and Goldstein laboratories, who named the transcription factor for its ability to bind sterol-responsive elements within the promoter of the low-density lipoprotein receptor gene [7]. It is now known that there are three SREBP isoforms (SREBP-1a, -1c, and -2) that have been well characterized. SREBP-1a and -1c are transcribed from the same gene, each by a distinct promoter, and the predominant SREBP-1 isoform in liver and adipose tissue is SREBP-1c. SREBP-2 is relatively selective in transcriptionally activating cholesterol biosynthetic genes and SREBP-1c has a greater role in regulating genes associated with fatty acid synthesis (reviewed in [36]). Although there is clear evidence that SREBP is an insulin-modulated transcription factor involved in the regulation of genes associated with cholesterol and lipid metabolism, there are less convincing studies to indicate that SREBPs are critical for adipogenesis. Mice deficient in SREBP-1 do not have a significantly decreased amount of white adipose tissue, but SREBP-2 levels were increased suggesting it might compensate for SREBP-1 in this animal model [37]. These in vivo studies are supported by additional transgenic studies where SREBP-1 deficient mice were crossed with ob/ob (leptin-deficient) mice and it was found that SREBP-1 was not required for the development of obesity [38]. These observations concluded that SREBP-1 regulation of lipogenesis was highly involved in the development of fatty livers, but was not a determinant of obesity in this animal model [38]. However, ectopic expression of a dominant-negative SREBP-1c was shown to attenuate adipocyte differentiation [39]. In addition, overexpression of SREBP-1c enhanced the adipogenic activity of PPAR-c [39] and other studies suggest that SREBP-1c contributes to the generation of PPAR-c ligands [40]. In summary, in vitro studies support a role for SREBP-1 in adipogenesis, whereas in vivo studies indicate that SREBPs are not required for the production or expansion of adipose tissue. 1.2.5 C/EBP
C/EBP transcription factors were the first family of transcription factors shown to play a critical role in the differentiation of fat cells in vitro. Today, we know that transgenic mice lacking both C/EBP-b and C/EBP-d or C/EBP-a alone have defective adipocyte differentiation [41, 42]. Prior to these in vivo observations, the cascade of induction of these three C/EBP family members was revealed by McKnight and collaborators who showed that C/EBP-b and -d were induced immediately after the
j7
j 1 Transcriptional Control of Adipogenesis and Fat Cell Gene Expression
8
induction of differentiation, whereas C/EBP-a expression did not occur until 4–5 days after the initiation of differentiation [43]. This group also demonstrated that C/ EBP-b and -d were responsible for inducing C/EBPa expression [44]. Ectopic expression studies conducted by several laboratories demonstrated the adipogenic capabilities of C/EBP-a or -b alone, or in the presence of C/EBP-d [21, 44–46]. Today, C/EBP-a and PPAR-c are considered the two primary transcription factors that mediate adipogenesis. However, cells lacking C/EBP-a are capable of adipogenesis, but are not insulin-sensitive [47, 48]. There is also evidence to indicate that C/EBPs may play a role in the induction of PPAR-c ligands [49]. In summary, both in vitro and in vivo studies indicate a substantial role for C/EBP-b, -d, and -a in adipogenesis. Although C/EBP-a may not be required for lipid accumulation, this transcription factor clearly plays a role in conferring insulin sensitivity in adipocytes. 1.2.6 PPAR-c
Although a number of transcription factors, including those mentioned above, have been shown to have profound effects on fat cell differentiation and the expression of adipocyte genes, only one adipocyte transcription factor has been shown to be necessary foradipogenesis.PPAR-c isa memberofthenuclearhormonereceptorsuperfamilythat is required for the development of adipocytes, and deletion of PPAR-c in mice results in placentaldysfunctionandembryonic lethality [50,51]. Asmentioned above,PPAR-c was originally identified as a transcription factor induced during differentiation that bound an enhancer element within the aP2 promoter [6]. Since that time, there have been multiple studies on the role of PPAR-c in adipocytes. A remarkable finding in 1995 was that the insulin-sensitizing drugs thiazolidinediones were ligands for PPAR-c [52]. These were some of the first molecular studies to indicate the importance of adipose tissue in insulin resistance. Many investigators were surprised to learn that activating a transcription factor whose expression was highly enriched in fat cells could contribute to whole-animal insulin sensitivity. It is now known that adipocytes secrete several hormones that can affect the activity of other tissues; however, the studies of PPAR-c have revealed that modulation of this transcription factor can contribute to systemic insulin resistance. Although the PPAR-c null mice are embryonic lethal [51], transgenic mice lacking PPAR-c specifically in adipose tissue exhibit greatly reduced sized fat pads, and insulin resistance in fat and liver [53]. However, PPAR-c heterozygote mice have enhanced insulin sensitivity [54]. Together, these studies suggest the amount of PPAR-c in adipose tissue is physiologically relevant. In the last several years, several studies have examinedpathways that are involved inregulating the levels of PPAR-c. In particular, the ubiquitin–proteasome system has emerged as an important regulator of PPAR-c proteins [55, 56]. In addition, a role for the ubiquitin-like protein SUMO (small ubiquitin-like modifier) in regulating PPAR-c has been demonstrated by several groups [57–60]. The phosphorylation of PPAR-c by mitogen-activated protein kinases is also an important modulator of the activity of this transcription factor (reviewed in [61]). A very recent study confirmed that PPAR-c knockdown prevented adipocyte differentiation, but also suggested that PPAR-c was not required for maintenance of the
1.3 Identification of Adipocyte Transcription Factor Target Genes
differentiated state after the cells had undergone adipogenesis [62]. These observations are supported many anecdotal observations that indicate that PPAR-c is decreased as adipocytesageinvitro.Inaddition,theincreaseoflifespanviacaloricrestrictionresultsin the induction of sirtuin (SIRT)-1 – a transcriptional modulator with deacetylase activity that represses PPAR-c activity in vivo [63]. This study also demonstrated that the repression of PPAR- c by SIRT1 was evident in 3T3-L1 adipocytes. Collectively, studies bynumerous laboratories demonstratethe adipogenic capabilities ofPPAR-c. However, theroleofthistranscriptionfactorinmatureadipocytesisnotwellunderstoodandrecent studies suggest that this transcription factor is not required for maintenance of the adipocyte following adipogenesis [62]. Nonetheless, PPAR-c expression and activity is controlled at multiple levels, including alternative promoter usage, tissue-limited expression, phosphorylation, acetylation, ubiquitylation, and SUMOylation. The multiple levels of regulation of this transcription factor suggest that controlling the amount and activity of PPAR-c is important. The role of PPAR-c in the development and treatment of diabetes is well established (reviewed in [64]), and the importance of PPARc in humans is indicated by several loss-of-function mutations in the PPAR-c gene that cause lipodystrophy and diabetes in humans ([65–67], reviewed in [68]). In addition to the transcription factors described above that promote adipogenesis, there are several other transcription factors that have been shown to have positive or negative effects on adipocyte differentiation (reviewed in [4]). Section 1.3 reveals specific target genes that have been identified as targets of the positive adipogenic transcriptional activators described above. The identification and characterization of these target genes has provided critical information in understanding the role of these proteins in both differentiating and mature fat cells.
1.3 Identification of Adipocyte Transcription Factor Target Genes
As stated in Section 1.2, adipogenesis occurs as a result of a transcriptional cascade that involves the tightly regulated induction of key transcription factors, including C/EBP-b, C/EBP-d, C/EBP-a, SREBP-1c, STAT-5, and PPAR-c. These adipogenic factors, in turn, induce the expression of various adipocyte genes that are important in conferring lipid accumulation, insulin sensitivity, and endocrine properties to mature adipocytes. In addition, many of these adipogenic factors possess the ability to regulate one anothers gene expression. These interactions add complexity to the pathways that regulated lipid and glucose metabolism. Hence, it is critical to identify the target genes of these adipogenic transcription factors in order to understand adipocyte gene expression and fat cell function. 1.3.1 C/EBP Target Genes
The three isoforms of the C/EBP family are differentially regulated and expressed at specific times in accordance with each proteins regulatory role in adipogenesis.
j9
j 1 Transcriptional Control of Adipogenesis and Fat Cell Gene Expression
10
C/EBP-b and -d are expressed very early in adipocyte differentiation in 3T3-L1 adipocytes, in contrast to C/EBP-a, whose expression is limited to the late phase of differentiation [43]. Both C/EBP-b and -d play important roles in the induction of PPAR-c gene expression [21], as functional C/EBP regulatory elements have been identified in the promoter of the PPAR-c gene [69]. In addition, investigators have shown that these C/EBP regulatory elements are also in the promoter of the C/EBP-a gene [70], supporting a role of C/EBP-b and -d in regulating the expression of C/EBPa [43, 44]. Hence, C/EBP-b and -d can modulate the transcriptional regulation of other primary players in adipogenesis (i.e., PPAR-c and C/EBP-a). C/EBP-b has also been shown to regulate other fat-specific genes, as the binding of C/EBP-b to C/EBP response elements in the adiponectin promoter is necessary for its transcription [71]. C/EBP-a plays a more diverse role in adipocyte gene expression, as it regulates more target genes that are influential not only in adipogenic pathways, but also genes that are important in insulin signaling and the production of endocrine hormones. C/EBP-a has the ability to affect the expression of other transcription factors that are necessary for adipogenesis. For example, C/EBP-a can directly modulate the transcription of PPAR-c through C/EBP response elements within the PPAR-c2 promoter [69, 72]. C/EBP-a can also transactivate the promoters of both aP2 [73, 74] and stearoyl-CoA desaturase (SCD) genes [73] during 3T3-L1 differentiation via specific sequence elements in the promoter. In addition, C/EBP-a can transactivate the insulin-responsive GLUT4 promoter in vitro [75] and the insulin receptor gene in vivo [76]. These studies clearly demonstrate the importance of this transcription factor in affecting glucose metabolism and insulin signaling. Adipocytes also have important endocrine functions, including the production and secretion of leptin and adiponectin. One study has demonstrated that C/EBP-a is a transcriptional activator of the leptin promoter via a functional C/EBP-binding site [77]. Similar to C/EBP-b, C/EBP-a can activate transcription of the murine adiponectin promoter via C/EBPbinding sites [78] and can modulate adiponectin expression in mature human adipocytes via interactions with C/EBP response elements in an intronic enhancer [79]. In summary, these studies indicate C/EBP-a can modulate the expression of important adipocyte transcription factors, key endocrine products of adipocytes, and genes associated with lipid and glucose metabolism. 1.3.2 SREBP-1 Target Genes
The identification of ADD-1 [8], later termed SREBP-1 due to its importance in cholesterol metabolism [7], is an important modulator of adipocyte gene expression. SREBP-1/ADD-1 appears to be responsible for the differentiation-dependent induction of fatty acid synthase (FAS) during adipogenesis [39]. In addition, one study has shown that C/EBP-b is under the direct control of SREBP-1c in 3T3-L1 adipocytes. In this study, SREBP-1c was shown to activate transcription via SREBP-binding sites in the C/EBP-b promoter [80]. Adiponectin gene expression has also been shown to be directly regulated by SREBP-1c, which binds sterol regulatory elements in the adiponectin promoter in mouse adipocytes in vitro and in vivo [81]. These data
1.3 Identification of Adipocyte Transcription Factor Target Genes
support SREBP-1cs regulatory involvement in mature adipocytes by mediating the expression of several adipogenic genes. Since SREBP-1 null mice are not defective in adipogenesis [37], the primary function of this transcription factor in adipocytes appears to be the regulation of genes associated with lipid accumulation and the endocrine properties of adipocytes. 1.3.3 PPAR-c Target Genes
PPAR-c, which is considered the master regulator of adipogenesis, exerts its effects directly in adipocytes, but is also known to be important in other cell types. PPAR-c can modulate the expression of a variety of genes that differ in their metabolic function. The first PPAR-c target gene identified was the aP2 gene. The aP2 gene contains a functional peroxisome proliferator response element (PPRE) within its promoter that plays a central role in its induction during adipogenesis [6]. Several studies also support a role for PPAR-c in the induction of other adipocyte transcription factors, including C/EBP-a and STAT-5A. It is known that PPAR-c and C/EBP-a can regulate each others expression during adipogenesis [48], and the crossregulation of PPAR-c and C/EBP-a is required for efficient adipogenesis [82]. Recently, PPAR-c was also found to regulate expression of STAT-5A through several identified PPREs [83]. Taken together, these studies demonstrate cross-talk between three transcription factors that are highly induced during adipogenesis and are known to play a role in adipose tissue development in vivo [28, 42, 50]. Through its transcriptional regulation of various genes, PPAR-c is functional in many biological processes, including lipid metabolism. PPAR-c regulates genes involved in lipoprotein metabolism, including lipoprotein lipase (LPL) whose expression is modulated in adipocytes via a PPRE within its promoter [84]. In addition, PPAR-c can directly modulate the transcription of hormone-sensitive lipase (HSL) [85], which is an important contributor to lipolysis. The malic enzyme, whose product is involved in lipogenesis, is a PPAR-c target gene [86]. The expression of acyl-CoA synthetase, which converts fatty acids to acyl-CoA for subsequent b-oxidation, is induced in differentiated adipocytes [87] and its expression can be modulated by a PPRE [88]. A functional PPRE in the murine fatty acid transport protein (FATP) gene is modulated by PPAR-c in 3T3-L1 adipocytes [89]. Gene expression of another fatty acid transporter gene, fatty acid translocase (FAT) [90], is induced by PPAR-c in adipose tissue in vivo [91]. The expression of SCD, an enzyme involved in fatty acid biosynthesis, is modulated by a PPRE promoter element [92] and may be regulated by PPAR-c in adipose tissue in vivo [90]. Two lipid droplet-associating proteins are also known PPAR-c target genes in adipocytes. A functional PPRE has been characterized in the murine perilipin gene promoter [93] and in the lipid droplet-associating protein, S3-12 [94]. Hence, PPAR-c regulates genes that play a role in lipogenesis, lipolysis, and lipid droplet formation. PPAR-c can also directly control genes whose expression contributes to glucose homeostasis and insulin signaling. The expression of phosphoenolpyruvate
j11
j 1 Transcriptional Control of Adipogenesis and Fat Cell Gene Expression
12
carboxykinase (PEPCK), a key enzyme in gluconeogenesis, is modulated by a PPAR-c-binding site in its promoter [95]. The insulin-stimulated glucose transporter, GLUT4, is upregulated by PPAR-c activation in rat adipose tissue in vivo [90] and in NIH-3T3 cells [96]. Rev-Erba (NR1D1) is another nuclear receptor whose expression is also induced during adipocyte differentiation [97]. Rev-Erba expression is induced by PPAR-c activation in rat adipose tissues in vivo as well as in 3T3-L1 adipocytes in vitro and this transcriptional induction occurs via a PPAR response element in the Rev-Erba promoter [98]. Therefore, Rev-Erba is a target gene of PPAR-c in adipose tissue, and is another member of the nuclear receptor superfamily that is modulated during adipogenesis and may contribute to the regulation of adipocyte gene expression. Although many studies on PPAR-c focus on the identification of target genes in white adipocytes, studies in brown adipocytes have shown that the uncoupling protein (UCP)-1 gene contains a PPRE that is bound and activated by PPAR-c [99]. It has been known for several years that PPAR-c ligands can increase the expression and plasma concentrations of adiponectin [100], and more recent study have observed that PPAR-c induces adiponectin in adipocytes via a PPRE in the human adiponectin promoter [101]. All of these results indicate that PPAR-c is not only required for regulating transcription factors that drive adipogenesis, but this nuclear receptor is important for modulating the adiponectin gene, which confers an important endocrine function to adipocytes. Overall, the identification of PPAR-c target genes in adipocytes has revealed that this nuclear receptor regulates a variety of genes that are involved in adipogenesis, insulin signaling, glucose homeostasis, and lipid metabolism. 1.3.4 STAT-5 Target Genes
It is widely accepted that STATproteins have cell-specific functions. Studies on STAT5 proteins have revealed their importance in adipogenesis in vitro and in vivo [27, 28]. Recent studies have focused on the identification of STAT-5 target genes in adipocytes. The promoter for acyl-CoA oxidase, the rate-limiting enzyme in peroxisomal fatty acid b-oxidation, contains a STAT-5-binding site that modulates its gene expression in fat cells [102]. Another study indicates that growth hormone also exerts stimulatory effects on adipogenesis through STAT-5A and -5B by enhancing the transcriptional activity of C/EBP-b/d and PPAR-c [31]. Transfection studies have demonstrated that aP2 promoter activity can be activated by STAT-5 [103]. Yet other studies have shown that STAT-5 mediates the inhibition of aP2 expression in rat primary preadipocytes [104]. This was the first study to suggest that STAT-5 proteins could act as transcriptional repressors. This observation has been supported by another study that revealed STAT-5A could act as a transcriptional repressor in adipocytes. A STAT-5A-binding site in the murine FAS promoter has been shown to mediate the repression of FAS transcription that occurs with prolactin treatment [105]. In addition to modulation of genes associated with lipid metabolism, STAT-5 can also modulate a gene associated with glucose metabolism. The gene for
1.3 Identification of Adipocyte Transcription Factor Target Genes
pyruvate dehydrogenase kinase (PDK)-4, a known regulator of glycolysis, is highly induced in adipocytes by growth hormone or prolactin (PRL) in a STAT-5-dependent manner [106]. Under these conditions, the induction of PDK-4 is accompanied by insulin resistance. It is well known that PRL and growth hormone are important modulators of lipid metabolism, and are also potent inducers of STAT-5 in adipocytes [103, 107]. Hence, many of the metabolic actions of these hormones could be mediated by STAT-5s direct modulation of target genes. Unfortunately, relatively few STAT-5 target genes have been identified in adipocytes. Nonetheless, we hypothesize that several other STAT-5A target genes will be identified that play a role in lipid or glucose metabolism. 1.3.5 Summary
It is clear that there are several transcription factors that are highly expressed during adipogenesis and are critical not only for lipid accumulation, but to confer insulin sensitivity and endocrine properties to mature adipocytes. The primary function of these proteins is to directly modulate target genes that contribute to the adipocyte phenotype (reviewed in Table 1.1). Although much emphasis has been placed on C/EBP-a and PPAR-c, there are clearly several other transcription factors that are important, including STAT-5 proteins and KLFs. However, very few target genes for these transcription factors have been identified. Interestingly, it is still not known which transcription factor(s) confer the adipocyte specific expression leptin. In the future, the identification of new or known adipocyte transcription factors and their target genes will be essential in enhancing our knowledge of adipogenesis and indicating what transcriptional modulators are required for the maintenance of lipid laden, insulin-sensitive, hormone-secreting fat cells.
Table 1.1 Target genes of key adipocyte transcription factors.
Adipogenic transcription factors
Characterized target genes
C/EBP-b C/EBP-d C/EBP-a
PPAR-c [21, 69], C/EBP-a [43, 70], adiponectin [71] PPAR-c [21, 69], C/EBP-a [43, 70] PPAR-c [69, 72], aP2 [73, 74], SCD [73], GLUT4 [75], insulin receptor [76], leptin [77], adiponectin [78, 79] FAS [39], C/EBP-b [80], adiponectin [81] aP2 [6], C/EBP-a [48], STAT-5A [83], LPL [84], HSL [85], malic enzyme [86], acyl-CoA synthetase [88], FATP [89], FAT [91], SCD [90, 92], perilipin [93], S3-12 [94], PEPCK [95], GLUT4 [90–96], Rev-Erba [97, 98], UCP-1 [99], adiponectin [100, 101] acyl-CoA oxidase [102], C/EBP-b/d [31], PPAR-c [31], aP2 [103, 104], FAS [105], PDK [106]
SREBP-1 PPAR-c
STAT-5
j13
j 1 Transcriptional Control of Adipogenesis and Fat Cell Gene Expression
14
References 1 Green, H. and Kehinde, O. (1975) An
2
3
4
5
6
7
8
9
10
established preadipose cell line and its differentiation in culture. II. Factors affecting the adipose conversion. Cell, 5, 19–27. Green, H. and Kehinde, O. (1976) Spontaneous heritable changes leading to increased adipose conversion in 3T3 cells. Cell, 7, 105–113. McKnight, S.L., Lane, M.D., and Gluecksohn-Waelsch, S. (1989) Is CCAAT/enhancer-binding protein a central regulator of energy metabolism? Genes Dev., 3, 2021–2024. Farmer, S.R. (2006) Transcriptional control of adipocyte formation. Cell Metab., 4, 263–273. Chawla, A., Schwarz, E.J., Dimaculangan, D.D., and Lazar, M.A. (1994) Peroxisome proliferator-activated receptor (PPAR) gamma: adiposepredominant expression and induction early in adipocyte differentiation. Endocrinology, 135, 798–800. Tontonoz, P., Hu, E., Graves, R.A., Budavari, A.I., and Spiegelman, B.M. (1994) mPPAR gamma 2: tissue-specific regulator of an adipocyte enhancer. Genes Dev., 8, 1224–1234. Yokoyama, C., Wang, X., Briggs, M.R., Admon, A., Wu, J., Hua, X., Goldstein, J.L., and Brown, M.S. (1993) SREBP-1, a basic-helix-loop-helix-leucine zipper protein that controls transcription of the low density lipoprotein receptor gene. Cell, 75, 187–197. Tontonoz, P., Kim, J.B., Graves, R.A., and Spiegelman, B.M. (1993) ADD1: a novel helix-loop-helix transcription factor associated with adipocyte determination and differentiation. Mol. Cell. Biol., 13, 4753–4759. Bernlohr, D.A., Angus, C.W., Lane, M.D., Bolanowski, M.A., and Kelly, T.J. Jr. (1984) Expression of specific mRNAs during adipose differentiation: identification of an mRNA encoding a homologue of myelin P2 protein. Proc. Natl. Acad. Sci. USA, 81, 5468–5472. Distel, R.J., Ro, H.S., Rosen, B.S., Groves, D.L., and Spiegelman, B.M. (1987)
11
12
13
14
15 16
17
18
19
20
Nucleoprotein complexes that regulate gene expression in adipocyte differentiation: direct participation of cfos. Cell, 49, 835–844. Karin, M., Liu, Z., and Zandi, E. (1997) AP-1 function and regulation. Curr. Opin. Cell Biol., 9, 240–246. Stephens, J.M., Butts, M.D., and Pekala, P.H. (1992) Regulation of transcription factor mRNA accumulation during 3T3L1 preadipocyte differentiation by tumour necrosis factor-alpha. J. Mol. Endocrinol., 9, 61–72. Stephens, J.M., Butts, M., Stone, R., Pekala, P.H., and Bernlohr, D.A. (1993) Regulation of transcription factor mRNA accumulation during 3T3-L1 preadipocyte differentiation by antagonists of adipogenesis. Mol. Cell. Biochem., 123, 63–71. Moitra, J., Mason, M.M., Olive, M., Krylov, D., Gavrilova, O., MarcusSamuels, B., Feigenbaum, L., Lee, E., Aoyama, T., Eckhaus, M., Reitman, M.L., and Vinson, C. (1998) Life without white fat: a transgenic mouse. Genes Dev., 12, 3168–3181. Darnell, J.E. Jr. (1997) STATs and gene regulation. Science, 277, 1630–1635. Pellegrini, S. and Dusanter-Fourt, I. (1997) The structure, regulation and function of the Janus kinases (JAKs) and the signal transducers and activators of transcription (STATs). Eur. J. Biochem., 248, 615–633. Schindler, C. and Darnell, J.E. Jr. (1995) Transcriptional responses to polypeptide ligands: the JAK–STAT pathway. Annu. Rev. Biochem., 64, 621–651. Schindler, C.W. (2002) Series introduction. JAK–STAT signaling in human disease. J. Clin. Invest., 109, 1133–1137. Stephens, J.M., Morrison, R.F., and Pilch, P.F. (1996) The expression and regulation of STATs during 3T3-L1 adipocyte differentiation. J. Biol. Chem., 271, 10441–10444. Harp, J.B., Franklin, D., Vanderpuije, A.A., and Gimble, J.M. (2001) Differential expression of signal
References
21
22
23
24
25
26
27
transducers and activators of transcription during human adipogenesis. Biochem. Biophys. Res. Commun., 281, 907–912. Wu, Z., Bucher, N.L., and Farmer, S.R. (1996) Induction of peroxisome proliferator-activated receptor gamma during the conversion of 3T3 fibroblasts into adipocytes is mediated by C/ EBPbeta, C/EBPdelta, and glucocorticoids. Mol. Cell. Biol., 16, 4128–4136. Stephens, J.M., Morrison, R.F., Wu, Z., and Farmer, S.R. (1999) PPARgamma ligand-dependent induction of STAT1, STAT5A, and STAT5B during adipogenesis. Biochem. Biophys. Res. Commun., 262, 216–222. Stewart, W.C., Morrison, R.F., Young, S.L., and Stephens, J.M. (1999) Regulation of signal transducers and activators of transcription (STATs) by effectors of adipogenesis: coordinate regulation of STATs 1, 5A, and 5B with peroxisome proliferator-activated receptor-gamma and C/AAAT enhancer binding protein-alpha. Biochim. Biophys. Acta, 1452, 188–196. Yarwood, S.J., Sale, E.M., Sale, G.J., Houslay, M.D., Kilgour, E., and Anderson, N.G. (1999) Growth hormonedependent differentiation of 3T3-F442A preadipocytes requires Janus kinase/ signal transducer and activator of transcription but not mitogen-activated protein kinase or p70 S6 kinase signaling. J. Biol. Chem., 274, 8662–8668. Shang, C.A. and Waters, M.J. (2003) Constitutively active signal transducer and activator of transcription 5 can replace the requirement for growth hormone in adipogenesis of 3T3-F442A preadipocytes. Mol. Endocrinol., 17, 2494–2508. Nanbu-Wakao, R., Morikawa, Y., Matsumura, I., Masuho, Y., Muramatsu, M.A., Senba, E., and Wakao, H. (2002) Stimulation of 3T3-L1 adipogenesis by signal transducer and activator of transcription 5. Mol. Endocrinol., 16, 1565–1576. Floyd, Z.E. and Stephens, J.M. (2003) STAT5A promotes adipogenesis in
28
29
30
31
32
33
34
nonprecursor cells and associates with the glucocorticoid receptor during adipocyte differentiation. Diabetes, 52, 308–314. Teglund, S., McKay, C., Schuetz, E., van Deursen, J.M., Stravopodis, D., Wang, D., Brown, M., Bodner, S., Grosveld, G., and Ihle, J.N. (1998) Stat5a and Stat5b proteins have essential and nonessential, or redundant, roles in cytokine responses. Cell, 93, 841–850. Fain, J.N., Ihle, J.H., and Bahouth, S.W. (1999) Stimulation of lipolysis but not of leptin release by growth hormone is abolished in adipose tissue from Stat5a and b knockout mice. Biochem. Biophys. Res. Commun., 263, 201–205. Baugh, J.E. Jr., Floyd, Z.E., and Stephens, J.M. (2007) The modulation of STAT5A/ GR complexes during fat cell differentiation and in mature adipocytes. Obesity, 15, 583–590. Kawai, M., Namba, N., Mushiake, S., Etani, Y., Nishimura, R., Makishima, M., and Ozono, K. (2007) Growth hormone stimulates adipogenesis of 3T3-L1 cells through activation of the Stat5A/5BPPARgamma pathway. J. Mol. Endocrinol., 38, 19–34. Mori, T., Sakaue, H., Iguchi, H., Gomi, H., Okada, Y., Takashima, Y., Nakamura, K., Nakamura, T., Yamauchi, T., Kubota, N., Kadowaki, T., Matsuki, Y., Ogawa, W., Hiramatsu, R., and Kasuga, M. (2005) Role of Kruppel-like factor 15 (KLF15) in transcriptional regulation of adipogenesis. J. Biol. Chem., 280, 12867–12875. Oishi, Y., Manabe, I., Tobe, K., Tsushima, K., Shindo, T., Fujiu, K., Nishimura, G., Maemura, K., Yamauchi, T., Kubota, N., Suzuki, R., Kitamura, T., Akira, S., Kadowaki, T., and Nagai, R. (2005) Kruppel-like transcription factor KLF5 is a key regulator of adipocyte differentiation. Cell Metab., 1, 27–39. Banerjee, S.S., Feinberg, M.W., Watanabe, M., Gray, S., Haspel, R.L., Denkinger, D.J., Kawahara, R., Hauner, H., and Jain, M.K. (2003) The Kruppellike factor KLF2 inhibits peroxisome proliferator-activated receptor-gamma
j15
j 1 Transcriptional Control of Adipogenesis and Fat Cell Gene Expression
16
35
36
37
38
39
40
41
42
expression and adipogenesis. J. Biol. Chem., 278, 2581–2584. Gray, S., Feinberg, M.W., Hull, S., Kuo, C.T., Watanabe, M., Sen-Banerjee, S., DePina, A., Haspel, R., and Jain, M.K. (2002) The Kruppel-like factor KLF15 regulates the insulin-sensitive glucose transporter GLUT4. J. Biol. Chem., 277, 34322–34328. Eberle, D., Hegarty, B., Bossard, P., Ferre, P., and Foufelle, F. (2004) SREBP transcription factors: master regulators of lipid homeostasis. Biochimie, 86, 839–848. Shimano, H., Shimomura, I., Hammer, R.E., Herz, J., Goldstein, J.L., Brown, M.S., and Horton, J.D. (1997) Elevated levels of SREBP-2 and cholesterol synthesis in livers of mice homozygous for a targeted disruption of the SREBP-1 gene. J. Clin. Invest., 100, 2115–2124. Yahagi, N., Shimano, H., Hasty, A.H., Matsuzaka, T., Ide, T., Yoshikawa, T., Amemiya-Kudo, M., Tomita, S., Okazaki, H., Tamura, Y., Iizuka, Y., Ohashi, K., Osuga, J., Harada, K., Gotoda, T., Nagai, R., Ishibashi, S., and Yamada, N. (2002) Absence of sterol regulatory elementbinding protein-1 (SREBP-1) ameliorates fatty livers but not obesity or insulin resistance in Lepob/Lepob mice. J. Biol. Chem., 277, 19353–19357. Kim, J.B. and Spiegelman, B.M. (1996) ADD1/SREBP1 promotes adipocyte differentiation and gene expression linked to fatty acid metabolism. Genes Dev., 10, 1096–1107. Kim, J.B., Wright, H.M., Wright, M., and Spiegelman, B.M. (1998) ADD1/SREBP1 activates PPARgamma through the production of endogenous ligand. Proc. Natl. Acad. Sci. USA, 95, 4333–4337. Tanaka, T., Yoshida, N., Kishimoto, T., and Akira, S. (1997) Defective adipocyte differentiation in mice lacking the C/ EBPbeta and/or C/EBPdelta gene. EMBO J., 16, 7432–7443. Wang, N.D., Finegold, M.J., Bradley, A., Ou, C.N., Abdelsayed, S.V., Wilde, M.D., Taylor, L.R., Wilson, D.R., and Darlington, G.J. (1995) Impaired energy homeostasis in C/EBP alpha knockout mice. Science, 269, 1108–1112.
43 Cao, Z., Umek, R.M., and McKnight, S.L.
44
45
46
47
48
49
50
51
(1991) Regulated expression of three C/EBP isoforms during adipose conversion of 3T3-L1 cells. Genes Dev., 5, 1538–1552. Yeh, W.C., Cao, Z., Classon, M., and McKnight, S.L. (1995) Cascade regulation of terminal adipocyte differentiation by three members of the C/EBP family of leucine zipper proteins. Genes Dev., 9, 168–181. Wu, Z., Xie, Y., Bucher, N.L., and Farmer, S.R. (1995) Conditional ectopic expression of C/EBP beta in NIH-3T3 cells induces PPAR gamma and stimulates adipogenesis. Genes Dev., 9, 2350–2363. Lin, F.T. and Lane, M.D. (1994) CCAAT/ enhancer binding protein alpha is sufficient to initiate the 3T3-L1 adipocyte differentiation program. Proc. Natl. Acad. Sci. USA, 91, 8757–8761. el Jack, A.K., Hamm, J.K., Pilch, P.F., and Farmer, S.R. (1999) Reconstitution of insulin-sensitive glucose transport in fibroblasts requires expression of both PPARgamma and C/EBPalpha. J. Biol. Chem., 274, 7946–7951. Wu, Z., Rosen, E.D., Brun, R., Hauser, S., Adelmant, G., Troy, A.E., McKeon, C., Darlington, G.J., and Spiegelman, B.M. (1999) Cross-regulation of C/EBP alpha and PPAR gamma controls the transcriptional pathway of adipogenesis and insulin sensitivity. Mol. Cell, 3, 151–158. Hamm, J.K., Park, B.H., and Farmer, S.R. (2001) A role for C/EBPbeta in regulating peroxisome proliferator-activated receptor gamma activity during adipogenesis in 3T3-L1 preadipocytes. J. Biol. Chem., 276, 18464–18471. Rosen, E.D., Sarraf, P., Troy, A.E., Bradwin, G., Moore, K., Milstone, D.S., Spiegelman, B.M., and Mortensen, R.M. (1999) PPAR gamma is required for the differentiation of adipose tissue in vivo and in vitro. Mol. Cell, 4, 611–617. Barak, Y., Nelson, M.C., Ong, E.S., Jones, Y.Z., Ruiz-Lozano, P., Chien, K.R., Koder, A., and Evans, R.M. (1999) PPAR gamma is required for placental, cardiac, and adipose tissue development. Mol. Cell, 4, 585–595.
References 52 Lehmann, J.M., Moore, L.B., Smith-
53
54
55
56
57
58
59
Oliver, T.A., Wilkison, W.O., Willson, T.M., and Kliewer, S.A. (1995) An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma). J. Biol. Chem., 270, 12953–12956. He, W., Barak, Y., Hevener, A., Olson, P., Liao, D., Le, J., Nelson, M., Ong, E., Olefsky, J.M., and Evans, R.M. (2003) Adipose-specific peroxisome proliferatoractivated receptor gamma knockout causes insulin resistance in fat and liver but not in muscle. Proc. Natl. Acad. Sci. USA, 100, 15712–15717. Miles, P.D., Barak, Y., He, W., Evans, R.M., and Olefsky, J.M. (2000) Improved insulin-sensitivity in mice heterozygous for PPAR-gamma deficiency. J. Clin. Invest., 105, 287–292. Hauser, S., Adelmant, G., Sarraf, P., Wright, H.M., Mueller, E., and Spiegelman, B.M. (2000) Degradation of the peroxisome proliferator-activated receptor gamma is linked to liganddependent activation. J. Biol. Chem., 275, 18527–18533. Floyd, Z.E. and Stephens, J.M. (2002) Interferon-gamma-mediated activation and ubiquitin-proteasome-dependent degradation of PPARgamma in adipocytes. J. Biol. Chem., 277, 4062–4068. Floyd, Z.E. and Stephens, J.M. (2004) Control of peroxisome proliferatoractivated receptor gamma2 stability and activity by SUMOylation. Obes. Res., 12, 921–928. Ohshima, T., Koga, H., and Shimotohno, K. (2004) Transcriptional activity of peroxisome proliferator-activated receptor gamma is modulated by SUMO1 modification. J. Biol. Chem., 279, 29551–29557. Yamashita, D., Yamaguchi, T., Shimizu, M., Nakata, N., Hirose, F., and Osumi, T. (2004) The transactivating function of peroxisome proliferator-activated receptor gamma is negatively regulated by SUMO conjugation in the aminoterminal domain. Genes Cells, 9, 1017–1029.
60 Pascual, G., Fong, A.L., Ogawa, S.,
61
62
63
64
65
66
67
Gamliel, A., Li, A.C., Perissi, V., Rose, D.W., Willson, T.M., Rosenfeld, M.G., and Glass, C.K. (2005) A SUMOylationdependent pathway mediates transrepression of inflammatory response genes by PPAR-gamma. Nature, 437, 759–763. Burns, K.A. and Vanden Heuvel, J.P. (2007) Modulation of PPAR activity via phosphorylation. Biochim. Biophys. Acta, 1771, 952–960. Liao, W., Nguyen, M.T., Yoshizaki, T., Favelyukis, S., Patsouris, D., Imamura, T., Verma, I.M., and Olefsky, J.M. (2007) Suppression of PPARc attenuates insulin-stimulated glucose uptake by affecting both GLUT1 and GLUT4 in 3T3-L1 adipocytes. Am. J. Physiol. Endocrinol. Metab., 293, E219–E227. Picard, F., Kurtev, M., Chung, N., ToparkNgarm, A., Senawong, T., Machado, D.O., Leid, M., McBurney, M.W., and Guarente, L. (2004) Sirt1 promotes fat mobilization in white adipocytes by repressing PPAR-gamma. Nature, 429, 771–776. Leff, T., Mathews, S.T., and Camp, H.S. (2004) Review: peroxisome proliferatoractivated receptor-gamma and its role in the development and treatment of diabetes. Exp. Diabesity Res., 5, 99–109. Monajemi, H., Zhang, L., Li, G., Jeninga, E.H., Cao, H., Maas, M., Brouwer, C.B., Kalkhoven, E., Stroes, E., Hegele, R.A., and Leff, T. (2007) Familial partial lipodystrophy phenotype resulting from a single-base mutation in deoxyribonucleic acid-binding domain of peroxisome proliferator-activated receptor-gamma. J. Clin. Endocrinol. Metab., 92, 1606–1612. Doney, A.S., Fischer, B., Leese, G., Morris, A.D., and Palmer, C.N. (2004) Cardiovascular risk in type 2 diabetes is associated with variation at the PPARG locus: a Go-DARTS study. Arterioscler. Thromb. Vasc. Biol., 24, 2403–2407. Barroso, I., Gurnell, M., Crowley, V.E., Agostini, M., Schwabe, J.W., Soos, M.A., Maslen, G.L., Williams, T.D., Lewis, H., Schafer, A.J., Chatterjee, V.K., and ORahilly, S. (1999) Dominant negative
j17
j 1 Transcriptional Control of Adipogenesis and Fat Cell Gene Expression
18
68
69
70
71
72
73
74
mutations in human PPARgamma associated with severe insulin resistance, diabetes mellitus and hypertension. Nature, 402, 880–883. Semple, R.K., Chatterjee, V.K., and ORahilly, S. (2006) PPAR gamma and human metabolic disease. J. Clin. Invest., 116, 581–589. Clarke, S.L., Robinson, C.E., and Gimble, J.M. (1997) CAAT/enhancer binding proteins directly modulate transcription from the peroxisome proliferatoractivated receptor gamma 2 promoter. Biochem. Biophys. Res. Commun., 240, 99–103. Christy, R.J., Kaestner, K.H., Geiman, D.E., and Lane, M.D. (1991) CCAAT/ enhancer binding protein gene promoter: binding of nuclear factors during differentiation of 3T3-L1 preadipocytes. Proc. Natl. Acad. Sci. USA, 88, 2593–2597. Kita, A., Yamasaki, H., Kuwahara, H., Moriuchi, A., Fukushima, K., Kobayashi, M., Fukushima, T., Takahashi, R., Abiru, N., Uotani, S., Kawasaki, E., and Eguchi, K. (2005) Identification of the promoter region required for human adiponectin gene transcription: association with CCAAT/enhancer binding protein-beta and tumor necrosis factor-alpha. Biochem. Biophys. Res. Commun., 331, 484–490. Elberg, G., Gimble, J.M., and Tsai, S.Y. (2000) Modulation of the murine peroxisome proliferator-activated receptor gamma 2 promoter activity by CCAAT/enhancer-binding proteins. J. Biol. Chem., 275, 27815–27822. Christy, R.J., Yang, V.W., Ntambi, J.M., Geiman, D.E., Landschulz, W.H., Friedman, A.D., Nakabeppu, Y., Kelly, T.J., and Lane, M.D. (1989) Differentiation-induced gene expression in 3T3-L1 preadipocytes: CCAAT/ enhancer binding protein interacts with and activates the promoters of two adipocyte-specific genes. Genes Dev., 3, 1323–1335. Herrera, R., Ro, H.S., Robinson, G.S., Xanthopoulos, K.G., and Spiegelman, B.M. (1989) A direct role for C/EBP and the AP-I-binding site in gene expression
75
76
77
78
79
80
81
82
linked to adipocyte differentiation. Mol. Cell. Biol., 9, 5331–5339. Kaestner, K.H., Christy, R.J., and Lane, M.D. (1990) Mouse insulin-responsive glucose transporter gene: characterization of the gene and transactivation by the CCAAT/enhancer binding protein. Proc. Natl. Acad. Sci. USA, 87, 251–255. McKeon, C. and Pham, T. (1991) Transactivation of the human insulin receptor gene by the CAAT/enhancer binding protein. Biochem. Biophys. Res. Commun., 174, 721–728. Hwang, C.S., Mandrup, S., MacDougald, O.A., Geiman, D.E., and Lane, M.D. (1996) Transcriptional activation of the mouse obese (ob) gene by CCAAT/ enhancer binding protein alpha. Proc. Natl. Acad. Sci. USA, 93, 873–877. Park, S.K., Oh, S.Y., Lee, M.Y., Yoon, S., Kim, K.S., and Kim, J.W. (2004) CCAAT/ enhancer binding protein and nuclear factor-Y regulate adiponectin gene expression in adipose tissue. Diabetes, 53, 2757–2766. Qiao, L., Maclean, P.S., Schaack, J., Orlicky, D.J., Darimont, C., Pagliassotti, M., Friedman, J.E., and Shao, J. (2005) C/ EBPalpha regulates human adiponectin gene transcription through an intronic enhancer. Diabetes, 54, 1744–1754. Le Lay, S., Lefrere, I., Trautwein, C., Dugail, I., and Krief, S. (2002) Insulin and sterol-regulatory element-binding protein-1c (SREBP-1C) regulation of gene expression in 3T3-L1 adipocytes. Identification of CCAAT/enhancerbinding protein beta as an SREBP-1C target. J. Biol. Chem., 277, 35625–35634. Seo, J.B., Moon, H.M., Noh, M.J., Lee, Y.S., Jeong, H.W., Yoo, E.J., Kim, W.S., Park, J., Youn, B.S., Kim, J.W., Park, S.D., and Kim, J.B. (2004) Adipocyte determination- and differentiationdependent factor 1/sterol regulatory element-binding protein 1c regulates mouse adiponectin expression. J. Biol. Chem., 279, 22108–22117. Rosen, E.D., Hsu, C.H., Wang, X., Sakai, S., Freeman, M.W., Gonzalez, F.J., and Spiegelman, B.M. (2002) C/EBPalpha induces adipogenesis through
References
83
84
85
86
87
88
89
90
PPARgamma: a unified pathway. Genes Dev., 16, 22–26. Olsen, H. and Haldosen, L.A. (2006) Peroxisome proliferator-activated receptor gamma regulates expression of signal transducer and activator of transcription 5A. Exp. Cell Res., 312, 1371–1380. Schoonjans, K., Peinado-Onsurbe, J., Lefebvre, A.M., Heyman, R.A., Briggs, M., Deeb, S., Staels, B., and Auwerx, J. (1996) PPARalpha and PPARgamma activators direct a distinct tissue-specific transcriptional response via a PPRE in the lipoprotein lipase gene. EMBO J., 15, 5336–5348. Yajima, H., Kobayashi, Y., Kanaya, T., and Horino, Y. (2007) Identification of peroxisome-proliferator responsive element in the mouse HSL gene. Biochem. Biophys. Res. Commun., 352, 526–531. Castelein, H., Gulick, T., Declercq, P.E., Mannaerts, G.P., Moore, D.D., and Baes, M.I. (1994) The peroxisome proliferator activated receptor regulates malic enzyme gene expression. J. Biol. Chem., 269, 26754–26758. Martin, G., Schoonjans, K., Lefebvre, A.M., Staels, B., and Auwerx, J. (1997) Coordinate regulation of the expression of the fatty acid transport protein and acyl-CoA synthetase genes by PPARalpha and PPARgamma activators. J. Biol. Chem., 272, 28210–28217. Schoonjans, K., Watanabe, M., Suzuki, H., Mahfoudi, A., Krey, G., Wahli, W., Grimaldi, P., Staels, B., Yamamoto, T., and Auwerx, J. (1995) Induction of the acyl-coenzyme A synthetase gene by fibrates and fatty acids is mediated by a peroxisome proliferator response element in the C promoter. J. Biol. Chem., 270, 19269–19276. Frohnert, B.I., Hui, T.Y., and Bernlohr, D.A. (1999) Identification of a functional peroxisome proliferator-responsive element in the murine fatty acid transport protein gene. J. Biol. Chem., 274, 3970–3977. Singh, A.H., Liu, S., Crombie, D.L., Boehm, M., Leibowitz, M.D., Heyman, R.A., Depre, C., Nagy, L., Tontonoz, P.,
91
92
93
94
95
96
97
and Davies, P.J. (2001) Differential effects of rexinoids and thiazolidinediones on metabolic gene expression in diabetic rodents. Mol. Pharmacol., 59, 765–773. Motojima, K., Passilly, P., Peters, J.M., Gonzalez, F.J., and Latruffe, N. (1998) Expression of putative fatty acid transporter genes are regulated by peroxisome proliferator-activated receptor alpha and gamma activators in a tissue- and inducer-specific manner. J. Biol. Chem., 273, 16710–16714. Miller, C.W. and Ntambi, J.M. (1996) Peroxisome proliferators induce mouse liver stearoyl-CoA desaturase 1 gene expression. Proc. Natl. Acad. Sci. USA, 93, 9443–9448. Nagai, S., Shimizu, C., Umetsu, M., Taniguchi, S., Endo, M., Miyoshi, H., Yoshioka, N., Kubo, M., and Koike, T. (2004) Identification of a functional peroxisome proliferator-activated receptor responsive element within the murine perilipin gene. Endocrinology, 145, 2346–2356. Dalen, K.T., Schoonjans, K., Ulven, S.M., Weedon-Fekjaer, M.S., Bentzen, T.G., Koutnikova, H., Auwerx, J., and Nebb, H.I. (2004) Adipose tissue expression of the lipid droplet-associating proteins S3-12 and perilipin is controlled by peroxisome proliferator-activated receptor-gamma. Diabetes, 53, 1243–1252. Tontonoz, P., Hu, E., and Spiegelman, B.M. (1995) Regulation of adipocyte gene expression and differentiation by peroxisome proliferator activated receptor gamma. Curr. Opin. Genet. Dev., 5, 571–576. Wu, Z., Xie, Y., Morrison, R.F., Bucher, N.L., and Farmer, S.R. (1998) PPARgamma induces the insulindependent glucose transporter GLUT4 in the absence of C/EBPalpha during the conversion of 3T3 fibroblasts into adipocytes. J. Clin. Invest., 101, 22–32. Chawla, A. and Lazar, M.A. (1993) Induction of Rev-ErbA alpha, an orphan receptor encoded on the opposite strand of the alpha-thyroid hormone receptor gene, during adipocyte differentiation. J. Biol. Chem., 268, 16265–16269.
j19
j 1 Transcriptional Control of Adipogenesis and Fat Cell Gene Expression
20
98 Fontaine, C., Dubois, G., Duguay, Y.,
Helledie, T., Vu-Dac, N., Gervois, P., Soncin, F., Mandrup, S., Fruchart, J.C., Fruchart-Najib, J., and Staels, B. (2003) The orphan nuclear receptor RevErbalpha is a peroxisome proliferatoractivated receptor (PPAR) gamma target gene and promotes PPARgammainduced adipocyte differentiation. J. Biol. Chem., 278, 37672–37680. 99 Sears, I.B., MacGinnitie, M.A., Kovacs, L.G., and Graves, R.A. (1996) Differentiation-dependent expression of the brown adipocyte uncoupling protein gene: regulation by peroxisome proliferator-activated receptor gamma. Mol. Cell. Biol., 16, 3410–3419. 100 Maeda, N., Takahashi, M., Funahashi, T., Kihara, S., Nishizawa, H., Kishida, K., Nagaretani, H., Matsuda, M., Komuro, R., Ouchi, N., Kuriyama, H., Hotta, K., Nakamura, T., Shimomura, I., and Matsuzawa, Y. (2001) PPARgamma ligands increase expression and plasma concentrations of adiponectin, an adipose-derived protein. Diabetes, 50, 2094–2099. 101 Iwaki, M., Matsuda, M., Maeda, N., Funahashi, T., Matsuzawa, Y., Makishima, M., and Shimomura, I. (2003) Induction of adiponectin, a fatderived antidiabetic and antiatherogenic factor, by nuclear receptors. Diabetes, 52, 1655–1663.
102 Coulter, A.A. and Stephens, J.M. (2006)
103
104
105
106
107
STAT5 activators modulate acyl CoA oxidase (AOX) expression in adipocytes and STAT5A binds to the AOX promoter in vitro. Biochem. Biophys. Res. Commun., 344, 1342–1345. Nanbu-Wakao, R., Fujitani, Y., Masuho, Y., Muramatu, M., and Wakao, H. (2000) Prolactin enhances CCAAT enhancerbinding protein-beta (C/EBP beta) and peroxisome proliferator-activated receptor gamma (PPAR gamma) messenger RNA expression and stimulates adipogenic conversion of NIH-3T3 cells. Mol. Endocrinol., 14, 307–316. Richter, H.E., Albrektsen, T., and Billestrup, N. (2003) The role of signal transducer and activator of transcription 5 in the inhibitory effects of GH on adipocyte differentiation. J. Mol. Endocrinol., 30, 139–150. Hogan, J.C. and Stephens, J.M. (2005) The regulation of fatty acid synthase by STAT5A. Diabetes, 54, 1968–1975. White, U.A., Coulter, A.A., Miles, T.K., and Stephens, J.M. (2007) The STAT5Amediated induction of pyruvate dehydrogenase kinase 4 expression by prolactin or growth hormone in adipocytes. Diabetes, 56, 1623–1629. Balhoff, J.P. and Stephens, J.M. (1998) Highly specific and quantitative activation of STATs in 3T3-L1 adipocytes. Biochem. Biophys. Res. Commun., 247, 894–900.
j21
2 Cellular and Molecular Basis of Functional Differences among Fat Depots Thomas Thomou, Tamara Tchkonia, and James L. Kirkland 2.1 Introduction
Variation in fat distribution is remarkable. Subjects matched for body mass index (BMI) sometimes differ vastly in how much fat is subcutaneous or visceral, or even the particular subcutaneous regions affected. Fat redistribution, especially from subcutaneous to visceral fat depots, has received increasing attention as a risk factor for atherosclerosis and other serious morbidities. The case for considering fat cells and their progenitors, preadipocytes, from different fat depots to be distinct cell subtypes that contribute to regional variation in function will be considered, as will molecular mechanisms responsible (Figure 2.1). 2.1.1 Fat Tissue Function
Different fat depots have distinct roles (Table 2.1). With respect to energy storage, subcutaneous fat, which can expand outward and is not restricted by the anatomic constraints that limit visceral fat growth, is specialized to provide long-term fuel storage. It is the main source of leptin, which signals the state of long-term fat stores to the brain [1–5]. The greater development of subcutaneous fat in females than males may have evolved to facilitate steady access to calories during pregnancy [6]. Visceral fat provides short-term storage and rapid access to calories that can be processed quickly by the liver. Larger visceral fat stores may have evolved in males to allow rapid access to energy required during hunting [6]. Fat is important in immunity. Complement components, cytokines, and chemokines, including tumor necrosis factor (TNF)-a, interleukin-6, and macrophage chemotactic factors, are released by adipose cells. High local fatty acid concentrations that are toxic to pathogenic bacteria, fungi, and other cell types contribute to the protective function of fat tissue. Preadipocytes and fat cells are resistant to cytotoxic levels of fatty acids [7]. Perhaps because of their secretory profile and high local fatty
j 2 Cellular and Molecular Basis of Functional Differences among Fat Depots
22
Mesenchymal Progenitor Cell Determination
Circulating Progenitors
Replication
Preadipocyte (2 subtypes) Differentiation Apoptosis
Dedifferentiation
Senescence Lipid Accumulation
Lipolysis Fat Cell Apoptosis/Necrosis
Figure 2.1 Fat tissue cell dynamics. Preadipocytes arise from multipotent mesenchymal progenitor cells, which may also be able to develop into muscle, bone, cartilage, and macrophages, and possibly from circulating progenitors. After becoming committed to the fat cell lineage through GATA, Wnt, and Notch signaling components, preadipocytes can replicate, differentiate into fat cells or possibly reverse determination to become multipotent progenitors again. There are at least two preadipocyte subtypes, one being more capable
of replication, differentiation into fat cells, and resisting apoptosis than the other. Cells of each subtype can convert into the other. Preadipocytes can be induced to differentiate by IGF-1, glucocorticoids, a burst of cAMP generation, fatty acids, and other factors. Differentiated fat cells can accumulate more lipid, release fatty acids through lipolysis, be removed through apoptosis, senescence, or necrosis, or possibly dedifferentiate into preadipocytes. The preadipocyte cell dynamic processes that vary among fat depots are underlined.
acid levels, infections and metastases are uncommon in fat depots. Subcutaneous fat acts as a barrier to infection entering through the skin. The greater omentum can migrate and wall off infection from ruptured viscera. The omentum hangs down from the stomach in bipeds, migrating around the abdomen during body movement Table 2.1 Fat tissue function.
Subcutaneous
Omental
Regeneration/wound response
long-term/protection against lipotoxicity ü mechanical ( ! growth to provide cushioning) insulation signaling long-term stores replication to fill voids
Anatomic constraints
none
rapid fatty acid release to central circulation üüü patching (adhesion/attachment, hemostasis) — injury response/maintain blood pressure bandage function/creeping fat/" other cell types very restricted, especially during pregnancy
Fuel storage/metabolic Innate immune Protective Temperature Endocrine/paracrine
2.1 Introduction
and peristalsis. In quadrupeds, epididymal or paraovarian fat, which is attached at the highest point in the abdomen, serves a function analogous to omental fat in bipeds. Omental fat releases attachment, pressor, and hemostatic factors, such as plasminogen-activated inhibitor-1, in addition to inflammatory cytokines and chemokines. It acts as a medicated bandage in the event of a perforated viscus or other intraabdominal catastrophe. Perhaps these protective functions of omental fat switch into contributing to metabolic syndrome when this depot is enlarged in obesity – a state rare in nature. Mesenteric fat may help to prevent systemic spread of enteral infections [8]. Mesenteric fat responds to inflammation by growing, perhaps to wall inflamed viscera off from the abdominal cavity. Indeed, radiologists and surgeons use creeping fat to identify segments of bowel affected by inflammatory bowel disease (Crohns disease, ulcerative colitis). Certain fat depots have a cushioning function, including fat over the joints, palms, and soles (the depots preserved in Berardinelli–Seip lipodystrophy [9]), as well as fat around the heart and kidneys, and retro-orbital fat. Fat tissue can grow in response to mechanical stress, adding to its cushioning function, reminiscent of the close association between preadipocytes and bone progenitors [10]. White fat has an insulating effect and is ideally situated under the skin to prevent heat loss. Brown fat, which is present mainly in central, deep fat depots surrounding the great blood vessels in infants, generates heat. Bone marrow fat cells produce paracrine regulators of blood cell generation [11, 12]. Bone marrow preadipocytes and osteoblasts can turn into each other under particular conditions [13–15]. Thus, in addition to storage of calories, fat depots are specialized to carry out distinct protective and regenerative functions. 2.1.2 Diversity in Fat Distribution
Environmental, epigenetic, genetic, and disease- and drug-associated processes likely combine to cause diversity in fat distribution. Environmental factors associated with increased central fat include physical inactivity, low socioeconomic status (or the stress associated with this), and poor education [16, 17]. Smoking leads to development of central obesity that is reversed after smoking cessation [16–19]. Moderate alcohol consumption is associated with decreased central obesity [17]. Drugs that alter fat distribution include sex steroids, glucocorticoids, and some AIDS protease inhibitors, which increase visceral fat while causing loss of subcutaneous fat from some areas [20–22]. Antidiabetic thiazolidinediones (TZDs; e.g., rosiglitazone, pioglitazone) increase total body fat, but do so by increasing subcutaneous fat, causing relative redistribution of fat from visceral to peripheral depots [23–25]. Although environmental factors have a substantial effect on fat distribution, heritable genetic and epigenetic mechanisms make an even stronger contribution. Of genetic factors, gender has the largest impact. Visceral fat constitutes approximately 20% of total fat in males, but only 6% in premenopausal females [26, 27]. Hormonal manipulation to convert males to females causes redistribution of fat
j23
j 2 Cellular and Molecular Basis of Functional Differences among Fat Depots
24
from visceral to subcutaneous depots, while the opposite occurs in female-tomale transsexuals [28, 29]. Although the postmenopausal state and male gender are associated with increased visceral fat, gender itself does not directly influence the relation between intra-abdominal fat and insulin sensitivity, underscoring the close ties between regional fat distribution and insulin responsiveness [30]. Effects of sex steroids on fat distribution are not straightforward. While testosterone administration causes visceral obesity in females, it reverses visceral obesity in hypogondal males [31]. Among subjects of the same gender, genetic factors account for over 60% of variation in visceral fat mass [32]. In monozygotic twins, 75% of variance in the increase of visceral fat after overfeeding is within twin pairs and only 25% among sets of twins [33], supporting a strong role for heritable factors. Over 50% of the variance in visceral fat mass has been attributed to single gene effects in segregation analyses, and only 20% to multifactorial effects [32]. While the genes most commonly accounting for altered regional fat distribution have not been identified, rare single gene mutations cause syndromes that profoundly affect distribution. The mutations that cause the Berardinelli–Seip and Dunnigan–Kobberling segmental lipodystrophy syndromes lead to altered fat distribution, diabetes, and hyperlipidemia [20, 34]. Berardinelli–Seip syndrome may be caused by a recessive mutation of the retinoid X receptor-a [35, 36], resulting in extensive subcutaneous fat loss except over the palms, soles, periarticular areas, and orbits [9, 35]. The Dunnigan–Kobberling syndrome results from a dominant mutation of lamin A/C nuclear envelope proteins, causing loss of subcutaneous fat except around the face and neck, with preserved or increased visceral fat. Thus, genetic factors, including gender and single- and multigene products, likely account for much of the variation in fat distribution. Fat tissue distribution changes throughout the lifespan, with increases in overall fat mass through middle age. In advanced old age, extensive loss of particular fat depots occurs, together with deposition of fat in marrow, liver, muscle, and other ectopic sites [37–44]. In old age, subcutaneous fat, especially in the extremities, tends to be lost first, with thinning of the skin over the dorsa of the hands and development of spindly legs. Subcutaneous fat loss proceeds centrally in old age and visceral fat tends to be lost last. This relative preservation of visceral compared to subcutaneous fat in older individuals is associated with increased metabolic syndrome prevalence [45]. 2.1.3 Regional Differences in Fat Tissue Growth
Certain fat depots enlarge during development, in obesity, or after partial lipectomy, principally through increases in the size of existing fat cells. Others enlarge through both fat cell enlargement and differentiation of preadipocytes into new fat cells [44, 46, 47]. Subcutaneous fat, with its long-term storage function, tends to grow by increasing fat cell number, with fat cell sizes approximating the most thermodynamically stable size for triolein droplets (Figure 2.2). Visceral fat, with its short-term
2.1 Introduction
SUBCUTANEOUS
OMENTAL
Figure 2.2 Mechanisms of fat tissue growth during progression of obesity vary among depots. Human subcutaneous fat, specialized to provide long-term nutrient storage and not encumbered by the anatomic constraints faced by visceral fat, grows through increases in fat cell number. This is facilitated by the higher
potential of subcutaneous than visceral preadipocytes for replication and adipogenesis. Visceral fat enlarges through increases in fat cell size rather than number, consistent with its role in storing and releasing nutrients rapidly and its limited space for growth.
lipid storage function, changes in size principally through increases or decreases in fat cell size, rather than changes in fat cell number. After fat tissue is removed, fat reappears in remaining depots [48–50]. For example, after liposuction, breast enlargement occurs in women [49]. Subcutaneous fat increases when visceral fat is removed from experimental animals [51]. Conversely, when subcutaneous fat is removed, visceral fat increases. This raises concerns about potential effects of liposuction on visceral fat and perhaps contributes to visceral fat enlargement associated with the subcutaneous fat loss in lipodystrophies and aging. In experimental animals, not every fat depot enlarges to the same extent after removal of fat from other sites. For example, after removal of other fat pads, inguinal fat mass increases, but epididymal fat mass remains unchanged [51]. Unilateral removal of epididymal or inguinal fat pads from animals results in disproportionate enlargement of ipsilateral compared to contralateral depots [52]. Hormones are unlikely to be responsible for this asymmetric response, but it is plausible that neurological events are. The sympathetic nervous system appears to be particularly relevant. Adrenergic stimulation promotes lipolysis through activating b-receptors or inhibits lipolysis through a-receptors. Ratios of b- to a-receptors vary among different fat depots [53, 54]. Following sympathetic drive, fat stores are greatest in depots with high numbers or affinities of a- relative to b-receptors. Regional variation in receptor densities could result from differences in nerve supply or the inherent properties of adipocytes. Indeed, these mechanisms may combine to cause functional differences among depots. Norepinephrine inhibits replication of cultured preadipocytes [55], while sympathetic denervation of fat tissue results in increased fat cell number [56]. Thus, although total fat mass increases toward a set point, individual fat depots exhibit distinct responses to lipectomy.
j25
j 2 Cellular and Molecular Basis of Functional Differences among Fat Depots
26
2.1.4 Disease Associations
Accumulation of central fat is associated with elevated risk of diabetes, hypertension, atherosclerosis, dyslipidemia, and cancers [6, 27, 50–64]. Central obesity is more closely associated with insulin resistance than total body fat [24, 62–64]. Even lean subjects (with a nonobese BMI) who have a high ratio of central to peripheral fat are insulin resistant [30]. Whether impaired insulin sensitivity associated with central fat is related mainly to increased visceral fat [24, 62–64] or increased abdominal subcutaneous together with visceral fat [57, 58] has been debated. The deep layer of abdominal subcutaneous fat is more strongly associated with insulin resistance than the superficial layer [59, 60]. Furthermore, increased visceral fat in computed tomography and magnetic resonance imaging studies is related to decreased antilipolytic effect of insulin, but this relation does not hold for abdominal subcutaneous fat [61]. Femoral subcutaneous fat might actually be protective [62]. Thus, increased visceral fat may be a powerful risk factor in central obesity, with further risk being added by abdominal subcutaneous fat [63]. Which of the major visceral fat depots (mesenteric and omental) is most closely associated with metabolic disease is not yet known, but venous drainage and preadipocyte and fat cell characteristics vary between these intra-abdominal depots [64–66]. The adverse metabolic impact of visceral obesity may be due to (i) an underlying process that predisposes both to visceral obesity and metabolic dysfunction, (ii) the location of visceral fat depots (with venous drainage through the liver and pancreas, increased intra-abdominal pressure), or (iii) inherent differences among fat depots in adipocyte characteristics, including their cytokine secretory profiles [31, 67]. In support of the first mechanism, both central obesity and insulin resistance occur in mice with mutations that interfere with insulin receptors in muscle [68, 69]. Injection of estrogen into the central nervous system without altering systemic estrogen levels affects both insulin sensitivity and fat distribution [70]. In support of the second mechanism, some of the venous drainage of visceral fat, particularly omental fat, is through the portal system. Therefore, metabolic, paracrine, and hormonal products released by visceral fat could affect the liver and pancreas directly. For example, high fatty acid concentrations impede hepatic insulin signaling [71] and increase hepatic gluconeogenesis [6], contributing to insulin resistance. Visceral obesity is associated with increased intra-abdominal pressure that may provoke sympathetic activity through effects on the kidneys [72]. In support of the third mechanism, many inherent differences in preadipocyte and fat cell function have been found among depots, as reviewed in Section 2.2. These three potential mechanisms likely combine to produce the metabolic effects of visceral obesity. Does selectively reducing visceral fat improve health? While the answer is not yet clear in humans, in rats surgical removal of visceral fat enhances hepatic insulin sensitivity and decreases hepatic glucose production (although venous drainage of epididymal and perinephric depots in rodents differs from that of omental fat in humans), while removing subcutaneous fat from hamsters has the opposite effect [73–75]. If this is also true in humans, substantial improvement in insulin
2.2 Physiology
sensitivity and metabolic risk profile might be feasible if drugs that selectively reduce visceral fat could be developed. A number of acquired diseases and drugs affect fat distribution. Inflammatory bowel disease results in local accumulation of fat tissue [8]. Limb paralysis results in loss of muscle and increased fat in the affected limb [76]. TZDs result in subcutaneous fat growth, but have little effect on visceral fat [23–25]. HIV protease inhibitors are associated with loss of fat over the face and extremities, but accumulation of dorsal subcutaneous and visceral fat [21, 22]. Sex steroids are associated with fat redistribution. Subcutaneous and visceral adipocytes differ in extent of their responses to glucocorticoids. Subcutaneous fat cells express fewer glucocorticoid receptors and exhibit less lipoprotein lipase activation in response to glucocorticoids [77, 78]. Activity of the enzyme that converts cortisone to the more actively adipogenic cortisol, 11b-hydroxysteroid dehydrogenase (HSD)-1, is higher in visceral fat [79, 80]. Increased circulating cortisone would therefore be predicted to cause more growth of visceral than subcutaneous fat, as occurs in Cushings syndrome. Fat tissue-specific overexpression of 11b-HSD-1 increases 11b-HSD-1 in all fat depots. This results in visceral obesity in transgenic mice, but has little effect on subcutaneous fat abundance [81]. Furthermore, glucocorticoids that bypass 11b-HSD-1 and inhibit endogenous glucocorticoid production, such as dexamethasone, still cause fat redistribution. Therefore, regional differences in responses to glucocorticoids downstream of 11b-HSD-1 likely contribute to interdepot variation in fat growth.
2.2 Physiology
For many years, it has been recognized that physiological characteristics of fat tissue isolated from various depots are remarkably different [43, 82–85]. Fat cells isolated from different depots vary in size, responses to insulin and lipolytic agents, lipoprotein binding, fatty acid transfer, production of secreted proteins, and other features [1–4, 6, 51, 77, 86–110]. Visceral fat cells undergo more fatty acid turnover and lipolysis than subcutaneous cells [102, 103]. This fits with clinical studies indicating increased fatty acid and triglyceride turnover in abdominal obesity [111–114]. Greater capacity of omental cells for hormone-stimulated lipolysis is related to presence of increased numbers of b-receptors and blunted a-receptor-mediated decline in cAMP levels compared to subcutaneous cells [97, 104, 106, 115]. Visceral adipocytes are also less responsive to antilipolytic effects of insulin [86, 103, 104, 107, 116]. Higher abundance of the exon 11 minus insulin receptor isoform in visceral than subcutaneous fat is associated with reduced insulin receptor affinity [1]. Reduced insulin receptor substrate-1 responsiveness also contributes to reduced insulin sensitivity and increased lipolysis in omental adipocytes [77, 78]. Increased lipolysis is balanced by increased fatty acid transfer into these cells, maintaining stability in cell size [117]. Increased visceral fat cell fatty acid flux may contribute to insulin resistance and hyperinsulinemia, since
j27
j 2 Cellular and Molecular Basis of Functional Differences among Fat Depots
28
these fatty acids travel directly to the liver where they stimulate gluconeogenesis and reduce insulin removal [86, 118–121]. Acylation-stimulating protein (ASP) promotes human fat cell triglyceride synthesis [87]. Post-translational modification of complement factor C3a, which is secreted by fat cells, leads to ASP generation. C3a mRNA abundance is higher in visceral than abdominal subcutaneous fat [88]. Higher expression of C3a and ASP in visceral than subcutaneous fat may act to counterbalance the greater lipolytic capacity of visceral fat by promoting triglyceride synthesis, contributing to higher fatty acid flux in visceral fat. Leptin mRNA levels and secretion are higher in abdominal subcutaneous than omental fat tissue [1–3], even after 12 days in culture [4, 5], and circulating leptin levels are correlated more closely with subcutaneous than visceral fat mass [89]. Since leptin signals the state of fat stores to the brain, changes in visceral fat content may exert less effect on feeding regulatory responses mediated by leptin than subcutaneous fat. In this respect, visceral fat mass may be subject to less central nervous system regulation than peripheral fat. Leptin also has an insulin-sensitizing effect on muscle [90–92]. Thus, greater secretion of leptin by subcutaneous than visceral fat, coupled with the proximity of subcutaneous fat to muscle, may contribute to low insulin sensitivity in central obesity. Cholesterol ester transfer protein (CETP), which mediates cholesterol metabolism, is produced by fat tissue [93]. CETP mRNA levels are higher in abdominal subcutaneous than omental fat [88]. While CETP mRNA levels may not predict protein secretion, subcutaneous fat cells have higher cholesterol content and highdensity lipoprotein-binding capacities than omental cells [122], suggesting a role of CETP release in regional differences in cholesterol metabolism. Angiotensinogen is produced by fat cells. Fat tissue contains all the machinery needed to convert angiotensinogen into angiotensin II [94–96]. Angiotensin II is involved in preadipocyte differentiation into fat cells, but may also contribute to the hypertension frequently associated with obesity. More angiotensinogen mRNA is present in omental than subcutaneous fat tissue and increased waist-to-hip ratios are associated with increased angiotensinogen mRNA [88, 97]. Visceral fat angiotensinogen production may contribute to the hypertension common in the metabolic syndrome. Thus, fat isolated from various regions differs in metabolic pathways that impact morbidity. An understanding of mechanisms responsible for these differences could be invaluable in developing interventions to reduce this morbidity. 2.2.1 Contribution of Inherent Cell Dynamic Mechanisms to Regional Differences
Is regional variation solely a result of influences extrinsic to adipose cells (e.g., hormonal and paracrine microenvironment, local nutrient availability, innervation, anatomic constraints, or regional variation in abundance of nonadipose cell types (macrophages, endothelial cells) or do differences in inherent characteristics of adipose cells also contribute? As evident from the foregoing, extrinsic factors are
2.2 Physiology
clearly important. There is mounting evidence that inherent properties of fat cells and their progenitors, preadipocytes, also contribute (Figure 2.1). New fat cells continue to appear from preadipocytes in adulthood [98–100]. Preadipocytes cultured under identical conditions, originating from different depots from the same individuals, retain distinct, fat depot-dependent characteristics after weeks in culture [47, 64–66, 101–104, 115, 116]. A problem with studies of effects of fat depot origin on preadipocyte function is that interdepot differences in extent of contamination of primary cultures with nonadipose cell types, such as mesothelial cells or macrophages, are a potential cause of apparent differences. However, interdepot differences in fatty acid uptake have been found at the single-cell level in cultured preadipocytes matched for lipid content [117]. Furthermore, regional variation in developmental gene expression profiles and capacities for adipogenesis, replication, and susceptibility to apoptosis persist for many cell generations in strains derived from single human preadipocytes, as will be reviewed below [64–66]. 2.2.2 Preadipocyte Function
The main job of preadipocytes is to differentiate into fat cells when required. Fat tissue has to be able to expand in times of nutrient excess to sequester cytotoxic fatty acids as less toxic triglycerides. Fat tissue storage capacity can increase acutely through increases in fat cell size. Once fat cells get too large, they may become susceptible to breakage and necrosis with ensuing macrophage infiltration of fat tissue [106]. Fat tissue expansion in times of sustained nutrient availability is most efficiently achieved through increases in fat cell number. This is an especially prominent mechanism of fat tissue expansion in subcutaneous depots. To allow such fat tissue expansion, the preadipocyte pool is large: preadipocytes account for 15–50% of cells in fat tissue, one of the largest progenitor pools in the body [99]. Fat tissue also turns over regularly, with fat cells having a half life estimated to be approximately 3 months [100] – another reason the preadipocyte pool needs to be large. Beyond giving rise to new fat cells, fat cell progenitors are an important cell type in their own right, actively producing paracrine factors, hormones, and metabolic signals in a manner distinct from that of differentiated fat cells [99, 107]. For example, most tissue-type plasminogen activator appears to be produced by preadipocytes rather than fat cells [108]. Furthermore, much of the immune function of fat tissue is attributable to preadipocytes, which react to bacterial antigens and can recruit macrophages [109]. Indeed, preadipocytes are so closely related to macrophages that their expression profiles are more like macrophages than fat cells. Preadipocytes even appear to be able to develop into macrophages, among other cell types [110, 111]. 2.2.3 Preadipocyte Replication
Preadipocytes from different fat depots differ in replicative potential [47, 66, 101–103, 112–114, 116, 123]. Preadipocytes from rat perirenal depots are capable of more
j29
j 2 Cellular and Molecular Basis of Functional Differences among Fat Depots
30
extensive replication than from epididymal depots [47, 101, 103, 104, 116, 123]. These differences are evident in colonies arising from single perirenal or epididymal preadipocytes after 3 weeks in identical cell culture conditions [103]. This indicates these differences are inherent. Higher replicative potential of perirenal preadipocytes is reflected in a greater increase in perirenal than epididymal fat cell number during depot growth in vivo [47]. Human abdominal subcutaneous preadipocytes are capable of more extensive replication than omental cells, with mesenteric preadipocytes being intermediate [66, 113, 114]. As in the rat, these regional differences in replicative potential are retained in colonies derived from single preadipocytes after several weeks in culture, indicating that regional variation in inherent preadipocyte replicative potential occurs across mammals. Consistent with greater replicative potential of subcutaneous than omental preadipocytes, telomeres are shorter in subcutaneous than omental cells [66]. This increased replicative history in subcutaneous cells may be related to the long-term lipid storage function of subcutaneous fat and the expansion of subcutaneous fat cell numbers that occurs in obesity. To address whether preadipocytes from different depots are distinct, preadipocyte strains were produced from single abdominal subcutaneous, mesenteric, and omental human preadipocytes by stably expressing human telomere reverse transcriptase (hTERT) [66]. These strains can be subcultured repeatedly and retain capacity for differentiation, while primary preadipocyte adipogenesis and replication decline with subculturing. Single subcutaneous, mesenteric, and omental hTERT preadipocytes that had undergone 35 population doublings were cultured for 21 days. The number of subcutaneous clones that achieved an additional 14 or more population doublings during the 21 days was 2.5-fold higher than omental clones. Thus, regional differences in preadipocyte replicative potential are heritable for many cell generations, do not depend on presence of other cell types, and are independent of telomerase activity. Heritable, possibly epigenetic processes, likely contribute to regional variation in fat tissue function. 2.2.4 Differences in Adipogenesis among Depots
Human preadipocyte capacity for adipogenesis may vary among fat depots, as indicated in several studies [65, 66, 102, 112, 115, 124–126]. In other studies, differences were not apparent [114, 127, 128], perhaps because of variability among subjects, the time point at which extent of differentiation was assessed, or culture media. In the studies in which regional differences were found, human abdominal subcutaneous preadipocytes had greater capacity for adipogenesis than omental cells. If left long enough in differentiation-promoting medium, omental preadipocytes eventually catch up to subcutaneous cells, possibly obscuring regional differences evident earlier during differentiation and contributing to discrepancies among studies [65]. In the studies in which differences among depots were found, human abdominal subcutaneous preadipocytes differentiated to a greater extent in response to TZDs than omental cells [65, 115, 124–126, 129]. TZDs bind to and activate the adipogenic transcription factor, peroxisome proliferator-activated receptor (PPAR)-c.
2.2 Physiology
Consistent with this, TZDs promote accumulation of fat in subcutaneous, but not visceral depots [23, 24]. Indeed, regional differences in TZD responsiveness could be a mechanism contributing to the antidiabetic effects of TZDs, since excess visceral relative to subcutaneous fat is associated with glucose intolerance [85]. Markers of adipogenesis (lipid accumulation, expression of the fatty acid-binding protein, aP2, and glycerol-3-phosphate dehydrogenase (G3PD) activity) are highest in human abdominal subcutaneous preadipocytes, intermediate in mesenteric cells, and lowest in omental cells following induction of differentiation. This pattern was also observed with respect to expression of PPAR-c and the CCAAT/enhancerbinding protein C/EBP-a – transcription factors necessary for adipogenesis to proceed. The aP2 and G3PD promoters respond to PPAR- and C/EBP-a [122, 130–132]. The magnitudes of the regional differences in C/EBP-a and PPAR-c expression are consistent with regional differences in aP2 and G3PD. Furthermore, ectopic expression of C/EBP-a in omental preadipocytes enhances capacity to accumulate lipid, suggesting genes downstream of C/EBP-a in omental preadipocytes are capable of responding to overexpressed levels of this adipogenic regulator [65]. Thus, mechanisms upstream of the level of adipogenic transcription factors appear to contribute to regional variation in function. Regional variation in adipogenesis is also found in cultured rat preadipocytes, indicating this occurs across mammals and does not result from particular features of subjects selected for the human studies. Under various conditions that promote differentiation, rat perirenal preadipocytes accumulate more lipid and develop higher levels of expression of differentiation-dependent genes than epididymal preadipocytes [47, 103, 104, 116]. Interdepot variation in cultured rat preadipocyte differentiation-dependent gene expression is reflected in patterns of fat tissue expression of the same genes among depots [104]. Despite exposure to hormonal manipulations in vivo, such as estrogen treatment, hypophysectomy, or castration in rats, preadipocytes cultured from various depots retain differences in adipogenesis, further implicating inherent differences among depots [133, 134]. To exclude effects of admixture with other cell types in primary preadipocytes in cultures isolated from different regions and to test effects of depot origin on adipogenesis definitively, preadipocytes cloned from different depots have been studied. The propensities of preadipocytes from different fat depots in primary cultures to switch on the differentiation program are reflected in colonies derived from single cells. In response to differentiation-inducing media, the proportion of differentiated cells in colonies derived from single preadipocytes is highest in abdominal subcutaneous clones, intermediate in mesenteric clones, and lowest in omental clones [65]. This was also found after 40 population doublings in strains made from single subcutaneous, mesenteric, and omental preadipocytes by stably expressing hTERT [66]. As in primary cultures, lipid accumulation, aP2 expression, G3PD activity, and C/EBP-a and PPAR-c are highest in subcutaneous, intermediate in mesenteric, and lowest in omental hTERT strains. Not every cell within clones differentiates at the same time. Differentiated cells appear later in visceral than subcutaneous clones. Although adipogenesis is delayed in omental preadipocytes, it does eventually proceed [65]. This is consistent with the
j31
j 2 Cellular and Molecular Basis of Functional Differences among Fat Depots
32
finding that PPAR-c mRNA abundance is similar in abdominal subcutaneous and omental whole fat tissue samples [115]. Those cells that acquire lipid inclusions within clones also exhibit C/EBP-a upregulation, irrespective of depot origin. This indicates that regional variation in adipogenesis depends on mechanisms upstream of transcription factor expression, otherwise cells with increased C/EBP-a but no lipid inclusions should be evident. As in human studies, regional differences are evident in colonies arising from single rat cells after weeks in culture [47, 103, 104]. Thus, capacity for adipogenesis depends on depot origin in preadipocytes cloned from both rats and humans, indicating preadipocytes from different depots are inherently distinct. 2.2.5 Regional Variation in Susceptibility to Apoptosis
More apoptotic fat cells are found in human omental than abdominal subcutaneous fat [112, 135, 136]. Consistent with this, preadipocytes from different depots vary in susceptibility to apoptosis induced by serum deprivation or TNF-a [65, 66, 112, 136]. As in the cases of regional differences in replication and adipogenesis, mesenteric preadipocytes are intermediate between subcutaneous and omental cells. Furthermore, regional differences in susceptibility to TNF-a-induced apoptosis are retained in hTERT-expressing strains after 40 population doublings. Thus, differences in preadipocyte replication, adipogenesis, and apoptosis among depots appear to be inherent. 2.2.6 Differences in Preadipocyte Subpopulations among Fat Depots
Two preadipocyte subtypes, one capable of more extensive replication, differentiation, and adipogenic transcription factor expression and less apoptosis in response to TNF-a than the other, are present in fat tissue of humans as well as rodents [110, 113, 137]. Both subtypes are found in hTERT strains derived from single preadipocytes, confirming both are of preadipocyte lineage. After subcloning cells of either subtype, both subtypes are found, indicating that switching can occur between them. The subtype with the lower capacities for replication, lipid accumulation, and C/EBPa expression, and greatest susceptibility to TNF-a-induced apoptosis is most abundant in omental preadipocyte populations. Thus, differences among depots in relative abundance of these subtypes could contribute to regional variation in replication, differentiation, and apoptosis. Characteristics of the subtypes also vary among depots. The omental rapidly and slowly replicating subtypes both accumulate less lipid than their subcutaneous counterparts. This implies that the subtypes from different depots are themselves distinct, that developmental imprinting of the cells occurs related to their microenvironment in vivo, or a combination of these mechanisms. Having a preadipocyte subtype that responds poorly to inducers of adipogenesis, yet can switch into a subtype that responds well, may ensure continued presence of
2.2 Physiology
the progenitor pool. If such a mechanism did not exist, all preadipocytes could be induced to differentiate into fat cells at the same time if insulin/insulin-like growth factor (IGF)-1 levels were high and other proadipogenic conditions existed. The presence of both subtypes could also serve to permit plasticity of the progenitor pool over time through selection for clones with particular properties. For example, inflammatory cytokine exposure could favor selection of the rapidly over the slowly replicating preadipocyte subtype. This could have long-term consequences for fat depot cellular composition and function. Additionally, the preadipocyte subtypes may develop into differentiated fat cells with distinct properties. In this regard, two populations of fat cells, one large and the other small, have been found in human fat and in fat-specific insulin receptor knockout mice [138–142]. 2.2.7 Differences in Preadipocyte Gene Expression Profiles among Depots
The large differences in preadipocyte cell dynamic properties (replication, adipogenesis, apoptosis, and subtype abundance) suggest that expression profiles of undifferentiated preadipocytes from different fat depots should be distinct. Indeed, genome-wide expression profiles of primary preadipocytes cultured in parallel from different depots of rats and humans are distinct [64, 143]. Over 500 genes vary significantly among human abdominal subcutaneous, mesenteric, and omental fat depots by more than 2-fold. Interestingly, mesenteric preadipocytes have expression patterns distinct from omental cells, indicating that visceral fat is not homogeneous. Genes involved in developmental processes constitute approximately 25% of the transcripts whose expression varies among depots in both humans and rodents [64, 143, 144], with this gene category being the one that differs most among depots. Mesenteric undifferentiated preadipocytes are distinct from omental cells with respect to developmental gene expression [64]. Depot-specific developmental gene expression profiles persist for 40 population doublings in hTERT strains, indicating developmental gene signatures are inherent. An example of a developmental gene distinctly expressed in omental and subcutaneous preadipocytes is pregnancy associated plasma protein A (PAPPA) [145]. PAPPA is a potent inhibitor of IGF-binding protein 4, which negatively regulates IGF-I activity [146]. Since omental cells are resistant to insulin and IGF-1, they may require more IGF-1 to survive than subcutaneous cells, and PAPPA may facilitate increased local IGF-1 bioavailability. Preadipocytes isolated from different fat depots also differ with respect to developmental genes belonging to the homeobox superfamily [145]. In particular, engrailed-1 (En-1) and members of the homeobox (Hox) clusters are differentially expressed in preadipocytes [145] as well as abdominal subcutaneous and visceral whole fat tissue [147, 148]. En-1 might be expressed within and up to the anatomic boundaries of a fat depot effectively demarcating it, much as this gene demarcates the limits of metameres in Drosophila melanogaster [149]. Hox genes are master regulators of developmental processes controlling the diversification of segments along the anteroposterior axis of animals [150]. During
j33
j 2 Cellular and Molecular Basis of Functional Differences among Fat Depots
34
embryogenesis, groups of cells become committed to form body structures, including limbs and organs [151]. Evidence is accumulating that the combination of Hox genes expressed within functional domains along the anteroposterior axis specifies development of structures within these domains [152]. In mammals, Hox genes are organized into four genomic clusters (A, B, C and D), each containing nine to 11 genes. Adjacent Hox genes are redundant in terms of function, as are paralogous Hox genes (i.e., HoxA9 and HoxC9) [153]. Hox genes that are more 30 in the genomic layout control more anterior structures [154]. Although Hox genes are believed to play a pivotal role in embryogenesis, their expression persists in adult tissue. A particular combination of Hox genes is expressed in every cell. This combination is referred to as the Hox code and is believed to be tightly associated with the positional identity of structures [155]. This cellular identity expressed through the Hox code is subject to regulation by an elaborate cellular memory mechanism [156]. The cellular memory that maintains inherent Hox gene expression is related to polycomb group (PcG) proteins. The later are subdivided into 2 groups: (1) polycomb (PcG), which facilitates stable repression of Hox gene expression, and (2) trithorax G (TrxG), which is responsible for continued activation of Hox genes through many cell generations [157]. PcG proteins are believed to control Hox gene expression by epigenetic processes, such as DNA and histone methylation [158]. Hox gene activation or repression coincides with a specific pattern of histone H3 lysine di- and trimethylation [159–161]. Those histone modifications are unique in that they span through large areas rather than being punctate, encompassing several adjacent Hox genes [159]. In particular, lysine 4 dimethylation of histone 3 (H3 K4) is associated with transcriptional activation, possibly by recruiting TrxG activating complexes [162]. H3 K27 trimethylation is believed to be repressive, possibly by recruiting PcG repressive complexes [163]. In addition, histone methylating is also regulated through the action of the histone de-methylation enzymes that fine-tune histone methylation [164]. Thus, Hox gene expression seems to be tightly regulated by histone methylation, histone demethylation, and recruitment of effector proteins (PcG) to the promoters of Hox genes. The function of Hox genes in fat tissue is still unknown. Several studies have suggested that Hox genes might be involved in differentiation and replication of other types of adult cells [165, 166]. For example, in hematopoietic progenitor cells, with which preadipocytes share a common ancestor, Hox genes are believed to regulate progression through progenitor stages by effects on replication and differentiation [165]. These two processes are of pivotal importance in fat tissue function and maintenance. Hox genes can respond to sex steroids [167] and retinoids [168], which are important for fat tissue function and distribution. Hox genes comprise a network of genes whose expression is maintained epigenetically through many cell generations and is pivotal for coordinated development. Whether these genes represent the master developmental regulators in fat tissue that shape distinct fat depots, are a constellation of molecular markers that identify depot-specific adipocyte lineages, or are imprinted during early development or later by the fat tissue microenvironment are issues that need scrutiny.
2.3 Conclusions
2.3 Conclusions
Fat is not a homogeneous organ. Depot-dependent differences among the preadipocytes from which new fat cells arise appear to be inherent. Regional variations in capacities for replication, adipogenesis, apoptosis, subtype abundance, and expression profiles persist for many cell generations in identical culture conditions in strains derived from single preadipocytes. This effectively excludes the possibilities that contamination of cultures with other cell types or effects of hormones, circulation, innervation, or other influences extrinsic to preadipocytes fully account for the regional differences in preadipocyte characteristics. Differences are found in rats as well as humans, suggesting that particular characteristics of subjects from whom preadipocytes were isolated do not account for regional differences. Differences in transcription factor expression appear to contribute to regional differences in adipogenesis. Together with the finding that multiple cell dynamic processes vary among depots (replication, adipogenesis, and apoptosis), as does developmental gene expression, it appears that upstream, possibly epigenetic mechanisms contribute to fat cell progenitors from different regions being effectively distinct cell subtypes. These inherent mechanisms, combined with local variation in fat depot cellular composition, circulation, neural, and other factors, probably account for regional differences in fat tissue function. Gender, obesity, or other factors likely further impact the cellular composition and paracrine microenvironment of adipose tissue [169–173] and influence variation in function among depots. Thus, human fat cell progenitors from different regions are distinct, consistent with different fat depots being separate mini-organs. Perhaps regional heterogeneity in other mesenchymal tissues, such as bone or muscle, is also related to local differences in the inherent properties of the progenitors from which they arise. Interestingly, visceral fat is not functionally homogeneous. Preadipocytes from one of the two main visceral depots, mesenteric fat, have preadipocyte cell dynamic characteristics and expression profiles distinct from omental preadipocytes, the other main visceral depot. Differences in lipid synthesis and lipolysis between omental and mesenteric fat have been found, at least in obese women [170, 171]. Mesenteric cannot be readily distinguished from omental fat by computed tomography, magnetic resonance imaging, or other clinical imaging methods. These findings raise the possibility that the distribution of visceral fat between the mesenteric and omental depots may have as yet unexplained clinical implications. Remarkably, developmental gene products are prominent among transcripts that exhibit regional variation among undifferentiated preadipocytes. Developmental genes may contribute to or be a marker of regional differences in fat tissue function. Differences in developmental gene profiles could be set during early development. Alternatively, expression of some of these developmental genes might be modified in adulthood or imprinted by the local microenvironment. What could set the chain of events in motion that results in interdepot variation in preadipocyte replication, adipogenesis, and susceptibility to apoptosis, subtype
j35
j 2 Cellular and Molecular Basis of Functional Differences among Fat Depots
36
abundance, and developmental gene expression profiles? Ultimately, epigenetic mechanisms, such as cytosine methylation, histone modifications (e.g., binding patterns, acetylation, and methylation), gene-silencing proteins, or other mechanisms that can be passed on to daughter cells, may be responsible for the differing characteristics of fat cells despite sharing the same genomic DNA. These fundamental processes remain to be explored. The interaction between subject characteristics, particularly BMI and aging, with regional differences in preadipocyte function needs to be examined. Since preadipocyte capacities for replication, adipogenesis, apoptosis, and gene expression profiles are affected by aging and obesity [38, 103, 174–181], such interactions are a strong possibility. Another interesting question is whether the pattern of regional variation in adipogenesis or replication of preadipocytes from subjects with peripheral obesity is distinct from that in subjects with visceral obesity. Few interventions are currently available for targeting specific fat depots. Liposuction and cosmetic surgery can be used to reduce areas of subcutaneous fat but might cause an increase in visceral fat [48–51]. Surgical approaches are not routinely available to reduce visceral fat. It may be possible to develop antiobesity drugs with region-specific effects since existing agents can alter fat distribution. For example, androgens reduce visceral fat in hypogonadal males, but increase it in premenopausal females. Reducing circulating glucocorticoids decreases visceral fat. Serotoninergic antidepressants, which appear from preliminary data to decrease abdominal fat mass, may do so by affecting hypothalamic–pituitary–adrenal axis activity [182]. Drugs that alter fat tissue cytokine production or sympathetic nervous system effects on fat tissue might improve regional fat distribution. Another potential approach may be to alter activity of adipogenic regulators and so change expression of their many downstream targets. Indeed, TZDs induce a relative increase in subcutaneous fat. If these approaches can be used to convert visceral fat cells into cells with properties more closely resembling those of subcutaneous cells, risks associated with central obesity may be reduced. It could even be possible to decrease visceral fat mass selectively. To aid in the rational development of such drugs, mechanisms responsible for regional obesity need to be understood more completely. A better understanding of these mechanisms may also point to new ways to treat cardiovascular and metabolic disease. Acknowledgments
The authors are grateful for administrative support by J. Armstrong. This work was funded by NIH grants AG13925, DK56891, and AG23960.
References 1 Lefebvre, A.M., Laville, M., Vega, N.,
Riou, J.P., van Gaal, L., Auwerx, J., and Vidal, H. (1998) Depot-specific
differences in adipose tissue gene expression in lean and obese subjects. Diabetes, 47, 98–103.
References 2 Hube, F., Lietz, U., Igel, M., Jensen, P.B.,
3
4
5
6
7
8
9
10
Tornqvist, H., Joost, H.G., and Hauner, H. (1996) Difference in leptin mRNA levels between omental and subcutaneous abdominal adipose tissue from obese humans. Horm. Metab. Res., 28, 690–693. Montague, C.T., Prins, J.B., Sanders, L., Digby, J.E., and ORahilly, S. (1997) Depot- and sex-specific differences in human leptin mRNA expression: implications for the control of regional fat distribution. Diabetes, 46, 342–347. Harmelen, V., Reynisdottir, S., Eriksson, P., Thorne, A., Hoffstedt, J., Lonnqvist, F., and Arner, P. (1998) Leptin secretion from subcutaneous and visceral adipose tissue in women. Diabetes, 47, 913–917. Zhang, H.H., Kumar, S., Barnett, A.H., and Eggo, M.C. (1999) Intrinsic sitespecific differences in the expression of leptin in adipocytes and its autocrine effects on glucose uptake. J. Clin. Endocrinol. Metab., 84, 2550–2556. Kissebah, A.H. and Krakower, G.R. (1994) Regional adiposity and morbidity. Physiol. Rev., 74, 761–811. Guo, W., Pirtskhalava, T., Tchkonia, T., Xie, W., Thomou, T., Han, J., Wang, T., Wong, S., Cartwright, A., Hegardt, F.G., Corkey, B.E., and Kirkland, J.L. (2007) Aging results in paradoxical susceptibility of fat cell progenitors to lipotoxicity. Am. J. Physiol. Endocrinol. Metab., 292, E1041–E1051. Karagiannides, I., Kokkotou, E., Tansky, M., Tchkonia, T., Giorgadze, N., OBrien, M., Leeman, S.E., Kirkland, J.L., and Pothoulakis, C. (2006) Induction of colitis causes inflammatory responses in fat depots: evidence for substance P pathways in human mesenteric preadipocytes. Proc. Natl. Acad. Sci. USA, 103, 5207–5212. Seip, M. and Trygstad, O. (1996) Generalized lipodystrophy, congenital and acquired (lipoatrophy). Acta Paediatr. Suppl., 413, 2–28. Knippenberg, M., Helder, M.N., Doulabi, B.Z., Semeins, C.M., Wuisman, P.I., and Klein-Nulend, J. (2005) Adipose tissuederived mesenchymal stem cells acquire
11
12
13
14
15
16
17
18
bone cell-like responsiveness to fluid shear stress on osteogenic stimulation. Tissue Eng., 11, 1780–1788. Yokota, T., Meka, C.S., Kouro, T., Medina, K.L., Igarashi, H., Takahashi, M., Oritani, K., Funahashi, T., Tomiyama, Y., Matsuzawa, Y., and Kincade, P.W. (2003) Adiponectin, a fat cell product, influences the earliest lymphocyte precursors in bone marrow cultures by activation of the cyclooxygenase-prostaglandin pathway in stromal cells. J. Immunol., 171, 5091–5099. Corre, J., Planat-Benard, V., Corberand, J.X., Penicaud, L., Casteilla, L., and Laharrague, P. (2004) Human bone marrow adipocytes support complete myeloid and lymphoid differentiation from human CD34 cells. Br. J. Haematol., 127, 344–347. Lecka-Czernik, B., Gubrij, I., Moerman, E., Kajkenova, O., Lipschitz, D., Manolagas, S., and Jilka, R. (1999) Inhibition of Osf2/Cbfa1 expression and terminal osteoblast differentiation by PPARgamma2. J. Cell. Biochem., 74, 357–371. Skillington, J., Choy, L., and Derynck, R. (2002) Bone morphogenetic protein and retinoic acid signaling cooperate to induce osteoblast differentiation of preadipocytes. J. Cell Biol., 159, 135–146. Birk, R.Z., Abramovitch-Gottlib, L., Margalit, I., Aviv, M., Forti, E., Geresh, S., and Vago, R. (2006) Conversion of adipogenic to osteogenic phenotype using crystalline porous biomatrices of marine origin. Tissue Eng., 12, 21–31. Emery, E., Schmid, T., Kahn, H., and Filozof, P. (1993) A review of the association between abdominal fat distribution, health outcome measures, and modifiable risk factors. Am. J. Health Promot., 7, 342–353. Rosmond, R. and Bj€ orntorp, P. (1999) Psychosocial and socio-economic factors in women and their relationship to obesity and regional body fat distribution. Int. J. Obes., 23, 138–145. Lissner, L., Bengtsson, C., Lapidus, L., and Bjorkelund, C. (1992) Smoking initiation and cessation in relation to body fat distribution based on data from a
j37
j 2 Cellular and Molecular Basis of Functional Differences among Fat Depots
38
19
20 21
22
23
24
25
26
27
28
study of Swedish women. Am. J. Public Health, 82, 273–275. Olshansky, S.J., Passaro, D.J., Hershow, R.C., Layden, J., Carnes, B.A., Brody, J., Hayflick, L., Butler, R.N., Allison, D.B., and Ludwig, D.S. (2006) A potential decline in life expectancy in the United States in the 21st century. New Engl. J. Med., 352, 1138–1145. Garg, A. (2000) Lipodystrophies. Am. J. Med., 108, 143–152. Carr, A., Samaras, K., Chisholm, D.J., and Cooper, D.A. (1998) Pathogenesis of HIV-1-protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistance. Lancet, 351, 1881–1883. Villarroya, F., Domingo, P., and Giralt, M. (2007) Lipodystrophy in HIV 1infected patients: lessons for obesity research. Int. J. Obes., 31, 1763–1776. Kelly, I., Han, T., Walsh, K., and Lean, M. (1999) Effects of a thiazolidinedione compound on body fat and fat distribution of patients with type 2 diabetes. Diabetes Care, 22, 288–293. Mori, Y., Murakawa, Y., Okada, K., Horikoshi, H., Yokoyama, J., Tajima, N., and Ikeda, Y. (1999) Effect of troglitazone on body fat distribution in type 2 diabetic patients. Diabetes Care, 22, 908–912. Smith, S.R., De Jonge, L., Volaufova, J., Li, Y., Xie, H., and Bray, G.A. (2005) Effect of pioglitazone on body composition and energy expenditure: a randomized controlled trial. Metabolism, 54, 24–32. Ross, R., Leger, L., Morris, D., deGuise, J., and Guardo, R. (1992) Quantification of adipose tissue by MRI: relationship with anthropometric variables. J. Appl. Physiol., 72, 787–795. Ross, R., Shaw, K., Rissanen, J., Martel, Y., de Guise, J., and Avruch, L. (1993) Adipose tissue distribution measured by magnetic resonance imaging in obese women. Am. J. Clin. Nutr., 57, 470–475. Elbers, J., Asscheman, H., Seidell, J., Megens, J., and Gooren, L. (1997) Longterm testosterone administration increases visceral fat in female to male transsexuals. J. Clin. Endocrinol. Metab., 82, 2044–2047.
29 Vague, J., Meignen, J.M., and Negrin, J.F.
30
31
32
33
34
35
36
37
38
39
(1984) Effects of testosterone and estrogens on deltoid and trochanter adipocytes in two cases of transsexualism. Horm. Metab. Res., 16, 380–381. Kahn, S., Prigeon, R., Schwartz, R., Fujimoto, W., Knopp, R., Brunzell, R., and Porte, D. (2001) Obesity, body fat distribution, insulin sensitivity and islet b-cell function as explanations for metabolic diversity. J. Nutr., 131, 354S–360. Montague, C. and ORahilly, S. (2000) The perils of portliness; causes and consequences of visceral adiposity. Diabetes, 49, 883–888. Bouchard, C., Rice, T., Lemieux, S., Depres, J.-P., Perusse, L., and Rao, D. (1996) Major gene for abdominal visceral fat area in the Quebec family study. Int. J. Obes., 20, 420–427. Bouchard, C., Despres, J.P., and Mauriege, P. (1993) Genetic and nongenetic determinants of regional fat distribution. Endocr. Rev., 14, 72–93. Agarwal, A.K. and Garg, A. (2006) Genetic basis of lipodystrophies and management of metabolic complications. Annu. Rev. Med., 57, 297–311. Garg, A., Wilson, R., Barnes, R., Arioglu, E., Zaidi, Z., Gurakan, F., Kocak, N., ORahilly, S., Taylor, S.I., Patel, S.B., and Bowcock, A.M. (1999) A gene for congenital generalized lipodystrophy maps to human chromosome 9q34. J. Clin. Endocrinol. Metab., 84, 3390–3394. Hegele, R.A. and Cao, H. (2001) Single nucleotide polymorphisms of RXRA encoding retinoid X receptor alpha. J. Hum. Genet., 46, 423–425. Silver, A.J., Guillen, C.P., Kahl, M.J., and Morley, J.E. (1993) Effect of aging on body fat. J. Am. Geriatr. Soc., 41, 211–213. Kirkland, J.L., Tchkonia, T., Pirtskhalava, T., Han, J., and Karagiannides, I. (2002) Adipogenesis and aging: does aging make fat go MAD? Exp. Gerontol., 37, 757–767. Yu, B.P., Masoro, E.J., Murata, I., Bertrand, H.A., and Lynd, F.T. (1982) Lifespan study of SPF Fischer 344 male
References
40
41
42
43
44
45
46
47
48
rats fed ad libitum or restricted diets: longevity, growth lean body mass and disease. J. Gerontol., 37, 130–141. Bertrand, H.A., Lynd, F.T., Masoro, E.J., and Yu, B.P. (1980) Changes in adipose mass and cellularity through the adult life of rats fed ad libitum or a lifeprolonging restricted diet. J. Gerontol., 35, 827–835. Das, M., Gabriely, I., and Barzilai, N. (2004) Caloric restriction, body fat and ageing in experimental models. Obes. Rev., 5, 13–19. Tchkonia, T., Corkey, B.E., and Kirkland, J.L. (2006) Current views of the fat cell as an endocrine cell: lipotoxicity, in Overweight and the Metabolic Syndrome: From Bench to Bedside (eds G.A. Bray and D.H. Ryan), Springer, New York, pp. 105–118. Kirkland, J.L. and Dax, E.M. (1984) Adipose hormone responsiveness and aging in the rat. J. Am. Geriatr. Soc., 32, 219–228. Kirkland, J.L. and Dobson, D.E. (1997) Preadipocyte function and aging: links between age-related changes in cell dynamics and altered fat cell function. J. Am. Geriatr. Soc., 45, 959–967. Rodriguez, A., Muller, D.C., Engelhardt, M., and Andres, R. (2005) Contribution of impaired glucose tolerance in subjects with the metabolic syndrome: Baltimore Longitudinal Study of Aging. Metabolism, 54, 542–547. DiGirolamo, M., Fine, J., Tagra, K., and Rossmanith, R. (1998) Qualitative regional differences in adipose tissue growth and cellularity in male Wistar rats fed ad libitum. Am. J. Physiol. Regul. Integr. Comp. Physiol., 274, R1460–R1467. Wang, H., Kirkland, J.L., and Hollenberg, C.H. (1989) Varying capacities for replication of rat adipocyte precursor clones and adipose tissue growth. J. Clin. Invest., 83, 1741–1746. Yost, T.J., Rodgers, C.M., and Eckel, R.H. (1993) Suction lipectomy: outcome relates to region-specific lipoprotein lipase activity and internal weight change. Plast. Reconstr. Surg., 92, 1101–1109.
49 Scarborough, D. and Bisaccia, E. (1991)
50
51
52
53
54
55
56
57
58
The occurrence of breast enlargement in females following liposuction. Am. J. Cosmetic Surg., 8, 97. Lambert, E., Hudson, D., Bloch, C., and Koeslag, J. (1991) Metabolic response to localized surgical fat removal in nonobese women. Aesthetic Plast. Surg., 8, 105–110. Mauer, M., Harris, R., and Bartness, T. (2001) The regulation of total body fat: lessions learned from lipectomy studies. Neurosci. Biobehav. Rev., 25, 15–28. Mauer, M. and Bartness, T. (1997) Fat padspecific compensatory mass increases after varying degreees of partial lipectomy in Siberian hamsters. Am. J. Physiol. Regul. Integr. Comp. Physiol., 273, R2117–R2123. Lafontan, M., Dang-Tran, L., and Berlan, M. (1979) Alpha-adrenergic antilipolytic effect of adrenaline in human fat cells of the thigh: comparison with adrenaline responsiveness of different fat deposits. Eur. J. Clin. Invest., 9, 261–266. Leibel, R. and Hirsch, J. (1987) Site- and sex-related differences in adrenoreceptor status of human adipose tissue. J. Clin. Endocrinol. Metab., 64, 1205–1210. Jones, D., Ramsay, T., Hausman, G., and Martin, R. (1992) Norepinephrine inhibits rat preadipocyte proliferation. Int. J. Obes., 16, 349–354. Cousin, B., Casteilla, L., Lafontan, M., Ambid, L., Langin, D., Berthault, M., and Penicaud, L. (1993) Local sympathetic denervation of white adipose tissue in rats induces preadipocyte proliferation without noticeable changes in metabolism. Endocrinology, 133, 2255–2262. Abate, N., Garg, A., Peshock, R.M., StrayGundersen, J., and Grundy, S.M. (1995) Relationships of generalized and regional adiposity to insulin sensitivity in men. J. Clin. Invest., 96, 88–98. Goodpaster, B., Kelley, D., Wing, R., Meier, A., and Thaete, F. (1999) Effects of weight loss on regional fat distribution and insulin sensitivity in obesity. Diabetes, 48, 839–847.
j39
j 2 Cellular and Molecular Basis of Functional Differences among Fat Depots
40
59 Kelley, D., Thaete, F., Troost, F., Huwe, T.,
66 Tchkonia, T., Giorgadze, N., Pirtskhalava,
and Goodpaster, B. (2000) Subdivisions of subcutaneous abdominal tissue and insulin resistance. Am. J. Physiol. Endocrinol. Metab., 278, E941–E948. Smith, S., Lovejoy, J., Greenway, F., Ryan, D., Dejonge, L., Bretonn, D.L., Volafova, J., and Bray, G. (2001) Contributions of total body fat, abdominal subcutaneous adipose tissue compartments, and visceral adipose tissue to the metabolic complications of obesity. Metabolism, 50, 425–435. Albu, J.B., Curi, M., Shur, M., Murphy, L., Matthews, D.E., and Pi-Sunyer, F.X. (1999) Systemic resistance to the antilipolytic effect of insulin in black and white women with visceral obesity. Am. J. Physiol. Endocrinol. Metab., 277, E551–E560. Van Pelt, R.E., Evans, E.M., Schechtman, K.B., Ehsani, A.A., and Kohrt, W.M. (2002) Contributions of total and regional fat mass to risk for cardiovascular disease in older women. Am. J. Physiol. Endocrinol. Metab., 282, E1023–E1028. Landchild, M., Knowles, N., Prigeon, R., Howell, W., Walden, C., Retzlaff, B., Knopp, R., and Kahn, S. (1999) Intraabdominal fat is a major contributor to insulin sensitivity in both lean and obese subjects. J. Invest. Med., 47, 77. Tchkonia, T., Lenburg, M., Thomou, T., Giorgadze, N., Frampton, G., Pirtskhalava, T., Cartwright, A., Cartwright, M., Flanagan, J., Karagiannides, I., Gerry, N., Forse, R.A., Tchoukalova, Y., Jensen, M.D., Pothoulakis, C., and Kirkland, J.L. (2007) Identification of depot-specific human fat cell progenitors through distinct expression profiles and developmental gene patterns. Am. J. Physiol. Endocrinol. Metab., 292, E298–E307. Tchkonia, T., Giorgadze, N., Pirtskhalava, T., Tchoukalova, Y., Karagiannides, I., Forse, R.A., DePonte, M., Stevenson, M., Guo, W., Han, J., Waloga, G., Lash, T.L., Jensen, M.D., and Kirkland, J.L. (2002) Fat depot origin affects adipogenesis in primary cultured and cloned human preadipocytes. Am. J. Physiol. Regul. Integr. Comp. Physiol., 282, R1286–R1296.
T., Thomou, T., DePonte, M., Koo, A., Forse, R.A., Chinnappan, D., Carmen Martin-Ruiz, C., von Zglinicki, T., and Kirkland, J.L. (2006) Fat depot-specific characteristics are retained in strains derived from single human preadipocytes. Diabetes, 55, 2571–2578. Heilbronn, L., Smith, S.R., and Ravussin, E. (2004) Failure of fat cell proliferation, mitochondrial function and fat oxidation results in ectopic fat storage, insulin resistance and type II diabetes mellitus. Int. J. Obes. Relat. Metab. Disord., 28 (Suppl. 4), S12–S21. Moller, N., OBrien, P., and Nair, K. (1998) Disruption of the relationship between fat content and leptin levels with aging in humans. J. Clin. Endocrinol. Metab., 83, 931–934. Bruning, J., Michael, M., Winnay, J., Hayashi, T., Horsch, D., Accili, D., Goodyear, L., and Kahn, C. (1998) A muscle-specific insulin receptor knockout exhibits features of the metabolic syndrome of NIDDM without altering glucose tolerance. Mol. Cell, 2, 559–569. Clegg, D.J., Brown, L.M., Woods, S.C., and Benoit, S.C. (2006) Gonadal hormones determine sensitivity to central leptin and insulin. Diabetes, 55, 978–987. Nagy, K., Levy, J., and Grunberger, G. (1990) High-fat feeding induces tissuespecific alteration in proportion of activated insulin receptors in rats. Acta Endocrinol., 122, 361–368. Sugarman, H., Windsor, A., Bessos, M., Kellum, J., Reines, H., and DeMaria, E. (1998) Effects of surgically induced weight loss on urinary bladder pressure, sagittal abdominal diameter and obesity co-morbidities. Int. J. Obes. Relat. Metab. Disord., 22, 230–235. Weber, R.V., Buckley, M.C., Fried, S.K., and Kral, J.G. (2000) Subcutaneous lipectomy causes a metabolic syndrome in hamsters. Am. J. Physiol. Regul. Integr. Comp. Physiol., 279, R936–R943. Barzilai, N., She, L., Liu, B.-Q., Vuguin, P., Cohen, P., Wang, J., and Rossetti, L. (1999) Surgical removal of visceral fat
60
61
62
63
64
65
67
68
69
70
71
72
73
74
References
75
76
77
78
79
80
81
reverses hepatic insulin resistance. Diabetes, 48, 94–98. Gabriely, I., Ma, X.H., Yang, X.M., Atzmon, G., Rajala, M.W., Berg, A.H., Scherer, P.E., Rossetti, L., and Barzilai, N. (2002) Removal of visceral fat prevents insulin resistance and glucose intolerance of aging: an adipokinemediated process? Diabetes, 51, 2951–2958. Modlesky, C.M., Bickel, C.S., Slade, J.M., Meyer, R.A., Cureton, K.J., and Dudley, G.A. (2004) Assessment of skeletal muscle mass in men with spinal cord injury using dual-energy X-ray absorptiometry and magnetic resonance imaging. J. Appl. Physiol., 96, 561–565. Zierath, J.R., Livingston, J.N., Thorne, A., Bolinder, J., Reynisdottir, S., Lonnqvist, F., and Arner, P. (1998) Regional difference in insulin inhibition of nonesterified fatty acid release from human adipocytes: relation to insulin receptor phosphorylation and intracellular signaling through the insulin receptor substrate-1 pathway. Diabetologia, 41, 1343–1354. Bashan, N., Dorfman, K., Tarnovscki, T., Harman-Boehm, I., Liberty, I.F., Bluher, M., Ovadia, S., Maymon-Zilberstein, T., Potashnik, R., Stumvoll, M., Avinoach, E., and Rudich, A. (2007) Mitogenactivated protein kinases, inhibitorykappaB kinase, and insulin signaling in human omental versus subcutaneous adipose tissue in obesity. Endocrinology, 148, 2955–2962. Bujalska, I., Kumar, S., and Stewart, P. (1997) Does central obesity reflect Cushings disease of the omentum? Lancet, 349, 1210–1213. Tomlinson, J.W., Moore, J., Cooper, M.S., Bujalska, I., Shahmanesh, M., Burt, C., Strain, A., Hewison, M., and Stewart, P.M. (2001) Regulation of expression of 11b-hydroxysteroid dehydrogenase type 1 in adipose tissue: tissue-specific induction by cytokines. Endocrinology, 142, 1982–1989. Masuzaki, H., Paterson, J., Shinyama, H., Mortin, N.M., Mullins, J.J., and Flier, J.S. (2001) A transgenic model of visceral
82
83 84
85
86
87
88
89
90
91
obesity and the metabolic syndrome. Science, 294, 2166–2170. Vague, J. (1956) The degree of masculine differentiation of obesities, a factor determining predisposition to diabetes, artherosclerosis, gout and uric calculous disease. Am. J. Clin. Nutr., 4, 20–34. Arner, P. (1997) Regional adiposity in man. J. Endocrinol., 155, 191–192. Kirkland, J.L., Cummins, P., Steppan, C., Dobson, D.E., and Cladaras, M.H. (1997) Decreasing preadipocyte differentiation capacity with aging is associated with blunted expression of the transcription factor, CCAAT enhancer binding protein a. Obes. Res., 5 (Suppl. 1), 22. Tchkonia, T., Karagiannides, I., Forse, R.A., and Kirkland, J.L. (2001) Different fat depots are distinct mini-organs. Curr. Opin. Endocrinol. Diabetes, 8, 227–234. Randle, P., Garland, P., Hales, C., and Newsholme, E. (1963) The glucose-fatty acid cycle. Its role in insulin sensitivity. Lancet, i, 785–789. Walsh, M.J., Sniderman, A.D., Cianflone, K., Vu, H., Rodriguez, M.A., and Forse, R.A. (1989) The effect of ASP on the adipocyte of the morbidly obese. J. Surg. Res., 46, 470–473. Dusserre, E., Moulin, P., and Vidal, H. (2000) Differences in mRNA expression of the proteins secreted by the adipocytes in human subcutaneous and visceral adipose tissues. Biochim. Biophys. Acta, 1500, 88–96. Bennett, F., McFarlane-Andersen, N., Wilks, R., Luke, A., Cooper, R., and Forrester, T. (1997) Leptin concentration in women is influenced by regional distribution of adipose tissue. Am. J. Clin. Nutr., 66, 1340–1344. Rossetti, L., Massillon, D., Barzilai, N., Vuguin, P., Chen, W., Hawkins, M., Wu, J., and Wang, J. (1997) Short term effects of leptin on hepatic gluconeogenesis and in vivo insulin action. J. Biol. Chem., 272, 27758–27763. Sivitz, W., Walsh, S., Morgan, D., Thomas, M., and Haynes, W. (1997) Effects of leptin on insulin sensitivity in normal rats. Endocrinology, 138, 3395–3401.
j41
j 2 Cellular and Molecular Basis of Functional Differences among Fat Depots
42
92 Zhang, Y., Proenca, R., Maffei, M.,
93
94
95
96
97
98
99
100
Barone, M., Leopold, L., and Friedman, J. (1994) Positional cloning of the mouse obese gene and its human homologue. Nature, 372, 425–432. Radeau, T., Lau, P., Robb, M., McDonnell, M., Ailhaud, G., and McPherson, R. (1995) Cholesterol ester transfer protein (CETP) mRNA abundance in human adipose tissue: relationship to cell size and membrane cholesterol content. J. Lipid Res., 36, 2552–2561. Frederich, R.C., Kahn, B.B., Peach, M.J., and Flier, J.S. (1992) Tissue-specific nutritional regulation of angiotensinogen in adipose tissue. Hypertension, 19, 339–344. Paul, M., Wagner, J., and Dzau, V. (1993) Gene expression of the reninangiotensin system in human tissues. Quantitative analysis by the polymerase chain reaction. J. Clin. Invest., 91, 2058–2064. Karlsson, C., Lindell, K., Ottoson, M., Sjostrom, L., Carlsson, B., and Carlsson, L. (1998) Human adipose tissue expresses angiotensinogen and enzymes required for its conversion to angiotensin II. J. Clin. Endocrinol. Metab., 83, 3925–3929. van Harmelen, V., Ariapart, P., BergstedtLindqvist, S., Reynisdottir, S., Hoffstedt, J., Lundkvist, I., Bringman, S., and Arner, P. (2000) The association of human adipose angiotensinogen gene expression with abdominal fat distribution in obesity. Int. J. Obes. Relat. Metab. Disord., 24, 673–678. Bertrand, H.A., Masoro, E.J., and Yu, B.P. (1978) Increasing adipocyte number as the basis for perirenal depot growth in adult rats. Science, 201, 1234–1235. Kirkland, J.L., Hollenberg, C.H., Kindler, S., and Gillon, W.S. (1994) Effects of age and anatomic site on preadipocyte number in rat fat depots. J. Gerontol., 49, B31–B35. Strawford, A., Antelo, F., Christiansen, M., and Hellerstein, M.K. (2004) Adipose tissue triglyceride turnover, de novo lipogenesis, and cell proliferation in humans measured with 2H2O. Am. J.
101
102
103
104
105
106
107
108
Physiol. Endocrinol. Metab., 286, E577–E588. Djian, P., Roncari, D.A.K., and Hollenberg, C.H. (1985) Adipocyte precursor clones vary in capacity for differentiation. Metabolism, 34, 880–883. Hauner, H. and Entenmann, G. (1991) Regional variation of adipose differentiation in cultured stromalvascular cells from the abdominal and femoral adipose tissue of obese women. Int. J. Obes., 15, 121–126. Kirkland, J.L., Hollenberg, C.H., and Gillon, W.S. (1990) Age, anatomic site, and the replication and differentiation of adipocyte precursors. Am. J. Physiol. Cell Physiol., 258, C206–C210. Kirkland, J.L., Hollenberg, C.H., and Gillon, W.S. (1996) Effects of fat depot site on differentiation-dependent gene expression in rat preadipocytes. Int. J. Obes., 20, S102–S107. Adams, M., Reginato, M.J., Shao, D., Lazar, M.A., and Chatterjee, V.K. (1997) Transcriptional activation by peroxisome proliferator-activated receptor c is inhibited by phosphorylation at a consensus mitogen-activated protein kinase site. J. Biol. Chem., 272, 5128–5132. Cinti, S., Mitchell, G., Barbatelli, G., Murano, I., Ceresi, E., Faloia, E., Wang, S., Fortier, M., Greenberg, A.S., and Obin, M.S. (2005) Adipocyte death defines macrophage localization and function in adipose tissue of obese mice and humans. J. Lipid Res., 46, 2347–2355. Kirkland, J.L., Tchkonia, T., Giorgadze, N., and Pirtskhalava, T. (2003) Adipose tissue as an endocrine organ: regional differences in adipocyte endocrine function. Prog. Obes. Res., 9, 87–95. Seki, T., Miyasu, T., Noguchi, T., Hamasaki, A., Sasaki, R., Ozawa, Y., Okukita, K., Declerck, P.J., and Ariga, T. (2001) Reciprocal regulation of tissuetype and urokinase-type plasminogen activators in the differentiation of murine preadipocyte line 3T3-L1 and the hormonal regulation of fibrinolytic factors in the mature adipocytes. J. Cell. Physiol., 189, 72–78.
References 109 Lacasa, D., Taleb, S., Keophiphath, M.,
110
111
112
113
114
115
116
Miranville, A., and Clement, K. (2007) Macrophage-secreted factors impair human adipogenesis: involvement of proinflammatory state in preadipocytes. Endocrinology, 148, 868–877. Prunet-Marcassus, B., Cousin, B., Caton, D., Andre, M., Penicaud, L., and Casteilla, L. (2006) From heterogeneity to plasticity in adipose tissues: site-specific differences. Exp. Cell Res., 312, 727–736. Charriere, G., Cousin, B., Arnaud, E., Andre, M., Bacou, F., Penicaud, L., and Casteilla, L. (2003) Preadipocyte conversion to macrophage. J. Biol. Chem., 278, 9850–9855. Niesler, C.U., Siddle, K., and Prins, J.B. (1998) Human preadipocytes display a depot-specific susceptibility to apoptosis. Diabetes, 47, 1365–1368. Tchkonia, T., Tchoukalova, Y.D., Giorgadze, N., Pirtskhalava, T., Karagiannides, I., Forse, R.A., Koo, A., Stevenson, M., Chinnappan, D., Cartwright, A., Jensen, M.D., and Kirkland, J.L. (2005) Abundance of two human preadipocyte subtypes with distinct capacities for replication, adipogenesis, and apoptosis varies among fat depots. Am. J. Physiol. Endocrinol. Metab., 288, E267–E277. van Harmelen, V., Rohrig, K., and Hauner, H. (2004) Comparison of proliferation and differentiation capacity of human adipocyte precursor cells from the omental and subcutaneous adipose tissue depot of obese subjects. Metabolism, 53, 632–637. Adams, M., Montague, C.T., Prins, J.B., Holder, J.C., Smith, S.A., Sanders, L., Digby, J.E., Sewter, C.P., Lazar, M.A., Chatterjee, V.K., and ORahilly, S. (1997) Activators of peroxisome proliferatoractivated receptor gamma have depotspecific effects on human preadipocyte differentiation. J. Clin. Invest., 100, 3149–3153. Djian, P., Roncari, D.A.K., and Hollenberg, C.H. (1983) Influence of anatomic site and age on the replication and differentiation of rat adipocyte precursors in culture. J. Clin. Invest., 72, 1200–1208.
117 Caserta, F., Tchkonia, T., Civelek, V.,
118
119
120
121
122 123
124
125
126
Prentki, M., Brown, N.F., McGarry, J.D., Forse, R.A., Corkey, B.E., Hamilton, J.A., and Kirkland, J.L. (2001) Fat depot origin affects fatty acid handling in cultured rat and human preadipocytes. Am. J. Physiol. Endocrinol. Metab., 280, E238–E247. Peiris, A.N., Struve, M.F., and Kissebah, A.H. (1987) Relationship of body fat distribution to the metabolic clearance of insulin in obese women. Int. J. Obes., 11, 581–589. Peiris, A.N., Mueller, R.A., Smith, G.A., Struve, M.F., and Kissebah, A.H. (1986) Splanchnic insulin metabolism in obesity. J. Clin. Invest., 78, 1648–1657. Kissebah, A.H. and Hennes, M.M.I. (1995) Central obesity and free fatty acid metabolism. Prostaglandins Leukot Essential Fatty Acids, 52, 209–211. Bevilacqua, S., Bonadonna, R., Buzzigoli, G., Boni, C., Ciociaro, D., Maccari, F., Giorico, M.A., and Ferrannini, E. (1987) Acute elevation of free fatty acid levels leads to hepatic insulin resistance in obese subjects. Metabolism, 36, 502–506. Perrin, S. (1995) Biochemistry, Boston University, Boston, MA. Miller, W.H., Faust, I.M., and Hirsch, J. (1984) Demonstration of de novo production of adipocytes in adult rats by biochemical and radioautographic techniques. J. Lipid Res., 25, 336–347. Digby, J., Crowley, V., Sewter, C., Whitehead, J., Prins, J., and ORahilly, S. (2000) Depot-related and thiazolidinedione-responsive expression of uncoupling protein 2 (UCP2) in human adipocytes. Int. J. Obes., 24, 585–592. Hauner, H., Wabitsch, M., and Pfeiffer, E.F. (1988) Differentiation of adipocyte precursor cells from obese and nonobese adult women from different adipose tissue sites. Horm. Metab. Res., 19 (Suppl.), 35–39. Montague, C.T., Prins, J.B., Sanders, L., Zhang, J., Sewter, C.P., Digby, J., Byrne, C.D., and ORahilly, S. (1998) Depotrelated gene expression in human subcutaneous and omental adipocytes. Diabetes, 47, 1384–1391.
j43
j 2 Cellular and Molecular Basis of Functional Differences among Fat Depots
44
127 Shahparaki, A., Grunder, L., and Sorisky,
128
129
130
131
132
133
134
A. (2002) Comparison of human abdominal subcutaneous versus omental preadipocyte differentiation in primary culture. Metabolism, 51, 1211–1215. van Harmelen, V., Dicker, A., Ryden, M., Hauner, H., Lonnqvist, F., Naslund, E., and Arner, P. (2002) Increased lipolysis and decreased leptin production by human omental as compared with subcutaneous preadipocytes. Diabetes, 51, 2029–2036. Burris, T., Pelton, P., Zhou, L., Osborne, M., Cryan, E., and Demarest, K. (1999) A novel method for analysis of nuclear receptor function at natural promoters: peroxisome proliferator-activated receptor gamma agonist actions on ap2 gene expression detected using branched DNA messenger RNA quantitation. Mol. Endocrinol., 13, 410–417. Barak, Y., Nelson, M.C., Ong, E.S., Jones, Y.Z., Ruiz-Lozano, P., Chien, K.R., Koder, A., and Evans, R.M. (1999) PPARc is required for placental, cardiac and adipose tissue development. Mol. Cell, 4, 585–595. Rosen, E.D., Sarraf, P., Troy, A.E., Bradwin, G., Moore, K., Milstone, D.S., Spiegelman, B.M., and Mortensen, R.M. (1999) PPARc is required for the differentiation of adipose tissue in vivo and in vitro. Mol. Cell, 4, 611–617. Hollenberg, A.N., Susulic, V.S., Madura, J.P., Zhang, B., Moller, D.E., Tontonoz, P., Sarraf, P., Spiegelman, B.M., and Lowell, B.B. (1997) Functional antagonism between CCAAT/enhancer binding protein-a and peroxisome proliferator-activated receptor-c on the leptin promoter. J. Biol. Chem., 272, 5283–5290. Kirkland, J.L., Hollenberg, C.H., Gillon, W., and Kindler, S. (1992) Effect of hypophysectomy on rat preadipocyte replication and differentiation. Endocrinology, 131, 2769–2773. Lacasa, D., Garcia, E., Agli, B., and Giudicelli, Y. (1997) Control of rat preadipocyte adipose conversion by ovarian status: regional specificity and possible involvement of the mitogenactivated protein kinase-dependent and
135
136
137
138
139
140
141
142
143
144
c-fos signaling pathways. Endocrinology, 138, 2729–2734. Prins, J.B., Walker, N.I., Winterford, C.M., and Cameron, D.P. (1994) Apoptosis of human adipocytes in vitro. Biochem. Biophys. Res. Commun., 201, 500–507. Papineau, D., Gagnon, A., and Sorisky, A. (2003) Apoptosis of human abdominal preadipocytes before and after differentiation into adipocytes in culture. Metabolism, 52, 987–992. Kirkland, J.L., Hollenberg, C.H., and Gillon, W.S. (1993) Two preadipocyte subtypes cloned from human omental fat. Obes. Res., 1, 87–91. Despres, J.P. and Angel, A. (1989) Scanning electron microscopy of very small fat cells and mature fat cells in human obesity. J. Lipid Res., 30, 293–299. DeMartinis, F.D. and Francendese, A. (1982) Very small fat cell populations: mammalian occurrence and effect of age. J. Lipid Res., 23, 1107–1120. DeMartinis, F.D. (1985) Very small fat cell populations determined by a modified osmium tetroxide-urea method. Am. J. Physiol. Cell Physiol., 249, C89–C96. Bluher, M., Michael, M.D., Peroni, O.D., Ueki, K., Carter, N., Kahn, B.B., and Kahn, C.R. (2002) Adipose tissue selective insulin receptor knockout protects against obesity and obesity-related glucose intolerance. Dev. Cell, 3, 25–38. Bluher, M., Patti, M.E., Gesta, S., Kahn, B.B., and Kahn, C.R. (2004) Intrinsic heterogeneity in adipose tissue of fatspecific insulin receptor knockout mice is associated with differences in patterns of gene expression. J. Biol. Chem., 279, 31891–31901. Gesta, S., Bluher, M., Yamamoto, Y., Norris, A.W., Berndt, J., Kralisch, S., Boucher, J., Lewis, C., and Kahn, C.R. (2006) Evidence for a role of developmental genes in the origin of obesity and body fat distribution. Proc. Natl. Acad. Sci. USA, 103, 6676–6681. Vohl, M.C., Sladek, R., Robitaille, J., Gurd, S., Marceau, P., and Richard, D. (2004) A survey of genes differentially expressed in subcutaneous and visceral
References
145
146
147
148
149
150
151
152
adipose tissue in men. Obes. Res., 12, 1217–1222. Tchkonia, T., Lenburg, M., Thomou, T., Giorgadze, N., Frampton, G., Pirtskhalava, T., Cartwright, A., Cartwright, M., Flanagan, J., Karagiannides, I., Gerry, N., Forse, R.A., Tchoukalova, Y., Jensen, M.D., Pothoulakis, C., and Kirkland, J.L. (2007) Identification of depot-specific human fat cell progenitors through distinct expression profiles and developmental gene patterns. Am. J. Physiol. Endocrinol. Metab., 292, E298–E307. Lawrence, J.B., Oxvig, C., Overgaard, M.T., Sottrup-Jensen, L., Gleich, G.J., Hays, L.G., Yates, J.R. 3rd, and Conover, C.A. (1999) The insulin-like growth factor (IGF)-dependent IGF binding protein-4 protease secreted by human fibroblasts is pregnancy-associated plasma protein-A. Proc. Natl Acad. Sci. USA, 96, 3149–3153. Gesta, S., Bluher, M., Yamamoto, Y., Norris, A.W., Berndt, J., Kralisch, S., Boucher, J., Lewis, C., and Kahn, C.R. (2006) Evidence for a role of developmental genes in the origin of obesity and body fat distribution. Proc. Natl. Acad. Sci. USA, 103, 6676–6681. Vohl, M.C., Sladek, R., Robitaille, J., Gurd, S., Marceau, P., Richard, D., Hudson, T.J., and Tchernof, A. (2004) A survey of genes differentially expressed in subcutaneous and visceral adipose tissue in men. Obes. Res., 12, 1217–1222. Ingham, P.W. and Martinez Arias, A. (1992) Boundaries and fields in early embryos. Cell, 68, 221–235. Slack, J.M. and Tannahill, D. (1992) Mechanism of anteroposterior axis specification in vertebrates. Lessons from the amphibians. Development, 114, 285–302. Koussoulakos, S. (2004) Vertebrate limb development: from Harrisons limb disk transplantations to targeted disruption of Hox genes. Anat. Embryol., 209, 93–105. Tarchini, B., Huynh, T.H., Cox, G.A., and Duboule, D. (2005) HoxD cluster scanning deletions identify multiple defects leading to paralysis in the mouse
153
154
155
156
157
158
159
160
161
162
mutant Ironside. Genes Dev., 19, 2862–2876. Martinez, P. and Amemiya, C.T. (2002) Genomics of the HOX gene cluster. Comp. Biochem. Physiol. B Biochem. Mol. Biol., 133, 571–580. Swalla, B.J. (2006) Building divergent body plans with similar genetic pathways. Heredity, 97, 235–243. Hunt, P. and Krumlauf, R. (1991) Deciphering the Hox code: clues to patterning branchial regions of the head. Cell, 66, 1075–1078. Maroulakou, I.G. and Spyropoulos, D.D. (2003) The study of HOX gene function in hematopoietic, breast and lung carcinogenesis. Anticancer Res., 23, 2101–2110. Gould, A. (1997) Functions of mammalian Polycomb group and trithorax group related genes. Curr. Opin. Genet. Dev., 7, 488–494. Bantignies, F. and Cavalli, G. (2006) Cellular memory and dynamic regulation of polycomb group proteins. Curr. Opin. Cell Biol., 18, 275–283. Bernstein, B.E., Kamal, M., Lindblad-Toh, K., Bekiranov, S., Bailey, D.K., Huebert, D.J., McMahon, S., Karlsson, E.K., Kulbokas, E.J. 3rd, Gingeras, T.R., Schreiber, S.L., and Lander, E.S. (2005) Genomic maps and comparative analysis of histone modifications in human and mouse. Cell, 120, 169–181. Sessa, L., Breiling, A., Lavorgna, G., Silvestri, L., Casari, G., and Orlando, V. (2007) Noncoding RNA synthesis and loss of Polycomb group repression accompanies the colinear activation of the human HOXA cluster. RNA, 13, 223–239. Bernstein, B.E., Mikkelsen, T.S., Xie, X., Kamal, M., Huebert, D.J., Cuff, J., Fry, B., Meissner, A., Wernig, M., Plath, K., Jaenisch, R., Wagschal, A., Feil, R., Schreiber, S.L., and Lander, E.S. (2006) A bivalent chromatin structure marks key developmental genes in embryonic stem cells. Cell, 125, 315–326. Milne, T.A., Briggs, S.D., Brock, H.W., Martin, M.E., Gibbs, D., Allis, C.D., and Hess, J.L. (2002) MLL targets SETdomain methyltransferase activity to Hox gene promoters. Mol. Cell, 10, 1107–1117.
j45
j 2 Cellular and Molecular Basis of Functional Differences among Fat Depots
46
163 Cao, R., Wang, L., Wang, H., Xia, L.,
164
165
166
167
168
169
170
171
172
Erdjument-Bromage, H., Tempst, P., Jones, R.S., and Zhang, Y. (2002) Role of histone H3 lysine 27 methylation in Polycomb-group silencing. Science, 298, 1039–1043. Christensen, J., Agger, K., Cloos, P.A., Pasini, D., Rose, S., Sennels, L., Rappsilber, J., Hansen, K.H., Salcini, A.E., and Helin, K. (2007) RBP2 belongs to a family of demethylases, specific for tri-and dimethylated lysine 4 on histone 3. Cell, 128, 1063–1076. Beslu, N., Krosl, J., Laurin, M., Mayotte, N., Humphries, K.R., and Sauvageau, G. (2004) Molecular interactions involved in HOXB4-induced activation of HSC selfrenewal. Blood, 104, 2307–2314. Lessard, J., Schumacher, A., Thorsteinsdottir, U., van Lohuizen, M., Magnuson, T., and Sauvageau, G. (1999) Functional antagonism of the PolycombGroup genes eed and Bmi1 in hemopoietic cell proliferation. Genes Dev., 13, 2691–2703. Akbas, G.E. and Taylor, H.S. (2004) HOXC and HOXD gene expression in human endometrium: lack of redundancy with HOXA paralogs. Biol. Reprod, 70, 39–45. Kessel, M. and Gruss, P. (1991) Homeotic transformations of murine vertebrae and concomitant alteration of Hox codes induced by retinoic acid. Cell, 67, 89–104. Fried, S. and Kral, J. (1987) Sex differences in regional distribution of fat cell size and lipoprotein lipase activity in morbidly obese patients. Int. J. Obes., 11, 129–140. Fried, S.K., Leibel, R.L., Edens, N., and Kral, J.G. (1993) Lipolysis in intraabdominal adipose tissues of obese men and women. Obes. Res., 1, 443–448. Edens, N.K., Fried, S.K., Kral, J.G., Hirsch, J., and Leibel, R.L. (1993) In vitro lipid synthesis in human adipose tissue from three abdominal sites. Am. J. Physiol. Endocrinol. Metabol., 265, E374–E379. Weisberg, S.P., McCann, D., Desai, M., Rosenbaum, M., Leibel, R.L., and Ferrante, A.W. (2003) Obesity is associated with macrophage
173
174
175
176
177
178
179
180
accumulation in adipose tissue. J. Clin. Invest., 112, 1796–1808. Xu, H., Barnes, G.T., Yang, Q., Tna, G., Yang, D., Chou, C.J., Sole, J., Nichols, A., Ross, J.S., Tartaglia, L.A., and Chen, H. (2003) Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J. Clin. Invest., 112, 1821–1830. Cartwright, M.J., Tchkonia, T., and Kirkland, J.L. (2007) Aging in adipocytes: potential impact of inherent, depotspecific mechanisms. Exp. Gerontol., 42, 463–471. Nair, S., Lee, Y.H., Rousseau, E., Cam, M., Tataranni, P.A., Baier, L.J., Bogardus, C., and Permana, P.A. (2005) Increased expression of inflammation-related genes in cultured preadipocytes/stromal vascular cells from obese compared with non-obese Pima Indians. Diabetologia, 48, 1784–1788. Dubois, S.G., Heilbronn, L.K., Smith, S.R., Albu, J.B., Kelley, D.E., and Ravussin, E. (2006) Decreased expression of adipogenic genes in obese subjects with type 2 diabetes. Obesity, 14, 1543–1552. Shillabeer, G., Forden, J.M., Russell, J.C., and Lau, D.C. (1990) Paradoxically slow preadipocyte replication and differentiation in corpulent rats. Am. J. Physiol. Endocrinol. Metab., 258, E368–E376. Permana, P.A., Nair, S., Lee, YH., LuczyBachman, G., Vozarova de Courten, B., and Tataranni, P.A. (2004) Subcutaneous abdominal preadipocyte differentiation in vitro inversely correlates with central obesity. Am. J. Physiol. Endocrinol. Metab., 286, E958–E962. Turkenkopf, I.J., Chow, G., East-Palmer, J., Greenwood, M.R., and Johnson, P.R. (1988) Regional and genotypic differences in stromal-vascular cells from obese and lean Zucker rats. Int. J. Obes. Relat. Metab. Disord., 12, 515–524. Karagiannides, I., Tchkonia, T., Dobson, D.E., Steppan, C.M., Cummins, P., Chan, G., Salvatori, K., HadzopoulouCladaras, M., and Kirkland, J.L. (2001) Altered expression of C/EBP family members results in decreased
References adipogenesis with aging. Am. J. Physiol. Regul. Integr. Comp. Physiol., 280, R1772–R1780. 181 Karagiannides, I., Thomou, T., Tchkonia, T., Pirtskhalava, T., Kypreos, K.E., Cartwright, A., Dalagiorgou, G., Lash, T.L., Farmer, S.R., Timchenko, N.A., and Kirkland, J.L. (2006) Increased CUG
triplet repeat binding protein-1 predisposes to impaired adipogenesis with aging. J. Biol. Chem., 281, 23025–23033. 182 Rosmond, R. and Bj€ orntorp, P. (2000) The role of antidepressants in the treatment of abdominal obesity. Med. Hypotheses, 54, 990–994.
j47
j49
3 Plasticity of the Adipose Organ Saverio Cinti 3.1 Introduction
For many years our group has been developing a new anatomic-functional concept –: the adipose organ. The innovative part of this concept tries to give an explanation to the fact that the two well-known and distinct adipose tissues (white adipose tissue (WAT) and brown adipose tissue (BAT)) are contained mixed together into a dissectible organ formed by several subcutaneous and visceral depots. It was generally believed that the two tissues are separated entities, with different functional activities, contained in different anatomical sites, but our studies demonstrate that anatomical sites exclusive for WAT or BAT do not exist. In fact, many subcutaneous and visceral depots in small mammals and some depots in humans are composed of a mixed tissue made up of white and brown adipocytes. The reason why these two different tissues are mixed together is not clear, but the problem is underestimated because it is easy to accepted that cells both denominated as adipocytes, in spite the fact that their morphology and physiology is completely different, are mixed together in the same organ. We offer an explanation for this anatomical organization – the plasticity of the adipose organ. In other words, the well-known phenomenon of reversible transformation of the adipose tissues due to physiological stimuli such as exposure to cold (the organ phenotype change from white to brown) or to the hormonal environment during pregnancy and lactation (part of the organ phenotype change from WAT to milk-secreting glands) induce a transformation of the phenotype of the adipose organ based on the intrinsic biologic properties of adipocytes that are able to undertake a reversible transdifferentiation. This concept opens a new perspective in the field of cell biology – the ability of differentiated cells of mammals to undergo a physiologic reversible process that drives into a new phenotype (with new morphology and physiology). In this chapter, we describe the most important data obtained in our and others laboratories to support this concept of the adipose organ with particular emphasis on data supporting the transdifferentiation as the main process at the base of its property of plasticity.
j 3 Plasticity of the Adipose Organ
50
3.2 Gross Anatomy Demonstrates that WAT and BAT are Mixed Together in the Adipose Organ
The adipose organ is a multidepot organ (Figure 3.1) [1–3]. In rodents, there are two main subcutaneous depots (anterior and posterior) and several visceral depots (mediastinic, omental, mesenteric, perirenal, retroperitoneal, perigonadic, and perivescical). Discrete subcutaneous depots are also dissectable at the level of the major joints in the limbs. The color of the organ is white and brown – the white parts are made mainly by white adipocytes; the brown parts are made mainly by brown adipocytes. The relative amounts of white and brown parts are genetically determined and depend on several factors (mainly age, sex, environmental temperature, and nutritional status). In most small rodents brown areas are visually evident in the interscapular, axillary, and cervical parts of the anterior subcutaneous depots, and in the mediastinic and perirenal visceral depots. In other words, it is anatomically evident that some subcutaneous (anterior) and visceral (mediastinic and perirenal) depots are composed in part by WAT and in part by BAT.
Figure 3.1 Gross anatomy of the adipose organ of adult female 129Sv mice. The subcutaneous and visceral depots were dissected and positioned on a template of the mice to show their location in the organism. The mouse on the left was maintained under warm conditions (28 C for 10 days) and the mouse on the right under cold conditions (6 C for 10 days). Note the visually evident transformation of the color of the organ due to the increase of BAT and decrease of WAT contained in the
organ. The organ is made up of two subcutaneous depots: A ¼ anterior (deep cervical, superficial cervical, interscapular, subscapular, axillothoracic) and F ¼ posterior (dorso-lumbar, inguinal, gluteal) and of several visceral depots: B ¼ mediastinal, C ¼ mesenteric, D ¼ retroperitoneal, and E ¼ abdomino-pelvic (perirenal, periovarian, parametrial, perivesical). Bar ¼ 1 cm. Reproduced from [4] with permission.
3.3 Light and Electron Microscopy show that White and Brown Adipocytes
In a recent paper, we described quantitative data of the anatomy of the adipose organ of Sv129 adult female mice. We calculated the total number of white and brown adipocytes contained in most depots (anterior subcutaneous, posterior subcutaneous, mediastinic, perirenal, perigonadic, perivescical, retroperitoneal, and mesenteric). Of note, we observed that perirenal, perigonadic, and perivescical depots that are usually described as distinct depots have a unique anatomy, and therefore we denominated this depot abdomino-pelvic. Our data show that, in this strain, all subcutaneous and all visceral depots contain both white and brown adipocytes mixed together. In some depots white adipocytes are more numerous than brown (posterior subcutaneous, mesenteric, and retroperitoneal); in other depots brown adipocytes are more numerous than white (anterior subcutaneous, mediastinic, and abdominopelvic). Interestingly, in these mice, 60% of the total amount of adipocytes of the adipose organ are brown [4].
3.3 Light and Electron Microscopy show that White and Brown Adipocytes have a Well-Defined and Distinct Morphology 3.3.1 WAT
These spherical cells (Figure 3.2) have a variable diameter depending on the size of the cytoplasmic lipid droplet. White adipocytes with a complete set of organelles, considered to be characteristic for differentiated cells, can be very small (less than 10 mm in diameter) in comparison with the average diameter of the adipocytes found in the different depots of adult mammals. Small adipocytes are often found in the adipose organ of young animals. In physiological conditions, the largest adipocytes
Figure 3.2 Scanning electron microscopy of BAT (a) and WAT (b). Brown adipocytes are polyhedral with a multilocular lipid depot. White adipocytes are spherical with a unilocular lipid depot. Bar ¼ left 40 mm; right 80 mm. Used with permission of The American Physiological Society.
j51
j 3 Plasticity of the Adipose Organ
52
Figure 3.3 Mouse subcutaneous WAT. Part of a white adipocyte is visible. Mitochondria (M) are small, elongated with randomly oriented cristae. BM ¼ basal membrane; L ¼ lipid droplet. Transmission electron microscopy. Bar ¼ 1.4 mm.
(diameter of about 90–100 mm) are found in epididymal fat of old animals. Human adipocytes are identical to those of rodents, but the size is 20–30% larger. The lipid vacuole is in direct contact with the cytosol (i.e., without any interposed membranous structure). The nucleus is compressed by the lipid droplet, but the cytoplasm near it is usually thicker than in the rest of the cell. Here, elongated mitochondria (Figure 3.3), Golgi complex, rough and smooth endoplasmic reticulum, vesicles, and other organelles are usually visible by transmission electron microscopy. Many pinocytotic vesicles are present in the proximity of the plasma membrane and an external lamina surrounds the cell. In general, small adipocytes have more numerous mitochondria than large adipocytes. 3.3.2 BAT
Brown adipocytes store triglycerides as numerous small vacuoles (multilocular cell) (Figure 3.2). The shape of brown adipocytes is polygonal or ellipsoid with a maximum diameter between a minimum of 15–20 mm and a maximum of 40–50 mm. The nucleus is usually central and the cytoplasm is rich in organelles. The most characteristic organelles are the mitochondria. They are numerous, big, and rich in transverse cristae (Figure 3.4). Peroxisomes, Golgi complex, rough and smooth endoplasmic reticulum, vesicles, and other organelles are also visible by transmission electron microscopy. Pinocytotic vesicles and external lamina are also present in this cell. Brown adipocytes are joined by gap junctions [5]. Over the last 27 years in which we have studied the adipose tissues, when an adipocyte with the light microscopic appearance of a multilocular cell was examined under the electron microscope, it always exhibited mitochondria that were characteristic and distinctive of brown adipocytes [3, 6]. This was independent of its
3.4 WAT and BAT have a Different Vascular and Nerve Supply
Figure 3.4 Rat interscapular BAT. Numerous brown adipocyte mitochondria packed with transverse cristae are visible. Three small lipid droplets (L) are also visible. Transmission electron microscopy. Bar ¼ 1.1 mm.
uncoupling protein (UCP)-1 expression. At variance with the researchers who hold that brown adipocytes are cells expressing UCP-1, we believe that expression of UCP1 merely reflects the cells thermogenic activity, and that a brown adipocyte is a cell with a distinctive morphology, a multilocular lipid content, and characteristic mitochondria. Moreover, the brown adipocytes of UCP-1 knockout mice are multilocular, while the morphology of their mitochondria is indistinguishable from that of white adipocytes (our unpublished data in collaboration with Barbara Cannon and Jan Nedergaard). In addition, the white adipocytes of aP2-UCP-1 transgenic mice, which express UCP-1 also in white adipocytes, are unilocular and their mitochondria are similar to those of brown adipocytes [7]. Multilocularity is widely considered to be a characteristic feature of developing white adipocytes (preadipocytes). In fact, this is true only in the first weeks of postnatal life, when the adipose organ is developing. In this specific situation there are some multilocular preadipocytes (committed to become white unilocular adipocytes), but they are small and easily distinguished from mature adipocytes [8–10]. For all these reasons, we believe that the multilocular adipocytes found in the adipose organ of adult animals must be considered thermogenically hypo functioning brown adipocytes when they are UCP-1-negative and thermogenically active when they are UCP-1-positive. In this chapter we use a nomenclature in accordance with this definition of brown adipocyte. 3.4 WAT and BAT have a Different Vascular and Nerve Supply
The adipose organ is diffuse into the organism and most of its depots receive vascular supply by regional visceral or parietal nerve-vascular bundles. Specific bundles are
j53
j 3 Plasticity of the Adipose Organ
54
present in the two main subcutaneous depots (murine adipose organ). The extension of the capillary network is quite different in the white and brown parts of the organ. In the brown areas the density of the capillaries is much higher than in the white areas. This may be due to the fact that since brown adipocytes are highly metabolic, they need rapid oxygen supply. Furthermore, a rapid heat dissipation is needed in order to avoid any heat-dependent cellular damage. The nerve supply to the adipose organ is different in the brown and white areas. The former are more innervated than the latter. In brown areas, numerous noradrenergic fibers are also found in fat lobules (parenchymal nerves), running with blood vessels (until the level of capillaries) and directly in contact with adipocytes. Adrenergic receptors (a1,2 and b1–3) are present in the adipose organ and all badrenoceptors are present on adipocytes. The density of parenchymal fibers varies according to the functional status of the organ. During cold exposure the noradrenergic parenchymal fibers increase their density in the brown part of the organ [11]. During fasting, the noradrenergic parenchymal fibers increase their density in the white part of the organ [12]. Vascular noradrenergic fibers are also immunoreactive for neuropeptide Y. The vast majority of these nerves also contain noradrenaline [12, 13], suggesting that they belong to the sympathetic nerve supply to WAT blood vessels. Brown and white areas also have a provision of sensory nerves [14] that are capsaicin-sensitive, and are immunoreactive for calcitonin gene-related peptide and substance P. The functional significance of these sensory nerves is not precisely known, although in the rat periovarian adipose depot they affect the recruitment of visceral brown adipocytes during cold acclimation [15]. Recently, a parasympathetic innervation of white fat with possible functional implications has been described, but the matter is still debated [16, 17].
3.5 WAT and BAT have a Different Physiology
White adipocytes have the main purpose to accumulate and release highly energetic molecules (fatty acids) that can supply fuel to the organism during intervals between meals. When the interval prolongs over the weeks, WAT represents the survival tissue. Brown adipocytes use the same molecules to produce heat (nonshivering thermogenesis). This function is due to a protein, UCP-1, exclusively present in mitochondria of brown adipocytes [18–23]. The signal for brown adipocyte activation is a temperature below thermoneutrality (34 C for mice, 28 C for rats, and 20–22 C for humans) that induces activation of the sympathetic nervous system. These neurons of the sympathetic chain directly reach brown adipocytes in the adipose organ [19]. The total volume of the adipose organ is dependent on the equilibrium between WAT and BAT activities because the main cytoplasmic structure (lipid droplets) can be dissipated (BAT) or accumulated (WAT). Of note, genetic ablation of BAT or of all b-adrenergic receptors induces obesity in mice [24, 25], although mice lacking UCP-1 are cold-sensitive, but not
3.6 Phenotype of the Adipose Organ is Variable: Plasticity of the Adipose Organ
obese [26]. On the other hand, ectopic expression of UCP-1 in WAT results in obesity resistance [27]. Accordingly, it has been shown recently that obesity-prone mice have less BAT than obesity-resistant mice [28]. In 1994, another primary function of white adipocytes was discovered – production of a hormone able to influence animal behavior concerning food intake [29]. This hormone, denominated leptin, also induces energy dispersion (via BAT and locomotor activation) and has gonadotrophic properties. Brown adipocytes in their classic multilocular configuration (i.e., during thermogenic activity) are not immunoreactive for leptin [30, 31]. A growing body of evidence suggests that the adipose organ produces several factors known as adipokines, controlling several important functions such as glucose and lipid metabolism, blood coagulation, blood pressure, and steroid hormones modulation (see other chapters of this book). The production of all these adipokines raised the recent concept of the adipose organ as an endocrine organ [32, 33]. It must be outlined that adipocytes are not the only cell type present in the adipose organ. It has been calculated that only about 50% of its cell content are adipocytes [34]. Vascular elements, preadipocytes, fibroblasts, mast cells, macrophages, nervous elements, and mesenchymal cells with unknown functions are usually found in all depots of the adipose organ.
3.6 Phenotype of the Adipose Organ is Variable: Plasticity of the Adipose Organ
It is well known that the anatomy of the adipose organ is variable. There are two physiologic conditions in which this phenomenon is quite evident – exposure (or acclimatation) to different temperatures and pregnancy/lactation. 3.6.1 Transformation of the Phenotype: Cold and Warm Exposure and Acclimatization
If we observe the adipose organ of cold-exposed mice we see that the color of the organ is changed, suggesting a change into a more brown phenotype (Figure 3.1). This wellknown reversible phenomenon is due to an increase in the number of brown adipocytes, capillaries, and noradrenergic parenchymal fibers of the adipose organ. The same phenomenon can be achieved by the administration of b3-adrenoceptor agonists and is suppressed in mice lacking b3-adrenoceptors [35, 36], suggesting that noradrenergic fibers play a central role mainly acting on b3-adrenoceptors of adipocytes. Accordingly, after cold exposure, the density of noradrenergic fibers increase in all parts of the adipose organ [11, 37]. Capillary density increases in close association with the increase in number of brown adipocytes that produce potent vasculotrophic factors such as vascular endothelial growth factor. The newly formed brown adipocytes could, in theory, derive from the development of pre-existing stem cells resident in the tissue, from migrating stem cells, or from the direct transformation of differentiated white adipocytes (transdifferentiation), or from a combination of the three phenomena. We think that reversible transdifferentiation is the
j55
j 3 Plasticity of the Adipose Organ
56
most important phenomenon underling this plasticity of the adipose organ for the following reasons: 1)
After cold acclimation a number of brown adipocytes appear in WAT that almost correspond to that of disappeared white adipocytes. From our calculations the total number of adipocytes of the adipose organ after 10 days of cold acclimation (Sv129 adult female mice) increases by 11 million (176 versus 187 million). Of note, the total number of brown adipocytes increases by 42 million and the total number of white adipocytes decreases by 31 million. These data suggest that, in the absence of histological signs of apoptosis or other forms of degeneration of white adipocytes, most of the newly formed brown adipocytes derive from direct transformation of white into brown adipocytes. The absence of necrosis or apoptosis is in line with the fact that the cold-induced adrenergic stimulus is protective of brown adipocytes [38], which are more subject to apoptosis than white adipocytes [39]. It has been recently reported that apoptosis occurs in white adipocytes after intracerebroventricular injection of leptin [40]; however, cold acclimation reduces leptin expression and leptinemia [41], and therefore leptininduced apoptosis can probably be ruled out in our study. 2) Between 80 and 95% of the newly formed brown adipocytes appearing in WAT after b3-adrenoceptor agonist treatment are bromodeoxyuridine (BrdU)-negative. The retroperitoneum depot of 20-week-old rats (Sprague-Dawley) is almost entirely composed by white adipocytes. After 7 days of treatment with the b3adrenoceptor agonist CL 316,243 about 17% of the adipocytes of this depot are brown adipocytes. Electron microscopy and biochemical studies together with immunohistochemistry demonstrate that these newly formed brown adipocytes are prevalently not thermogenically active (only 8% of them are UCP-1-positive) and show evidence for intense mitochondria biogenesis. Importantly, many adipocytes with intermediate morphology between white and brown adipocytes were found by electron microscopy. BrdU experiments showed that the mitotic index of these adipocytes was very low (5%; i.e., 95% of these adipocytes were BrdU-negative, implying that they have not had a mitotic process) [35]. Of note, recently, Granneman et al. obtained similar results: 80% of the multilocular cells (we do not use the term brown here in respect to the authors definition) were BrdU-negative [42]. 3) After cold acclimation adipocyte precursors do not increase in WAT in spite of the striking increase of brown adipocytes. Electron microscopy can easily detect adipocyte precursors in the developing adipose organ or in the adipose organ of adrenergic stimulated animals in both WAT and BAT [1]. We found rare adipocyte precursors in WAT of cold-exposed and acclimated animals, but quantitative evaluation demonstrates that their number was similar to that found in room temperature control animals (our unpublished observations) and we were not able to find adipocyte precursors in WATof rats treated with the b3-adrenoceptor agonist CL 316,243 [35]. 4) After cold acclimation and b3-adrenoceptor agonist treatment a new form of UCP-1-positive brown adipocytes appear in WAT with intermediate aspects
3.6 Phenotype of the Adipose Organ is Variable: Plasticity of the Adipose Organ
Figure 3.5 Adipocytes with intermediate features between white and brown adipocytes (paucilocular transdifferentiating adipocytes). After cold exposure transdifferentiating paucilocular adipocytes appear in WAT with lipid accumulation similar to white adipocytes
(L) and mitochondria similar to those of brown adipocytes. Note that together with large brown mitochondria (B), some small white mitochondria are also visible (W) in the same cell. CAP ¼ capillary. Transmission electron microscopy. Bar ¼ 1 mm.
between white and brown adipocytes. In a recent study we found that cold acclimatization or treatment with b3 agonist induces the appearance in WAT of numerous UCP-1-positive multilocular adipocytes with intermediate morphology between white and brown adipocytes by electron microscopy. The two main aspects of these cells are the presence of a predominant lipid vacuole in the cytoplasm, and a mitochondria population with different intermediate forms between white and brown mitochondria (Figure 3.5). 5) Isolated brown adipocytes have intermediate aspects between white and brown adipocytes. Early in vitro studies from our laboratory showed that adipocytes developed from the stromal vascular fraction obtained from the interscapular BAT of young rats and from humans have intermediate morphology between white and brown adipocytes, including mitochondria with intermediate features [43, 44]. The addition of noradrenaline to the culture medium induces a more typical morphology of the mitochondria of those adipocytes (rats) [45]. In line with these studies, the genetic removal of all types of b-adrenoceptors in mice induces a transformation of the morphology of interscapular BATadipocytes that became unilocular and express leptin [25]. Again, the mitochondria of those cells have intermediate features between white and brown adipocytes. 6) The morphology and protein expression of brown adipocytes is variable in relationship to the level of noradrenaline in the tissue. In murine interscapular BAT of warm-acclimated animals the noradrenaline level is lower than in the interscapular BAT of cold-acclimated animals and the morphology of brown
j57
j 3 Plasticity of the Adipose Organ
58
adipocytes varies in these conditions as follows: in cold-acclimated animals brown adipocytes have the classic morphology with multilocular lipid droplets and big mitochondria reach of cristae. These cells express UCP-1 and do not express leptin nor S-100B (a protein expressed in white adipocytes and preadipocytes that could be implicated in the organization of the cytoskeleton). Warm acclimated animals show brown adipocytes with unilocular lipid droplet and mitochondria with intermediate features between those of white and brown adipocytes. These adipocytes express leptin and S-100B, but not UCP-1 [31, 46]. Genetically obese ob/ob and db/db mice have a reduced noradrenaline flux to interscapular BAT and brown adipocytes have the same characteristic of the above-described adipocytes of warm-acclimated mice. The above reported data came mainly from our laboratories, but fit with data obtained by other laboratories showing that after cold acclimation of rodents the DNA does not increase in WAT nor does the number of adipocytes. Furthermore, an antiproliferative effect of the sympathetic nervous system on WAT has been recently shown [47]. White into brown transdifferentiation is also suggested by in vitro studies using primary cultures from human subcutaneous adipose tissue: in these papers, UCP-1 expression was induced by treatment with peroxisome proliferator activated receptor-c (PPAR)-c agonists [48] or PPAR-c coactivator-1 transfection [49]. Altogether these data suggest a possible role for b3-adrenoceptors agonists in the treatment of human obesity and diabetes. Human WAT is immunoreactive to b3-adrenoceptors monoclonal highly specific antibodies [50], but a b3-adrenoceptors agonist producing curative effects for human obesity has not yet been identified [51]. 3.6.2 Transformation of the Phenotype: Pregnancy and Lactation
The mammary gland is composed of branched epithelial ducts infiltrating subcutaneous adipose tissue and connected to a nipple. In adult female mice three bilateral nipples are connected to epithelial ducts infiltrating the whole anterior subcutaneous fat depot of the adipose organ. Two bilateral nipples are connected to epithelial ducts infiltrating the whole posterior subcutaneous fat depot of the adipose organ. Therefore, virgin adult (postpuberal) female mice are provided by five bilateral incomplete mammary glands that are ready to became milk-secreting glands during pregnancy and lactation. The two subcutaneous depots containing the glands differ from that of male mice only for the presence of the above-described branched epithelial ducts. The adipose component of these depots follows the general rules described above for the adipose organ – a mixed composition of white and brown adipocytes (with the relative amount depending mainly on age, strain, and environmental conditions). Of note, adipocytes of the mammary glands express the prolactin receptor [52]. During pregnancy and lactation the anatomy of the mammary glands becomes complete with progressive reduction of adipocytes and the formation of
3.6 Phenotype of the Adipose Organ is Variable: Plasticity of the Adipose Organ
milk-secreting lobuloalveolar epithelial glands. This plastic phenomenon is reversible and at the end of lactation the milk-secreting components of the gland disappear to give room for the reappearing adipocytes with a complete reconstruction of the pregravidic anatomy of the gland. This phenomenon was previously viewed as being due to a hiding among the glands of adipocytes that undergo a delipidation process during pregnancy and a lipid refilling process of adipocytes in the postlactation period. Our recent morphological studies combined with the Crelox fate mapping technique on the mammary gland suggested that adipocytes undergo a reversible adipoepithelial transdifferentiation process during pregnancy and lactation [53]. 3.6.3 Transformation of the Phenotype: Hypertrophy and Hyperplasia (Positive Energy Balance: Overweight and Obesity)
When the energy balance becomes positive, the adipose organ increases its white part. White adipocytes undergo hypertropy followed by hyperplasia. In fact, it has been proposed that adipocytes have a maximum volume and cannot be further expanded. This maximum volume, also referred to as critical cell size, is genetically determined and specific for each depot [54]. Adipocytes with the critical cell size trigger an increase in cell numbers [55, 56]. Not all depots have the same tendency to hypertrophy and hyperplasia – the former seems to be more characteristic of epididymal and mesenteric depots, the latter of inguinal and perirenal depots [54]. Adipose tissue expresses numerous factors that could be implicated in modulation of adipogenesis: insulin-like growth factor-1, transforming growth factor-b, tumor necrosis factor (TNF)-a, macrophage colony-stimulating factor, angiotensin II, autotaxin-lysophosphatidic acid, leptin, resistin, and so on [57]. Interestingly, it has been shown in mice that obesity induced by a high-fat diet is hypertrophic, while obesity induced by hypothalamic lesions due to administration of monosodium glutamate is hyperplastic [58]. It has been suggested recently that adipocyte precursors can derive from bone marrow [59]. It has been shown that the WAT of obese mice and humans is infiltrated by macrophages, and that the level of infiltration correlates with body mass index (BMI) and mean size of adipocytes [60–62]. This infiltration seems to be an important cause for the insulin resistance associated with obesity. We observed recently that macrophages are mainly located at the level of dead adipocytes in WAT of obese mice, obese humans, and in transgenic mice that are lean but with hypertrophic adipocytes (hormone-sensitive lipase knockout mice) [63]. Also, the brown part of the organ is modified under this condition of positive energy balance. In obese mice, the rate of apoptosis of brown adipocytes increases and this is strongly attenuated in mice lacking TNF-a receptors [64]. In obese animals the morphology of brown adipocytes gradually changes into a morphology similar to that of white adipocytes, including transformation of the multilocular lipid depot into a unilocular one. This is accompanied by activation of the leptin gene and these cells are leptin-immunoreactive [30, 31].
j59
j 3 Plasticity of the Adipose Organ
60
3.6.4 Transformation of the Phenotype: Hypoplasia (Negative Energy Balance: Caloric Restriction and Fasting)
The morphology of the adipose organ during fasting is quite characteristic, because a variable amount of slimmed cells are present in WAT. The slimmed cells are barely visible by light microscopy, but they are easily recognized by electron microscopy – they have a specific ultrastructural morphology: cytoplasmic irregular and thin projections with numerous invaginations rich of pinocytotic vesicles (Figure 3.6). These projections enlarge in the proximity of the nucleus and of the residual lipid droplet. In acute fasting, completely delipidized adipocytes can be found near apparently unaffected unilocular cells. Vasculogenesis and neurogenesis is also found in WAT of fasted animals. Capillaries are often surrounded by the thin cytoplasmic projections of the slimmed adipocytes. Neurogenesis is mainly supported by an increase of noradrenergic fibers [12]. In chronic caloric restriction, the reduction in size of adipocytes is homogeneously distributed [65].
Figure 3.6 White adipocytes of retroperitoneal WAT of an adult rat fasted for 3 days. The adipocyte on the right part of the figure (L) shows a tail of slimmed cytoplasm (arrow). The adipocyte on the bottom part of the figure
exhibits few, small lipid droplets (L) and numerous cytoplasmic introflections (arrowheads). CAP ¼ capillary. Transmission electron microscopy. Bar ¼ 2.3 mm. Reproduced from [1] with permission.
3.7 Adipose Organ of Humans
3.7 Adipose Organ of Humans
The basic concepts of the adipose organ of small mammals reported above are probably applicable also to the adipose organ of humans. In fact, WAT, BAT, and mixed adipose tissues are also present in the adipose organ of humans, with most of the morphological and physiological characteristics described for the murine adipose organ. Although a detailed description of the gross anatomy of the human adipose organ has never been performed, it is well known that it is composed of subcutaneous and visceral depots. In humans, the subcutaneous adipose tissue is in continuity with the dermal adipose tissue (in rodents, dermal adipose tissue is separated from subcutaneous adipose tissue by a smooth muscle layer) and it is not limited to defined areas, but is present as a continuous layer beneath the skin. Mammary and gluteofemoral subcutaneous adipose tissues are more developed in females than in males. Visceral depots correspond to those described above for the rodent adipose organ, but the omental depot is particularly well developed in humans. The weight of the human adipose organ of lean adults is about 8–18% of the body weight in males and 14–28% in females (about 5% in monkeys) [66]. Light and electron microscopy of human adipose tissues is identical to that of murine adipose tissues. Development of the human adipose organ extends for a long period, until puberty, mainly through proliferation [67]. During the first year of age there is mainly an increase in size. In line with these data, the number of adipocytes, total fat mass, and the percentage of body fat correlate positively with age in both sexes. Instead, adipocyte size does not seem to positively correlate with age, but it seems to be correlated to the amount of fat mass and percentage in both sexes [67]. In massively obese humans, the adipose organ can increase 4 times and reach 60–70% of body weight [48]. In the case of negative energy balance, the adipose organ reduces its volume and adipocytes reduce their size. The reduction in size of adipocytes is important because the size of adipocytes correlates with insulin sensitivity [68]. Completely delipidized adipocytes can be found in the adipose tissue of subjects with negative energy balance. The morphology of delipidized adipocytes is quite similar to that described above for the equivalent cells of mice or rats. The fate of these delipidized adipocytes is still debated; some authors suggest that they undergo apoptosis. Not all depots react in the same way to negative energy balance. Subcutaneous adipose tissue from the gluteofemoral region of premenopausal women is more resistant to slimming than the subcutaneous abdominal adipose tissue, but after menopause the slimming process is similar. This seems to be due to a combination of increased lipoprotein lipase activity and reduced lipolytic activity in the gluteofemoral adipose tissue. The reduced lipolytic activity seems to be due to a relative preponderance of antilipolytic activity of a2-adrenoceptors over the lipolytic b-adrenoceptors [69]. In general, a2-adrenoceptors are more abundant in human adipose tissue than in murine adipose tissue. In genetically modified mice lacking b3- and expressing human a2-adrenoceptors, a high-fat diet induces hyperplasia (but not
j61
j 3 Plasticity of the Adipose Organ
62
hypertrophy) of adipose tissue and mice are insulin-sensitive. These experiments are in line with the importance of a2-adrenoceptors for adipocyte hyperplasia and with the relationship of their size with insulin sensitivity [70]. Like the murine adipose organ, the human adipose organ contains BAT. It is easy to understand that the surface/volume relationship of the human body is quite different from that of small mammals and therefore human thermodispersion is much lower than in rodents. This alone justifies a reduced need for BAT in adult humans. Newborns have a different surface/volume relationship and a considerable amount of BAT is present at that age. Nevertheless, brown adipocytes dispersed among white adipocytes have been described in several histological studies (including studies showing the presence of UCP-1) [71, 72]. BAT in human newborns has been described in almost all the same sites described for rodents, and UCP-1 gene expression was found in biopsies from visceral adipose tissue of adult lean and obese patients. In the same paper, the authors calculated the presence of one brown adipocyte for every 100–200 white adipocytes in the visceral adipose tissue of adult lean humans [73]. BAT has also been described to be increased in outdoor workers in northern Europe [74] and in patients with pheochromocytoma (a noradrenaline-secreting tumor). Furthermore, rare cases of hibernoma (BAT tumors occurring in several anatomical sites, including subcutaneous and visceral fat) have been described (about 100 cases have been described in the literature [75], and we recently observed a case (Figure 3.7) in which brown adipocytes expressed UCP-1 and had the classic electron microscopy with typical mitochondria). Brown adipocytes are able to incorporate high levels of glucose and fluorodeoxyglucose is used in radiology (positron emission tomography (PET)) to identify tissues with a high rate of glucose incorporation such as tumor metastasis. Through
Figure 3.7 Human subcutaneous WAT of the neck. UCP-1 immunohistochemistry. UCP-1immunoreactive multilocular brown adipocytes (brown) are mixed with unstained unilocular
white adipocytes. Light microscopy. (UCP-1 antibody kindly provided by Dr. Daniel Ricquier, Paris.) Bar ¼ 50 mm. Reproduced from FASEB Journal with permission.
References
the extensive use of this technique important amounts of BAT have been found recently in adult humans [76, 77]. The anatomical sites described as normal sites for human BATare the root of the neck and the root of the upper limbs, but also near the vertebral column in the intercostal spaces [78]. Of note, the PET density of human BAT increases after cold exposure especially during winter time [79]. In biopsies of human adults from the perithyroid area of the neck, corresponding to one of the areas PET-positive in other patients with the same age and BMI, we found UCP-1-positive brown adipocytes by immunohistochemistry (Figure 3.7). The physiological role of BAT in humans is debated, but the possibility to artificially increase it in order to treat obesity and related disorders cannot be excluded. On this matter, it is interesting to note that human adults with a reduced brown phenotype of abdominal subcutaneous adipose tissue have a reduced insulin sensitivity and that human white adipocyte precursors can be induced in vitro to express UCP-1 by administration of drugs [48, 80].
References 1 Cinti, S. (1999) The Adipose Organ, Kurtis,
8 Napolitano, L. (1963) The differentiation
Milan. Cinti, S. (2001) The adipose organ: morphological perspectives of adipose tissues. Proc. Nutr. Soc., 60, 319–328. Cinti, S. (2002) Adipocyte differentiation and transdifferentiation: plasticity of the adipose organ. J. Endocrinol. Invest., 25, 823–835. Murano, I., Zingaretti, M.C., and Cinti, S. (2005) Adipocytes, 1, 121–130. Barbatelli, G., Heinzelmann, M., Ferrara, P., Morroni, M., and Cinti, S. (1994) Quantitative evaluations of gap junctions in old rat brown adipose tissue after cold acclimation: a freeze-fracture and ultrastructural study. Tissue Cell, 26, 667–676. Cousin, B., Cinti, S., Morroni, M., Raimbault, S., Ricquier, D., Penicaud, L., and Casteilla, L. (1992) Occurrence of brown adipocytes in rat white adipose tissue: molecular and morphological characterization. J. Cell Sci., 103, 931–942. Rossmeisl, M., Barbatelli, G., Flachs, P., Brauner, P., Zingaretti, M.C., Marelli, M., Janovska, P., Horakova, M., Syrovy, I., Cinti, S., and Kopecky, J. (2002) Expression of the uncoupling protein 1 from the aP2 gene promoter stimulates mitochondrial biogenesis in unilocular adipocytes in vivo. Eur. J. Biochem., 269, 19–28.
of white adipose cells an electron microscope study. J. Cell Biol., 18, 663–679. Hausman, G.J., Campion, D.R., McNamara, J.P., Richardson, R.L., and Martin, R.J. (1981) Adipose tissue development in the fetal pig after decapitation. J. Anim. Sci., 53, 1634–1644. Cinti, S., Cigolini, M., Bosello, O., and Bjorntorp, P. (1984) A morphological study of the adipocyte precursor. J. Submicrosc. Cytol., 16, 243–251. De Matteis, R., Ricquier, D., and Cinti, S. (1998) TH-, N-, SP-, and CGRPimmunoreactive nerves in interscapular brown adipose tissue of adult rats acclimated at different temperatures: an immunohistochemical study. J. Neurocytol., 27, 877–886. Giordano, A., Frontini, A., Murano, I., Tonello, C., Marino, M.A., Carruba, M.O., Nisoli, E., and Cinti, S. (2005) Regionaldependent increase of sympathetic innervation in rat white adipose tissue during prolonged fasting. J. Histochem. Cytochem., 53, 679–687. Cannon, B. and Nedergaard, J. (1986) Brown adipose tissue thermogenesis in neonatal and cold-adapted animals. Biochem. Soc. Trans., 14, 233–236.
2
3
4 5
6
7
9
10
11
12
13
j63
j 3 Plasticity of the Adipose Organ
64
14 Cinti, S. (1999) Adipose tissues and 15
16
17
18
19 20
21 22
23
24
obesity. Ital. J. Anat. Embryol., 104, 37–51. Giordano, A., Morroni, M., Carle, F., Gesuita, R., Marchesi, G.F., and Cinti, S. (1998) Sensory nerves affect the recruitment and differentiation of rat periovarian brown adipocytes during cold acclimation. J. Cell Sci., 111, 2587–2594. Kreier, F., Fliers, E., Voshol, P.J., Van Eden, C.G., Havekes, L.M., Kalsbeek, A., Van Heijningen, C.L., Sluiter, A.A., Mettenleiter, T.C., Romijn, J.A., Sauerwein, H.P., and Buijs, R.M. (2002) Selective parasympathetic innervation of subcutaneous and intra-abdominal fat – functional implications. J. Clin. Invest., 110, 1243–1250. Giordano, A., Song, C.K., Bowers, R.R., Ehlen, J.C., Frontini, A., Cinti, S., and Bartness, T.J. (2006) White adipose tissue lacks significant vagal innervation and immunohistochemical evidence of parasympathetic innervation. Am. J. Physiol. Regul. Integr. Comp. Physiol., 291, R1243–R1255. Cannon, B., Hedin, A., and Nedergaard, J. (1982) Exclusive occurrence of thermogenin antigen in brown adipose tissue. FEBS Lett., 150, 129–132. Trayhurn, P. and Nicholls, D. (1986) Brown Adipose Tissue, Edward Arnold, London. Cinti, S., Zancanaro, C., Sbarbati, A., Cicolini, M., Vogel, P., Ricquier, D., and Fakan, S. (1989) Immunoelectron microscopical identification of the uncoupling protein in brown adipose tissue mitochondria. Biol. Cell, 67, 359–362. Klaus, S. (2001) Adipose Tissues. Eureka.com, Austin, TX. Ricquier, D., Casteilla, L., and Bouillaud, F. (1991) Molecular studies of the uncoupling protein. FASEB J., 5, 2237–2242. Cannon, B. and Nedergaard, J. (2004) Brown adipose tissue: function and physiological significance. Physiol. Rev., 84, 277–359. Lowell, B.B., S-Susulic, V., Hamann, A., Lawitts, J.A., Himms-Hagen, J., Boyer, B.B., Kozak, L.P., and Flier, J.S. (1993) Development of obesity in transgenic
25
26
27
28
29
30
31
32
33
34
mice after genetic ablation of brown adipose tissue. Nature, 366, 740–742. Bachman, E.S., Dhillon, H., Zhang, C.Y., Cinti, S., Bianco, A.C., Kobilka, B.K., and Lowell, B.B. (2002) bAR signaling required for diet-induced thermogenesis and obesity resistance. Science, 297, 843–845. Enerback, S., Jacobsson, A., Simpson, E.M., Guerra, C., Yamashita, H., Harper, M.E., and Kozak, L.P. (1997) Mice lacking mitochondrial uncoupling protein are cold-sensitive but not obese. Nature, 387, 90–94. Kopecky, J., Hodny, Z., Rossmeisl, M., Syrovy, I., and Kozak, L.P. (1996) Reduction of dietary obesity in aP2-UCP transgenic mice: physiology and adipose tissue distribution. Am. J. Physiol. Endocrinol. Metab., 270, E768–E775. Almind, K., Manieri, M., Sivitz, W.I., Cinti, S., and Kahn, C.R. (2007) Ectopic brown adipose tissue in muscle provides a mechanism for differences in risk of metabolic syndrome in mice. Proc. Natl. Acad. Sci. USA, 104, 2366–2371. Zhang, Y., Proenca, R., Maffei, M., Barone, M., Leopold, L., and Friedman, J.M. (1994) Positional cloning of the mouse obese gene and its human homologue. Nature, 372, 425–432. Cinti, S., Frederich, R.C., Zingaretti, M.C., De Matteis, R., Flier, J.S., and Lowell, B.B. (1997) Immunohistochemical localization of leptin and uncoupling protein in white and brown adipose tissue. Endocrinology, 138, 797–804. Cancello, R., Zingaretti, M.C., Sarzani, R., Ricquier, D., and Cinti, S. (1998) Leptin and UCP1 genes are reciprocally regulated in brown adipose tissue. Endocrinology, 139, 4747–4750. Kershaw, E.E. and Flier, J.S. (2004) Adipose tissue as an endocrine organ. J. Clin. Endocrinol. Metab., 89, 2548–2556. Trayhurn, P. and Wood, I.S. (2004) Adipokines: inflammation and the pleiotropic role of white adipose tissue. Br. J. Nutr., 92, 347–355. Bukowiecki, L., Collet, A.J., Follea, N., Guay, G., and Jahjah, L. (1982) Brown adipose tissue hyperplasia: a fundamental mechanism of adaptation to cold and
References
35
36
37
38
39
40
41
42
hyperphagia. Am. J. Physiol. Endocrinol. Metab., 242, E353–E359. Himms-Hagen, J., Melnyk, A., Zingaretti, M.C., Ceresi, E., Barbatelli, G., and Cinti, S. (2000) Multilocular fat cells in WAT of CL-316243-treated rats derive directly from white adipocytes. Am. J. Physiol. Cell Physiol., 279, C670–C681. Jimenez, M., Barbatelli, G., Allevi, R., Cinti, S., Seydoux, J., Giacobino, J.P., Muzzin, P., and Preitner, F. (2003) Beta 3adrenoceptor knockout in C57BL/6J mice depresses the occurrence of brown adipocytes in white fat. Eur. J. Biochem., 270, 699–705. Giordano, A., Morroni, M., Santone, G., Marchesi, G.F., and Cinti, S. (1996) Tyrosine hydroxylase, neuropeptide Y, substance P, calcitonin gene-related peptide and vasoactive intestinal peptide in nerves of rat periovarian adipose tissue: an immunohistochemical and ultrastructural investigation. J. Neurocytol., 25, 125–136. Nisoli, E., Regianini, L., Bulbarelli, A., Briscini, L., Breacale, R., and Carruba, M.O. (2001) Protective effects of noradrenaline against tumor necrosis factor alpha- induced apoptosis in cultured rat brown adipocytes: role of nitric oxideinduced heat shock protein 70 expression. Int. J. Obes. Relat. Metab. Disord., 25, 1421–1430. Nisoli, E., Cardile, A., Bulbarelli, A., Tedesco, L., Bracale, R., Cozzi, V., Morroni, M., Cinti, S., Valerio, A., and Carruba, M.O. (2006) White adipocytes are less prone to apoptotic stimuli than brown adipocytes in rodent. Cell Death Differ., 13, 2154–2156. Gullicksen, P.S., Hausman, D.B., Dean, R.G., Hartzell, D.L., and Baile, C.A. (2003) Adipose tissue cellularity and apoptosis after intracerebroventricular injections of leptin and 21 days of recovery in rats. Int. J. Obes. Relat. Metab. Disord., 27, 302–312. Rayner, D.V. and Trayhurn, P. (2001) Regulation of leptin production: sympathetic nervous system interactions. J. Mol. Med., 79, 8–20. Granneman, J.G., Li, P., Zhu, Z., and Lu, Y. (2005) Metabolic and cellular plasticity in white adipose tissue I: effects of
43
44
45
46
47
48
49
50
51
beta3-adrenergic receptor activation. Am. J. Physiol. Endocrinol. Metab., 289, E608–E616. Cigolini, M., Cinti, S., Bosello, O., Brunetti, L., and Bjorntorp, P. (1986) Isolation and ultrastructural features of brown adipocytes in culture. J. Anat., 145, 207–216. Cigolini, M., Cinti, S., Brunetti, L., Bosello, O., Osculati, F., and Bjorntorp, P. (1985) Human brown adipose cells in culture. Exp. Cell Res., 159, 261–266. Cinti, S., Cigolini, M., Sbarbati, A., Zancanaro, C., and Bjorntorp, P. (1987) Effects of noradrenaline exposure on rat brown adipocytes in cultures. An ultrastructural study. Tissue Cell, 19, 809–815. Barbatelli, G., Morroni, M., Vinesi, P., Cinti, S., and Michetti, F. (1993) S-100 protein in rat brown adipose tissue under different functional conditions: a morphological, immunocytochemical, and immunochemical study. Exp. Cell Res., 208, 226–231. Foster, M.T. and Bartness, T.J. (2006) Sympathetic but not sensory denervation stimulates white adipocyte proliferation. Am. J. Physiol. Regul. Integr. Comp. Physiol., 291, R1630–R1637. Prins, J.B. and ORahilly, S. (1997) Regulation of adipose cell number in man. Clin. Sci., 92, 3–11. Tiraby, C., Tavernier, G., Lefort, C., Larrouy, D., Bouillaud, F., Ricquier, D., and Langin, D. (2003) Acquirement of brown fat cell features by human white adipocytes. J. Biol. Chem., 278, 33370–33376. De Matteis, R., Arch, J.R., Petroni, M.L., Ferrari, D., Cinti, S., and Stock, M.J. (2002) Immunohistochemical identification of the beta3-adrenoceptor in intact human adipocytes and ventricular myocardium: effect of obesity and treatment with ephedrine and caffeine. Int. J. Obes. Relat. Metab. Disord., 26, 1442–1450. Larsen, T.M., Toubro, S., van Baak, M.A., Gottesdiener, K.M., Larson, P., Saris, W.H., and Astrup, A. (2002) Effect of a 28-d treatment with L-796568, a novel beta3-adrenergic receptor agonist, on energy expenditure and body composition
j65
j 3 Plasticity of the Adipose Organ
66
52
53
54
55
56
57
58
59
60
in obese men. Am. J. Clin. Nutr., 76, 780–788. Ling, C., Hellgren, G., Gebre-Medhin, M., Dillner, K., Wennbo, H., Carlsson, B., and Billig, H. (2000) Prolactin (PRL) receptor gene expression in mouse adipose tissue: increases during lactation and in PRLtransgenic mice. Endocrinology, 141, 3564–3572. Morroni, M., Giordano, A., Zingaretti, M.C., Boiani, R., De Matteis, R., Kahn, B.B., Nisoli, E., Tonello, C., Pisoschi, C., Luchetti, M.M., Marelli, M., and Cinti, S. (2004) Reversible transdifferentiation of secretory epithelial cells into adipocytes in the mammary gland. Proc. Natl. Acad. Sci. USA, 101, 16801–16806. DiGirolamo, M., Fine, J.B., Tagra, K., and Rossmanith, R. (1998) Qualitative regional differences in adipose tissue growth and cellularity in male Wistar rats fed ad libitum. Am. J. Physiol. Regul. Integr. Comp. Physiol., 274, R1460–R1467. Faust, I.M., Johnson, P.R., Stern, J.S., and Hirsch, J. (1978) Diet-induced adipocyte number increase in adult rats: a new model of obesity. Am. J. Physiol. Endocrinol. Metab., 235, E279–E286. Bjorntorp, P. (1991) Visceral fat accumulation: the missing link between psychosocial factors and cardiovascular disease? J. Intern. Med., 230, 195–201. Ahima, R.S. and Flier, J.S. (2000) Adipose tissue as an endocrine organ. Trends Endocrinol. Metab., 11, 327–332. Imai, T., Jiang, M., Kastner, P., Chambon, P., and Metzger, D. (2001) Selective ablation of retinoid X receptor alpha in hepatocytes impairs their lifespan and regenerative capacity. Proc. Natl. Acad. Sci. USA, 98, 4581–4586. Crossno, J.T. Jr., Majka, S.M., Grazia, T., Gill, R.G., and Klemm, D.J. (2006) Rosiglitazone promotes development of a novel adipocyte population from bone marrow-derived circulating progenitor cells. J. Clin. Invest., 116, 3220–3228. Weisberg, S.P., McCann, D., Desai, M., Rosenbaum, M., Leibel, R.L., and Ferrante, A.W. Jr. (2003) Obesity is associated with macrophage accumulation in adipose tissue. J. Clin. Invest., 112, 1796–1808.
61 Xu, H., Barnes, G.T., Yang, Q., Tan, G.,
62
63
64
65
66
67
68
Yang, D., Chou, C.J., Sole, J., Nichols, A., Ross, J.S., Tartaglia, L.A., and Chen, H. (2003) Chronic inflammation in fat plays a crucial role in the development of obesityrelated insulin resistance. J. Clin. Invest., 112, 1821–1830. Cancello, R., Henegar, C., Viguerie, N., Taleb, S., Poitou, C., Rouault, C., Coupaye, M., Pelloux, V., Hugol, D., Bouillot, J.L., Bouloumie, A., Barbatelli, G., Cinti, S., Svensson, P.A., Barsh, G.S., Zucker, J.D., Basdevant, A., Langin, D., and Clement, K. (2005) Reduction of macrophage infiltration and chemoattractant gene expression changes in white adipose tissue of morbidly obese subjects after surgery-induced weight loss. Diabetes, 54, 2277–2286. Cinti, S., Mitchell, G., Barbatelli, G., Murano, I., Ceresi, E., Faloia, E., Wang, S., Fortier, M., Greenberg, A.S., and Obin, M.S. (2005) Adipocyte death defines macrophage localization and function in adipose tissue of obese mice and humans. J. Lipid Res., 46, 2347–2355. Giordano, A., Nisoli, E., Tonello, C., Cancello, R., Carruba, M.O., and Cinti, S. (2000) Expression and distribution of heme oxygenase-1 and -2 in rat brown adipose tissue: the modulatory role of the noradrenergic system. FEBS Lett., 487, 171–175. Napolitano, L. and Gagne, H.T. (1963) Lipid-depleted white adipose cells: an electron microscope study. Anat. Rec., 147, 273–293. Pond, C.M. and Mattacks, C.A. (1987) The anatomy of adipose tissue in captive Macaca monkeys and its implications for human biology. Folia Primatol., 48, 164–185. Chumlea, W.C., Knittle, J.L., Roche, A.F., Siervogel, R.M., and Webb, P. (1981) Size and number of adipocytes and measures of body fat in boys and girls 10 to 18 years of age. Am. J. Clin. Nutr., 34, 1791–1797. Stern, J.S., Batchelor, B.R., Hollander, N., Cohn, C.K., and Hirsch, J. (1972) Adiposecell size and immunoreactive insulin levels in obese and normal weight adults. Lancet, ii, 948–951.
References 69 Rebuffe-Scrive, M., Eldh, J., Hafstrom,
70
71
72
73
74
L.O., and Bjorntorp, P. (1986) Metabolism of mammary, abdominal, and femoral adipocytes in women before and after menopause. Metabolism, 35, 792–797. Valet, P., Grujic, D., Wade, J., Ito, M., Zingaretti, M.C., Soloveva, V., Ross, S.R., Graves, R.A., Cinti, S., Lafontan, M., and Lowell, B.B. (2000) Expression of human alpha 2-adrenergic receptors in adipose tissue of beta 3-adrenergic receptordeficient mice promotes diet-induced obesity. J. Biol. Chem., 275, 34797–34802. Kortelainen, M.L., Pelletier, G., Ricquier, D., and Bukowiecki, L.J. (1993) Immunohistochemical detection of human brown adipose tissue uncoupling protein in an autopsy series. J. Histochem. Cytochem., 41, 759–764. Garruti, G. and Ricquier, D. (1992) Analysis of uncoupling protein and its mRNA in adipose tissue deposits of adult humans. Int. J. Obes. Relat. Metab. Disord., 16, 383–390. Oberkofler, H., Dallinger, G., Liu, Y.M., Hell, E., Krempler, F., and Patsch, W. (1997) Uncoupling protein gene: quantification of expression levels in adipose tissues of obese and non-obese humans. J. Lipid Res., 38, 2125–2133. Huttunen, P., Hirvonen, J., and Kinnula, V. (1981) The occurrence of brown adipose tissue in outdoor workers. Eur. J. Appl. Physiol. Occup. Physiol., 46, 339–345.
75 Pifferi, M., Cangiotti, A.M., Ragazzo, V.,
76
77
78
79
80
Baldini, G., Cinti, S., and Boner, A.L. (2001) Primary ciliary dyskinesia: diagnosis in children with inconclusive ultrastructural evaluation. Pediatr. Allergy Immunol., 12, 274–282. Gelfand, M.J., OHara, S.M., Curtwright, L.A., and Maclean, J.R. (2005) Premedication to block [18 F]FDG uptake in the brown adipose tissue of pediatric and adolescent patients. Pediatr. Radiol., 35, 984–990. Hany, T.F., Gharehpapagh, E., Kamel, E.M., Buck, A., Himms-Hagen, J., and von Schulthess, G.K. (2002) Brown adipose tissue: a factor to consider in symmetrical tracer uptake in the neck and upper chest region. Eur. J. Nucl. Med. Mol. Imaging., 29, 1393–1398. Nedergaard, J., Bengtsson, T., and Cannon, B. (2007) Unexpected evidence for active brown adipose tissue in adult humans. Am. J. Physiol. Endocrinol. Metab., 293, E444–E452. Masayuki, S.Y.O., Masayuki, T., Tomohito, K., and Kunihiro, N. (2007) Human brown adipose tissue evaluated by FDG-PET: activation by cold exposure. Int. J. Obes., 31 (Suppl. 1), S32. Yang, X., Enerback, S., and Smith, U. (2003) Reduced expression of FOXC2 and brown adipogenic genes in human subjects with insulin resistance. Obes. Res., 11, 1182–1191.
j67
j69
4 Biology of Adipose Tissue Stem Cells Jeffrey M. Gimble, Bruce A. Bunnell, and Farshid Guilak 4.1 Introduction
The broad definition of a stem cell is a cell that has the ability to self-renew and differentiate into one or more specialized terminally differentiated cell types. It has become evident that stem cells persist in and can be isolated from many adult tissues. Adipose tissue represents an abundant and accessible source of adult stem cells with the ability to differentiate along multiple lineage pathways. This chapter summarizes the origins, isolation, characterization, and differentiation potential of adiposederived stem cells (ASCs) in both in vitro and in vivo models.
4.2 In Situ Localization and Embryology
The topic of adipose tissue embryology has been the subject of a number of excellent and thorough reviews [1, 2]. The embryonic mesoderm gives rise to most, if not all, adipose tissues. The adipose depots first appear as condensations of mesenchymal cells that are spindle-like fibroblasts characterized by an abundant endoplasmic reticulum and a high nuclear-to-cytoplasmic ratio [3]. By the second trimester in humans, the fat depots contain preadipocytes distinguished by the paranuclear localization of lipid vacuoles, mitochondria, and other organelles [1, 2]. Eventually, the lipid vacuoles within the cells become spherical and/or multilocular, and are associated with glycogen granules and increased numbers of mitochondria [3]. The first mature adipocytes have been reported to lie close to capillaries, and this suggests that a possible relationship exists between pericytes and adipogenic progenitors or stem cells. Isotopic labeling and in vitro studies in rodent models have demonstrated that adipocyte progenitors continue to proliferate throughout life [4–6]. In addition, the adipocytes increase their size when animals are placed on a high-fat diet [7, 8]. Radioisotope turnover studies indicate that rat adipose tissues contain two cell populations – one with a rapid turnover rate measured in days and one with a
j 4 Biology of Adipose Tissue Stem Cells
70
longer half-life of months to years [6]. Consistent with this, in vitro studies using human adipose tissue confirm the presence of at least two populations based on proliferative rates, although the relative abundance of each population varies between adipose depots [9]. Likewise, in vivo studies of human subjects using 2 H2 O mass isoptemer distribution analysis estimate that adipose tissue cells have a half-life of between 8 and 15 months [10], suggesting the need for a local stem cell population to support continual renewal of adipose cells. Nonetheless, there remains room for further investigation. For example, stem cell populations in the hair follicle have been identified base on their long-term retention of bromodeoxyuridine labeling [11] and such methods should be applied in studies of adipose tissue depots.
4.3 Isolation Methods
The isolation of cells from adipose tissue was pioneered by Rodbell et al. in the mid1960s using the rat as an experimental model [12–15]. These methods were further refined and developed by Ailhaud, Arner, Bjorntorp, Hauner, Smith, and others for use on adipose tissue isolated from human and other species [16–22]. The advent of tumescent liposuction methods [23] further simplified the isolation procedure by providing a minced tissue homogenate starting material without significant damage to the stem cell population [24, 25]. However, it should be noted that ultrasoundassisted liposuction has been found to reduce the yield and viability of the isolated adipose-derived cells [26]. Currently, most laboratories wash the tumescent lipoaspirate tissue or minced resected adipose tissue with a buffered salt solution, digest it in collagenase solution for periods of up to 1 h at 37 C, and collect the preadipocyte stromal cells in a stromal vascular fraction by differential centrifugation. The collagenase should be screened prior to use since this enzyme activity can vary between lots even when purchased from the same manufacturer [27]. At this stage, some laboratories plate the pellet directly to select for a plastic adherent cell population over a 24- to 72-h period [28]. Others laboratories first filter the cell pellet through a 40- to 200-mm nylon mesh before plating. Alternatively, investigators are beginning to use antibody-based methods (flow cytometry, magnetic immunobeads) to select for a stromal vascular fraction cell subpopulation based on surface immunophenotype. There is recent evidence that cells with characteristics similar to those found in the stromal vascular fraction can be recovered directly from lipoaspirate fluid without collagenase digestion [29] and it is possible that more laboratories will employ this modified isolation method in the future. 4.3.1 Yield, Proliferation Rate, Depot, and Aging Influences
Following collagenase digestion, around 310 000 nucleated cells are recovered per milliliter of lipoaspirate tissue [30]. Of these, around 3% are adherent to plastic in
4.4 Characterization
the presence of 10% fetal bovine serum based on a colony-forming unit-fibroblast assay and yield around 250 000 ASCs within a 6-day culture period [30]. The adherent ASCs proliferate with a doubling time between 3.2 and 4.7 days [30, 31]. The results obtained by others are comparable [26, 29, 32, 33]. According to one report, the cells recovered from the various subcutaneous adipose depots display similar proliferative and immunophenotypic features in vitro [26]. However, there is evidence that human adipose tissue cells from subcutaneous depots are distinct when compared to those from mesenteric or omental sites [9, 34–36]. There have been variable reports concerning the effect of age on the yield of ASCs per unit volume of subcutaneous adipose tissue. While initial reports described a decrease in ASC numbers with advancing age [20], more recent studies from the same investigators and others did not confirm this finding [37–39]. Indeed, it has been suggested that adipogenesis may be the default differentiation pathway for aging mesenchymal stromal cells and this may account for the accumulation of ectopic adipose depots in older individuals [40].
4.4 Characterization
Multiple criteria have been used to characterize adipose-derived cells, including immunophenotype by cell surface antigens, immunogenicity, proteomic or genomic expression profiles, cytokine profile, or clonality. 4.4.1 Immunophenotype
Due to the success in using surface antigens to distinguish between hematopoietic cell populations, a number of investigators have used flow cytometry [30, 33, 41–46]. The immunophenotype of the adipose-derived cells changes as a function of plastic adherence and expansion [30, 45]. Overall, the immunophenotype of passaged ASCs is similar to that of bone marrow-derived mesenchymal stem cells (MSCs). 4.4.2 Immunogenicity
The immunogenic features of adipose-derived cells have been examined as a function of isolation and expansion. While freshly isolated stromal vascular fraction cells initiate a mixed lymphocyte reaction (MLR), plastic adherent ASCs do not [45, 47–50]. Indeed, the passaged ASCs suppress an active MLR between initiated between responder and stimulator peripheral blood monocytes [45, 48, 49]. These immunosuppressive effects appears to be mediated, in part, by secreted factors such as prostaglandin E2 [47]. The immunogenic features of the ASCs are similar to those of bone marrow-derived MSCs [48, 51].
j71
j 4 Biology of Adipose Tissue Stem Cells
72
4.4.3 Proteomic and Transcriptomic Analysis
A limited number of laboratories have used global methodologies to characterize the adipose-derived cells. Mass spectrometry proteomic analyses have identified around 170 proteins in undifferentiated human ASC protein extracts [52] and around 80 proteins in conditioned medium from human ASCs [53]. Upon adipocyte differentiation, over 40 cellular proteins were induced more than 2-fold while over 10 proteins were reduced more than 3-fold [52]. Overall, the ASC proteome exhibited greater than 55% similarity or identity with the published proteome described of human bone marrow-derived MSCs [52, 54]. However, this may be an underestimate since a direct comparison of human ASC and MSC proteomes reveals that the proteins detected in the two cell populations share greater than 98% identity, with no novel cell-typespecific proteins being identified (Izadpanah et al., in preparation). Transcriptomic approaches have been used to characterize undifferentiated human ASCs in relation to their immunophenotype [44]. Comparison of the human ASC transcriptome to that of human MSCs in the undifferentiated [44] and lineage differentiated state (adipocyte, chondrocyte, osteoblast) [55] revealed a high degree of similarity. 4.4.4 Cytokine Profile
The ASCs secrete a number of cytokines based on analyses of conditioned medium of the undifferentiated and adipocyte differentiated cells. As expected, adipogenic conditions induce human ASC expression of adipokines, including leptin, adiponectin, and the serine protease inhibitor, plasminogen activation inhibitor-1 [28, 53]. It is of interest that adipocyte differentiated ASCs release multiple serine protease inhibitors, suggesting that this secreted protein family plays a role in adipocyte function [53]. Likewise, human ASCs express a number of angiogenic cytokines, including vascular endothelial growth factor and hepatocyte growth factor (HGF) [56– 58]. The ASCs induce their expression of HGF following exposure to exogenous basic fibroblast growth factor (bFGF), epidermal growth factor, and ascorbate [59]. In addition, the human ASCs express inflammatory and hematopoietic cytokines at a constitutive level that is induced further following exposure to endotoxin or lipopolysaccharide [59]. Overall, the cytokine expression profile of the human ASCs is similar to that reported for human bone marrow-derived MSCs [59]. 4.4.5 Clonality
The hallmarks of a stem cell are the ability to self-replicate and to differentiate along multiple lineage pathways. Several laboratories have used clonal assays to demonstrate that progeny isolated from a single adherent human adipose-derived cell have multipotentiality in vitro [33, 60]. Over 50% of the ring-cloned ASC lines from three different donors differentiated along two or more lineage pathways following
4.5 Differentiation and Potential Utility for Regenerative Medicine
expansion over 22–25 passages [60]; however, the percentage of multipotential clones isolated by limit dilution methods was lower [33]. Nevertheless, these findings support the stem cell identification applied to the culture-expanded adherent adipose-derived cell populations. Further in vivo studies evaluating the ability to transplant multipotential ASCs successively between individual animals will be necessary to prove their stem cell nature.
4.5 Differentiation and Potential Utility for Regenerative Medicine
The abundance and accessibility of human adipose tissue makes ASCs an attractive source of adult stem cells for tissue engineering and regenerative medical applications. Transplanted adult stem cells may improve recovery in damaged tissues through lineage-specific differentiation and repopulation of the damaged organ, and/or through the release of paracrine factors modulating the regenerative capacity of endogenous cells in the host tissue. In vitro and in vivo studies have shown that ASCs possess broad differentiation ability as summarized below. 4.5.1 Mesodermal Lineages
In response to specific inductive cocktails of cytokines and chemical agents, human ASCs display biochemical and morphological markers of adipocytes, cardiomyocytes, chondrocytes, endothelial cells, osteoblasts, hematopoietic supporting stromal cells, skeletal myocytes, and smooth muscle cells [28, 32, 33, 56–59, 61–76]. Multiple groups have compared the chondrogenic and osteogenic capacity of ASCs to bone marrow-derived MSCs in parallel assays [55, 77–81]. Some authors have concluded that the ASCs are less robust than MSCs in their ability to differentiate along these pathways [77, 78]; however, it should be noted that the culture conditions utilized in such studies often have been optimized for MSCs rather than ASCs and thus direct comparisons are not particularly meaningful. Indeed, recent studies have found that ASC chondrogenesis is improved markedly upon induction with bone morphogenetic proteins [79, 82, 83], whereas MSCs assume a hypertrophic phenotype under the same conditions. Likewise, the passage number of the ASCs also influences their chondrogenic potential [84]. Further studies will be necessary to define the appropriate ASC-specific growth medium for each lineage pathway. 4.5.2 Endodermal and Ectodermal Lineages
Although adipose tissue has mesodermal origins in the embryo, the ASCs can display biochemical and morphological characteristics of embryonic endodermal and ectodermal cells. In response to oncostatin M, HGF, bFGF, and other factors, ASCs
j73
j 4 Biology of Adipose Tissue Stem Cells
74
express albumin, urea, and a-fetoprotein in a manner similar to hepatocytes [85–87]. Likewise, in response to a cocktail containing activin, extendin, and additional factors, the ASCs express mRNAs encoding insulin, glucagon, and other pancreatic islet cell-associated products [88]. In the presence of retinoids, the ASCs express cytokeratins consistent with epithelial cell differentiation [89]. Multiple groups have demonstrated that ASCs exposed to antioxidants in serum-free conditions assume the morphology and express the proteins (nestin, intermediate filament M, NeuN) associated with neuronal differentiation [90–97]. Altogether, these findings support the characterization of ASCs as a pluripotent stem cell population.
4.6 Conclusions
The ASCs meet many of the criteria of an ideal adult stem cell [98]. The source tissue is accessible and yields millions to billions of cells. The ASCs themselves are multipotent, can be transplanted in autologous manner, and can be manufactured according to defined methods consistent with current Good Manufacturing Practices. Nevertheless, several questions remain to be answered. Can allogeneic ASCs be transplanted in a safe and effective manner? Do ASCs have the risk of causing tumors after long-term implantation in animal models? Do ASCs exert some of the regenerative potential at a site of injury through the release of growth factors or their metabolic function? These and other issues will engage investigators in the years to come.
Acknowledgments
The authors acknowledge support from the Pennington Biomedical Research Center Clinical Nutrition Research Unit (P30 DK072476) (J.M.G.), the Pennington Biomedical Research Foundation (J.M.G.), the National Center for Research Resources (B.A.B.), NIH grant RR00164 (B.A.B.), the State of Louisiana Millennium Health Excellence Fund (B.A.B.), the Louisiana Gene Therapy Research Consortium (B.A. B.), NIH grants AR50245 and AG157678 (F.G.), and editorial assistance from Ms. Laura Dallam and Ms. Lori Steib.
References 1 Martin, R.J., Hausman, G.J., and
3 Soda, R. and Tavassoli, M. (1983)
Hausman, D.B. (1998) Regulation of adipose cell development in utero. Proc. Soc. Exp. Biol. Med., 219, 200–210. 2 Nnodim, J.O. (1987) Development of adipose tissues. Anat. Rec., 219, 331–337.
Adipocyte stem cell: a brief review. Int. J. Cell Cloning, 1, 79–84. 4 Bjorntorp, P., Karlsson, M., Gustafsson, L., Smith, U., Sjostrom, L., Cigolini, M., Storck, G., and Pettersson, P. (1979) Quantitation of different cells in the
References
5
6
7
8
9
10
11
12
13
epididymal fat pad of the rat. J. Lipid Res., 20, 97–106. Hollenberg, C.H. and Vost, A. (1969) Regulation of DNA synthesis in fat cells and stromal elements from rat adipose tissue. J. Clin. Invest., 47, 2485–2498. Klyde, B.J. and Hirsch, J. (1979) Isotopic labeling of DNA in rat adipose tissue: evidence for proliferating cells associated with mature adipocytes. J. Lipid Res., 20, 691–704. Faust, I.M., Johnson, P.R., Stern, J.S., and Hirsch, J. (1978) Diet-induced adipocyte number increase in adult rats: a new model of obesity. Am. J. Physiol. Endocrinol. Metab., 235, E279–286. Klyde, B.J. and Hirsch, J. (1979) Increased cellular proliferation in adipose tissue of adult rats fed a high-fat diet. J. Lipid Res., 20, 705–715. Tchkonia, T., Tchoukalova, Y.D., Giorgadze, N., Pirtskhalava, T., Karagiannides, I., Forse, R.A., Koo, A., Stevenson, M., Chinnappan, D., Cartwright, A., Jensen, M.D., and Kirkland, J.L. (2005) Abundance of two human preadipocyte subtypes with distinct capacities for replication, adipogenesis, and apoptosis varies among fat depots. Am. J. Physiol. Endocrinol. Metab., 288, E267–E277. Strawford, A., Antelo, F., Christiansen, M., and Hellerstein, M.K. (2004) Adipose tissue triglyceride turnover, de novo lipogenesis, and cell proliferation in humans measured with 2 H2 O. Am. J. Physiol. Endocrinol. Metab., 286, E577–E588. Braun, K.M., Niemann, C., Jensen, U.B., Sundberg, J.P., Silva-Vargas, V., and Watt, F.M. (2003) Manipulation of stem cell proliferation and lineage commitment: visualisation of label-retaining cells in wholemounts of mouse epidermis. Development, 130, 5241–5255. Rodbell, M. (1964) Metabolism of isolated fat cells. I. Effects of hormones on glucose metabolism and lipolysis. J. Biol. Chem., 239, 375–380. Rodbell, M. (1966) Metabolism of isolated fat cells. II. The similar effects of phospholipase C (Clostridium perfringens alpha toxin) and of insulin on glucose and
14
15
16
17
18
19
20
21
22
23
amino acid metabolism. J. Biol. Chem., 241, 130–139. Rodbell, M. (1966) The metabolism of isolated fat cells. IV. Regulation of release of protein by lipolytic hormones and insulin. J. Biol. Chem., 241, 3909–3917. Rodbell, M. and Jones, A.B. (1966) Metabolism of isolated fat cells. 3. The similar inhibitory action of phospholipase C (Clostridium perfringens alpha toxin) and of insulin on lipolysis stimulated by lipolytic hormones and theophylline. J. Biol. Chem., 241, 140–142. Bjorntorp, P., Karlsson, M., Pertoft, H., Pettersson, P., Sjostrom, L., and Smith, U. (1978) Isolation and characterization of cells from rat adipose tissue developing into adipocytes. J. Lipid Res., 19, 316–324. Deslex, S., Negrel, R., Vannier, C., Etienne, J., and Ailhaud, G. (1987) Differentiation of human adipocyte precursors in a chemically defined serum-free medium. Int. J. Obes., 11, 19–27. Engfeldt, P., Arner, P., and Ostman, J. (1980) Influence of adipocyte isolation by collagenase on phosphodiesterase activity and lipolysis in man. J. Lipid Res., 21, 443–448. Hauner, H., Wabitsch, M., and Pfeiffer, E.F. (1988) Differentiation of adipocyte precursor cells from obese and nonobese adult women and from different adipose tissue sites. Horm. Metab. Res. Suppl., 19, 35–39. Hauner, H., Entenmann, G., Wabitsch, M., Gaillard, D., Ailhaud, G., Negrel, R., and Pfeiffer, E.F. (1989) Promoting effect of glucocorticoids on the differentiation of human adipocyte precursor cells cultured in a chemically defined medium. J. Clin. Invest., 84, 1663–1670. Smith, U., Sj€ ostr€ om, L., and Bj€ ornstorp, P. (1972) Comparison of two methods for determining human adipose cell size. J. Lipid Res., 13, 822–824. Van, R.L., Bayliss, C.E., and Roncari, D.A. (1976) Cytological and enzymological characterization of adult human adipocyte precursors in culture. J. Clin. Invest., 58, 699–704. Illouz, Y.G. (1983) Body contouring by lipolysis: a 5-year experience with over
j75
j 4 Biology of Adipose Tissue Stem Cells
76
24
25
26
27
28
29
30
31
3000 cases. Plast. Reconstr. Surg., 72, 591–597. Lalikos, J.F., Li, Y.Q., Roth, T.P., Doyle, J.W., Matory, W.E., and Lawrence, W.T. (1997) Biochemical assessment of cellular damage after adipocyte harvest. J. Surg. Res., 70, 95–100. Moore, J.H., Jr., Kolaczynski, J.W., Morales, L.M., Considine, R.V., Pietrzkowski, Z., Noto, P.F., and Caro, J.F. (1995) Viability of fat obtained by syringe suction lipectomy: effects of local anesthesia with lidocaine. Aesthetic Plast. Surg., 19, 335–339. Oedayrajsingh-Varma, M.J., van Ham, S.M., Knippenberg, M., Helder, M.N., Klein-Nulend, J., Schouten, T.E., Ritt, M.J., and van Milligen, F.J. (2006) Adipose tissue-derived mesenchymal stem cell yield and growth characteristics are affected by the tissue-harvesting procedure. Cytotherapy, 8, 166–177. Williams, S.K., McKenney, S., and Jarrell, B.E. (1995) Collagenase lot selection and purification for adipose tissue digestion. Cell Transplant., 4, 281–289. Halvorsen, Y.D., Bond, A., Sen, A., Franklin, D.M., Lea-Currie, Y.R., Sujkowski, D., Ellis, P.N., Wilkison, W.O., and Gimble, J.M. (2001) Thiazolidinediones and glucocorticoids synergistically induce differentiation of human adipose tissue stromal cells: biochemical, cellular, and molecular analysis. Metabolism, 50, 407–413. Yoshimura, K., Shigeura, T., Matsumoto, D., Sato, T., Takaki, Y., Aiba-Kojima, E., Sato, K., Inoue, K., Nagase, T., Koshima, I., and Gonda, K. (2006) Characterization of freshly isolated and cultured cells derived from the fatty and fluid portions of liposuction aspirates. J. Cell. Physiol., 208, 64–76. Mitchell, J.B. McIntosh F M.K. Zvonic, S., Garrett, S., Floyd, Z.E., Kloster, A., Halvorsen, Y.D., Storms, R.W., Goh, B., Kilroy, G.S., Wu, X., and Gimble, J.M. (2006) The immunophenotype of human adipose derived cells: temporal changes in stromal- and stem cell-associated markers. Stem Cells, 24, 376–385. Sen, A., Lea-Currie, Y.R., Sujkowska, D., Franklin, D.M., Wilkison, W.O.,
32
33
34
35
36
37
38
Halvorsen, Y.D., and Gimble, J.M. (2001) Adipogenic potential of human adipose derived stromal cells from multiple donors is heterogeneous. J. Cell Biochem., 81, 312–319. Zuk, P.A., Zhu, M., Mizuno, H., Huang, J., Futrell, J.W., Katz, A.J., Benhaim, P., Lorenz, H.P., and Hedrick, M.H. (2001) Multilineage cells from human adipose tissue: implications for cell-based therapies. Tissue Eng., 7, 211–228. Zuk, P.A., Zhu, M., Ashjian, P., De Ugarte, D.A., Huang, J.I., Mizuno, H., Alfonso, Z.C., Fraser, J.K., Benhaim, P., and Hedrick, M.H. (2002) Human adipose tissue is a source of multipotent stem cells. Mol. Biol. Cell, 13, 4279–4295. Tchkonia, T., Giorgadze, N., Pirtskhalava, T., Tchoukalova, Y., Karagiannides, I., Forse, R.A., DePonte, M., Stevenson, M., Guo, W., Han, J., Waloga, G., Lash, T.L., Jensen, M.D., and Kirkland, J.L. (2002) Fat depot origin affects adipogenesis in primary cultured and cloned human preadipocytes. Am. J. Physiol. Regul. Integr. Comp. Physiol., 282, R1286–R1296. Tchkonia, T., Giorgadze, N., Pirtskhalava, T., Thomou, T., DePonte, M., Koo, A., Forse, R.A., Chinnappan, D., Martin-Ruiz, C., von Zglinicki, T., and Kirkland, J.L. (2006) Fat depot-specific characteristics are retained in strains derived from single human preadipocytes. Diabetes, 55, 2571–2578. Tchkonia, T., Lenburg, M., Thomou, T., Giorgadze, N., Frampton, G., Pirtskhalava, T., Cartwright, A., Cartwright, M., Flanagan, J., Karagiannides, I., Gerry, N., Forse, R.A., Tchoukalova, Y., Jensen, M.D., Pothoulakis, C., and Kirkland, J.L. (2007) Identification of depot-specific human fat cell progenitors through distinct expression profiles and developmental gene patterns. Am. J. Physiol. Endocrinol. Metab., 292, E298–E307. Kirkland, J.L., Hollenberg, C.H., Kindler, S., and Gillon, W.S. (1994) Effects of age and anatomic site on preadipocyte number in rat fat depots. J. Gerontol., 49, B31–35. Kirkland, J.L., Hollenberg, C.H., and Gillon, W.S. (1996) Effects of fat depot site
References
39
40
41
42
43
44
45
46
on differentiation-dependent gene expression in rat preadipocytes. Int. J. Obes. Relat. Metab. Disord., 20 (Suppl. 3), S102–S107. van Harmelen, V., Skurk, T., Rohrig, K., Lee, Y.M., Halbleib, M., Aprath-Husmann, I., and Hauner, H. (2003) Effect of BMI and age on adipose tissue cellularity and differentiation capacity in women. Int. J. Obes. Relat. Metab. Disord., 27, 889–895. Kirkland, J.L., Tchkonia, T., Pirtskhalava, T., Han, J., and Karagiannides, I. (2002) Adipogenesis and aging: does aging make fat go MAD? Exp. Gerontol., 37, 757–767. Aust, L., Devlin, B., Foster, S.J., Halvorsen, Y.D., Hicok, K., du Laney, T., Sen, A., Willingmyre, G.D., and Gimble, J.M. (2004) Yield of human adipose-derived adult stem cells from liposuction aspirates. Cytotherapy, 6, 7–14. Festy, F., Hoareau, L., Bes-Houtmann, S., Pequin, A.M., Gonthier, M.P., Munstun, A., Hoarau, J.J., Cesari, M., and Roche, R. (2005) Surface protein expression between human adipose tissue-derived stromal cells and mature adipocytes. Histochem. Cell Biol., 124, 113–121. Gronthos, S., Franklin, D.M., Leddy, H.A., Robey, P.G., Storms, R.W., and Gimble, J.M. (2001) Surface protein characterization of human adipose tissue-derived stromal cells. J. Cell. Physiol., 189, 54–63. Katz, A.J., Tholpady, A., Tholpady, S.S., Shang, H., and Ogle, R.C. (2005) Cell surface and transcriptional characterization of human adiposederived adherent stromal (hADAS) cells. Stem Cells, 23, 412–423. McIntosh, K., Zvonic, S., Garrett, S., Mitchell, J.B., Floyd, Z.E., Hammill, L., Kloster, A., Halvorsen, Y.D., Ting, J.P., Storms, R.W., Goh, B., Kilroy, G., Wu, X., and Gimble, J.M. (2006) The immunogenicity of human adipose derived cells: temporal changes in vitro. Stem Cells, 24, 1245–1253. Varma, M.J., Breuls, R.G., Schouten, T.E., Jurgens, W.J., Bontkes, H.J., Schuurhuis, G.J., van Ham, S.M., and van Milligen, F.J. (2007) Phenotypical and functional characterization of freshly isolated adipose tissue-derived stem cells. Stem Cells Dev., 16, 91–104.
47 Cui, L., Yin, S., Liu, W., Li, N., Zhang, W.,
48
49
50
51
52
53
54
and Cao, Y. (2007) Expanded adiposederived stem cells suppress mixed lymphocyte reaction by secretion of prostaglandin E2. Tissue Eng., 13, 1185–1195. Le Blanc, K., Tammik, C., Rosendahl, K., Zetterberg, E., and Ringden, O. (2003) HLA expression and immunologic properties of differentiated and undifferentiated mesenchymal stem cells. Exp. Hematol., 31, 890–896. Puissant, B., Barreau, C., Bourin, P., Clavel, C., Corre, J., Bousquet, C., Taureau, C., Cousin, B., Abbal, M., Laharrague, P., Penicaud, L., Casteilla, L., and Blancher, A. (2005) Immunomodulatory effect of human adipose tissuederived adult stem cells: comparison with bone marrow mesenchymal stem cells. Br. J. Haematol., 129, 118–129. Yanez, R., Lamana, M.L., Garcia-Castro, J., Colmenero, I., Ramirez, M., and Bueren, J.A. (2006) Adipose tissue-derived mesenchymal stem cells have in vivo immunosuppressive properties applicable for the control of the graft-versus-host disease. Stem Cells, 24, 2582–2591. Bartholomew, A., Sturgeon, C., Siatskas, M., Ferrer, K., McIntosh, K., Patil, S., Hardy, W., Devine, S., Ucker, D., Deans, R., Moseley, A., and Hoffman, R. (2002) Mesenchymal stem cells suppress lymphocyte proliferation in vitro and prolong skin graft survival in vivo. Exp. Hematol., 30, 42–48. Delany, J., Floyd, Z.E., Zvonic, S., Smith, A., Gravois, A., Reiners, E., Wu, X., Kilroy, G., Lefevre, M., and Gimble, J.M. (2005) Proteomic analysis of primary cultures of human adipose derived stem cells: modulation by adipogenesis. Mol. Cell. Proteomics, 4, 731–740. Zvonic, S., Lefevre, M., Kilroy, G., Floyd, Z.E., Delany, J.P., Kheterpal, I., Gravois, A., Dow, R., White, A., Wu, X., and Gimble, J.M. (2006) Secretome of primary cultures of human adipose-derived stem cells (ASCs): modulation of serpins by adipogenesis. Mol. Cell. Proteomics, 6, 18–28. Wang, D., Park, J.S., Chu, J.S., Krakowski, A., Luo, K., Chen, D.J., and Li, S. (2004)
j77
j 4 Biology of Adipose Tissue Stem Cells
78
55
56
57
58
59
60
61
Proteomic profiling of bone marrow mesenchymal stem cells upon transforming growth factor beta1 stimulation. J. Biol. Chem., 279, 43725–43734. Liu, T.M., Martina, M., Hutmacher, D.W., Hoi, J., Hui, P., Lee, E.H., and Lim, B. (2007) Identification of common pathways mediating differentiation of bone marrow and adipose tissues derived human mesenchymal stem cells (MSCs) into three mesenchymal lineages. Stem Cells, 25, 750–760. Miranville, A., Heeschen, C., Sengenes, C., Curat, C.A., Busse, R., and Bouloumie, A. (2004) Improvement of postnatal neovascularization by human adipose tissue-derived stem cells. Circulation, 110, 349–355. Planat-Benard, V., Silvestre, J.S., Cousin, B., Andre, M., Nibbelink, M., Tamarat, R., Clergue, M., Manneville, C., SaillanBarreau, C., Duriez, M., Tedgui, A., Levy, B., Penicaud, L., and Casteilla, L. (2004) Plasticity of human adipose lineage cells toward endothelial cells: physiological and therapeutic perspectives. Circulation, 109, 656–663. Rehman, J., Traktuev, D., Li, J., MerfeldClauss, S., Temm-Grove, C.J., Bovenkerk, J.E., Pell, C.L., Johnstone, B.H., Considine, R.V., and March, K.L. (2004) Secretion of angiogenic and antiapoptotic factors by human adipose stromal cells. Circulation, 109, 1292–1298. Kilroy, G.E., Foster, S., Wu, X., Ruiz, J., Sherwood, S., Heifetz, A., Ludlow, J.W., Stricker, D.M., Potiny, S., Green, P., Halvorsen, Y.D.C., Cheatham, B., Storms, R.W., and Gimble, J.M. (2007) Cytokine profile of human adipose-derived stem cells: expression of angiogenic, hematopoietic, and pro-inflammatory factors. J. Cell. Physiol., 212, 702–709. Guilak, F., Lott, K.E., Awad, H.A., Cao, Q., Hicok, K.C., Fermor, B., and Gimble, J.M. (2006) Clonal analysis of the differentiation potential of human adipose-derived adult stem cells. J. Cell. Physiol., 206, 229–237. Corre, J., Barreau, C., Cousin, B., Chavoin, J.P., Caton, D., Fournial, G., Penicaud, L., Casteilla, L., and Laharrague, P. (2006)
62
63
64
65
66
67
68
Human subcutaneous adipose cells support complete differentiation but not self-renewal of hematopoietic progenitors. J. Cell. Physiol., 208, 282–288. Cowan, C.M., Shi, Y.Y., Aalami, O.O., Chou, Y.F., Mari, C., Thomas, R., Quarto, N., Contag, C.H., Wu, B., and Longaker, M.T. (2004) Adipose-derived adult stromal cells heal critical-size mouse calvarial defects. Nat. Biotechnol., 22, 560–567. Cowan, C.M., Aalami, O.O., Shi, Y.Y., Chou, Y.F., Mari, C., Thomas, R., Quarto, N., Nacamuli, R.P., Contag, C.H., Wu, B., and Longaker, M.T. (2005) Bone morphogenetic protein 2 and retinoic acid accelerate in vivo bone formation, osteoclast recruitment, and bone turnover. Tissue Eng., 11, 645–658. Erickson, G.R., Gimble, J.M., Franklin, D.M., Rice, H.E., Awad, H., and Guilak, F. (2002) Chondrogenic potential of adipose tissue-derived stromal cells in vitro and in vivo. Biochem. Biophys. Res. Commun., 290, 763–769. Gaustad, K.G., Boquest, A.C., Anderson, B.E., Gerdes, A.M., and Collas, P. (2004) Differentiation of human adipose tissue stem cells using extracts of rat cardiomyocytes. Biochem. Biophys. Res. Commun., 314, 420–427. Halvorsen, Y.D., Franklin, D., Bond, A.L., Hitt, D.C., Auchter, C., Boskey, A.L., Paschalis, E.P., Wilkison, W.O., and Gimble, J.M. (2001) Extracellular matrix mineralization and osteoblast gene expression by human adipose tissuederived stromal cells. Tissue Eng., 7, 729–741. Jeon, E.S., Moon, H.J., Lee, M.J., Song, H.Y., Kim, Y.M., Bae, Y.C., Jung, J.S., and Kim, J.H. (2006) Sphingosylphosphorylcholine induces differentiation of human mesenchymal stem cells into smooth-muscle-like cells through a TGFb-dependent mechanism. J. Cell Sci., 119, 4994–5005. Lee, J.H. and Kemp, D.M. (2006) Human adipose-derived stem cells display myogenic potential and perturbed function in hypoxic conditions. Biochem. Biophys. Res. Commun., 341, 882–888.
References 69 Lee, W.C., Rubin, J.P., and Marra, K.G.
70
71
72
73
74
75
76
77
(2006) Regulation of alpha-smooth muscle actin protein expression in adiposederived stem cells. Cells Tissues Organs, 183, 80–86. Martinez-Estrada, O.M., Munoz-Santos, Y., Julve, J., Reina, M., and Vilaro, S. (2005) Human adipose tissue as a source of Flk1 þ cells: new method of differentiation and expansion. Cardiovasc. Res., 65, 328–333. Mizuno, H., Zuk, P.A., Zhu, M., Lorenz, H.P., Benhaim, P., and Hedrick, M.H. (2002) Myogenic differentiation by human processed lipoaspirate cells. Plast. Reconstr. Surg., 109, 199–209 discussion 210–191. Moon, M.H., Kim, S.Y., Kim, Y.J., Kim, S.J., Lee, J.B., Bae, Y.C., Sung, S.M., and Jung, J.S. (2006) Human adipose tissuederived mesenchymal stem cells improve postnatal neovascularization in a mouse model of hindlimb ischemia. Cell Physiol. Biochem., 17, 279–290. Planat-Benard, V., Menard, C., Andre, M., Puceat, M., Perez, A., Garcia-Verdugo, J.M., Penicaud, L., and Casteilla, L. (2004) Spontaneous cardiomyocyte differentiation from adipose tissue stroma cells. Circ. Res., 94, 223–229. Rangappa, S., Fen, C., Lee, E.H., Bongso, A., and Sim, E.K. (2003) Transformation of adult mesenchymal stem cells isolated from the fatty tissue into cardiomyocytes. Ann. Thorac. Surg., 75, 775–779. Strem, B.M., Zhu, M., Alfonso, Z., Daniels, E.J., Schreiber, R., Beygui, R., MacLellan, W.R., Hedrick, M.H., and Fraser, J.K. (2005) Expression of cardiomyocytic markers on adipose tissue-derived cells in a murine model of acute myocardial injury. Cytotherapy, 7, 282–291. Wickham, M.Q., Erickson, G.R., Gimble, J.M., Vail, T.P., and Guilak, F. (2003) Multipotent stromal cells derived from the infrapatellar fat pad of the knee. Clin. Orthop. Rel. Res., (412), 196–212. Huang, J.I., Kazmi, N., Durbhakula, M.M., Hering, T.M., Yoo, J.U., and Johnstone, B. (2005) Chondrogenic potential of progenitor cells derived from human bone marrow and adipose tissue: a
78
79
80
81
82
83
84
85
patient-matched comparison. J. Orthop. Res., 23, 1383–1389. Im, G.I., Shin, Y.W., and Lee, K.B. (2005) Do adipose tissue-derived mesenchymal stem cells have the same osteogenic and chondrogenic potential as bone marrowderived cells? Osteoarthritis Cartilage, 13, 845–853. Knippenberg, M., Helder, M.N., Zandieh Doulabi, B., Wuisman, P.I., and KleinNulend, J. (2006) Osteogenesis versus chondrogenesis by BMP-2 and BMP-7 in adipose stem cells. Biochem. Biophys. Res. Commun., 342, 902–908. Mochizuki, T., Muneta, T., Sakaguchi, Y., Nimura, A., Yokoyama, A., Koga, H., and Sekiya, I. (2006) Higher chondrogenic potential of fibrous synovium- and adipose synovium-derived cells compared with subcutaneous fat-derived cells: distinguishing properties of mesenchymal stem cells in humans. Arthritis Rheum, 54, 843–853. Zheng, B., Cao, B., Li, G., and Huard, J. (2006) Mouse adipose-derived stem cells undergo multilineage differentiation in vitro but primarily osteogenic and chondrogenic differentiation in vivo. Tissue Eng., 12, 1891–1901. Estes, B.T., Wu, A.W., and Guilak, F. (2006) Potent induction of chondrocytic differentiation of human adipose-derived adult stem cells by bone morphogenetic protein 6. Arthritis Rheum., 54, 1222–1232. Hennig, T., Lorenz, H., Thiel, A., Goetzke, K., Dickhut, A., Geiger, F., and Richter, W. (2007) Reduced chondrogenic potential of adipose tissue derived stromal cells correlates with an altered TGFbeta receptor and BMP profile and is overcome by BMP-6. J. Cell. Physiol., 211, 682–691. Estes, B.T., Wu, A.W., Storms, R.W., and Guilak, F. (2006) Extended passaging, but not aldehyde dehydrogenase activity, increases the chondrogenic potential of human adipose-derived adult stem cells. J. Cell. Physiol., 209, 987–995. Seo, M.J., Suh, S.Y., Bae, Y.C., and Jung, J.S. (2005) Differentiation of human adipose stromal cells into hepatic lineage in vitro and in vivo. Biochem. Biophys. Res. Commun., 328, 258–264.
j79
j 4 Biology of Adipose Tissue Stem Cells
80
86 Talens-Visconti, R., Bonora, A., Jover, R.,
87
88
89
90
91
Mirabet, V., Carbonell, F., Castell, J.V., and Gomez-Lechon, M.J. (2006) Human mesenchymal stem cells from adipose tissue: differentiation into hepatic lineage. Toxicol. In Vitro, 21, 324–329. Talens-Visconti, R., Bonora, A., Jover, R., Mirabet, V., Carbonell, F., Castell, J.V., and Gomez-Lechon, M.J. (2006) Hepatogenic differentiation of human mesenchymal stem cells from adipose tissue in comparison with bone marrow mesenchymal stem cells. World J. Gastroenterol., 12, 5834–5845. Timper, K., Seboek, D., Eberhardt, M., Linscheid, P., Christ-Crain, M., Keller, U., Muller, B., and Zulewski, H. (2006) Human adipose tissue-derived mesenchymal stem cells differentiate into insulin, somatostatin, and glucagon expressing cells. Biochem. Biophys. Res. Commun., 341, 1135–1140. Brzoska, M., Geiger, H., Gauer, S., and Baer, P. (2005) Epithelial differentiation of human adipose tissue-derived adult stem cells. Biochem. Biophys. Res. Commun., 330, 142–150. Ashjian, P.H., Elbarbary, A.S., Edmonds, B., DeUgarte, D., Zhu, M., Zuk, P.A., Lorenz, H.P., Benhaim, P., and Hedrick, M.H. (2003) In vitro differentiation of human processed lipoaspirate cells into early neural progenitors. Plast. Reconstr. Surg., 111, 1922–1931. Fujimura, J., Ogawa, R., Mizuno, H., Fukunaga, Y., and Suzuki, H. (2005) Neural differentiation of adipose-derived stem cells isolated from GFP transgenic mice. Biochem. Biophys. Res. Commun., 333, 116–121.
92 Kang, S.K., Lee, D.H., Bae, Y.C., Kim,
93
94
95
96
97
98
H.K., Baik, S.Y., and Jung, J.S. (2003) Improvement of neurological deficits by intracerebral transplantation of human adipose tissue-derived stromal cells after cerebral ischemia in rats. Exp. Neurol., 183, 355–366. Kang, S.K., Putnam, L.A., Ylostalo, J., Popescu, I.R., Dufour, J., Belousov, A., and Bunnell, B.A. (2004) Neurogenesis of Rhesus adipose stromal cells. J. Cell Sci., 117, 4289–4299. Krampera, M., Marconi, S., Pasini, A., Galie, M., Rigotti, G., Mosna, F., Tinelli, M., Lovato, L., Anghileri, E., Andreini, A., Pizzolo, G., Sbarbati, A., and Bonetti, B. (2007) Induction of neural-like differentiation in human mesenchymal stem cells derived from bone marrow, fat, spleen and thymus. Bone, 40, 382–390. Safford, K.M., Hicok, K.C., Safford, S.D., Halvorsen, Y.D., Wilkison, W.O., Gimble, J.M., and Rice, H.E. (2002) Neurogenic differentiation of murine and human adipose-derived stromal cells. Biochem. Biophys. Res. Commun., 294, 371–379. Safford, K.M., Safford, S.D., Gimble, J.M., Shetty, A.K., and Rice, H.E. (2004) Characterization of neuronal/glial differentiation of murine adipose-derived adult stromal cells. Exp. Neurol., 187, 319–328. Safford, K.M. and Rice, H.E. (2005) Stem cell therapy for neurologic disorders: therapeutic potential of adipose-derived stem cells. Curr. Drug Targets, 6, 57–62. Gimble, J.M. (2003) Adipose tissuederived therapeutics. Expert Opin. Biol. Ther., 3, 705–713.
Part Two Metabolic Functions of Adipose Tissue
j83
5 Molecular Mechanisms of Adipocyte Lipolysis James G. Granneman and Hsiao-Ping H. Moore 5.1 Introduction
The storage and mobilization of lipid are fundamental cellular processes and multicellular organisms, from insects to mammals, have evolved specialized cells that store lipid energy in times of excess for mobilization in times of need. In mammals, adipose tissue functions as a highly specialized lipid energy buffer that stores excess energy as triglyceride for systemic mobilization as free fatty acids (FFAs). Although it is well established that triglyceride stores are dynamically regulated, the cellular and molecular bases of this dynamic regulation are just now being revealed. Recent work indicates that storage and mobilization of intracellular lipid involves the assembly of specialized subcellular structures (i.e., lipid droplets), the targeting of unique protein scaffolds and enzymes, and the dynamic trafficking of lipases and regulatory proteins. The significance of these interactions is not well understood. However, adipocytes are a key source of fatty acids during fasting, exercise, and in insulin-resistant states, and alterations in adipose tissue lipolysis can have an important impact on energy balance and insulin sensitivity. It is likely a better understanding of the new lipid droplet biology and the molecular mechanisms of lipolysis will lead to new therapeutic approaches to obesity and diabetes.
5.2 Key Players in Adipocyte Lipolysis
Adipocyte lipolysis is a multifaceted phenomenon that is subject to distinct temporal controls, many of which are poorly understood. This chapter focuses on protein trafficking during rapid, hormone-stimulated lipolysis (for recent reviews on the general regulation of lipolysis, see [1, 2]). Interest in lipolytic protein trafficking stems from the seminal work of Londos et al. (reviewed in [3, 4]). These investigators demonstrated that hormone-stimulated lipolysis is directly related to the level of protein kinase A (PKA) activation [5, 6]. Thus, major signals that acutely inhibit
j 5 Molecular Mechanisms of Adipocyte Lipolysis
84
Figure 5.1 Rapid regulation of adipocyte lipolysis of PKA. Adipocyte lipolysis is regulated by diverse stimulatory and inhibitory ligands acting through G-protein coupled receptors (GPCR) that transverse the plasma membrane bilayer. GPCR-generated signals are integrated by adenylyl cyclase, which generates cAMP. In addition, insulin suppresses lipolysis through protein kinase B (PKB)-dependent activation of
phosphodiesterase 3 (PDE3), which degrades cAMP to AMP. Signals controlling lipolysis converge at PKA, which directly phosphorylates HSL and PLINA, the major PKA substrate in fat cells. PLINA is targeted to the surface of lipid droplets that are covered by a phospholipid monolayer. ATGL and its coactivator, CGI-58, are key elements PKA-regulated lipolysis, yet neither appears to be direct targets of PKA.
(e.g., insulin and adenosine) or stimulate (e.g., catecholamines) lipolysis converge at the level of PKA (Figure 5.1). In addition, they discovered perilipin (PLIN) as a major lipid coat protein in adipocytes and demonstrated that this protein is the dominant target of PKA activation [7]. Lastly, they showed that hormone-sensitive lipase (HSL), itself a target of PKA, translocates to lipid droplet surfaces during PKA activation [8]. Together, these observations provided a conceptual framework whereby lipolysis is regulated by the PKA-dependent trafficking of proteins to lipid droplet surfaces. 5.2.1 Lipid Droplets and Droplet Scaffold Proteins
Virtually all cells can accumulate small amounts of neutral lipid in structures termed lipid droplets or lipid bodies. Until relatively recently, these structures were
5.2 Key Players in Adipocyte Lipolysis
considered to be inert repositories of lipid; however, recent series of proteomic and lipidomic experiments have clearly established that lipid droplets are heterogeneous, dynamic organelles involved in the synthesis, movement and degradation of lipid [3, 4, 9–15]. Lipid droplets of adipocytes are thought to form in a specialized subdomain of the endoplasmic reticulum [16], and are sequentially bound by several proteins containing conserved PAT (for PLIN/adipose differentiation-related protein (ADRP)/ Tip-47) domains as they migrate and enlarge [17–19]. The biology of PAT proteins is an active area of research and accumulating evidence suggests that specific PAT proteins play specialized roles in lipid droplet biology [4, 18–20]. PAT proteins have functionally divided in to those that translocate between the cytoplasm and lipid droplet surface, and those that are constitutively bound to the lipid droplet surface. Exchangeable PATs, or ePATs [18], appear to be involved in the assembly and enlargement of lipid droplets, and include S3-12, Tip-47 and to some extent lipid storage droplet protein-5 (also known as myocardial lipid droplet protein and oxidative tissues-enriched PAT protein). PAT proteins that are constitutively bound to lipid droplets (i.e., cPATs) include ADRP and PLIN. ADRP expression is upregulated during lipid droplet formation and is induced by conditions that expose adipocytes elevated levels of fatty acid [21, 22]; however, mature white adipocytes normally express little if any ADRP in vivo. Both PLIN and ADRP are unstable proteins that are stabilized when targeted to lipid droplets [23, 24]. Recently, two members of the cell death-inducing DNA fragmentation factor Alike effector (CIDE) protein family, CIDEA and CIDEC (also known as fat-specific protein-27), have been shown to be targeted to adipocyte lipid droplets. These proteins have some sequence homology to PLIN and ADRP, and appear to play a role in the formation and structure of adipocyte lipid droplets [25, 26]. CIDEA is expressed in human white adipose tissue, and CIDEA levels in obesity are correlated with insulin sensitivity and decreased lipolysis [26, 27]. In mice, CIDEA is expressed in brown, not white, fat, and knockout of the CIDEA elevates thermogenesis and brown fat metabolism [28–30]. CIDEC protein is found in white fat cells where its expression promotes triglyceride storage [25, 28, 29]. CIDEC appears to be critical for maintaining the unilocular phenotype of typical white adipocytes [31]. Interestingly, mice lacking Cidec have elevated thermogenesis, expanded mitochondrial biogenesis in white fat, and are resistant to dietinduced obesity [31]. The neutral lipid core of adipocyte lipid droplets is surrounded by a monolayer of phospholipid [32], and it has been proposed that the monolayer phospholipid composition plays a role in the activity of lipolytic effectors [33]. Although the phospholipid composition of the adipocyte lipid droplet monolayer is not known, that of HepG2 cells is unique among intracellular membranes [34]. Recently, Guo et al. [35] conducted a functional genomic screen of genes involved in lipid droplet formation in Drosophila S2 cells. Interestingly, numerous genes of phospholipid metabolism had strong effects on lipid droplet number and size, indicating that the phospholipid composition of the monolayer strongly affects formation and maintenance of lipid droplet structures.
j85
j 5 Molecular Mechanisms of Adipocyte Lipolysis
86
Of the PAT proteins expressed in adipocytes, there is compelling evidence that PLINA, a PLIN splice variant, plays a central role in orchestrating hormonestimulated lipolysis in adipocytes (discussed in detail below). PLINA is the major lipid droplet PAT protein of fully differentiated adipocytes [17, 19]. PLINA can be phosphorylated at up to six sites by PKA and is the major target of PKA phosphorylation in adipocytes [7]. Recent evidence indicates that PLIN is a multifunctional protein, capable of lowering basal lipolysis, promoting lipolysis after PKA activation, and controlling lipid droplet fragmentation through mechanisms that are lipasedependent and -independent. Basal lipolytic rate is inversely related to PLIN expression [36]. Given its location and effect on basal lipolysis, PLIN was initially hypothesized to form a protective barrier that shielded triglyceride from cellular lipases, and that PKA phosphorylation led to the dissociation of PLIN, loss of the protective barrier, and subsequent attack by intracellular lipases. However, recent data suggest that Plin does not form a continuous barrier at the lipid droplet surface, but rather may provide a scaffold for the targeting and trafficking of lipolytic effectors. For example, proteomic studies demonstrate that lipid droplets contain numerous proteins, including lipases, in addition to PLIN [11, 37]. Furthermore, the abundance of PLIN protein is largely unrelated to fat cell size [38, 39] and high-resolution immunofluorescence analysis indicate a discontinuous pattern of PLIN on the surface of large droplets of mature fat cells [32, 40, 41]. Genetic deletion of Plin in mice largely abrogates hormone-stimulated lipolysis [42–44]. Furthermore, expression of wild-type PlinA, but not phosphorylationdefective mutants, restores PKA-dependent lipolysis in adipocytes differentiated from Plin null mice [43]. Reconstitution experiments in heterologous (non-fat cell) systems demonstrate that PLINA confers the ability of PKA to increase HSLdependent and -independent lipolysis [45–48]. It is important to note that PLIN regulation of lipolysis is complex and involves phosphorylation-dependent and independent interactions among different functional domains of the protein [48]. Recent work has identified a single PKA site in PLINA, Ser517, that appears to globally regulates PKA-dependent lipolysis in fat cells [49]. 5.2.2 Lipases 5.2.2.1 HSL Until recently, HSL was considered to be the major, if not exclusive, lipase mediating hormone-stimulated lipolysis (reviewed in [50–52]). HSL exhibits strong diglyceride lipase hydrolase activity, and 10- and 5- fold weaker activity against triglyceride and monoglyceride substrates, respectively [53]. Interestingly, phosphorylation of HSL by PKA increases its activity toward triglyceride, but not aqueous esterase substrates [54]. Hormone-stimulated lipolysis (measured by cellular FFA release) is significantly impaired, but not eliminated, in HSL knockout mice. Adipocytes of HSL null mice are largely incapable of releasing glycerol and have massive accumulation of cellular
5.2 Key Players in Adipocyte Lipolysis
diacylglycerol – clearly demonstrating the importance of HSL as a diglyceride lipase [55]. 5.2.2.2 Adipose Triglyceride Lipase The fact that loss of HSL does not abolish hormone stimulated lipolysis indicated the existence of another triglyceride lipase in adipose tissue. The identification of a second major lipase, adipose triglyceride lipase (ATGL, also known as desnutrin, TTS-2.1; UniGene name PNPLA2 (patatin-like phospholipase domain-containing2)) [56–58] and the discovery that comparative gene identification (UniGene name ABHD5 (a/b-hydrolase domain-containing protein-5), a PLIN-interacting protein [59, 60], is a key coactivator of ATGL [61] greatly advanced our understanding of the biochemical basis of adipose tissue lipolysis. ATGL is a member of the patatin-domain containing family of proteins. While most abundant in fat, ATGL is found in numerous tissues [57, 58]. ATGL has strong triglyceride hydrolase activity, but no activity against diglyceride or monoglyceride substrates [58]. Interestingly, ATGL has low, but detectable transacylase and phospholipase activities [56, 62]. It is unclear how these minor activities of ATGL are regulated in adipocytes or if they are involved in hormone-stimulated lipolysis. ATGL is a phosphoprotein; however, it is not a direct PKA target [9, 58]. Genetic disruption of Atgl in mice results in massive lipid accumulation in muscle (cardiac and skeletal), liver, kidney and testes [63]. Atgl deletion reduces isoproterenol-stimulated lipolysis in white fat explants by more than 70%, corresponding to the loss in total triglyceride hydrolase activity. Similar results have been observed using small hairpin RNA knockdown in cultured cells [64, 65]. Atgl null mice have a profound defect in lipid mobilization during fasting and are cold-intolerant. Human mutations of ATGL have been discovered that result in ectopic lipid accumulation and myopathy – demonstrating the importance of this lipase in humans [66–68]. Interestingly, a C-terminal truncation mutation of ATGL that abrogates activity in vivo does not inhibit activity in vitro; rather, the mutation results in mistargeting of the protein away from lipid droplets in vivo [69]. These observations further reinforce the importance of lipase targeting and trafficking in the regulation of lipolysis. 5.2.2.3 CGI-58 CGI-58 (officially, a/b-hydrolase domain-containing protein-5) belongs to the esterase/lipase subfamily of proteins containing a/b-hydrolase folds. However, unlike bona fide lipases, the predicted catalytic serine within the consensus GXSXG motif contains asparagine [70], and thus CGI-58 exhibits no lipase activity [61, 71]. Rare homozygous mutations of CGI-58 results in Chanarin–Dorfman syndrome (Mendelian Inheritance in Man #27630) that is characterized by ectopic lipid accumulation in numerous tissues [70, 72–75]. A major advance in understanding the function of CGI-58 came with the discovery that CGI-58 dramatically increases the triglyceride hydrolase activity of ATGL owing to a direct interaction between these proteins [61]. A second key feature of CGI-58, discussed below, is its ability to associate with PAT proteins, in particular PLIN [59, 60, 71]. Very recently, CGI-58 was found to mediate the acylation of lysophosphatidic acid [76]. The significance of this activity is presently
j87
j 5 Molecular Mechanisms of Adipocyte Lipolysis
88
unclear; however, mutations of CGI-58 that result in Chanarin–Dorfman syndrome do not affect this acyltransferase activity. 5.2.2.4 Other Lipases and the Biological Significance of HSL versus ATGL A recent proteomic survey using activity-based probes concluded that ATGL, HSL, and monoglyceride lipase are the major lipases in mouse adipose tissue [77], while combined pharmacological, immunological, and genetic approaches strongly indicate that ATGL and HSL constitute greater than 90% of triglyceride hydrolase activity in fat cell extracts [78–80]. It is important to remember, however, that triglyceride hydrolase activities against artificial triglyceride emulsions may not reflect activity against biological substrates within the cell [69]. ATGL and HSL appear to work in concert during PKA activation because of their complementary enzymatic activities. Moreover, the relative contribution of each of these lipases is unlikely to be fixed, but rather will depend on factors like nutritional status (fasting selectively upregulates ATGL [57]), subcellular targeting of ATGL, and the relative abundance of CGI-58.
5.3 Lipolytic Protein Trafficking 5.3.1 PLIN Subcellular Targeting
As mentioned above, there is strong evidence that lipolysis occurs at lipid droplets, which have a unique protein composition, and that PLIN is indispensable in regulating the access and activity of lipases at these lipid droplet surfaces. Immunoelectron microscopic analysis of adipocytes demonstrated that PLIN is on the surface of lipid droplets [32]. Original immunofluorescence analysis in cultured model adipocytes found PLIN to be targeted to numerous small lipid droplets, while staining of larger lipid droplets was described as discontinuous [32]. When 3T3-L1 adipocytes are grown under conditions that allow development of both large (more than 10 mm) and small droplets, PLIN appears to accumulate preferentially on small lipid droplets [41, 81] (see also [45]). As mentioned above, fat cells appear to express variable amounts of PLIN that is unrelated to the lipid droplet surface area. To the extent that PLIN defines where lipolysis occurs, these observations suggest there is heterogeneity with respect to amount and location of droplet structures that are competent for hormone-stimulated lipolysis [41]. 5.3.2 Interactions with CGI-58
CGI-58 was independently discovered by two groups as a PLIN-interacting protein [59, 60]. In preadipocytes, CGI-58 is cytosolic and endogenous or ectopic expression of PLIN results in targeting of CGI-58 to lipid droplets [59]. Double-label immunofluorescence analysis indicates that CGI-58 and PLIN are highly colocalized
5.3 Lipolytic Protein Trafficking
in unstimulated adipocytes [37, 59]. CGI-58 rapidly (within minutes) dissociates from PLIN following forskolin stimulation and becomes progressively cytosolic, while PLIN remains on lipid droplet surfaces [37, 71]. In vitro experiments demonstrated that CGI-58 binds directly to PLIN, but not phosphorylated PLIN [59, 71]. Imaging the molecular interaction of PLIN and CGI-58 in live cells by fluorescence resonance energy transfer (FRET) indicates that PKA activation rapidly triggers dissociation of CGI-58 and PLIN in a manner that is entirely dependent upon PLIN phosphorylation [37]. Double-label immunofluorescence analysis of 3T3-L1 adipocytes demonstrates that stimulation simultaneously decreases the colocalization of CGI-58 with PLIN while increasing it with ATGL [37]. 5.3.3 Interactions with HSL
It is well established that HSL translocates to neutral lipid fractions following PKA activation [8, 82]. PKA-induced HSL translocation to lipid droplets does not occur in cells lacking PLIN and is conferred by ectopic PLIN expression [43, 46]. In cells expressing PLIN, forskolin triggers HSL translocation to droplets containing PLIN, but not to droplets lacking PLIN [37]. Interestingly, although PKA-induced HSL translocation in adipocytes requires PLIN, it does not require PLIN phosphorylation [43]. Experiments with fluorescent reporters demonstrate that HSL translocation begins within 1 min following forskolin stimulation and is essentially complete by 5 min. Translocation results in very close molecular proximity between HSL and PLIN (less than 8 nm) as determined by FRET experiments [37]. Similarly, Miyoshi et al. [43] found that stimulation promotes the ability to chemically cross-link endogenous HSL and PLIN in differentiated embryonic fibroblasts. Cross-linking, FRET, and protein complementation experiments indicate that PKA activation generates a complex containing PLIN and HSL [37, 43]; however, analysis of phosphorylation-defective mutants of PLIN in adipocytes strongly indicates that HSL translocation is not sufficient to initiate lipolysis in the absence of PLIN phosphorylation [43]. Thus, PLIN phosphorylation affects HSL activity beyond its ability to promote translocation, but it is not known whether this effect involves direct interactions with phosphorylated PLIN, or is brought about indirectly by such factors as ATGL activation (and generation of diglyceride substrate) or droplet remodeling. 5.3.4 Interactions with ATGL
In the basal state, ATGL is found in the cytoplasm [37, 57, 62] and on lipid droplets [9, 58], including those containing PLIN [37]. Stimulation elicits minor translocation of ATGL to lipid droplets [37, 83], but does not improve the colocalization of ATGL with PLIN. Unlike HSL, ATGL does not interact with PLIN, as judged by FRET and bimolecular fluorescence complementation assays [37]. The mechanism of ATGL translocation is likely to be indirect, since ATGL is not a substrate for PKA [58].
j89
j 5 Molecular Mechanisms of Adipocyte Lipolysis
90
Possible mechanisms include PLIN-induced remodeling of the lipid droplet surface and/or interactions with released CGI-58. It should be noted that a considerable amount of ATGL resides on PLIN-containing lipid droplets in the basal state and its activation might be triggered by local release of CGI-58 from PLIN. In this regard, although stimulation provokes release of CGI-58 from PLIN, some CGI-58 is retained on these lipid droplets during PKA activation and could represent sites of ATGL activation [37, 59]. As mentioned above, immunofluorescence studies indicate that forskolin increases the colocalization of CGI-58 and ATGL. Since stimulation does not alter the overall colocalization of ATGL and PLIN, the stimulation-induced increase in colocalization of CGI-58 and ATGL may involve subcellular structures that lack PLIN. 5.3.5 Disruption and Dispersion of Lipid Droplets Following PKA Activation
Recently, Yamaguchi et al. [71] observed the formation of microdroplets within 10 min of PKA activation using coherent anti-Stokes Raman microscopy. As these microdroplets first appeared some distance from larger lipid droplets, and seemed to grow in size and number over the course of stimulation, it was proposed that the droplets were not directly derived from fragmentation of larger lipid droplets. It is possible that these microdroplets are formed from the re-esterification of mobilized fatty acids; however, the exact source of triglyceride contained in the microdroplets and its relation to lipolysis are presently unclear. Sustained PKA activation produced by forskolin dramatically fragments lipid droplets in cultured adipocytes. In contrast to the microdroplet formation mentioned above, this fragmentation first appears after 30 min, with extensive fragmentation seen by 8 h [84]. Given that the appearance of the microdroplets coincides with loss of larger droplets, and the microdroplets contain both PLIN and lipid, it seems highly likely that these structures are derived from larger, PLIN-containing lipid droplets. Significantly, this massive lipid droplet fragmentation occurs in the presence of pharmacological inhibition of lipolysis [84]. Further analysis of this phenomenon demonstrated that lipid droplet fragmentation requires phosphorylation of PLIN on Ser492. Fragmentation greatly increases the lipid droplet surface area that is exposed to cytoplasm, as well as dramatically increasing the lipid droplet curvature – either of which could increase lipase activity. Indeed, it was recently reported that mutation of Ser492 reduces PKA-stimulated lipolysis in differentiated embryonic fibroblasts [65]. On the other hand, mutation of Ser517 nearly eliminates PKA-induced lipolysis, yet has little effect on fragmentation. Thus, while fragmentation likely promotes lipolysis, fragmentation per se is not sufficient to initiate it [65]. 5.3.6 Additional Interactions
Caveolin1 (Cav1) is a structural protein of caveolae – membrane invaginations involved in cholesterol metabolism, lipid transport and signal transduction [85].
5.4 Working Model and Unresolved Issues
Adipocytes are among the cell types that express the greatest amounts of Cav1. Cav1 translocates to lipid droplets in response to elevated fatty acids or cholesterol [86, 87] and during sustained lipolytic activation [11]. Importantly, mice lacking Cav1 have dramatically impaired ability to stimulate lipolysis in brown and white adipocytes [88, 89]. The architecture of the lipid droplet surface of adipocytes is disturbed in Cav1deficient mice and these mice are unable to phosphorylate PLIN during b-adrenergic stimulation [88]. Thus, Cav1 is important in organizing the signaling pathway leading from receptors to lipid droplet activation. Recent proteomic analysis has revealed a surprisingly large number of vesicular trafficking proteins – those involved in membrane budding, targeting and fusion – in lipid droplets purified from a variety of cell lines [9, 11, 13, 90, 91]. Rab5, Rab7, Rab11, Rab14, and Rab18 have been consistently found on lipid droplets in different cell types, implying that they play fundamental roles in lipid droplet functions. Immunoelectron microscopic examination clearly confirmed the specific localization of Rab18 to lipid droplet surfaces [90, 92, 93], and only the GTP-bound form of Rab18 was targeted to lipid droplets [90]. Moreover, the amount of Rab18 on lipid droplets was positively correlated with the lipolytic activity of the cell [11, 93]. Overexpression of active Rab18 reduces the amount of ADRP on lipid droplets, and concomitantly induces close apposition of endoplasmic reticulum membranes to lipid droplets [90]. Since a major function of Rab-GTPases is to recruit specific tethering factors that bring transport vesicle and target membrane into close proximity [94], these emerging data indicate that Rabs are bona fide lipid droplet constituents that might be involved in tethering lipid droplets to specific membranes during lipolytic activation.
5.4 Working Model and Unresolved Issues
A model of PKA-induced lipolytic protein trafficking is depicted in Figure 5.2 and focuses on the central role of PLIN. In the basal state, PLIN and CGI-58 are tightly bound. Some ATGL is localized to lipid droplets containing PLIN; however, ATGL is likely to be inactive, since its coactivator is sequestered by PLIN. PKA activation leads to PLIN phosphorylation, which has two parallel effects. (i) PLIN phosphorylation frees CGI-58 to activate ATGL on lipid droplets surfaces with or without PLIN. (ii) PKA activation promotes the rapid translocation of HSL to PLIN-containing lipid droplets. ATGL activity is directed toward triglyceride substrate and its activation by CGI-58 may be the event that initiates lipolysis. Although HSL has triglyceride hydrolase activity, its role as a DG lipase seems to be rate-limiting [58, 95]. Nonetheless, the coordinated regulation of these lipases at PLIN-containing lipid droplets appears to be essential for full, regulated lipolysis. The model presented above leaves many important questions unresolved. PLIN clearly regulates the activity and accessibility of cellular lipases during PKA activation; however, the biochemical and biophysical bases are uncertain. Targeting of ATGL and HSL to lipid droplet surfaces does not appear to be sufficient to trigger lipolysis in the
j91
j 5 Molecular Mechanisms of Adipocyte Lipolysis
92
Figure 5.2 Protein trafficking during initiation of lipolysis. Under basal conditions, PLIN and CGI-58 form a complex on the surface of lipid droplets. HSL is mainly cytosolic, while ATGL is localized to lipid droplets, including those containing PLIN. Stimulation by PKA activation leads to trafficking of HSL and CGI-58 (green arrows). Phosphorylation of PLIN releases CGI-58, which then activates ATGL. As ATGL acts exclusively on triglyceride (TG), it is likely that ATGL initiates generation of FFA.
Phosphorylation of HSL promotes its translocation and tight association with Plin. A major component of HSL activity likely depends on generation of diglyceride (DG) substrate from the action of ATGL, while monoglyceride (MG) lipase acts to liberate glycerol and the final FFA. Not illustrated are potential effects of Plin phosphorylation on the biophysical properties of the lipid droplet surface, and the effects of sustained activity on lipid droplet fragmentation and movement.
absence of PLIN phosphorylation [43]. Thus, initiation of lipolysis likely involves PLIN phosphorylation-dependent events beyond simple lipase recruitment. It is unclear whether PKA-dependent release of CGI-58 from PLIN is sufficient to activate ATGL or whether PLIN-induced remodeling of the lipid droplet surface plays a role. PLIN appears to interact with multiple proteins and it will be important to clarify how these interacts are organized. For example, CGI-58 interacts with both ATGL and PLIN, but it is unclear whether these interactions are mutually exclusive within cells. Bimolecular fluorescence complementation experiments suggest that PLIN assembles into higher-order structures with itself [37]. The structure role that PLIN might play in the formation, maintenance and dispersion of lipid droplets is an important topic of future research. The demonstration of PKA-dependent, lipase-independent droplet fragmentation and the identification of multiple Rab subtypes on lipid droplets raise a host of questions. Rab-mediated membrane tethering may facilitate lipolytic signaling and/ or shutting of lipolytic products to individual organelles or to the cell surface. The latter could occur through transient intercompartmental contact sites without membrane fusion [96]. It is interesting to note that lipolytic stimulation increases pinocytic activity that shifts a fraction of cell surface G-proteins to endocytic
References
membranes [97]. This raises the possibility that Rab-mediated tethering of endosomes to lipid droplets [92] may enhance lipid droplet-to-cell surface communication (hormone signaling or egress of FFA) via an endosomal intermediate. Finally, virtually everything we know about lipolytic trafficking is derived from model cells grown on two-dimensional surfaces. Owing to the stark differences in cellular morphology, it will be important to confirm hypotheses developed in model cells in true unilocular fat cells in vitro and in situ. Acknowledgments
The authors wish to thank E. Mottillo for comments and R. Granneman for illustrations. Supported by NIH grants DK 062292 and DK 076629, ADA grant RA50, and the Department of Veterans Affairs.
References 1 Duncan, R.E., Ahmadian, M., Jaworski,
2 3
4 5 6 7
8
9
10
11
K., Sarkadi-Nagy, E., and Sul, H.S. (2007) Annu. Rev. Nutr., 27, 79–101. Langin, D. and Arner, P. (2006) Trends Endocrinol. Metab., 17, 314–320. Londos, C., Brasaemle, D.L., Schultz, C.J., Adler-Wailes, D.C., Levin, D.M., Kimmel, A.R., and Rondinone, C.M. (1999) Ann. NY Acad. Sci., 892, 155–168. Londos, C., Sztalryd, C., Tansey, J.T., and Kimmel, A.R. (2005) Biochimie, 87, 45–49. Honnor, R.C., Dhillon, G.S., and Londos, C. (1985) J. Biol. Chem., 260, 15130–15138. Honnor, R.C., Dhillon, G.S., and Londos, C. (1985) J. Biol. Chem., 260, 15122–15129. Greenberg, A.S., Egan, J.J., Wek, S.A., Garty, N.B., Blanchette-Mackie, E.J., and Londos, C. (1991) J. Biol. Chem., 266, 11341–11346. Egan, J.J., Greenberg, A.S., Chang, M.K., Wek, S.A., Moos, M.C. Jr., and Londos, C. (1992) Proc. Natl. Acad. Sci. USA, 89, 8537–8541. Bartz, R., Zehmer, J.K., Zhu, M., Chen, Y., Serrero, G., Zhao, Y., and Liu, P. (2007) J. Proteome Res., 5, 3256–3265. Beller, M., Riedel, D., Jansch, L., Dieterich, G., Wehland, J., Jackle, H., and Kuhnlein, R.P. (2006) Mol. Cell. Proteomics, 5, 1082–1094. Brasaemle, D.L., Dolios, G., Shapiro, L., and Wang, R. (2004) J. Biol. Chem., 279, 46835–46842.
12 Cermelli, S., Guo, Y., Gross, S.P., and
13
14
15
16 17 18
19
20
21 22
Welte, M.A. (2006) Curr. Biol., 16, 1783–1795. Liu, P., Ying, Y., Zhao, Y., Mundy, D.I., Zhu, M., and Anderson, R.G. (2004) J. Biol. Chem., 279, 3787–3792. Tansey, J.T., Sztalryd, C., Hlavin, E.M., Kimmel, A.R., and Londos, C. (2004) IUBMB Life, 56, 379–385. Bartz, R., Zehmer, J.K., Zhu, M., Chen, Y., Serrero, G., Zhao, Y., and Liu, P. (2007) J. Proteome Res., 6, 3256–3265. Martin, S. and Parton, R.G. (2006) Nat. Rev. Mol. Cell. Biol., 7, 373–378. Nagayama, M., Uchida, T., and Gohara, K. (2007) J. Lipid Res., 48, 9–18. Wolins, N.E., Brasaemle, D.L., and Bickel, P.E. (2006) FEBS Lett., 580, 5484–5491. Wolins, N.E., Quaynor, B.K., Skinner, J.R., Schoenfish, M.J., Tzekov, A., and Bickel, P.E.(2005)J.Biol.Chem.,280,19146–19155. Wolins, N.E., Quaynor, B.K., Skinner, J.R., Tzekov, A., Croce, M.A., Gropler, M.C., Varma, V., Yao-Borengasser, A., Rasouli, N., Kern, P.A., Finck, B.N., and Bickel, P.E. (2006) Diabetes, 55, 3418–3428. Gao, J., Ye, H., and Serrero, G. (2000) J. Cell. Physiol., 182, 297–302. Granneman, J.G., Li, P., Zhu, Z., and Lu, Y. (2005) Am. J. Physiol. Endocrinol. Metab., 289, E608–E616.
j93
j 5 Molecular Mechanisms of Adipocyte Lipolysis
94
23 Brasaemle, D.L., Barber, T., Kimmel, A.R.,
24
25
26
27
28
29
30
31
32
33 34
35
and Londos, C. (1997) J. Biol. Chem., 272, 9378–9387. Brasaemle, D.L., Barber, T., Wolins, N.E., Serrero, G., Blanchette-Mackie, E.J., and Londos, C. (1997) J. Lipid Res., 38, 2249–2263. Keller, P., Petrie, J.T., De Rose, P., Gerin, I., Wright, W.S., Chiang, S.H., Nielsen, A.R., Fischer, C.P., Pedersen, B.K., and MacDougald, O.A. (2008) J. Biol. Chem., 283, 14355–14365. Puri, V., Ranjit, S., Konda, S., Nicoloro, S.M.,Straubhaar,J.,Chawla,A.,Chouinard, M., Lin, C., Burkart, A., Corvera, S., Perugini,R.A.,andCzech,M.P.(2008)Proc. Natl. Acad. Sci. USA, 105, 7833–7838. Gummesson, A., Jernas, M., Svensson, P.A., Larsson, I., Glad, C.A., Schele, E., Gripeteg, L., Sjoholm, K., Lystig, T.C., Sjostrom, L., Carlsson, B., Fagerberg, B., and Carlsson, L.M. (2007) J. Clin. Endocrinol. Metab., 92, 4759–4765. Li, J.Z. and Li, P. (2007) Novartis Found. Symp., 286, 155–159; discussion 159–163, 196–203. Qi, J., Gong, J., Zhao, T., Zhao, J., Lam, P., Ye, J., Li, J.Z., Wu, J., Zhou, H.M., and Li, P. (2008) EMBO J., 27, 1537–1548. Zhou, Z., Yon Toh, S., Chen, Z., Guo, K., Ng, C.P., Ponniah, S., Lin, S.C., Hong, W., and Li, P. (2003) Nat. Genet., 35, 49–56. Nishino, N., Tamori, Y., Tateya, S., Kawaguchi, T., Shibakusa, T., Mizunoya, W., Inoue, K., Kitazawa, R., Kitazawa, S., Matsuki, Y., Hiramatsu, R., Masubuchi, S., Omachi, A., Kimura, K., Saito, M., Amo, T., Ohta, S., Yamaguchi, T., Osumi, T., Cheng, J., Fujimoto, T., Nakao, H., Nakao, K., Aiba, A., Okamura, H., Fushiki, T., and Kasuga, M. (2008) J. Clin. Invest., 118, 2808–2821. Blanchette-Mackie, E.J., Dwyer, N.K., Barber, T., Coxey, R.A., Takeda, T., Rondinone, C.M., Theodorakis, J.L., Greenberg, A.S., and Londos, C. (1995) J. Lipid Res., 36, 1211–1226. Okuda, H., Morimoto, C., and Tsujita, T. (1994) J. Lipid Res., 35, 36–44. Tauchi-Sato, K., Ozeki, S., Houjou, T., Taguchi, R., and Fujimoto, T. (2002) J. Biol. Chem., 277, 44507–44512. Guo, Y., Walther, T.C., Rao, M., Stuurman, N., Goshima, G., Terayama, K., Wong, J.S.,
36
37
38
39
40 41
42
43
44
45
46
47
48
Vale, R.D., Walter, P., and Farese, R.V. (2008) Nature, 453, 657–661. Brasaemle, D.L., Rubin, B., Harten, I.A., Gruia-Gray, J., Kimmel, A.R., and Londos, C. (2000) J. Biol. Chem., 275, 38486–38493. Granneman, J.G., Moore, H.P., Granneman, R.L., Greenberg, A.S., Obin, M.S., and Zhu, Z. (2007) J. Biol. Chem., 282, 5726–5735. DEon, T.M., Souza, S.C., Aronovitz, M., Obin, M.S., Fried, S.K., and Greenberg, A.S. (2005) J. Biol. Chem., 280, 35983–35991. Nikonova, L., Koza, R.A., Mendoza, T., Chao, P.M., Curley, J.P., and Kozak, L.P. (2008) FASEB J., 22, 3925–3937. Granneman, J.G. and Moore, H.P. (2008) Trends Endocrinol. Metab., 19, 3–9. Moore, H.P., Silver, R.B., Mottillo, E.P., Bernlohr, D.A., and Granneman, J.G. (2005) J. Biol. Chem., 280, 43109–43120. Martinez-Botas, J., Anderson, J.B., Tessier, D., Lapillonne, A., Chang, B.H., Quast, M.J., Gorenstein, D., Chen, K.H., and Chan, L. (2000) Nat. Genet., 26, 474–479. Miyoshi, H., Souza, S.C., Zhang, H.H., Strissel, K.J., Christoffolete, M.A., Kovsan, J., Rudich, A., Kraemer, F.B., Bianco, A.C., Obin, M.S., and Greenberg, A.S. (2006) J. Biol. Chem., 281, 15837–15844. Tansey, J.T., Sztalryd, C., Gruia-Gray, J., Roush, D.L., Zee, J.V., Gavrilova, O., Reitman, M.L., Deng, C.X., Li, C., Kimmel, A.R., and Londos, C. (2001) Proc. Natl. Acad. Sci. USA, 98, 6494–6499. Souza, S.C., Muliro, K.V., Liscum, L., Lien, P., Yamamoto, M.T., Schaffer, J.E., Dallal, G.E., Wang, X., Kraemer, F.B., Obin, M., and Greenberg, A.S. (2002) J. Biol. Chem., 277, 8267–8272. Sztalryd, C., Xu, G., Dorward, H., Tansey, J.T., Contreras, J.A., Kimmel, A.R., and Londos, C. (2003) J. Cell Biol., 161, 1093–1103. Tansey, J.T., Huml, A.M., Vogt, R., Davis, K.E., Jones, J.M., Fraser, K.A., Brasaemle, D.L., Kimmel, A.R., and Londos, C. (2003) J. Biol. Chem., 278, 8401–8406. Zhang, H.H., Souza, S.C., Muliro, K.V., Kraemer, F.B., Obin, M.S., and Greenberg, A.S. (2003) J. Biol. Chem., 278, 51535–51542.
References 49 Miyoshi, H., Perfield, J.W.2nd., Souza,
50 51 52 53
54 55
56
57
58
59
60
61
62
S.C., Shen, W.J., Zhang, H.H., Stancheva, Z.S., Kraemer, F.B., Obin, M.S., and Greenberg, A.S. (2007) J. Biol. Chem., 282, 996–1002. Holm, C. (2003) Biochem. Soc. Trans., 31, 1120–1124. Kraemer, F.B. and Shen, W.J. (2002) J. Lipid Res., 43, 1585–1594. Yeaman, S.J. (2004) Biochem. J., 379, 11–22. Belfrage, P., Jergil, B., Stralfors, P., and Tornqvist, H. (1978) Adv. Exp. Med. Biol., 101, 113–126. Yeaman, S.J. (1990) Biochim. Biophys. Acta, 1052, 128–132. Haemmerle, G., Zimmermann, R., Hayn, M., Theussl, C., Waeg, G., Wagner, E., Sattler, W., Magin, T.M., Wagner, E.F., and Zechner, R. (2002) J. Biol. Chem., 277, 4806–4815. Jenkins, C.M., Mancuso, D.J., Yan, W., Sims, H.F., Gibson, B., and Gross, R.W. (2004) J. Biol. Chem., 279, 48968–48975. Villena, J.A., Roy, S., Sarkadi-Nagy, E., Kim, K.H., and Sul, H.S. (2004) J. Biol. Chem., 279, 47066–47075. Zimmermann, R., Strauss, J.G., Haemmerle, G., Schoiswohl, G., BirnerGruenberger, R., Riederer, M., Lass, A., Neuberger, G., Eisenhaber, F., Hermetter, A., and Zechner, R. (2004) Science, 306, 1383–1386. Subramanian, V., Rothenberg, A., Gomez, C., Cohen, A.W., Garcia, A., Bhattacharyya, S., Shapiro, L., Dolios, G., Wang, R., Lisanti, M.P., and Brasaemle, D.L. (2004) J. Biol. Chem., 279, 42062–42071. Yamaguchi, T., Omatsu, N., Matsushita, S., and Osumi, T. (2004) J. Biol. Chem., 279, 30490–30497. Lass, A., Zimmermann, R., Haemmerle, G., Riederer, M., Schoiswohl, G., Schweiger, M., Kienesberger, P., Strauss, J.G., Gorkiewicz, G., and Zechner, R. (2006) Cell Metab., 3, 309–319. Notari, L., Baladron, V., Aroca-Aguilar, J.D., Balko, N., Heredia, R., Meyer, C., Notario, P.M., Saravanamuthu, S., Nueda, M.L., Sanchez-Sanchez, F., Escribano, J., Laborda, J., and Becerra, S.P. (2006) J. Biol. Chem., 281, 38022–38037.
63 Haemmerle, G., Lass, A., Zimmermann,
64
65
66
67
68
69
70
71
72
73
74
R., Gorkiewicz, G., Meyer, C., Rozman, J., Heldmaier, G., Maier, R., Theussl, C., Eder, S., Kratky, D., Wagner, E.F., Klingenspor, M., Hoefler, G., and Zechner, R. (2006) Science, 312, 734–737. Kershaw, E.E., Hamm, J.K., Verhagen, L.A., Peroni, O., Katic, M., and Flier, J.S. (2006) Diabetes, 55, 148–157. Miyoshi, H., Perfield, J.W. 3rd, Souza, S.C., Shen, W.J., Zhang, H.H., Stancheva, Z.S., Kraemer, F.B., Obin, M.S., and Greenberg, A.S. (2006) J. Biol. Chem., 282, 996–1002. Akiyama, M., Sakai, K., Ogawa, M., McMillan, J.R., Sawamura, D., and Shimizu, H. (2007) Muscle Nerve, 36, 856–859. Fischer, J., Lefevre, C., Morava, E., Mussini, J.M., Laforet, P., Negre-Salvayre, A., Lathrop, M., and Salvayre, R. (2007) Nat. Genet., 39, 28–30. Kobayashi, K., Inoguchi, T., Maeda, Y., Nakashima, N., Kuwano, A., Eto, E., Ueno, N., Sasaki, S., Sawada, F., Fujii, M., Matoba, Y., Sumiyoshi, S., Kawate, H., and Takayanagi, R. (2008) J. Clin. Endocrinol. Metab., 93, 2877–2884. Schweiger, M., Schoiswohl, G., Lass, A., Radner, F.P., Haemmerle, G., Malli, R., Graier, W., Cornaciu, I., Oberer, M., Salvayre, R., Fischer, J., Zechner, R., and Zimmermann, R. (2008) J. Biol. Chem., 283, 17211–17220. Lefevre, C., Jobard, F., Caux, F., Bouadjar, B., Karaduman, A., Heilig, R., Lakhdar, H., Wollenberg, A., Verret, J.L., Weissenbach, J., Ozguc, M., Lathrop, M., Prudhomme, J.F., and Fischer, J. (2001) Am. J. Hum. Genet., 69, 1002–1012. Yamaguchi, T., Omatsu, N., Morimoto, E., Nakashima, H., Ueno, K., Tanaka, T., Satouchi, K., Hirose, F., and Osumi, T. (2007) J. Lipid Res., 48, 1078–1089. Akiyama, M., Sawamura, D., Nomura, Y., Sugawara, M., and Shimizu, H. (2003) J. Invest. Dermatol., 121, 1029–1034. Ben Selma, Z., Yilmaz, S., Schischmanoff, P.O., Blom, A., Ozogul, C., Laroche, L., and Caux, F. (2007) J. Invest. Dermatol., 127, 2273–2276. Caux, F., Selma, Z.B., Laroche, L., Prudhomme, J.F., and Fischer, J. (2004) Am. J. Med. Genet. A, 129, 214.
j95
j 5 Molecular Mechanisms of Adipocyte Lipolysis
96
75 Demerjian, M., Crumrine, D.A., Milstone,
76
77
78
79
80
81
82
83
84
L.M., Williams, M.L., and Elias, P.M. (2006) J. Invest. Dermatol., 126, 2032–2038. Ghosh, A.K., Ramakrishnan, G., Chandramohan, C., and Rajasekharan, R. (2008) J. Biol. Chem., 283, 24525–24533. Birner-Gruenberger, R., Susani-Etzerodt, H., Waldhuber, M., Riesenhuber, G., Schmidinger, H., Rechberger, G., Kollroser, M., Strauss, J.G., Lass, A., Zimmermann, R., Haemmerle, G., Zechner, R., and Hermetter, A. (2005) Mol. Cell. Proteomics, 4, 1710–1717. Claus, T.H., Lowe, D.B., Liang, Y., Salhanick, A.I., Lubeski, C.K., Yang, L., Lemoine, L., Zhu, J., and Clairmont, K.B. (2005) J. Pharmacol. Exp. Ther., 315, 1396–1402. Langin, D., Dicker, A., Tavernier, G., Hoffstedt, J., Mairal, A., Ryden, M., Arner, E., Sicard, A., Jenkins, C.M., Viguerie, N., van Harmelen, V., Gross, R.W., Holm, C., and Arner, P. (2005) Diabetes, 54, 3190–3197. Schweiger, M., Schreiber, R., Haemmerle, G., Lass, A., Fledelius, C., Jacobsen, P., Tornqvist, H., Zechner, R., and Zimmermann, R. (2006) J. Biol. Chem., 281, 40236–40241. Granneman, J.G., Li, P., Lu, Y., and Tilak, J. (2004) Am. J. Physiol. Endocrinol. Metab., 287, E574–E582. Clifford, G.M., Londos, C., Kraemer, F.B., Vernon, R.G., and Yeaman, S.J. (2000) J. Biol. Chem., 275, 5011–5015. Okazaki, H., Osuga, J., Tamura, Y., Yahagi, N., Tomita, S., Shionoiri, F., Iizuka, Y., Ohashi, K., Harada, K., Kimura, S., Gotoda, T., Shimano, H., Yamada, N., and Ishibashi, S. (2002) Diabetes, 51, 3368–3375. Marcinkiewicz, A., Gauthier, D., Garcia, A., and Brasaemle, D.L. (2006) J. Biol. Chem., 281, 11901–11909.
85 Pilch, P.F., Souto, R.P., Liu, L.,
86
87
88
89
90
91
92
93
94
95
96 97
Jedrychowski, M.P., Berg, E.A., Costello, C.E., and Gygi, S.P. (2007) J. Lipid Res., 48, 2103–2111. Le Lay, S., Hajduch, E., Lindsay, M.R., Le Liepvre, X., Thiele, C., Ferre, P., Parton, R.G., Kurzchalia, T., Simons, K., and Dugail, I. (2006) Traffic, 7, 549–561. Pol, A., Martin, S., Fernandez, M.A., Ferguson, C., Carozzi, A., Luetterforst, R., Enrich, C., and Parton, R.G. (2004) Mol. Biol. Cell, 15, 99–110. Cohen, A.W., Razani, B., Schubert, W., Williams, T.M., Wang, X.B., Iyengar, P., Brasaemle, D.L., Scherer, P.E., and Lisanti, M.P. (2004) Diabetes, 53, 1261–1270. Cohen, A.W., Schubert, W., Brasaemle, D.L., Scherer, P.E., and Lisanti, M.P. (2005) Diabetes, 54, 679–686. Ozeki, S., Cheng, J., Tauchi-Sato, K., Hatano, N., Taniguchi, H., and Fujimoto, T. (2005) J. Cell Sci., 118, 2601–2611. Turro, S., Ingelmo-Torres, M., Estanyol, J.M., Tebar, F., Fernandez, M.A., Albor, C.V., Gaus, K., Grewal, T., Enrich, C., and Pol, A. (2006) Traffic, 7, 1254–1269. Liu, P., Bartz, R., Zehmer, J.K., Ying, Y.S., Zhu, M., Serrero, G., and Anderson, R.G. (2007) Biochim. Biophys. Acta, 1773, 784–793. Martin, S., Driessen, K., Nixon, S.J., Zerial, M., and Parton, R.G. (2005) J. Biol. Chem., 280, 42325–42335. Grosshans, B.L., Ortiz, D., and Novick, P. (2006) Proc. Natl. Acad. Sci. USA, 103, 11821–11827. Zechner, R., Strauss, J.G., Haemmerle, G., Lass, A., and Zimmermann, R. (2005) Curr. Opin. Lipidol., 16, 333–340. Levine, T. and Loewen, C. (2006) Curr. Opin. Cell. Biol., 18, 371–378. Haraguchi, K. and Rodbell, M. (1990) Proc. Natl. Acad. Sci. USA, 87, 1208–1212.
j97
6 New Developments in the Lipolytic Processing of Triglyceride-Rich Lipoproteins Andre Bensadoun, Anne P. Beigneux, Loren G. Fong, and Stephen G. Young 6.1 Introduction
Most of the triglycerides in plasma are contained in chylomicrons and very-lowdensity lipoproteins (VLDL). The transfer of this lipid fuel from lipoprotein particles to tissues requires that triglycerides undergo hydrolysis. The hydrolysis of lipoprotein triglycerides is an enzymatic process that occurs along the surface of the capillary endothelium. By far the most important enzyme for triglyceride hydrolysis is lipoprotein lipase (LPL). Inhibition of LPL with an LPL-specific antiserum results in a complete and nearly instantaneous block of triglyceride hydrolysis [1]. LPL is expressed at significant levels in adipose tissue, heart, and skeletal muscle. Although LPL expression is essentially absent in the adult liver, LPL is expressed highly in the rodent liver during the suckling period [2]. The rationale for high hepatic LPL activity in suckling rodents is not fully understood, but this adaptation presumably allows the liver to accumulate lipids for use as fuel. In tissues expressing LPL, the enzyme is synthesized exclusively in parenchymal cells (e.g., adipocytes, cardiomyocytes, and skeletal myocytes) and then transported to the luminal surface of the capillary endothelium. LPL binds avidly to heparan sulfate chains on cultured endothelial cells in vitro [3] and most have presumed that the same type of binding also occurs in vivo. Very recent data indicate that LPL also binds to a newly discovered membrane-tethered protein on the luminal surface of endothelial cells, glycosylphosphatidylinositol-anchored high-density lipoprotein-binding protein 1 (GPIHBP1) [4]. LPL expression is regulated differentially in different tissues, providing a mechanism for regulating the delivery of triglyceride fatty acids in a tissue-specific manner. LPL may have other functions that are independent of its catalytic activity. LPL binds to members of the LDL receptor family and to plasma lipoproteins, providing a potential mechanism for enhancing the uptake of remnant lipoproteins – a function that has been referred to as a bridging function [5]. There is also some evidence that
j 6 New Developments in the Lipolytic Processing of Triglyceride-Rich Lipoproteins
98
LPL can mediate the selective uptake of cholesterol esters from low-density lipoproteinLDL particles [6]. Owing to the central role of triglyceride hydrolysis in plasma lipid metabolism, the molecular mechanisms for the regulation of LPL activity have been studied intensively. These studies have consistently pointed to posttranslational mechanisms as being most important for the short-term regulation of LPL. Important progress in understanding this post-translational regulation was reported recently by the Olivecrona group – they found that the angiopoietin-like proteins play a major role in regulating the enzymatic activity of LPL [7]. LPL is also regulated at the transcriptional level, and this topic has been extensively and expertly presented in several recent articles [8–10]. Chylomicrons and VLDL contain a hydrophobic triglyceride and cholesterol ester core stabilized in the aqueous plasma environment by a polar surface coat of phospholipids, cholesterol, and apolipoproteins. Several of the apolipoproteins on triglyceride-rich lipoproteins modulate the rate of triglyceride hydrolysis, while others are important for mediating the cellular uptake of remnant lipoproteins. A recently identified apolipoprotein, apo-AV, plays a very important role in enhancing the rate of triglyceride lipolysis in vivo [11]. This chapter focuses on newer aspects of LPL biology, including the regulation of LPL activity by angiopoietin-like proteins, by apo-AV, and by the newly discovered LPL-binding protein, GPIHBP1.
6.2 LPL
Human LPL is a 448-amino-acid glycoprotein. The amino acid sequence of human LPL is highly conserved; 87–94% identical to other mammalian LPLs and 76% identical to chicken LPL [12]. Based on analyses of amino acid sequence and gene structure, LPL is a member of a larger lipase gene family that includes hepatic lipase, endothelial lipase, pancreatic lipase, pancreatic lipase-related protein-1 and -2, and phosphatidylserine phospholipase A1 [13]. Human LPL is N-glycosylated at Asn43 and Asn359. N-linked glycosylation at Asn43 is necessary for both secretion and maturation of active LPL [14]. LPL is catalytically active as a dimer [15]. Dimerization of the enzyme and processing of the oligosaccharides are likely interrelated. Glucose trimming of the high mannose oligosaccharides by glucosidases (but not mannose removal) is essential for dimerization and full enzyme activation [16]. Translocation to the cis-Golgi is not required for the maturation of enzymatically active LPL [16]. In chicken LPL, the oligosaccharide at Asn45 is sulfated [17]. By sequential exoglycosidase digestion, thin-layer chromatography of the released monosaccharides, and the use of glycosylation inhibitors, the sulfated sugar was shown to be a core N-acetylglucosamine. The kinetics of acid hydrolysis of the sulfated sugar indicated the presence of a single class of primary sulfate groups in an ester linkage to the oxygen on C6 of the core N-acetylglucosamine. The relevance of the sulfation of the
6.3 Functional Domains of LPL
carbohydrate chain has not been fully elucidated; desulfation of the enzyme by culturing cells in the presence of chlorate, an inhibitor of sulfate adenyltransferase, has no effect on catalytic efficiency of LPL or on the ability of the enzyme to bind to heparan sulfate chains on adipocytes [18]. The tertiary folding pattern of LPL has been inferred from the crystal structure of another member of the same lipase family, pancreatic lipase [19]. The proposed molecular model for LPL structure contains two domains, a large N-terminal domain with the a/b-fold characteristic of the mammalian lipase gene family and a smaller C-terminal domain with a b-sandwich structure. The N-terminal domain contains the catalytic triad of the enzyme (Ser132, Asp156, and His241). By analogy with pancreatic lipase, the active Ser132 is covered with a lid structure (residues 237–261), which is located between two conserved cysteine residues. Upon addition of lipid substrate, the orientation of the lid and of two surface loops changes, so that the lipid substrate is accessible to the catalytic site of the enzyme. LPL activity requires the presence of apo-CII, an apolipoprotein found in both high-density lipoprotein (HDL) and VLDL, for maximal catalytic activity [20, 21]. In the absence of lipid substrates, LPL forms a stable surface film with apo-CII [21]. This tight interaction suggests that, in vivo, triglyceride-rich lipoproteins may bind, at least in part, to the surface of the endothelium via the binding of apo-CII on lipoproteins to LPL bound to a specific endothelial cell receptor.
6.3 Functional Domains of LPL
The availability of the crystal structure for pancreatic lipase [22] and a predicted structure for LPL [19] has made it feasible to identify functional domains of LPL by domain-exchange methods. LPL and hepatic lipase are structurally similar but have significant differences in substrate specificity and binding interactions. Schotz, Wong, and coworkers [23–25] constructed chimeras with the N-terminal domain of LPL and the C-terminal domain of hepatic lipase (LPL/HL chimeras), as well as the reverse chimeras (HL/LPL chimeras). The properties of these chimeras were characterized, with the goal of identifying important functional domains. The regions of LPL necessary for maximal apo-CII activation was localized to both the N-terminal domain and a C-terminal LPL domain. The fluorescent hydrophobic probe 1,10 -bis(aniline)-4,40 -bis(naphthalene)-8,80 -disulfonate (bis-ANS) binds tightly to LPL and inhibits its enzymatic activity [26]. Apo-CII restored LPL activity in a competitive fashion. The bis-ANS binding site was located in a peptide in the center of the N-terminal domain, suggesting that the same sequence may be important for the LPL–apo-CII interaction. The catalytic site of LPL – as predicted from the structure of pancreatic lipase and later confirmed by site-directed mutagenesis [27] – was localized to the N-terminus of LPL by the domain-exchange strategy. The characteristic inhibition of LPL by 1 M NaCl was also dependent on sequences in the N-terminal domain. The major heparin-binding domain and the substrate-binding domains were assigned to the
j99
j 6 New Developments in the Lipolytic Processing of Triglyceride-Rich Lipoproteins
100
C-terminal domain. Extensive studies involving both site-directed mutagenesis and deletion analysis demonstrated unequivocally that the lid sequence covering the catalytic site interacts with lipid substrates and governs enzyme–substrate specificity [28]. Identification of specific residues essential for heparin binding were guided by site-directed mutagenesis [29] in the four positively charged clusters (clusters 1, 2, 3, and 4) predicted by van Tilbeurgh from the models of LPL structure [19]. In agreement with domain-exchange studies [13], the most significant residues for heparin interaction are located in the C-terminal domain [29]. Mutation of Lys321, Arg405, Arg407, Lys409, and Lys416 (cluster 4) in chicken LPL results in significantly reduced affinity for heparin. A triple mutant (R405N, R407N, K409N) displayed almost no high-affinity binding to heparin [29]. Amino acid residues that make a lesser contribution to the overall heparin-binding affinity were identified within the N-terminal domain in clusters 1 and 2 [30], whereas cluster 3 was not found to be a functional heparin-binding site [30]. In the dimeric holoenzyme, there are a total of six functional heparin-binding regions (clusters 1, 2, and 4 on each monomeric subunit). In the monomer, these three functional clusters are predicted to lie on one face of the protein, all within 10–16 A of one another [19]. Studies of a recombinant lipase molecule have suggested that the two LPL monomers are positioned within the dimer in a head-to-tail conformation [31]. The specific molecular orientation of the heparin-binding domains in the dimeric holoenzyme enzyme awaits clarification and will likely be defined by crystallization studies of heparin–LPL complexes.
6.4 Regulation of LPL Activity by Angiopoietin-Like Proteins
Changes in adipose tissue LPL activity with fasting and refeeding have been studied extensively as a model of post-transcriptional LPL regulation. Recently, the Olivecrona laboratory showed that decreased LPL activity in adipose tissue after a fast was due mainly to a change in LPL-specific activity, with little change in total enzyme mass [32]. Interestingly, all of the decreased LPL mass and activity was due to a decrease in the specific activity of the extracellular pool [33]; there was no change in LPL mass or activity within the adipocyte pool, suggesting that the decreased LPL activity with fasting could be due to the inactivation of LPL within the extracellular pool [34]. The molecular basis for the decrease in LPL specific activity was recently shown to be due to the conversion, by angiopoietin-like protein 4 (ANGPTL4), of active dimeric LPL to inactive monomeric LPL [35]. A transient interaction of the coil-coiled domain of ANGPTL4 with active LPL leads to the formation of inactive monomeric LPL. The formation of inactive monomer is thought to occur as a result of a change in the conformation of the folded monomer. The amount of ANGPTL4, relative to active LPL, required for enzyme inactivation is quite low, suggesting that ANGPTL4 may act as a catalyst or as an extracellular chaperone. The ANGPTL4 mRNA turns over
6.5 Role of GPIHBP1 in the Lipolysis of Triglyceride-Rich Lipoproteins
rapidly, consistent with a role in minute-to-minute changes in LPL specific activity within adipose tissue. Interestingly, levels of ANGPTL4 mRNA are correlated with adipose tissue LPL activity, irrespective of nutritional state [35].
6.5 Role of GPIHBP1 in the Lipolysis of Triglyceride-Rich Lipoproteins
GPIHBP1 is a newly discovered endothelial cell protein required for optimal lipolytic processing of triglyceride-rich lipoproteins. GPIHBP1 was first identified, by expression cloning, as a molecule that confers upon CHO cells the ability to bind to HDL and was initially proposed to have a role in cholesterol transport [36]. The structure of GPIHBP1 is intriguing. The molecule contains a hydrophobic region corresponding to a signal sequence. This domain is followed by a highly negatively charged domain, with 17 out of 25 residues in the mouse sequence and 21 out of 25 residues in the human sequence being glutamate and aspartate. Following this acidic domain, there is a cysteine-rich Ly-6 domain similar to that in the receptor for urokinase-type plasminogen activator. The C-terminal domain contains a hydrophobic sequence that specifies the addition of a glycosylphosphatidylinositol anchor. The molecule contains a consensus sequence for N-glycosylation at Asn76. To characterize the function and physiologic importance of GPIHBP1 in vivo, Beigneux et al. [4] created Gpihbp1-deficent mice (Gpihbp1/). Gpihbp1/ mice exhibited severe hypertriglyceridemia – a phenotype that was obvious in all mice by 6–10 weeks of age. On a low-fat chow diet, adult Gpihbp1/ mice have plasma triglyceride levels above 1000 mg/dl, with some having triglyceride levels above 5000 mg/dl. The plasma cholesterol levels in Gpihbp1/ mice are also quite elevated (above 300 mg/dl). The plasma lipid levels in heterozygous knockout mice (Gpihbp1 þ /) are not different from that of wild-type mice. Size-fractionation of plasma lipoproteins from Gpihbp1/ mice by gel filtration revealed that the vast majority of the triglyceride and cholesterol in the plasma was contained in large triglyceride-rich lipoproteins. Sizing of lipoproteins from Gpihbp1/ mice revealed that many were quite immense (15.4% of the particles were greater than 122 nm in diameter). The triglyceride-rich lipoproteins in Gpihbp1/ mice were enriched in apo-B48. Both the Gpihbp1/ mice and wild-type control mice were given a retinyl palmitate clearance test – a test that assesses the clearance rate of chylomicrons from the plasma. In wild-type control mice, the retinyl palmitate levels peaked between 1 and 3 h, and were essentially undetectable by 10 h. In the Gpihbp1/ mice, the peak retinyl palmitate levels were more than 10-fold higher than in the wild-type mice and the high levels of the retinyl esters persisted for more than 24 h [4]. Thus, the clearance of chylomicrons from the plasma of Gpihbp1/ mice was dramatically impaired. Immunofluorescence microscopy revealed that GPIHBP1 is expressed only in the capillary endothelial cells of tissues that express LPL (e.g., adipose tissue, skeletal
j101
j 6 New Developments in the Lipolytic Processing of Triglyceride-Rich Lipoproteins
102
muscle, and heart), colocalizing with CD31 – an endothelial cell marker. Confocal microscopy demonstrated that GPIHBP1 is expressed on the luminal surface of the capillary endothelium in these tissues. GPIHBP1 was not present in the capillary endothelium of the brain – a tissue that relies more on glucose uptake than triglyceride hydrolysis [4]. Owing to the gross hypertriglyceridemia in Gpihbp1/ mice and the localization of GPIHBP1 on the luminal surface of the capillary endothelium, Beigneux et al. [4] hypothesized that GPIHBP1 could be an endothelial cell receptor for triglyceride-rich lipoproteins, LPL, or both. Experiments with GPIHPB1-overexpressing CHOpgsA745 cells (a mutant CHO cell line deficient in the ability to produce heparan sulfate chains) demonstrated specific and saturable high-affinity binding of LPL to GPIHBP1. The LPL bound to GPIHBP1 was readily releasable by heparin. GPIHBP1 also binds chylomicrons. Fluorescently labeled chylomicrons (isolated from the plasma of Gpihbp1/ mice) bound avidly to GPIHBP1-expressing CHO cells, as judged by confocal fluorescent microscopy. Pretreatment of GPIHBP1-expressing CHO cells with a phosphatidylinositol-specific phospholipase C eliminated the binding of LPL and chylomicrons to cells, strongly supporting the view that both the LPL and the chylomicrons were bound to a glycosylphosphatidylinositol-anchored molecule on the surface of the cell. Additional experiments revealed that apoAV, a newly discovered apolipoprotein with an important role in triglyceride metabolism, binds avidly to GPIHBP1 [4]. LPL in the vascular bed has been widely thought to be bound to heparan sulfate proteoglycans (HSPGs) on the surface of the endothelium [9]. The discovery of GPIHBP1, a new LPL-binding protein, raised the possibility that Gpihbp1/ mice might have lower-than-normal levels of LPL in the plasma following an injection of heparin. Indeed, we observed reduced amounts of heparin-releasable LPL in Gpihbp1/ mice, compared with wild-type mice, in four independent experiments, although this difference did not achieve statistical significance. The average reduction in postheparin LPL activity in Gpihbp1/ mice was 41%. We had expected to observe a greater reduction in heparin-releasable LPL in Gpihbp1/ mice, given the severity of the chylomicronemia. However, it is important to point out that the levels of LPL mass and activity in postheparin plasma may not be a reliable measure of the amount of physiologically relevant, active LPL on the surface of the capillary endothelium. Northern blot studies have indicated that GPIHBP1 and LPL are expressed highly in adipose tissue, heart, and skeletal muscle [4]. GPIHBP1 expression is clearly regulated by fasting and refeeding [4]. It is conceivable that the regulation of GPIHBP1 expression could help controlling the amount of LPL within capillaries, thereby contributing to the regulation of fatty acid delivery to vital tissues. As GPIHBP1 binds both LPL and chylomicrons, and because this molecule is clearly essential for the efficient lipolytic processing of chylomicrons, Beigneux et al. [4] proposed that GPIHBP1 functions as a platform for lipolysis, perhaps by bringing LPL and triglyceride-rich lipoproteins into close proximity on the surface of endothelial cells.
6.6 Role of Apo-AV in Lipolysis
6.6 Role of Apo-AV in Lipolysis
Apo-AV is a newly discovered apolipoprotein that has a major impact on plasma triglyceride metabolism. The gene encoding this protein was identified by comparative genomics [37] and by differential display in a screen for proteins involved in liver regeneration [38]. The APOAV gene encodes a mature protein with a molecular weight of 39 kDa and is expressed only in the liver. Overexpression of human APOAV in transgenic mice reduces plasma triglyceride level by 70% [39], while targeted inactivation of mouse Apoav increased plasma triglyceride levels by fourfold [37]. Commonly occurring polymorphisms in the human APOAV gene are strongly associated with plasma triglyceride levels [40], and truncating mutations in apo-AV have been reported to cause severe hypertriglyceridemia [41]. Although apo-AV clearly has a major impact on plasma triglyceride metabolism, the concentration of apo-AV in the plasma is extremely low, compared with the concentrations of other apolipoproteins. In one study of normolipidemic subjects, the plasma concentration of apo-AV varied between 24 and 406 mg/l [42]. The molecular mechanisms by which apo-AV modulates triglyceride metabolism are still somewhat unsettled. Owing to its high affinity for lipids, it has been suggested that apo-AV could inhibit lipidation of apolipoprotein B during VLDL assembly [43] and thus decrease VLDL triglyceride secretion. Indeed, in one study involving adenoviral overexpression of apo-AV, a roughly 30% decrease in VLDL triglyceride production was observed [44] with no change in apo-B production rate. The decrease in triglyceride secretion was dependent on the amount apo-AV adenoviral vector that was administered. In transgenic mice overexpressing human apo-AV, however, the hepatic VLDL and chylomicron production rates were not different from control mice [45]. The reason for the apparent discrepancy is not known, but it is likely that the levels of apo-AV expression were quite different in the different studies. A complete deficiency of apo-AV in mice delays chylomicron clearance [46] and overproduction of human apo-AV increases the clearance of VLDL [47]. The possibility that apo-AV causes triglyceride lowering by stimulating LPL activity has also been examined, but the results of different studies have not been consistent. In one report [44], LPL activity was stimulated by recombinant apo-AV in a dose-dependent manner (by as much as 2.3-fold). A smaller stimulation in LPL activity, although highly significant, was observed by Fruchart-Najib et al. [47] when comparing the hydrolysis of apo-AV–deficient VLDL and the same VLDL sample that had been supplemented with recombinant apo-AV. In another study, however, activation of LPL activity was observed only when the LPL was bound to proteoglycans (HSPG) [45]. Lookene et al. [48] examined three different substrates – VLDL, triglyceride phospholipid emulsions, and dimyristoylphosphatidylcholine (DMPC) liposomes – and failed to show a stimulatory effect of apo-AV on LPL activity. In the same report, these authors reported that DMPC–apo-AV disks bind avidly to a heparin–Sepharose columns. Apo-AV could be eluted from these columns with 0.36 M NaCl. The apo-AV–heparin interaction was also demonstrated by surface plasmon resonance.
j103
j 6 New Developments in the Lipolytic Processing of Triglyceride-Rich Lipoproteins
104
Interaction of VLDL and chylomicrons with the immobilized HSPG or with immobilized HSPG and LPL was enhanced in the presence of apo-AV. These studies strongly suggest that apo-AV promotes the formation of HSPG/LPL/triglyceride-rich lipoprotein complexes. In vivo, the presence of apo-AV could enhance the binding of VLDL and chylomicrons to the surface of capillaries, thereby enhancing lipolysis.
6.7 Newly Discovered Regulators of LPL Activity and their Physiological Significance
Several observations [4] support the concept that GPIHBP1 acts as a platform for lipolysis, bringing LPL into close proximity with triglyceride-rich lipoproteins. (i) Gpihbp1/ mice develop severe chylomicronemia, underscoring the physiological importance of GPIHBP1 in chylomicron clearance. (ii) In vitro, GPIHBP1 binds both LPL and chylomicrons avidly. (iii) GPIHBP1 is expressed on the luminal surface of capillary endothelial cells – where lipolysis is known to occur – and exclusively in tissues that express high levels of LPL. (iv) Apo-AV–phospholipid disks bind avidly to GPIHBP1-expressing CHO cells [4], raising the possibility that a direct interaction between apo-AV and GPIHBP1 could be important for the lipolysis of triglyceriderich lipoproteins. We postulate that the same positively charged region of apo-AV that binds to heparin [48], residues 186–227, interacts with the N-terminal acidic domain of GPIHBP1. It is possible, of course, that other apolipoproteins with heparinbinding domains [49], such as apo-E and apo-B, also bind to GPIHBP1. However, the fact that apo-AV-deficient mice develop hypertriglyceridemia [37] suggests that apoAV and GPIHBP1 are partners in the lipolytic processing pathway. One of the puzzles surrounding Gpihbp1/ mice is that the chylomicronemia is severe, yet significant amounts of LPL can be released into the circulation by heparin. With a respectable amount of LPL being released by heparin, why is the chylomicronemia in Gpihbp1/ mice so severe? One possibility is that LPL bound to GPIHBP1 on the surface of capillaries is far more enzymatically active than LPL bound to other molecules, such as HSPGs. Another possibility is that, in vivo, GPIHPB1 is effectively the only site of attachment for LPL within the lumen of capillaries. LPL is likely released by heparin from other sites (e.g., HSPGs within the basement membranes of capillaries, HSPGs on the surface of myocytes and adipocytes), but that LPL is likely irrelevant to chylomicron processing. The LPL that is released by heparin in Gpihbp1/ mice could come exclusively from these other sites and therefore could be functionally irrelevant to triglyceride hydrolysis in the lumen of capillaries. There are other mysteries surrounding GPIHBP1. It will be important to determine if GPIHBP1, like the related urokinase-type plasminogen activator receptor, forms dimeric structures that preferentially partition in lipid rafts [50]. Dimerization of GPIHBP1, or clustering of GPIHBP1 in lipid rafts, could bring triglyceride-rich lipoproteins and LPL into close proximity. The localization of lipolysis complexes in lipid rafts might make physiological sense, as the fatty acid transporter CD36 has also been localized in lipid rafts [51]. Also, it will be interesting to further explore the
References
observation that GPIHBP1 binds to HDL [36]. Which apolipoproteins are important for this interaction? Also, does this interaction have a significant role in plasma lipid metabolism? Could HDL binding to GPIHBP1 somehow facilitate the delivery of apo-CII to LPL or facilitate the transfer of the surface components of triglyceride-rich LPL to HDL? These issues will require additional investigation.
References 1 Kompiang, I.P., Bensadoun, A., and Yang,
2
3
4
5
6
M.W.W. (1976) Effect of anti-lipoprotein lipase serum on plasma triglyceride removal. J. Lipid Res., 17, 498. Langner, C.A., Birkenmeier, E.H., BenZeev, O., Schotz, M.C., Sweet, H.O., Davisson, M.T., and Gordon, J.I. (1989) The fatty liver dystrophy ( fld) mutation. A new mutant mouse with a developmental abnormality in triglyceride metabolism and associated tissue-specific defects in lipoprotein lipase and hepatic lipase activities. J. Biol. Chem., 264, 7994–8003. Merkel, M., Eckel, R.H., and Goldberg, I.J. (2002) Lipoprotein lipase: genetics, lipid uptake and regulation. J. Lipid Res., 43, 1997–2006. Beigneux, A.P., Davies, B.S.J., Gin, P., Weinstein, M.M., Farber, E., Qiao, X., Peale, F., Bunting, S., Walzem, R.L., Wong, J.S., Blaner, W.S., Ding, Z.M., Melford, K., Wongsiriroj, N., Shu, X., de Sauvage, F., Ryan, R.O., Fong, L.G., Bensadoun, A., and Young, S.G. (2007) Glycosylphosphatidylinositol-anchored high-density lipoprotein-binding protein1 plays a critical role in the lipolytic processing of chylomicrons. Cell Metab., 5, 279–291. Merkel, M., Kako, Y., Radner, H., Cho, I.S., Ramasamy, R., Brunzell, J.D., and Breslow, J.L. (1998) Catalytically inactive lipoprotein lipase expression in muscle of transgenic mice increases very low density lipoprotein uptake: direct evidence that lipoprotein lipase bridging occurs in vivo. Proc. Natl. Acad. Sci. USA, 95, 13841–13846. Seo, T., Al-Haideri, M., Treskova, E., Worgall, T.S., Kako, Y., Goldberg, I.J., and Deckelbaum, R.J. (2000) Lipoprotein lipase-mediated selective uptake from low density lipoprotein requires cell surface
7
8
9
10
11
12
13
14
proteoglycans and is independent of scavenger receptor class B type 1. J. Biol. Chem., 275, 30355–30362. Sukonina, V., Lookene, A., Olivecrona, T., and Olivecrona, G. (2006) Angiopoietinlike protein 4 converts lipoprotein lipase to inactive monomers and modulates lipase activity in adipose tissue. Proc. Natl. Acad. Sci. USA, 103, 17450–17451. Merkel, M., Eckel, R.H., and Goldberg, I.J. (2002) Lipoprotein lipase: genetics, lipid uptake, and regulation. J. Lipid Res., 43, 1997–2006. Preiss-Landl, K., Zimmermann, R., Hammerle, G., and Zechner, R. (2002) Lipoprotein lipase: the regulation of tissue specific expression and its role in lipid and energy metabolism. Curr. Opin. Lipidol., 13, 471–481. Mead, J.R., Irvine, S.A., and Ramji, D.P. (2002) Lipoprotein lipase: Structure, function, regulation, and role in disease. J. Mol. Med., 80, 753–769. Calandra, S., Oliva, C.P., Tarugi, P., and Bertolini, S. (2006) APOAV and triglyceride metabolism, lesson from human APOAV deficiency. Curr. Opin. Lipidol., 17, 122–127. Wang, C.S., Hartsuck, J., and McConathy, W.J. (1992) Structure and functional properties of lipoprotein lipase. Biochim. Biophys. Acta, 1123, 1–17. Wong, H. and Schotz, M.C. (2002) The lipase gene family. J. Lipid Res., 43, 993–999. Semenkovich, C.F., Luo, C.C., Nakanishi, M.K., Chen, S.H., Smith, L.C., and Chan, L. (1990) In vitro expression and sitespecific mutagenesis of the cloned human lipoprotein lipase gene. Potential N-linked glycosylation site asparagine 43 is important for both enzyme activity and secretion. J. Biol. Chem., 265, 5429–5433.
j105
j 6 New Developments in the Lipolytic Processing of Triglyceride-Rich Lipoproteins
106
15 Osborne, J.C. Jr., Bengtsson-Olivecrona,
16
17
18
19
20
21
22
23
24
G., Lee, N.S., and Olivecrona, T. (1985) Studies on inactivation of lipoprotein lipase: role of the dimer to monomer dissociation. Biochemistry, 24, 5606–5611. Ben-Zeev, O., Doolittle, M.H., Davis, R.C., Elovson, J., and Schotz, M.C. (1992) Maturation of lipoprotein lipase. Expression of full catalytic activity requires glucose trimming but not translocation to the cis-Golgi compartment. J. Biol. Chem., 267, 6219–6227. Hoogewerf, A. and Bensadoun, A. (1991) Occurrence of sulfate in the asparaginelinked complex oligosaccharide of lipoprotein lipase. J. Biol. Chem., 266, 1048–1057. Hoogewerf, A.J., Cisar, L.A., Evans, D.C., and Bensadoun, A. (1991) Effect of chlorate on the sulfation of lipoprotein lipase and heparan sulfate proteoglycans: sulfation of heparan sulfate proteoglycans affects lipoprotein lipase degradation. J. Biol. Chem., 266, 16564–16571. Van Tilbeurgh, H.V., Roussel, A., Lalouel, J.M., and Cambillau, C. (1994) Lipoprotein lipase. Molecular model based on the pancreatic lipase X-ray structure: consequences for heparin binding and catalysis. J. Biol. Chem., 269, 4626–4633. Scanu, A. (2006) Serum high-density lipoprotein: effect of change in structure on activity of chicken adipose tissue lipase. Science, 153, 640–641. Miller, A.L. and Smith, L.C. (1973) Activation of lipoprotein lipase by apolipoprotein glutamic acid. Formation of a stable surface film. J. Biol. Chem., 248, 3359–3362. Winkler, F.K., DArcy, A., and Hunziker, W. (1990) Structure of human pancreatic lipase. Nature, 343, 771–774. Wong, H.R., Davis, R.C., Nikazy, J., Seebart, K.E., and Schotz, M.C. (1991) Domain exchange: characterization of a chimeric lipase of hepatic lipase and lipoprotein lipase. Proc. Natl. Acad. Sci. USA, 88, 11290–11294. Davis, R.C., Wong, H., Nikazy, J., Seebart, K.E., and Schotz, M.C. (1992) Chimeras of hepatic lipase and lipoprotein lipase: domain localization of enzyme-specific
25
26
27
28
29
30
31
32
properties. J. Biol. Chem., 267, 21499–21504. Hill, J.S., Yang, D., Nikazy, J., Curtiss, L.K., Sparrow, J.T., and Wong, H. (1998) Subdomain chimeras of hepatic and lipoprotein lipase: localization of heparin and cofactor binding. J. Biol. Chem., 273, 30979–30984. Lookene, A., Zhang, L., Tougu, V., and Olivecrona, G. (2003) 1,10 -Bis(aniline)4,40 -bis(naphtalene)-8,80 -disulfonate acts as an inhibitor of lipoprotein lipase and competes for binding with apolipoprotein CII. J. Biol. Chem., 278, 37183–37194. Emmerich, J., Beg, O.U., Peterson, J., Previato, L., Brunzell, J.D., Brewer, H.B., and Santamarina-Fojo, S. (1992) Human lipoprotein lipase. Analysis of the catalytic triad by site-directed mutagenesis of Ser132, Asp-156, and His-241. J. Biol. Chem., 267, 4161–4165. Dugi, K.A., Dichek, H.L., Talley, G.D., Brewer, B. Jr., and Santamarina-Fojo, S. (1992) Human lipoprotein lipase: the loop covering the catalytic site is essential for interaction with lipid substrates. J. Biol. Chem., 267, 25086–25091. Sendak, R.A. and Bensadoun, A. (1998) Identification of a heparin-binding domain in the distal carboxyl-terminal region of lipoprotein lipase by site directed mutagenesis. J. Lipid Res., 39, 1310–1315. Hata, A., Ridinger, D.N., Sutherland, S., Emi, M., Shuhua, Z., Myers, R.L., Ren, K., Cheng, T., Inoue, I., Wilson, D.E., Iverius, P.H., and Lalouel, J.M. (1993) Binding of lipoprotein lipase to heparin. Identification of five critical residues in two distinct segments of the amino-terminal domain. J. Biol. Chem., 268, 8447–8457. Wong, H.D., Yang, D., Hill, J.S., Davis, R.C., Nikazy, J., and Schotz, M.C. (1997) A molecular biology-based approach to resolve the subunit orientation of lipoprotein lipase. Proc. Natl. Acad. Sci. USA, 94, 5594–5598. Bergo, M., Olivecrona, G., and Olivecrona, T. (1996) Forms of lipoprotein lipase in rat tissues: in adipose tissue the proportion of inactive lipase increases on fasting. Biochem. J., 313, 893–898.
References 33 Wu, G., Olivecrona, G., and Olivecrona, T.
34
35
36
37
38
39
40
(2003) The distribution of lipoprotein lipase in rat adipose tissue. Changes with nutritional state engage the extracellular enzyme. J. Biol. Chem., 278, 11925–11930. Bergo, M., Wu, G., Ruge, T., and Olivecrona, T. (2002) Down-regulation of adipose tissue lipoprotein lipase during fasting requires that a gene, separate from the lipase gene, is switched on. J. Biol. Chem., 277, 11927–11932. Sukonina, V., Lookene, A., Olivecrona, T., and Olivecrona, G. (2006) Angiopoietinlike protein4 converts lipoprotein lipase to inactive monomers and modulates lipase activity in adipose tissue. Proc. Natl. Acad. Sci. USA, 103, 17450–17455. Ioka, R.X., Kang, M.J., Kamiyama, S., Kim, D.H., Magouri, K., Kamataki, A., Ito, Y., Takei, Y.A., Sasaki, M., Suzuki, T., Sasano, H., Kahashi, S., Sakai, J., Fugino, T., and Yamamoto, T.Y. (2003) Expression cloning and characterization of a novel glycosylphosphatidylinositol-anchored high density lipoprotein-binding protein, GPI-HBP1. J. Biol. Chem., 278, 7344–7349. Pennacchio, L.A., Olivier, M., Hubacek, J.A., Cox, D.R., Fruchart, J.C., Krauss, R.M., and Rubin, E.M. (2001) An apolipoprotein influencing triglycerides in humans and mice revealed by comparative sequencing. Science, 294, 169–173. Van der Vliet, H.N., Sammels, M.G., Leegwater, A.C., Levels, J.H., Reitma, P.H., Boers, W., and Chalumeau, R.A. (2001) Apolipoprotein A-V: A novel apolipoprotein associated with an early phase of liver regeneration. J. Biol. Chem., 276, 44512–44520. Van der Vliet, H.N., Schaap, F.G., Levels, J.H., Ottenhoff, R., Looije, N., Wesseling, J.G., Groen, A.K., and Chalumeau, R.A. (2002) Adenoviral expression of apolipoprotein A-V reduces serum levels of triglycerides and cholesterol in mice. Biochem. Biophys. Res. Commun., 295, 1156–1159. Pennacchio, L.A., Olivier, M., Hubacek, J.A., Kraus, R.M., Rubin, E.M., and Cohen, J.C. (2002) Two independent apolipoprotein A5 haplotypes influence
41
42
43
44
45
46
human plasma triglyceride levels. Hum. Mol. Genet., 11, 3031–3038. Marcais, C., Verges, B., Charriere, S., Pruneta, V., Merlin, M., Billon, S., Perrot, L., Drai, J., Sassolas, A., Pennachio, L.A., Fruchart-Najib, J., Fruchart, J.C., Durlach, V., and Moulin, P. (2005) ApoA5 Q139X truncation predisposes to late-onset hyperchylomicronemia due to lipoprotein lipase impairment. J. Clin. Invest., 115, 2862–2869. OBrien, P.J., Alborn, W.E., Sloan, J.H., Ulmer, M., Boodhoo, A., Knierman, M.D., Schultze, A.E., and Konrad, R.J. (2000) The novel apolipoprotein A5 is present in human serum, is associated with VLDL, HDL and chylomicrons, and circulates at very low concentrations compared with other apolipoproteins. Clin. Chem., 51, 351–359. Weinberg, R.B., Cook, V.R., Beckstead, J.A., Martin, D.D., Gallagher, J.W., Shelness, G.S., and Ryan, R.O. (2003) Structure and interfacial properties of human apolipoprotein A-V. J. Biol. Chem., 278, 34438–34444. Schaap, F.G., Rensen, P.C., Voshol, P.J., Vrins, C., van der Vliet, H.N., Chamuleau, R.A., Havekes, L.M., Groen, A.K., and van Dijk, K.W. (2004) ApoAV reduces plasma triglycerides by inhibiting very low density lipoprotein-triglyceride (VLDL-TG) production and stimulating lipoprotein lipase-mediated VLDL-TG hydrolysis. J. Biol. Chem., 279, 27941–27947. Merkel, M., Loeffler, B., Kluger, M., Fabig, N., Geppert, G., Pennacchio, L.A., Laatsch, A., and Heeren, J. (2005) Apolipoprotein AV accelerates plasma hydrolysis of triglyceride-rich lipoproteins by interaction with proteoglycan-bound lipoprotein lipase. J. Biol. Chem., 280, 21553–21560. Grosskopf, I., Baroukh, N., Lee, S.J., Kamari, Y., Harats, D., Rubin, E.M., Pennacchio, L.A., and Cooper, A.D. (2005) Apolipoprotein A-V deficiency results in marked hypertriglyceridemia attributable to decreased lipolysis of triglyceride-rich lipoproteins and removal of their remnants. Arterioscler. Throm. Vasc. Biol., 25, 2573–2579.
j107
j 6 New Developments in the Lipolytic Processing of Triglyceride-Rich Lipoproteins
108
47 Fruchart-Najib, J., Baug e, E., Niculescu,
L.S., Pham, T., Thomas, B., Rommens, C., Majd, Z., Brewer, B., Pennacchio, L.E., and Fruchart, J.C. (2004) Mechanism of triglyceride lowering in mice expressing human apolipoprotein A5. Biochem. Biophys. Res. Commun., 319, 397–404. 48 Lookene, A., Beckstead, J.A., Nilsson, S., Olivecrona, G., and Ryan, R.O. (2005) Apolipoprotein A-V–heparin interactions. Implications for plasma lipoprotein metabolism. J. Biol. Chem., 280, 25383–25387. 49 Cardin, A.D. and Weintraub, H.J. (1989) Molecular modeling of protein–
glycosaminoglycan interactions. Aterioscler. Thromb. Vasc. Biol., 9, 21–32. 50 Cunningham, O., Andolfo, A., Santovito, M.L., Luzzolino, L., Blasi, F., and Sidenius, N. (2003) Dimerization controls the lipid raft partitioning of uPAR/CD87 and regulates its biological functions. EMBO J., 22, 5994–6003. 51 Zeng, Y., Tao, N., Chung, K.N., Heuser, J.E., and Lublin, D.M. (2003) Endocytosis of oxidized low density lipoprotein through scavenger receptor CD36 utilizes a lipid raft pathway that does not require caveolin-1. J. Biol. Chem., 278, 45931–45936.
j109
7 Intracellular Fatty Acid Transport, Activation, and Trafficking Doug Mashek 7.1 Introduction
Adipose tissue, perhaps more than any other tissue, is characterized by its lipid content. By definition, lipids are hydrophobic molecules and, thus, are not soluble in cytosol. Since lipids cannot simply diffuse throughout the cell, numerous proteins are responsible for their movement. The focus of this chapter is to detail these intracellular lipid transport proteins, including their role in facilitating lipid metabolism and mediating the regulatory effects of lipids on physiological functions within the cell as well as their role in disease development. Although there are thousands of unique lipids present in adipocytes, this chapter will center upon proteins involved in the intracellular transport of fatty acids, their activation to acyl-CoAs, and the partitioning of these acyl-CoAs, which serve as important intermediates in many lipid metabolic pathways. Fatty acids are derived from numerous sources within cells, with the predominant sources being exogenous uptake, de novo synthesis or hydrolysis of intracellular lipids such as triacylglycerol or phospholipids. The flux of fatty acids from these sources to their distinct metabolic fates has a large impact on energy metabolism and serves many regulatory functions within cells. As fatty acids and acyl-CoAs are potent signaling molecules, dysregulation of their transport and partitioning appears to play a significant role in the development of prevalent diseases such as type 2 diabetes and obesity.
7.2 Fatty Acid-Binding Protein Family
In 1972, a group of researchers discovered that rat tissues contained a small, abundant cytosolic protein that bound fatty acids [1]. This original fatty acid-binding protein (FABP) is now recognized as a member of a multigene family of FABPs that serve a primary role in intracellular fatty acid trafficking. Although the FABP family consists of at least 10 unique members, this chapter will only focus upon the two
j 7 Intracellular Fatty Acid Transport, Activation, and Trafficking
110
members that are expressed in adipose tissue. The first member of this pair, FABP-4 (also known as aP2, adipocyte lipid-binding protein, and A-FABP), is highly expressed in macrophages and adipocytes where it comprises up to 6% of total cytosolic protein [2–4]. The second member, FABP-5 (also known as Mal-1, E-FABP and keratinocyte lipid-binding protein), is expressed in numerous tissues including adipose tissue where its expression is low relative to FABP-4 [5]. FABP-4 and -5 isoforms share considerable homology (52%), and the protein structures of all FABP isoforms are highly conserved and consist of a twisted-barrel comprised of antiparallel b-strands surrounding a hydrophobic core where fatty acids and other lipids bind [6]. FABP-4 and -5 bind fatty acids; however, unlike some other FABP members, they also bind different lipids with various affinities. FABP-4 has the highest binding affinity for saturated long-chain fatty acids although it also binds unsaturated fatty acids and retinoic acid [7–9]. In addition to binding fatty acids, FABP-5 also binds numerous eicosanoids, but unlike FABP-4 it does not bind retinoic acid [2, 10]. FABPs are thought to bind and transport fatty acids through one of two possible mechanisms [11]. The first mechanism, which appears to be that used by liver FABP, involves aqueous diffusion of the fatty acid from a donor membrane followed by binding to FABP and diffusion to another acceptor membrane. Thus, fatty acids disassociate from membranes into the cytosol where they are rapidly bound by a particular FABP. Subsequently, fatty acids are released from a FABP and rapidly resorb into a nearby membrane. However, in-line with the second mechanism, most FABPs, including FABP-4 and -5, appear to physically interact with donor membranes and facilitate dissociation of the fatty acid from the lipid bilayer followed by transport through the cytosol to an acceptor membrane. This transfer of fatty acid between FABP and membranes involves transient collision of FABP with membranes. Additionally, the collision between FABPs and membranes appears to be enhanced by the availability of the ligand (i.e., fatty acid) and electrostatic interactions with anionic phospholipids in the membranes [12]. Therefore, fatty acid flux and membrane composition may both contribute to the function of FABPs. 7.2.1 Function and Regulation of FABP-4
Most insights into the physiological role of FABP-4 have been derived from a series of studies utilizing knockout animal models. Although mice that lack FABP-4 appear normal under chow-fed conditions, challenging them with a high-fat diet invokes marked phenotypical changes. When fed a high-fat diet, FABP-4 null mice gain more weight including increased fat mass compared to wild-type C57Bl6/J mice [13]. Despite the increase in weight and fat mass, FABP-4 null mice fed a high-fat diet have lower serum concentrations of insulin, glucose, and triglycerides. The most surprising change is that FABP-4 null mice do not develop insulin resistance, which generally accompanies high-fat feeding induced obesity. Therefore, FABP-4 null mice represent a unique model that uncouples obesity from the common comorbidity of insulin resistance and diabetes. Although FABP-4 is the predominant isoform of FABP in adipose, it is interesting to note that FABP-5 is upregulated
7.2 Fatty Acid-Binding Protein Family
approximately 20-fold in FABP-4 null mice. Therefore, the true effect of FABP-4 knockdown is somewhat confounded by the upregulation of FABP-5. Regardless, it is clear that FABP-5 is unable to completely compensate for the lack of FABP-4. The unique phenotype exhibited in FABP-4 knockout mice raises the question of how the lack of FABP-4 expression specifically affects adipose tissue metabolism. Further characterization of adipose fatty acid metabolism in FABP-4 null mice has revealed a functional role of FABP-4 in triacylglycerol hydrolysis and fatty acid efflux. Under both basal conditions or during isoproterenol stimulation to induce lipolysis, glycerol release from FABP-4 null adipocytes is significantly attenuated [14, 15]. These data are supported by in vivo studies using stable isotopes of fatty acids that show nearly a 60% decrease in serum free fatty acid (FFA) appearance rate in FABP-4 null mice [16]. Additionally, relative to wild-type mice, intracellular concentrations of fatty acids are also elevated in FABP-4 null mice [14]. Thus, fatty acid efflux is reduced in the absence of FABP-4 and, likely as a consequence, intracellular fatty acids accumulate. Despite decreases in fatty acid release from adipose tissue, FABP-4 null mice have increased or unchanged concentrations of serum FFAs [13, 16, 17]. These data suggest that the rate of whole-body fatty acid disappearance is greatly reduced in FABP-4 null mice. Indeed, fatty acid utilization in FABP-4 null mice is lower than wild-type mice, thus explaining the increased serum FFA pool [16]. The exact mechanism explaining the compensatory changes in fatty acid disposal in nonadipose tissue of FABP-4 null mice remains unknown. The important discovery that FABP-4 directly interacts with and enhances the activity of hormone-sensitive lipase (HSL) provides a key mechanism through which FABP-4 may influence fatty acid efflux [18]. Since this original finding, it has been shown that fatty acid binding is a prerequisite for the interaction between FABP-4 and HSL [19]. Thereby, only upon fatty acid binding to FABP-4 can it interact with HSL to facilitate its catalytic functions. How does FABP-4 enhance HSL activity? HSL is inhibited by one of its end-products, in this case fatty acids [20]. By binding to fatty acids, FABP-4 releases this inhibition on HSL [21]. Thus, FABP-4-mediated transport of fatty acid away from HSL may mediate triacylglycerol hydrolysis and fatty acid efflux by (i) increasing HSL activity through the removal of its inhibitor (i.e., fatty acids) and (ii) transporting fatty acids released from triacylglycerol hydrolysis to the plasma membrane where efflux occurs. It will be of interest to determine if acyl-CoAs or FABPs also influence the activity of the recently discovered adipose triacylglycerol lipase [22]. The increased fat mass in FABP-4 null mice could easily be attributed to decreased rates of lipolysis. However, adipocytes from FABP-4 null mice exhibit elevated rates of de novo fatty acid synthesis, which may also contribute to increased fat mass [17, 23]. The increase in de novo synthesis is reflected by increased glucose disposal in adipose tissue of FABP-4 null animals [23]. Despite these novel findings, the mechanism explaining how FABP-4 alters glucose uptake and conversion to fat has not been identified. Additionally, it is not known how adipose tissue contributes to improving insulin sensitivity in FABP-4 null mice. As would be expected of a protein so central to adipocyte metabolism, FABP-4 expression is highly regulated. FABP-4, measured at both the mRNA and protein
j111
j 7 Intracellular Fatty Acid Transport, Activation, and Trafficking
112
level, is higher in subcutaneous adipose tissue compared with omental adipose tissue [24, 25]. This may explain why FABP-4 null mice show more pronounced increases in fat mass in subcutaneous rather than visceral adipose depots [17]. FABP4 expression increases following exposure to fatty acids under both in vitro and in vivo conditions [26–28]. Therefore, perhaps it is not surprising that FABP-4 expression increases in adipose tissue following weight loss in human subjects [29]. Fatty acids mediate these changes in FABP-4 levels primarily through their activation of transcription. Peroxisome proliferator-activated receptor (PPAR)-c is a major transcription factor involved in adipocyte differentiation and energy metabolism. The promoter region of FABP-4 contains the conserved DNA-binding domain for PPAR-c and consequently FABP-4 expression is responsive to PPAR-c activation [30]. Since fatty acids are ligands for PPAR-c, the increased expression of FABP-4 following increased exposure to fatty acids is likely due in large part to PPAR-c activation. As would be expected, FABP-4 expression is also highly upregulated, as is PPAR-c, during adipocyte differentiation [27]. Additionally, the upstream region of the FABP-4 gene contains an activator protein 1 site, a CCAAT/enhancer-binding protein (C/EBP) site and a fat-specific element, the latter of which is required for expression [31–33]. 7.2.2 Function and Regulation of FABP-5
Likely because of its lower expression, FABP-5 has not been as extensively studied as FABP-4 in adipose tissue. Yet, both transgenic and knockout models of FABP-5 have been developed to help elucidate the function of FABP-5. Compared to wild-type mice, FABP-5 null mice fed a chow diet consumed the same amount of chow, and had similar body weight and composition. Despite the lack of visible changes, FABP-5 null mice have reduced serum triacylglycerol and cholesterol, and increased serum FFAs [34]. However, there are no differences in the above-mentioned metabolites when animals are fed a high-fat diet despite similar changes in body weight and adiposity compared to control animals. FABP-5 null mice also have elevated blood glucose although their insulin sensitivity was improved, but not normalized, in response to high-fat feeding. Similarly, ablation of FABP-5 is able to partially alleviate the insulin resistance in ob/ob mice. Thus, like FABP-4 null mice, the lack of FABP-5 is able to somehow alleviate the development of insulin resistance induced through high-fat feeding or in a genetic rodent model of obesity and insulin resistance. Although FABP-5 null mice do not show altered FABP-4 expression to compensate for the lack of FABP-5, the same is not true in FABP-5 transgenic mice – the level of FABP-4 protein in the FABP-5 transgenic mice is reduced approximately 50% [34, 35]. Overexpression of FABP-5 exacerbates insulin resistance despite similar body weights and fat mass between the transgenic and wild-type mice [35]. As expected, mice transgenic for FABP-5 have increased rates of fatty acid release from adipocytes, thus supporting previous data highlighting an important role of FABPs in fatty acid efflux. Through the same mechanism as FABP-4, FABP-5 also interacts and regulates HSL to control fatty acid hydrolysis [19]. Despite the increase in FFA efflux from
7.3 Fatty Acid Activation and Channeling
adipocytes isolated from FABP-5 null mice, no changes in serum FFAs were noted, suggesting that whole-body fatty acid utilization increased to compensate for the increased rate of fatty acid appearance [17]. Owing to the compensatory changes in expression of FABP isoforms resulting from genetic manipulation of FABP-4 or -5 expression, a double-knockout model has been created [36]. These mice, which lack both FABP-4 and -5, are completely resistant to diet-induced obesity and insulin resistance. To further characterize these mice, they were crossed with obese leptin-deficient ob/ob mice. The resulting offspring remained obese, but had improved insulin sensitivity. Furthermore, FABP-4 and -5 double-knockout ob/ob mice have decreased fatty liver infiltration, but unaltered muscle AMP-activated protein kinase (AMPK) activity. Interestingly, double knockouts on a wild-type background have increased muscle AMPK activity. Thus, these results suggest leptin may mediate some of the observed phenotypical effects of altering FABP expression. In support, other studies performed on FABP-4 and/or -5 knockout mice also show altered adipokine levels, especially those of leptin and adiponectin [17, 36]. Therefore, changes in adipokine expression and secretion may be partially responsible for the effects of FABP-4 and -5 on altering energy metabolism. Unlike FABP-4, expression of FABP-5 is higher in omental fat compared with subcutaneous adipose depots and is higher in lean compared with obese subjects [29, 37]. Additionally, FABP-5 expression is sharply increased upon weight loss even more so than FABP-4. In sharp contrast to FABP-4, the peroxisome proliferator response element is not functional on FABP-5; thus, this isoform is not responsive to PPAR activation [38]. FABP-5 also enhances the fatty acid-mediated activation of PPAR-d, but not other PPAR isoforms [39].
7.3 Fatty Acid Activation and Channeling: Role of Long-Chain Acyl-CoA Synthetases and Fatty Acid Transport Proteins
With the exception of fatty acids destined for efflux or eicosanoid synthesis, fatty acids must first be activated to their acyl-CoA derivatives prior to entering either anabolic or catabolic pathways. This ATP-utilizing reaction is catalyzed by the acyl-CoA synthetase family of enzymes. The family of acyl-CoA synthetases, which show reactivity towards long chain fatty acids, was originally comprised of five long-chain acyl-CoA synthetases (ACSLs) [40]. However, it is now recognized that members of the fatty acid transport protein (FATP) family also possess activity to long- or very-long-chain fatty acids [41]. In white adipose tissue, ACSL-1 is the predominant isoform, although its expression varies among adipose depots; the highest expression is noted in subcutaneous adipose tissue [42]. Of the other isoforms, ACSL-3, -4, and -5 are expressed at lower levels in white adipose tissue, whereas in brown adipose tissue ACSL-5, along with ACSL-1, are highly expressed [42]. FATP-1 and -4 appear to be the only members of the FATP family to be expressed at significant levels in adipose tissue [43].
j113
j 7 Intracellular Fatty Acid Transport, Activation, and Trafficking
114
In addition to their unique tissue expression patterns, members of the ACSL and FATP families are membrane proteins that localize to different intracellular organelles. In adipocytes or 3T3-L1 cells, ACSL-1 localizes to the endoplasmic reticulum, plasma membrane, and glucose transporter 4 (GLUT4) vesicles [44–46]. Additionally, in 3T3-L1 cells, ACSL-1, -3 and -4 localize to lipid droplets during b-adrenergic stimulation, but only ACSL-1 is present under basal (i.e., unstimulated) conditions [47]. Therefore, despite being intrinsic membrane proteins, there is direct evidence of transport to and from lipid droplets under different physiological conditions. FATP-1 appears to be localized to many organelles in 3T3-L1 adipocytes including microsomes, nuclei, mitochondria, Golgi, and the plasma membrane, whereas the location of FATP-4 in adipocytes has not been characterized [44, 48]. Similar to the movement of ACSL isoforms to lipid droplets, the shuttling of FATP-1 and ACSL-1 to the plasma membrane is also regulated. Insulin stimulates FATP-1 movement to the plasma membrane although the proportion of total FATP-1 that is present on the plasma membrane remains relatively low (around 10%) [49]. Similarly, the stimulation of GLUT4 translocation to the plasma membrane is thought to be responsible for the movement of ACSL-1 in the presence of insulin [45]. This theory holds that ACSL-1, which is present on Golgi, migrates with GLUT4 vesicles as they bud off of the Golgi and translocate to the plasma membrane in response to insulin. As would be expected from their different intracellular locations, individual ACSL and FATP isoforms distinctly alter fatty acid channeling. These findings have been verified in a variety of tissues and cell lines, although the role of distinct ACSL and FATP isoforms, especially the former, in fatty acid partitioning in adipose tissue has been less characterized. It is known that tissue homogenate and organellespecific acyl-CoA synthetase activity changes in response to dietary or hormonal alterations. For example, total adipose (depot not specified) acyl-CoA synthetase activity towards palmitate is decreased following a 16 h fast; total activity is also decreased in diabetic rats [50]. Measurements of acyl-CoA synthetase activity in subcellular fractions reveals that although activity in mitochondria/nuclear fractions increases after a 16 h fast, concurrent decreases of activity in microsomes, cytosol, and the plasma membrane account for the net reduction in total cell acyl-CoA synthetase activity. Additionally, insulin treatment of adipocytes results in a small increase in acyl-CoA synthetase specific activity in low-density microsomes and nearly doubles the activity intrinsic to the plasma membrane. Yet, the amount of ACSL-1 that translocates to the plasma membrane only increases 22%. Thus, more than ACSL-1 translocation is responsible for the marked increase in plasma membrane ACS activity. Perhaps parallel FATP-1 translocation to the plasma membrane or post-translational modifications such as phosphorylation of either ACSL-1 or FATP-1 account for these differences. Thus, it is evident from these studies that measuring total acyl-CoA synthetase activity may not truly reflect actual changes in redistributing acyl-CoA synthetase activity within cells following nutritional or physiological alterations. Acyl-CoA synthetase activity and expression of individual isoforms is regulated differently between fat depots. For example, fasting decreases and refeeding in-
7.3 Fatty Acid Activation and Channeling
creases acyl-CoA synthetase activity towards palmitate in gonadal adipose homogenates, however, these nutritional manipulations have no effect on acyl-CoA synthetase activity in inguinal adipose tissue [42]. The same study showed that protein abundance of ACSL-1 in both adipose depots decreases with fasting and increases with refeeding although the changes are more pronounced in gonadal adipose tissue. Furthermore, exercise decreases acyl-CoA synthetase activity in mesenteric adipose tissue concurrent with decreases in ACSL-1 mRNA levels, whereas exercise had no effect on acyl-CoA synthetase activity and mRNA abundance in subcutaneous fat [51]. Based upon this information, it is tempting to speculate that alterations in specific ACSL or FATP isoforms may, at least in part, mediate the distinct differences in fatty acid metabolism between visceral and subcutaneous fat depots. During differentiation of 3T3-L1 cells, ACSL-1 mRNA abundance increases approximately 160-fold, whereas mRNA of other ACSL isoforms remains unchanged [52]. As this change in ACSL-1 mRNA coincides with the accumulation of triacylglycerol in differentiating 3T3-L1 cells, it is logical to speculate that ACSL-1 plays a major role in triacylglycerol synthesis. Yet, to date, no studies in adipose tissue have defined the role of ACSL-1 in fatty acid partitioning and triacylglycerol synthesis. Heart-specific overexpression of ACSL-1 increases triacylglycerol content of cardiomyocytes, whereas overexpression of ACSL-1 in hepatocytes does not alter oleic acid incorporation into triacylglycerol synthesis, but decreases triacylglycerol turnover in addition to increasing phospholipid and cholesterol ester synthesis [53, 54]. It is possible that ACSL-1 serves a different physiological function in adipose tissue compared to liver, which has been suggested [55]. For example, ACSL-1 interacts with FATP-1 in adipocytes [56]. However, since FATP-1 is not highly expressed in liver, the role of ACSL-1 in fatty acid channeling may be different in liver relative to adipose tissue due to the expression of proteins it interacts with. Conversely, ACSL-1 may contribute to the increase in triacylglycerol accumulation in adipose tissue through altering triacylglycerol turnover. Regarding the latter, perhaps ACSL-1 enhances activation of fatty acids released from triacylglycerol hydrolysis and preferentially channels these acyl-CoAs back to re-esterification pathways resulting in an increased triacylglycerol pool. Clearly, future studies that manipulate ACSL-1 expression or its post-translational processing will provide valuable information regarding its role in adipose lipid handling. Although ACSL-3, -4, and -5 are expressed in adipose tissue, albeit at relatively low levels, their function in fatty acid activation and channeling in adipose tissue has not been defined [42]. Previous studies have pointed towards a role for ACSL-5 in partitioning exogenous fatty acids directly to triacylglycerol synthesis in hepatoma cells [57]. Additionally, ACSL-4 has a preference for long-chain unsaturated fatty acids, specifically arachidonic acid [58]. Therefore it has been linked to changes in steroid synthesis and may play an important role in phospholipid metabolism [59]. However, at the moment, we can only speculate about the specific roles of these isoforms in adipose tissue. In addition to their involvement in fatty acid uptake, FATP-1 and -4 are important enzymes in activating and partitioning fatty acids in adipose tissue. In
j115
j 7 Intracellular Fatty Acid Transport, Activation, and Trafficking
116
order to study the distinct roles of FATP-1 and -4, Lobo et al. characterized fatty acid handling in stable small hairpin RNA knockdowns of 3T3-L1 cells [49]. Suppressing either FATP isoform results in decreased content of triacylglycerol, diacylglycerol, and monoacylglycerol. Yet, while knockdown of FATP-1 suppresses uptake of C16 : 0, C18 : 1, or C20 : 4, especially in response to insulin, blocking FATP-4 expression has no effect on fatty acid uptake. These data suggest that FATP-1 and -4 may regulate the concentration of these lipid pools through unique mechanisms. In support of these differences, further characterization of the cells shows that rates of palmitate incorporation into the above-mentioned glycerolipids decreases in FATP-1 knockdown cells, but is unaffected in FATP-4 knockdowns. Additionally, basal glycerol and fatty acid release from cells increases in FATP-4 knockdowns, whereas basal fatty acid release decreases in FATP-1 knockdowns. Therefore, it appears that FATP-1 may enhance fatty acid uptake, activation, and channeling to the triacylglycerol synthetic pathway. In contrast to altering synthesis rates, FATP-4 may decrease monoacylglycerol, diacylglycerol, and triacylglycerol content by enhancing the hydrolysis of these glycerolipids. The data elegantly show that FATP-1 and -4 have comparable effects on triacylglycerol content, but mediate these effects through two distinct mechanisms. Additionally, whole-body FATP-1 knockout mice have altered gene expression profiles, adipokine levels, and susceptibility to insulin resistance and obesity [60]. However, from these models it is difficult to ascertain the role of the adipocyte relative to other tissues that express these isoforms and to differentiate the effects of intracellular fatty acid and acylCoA metabolism from the effects on fatty acid transport.
7.4 Role of Acyl-CoA-Binding Protein in Acyl-CoA Metabolism
Once formed in cells, acyl-CoAs can be metabolized through numerous pathways. Yet, like fatty acids, acyl-CoAs are also hydrophobic and require proteins to facilitate their intracellular movement. Acyl-CoA-binding protein (ACBP) serves this role (Figure 7.2 highlights the roles of ACBP and FABPs in adipocyte lipid metabolism). The predominant mammalian ACBP is ubiquitously expressed although its highest level of expression is in the liver [5]. Unlike FABPs, which bind numerous ligands, ACBP binds acyl-CoAs exclusively [61] and with high affinity (KD ¼ 1–5 nM) [62]. Intracellular unbound acyl-CoA concentrations are low (below 10 nM) and acyl-CoAs readily incorporate into lipid bilayers such that the acyl chain is inserted laterally into membranes with the CoA headgroup remaining external to the membrane [63]. As a result, the majority of acyl-CoAs appear to be incorporated into membranes with a small fraction remaining in the cytosol. For example, mass spectrometric analysis of liver acyl-CoAs revealed that 98% of acyl-CoAs were bound in membranes [64]. It now appears that ACBP is able to desorb acyl-CoAs directly from membranes [63] in a manner that is dependent upon the charge and curvature of the membranes [65]. Similar to the FABPs, ACBP expression is regulated by PPAR-c [66]. ACBP expression increases dramatically during adipocyte differentiation although it
7.5 Regulation and Function of Distinct Fatty Acid and Acyl-CoA Pools
Figure 7.1 ACSLs and FATPs control fatty acid and acyl-CoA partitioning. FATP-1 appears to activate fatty acids that are destined for triacylglycerol synthesis, whereas FATP-4 may preferentially activate fatty acids released from triacylglycerol hydrolysis and promote their reesterification back into triacylglycerol. ACSL-1 has been suggested to serve a similar role in reesterification in hepatocytes although its role in adipocyte fatty acid metabolism remains
unknown. Both FATP-1 and ACSL-1 may be involved in the activation of fatty acids as they are transported across the plasma membrane. The role of other ACSL isoforms has not been studied. Solid lines represent sources of intracellular fatty acids and dotted lines reflect fates of fatty acids. Abbreviations not listed in text: FA, fatty acid; TAG, triacylglycerol; PL, phospholipid.
appears that other transcription factors in addition to PPAR-c are responsible for this increase [67]. The importance of ACBP upregulation during adipocyte differentiation is highlighted by the fact that antisense knockdown of ACBP blocks differentiation in 3T3-L1 cells [68]. Insights into the function of ACBP in liver are supportive for this dual role in controlling adipocyte differentiation and energy metabolism. Interestingly, liver ACBP expression is under the regulation of both PPAR-a and sterol regulatory element-binding protein (SREBP)-1c, which control catabolic and anabolic pathways of fatty acid metabolism, respectively [69]. Finally, an important function of ACBP in adipocytes might involve the regulation of several enzymes such as ACSLs and acetyl-CoA carboxylase, which produce acylCoAs as the end-product [70]. Similar to the effects of FABPs on HSL, ACBPs alleviate product inhibition and thereby enhance enzymatic activity. Thus, ACBPs can potentially regulate adipose tissue physiology at numerous steps, although few studies have characterized its function in depth.
7.5 Regulation and Function of Distinct Fatty Acid and Acyl-CoA Pools
Intracellular fatty acids and acyl-CoAs are bioactive signaling molecules that serve a multitude of functions within cells beyond being substrates for lipid metabolic
j117
j 7 Intracellular Fatty Acid Transport, Activation, and Trafficking
118
Figure 7.2 FABPs and ACBP mediate intracellular fatty acid and acyl-CoA metabolism and signaling. Intracellular fatty acids, which can be derived from multiple sources, are activated to acyl-CoAs prior to their metabolism. ACBPs facilitate acyl-CoA synthetase activity by removal of acyl-CoA, which acts through end-product inhibition. Subsequently, ACBP facilitates acylCoA metabolism to triacylglycerol and other lipids or transports acyl-CoAs to the nucleus where the acyl-CoAs can serve as signaling molecules that regulate gene expression; the specific transcription factors regulated by acylCoAs in adipocytes is not known. FABPs bind to
intracellular fatty acids and appear to play a major role in triacylglycerol hydrolysis. FABPs directly interact with and enhance HSL activity by removing fatty acids, which inhibit HSL, and subsequently promote fatty acid efflux by transporting fatty acids to the plasma membrane. FABPs also can transport fatty acids to the nucleus to regulate transcription factors such as PPAR-c to control gene expression. Solid lines represent sources of intracellular fatty acids and dotted lines reflect fates of fatty acids. Abbreviations not listed in text: FA, fatty acid; TAG, triacylglycerol; PL, phospholipid.
pathways (Figure 7.3). Perhaps the most documented function of fatty acids and acylCoAs is their ability to regulate a host of transcription factors to control gene expression. For example, fatty acids and acyl-CoAs are ligands for PPAR-c, which is known to regulate numerous adipocyte functions including differentiation, metabolism and adipokine secretion. Thus, because FABPs, ACSLs, FATPs, and ACBP control the intracellular concentration and distribution of fatty acids and acylCoAs they mediate the effects of these signaling molecules on gene expression. Indeed, overexpression of either FABP-4 or ACBP attenuates the activation of the PPARs, especially PPAR-c [71]. Additionally, both FABP-4 and ACBP colocalize to the nucleus, thus suggesting that these proteins are responsible for the trafficking of fatty acids and acyl-CoAs to the nucleus where they can carry out their regulatory effects on gene expression. Further studies reveal that FABP-4 directly interacts with
7.6 Contribution of Fatty Acid and Acyl-CoA Metabolism to Metabolic Diseases
j119
Allosteric regulators of metabolic enzymes: ACC, ACSL, ANT, G6PDH, HSL, PDH Protein kinases/phosphatases: AMPK, PKC, PP2A
Ligands for transcription factors (e.g. PPAR- γ ) Inhibitors of transcription factors (e.g. SREBP-1)
ATP-sensitive K+ channels
FAs/acyl-CoAs Monoacylglycerol
Kir channels Membrane trafficking
Diacylglycerol
Protein acylation
TAG β-oxidation Figure 7.3 Intracellular fatty acids and acylCoAs have diverse functions in cells. In addition to serving as substrates for glycerolipid synthesis or b-oxidation pathways, fatty acids and acyl-CoAs also play a large role in regulating energy metabolism, cell signaling and homeostasis in adipocytes. Abbreviations not listed in text: ACC, acetyl-CoA
ER stress
carboxylase; ANT, adenine nucleotide translocator; ER, endoplasmic reticulum; G6PDH, glucose-6-phosphate dehydrogenase; Kir, inwardly rectifying K þ channels; PDH, pyruvate dehydrogenase; PKC, protein kinase C; PP2A, protein phosphatase 2A; TAG, triacylglycerol.
PPAR-c and that its targeting to the nucleus is enhanced under stimulation with fatty acid [39, 72]. Although physical interaction between ACBP and transcription factors has not been shown in adipose tissue, ACBP is known to directly interact with and stimulate hepatocyte nuclear factor-4a activity in liver [73]. In addition to their regulation of gene expression, fatty acids and/or acyl-CoAs regulate other intracellular physiological processes. Acyl-CoAs act as allosteric inhibitors of numerous enzymes involved in pathways of energy metabolism such as HSL and acetyl-CoA carboxylase. Thus, accumulation of acyl-CoAs would signal the cell to block lipolysis or de novo fatty acid synthesis to prevent further production of intracellular fatty acids and acyl-CoAs. Moreover, acyl-CoAs regulate numerous processes involved in cell homeostasis including ATP-sensitive K þ channels [74], protein kinases [75, 76] and endoplasmic reticulum stress [77], the latter of which has been implicated in the etiology of type 2 diabetes [78]. Thus, altering fatty acid and/or acyl-CoA pools can have drastic consequences on cellular physiology well beyond simply altering lipid metabolism.
7.6 Contribution of Fatty Acid and Acyl-CoA Metabolism to Metabolic Diseases
Owing to the intimate role fatty acids and acyl-CoAs play in so many physiological processes, it is not surprising that disruption of fatty acid and acyl-CoA homeostasis
j 7 Intracellular Fatty Acid Transport, Activation, and Trafficking
120
is closely tied to the development of multiple diseases. For example, polymorphisms in FABP-4, FATP-1, FATP-4, and ACBP are linked to changes in blood lipids and/or risk for insulin resistance and type 2 diabetes (Table 7.1). The importance of FABP-4 is further highlighted with the recent discovery of a novel inhibitor to FABP-4 [79]. Administration of this inhibitor to an apolipoprotein E null mouse model of atherosclerosis decreases aortic lesions during both early and late stages of intervention. Similarly, the FABP-4 inhibitor improved insulin signaling and sensitivity in the ob/ob obese diabetic mouse model. Thus, altering FABP-4, through pharmaceutical therapy or natural allelic variation, may have a great impact on the development of diseases including both coronary heart disease and type 2 diabetes. Although the natural genetic variation in these genes is important in identifying individuals susceptible to disease, it will be of great interest to further identify how environmental factors such as diet interact with these specific genotypes. For example, if a specific ACSL or FATP isoform shows preference
Table 7.1 The effects of single nucleotide polymorphisms (SNPs) in genes involved in intracellular fatty acid and acyl-CoA trafficking with risk factors for disease and disease outcomes in humans.
Gene
Polymorphism
Phenotype
Reference
FABP-4
T-87C SNP in the C/EBPbinding site of FABP-4 promoter; decreases FABP-4 expression
[84]
FABP-4
A-376C SNP
FATP-1
A/G SNP in intron 8
FATP-1
A/G SNP in intron 8
FATP-4
Gly209Ser
ACSL-5
SNP in 5 0 -untranslated region; increases ACSL-5 expression in muscle SNP in promoter
decreased plasma triacylglycerol, decreased risk for type 2 diabetes (odds ratio ¼ 0.52 for obese subjects and 0.87 for lean subjects) and cardiovascular disease predicts insulin sensitivity and body composition in conjunction with PPAR-c polymorphism increased plasma triacylglycerol increased postprandial triacylglycerol, altered plasma FFA and LDL particle size decreased body mass index, plasma triacylglycerol, FFA, and glucose, and increased insulin increased responsiveness to weight loss
ACBP
decreased risk for type 2 diabetes
[85]
[86] [87]
[88]
[89]
[90]
References
for a fatty acid of certain chain length, then individuals with mutations in that isoform may respond very differently when fed a diet containing high amounts of that fatty acid. Such studies that combine genetic and environmental influences will have a large impact on furthering our ability to identify individuals susceptible to disease. In addition to genetic variation, the expression of fatty acid trafficking proteins is also commonly tied to disease. For example, FATP-4 expression correlates positively with obesity and insulin resistance in human subjects [80, 81]. Interestingly, ACSL-1 expression in adipose tissue is negatively correlated with insulin resistance and central obesity in humans [81], whereas its expression is upregulated in liver and adipose tissue of several rodent models of obesity [82, 83]. It should be noted that it is not known whether changes in expression of these proteins play a role in the development of disease or if they are simply a consequence of the altered metabolic state.
7.7 Conclusions
The intracellular trafficking and partitioning of fatty acids and their acyl-CoA metabolites affect a multitude of intracellular processes. As a result, the regulation of FABPs, ACSLs, FATPs, and ACBP directly control energy metabolism and lipidmediated cell signaling. The consequences of these changes are evident by the striking phenotypes of knockout or transgenic animal models that show the importance of these proteins on whole-body energy metabolism and the development of insulin resistance and obesity. Additionally, genetic variation in these proteins is linked to numerous diseases and altered metabolic functions in humans. Further characterization of these proteins or identification of novel proteins involved in fatty acid and acyl-CoA metabolism should significantly contribute to our understanding of adipose tissue metabolism and its role in disease etiology. Taken as a whole, this group of proteins has great potential as targets for nutritional or pharmaceutical therapies to help prevent or treat metabolic diseases.
References 1 Ockner, R.K., Manning, J.A.,
3 Fu, Y., Luo, N., and Lopes-Virella, M.F.
Poppenhausen, R.B., and Ho, W.K. (1972) A binding protein for fatty acids in cytosol of intestinal mucosa, liver, myocardium, and other tissues. Science, 177, 56–58. 2 Bernlohr, D.A., Simpson, M.A., Hertzel, A.V., and Banaszak, L.J. (1997) Intracellular lipid-binding proteins and their genes. Annu. Rev. Nutr., 17, 277–303.
(2000) Oxidized LDL induces the expression of ALBP/aP2 mRNA and protein in human THP-1 macrophages. J. Lipid Res., 41, 2017–2023. 4 Spiegelman, B.M. and Green, H. (1980) Control of specific protein biosynthesis during the adipose conversion of 3T3 cells. J. Biol. Chem., 255, 8811–8818.
j121
j 7 Intracellular Fatty Acid Transport, Activation, and Trafficking
122
5 Su, A.I., Cooke, M.P., Ching, K.A., Hakak,
6
7
8
9
10
11
12
13
Y., Walker, J.R., Wiltshire, T., Orth, A.P., Vega, R.G., Sapinoso, L.M., Moqrich, A., Patapoutian, A., Hampton, G.M., Schultz, P.G., and Hogenesch, J.B. (2002) Largescale analysis of the human and mouse transcriptomes. Proc. Natl. Acad. Sci. USA, 99, 4465–4470. Hertzel, A.V. and Bernlohr, D.A. (2000) The mammalian fatty acid-binding protein multigene family: molecular and genetic insights into function. Trends Endocrinol. Metab., 11, 175–180. Kane, C.D., Coe, N.R., Vanlandingham, B., Krieg, P., and Bernlohr, D.A. (1996) Expression, purification, and ligandbinding analysis of recombinant keratinocyte lipid-binding protein(MAL-1), an intracellular lipid-binding found overexpressed in neoplastic skin cells. Biochemistry, 35, 2894–2900. Glatz, J.F. and van der Vusse, G.J. (1996) Cellular fatty acid-binding proteins: their function and physiological significance. Prog. Lipid Res., 35, 243–282. Hanhoff, T., Lucke, C., and Spener, F. (2002) Insights into binding of fatty acids by fatty acid binding proteins. Mol. Cell. Biochem., 239, 45–54. Siegenthaler, G., Hotz, R., ChatellardGruaz, D., Didierjean, L., Hellman, U., and Saurat, J.H. (1994) Purification and characterization of the human epidermal fatty acid-binding protein: localization during epidermal cell differentiation in vivo and in vitro. Biochem. J., 302, 363–371. Thumser, A.E. and Storch, J. (2000) Liver and intestinal fatty acid-binding proteins obtain fatty acids from phospholipid membranes by different mechanisms. J. Lipid Res., 41, 647–656. Falomir-Lockhart, L.J., Laborde, L., Kahn, P.C., Storch, J., and Corsico, B. (2006) Protein–membrane interaction and fatty acid transfer from intestinal fatty acidbinding protein to membranes. Support for a multistep process. J. Biol. Chem., 281, 13979–13989. Hotamisligil, G.S., Johnson, R.S., Distel, R.J., Ellis, R., Papaioannou, V.E., and Spiegelman, B.M. (1996) Uncoupling of obesity from insulin resistance through a targeted mutation in aP2, the adipocyte
14
15
16
17
18
19
20
21
22
fatty acid binding protein. Science., 274, 1377–1379. Coe, N.R., Simpson, M.A., and Bernlohr, D.A. (1999) Targeted disruption of the adipocyte lipid-binding protein (aP2 protein) gene impairs fat cell lipolysis and increases cellular fatty acid levels. J. Lipid Res., 40, 967–972. Uysal, K.T., Scheja, L., Wiesbrock, S.M., Bonner-Weir, S., and Hotamisligil, G.S. (2000) Improved glucose and lipid metabolism in genetically obese mice lacking aP2. Endocrinology, 141, 3388–3396. Baar, R.A., Dingfelder, C.S., Smith, L.A., Bernlohr, D.A., Wu, C., Lange, A.J., and Parks, E.J. (2005) Investigation of in vivo fatty acid metabolism in AFABP/aP2/ mice. Am. J. Physiol. Endocrinol. Metab., 288, E187–E193. Hertzel, A.V., Smith, L.A., Berg, A.H., Cline, G.W., Shulman, G.I., Scherer, P.E., and Bernlohr, D.A. (2006) Lipid metabolism and adipokine levels in fatty acid-binding protein null and transgenic mice. Am. J. Physiol. Endocrinol. Metab., 290, E814–E823. Shen, W.J., Sridhar, K., Bernlohr, D.A., and Kraemer, F.B. (1999) Interaction of rat hormone-sensitive lipase with adipocyte lipid-binding protein. Proc. Natl. Acad. Sci. USA, 96, 5528–5532. Jenkins-Kruchten, A.E., Bennaars-Eiden, A., Ross, J.R., Shen, W.J., Kraemer, F.B., and Bernlohr, D.A. (2003) Fatty acidbinding protein–hormone-sensitive lipase interaction. Fatty acid dependence on binding. J. Biol. Chem., 278, 47636–47643. Fain, J.N. and Shepherd, R.E. (1975) Free fatty acids as feedback regulators of adenylate cyclase and cyclic 30 : 50 -AMP accumulation in rat fat cells. J. Biol. Chem., 250, 6586–6592. Shen, W.J., Liang, Y., Hong, R., Patel, S., Natu, V., Sridhar, K., Jenkins, A., Bernlohr, D.A., and Kraemer, F.B. (2001) Characterization of the functional interaction of adipocyte lipid-binding protein with hormone-sensitive lipase. J. Biol. Chem., 276, 49443–49448. Zimmermann, R., Strauss, J.G., Haemmerle, G., Schoiswohl, G., BirnerGruenberger, R., Riederer, M., Lass, A.,
References
23
24
25
26
27
28
29
Neuberger, G., Eisenhaber, F., Hermetter, A., and Zechner, R. (2004) Fat mobilization in adipose tissue is promoted by adipose triglyceride lipase. Science, 306, 1383–1386. Shaughnessy, S., Smith, E.R., Kodukula, S., Storch, J., and Fried, S.K. (2000) Adipocyte metabolism in adipocyte fatty acid binding protein knockout mice (aP2/) after short-term high-fat feeding: functional compensation by the keratinocyte [correction of keritinocyte] fatty acid binding protein. Diabetes, 49, 904–911. Fisher, R.M., Thorne, A., Hamsten, A., and Arner, P. (2002) Fatty acid binding protein expression in different human adipose tissue depots in relation to rates of lipolysis and insulin concentration in obese individuals. Mol. Cell. Biochem., 239, 95–100. Tchkonia, T., Giorgadze, N., Pirtskhalava, T., Tchoukalova, Y., Karagiannides, I., Forse, R.A., DePonte, M., Stevenson, M., Guo, W., Han, J., Waloga, G., Lash, T.L., Jensen, M.D., and Kirkland, J.L. (2002) Fat depot origin affects adipogenesis in primary cultured and cloned human preadipocytes. Am. J. Physiol. Regul. Integr. Comp. Physiol., 282, R1286–R1296. Haunerland, N.H., Chen, X., Andolfatto, P., Chisholm, J.M., and Wang, Z. (1993) Developmental changes of FABP concentration, expression, and intracellular distribution in locust flight muscle. Mol. Cell. Biochem., 123, 153–158. Amri, E.Z., Bertrand, B., Ailhaud, G., and Grimaldi, P. (1991) Regulation of adipose cell differentiation. I. Fatty acids are inducers of the aP2 gene expression. J. Lipid Res., 32, 1449–1456. Grimaldi, P.A., Knobel, S.M., Whitesell, R.R., and Abumrad, N.A. (1992) Induction of aP2 gene expression by nonmetabolized long-chain fatty acids. Proc. Natl. Acad. Sci. USA, 89, 10930–10934. Fisher, R.M., Eriksson, P., Hoffstedt, J., Hotamisligil, G.S., Thorne, A., Ryden, M., Hamsten, A., and Arner, P. (2001) Fatty acid binding protein expression in different adipose tissue depots from lean and obese individuals. Diabetologia, 44, 1268–1273.
30 Tontonoz, P., Hu, E., and Spiegelman,
31
32
33
34
35
36
37
B.M. (1995) Regulation of adipocyte gene expression and differentiation by peroxisome proliferator activated receptor gamma. Curr. Opin. Genet. Dev., 5, 571–576. Ross, S.R., Graves, R.A., Greenstein, A., Platt, K.A., Shyu, H.L., Mellovitz, B., and Spiegelman, B.M. (1990) A fat-specific enhancer is the primary determinant of gene expression for adipocyte P2 in vivo. Proc. Natl. Acad. Sci. USA, 87, 9590–9594. Coe, N.R. and Bernlohr, D.A. (1998) Physiological properties and functions of intracellular fatty acid-binding proteins. Biochim. Biophys. Acta, 1391, 287–306. Gerbens, F., Jansen, A., van Erp, A.J., Harders, F., Meuwissen, T.H., Rettenberger, G., Veerkamp, J.H., and te Pas, M.F. (1998) The adipocyte fatty acidbinding protein locus: characterization and association with intramuscular fat content in pigs. Mamm. Genome., 9, 1022–1026. Maeda, K., Uysal, K.T., Makowski, L., Gorgun, C.Z., Atsumi, G., Parker, R.A., Bruning, J., Hertzel, A.V., Bernlohr, D.A., and Hotamisligil, G.S. (2003) Role of the fatty acid binding protein mal1 in obesity and insulin resistance. Diabetes, 52, 300–307. Hertzel, A.V., Bennaars-Eiden, A., and Bernlohr, D.A. (2002) Increased lipolysis in transgenic animals overexpressing the epithelial fatty acid binding protein in adipose cells. J. Lipid Res., 43, 2105–2111. Maeda, K., Cao, H., Kono, K., Gorgun, C.Z., Furuhashi, M., Uysal, K.T., Cao, Q., Atsumi, G., Malone, H., Krishnan, B., Minokoshi, Y., Kahn, B.B., Parker, R.A., and Hotamisligil, G.S. (2005) Adipocyte/ macrophage fatty acid binding proteins control integrated metabolic responses in obesity and diabetes. Cell Metab., 1, 107–119. Fisher, R.M., Hoffstedt, J., Hotamisligil, G.S., Thorne, A., and Ryden, M. (2002) Effects of obesity and weight loss on the expression of proteins involved in fatty acid metabolism in human adipose tissue. Int. J. Obes. Relat. Metab. Disord., 26, 1379–1385.
j123
j 7 Intracellular Fatty Acid Transport, Activation, and Trafficking
124
38 Schachtrup, C., Emmler, T., Bleck, B.,
39
40
41
42
43
44
45
46
Sandqvist, A., and Spener, F. (2004) Functional analysis of peroxisomeproliferator-responsive element motifs in genes of fatty acid-binding proteins. Biochem. J., 382, 239–245. Tan, N.S., Shaw, N.S., Vinckenbosch, N., Liu, P., Yasmin, R., Desvergne, B., Wahli, W., and Noy, N. (2002) Selective cooperation between fatty acid binding proteins and peroxisome proliferatoractivated receptors in regulating transcription. Mol. Cell. Biol., 22, 5114–5127. Mashek, D.G., Bornfeldt, K.E., Coleman, R.A., Berger, J., Bernlohr, D.A., Black, P., DiRusso, C.C., Farber, S.A., Guo, W., Hashimoto, N., Khodiyar, V., Kuypers, F.A., Maltais, L.J., Nebert, D.W., Renieri, A., Schaffer, J.E., Stahl, A., Watkins, P.A., Vasiliou, V., and Yamamoto, T.T. (2004) Revised nomenclature for the mammalian long-chain acyl-CoA synthetase gene family. J. Lipid Res., 45, 1958–1961. DiRusso, C.C., Li, H., Darwis, D., Watkins, P.A., Berger, J., and Black, P.N. (2005) Comparative biochemical studies of the murine fatty acid transport proteins (FATP) expressed in yeast. J. Biol. Chem., 280, 16829–16837. Mashek, D.G., Li, L.O., and Coleman, R.A. (2006) Rat long-chain acyl-CoA synthetase mRNA, protein, and activity vary in tissue distribution and in response to diet. J. Lipid Res., 47, 2004–2010. Stahl, A. (2004) A current review of fatty acid transport proteins (SLC27). Pflugers Arch., 447, 722–727. Gargiulo, C.E., Stuhlsatz-Krouper, S.M., and Schaffer, J.E. (1999) Localization of adipocyte long-chain fatty acyl-CoA synthetase at the plasma membrane. J. Lipid Res., 40, 881–892. Sleeman, M.W., Donegan, N.P., HellerHarrison, R., Lane, W.S., and Czech, M.P. (1998) Association of acyl-CoA synthetase1 with GLUT4-containing vesicles. J. Biol. Chem., 273, 3132–3135. Milger, K., Herrmann, T., Becker, C., Gotthardt, D., Zickwolf, J., Ehehalt, R., Watkins, P.A., Stremmel, W., and Fullekrug, J. (2006) Cellular uptake of fatty acids driven by the ER-localized acyl-CoA
47
48
49
50
51
52
53
54
55
synthetase FATP4. J. Cell Sci., 119, 4678–4688. Brasaemle, D.L., Dolios, G., Shapiro, L., and Wang, R. (2004) Proteomic analysis of proteins associated with lipid droplets of basal and lipolytically stimulated 3T3-L1 adipocytes. J. Biol. Chem., 279, 46835–46842. Schaffer, J.E. and Lodish, H.F. (1994) Expression cloning and characterization of a novel adipocyte long chain fatty acid transport protein. Cell, 79, 427–436. Lobo, S., Wiczer, B.M., Smith, A.J., Hall, A.M., and Bernlohr, D.A. (2007) Fatty acid metabolism in adipocytes: functional analysis of fatty acid transport proteins 1 and 4. J. Lipid Res., 48, 609–620. Wang, Y.L., Guo, W., Zang, Y., Yaney, G.C., Vallega, G., Getty-Kaushik, L., Pilch, P., Kandror, K., and Corkey, B.E. (2004) Acyl coenzyme a synthetase regulation: putative role in long-chain acyl coenzyme a partitioning. Obes. Res., 12, 1781–1788. Shimomura, I., Tokunaga, K., Kotani, K., Keno, Y., Yanase-Fujiwara, M., Kanosue, K., Jiao, S., Funahashi, T., Kobatake, T., and Yamamoto, T. (1993) Marked reduction of acyl-CoA synthetase activity and mRNA in intra-abdominal visceral fat by physical exercise. Am. J. Physiol. Endocrinol. Metab., 265, E44–50. Marszalek, J.R., Kitidis, C., Dararutana, A., and Lodish, H.F. (2004) Acyl-CoA synthetase 2 overexpression enhances fatty acid internalization and neurite outgrowth. J. Biol. Chem., 279, 23882–23891. Chiu, H.C., Kovacs, A., Ford, D.A., Hsu, F.F., Garcia, R., Herrero, P., Saffitz, J.E., and Schaffer, J.E. (2001) A novel mouse model of lipotoxic cardiomyopathy. J. Clin. Invest., 107, 813–822. Li, L.O., Mashek, D.G., An, J., Doughman, S.D., Newgard, C.B., and Coleman, R.A. (2006) Overexpression of rat long chain acyl-Coa synthetase 1 alters fatty acid metabolism in rat primary hepatocytes. J. Biol. Chem., 281, 37246–37255. Mashek, D.G. and Coleman, R.A. (2006) Cellular fatty acid uptake: the contribution of metabolism. Curr. Opin. Lipidol., 17, 274–278.
References 56 Richards, M.R., Harp, J.D., Ory, D.S., and
57
58
59
60
61
62
63
64
Schaffer, J.E. (2006) Fatty acid transport protein 1 and long-chain acyl coenzyme A synthetase 1 interact in adipocytes. J. Lipid Res., 47, 665–672. Mashek, D.G., McKenzie, M.A., Van Horn, C.G., and Coleman, R.A. (2006) Rat long chain acyl-CoA synthetase 5 increases fatty acid uptake and partitioning to cellular triacylglycerol in McArdle-RH7777 cells. J. Biol. Chem., 281, 945–950. Kang, M.J., Fujino, T., Sasano, H., Minekura, H., Yabuki, N., Nagura, H., Iijima, H., and Yamamoto, T.T. (1997) A novel arachidonate-preferring acyl-CoA synthetase is present in steroidogenic cells of the rat adrenal, ovary, and testis. Proc. Natl. Acad. Sci. USA, 94, 2880–2884. Maloberti, P., Castilla, R., Castillo, F., Maciel, F.C., Mendez, C.F., Paz, C., and Podesta, E.J. (2005) Silencing the expression of mitochondrial acyl-CoA thioesterase I and acyl-CoA synthetase 4 inhibits hormone-induced steroidogenesis. FEBS J., 272, 1804–1814. Wu, Q., Ortegon, A.M., Tsang, B., Doege, H., Feingold, K.R., and Stahl, A. (2006) FATP1 is an Insulin-sensitive fatty acid transporter involved in diet-induced obesity. Mol. Cell. Biol., 26, 3455–3467. Knudsen, J., Jensen, M.V., Hansen, J.K., Faergeman, N.J., Neergaard, T.B., and Gaigg, B. (1999) Role of acylCoA binding protein in acylCoA transport, metabolism and cell signaling. Mol. Cell. Biochem., 192, 95–103. Taskinen, J.P., van Aalten, D.M., Knudsen, J., and Wierenga, R.K. (2007) High resolution crystal structures of unliganded and liganded human liver ACBP reveal a new mode of binding for the acyl-CoA ligand. Proteins, 66, 229–238. Cohen Simonsen, A., Bernchou Jensen, U., Faergeman, N.J., Knudsen, J., and Mouritsen, O.G. (2003) Acyl-coenzyme A organizes laterally in membranes and is recognized specifically by acyl-coenzyme A binding protein. FEBS Lett., 552, 253–258. Huang, H., Atshaves, B.P., Frolov, A., Kier, A.B., and Schroeder, F. (2005) Acylcoenzyme A binding protein expression
65
66
67
68
69
70
71
alters liver fatty acyl-coenzyme A metabolism. Biochemistry, 44, 10282–10297. Chao, H., Martin, G.G., Russell, W.K., Waghela, S.D., Russell, D.H., Schroeder, F., and Kier, A.B. (2002) Membrane charge and curvature determine interaction with acyl-CoA binding protein (ACBP) and fatty acyl-CoA targeting. Biochemistry, 41, 10540–10553. Helledie, T., Grontved, L., Jensen, S.S., Kiilerich, P., Rietveld, L., Albrektsen, T., Boysen, M.S., Nohr, J., Larsen, L.K., Fleckner, J., Stunnenberg, H.G., Kristiansen, K., and Mandrup, S. (2002) The gene encoding the acyl-CoA-binding protein is activated by peroxisome proliferator-activated receptor gamma through an intronic response element functionally conserved between humans and rodents. J. Biol. Chem., 277, 26821–26830. Neess, D., Kiilerich, P., Sandberg, M.B., Helledie, T., Nielsen, R., and Mandrup, S. (2006) ACBP – a PPAR and SREBP modulated housekeeping gene. Mol. Cell. Biochem., 284, 149–157. Mandrup, S., Sorensen, R.V., Helledie, T., Nohr, J., Baldursson, T., Gram, C., Knudsen, J., and Kristiansen, K. (1998) Inhibition of 3T3-L1 adipocyte differentiation by expression of acyl-CoAbinding protein antisense RNA. J. Biol. Chem., 273, 23897–23903. Sandberg, M.B., Bloksgaard, M., DuranSandoval, D., Duval, C., Staels, B., and Mandrup, S. (2005) The gene encoding acyl-CoA-binding protein is subject to metabolic regulation by both sterol regulatory element-binding protein and peroxisome proliferator-activated receptor alpha in hepatocytes. J. Biol. Chem., 280, 5258–5266. Rasmussen, J.T., Rosendal, J., and Knudsen, J. (1993) Interaction of acyl-CoA binding protein (ACBP) on processes for which acyl-CoA is a substrate, product or inhibitor. Biochem. J., 292, 907–913. Helledie, T., Antonius, M., Sorensen, R.V., Hertzel, A.V., Bernlohr, D.A., Kolvraa, S., Kristiansen, K., and Mandrup, S. (2000) Lipid-binding proteins modulate ligand-
j125
j 7 Intracellular Fatty Acid Transport, Activation, and Trafficking
126
72
73
74
75
76
77
78
dependent trans-activation by peroxisome proliferator-activated receptors and localize to the nucleus as well as the cytoplasm. J. Lipid Res., 41, 1740–1751. Adida, A. and Spener, F. (2006) Adipocytetype fatty acid-binding protein as intercompartmental shuttle for peroxisome proliferator activated receptor gamma agonists in cultured cell. Biochim. Biophys. Acta, 1761, 172–181. Petrescu, A.D., Payne, H.R., Boedecker, A., Chao, H., Hertz, R., Bar-Tana, J., Schroeder, F., and Kier, A.B. (2003) Physical and functional interaction of acylCoA-binding protein with hepatocyte nuclear factor-4 alpha. J. Biol. Chem., 278, 51813–51824. Larsson, O., Deeney, J.T., Branstrom, R., Berggren, P.O., and Corkey, B.E. (1996) Activation of the ATP-sensitive K þ channel by long chain acyl-CoA. A role in modulation of pancreatic beta-cell glucose sensitivity. J. Biol. Chem., 271, 10623–10626. Taylor, E.B., Ellingson, W.J., Lamb, J.D., Chesser, D.G., and Winder, W.W. (2005) Long-chain acyl-CoA esters inhibit phosphorylation of AMP-activated protein kinase at threonine-172 by LKB1/STRAD/ MO25. Am. J. Physiol. Endocrinol. Metab., 288, E1055–E1061. Majumdar, S., Rossi, M.W., Fujiki, T., Phillips, W.A., Disa, S., Queen, C.F., Johnston, R.B. Jr., Rosen, O.M., Corkey, B.E., and Korchak, H.M. (1991) Protein kinase C isotypes and signaling in neutrophils. Differential substrate specificities of a translocatable calciumand phospholipid-dependent beta-protein kinase C and a phospholipid-dependent protein kinase which is inhibited by long chain fatty acyl coenzyme A. J. Biol. Chem., 266, 9285–9294. Kharroubi, I., Ladriere, L., Cardozo, A.K., Dogusan, Z., Cnop, M., and Eizirik, D.L. (2004) Free fatty acids and cytokines induce pancreatic beta-cell apoptosis by different mechanisms: role of nuclear factor-kappab and endoplasmic reticulum stress. Endocrinology, 145, 5087–5096. Harding, H.P. and Ron, D. (2002) Endoplasmic reticulum stress and the
79
80
81
82
83
84
85
development of diabetes: a review. Diabetes, 51 (Suppl. 3), S455–S461. Furuhashi, M., Tuncman, G., Gorgun, C.Z., Makowski, L., Atsumi, G., Vaillancourt, E., Kono, K., Babaev, V.R., Fazio, S., Linton, M.F., Sulsky, R., Robl, J.A., Parker, R.A., and Hotamisligil, G.S. (2007) Treatment of diabetes and atherosclerosis by inhibiting fatty-acidbinding protein aP2. Nature, 447, 959–965. Gertow, K., Pietilainen, K.H., YkiJarvinen, H., Kaprio, J., Rissanen, A., Eriksson, P., Hamsten, A., and Fisher, R.M. (2004) Expression of fatty-acidhandling proteins in human adipose tissue in relation to obesity and insulin resistance. Diabetologia, 47, 1118–1125. Gertow, K., Rosell, M., Sjogren, P., Eriksson, P., Vessby, B., de Faire, U., Hamsten, A., Hellenius, M.L., and Fisher, R.M. (2006) Fatty acid handling protein expression in adipose tissue, fatty acid composition of adipose tissue and serum, and markers of insulin resistance. Eur. J. Clin. Nutr., 60, 1406–1413. Shimomura, I., Tokunaga, K., Jiao, S., Funahashi, T., Keno, Y., Kobatake, T., Kotani, K., Suzuki, H., Yamamoto, T., and Tarui, S. (1992) Marked enhancement of acyl-CoA synthetase activity and mRNA, paralleled to lipoprotein lipase mRNA, in adipose tissues of Zucker obese rats (fa/ fa). Biochim. Biophys. Acta, 1124, 112–118. Memon, R.A., Fuller, J., Moser, A.H., Smith, P.J., Grunfeld, C., and Feingold, K.R. (1999) Regulation of putative fatty acid transporters and acyl-CoA synthetase in liver and adipose tissue in ob/ob mice. Diabetes, 48, 121–127. Tuncman, G., Erbay, E., Hom, X., De Vivo, I., Campos, H., Rimm, E.B., and Hotamisligil, G.S. (2006) A genetic variant at the fatty acid-binding protein aP2 locus reduces the risk for hypertriglyceridemia, type 2 diabetes, and cardiovascular disease. Proc. Natl. Acad. Sci. USA, 103, 6970–6975. Damcott, C.M., Moffett, S.P., Feingold, E., Barmada, M.M., Marshall, J.A., Hamman, R.F., and Ferrell, R.E. (2004) Genetic variation in fatty acid-binding protein-4 and peroxisome proliferatoractivated receptor gamma interactively
References influence insulin sensitivity and body composition in males. Metabolism, 53, 303–309. 86 Meirhaeghe, A., Martin, G., Nemoto, M., Deeb, S., Cottel, D., Auwerx, J., Amouyel, P., and Helbecque, N. (2000) Intronic polymorphism in the fatty acid transport protein 1 gene is associated with increased plasma triglyceride levels in a French population. Arterioscler. Thromb. Vasc. Biol., 20, 1330–1334. 87 Gertow, K., Skoglund-Andersson, C., Eriksson, P., Boquist, S., Orth-Gomer, K., Schenck-Gustafsson, K., Hamsten, A., and Fisher, R.M. (2003) A common polymorphism in the fatty acid transport protein-1 gene associated with elevated post-prandial lipaemia and alterations in LDL particle size distribution. Atherosclerosis, 167, 265–273. 88 Gertow, K., Bellanda, M., Eriksson, P., Boquist, S., Hamsten, A., Sunnerhagen, M., and Fisher, R.M. (2004) Genetic
and structural evaluation of fatty acid transport protein-4 in relation to markers of the insulin resistance syndrome. J. Clin. Endocrinol. Metab., 89, 392–399. 89 Adamo, K.B., Dent, R., Langefeld, C.D., Cox, M., Williams, K., Carrick, K.M., Stuart, J.S., Sundseth, S.S., Harper, M.E., McPherson, R., and Tesson, F. (2007) Peroxisome proliferator-activated receptor gamma 2 and acyl-CoA synthetase 5 polymorphisms influence diet response. Obesity, 15, 1068–1075. 90 Fisher, E., Nitz, I., Gieger, C., Grallert, H., Gohlke, H., Lindner, I., Dahm, S., Boeing, H., Burwinkel, B., Rathmann, W., Wichmann, H.E., Schrezenmeir, J., Illig, T., and Doring, F. (2007) Association of acyl-CoA-binding protein (ACBP) single nucleotide polymorphisms and type 2 diabetes in two German study populations. Mol. Nutr. Food Res., 51, 178–184.
j127
j129
8 Aquaporins and Adipose Tissue: Lesson from Discovery to Physiopathology and to the Clinic of Aquaporin Adipose (AQP7) Ken Kishida 8.1 Introduction
The metabolic syndrome comprises a cluster of insulin resistance, elevated blood pressure, and atherogenic dyslipidemia, and is a major cause of cardiovascular disease in industrial countries [1]. Accumulation of body fat, especially intraabdominal fat deposits, stands upstream of the metabolic syndrome [1]. In the early 1990s, our group pioneered research on the molecular mechanism of the metabolic syndrome [2–4]. We analyzed the gene expression profile of human adipose tissue in collaboration with the Human Body Map Project team, and found that adipose tissue, especially visceral fat, expressed a variety of genes for secretory proteins, including growth factors and cytokines [5]. Traditionally, adipose tissue has been considered as a simple energy storage organ in which lipogenesis and lipolysis are observed in response to whole-body energy balance, but it is also currently understood as an endocrine organ that secretes a variety of bioactive molecules [5]. We named these adipocyte-derived molecules adipocytokines [1]. We and others have provided evidence for the potential role of dysregulation of adipocytokines in the development of the metabolic syndrome [1]. To find a novel therapy for metabolic syndrome, it is necessary to focus on the biology and science of adipocyte that the authors have named adiposcience. Adipocytes hydrolyze triglyceride and rapidly liberate free fatty acids (FFAs) and glycerol into the circulation [6]. The underlying mechanism responsible for glycerol release from adipocytes remains unclear. Our team also discovered a highly expressed gene from the human adipose tissue cDNA library in 1997 [5]. This gene, encoded by a protein belonging to the aquaporin (AQP) family, was named AQP adipose (aquaporin adipose AQPap) [21, 22], which also had glycerol permeability and was later found to be a human homolog of AQP7 [9]. In this chapter, we review a series of studies on AQP7 to define the function and significance of the glycerol gateway molecule, and discuss the relation between AQPs and glycerol metabolism.
j 8 Aquaporins and Adipose Tissue: Lesson from Discovery to Physiopathology
130
Figure 8.1 Schematic presentation of lipogenesis in adipocytes. Under lipogenic conditions, b-cells in the pancreas secret insulin in response to an increase in plasma glucose concentration. Insulin binds to the insulin receptor located on the surface of adipocytes, transfers GLUT4 to the plasma membrane, and takes glucose into the cell. Intracellular glucose
is converted to glycerol-3-phosphate (glycerol-3P). Insulin also activates LPL located on the cell surface of the vascular endothelium. ActivatedLPL removes fatty acids from intestine-derived CM and liver-derived VLDL, and then fatty acids are taken into adipocytes. Fatty acids and glycerol-3-phosphate are esterified into triglyceride (TG).
8.2 Characteristics of Adipocytes and Gycerol Metabolism in the Mammalian Body
Adipocytes continuously synthesize (lipogenesis) and hydrolyze (lipolysis) triglyceride in response to whole-body energy balance (Figures 8.1 and 8.2) [6]. Adipocytes have a unique feature – lipid droplets occupy a large part of the intracellular region, while the nucleus and cytosome are located in the periphery. In comparison, the nucleus is located in the center of cell in other tissue cells. Thus, adipocytes are morphologically characterized by triglyceride accumulation. The b-cells in the pancreas secret insulin in response to an increase in plasma glucose concentration during feeding. Insulin acts on adipose tissues as well as skeletal muscles, transfers glucose transporter 4 (GLUT4) to plasma membrane, and takes glucose into the cell [11]. In addition, insulin activates lipoprotein lipase (LPL) located on the cell surface of the vascular endothelium. LPL removes fatty acids from intestine-derived chylomicron (CM) and liver-derived very-low-density lipoprotein (VLDL), and then fatty acids are taken into adipocytes [12]. In adipocytes, glycerol-3-phosphates converted from glucose and fatty acids are esterified into triglyceride.
8.2 Characteristics of Adipocytes and Gycerol Metabolism in the Mammalian Body
Catecholamine
Insulin
Lipolysis HSL
Nucleus
translocation HSL
TG Glycerol transporter ?
FFA transporter
FFA
Glycerol
Portal vein Glycerol transporter ?
Liver
FFA oxidations Gluconeogenesis
Figure 8.2 Schematic presentation of lipolysis in adipocytes, and pathway of glycerol and FFA from adipocytes to liver. Under lipolysis or starvation, sympathetic nerves are activated and catecholamines are increased. Catecholamines stimulate adrenergic receptors located on the surface of adipocytes. Activation of adrenergic receptors results in activation of HSL. HSL
hydrolyzes triglyceride (TG) to FFA and glycerol, and both are released into the bloodstream. FFAs are partly re-esterified to triglyceride and incorporated to lipoprotein, and glycerol is used as a substrate of gluconeogenesis in liver. We hypothesized that AQP7 may function as a glycerol transporter in adipocytes [52].
Fatty acid-binding protein (FABP; aP2) [13], fatty acid translocase (FAT) [14], and fatty acid transport protein (FATP) [8, 15] are recognized as fatty acid transporters in adipocytes (Figure 8.1). In contrast to the feeding state, exercise and/or fasting induce lipolysis in adipocytes [16]. Fasting stimulates sympathetic nerves and elevates catecholamines, such as adrenaline and noradrenalin, which in turn stimulate adrenergic receptors located on the surface of adipocytes. Activation of adrenergic receptors results in converting ATP to cAMP. Elevation of intracellular cAMP activates hormone-sensitive lipase (HSL) by phosphorylation. Phosphorylated HSL hydrolyzes triglyceride to FFA and glycerol, and both are released into the bloodstream. FFA and glycerol are utilized for thermogenesis and gluconeogenesis, respectively (Figure 8.2). During the long history of mammals and humans, starvation has been a matter of life or death. Adipocytes play a crucial role in energy supply under starvation to maintain
j131
j 8 Aquaporins and Adipose Tissue: Lesson from Discovery to Physiopathology
132
energy homeostasis and have contributed to the survival of animals during long fasting periods. During lipolysis, adipocytes liberate FFA and glycerol rapidly outside the cells. It had been considered that FFA and glycerol are transported outside the cell by simple diffusion. Interestingly, recent studies revealed the participation of several molecules in the transport of FFA, such as FATP [8, 15], FABP [13], and FAT [14]. However, the molecular mechanism involved in the transport of glycerol was poorly understood. The rapid increase in glycerol production during lipolysis results in an acute rise in intracellular osmotic pressure, which could damage the cell. We hypothesized that adipocytes may have a molecule for glycerol (Figure 8.2)
8.3 Adipose Glycerol Channel: AQP7 8.3.1 AQP7: A Putative Adipose-Specific Glycerol Channel
The AQPs are a group of channel-forming integral membrane proteins that selectively transport water and, in some cases, small neutral solutes, such as glycerol and urea [16–18]. The discovery of AQPs led to the finding that rapid movement of water molecules across the cell membrane is required in specialized cell types or tissues [16–18]. The AQPs are a family of homologous water channels widely distributed in plants, unicellular organisms, invertebrates, and vertebrates [16–19]. There are two subfamilies – the aquaporins, which transport only water, and the aquaglyceroporins, which transport glycerol in addition to water (Figure 8.3a) [19, 20]. Many investigators have demonstrated that AQPs play a crucial role in maintaining water homeostasis, but the physiological significance of some AQPs as a glycerol channel is not fully understood. For example, the studies of AQP2, as the gene responsible for nephrogenic diabetes insipidus, highlighted the significance of AQP in human diseases [7]. We analyzed the gene expression profile of human visceral and subcutaneous fat to clarify the molecular mechanism of obesity-related diseases [5]. We identified a novel cDNA belonging to the AQP family during this analysis, and named it AQPap because its mRNA is expressed abundantly in adipose tissues and adipocytes [10, 21, 22]. AQPap is a human counterpart of AQP7 that was independently cloned from rat testes by another group at the same time [9]. In Figure 8.4, each AQP is specifically expressed in specialized tissues. The adipose tissue expresses two aquaporins, AQP1 and AQP7. AQP7 is highly expressed in white adipose tissue (WAT), brown adipose tissue (BAT), and testes [22]. The testes express a shorter size of AQP7 mRNA because of a different polyadenylation site [10]. A weak expression of AQP7 is also observed in the heart, skeletal muscles, and kidneys [22]. We analyzed the function of AQP7 using in Xenopus oocytes. AQP7-expressing Xenopus oocytes showed water and glycerol permeability [10, 21] (Figure 8.3b). This gain of function was inhibited by HgCl2 and recovered by 2-mercaptoethanol, similar
8.3 Adipose Glycerol Channel: AQP7
AQP2 (WCH-CD) AQP5
(a)
AQP0 (MIP) AQP6 AQP4 (MIWC) AQP1 (CHIP) AQP8 AQP11 AQP12
Mammalian aquaporins out NA P
P NA
in
(GlpF)
NH2
AQP7 (AQPap) AQP3 AQP9
COOH
AQP10
aquaglyceroporins (b)
Water Permeability (pmol/min/oocyte)
(x10-4cm/s)
400 300 200 100 0 H2O
6 5
Glycerol Uptake
4 3 2 1 0
AQP7
Figure 8.3 Phylogenic analysis of the mammalian AQPs and functional analysis of AQP7 in Xenopus oocytes. The phylogenic tree of the mammalian AQP gene family is shown (a). Water-permeable AQPs are AQP0, 1, 2, 4, 5, 6 and 8. Glycerol-permeable aquaglyceroporins are boxed (AQP3, 7, 9, 10 and GlpF). GlpF is the Escherichia coli homolog. AQP11 and AQP12
H2O
AQP7
belong to the unclassified subfamily. Osmotic water permeability (Pf ) and [14C]glycerol uptake of oocytes injected with water (open bar) or 50 ng of human AQPap cRNA (closed bar) are shown (b). The oocytes injected with AQP7 cRNA showed 4.5-fold stimulation of glycerol uptake compared with those of water-injected oocytes [10].
to the other AQPs [21, 22]. These results indicated that AQP7 could be subcategorized as an aquaglyceroporin. In mammals, AQP3, 7, 9, and 10 are considered to belong to the aquaglyceroporin subfamily at present (Figure 8.3a) [19, 20]. AQP1 is a simple water channel (Figure 8.3a). Therefore, AQP7 is the sole aquaglyceroporin in the adipose tissue (Figure 8.4). During the differentiation of 3T3-L1 adipocytes, the amount of glycerol released into the media increases and such an increase correlates with augmentation of the AQP7 mRNA expression level [22]. Many adipose-specific genes are controlled by the
j133
j 8 Aquaporins and Adipose Tissue: Lesson from Discovery to Physiopathology Eye Brain Heart Lung Muscle Stomach Intestine Liver Pancreas Spleen Kidney Testis WAT BAT
134
AQP0 AQP1 AQP2 AQP3 AQP4 AQP5 AQP6 AQP7 (AQPap) AQP8 AQP9 AQP11 AQP12 36B4 Figure 8.4 Tissue distribution of AQPs in mice. C57Black6 mice (12 weeks old) were sacrificed in the fed state and various tissues were removed. RNAs were extracted and subjected to Northern blot analyses. Shown is Northern blotting analysis of AQPs in the various tissues. From [22, 23].
nuclear factor peroxisome proliferator-activated receptor (PPAR)-c, which is a master regulator of adipocytes differentiation and regulates several adipose-specific genes at the transcriptional level [24]. PPAR-c forms a heterodimer with retinoic acid X receptor (RXR)-a and binds to peroxisome proliferator response element (PPRE) [24]. We identified the PPRE sequence in the AQP7 promoter [25]. The heterodimer of PPAR-c and RXR-a binds to the PPRE site of the AQP7 promoter and upregulates AQP7 mRNA expression in adipocytes (Figure 8.5a). Furthermore, transfection of PPAR/RXR and exogenous PPAR-c ligands, thiazolidinediones, stimulated the promoter activity of AQP7 [25]. AQP7 PPRE actually bound to PPAR/RXR complex (Figure 8.5) [25]. AQP7 is the adipose-specific novel PPAR-c target gene. 8.3.2 Function and Regulation of AQP7 in Adipocytes
Catecholamine activates lipolysis and may accelerate glycerol release from adipocytes through AQP7. Epinephrine does not affect AQP7 gene expression (Figure 8.6a). In 3T3-L1 adipocytes, AQP7 is localized at the periphery of the nucleus in the steady state [22]. However, AQP7 translocates to the plasma membrane following epinephrine stimulation, which induces lipolysis (Figure 8.6b) [22]. Epinephrine elevates
8.3 Adipose Glycerol Channel: AQP7
Figure 8.5 Specific binding of the PPAR-c/ RXR-a complex to the PPRE in the AQP7 promoter. The putative PPRE in the AQP7 promoter is underlined (a). The PPAR-c/RXR-a
complex directs and specifically binds to the PPRE in the AQP7 promoter as shown by electrophoretic mobility shift assay (b) [25].
intracellular cAMP levels through adrenergic receptor and then activates protein kinase A (PKA). Interestingly, similar results are observed in AQP2, which is a key water channel of kidney [26]. Briefly, AQP2 exists in the principal cells of the renal collecting duct. Immunogold electron microscopy studies showed that very little AQP2 protein is found in the apical membrane of collecting duct principal cells, but most AQP2 protein exists in the membranes of intracellular vesicles. However, AQP2 protein relocates to the apical plasma membrane when collecting duct cells are stimulated by vasopressin – an antidiuretic hormone released from the brain [26]. Vasopressin binds to V2 receptor at the basolateral membrane of the renal collecting duct causing activation of a G-coupled adenylyl cyclase cascade that results in phosphorylation of AQP2 by PKA [27]. The phosphorylation site of AQP2 is located at residue 256 on the C-terminus of its protein. Phosphorylated AQP2 moves to the apical plasma membrane. These results suggest that AQP7, as well as AQP2, may be phosphorylated by PKA under the activation of adrenergic receptor. It is necessary to determine the phosphorylation site of AQP7 in the future. Moreover, fasting activates lipolysis. We investigated the regulation of AQP7 expression during fasting and refeeding in animals. In mice, fasting was associated with increased AQP7 mRNA level, whereas refeeding reduced the level in parallel with plasma glycerol levels [10]. These nutrition-related changes in AQP7 and plasma glycerol were in clear contrast to insulin levels (Figure 8.6c) [10]. The expression of
j135
j 8 Aquaporins and Adipose Tissue: Lesson from Discovery to Physiopathology
136
Figure 8.6 Catecholamine-induced translocation and insulin-mediated repression of the AQP7 through negative IRE. We examined the effect of lipolytic hormone on AQP7 mRNA levels. Administration of epinephrine did not change AQP7 mRNA levels in 3T3-L1 adipocytes (a). When the 3T3-L1 adipocytes were stimulated by epinephrine for 20 min, the signal in the plasma membrane became robust in comparison to the intracellular regions, suggesting that AQP7 was translocated from intracellular regions to the plasma membrane (b) [22]. Next, we examined the effect of fasting on AQP7 mRNA expression in adipose tissues. Adipose AQP7 mRNA levels were increased by
fasting and suppressed by refeeding, similar to the change of glycerol. Plasma insulin levels were decreased in the fasted mice and restored in the refed mice (c). We found negative IRE in the human and mouse AQP7 promoter. Single point mutation analysis of the IRE sequence in the AQPap promoter using the promoter assay in 3T3-L1 adipocytes (d) [10]. The bases in the heptanucleotide IRE are numbered 1–7. The value for the wild-type construct without insulin was arbitrarily set at 1.0. In the lower panel, the percent inhibition of AQPap-mediated luciferase activity in mutant constructs by insulin is plotted below the corresponding mutated base pair.
AQP7 was upregulated in the adipose tissue of streptozotocin (STZ)-induced insulin deficient mice [10]. In fact, in 3T3-L1 adipocytes, insulin suppresses AQP7 mRNA levels in a dose- and time-dependent manners. Many genes negatively controlled by insulin such as glucose-6-phosphatase and phosphoenolpyruvate carboxykinase (PEPCK), which are key enzymes of gluconeogenesis, have a negative insulin
8.3 Adipose Glycerol Channel: AQP7
response element (IRE) in their promoter. We found IRE in the promoter of AQP7 [10]. Single nucleotide substitution analysis revealed that four core nucleotides at the center of AQP7 IRE, GTTT, are necessary for the negative regulation by insulin (Figure 8.6d) [10]. These results indicated that AQP7 mRNA expression is closely regulated by insulin at the transcriptional level. Taken together, plasma adipocytederived glycerol levels through AQP7 are partly determined by insulin and catecholamine (Figure 8.7). 8.3.3 Human AQP7 Genetic Mutation
Next, we studied the mutations in the human AQP7 gene for further clarification of the significance of AQP7. We screened human AQP7 gene mutation in 160 subjects including controls, diabetics, and obese individuals, and three types of polymorphism, which predict three types of missense mutation were identified: R12C (a C ! T substitution at nucleotide 206 in exon 3 led to substitution of arginine with cysteine at position 12, which resides in the N-terminal cytoplasmic domain),
Fasting (Lipolysis state) Insulin
Catecholamine
PI3K-pathway Nucleus HSL
AQP7
translocation
DNA
transcription
HSL
TG AQP7
FFA
Glycerol
Figure 8.7 Schematic presentation of the regulatory mechanisms that control adipose AQP7 under the fasting state. Catecholamine translocates HSL to the lipid droplets, while related stimuli move AQP7 to the plasma membrane. HSL hydrolyzes triglyceride (TG) to fatty acids and glycerol. Moreover, AQP7 mRNA levels are elevated by the decrease of the insulin
signaling cascade. Thus, long-term regulation of AQP7 is under the control of insulin, whereas short-term regulation is under the control of catecholamines. These two different regulatory pathways of AQP7 ensure the efficient release of glycerol from adipocytes under fasting conditions. PI3K, phosphoinositide-3-kinase.
j137
j 8 Aquaporins and Adipose Tissue: Lesson from Discovery to Physiopathology
138
one subject; V59L (a G ! C substitution at nucleotide 347 in exon 4 caused substitution of valine with leucine at position 59, which resides in the first bilayer-spanning domain), 13 subjects; and G264V (a G ! T substitution at nucleotide 963 in exon 8 led to substitution of glycine with valine at position 264, which resides in the sixth bilayer-spanning domain), six subjects (Figure 8.8a) [28]. When we injected cRNA carrying each mutation, oocytes normally expressed AQP7 protein [28]. V59L and R12C were functionally normal, but the G264V mutation lacked both water and glycerol permeability, while those expressing R12C or V59L mutant proteins retained water and glycerol permeability (Figure 8.8b) [28]. G264V mutation is located in the sixth bilayer-spanning domain. Structural analysis of AQP1 shows that the conserved GxxxG motif in the third and sixth bilayer-spanning domain is important for functional pore conformation of AQP family protein; glycine can be sometimes replaced by alanine in the motif (Figure 8.8c) [29]. In the sixth bilayerspanning domain of human AQP7, A260, G264, and G268 form this motif. The functional defect in the G264V mutant might be caused by a disturbance of this motif (Figure 8.8c) [28]. We found a homozygote carrying the G264V mutation. When
(a)
Glycerol Uptake
(b) 3
G264V
V59L
2
in
1
COOH
NH2
(c)
0
(d)
Transmembrane Helix-Helix Association GXXXG Motif Helix 3 and 6 AQP7 264 GAYLG AQP3
213
GTSMG
AQP9
208
GLNSG
Figure 8.8 Genetic mutations of the human AQP7 gene, and functional analysis of the AQP7 mutant proteins in both Xenopus oocytes and human. Three identified missense mutations, AQP7-R12C, V59L and G264V, in the topology of AQP7. NAA and NPS are amino acid residues composed of NPA motifs highly conserved among AQP family proteins (a). We note the functions of these mutant AQP7 proteins using
WT R12C V59L G264V
H2O Fold change (arbitrary unit)
R12C
out NS P
A NA
3.5
Plasma glycerol
3.0 2.5
WT
2.0 1.5
G264V
1.0 0
0 15 30 Exercise time (min)
glycerol permeability of oocytes expressing the G264V mutant is lower (WT, wild-type) (b). G264V is located in the GXXXG motif in the a- helix structures present in the third and sixth transmembrane region (c). This motif is well conserved in aquaglyceroporins (c). The plasma glycerol level is not increased in the subject homozygous for the G264V mutation during exercise (d) [28].
8.3 Adipose Glycerol Channel: AQP7
subjected to physical exercise after prolonged (20 h) fasting, the subjects with homozygous mutation of G264V showed a similar exercise-induced rise in plasma noradrenalin compared to healthy volunteers, whereas the increase in plasma glycerol was apparently disturbed during exercise (Figure 8.8d) [28]. This result indicates that AQP7 may be a crucial molecule for maintaining plasma glycerol levels in human. However, obesity and diabetes were not observed in subjects with homozygous mutation of G264V. Furthermore, it has been reported that single nucleotide polymorphisms (SNPs) in the AQP7 gene may modulate the risk of obesity and dysregulated glycerol release [30]. Further analysis of the human AQP7 gene and/or frequency of the AQP7 mutation or SNP in subjects with the metabolic syndrome should be performed in the future. 8.3.4 Adipose-Derived Glycerol and Gluconeogenesis through AQP7 – Lessons from AQP7-Deficient Mice and Cells
We identified only one subject with a loss-of-function mutation of AQP7 [28]. To further clarify the physiological function of AQP7 in vivo, we generated AQP7 knockout mice and analyzed their phenotype [31]. We removed exons 1, 2, and 3, and replaced them with a neo cassette. No difference was found in plasma FFA levels between wild-type and knockout mice, but AQP7 knockout mice exhibit lower portal glycerol concentrations under fasting state than wild-type mice under the same condition [31]. Administration of b3-adrenergic agonist, which specifically affects adipocytes and enhances lipolysis, results in impaired plasma glycerol elevation in AQP7 knockout mice, but does not modulate the normal increase of plasma FFA in both wild-type and AQP7 knockout mice [31]. Similar results are obtained in in vitro 3T3-L1 adipocytes introduced by RNA interference (RNAi) [31]. Briefly, epinephrinemediated glycerol release is significantly disturbed in AQP7 knockdown 3T3-L1 adipocytes, while epinephrine-mediated FFA release from AQP7 knockdown adipocytes is similar to that of 3T3-L1 adipocytes transfected with control RNAi. A longer starvation test demonstrated that AQP7 knockout mice exhibit impaired plasma glycerol elevation associated with severe hypoglycemia in comparison with wild-type mice [31]. The results of a series of studies indicate that AQP7 acts as an adipose glycerol channel in vivo and that adipose-derived glycerol is a significant substrate for gluconeogenesis (Figure 8.9a). During the experiments with AQP7 knockout mice, we noticed an unexpected phenotype. There is no difference in body weight of wild-type and AQP7 knockout mice at a young age, but we found that AQP7 knockout mice developed mild obesity after 12 weeks of age [11]. Adipose tissue weights of AQP7 knockout mice are significantly heavier than wild-type mice at 20 weeks of age. The mass of the WATwas larger in knockout mice compared to wild-type mice (Figure 8.9b) [32]. Histological analysis shows an increase in hypertrophic adipocytes in AQP7 knockout mice [32]. Recently, Hara-Chikuma et al. [33] also reported an increased number of hypertrophic adipocytes in AQP7 knockout mice, although the body weights of their AQP7 knockout mice were similar to those of wild-type mice. The difference of phenotypes
j139
j 8 Aquaporins and Adipose Tissue: Lesson from Discovery to Physiopathology
140
Figure 8.9 Schematic presentation of the physiological role of AQP7 based on the analysis of AQP7 knockout mice. (a) Summary of younger mice. Under starvation, AQP7 knockout (AQP7-KO) mice exhibit impairment of plasma glycerol elevation that results in severe hypoglycemia in comparison with wildtype (WT) mice. There is evidence that AQP7 acts as an adipose glycerol channel in vivo and that adipose-derived glycerol is a significant substrate for gluconeogenesis [31]. (b) Summary and photo of older mice. AQP7
knockout mice develop obesity accompanied by adipocyte hypertrophy after 12 weeks of age. The high intracellular glycerol contents induce the enzymatic activity of glycerol kinase in adipose tissues of AQP7 knockout mice at a young age. Glycerol kinase promotes re-esterification of glycerol and accelerates triglyceride (TG) accumulation in adipocytes. Moreover, AQP7 knockout mice exhibit whole-body insulin resistance associated with obesity [32]. Glycerol3-P, glycerol-3-phosphate.
may be accounted for by the genetic background of mice. Why was AQP7 deficiency associated with the development of obesity? Intracellular glycerol contents of AQP7 knockout mice are significantly higher than those of wild-type mice at a young age [32]. Under normal conditions, the adipose tissue exhibits only low glycerol kinase activity and it is believed that glycerol is not reused for lipogenesis in adipocytes. A recent study reported that glycerol induces conformational changes and enzymatic activity of glycerol kinase, which is a key enzyme in the conversion of glycerol to glycerol-3-phosphate [34–36]. Actually, the activity of adipose glycerol kinase of AQP7 knockout mice is elevated before development of obesity, relative to
8.4 Hepatic Glycerol Channel: AQP9
wild-type mice. A previous study indicated that overexpression of glycerol kinase promotes re-esterification of glycerol and accelerates triglyceride accumulation in adipocytes [36]. Knockdown of AQP7 in 3T3-L1 adipocytes using RNAi increases intracellular glycerol content, elevates glycerol kinase activity, enhances oleic acid uptake, and finally results in triglyceride accumulation (Figure 8.9b) [32]. Thus, AQP7 knockout mice exhibit whole-body insulin resistance associated with obesity. In summary, a deficiency of adipose AQP7 influences not only glycerol metabolism, but also glucose metabolism in vivo.
8.4 Hepatic Glycerol Channel: AQP9 8.4.1 AQP9: A Putative Hepatic-Specific Glycerol Channel
AQP9 was independently identified in human leukocytes and liver [37], and rat liver [38, 39]. AQP9 is also highly expressed in mouse liver and testes (Figure 8.4). In hepatocytes, immunohistochemistry showed that AQP9 is localized at the sinusoidal plasma membrane [40]. Rat AQP9-expressing Xenopus oocytes exhibit water and glycerol permeability [37, 39]. A series of studies on Xenopus oocytes also demonstrated that rat AQP9 permeates urea, mannitol, sorbitol, and uracil. Consistent with this finding, another group found that rat AQP9 is permeable to water, glycerol, and urea [39]. These results indicate a broad selectivity of rat AQP9. However, another group found AQP9-induced permeability to be restricted to water and urea in humans [37]. Thus, there are conflicting results regarding AQP9-induced permeability between rats and humans. Intra-abdominal visceral fat accumulates mainly in the mesentery [2–4]. The anatomical distribution of intra-abdominal visceral fat indicates that substances released from the visceral fat directly flow into the liver via the portal vein [2–4]. FFA derived from visceral fat during lipolysis elevates liver acyl-CoA synthetase and microsomal triglyceride transfer protein mRNA levels, and reduces degradation of apolipoprotein B. These changes induce the release of apolipoprotein B from the liver and increase plasma triglyceride concentrations. Hypertriglyceridemia, which is often observed in subjects with visceral fat accumulation, is partly accounted for by the increase in FFA derived from adipose tissues [41]. Glycerol, which is another product from adipose triglyceride during lipolysis, flows directly into the liver via the portal vein and becomes a substrate for gluconeogenesis. The liver has glycerol kinase activity and can activate glycerol to use it for gluconeogenesis [34, 36]. Expression of AQP1, 8 and 9 was identified in the liver (Figure 8.4). The only aquaglyceroporin among these AQPs is AQP9 (Figure 8.3a). AQP9 is considered as the sole glycerol channel in liver and is localized at the sinusoidal plasma membrane facing the portal vein [40]. Taken together, AQP9 may act as a channel of glycerol uptake in the liver (Figure 8.2). AQP9 mRNA levels increase by fasting and decrease by feeding [42]. These changes in AQP9 mRNA are similar to those of glycerol kinase,
j141
j 8 Aquaporins and Adipose Tissue: Lesson from Discovery to Physiopathology
142
which is a key enzyme involved in the conversion of glycerol to glycerol-3-phosphate, and PEPCK, which is a key enzyme for gluconeogenesis. Insulin suppresses AQP9 mRNA levels in a time- and dose-dependent manner in H4IIE rat hepatocytes. Administration of STZ results in increased AQP9 mRNA [42] and protein [43] levels in insulin-insufficient mice. Promoter analysis demonstrates that insulin closely reduces AQP9 mRNA at the transcriptional level through IRE on AQP9 promoter, as in the regulation of AQP7 by insulin. 8.4.2 Gluconeogenesis through AQP9 – Lessons from AQP9-Deficient Mice
Another group generated AQP9 knockout mice and analyzed their phenotype [44]. In the absence of physiological stress, knockout mice did not display any visible behavioral or severe physical abnormalities. Compared with control mice, plasma levels of glycerol and triglycerides were markedly increased in AQP9 knockout mice, whereas glucose, urea, FFAs, and cholesterol were not significantly different. Oral administration of glycerol to fasted mice resulted in an acute rise in blood glucose levels in AQP9 knockout mice, revealing no defect in utilization of exogenous glycerol as a gluconeogenic substrate and indicating a high gluconeogenic capacity in nonhepatic organs. In summary, AQP9 is important for hepatic glycerol metabolism, and may play a role in glycerol and glucose metabolism in diabetes mellitus.
(a)
Visceral Fat AQP7 mRNA
(b) 2
arbitrary unit
3 arbitrary unit
Hepatic AQP9 mRNA
2
1
1
0
0
Fast Fed Lean
Fast Fed Obese
Figure 8.10 Overexpression of adipose AQP7 and hepatic AQP9 in obesity. Total RNA (10 mg) of visceral fat and liver in obese db þ /db þ (n ¼ 8) and lean db þ /db þ (n ¼ 8) mice were analyzed by Northern blotting. Columns and bars represent the mean standard error of the results. Two aquaglyceroporins, adipose AQP7
Fast Fed Lean
Fast Fed Obese
(a) and hepatic AQP9 (b), are coordinately regulated. Both AQPs are upregulated under starvation and downregulated after feeding. However, downregulation of both AQP7 and AQP9 expression is blunted and remains high in obesity [42].
8.6 Dysregulation of AQP7 and AQP9 in Obesity with Insulin Resistance
j143
8.5 Coordination of Adipose Glycerol Channel, AQP7, and Hepatic Glycerol Channel, AQP9
In the feeding state, an increase in plasma insulin concentration results in suppression of lipolysis and the mRNA expression of adipose AQP7, and in reduced glycerol release from adipocytes (Figure 8.10) [10, 22, 42]. Feeding also reduces hepatic AQP9 mRNA and glycerol-based gluconeogenesis (Figure 8.11) [42]. In the physiological feeding state, high plasma insulin coordinately suppresses the AQP7 mRNA for glycerol release from adipocytes and AQP9 in mRNA for glycerol uptake into liver, through the IRE in the AQP7 and AQP9 gene promoter, respectively [10, 42].
8.6 Dysregulation of AQP7 and AQP9 in Obesity with Insulin Resistance
We also studied the regulation of AQP7 and AQP9 in obesity. Both adipose AQP7 and hepatic AQP9 were suppressed in the fed state of lean mice through insulin Glucose
Fasted state
Glucose
Fed state
Gluconeogenesis
Gluconeogenesis
Liver
Adipocyte
Liver
Adipocyte AQP9
AQP9
FFA
TG
Glucose
FFA
TG
FFA
Glycerol Glycerol AQP7 Portal vein
Glycerol AQP7
Portal vein Glucose
Obesity-Overnutrition (Fed state: Insulin resistance)
Gluconeogenesis Liver AQP9
TG Glycerol AQP7
Portal vein
Adipocyte
Figure 8.11 Schematic presentation of physiological and pathophysiological involvement of adipose AQP7 and hepatic AQP9. The coordinated regulation of AQP7 and AQP9 in the physiological fasted and fed states may lead to systemic glucose metabolism via
adipose-derived glycerol. In contrast, in the pathological fed state of insulin resistance, the coordinated augmentation of AQP7 and AQP9, in spite of hyperinsulinemia, augments the utilization of glycerol for hepatic glucose production [42]. TG, triglyceride.
j 8 Aquaporins and Adipose Tissue: Lesson from Discovery to Physiopathology
144
(Figure 8.10) [10, 42]. However, the suppression of the two AQPs is impaired in obese and insulin-resistant animals in spite of hyperinsulinemia, resulting in portal hyperglycerolemia, which at least partly participates in the systemic hyperglycemia (Figures 8.10 and 8.11) due to more utilization of adipose-derived glycerol for hepatic glucose production and release [42]. Considered collectively, physiological and pathological coordinated regulation of organ-specific glycerol channels, adipose AQP7 and hepatic AQP9, may contribute to glycerol and glucose metabolism (Figure 8.11) [42].
8.7 Conclusions
The discovery of AQP has made a great impact on life sciences. Structural and functional analyses of AQPs indicate that AQPs do not only permeate water. Novel metabolic mechanisms have been clarified by the demonstration that some AQPs act as glycerol channels. Glycerol release is enhanced with increased expression of adipose AQP7 to maintain glucose levels during starvation. However, in AQP7 knockout mice glycerol release is disturbed and causes hypoglycemia [23, 31, 32, 45– 47]. Take together, we demonstrated that AQP7 serves as a glycerol channel in adipocytes [23]. Investigation of AQP-dependent glycerol metabolism should provide a pivotal insight for the design of novel therapeutic strategies to combat metabolic syndrome [48–51].
References 1 Funahashi, T., Nakamura, T., Shimomura,
I., Maeda, K., Kuriyama, H., Takahashi, M., Arita, Y., Kihara, S., and Matsuzawa, Y. (1999) Role of adipocytokines on the pathogenesis of atherosclerosis in visceral obesity. Intern. Med., 38, 202–206. 2 Fujioka, S., Matsuzawa, Y., Tokunaga, K., and Tarui, S. (1987) Contribution of intraabdominal fat accumulation to the impairment of glucose and lipid metabolism in human obesity. Metabolism, 36, 54–59. 3 Kanai, H., Matsuzawa, Y., Kotani, K., Keno, Y., Kobatake, T., Nagai, Y., Fujioka, S., Tokunaga, K., and Tarui, S. (1990) Close correlation of intra-abdominal fat accumulation to hypertension in obese women. Hypertension, 16, 484–490. 4 Nakamura, T., Tokunaga, K., Shimomura, I., Nishida, M., Yoshida, S., Kotani, K., Islam, A.H., Keno, Y. et al. (1994)
5
6 7
8
9
Contribution of visceral fat accumulation to the development of coronary artery disease in non-obese men. Atherosclerosis, 107, 239–246. Maeda, K., Okubo, K., Shimomura, I., Mizuno, K., Matsuzawa, Y., and Matsubara, K. (1997) Analysis of an expression profile of genes in the human adipose tissue. Gene, 190, 227–235. Ramsay, T.G. (1996) Fat cells. Endocrinol. Metab. Clin. North Am., 25, 847–870. Sasaki, S. (2004) Nephrogenic diabetes insipidus: update of genetic and clinical aspects. Nephrol. Dial. Transplant., 19, 1351–1353. Schaffer, J.E. and Lodish, H.F. (1994) Expression cloning and characterization of a novel adipocyte long chain fatty acid transport protein. Cell, 79, 427–436. Ishibashi, K., Kuwahara, M., Gu, Y., Kageyama, Y., Tohsaka, A., Suzuki, F.,
References
10
11
12
13
14
15
16
17
18
Marumo, F., and Sasaki, S. (1997) Cloning and functional expression of a new water channel abundantly expressed in the testis permeable to water, glycerol, and urea. J. Biol. Chem., 272, 20782–20786. Kishida, K., Shimomura, I., Kondo, H., Kuriyama, H., Makino, Y., Nishizawa, H., Maeda, N., Matsuda, M. et al. (2001) Genomic structure and insulin-mediated repression of the aquaporin adipose (AQPap), adipose-specific glycerol channel. J. Biol. Chem., 276, 36251–36260. Shepherd, P.R. and Kahn, B.B. (1999) Glucose transporters and insulin actionimplications for insulin resistance and diabetes mellitus. N. Engl. J. Med., 341, 248–257. Mead, J.R., Irvine, S.A., and Ramji, D.P. (2002) Lipoprotein lipase: structure, function, regulation, and role in disease. J. Mol. Med., 80, 753–769. Stremmel, W., Strohmeyer, G., Borchard, F., Kochwa, S., and Berk, P.D. (1985) Isolation and partial characterization of a fatty acid binding protein in rat liver plasma membranes. Proc. Natl. Acad. Sci. USA, 82, 4–8. Ibrahimi, A., Sfeir, Z., Magharaie, H., Amri, E.Z., Grimaldi, P., and Abumrad, N.A. (1996) Expression of the CD36 homolog (FAT) in fibroblast cells: effects on fatty acid transport. Proc. Natl. Acad. Sci. USA, 93, 2646–2651. Motojima, K., Passilly, P., Peters, J.M., Gonzalez, F.J., and Latruffe, N. (1998) Expression of putative fatty acid transporter genes are regulated by peroxisome proliferator-activated receptor alpha and gamma activators in a tissueand inducer-specific manner. J. Biol. Chem., 273, 16710–16714. Heymann, J.B. and Engel, A. (1999) Aquaporins: phylogeny, structure, and physiology of water channels. News Physiol. Sci., 14, 187–193. Agre, P., King, L.S., Yasui, M., Guggino, W.B., Ottersen, O.P., Fujiyoshi, Y., Engel, A., and Nielsen, S. (2002) Aquaporin water channels – from atomic structure to clinical medicine. J. Physiol., 542, 3–16. Agre, P. (2004) Nobel Lecture. Aquaporin water channels. Biosci. Rep., 24, 127–163.
19 Ishibashi, K. (2006) Aquaporin subfamily
20
21
22
23
24
25
26
27
with unusual NPA boxes. Biochim. Biophys. Acta, 1758, 989–993. Hara-Chikuma, M. and Verkman, A.S. (2006) Physiological roles of glyceroltransporting aquaporins: the aquaglyceroporins. Cell. Mol. Life Sci., 63, 1386–1392. Kuriyama, H., Kawamoto, S., Ishida, N., Ohno, I., Mita, S., Matsuzawa, Y., Matsubara, K., and Okubo, K. (1997) Molecular cloning and expression of a novel human aquaporin from adipose tissue with glycerol permeability. Biochem. Biophys. Res. Commun., 241, 53–58. Kishida, K., Kuriyama, H., Funahashi, T., Shimomura, I., Kihara, S., Ouchi, N., Nishida, M., Nishizawa, H. et al. (2000) Aquaporin adipose, a putative glycerol channel in adipocytes. J. Biol. Chem., 275, 20896–20902. Hibuse, T., Maeda, N., Nagasawa, A., and Funahashi, T. (2006) Aquaporins and glycerol metabolism. Biochim. Biophys. Acta, 1758, 1004–1011. Schoonjans, K., Martin, G., Staels, B., and Auwerx, J. (1997) Peroxisome proliferatoractivated receptors, orphans with ligands and functions. Curr. Opin. Lipidol., 8, 159–166. Kishida, K., Shimomura, I., Nishizawa, H., Maeda, N., Kuriyama, H., Kondo, H., Matsuda, M., Nagaretani, H. et al. (2001) Enhancement of the aquaporin adipose gene expression by a peroxisome proliferator-activated receptor gamma. J. Biol. Chem., 276, 48572–48579. Nielsen, S., Chou, C.L., Marples, D., Christensen, E.I., Kishore, B.K., and Knepper, M.A. (1995) Vasopressin increases water permeability of kidney collecting duct by inducing translocation of aquaporin-CD water channels to plasma membrane. Proc. Natl. Acad. Sci. USA, 92, 1013–1017. Kuwahara, M., Fushimi, K., Terada, Y., Bai, L., Marumo, F., and Sasaki, S. (1995) cAMP-dependent phosphorylation stimulates water permeability of aquaporin-collecting duct water channel protein expressed in Xenopus oocytes. J. Biol. Chem., 270, 10384–10387.
j145
j 8 Aquaporins and Adipose Tissue: Lesson from Discovery to Physiopathology
146
28 Kondo, H., Shimomura, I., Kishida, K.,
29
30
31
32
33
34
35
Kuriyama, H., Makino, Y., Nishizawa, H., Matsuda, M., Maeda, N. et al. (2002) Human aquaporin adipose (AQPap) gene. Genomic structure, promoter analysis and functional mutation. Eur. J. Biochem., 269, 1814–1826. Murata, K., Mitsuoka, K., Hirai, T., Walz, T., Agre, P., Heymann, J.B., Engel, A., and Fujiyoshi, Y. (2000) Structural determinants of water permeation through aquaporin-1. Nature, 407, 599–605. Prudente, S., Flex, E., Morini, E., Turchi, F., Capponi, D., De Cosmo, S., Tassi, V., Guida, V. et al. (2007) A functional variant of the adipocyte glycerol channel Aquaporin 7 gene is associated with obesity and related metabolic abnormalities. Diabetes, 56, 1468–1474. Maeda, N., Funahashi, T., Hibuse, T., Nagasawa, A., Kishida, K., Kuriyama, H., Nakamura, T. Kihara, S. et al. (2004) Adaptation to fasting by glycerol transport through aquaporin 7 in adipose tissue. Proc. Natl. Acad. Sci. USA, 101, 17801–17806. Hibuse, T., Maeda, N., Funahashi, T., Yamamoto, K., Nagasawa, A., Mizunoya, W., Kishida, K., Inoue, K. et al. (2005) Aquaporin 7 deficiency is associated with development of obesity through activation of adipose glycerol kinase. Proc. Natl. Acad. Sci. USA, 102, 10993–10998. Hara-Chikuma, M., Sohara, E., Rai, T., Ikawa, M., Okabe, M., Sasaki, S., Uchida, S., and Verkman, A.S. (2005) Progressive adipocyte hypertrophy in aquaporin-7 deficient mice: adipocyte glycerol permeability as a novel regulator of fat accumulation. J. Biol. Chem., 280, 15493–15496. Yeh, J.I., Charrier, V., Paulo, J., Hou, L., Darbon, E., Claiborne, A., Hol, W.G., and Deutscher, J. (2004) Structures of enterococcal glycerol kinase in the absence and presence of glycerol: correlation of conformation to substrate binding and a mechanism of activation by phosphorylation. Biochemistry, 43, 362–373. Guan, H.P., Li, Y., Jensen, M.V., Newgard, C.B., Steppan, C.M., and Lazar, M.A.
36
37
38
39
40
41
42
43
(2002) A futile metabolic cycle activated in adipocytes by antidiabetic agents. Nat. Med., 8, 1122–1128. Lin, E.C. (1977) Glycerol utilization and its regulation in mammals. Annu. Rev. Biochem., 46, 765–795. Ishibashi, K., Kuwahara, M., Gu, Y., Tanaka, Y., Marumo, F., and Sasaki, S. (1998) Cloning and functional expression of a new aquaporin (AQP9) abundantly expressed in the peripheral leukocytes permeable to water and urea, but not to glycerol. Biochem. Biophys. Res. Commun., 244, 268–274. Tsukaguchi, H., Shayakul, C., Berger, U.V., Mackenzie, B., Devidas, S., Guggino, W.B., van Hoek, A.N., and Hediger, M.A. (1998) Molecular characterization of a broad selectivity neutral solute channel. J. Biol. Chem., 273, 24737–24743. Ko, S.B., Uchida, S., Naruse, S., Kuwahara, M., Ishibashi, K., Marumo, F., Hayakawa, T., and Sasaki, S. (1999) Cloning and functional expression of rAOP9L a new member of aquaporin family from rat liver. Biochem. Mol. Biol. Int., 47, 309–318. Elkjaer, M., Vajda, Z., Nejsum, L.N., Kwon, T., Jensen, U.B., AmiryMoghaddam, M., Frokiaer, J., and Nielsen, S. (2000) Immunolocalization of AQP9 in liver, epididymis, testis, spleen, and brain. Biochem. Biophys. Res. Commun., 276, 1118–1128. Kuriyama, H., Yamashita, S., Shimomura, I., Funahashi, T., Ishigami, M., Aragane, K., Miyaoka, K., Nakamura, T. et al. (1998) Enhanced expression of hepatic acylcoenzyme A synthetase and microsomal triglyceride transfer protein messenger RNAs in the obese and hypertriglyceridemic rat with visceral fat accumulation. Hepatology, 27, 557–562. Kuriyama, H., Shimomura, I., Kishida, K., Kondo, H., Furuyama, N., Nishizawa, H., Maeda, N., Matsuda, M. et al. (2002) Coordinated regulation of fat-specific and liver-specific glycerol channels, aquaporin adipose and aquaporin 9. Diabetes, 51, 2915–2921. Carbrey, J.M., Gorelick-Feldman, D.A., Kozono, D., Praetorius, J., Nielsen, S., and
References
44
45
46
47
Agre, P. (2003) Aquaglyceroporin AQP9: solute permeation and metabolic control of expression in liver. Proc. Natl. Acad. Sci. USA, 100, 2945–2950. Rojek, A.M., Skowronski, M.T., Fuchtbauer, E.M., Fuchtbauer, A.C., Fenton, R.A., Agre, P., Frokiaer, J., and Nielsen, S. (2007) Defective glycerol metabolism in aquaporin 9 (AQP9) knockout mice. Proc. Natl. Acad. Sci. USA, 104, 3609–3614. Fruhbeck, G., Catalan, V., GomezAmbrosi, J., and Rodriguez, A. (2006) Aquaporin-7 and glycerol permeability as novel obesity drug-target pathways. Trends Pharmacol. Sci., 27, 345–347. Rodriguez, A., Catalan, V., GomezAmbrosi, J., and Fruhbeck, G. (2006) Role of aquaporin-7 in the pathophysiological control of fat accumulation in mice. FEBS Lett., 580, 4771–4776. Wintour, E.M. and Henry, B.A. (2006) Glycerol transport: an additional target for obesity therapy? Trends Endocrinol. Metab., 17, 77–78.
48 Fruhbeck, G. (2005) Obesity: aquaporin
enters the picture. Nature, 438, 436–437. 49 MacDougald, O.A. and Burant, C.F. (2005)
Obesity and metabolic perturbations after loss of aquaporin 7, the adipose glycerol transporter. Proc. Natl. Acad. Sci. USA, 102, 10759–10760. 50 Lee, D.H., Park, D.B., Lee, Y.K., An, C.S., Oh, Y.S., Kang, J.S., Kang, S.H., and Chung, M.Y. (2005) The effects of thiazolidinedione treatment on the regulations of aquaglyceroporins and glycerol kinase in OLETF rats. Metabolism, 54, 1282–1289. 51 Rojek, A.M., Skowronski, M.T., Fuchtbauer, E.M., Fuchtbauer, A.C., Fenton, R.A., Agre, P., Frokiaer, J., and Nielsen, S. (2007) Defective glycerol metabolism in aquaporin 9 (AQP9) knockout mice. Proc. Natl. Acad. Sci. USA, 104, 3609–3614. 52 Londos, C., Brasaemle, D.L., Schultz, C.J., Adler-Wailes, D.C., Levin, D.M., Kimmel, A.R., and Rondinone, C.M. (1999) On the control of lipolysis in adipocytes. Ann. NY Acad. Sci., 892, 155–168.
j147
j149
9 Signaling Pathways Controlling Lipolysis and Lipid Mobilization in Humans Max Lafontan 9.1 Introduction
There are two types of adipose tissue, distinguished histologically and functionally – white adipose tissue (WAT) and brown adipose tissue (BAT). Both tissues have in common adipocytes that store lipid in the form of triacylglycerols and control the process of lipolysis where triacylglycerols are broken down to energy-rich nonesterified fatty acids (NEFAs) and glycerol. Although the control of lipolysis is very similar in both fat deposits, WAT and BAT functional roles differ noticeably. BAT is specialized in the production of heat and persists throughout life in rodents, but probably disappears soon after birth in larger mammals and humans [1]. In humans, BAT is not thought to contribute to a large part of thermogenesis in humans [2]. The physiological role of WAT is the storage of excess energy in the form of triacylglycerols and the supply of energy-rich fatty acids to other tissues, when needed. In fact, WAT exerts a buffering function by a control of the influx of fatty acids into the circulation that occurs after meals and the delivery of NEFAs from the triacylglycerol stores into the circulation according to the bodys need for energy [3]. This is achieved by efficient and highly regulated pathways whereby the triacylglycerols stored in the adipocyte are hydrolyzed and fatty acids delivered to the plasma. In general, fat mobilization and fat deposition are reciprocally regulated, so that fatty acids flow in and out of the adipocyte according to the nutritional and physiological state of the organism. Lipolysis and fat mobilization are regulated by multiple mechanisms [4–8]. Lipolysis regulation depends on the acute interplay between various stimulating and inhibiting pathways. Insulin plays a major role in the control of lipolysis and NEFA disposal; it inhibits the rate of lipolysis and NEFA efflux by fat cells. Outside the antilipolytic action of insulin, the physiological role of other agents exhibiting antilipolytic effects (i.e., adenosine, prostaglandins, neuropeptide Y (NPY) and peptide YY (PYY), ligands of nicotinic acid receptor) remains to be elucidated. Fat mobilization is stimulated primarily (at least acutely) by catecholamines and
j 9 Signaling Pathways Controlling Lipolysis and Lipid Mobilization in Humans
150
natriuretic peptides. Catecholamines (epinephrine and norepinephrine) acting through b-adrenoceptors stimulate adenylyl cyclase, producing cAMP from ATP. Natriuretic peptides (atrial natriuretic peptide (ANP) and brain natriuretic peptide (BNP)), acting through natriuretic peptide receptor (NPR)-A that possesses guanylyl cyclase activity, generate cGMP; the two second messengers-dependent pathways are able to stimulate lipolysis (Figure 9.1). The lipolytic effect of other factors such as growth hormone and tumor necrosis factor (TNF)-a appears after long-lasting exposure of adipocytes to the cytokine [8].
Figure 9.1 Major pathways involved in the control of human fat cell lipolysis. Catecholamines stimulate both b1/b2- and a2adrenergic receptors in human fat cells. ANPs, acting via type A (NPR-A) and C (NPR-C) receptors, and insulin are also involved in the control of lipolysis. Protein kinases (PKA and PKG (cGK-I)) activated by intracellular increment of cAMP and cGMP, respectively, are involved in target proteins phosphorylation. Perilipin phosphorylation induces an important physical alteration of the droplet surface that facilitates the action of HSL and dissociation of the ATGL regulator CGI-58 from perilipin. CGI58 promotes the triacylglycerol lipase activity of ATGL. PKA-dependent HSL phosphorylation
promotes its translocation from the cytosol to the surface of the lipid droplet, and its activation. Both activated lipases contribute synergistically to the initiation of lipolysis. Docking of ALBP to HSL favors the fat cell outflow of NEFAs released by the hydrolysis of triglycerides. Glycerol outflow from fat cell is controlled by AQP7. PKA and PKG are also able to phosphorylate a number of other substrates and can also influence the secretion of various adipocyte productions (not shown in the diagram). AC, adenylyl cyclase; AQP7, aquaporin 7 GC, guanylyl cyclase; PI3-K, phosphatidylinositol-3-phosphate kinase; (P) phosphorylation of HSL and perilipin, ( þ ) stimulation; () inhibition.
9.2 Role of Lipases in the Regulation of Hydrolysis of Fat Cell Triacylglycerols
9.2 Role of Lipases in the Regulation of Hydrolysis of Fat Cell Triacylglycerols 9.2.1 Hormone-Sensitive Lipase
The rate-limiting step in lipolysis is the hydrolysis of triacylglycerols by adipocyte lipases (Figure 9.1). The hydrolysis of triacylglycerols involves lipases and lipid droplet-associated proteins, the activation/inhibition of which is under the tight control of signaling molecules. Triacylglycerols are broken down into diacylglycerols and then into monoacylglycerols. The final step in the hydrolysis of triacylglycerols is catalyzed by monoacylglycerol lipase – an abundant lipase that is not regulated by hormonal signals [9]. At each step of hydrolysis, one molecule of free fatty acid appears and final step generates fatty acid and glycerol, which are released by adipocytes. Hormone-sensitive lipase (HSL) is a multifunctional enzyme that possesses triacylglycerol, diacylglycerol, cholesterol ester, and retinyl ester hydrolase activities [8, 10]. The main metabolic role of HSL is hydrolysis of triacylglycerols and diacylglycerols. HSL activation is induced by its phosphorylation by protein kinase A (PKA) and protein kinase G (PKG) – an action leading to the activation of its catalytic activity. HSL is mainly distributed in the cytosol in the resting state; upon its phosphorylation by PKA and PKG, it is translocated to the surface of lipid droplets that are coated with perilipin. Under basal conditions, perilipin suppresses lipolysis by blocking access of the lipases to the lipid droplet; it is also phosphorylated by PKA and PKG [11]. Perilipin phosphorylation is essential for the fragmentation and dispersion of the lipid droplet, and full stimulation of lipolysis by catecholamines and other lipolytic hormones [12–14]. HSL translocation requires the phosphorylation of both HSL and perilipin [15]. Adipocyte lipid-binding protein (ALBP), also known as fatty acid binding protein 4 (FABP4), is another regulator of HSL; it interacts with the N-terminal region of HSL and forms an ALBP–HSL complex. The lipolytic activity of HSL is increased through its ability to bind and sequester NEFAs via such a specific protein–protein interaction. The ALBP–HSL complex translocates to the surface of the lipid droplets upon lipolytic stimulation and contributes to NEFA outflow [16]. Glycerol outflow from fat cells is critical for normal triglyceride/fatty acid metabolism; it is controlled by aquaporin 7 (AQP7) [17]. Glycerol transport defect due to AQP7 gene mutation in humans [18] or gene invalidation in mice results in obesity and insulin resistance in mice [19]. 9.2.2 Adipose Tissue Triglyceride Lipase
A novel lipase, adipose tissue triglyceride lipase (ATGL), belonging to a family of closely related proteins containing a patatin-like domain [20–22] has recently been discovered. ATGL has a triglyceride activity but does not show significant diglyceride lipase activity. Together with HSL, ATGL participates in mouse adipose tissue lipolysis; these two enzymes are responsible for more than 95% of triacylglycerol
j151
j 9 Signaling Pathways Controlling Lipolysis and Lipid Mobilization in Humans
152
hydrolysis activity in mouse fat cells [23, 24]. In mice, ATGL deficiency causes a drastic reduction in stimulated lipolysis and ATGL is required for PKA-stimulated lipolysis in adipocytes derived from mouse embryonic fibroblasts [13, 22, 24]. In human fat cells, ATGL appears to be of less importance than HSL in regulating catecholamine-induced lipolysis and cannot replace HSL when the enzyme activity is blocked by pharmacological inhibitors [25, 26]. ATGL participates in basal lipolysis; HSL blockade completely inhibits glycerol release, reduces nonhormonal (basal) lipolysis by 50%, and partly suppresses NEFA release initiated by lipolytic agents. ATGL is activated by a key coactivator, comparative gene identification-58 (CGI-58; also identified as a/b-hydrolase domain-containing-5) [27, 28]. It belongs to the esterase/thioesterase/lipase subfamily of proteins structurally characterized by the presence of a/b-hydrolase folds. Mutations in the CGI-58 gene are associated with a genetic disease characterized by neutral lipid accumulation in several tissues (i.e., Chanarin–Dorfman syndrome). As CGI-58 interacts with perilipins on the surface of the lipid droplets, a complex interplay has been proposed between ATGL, perilipins, and CGI-58 [27, 29, 30]. Trafficking and interaction of these key proteins has recently been reassessed in 3T3-L1 adipocytes and the role of perilipin was clarified. Perilipin mediates hormone-stimulated lipolysis via direct and indirect mechanisms. Perilipin directly regulates the access of HSL to substrate via close, if not direct, interactions, as previously observed [11]. It also indirectly controls ATGL activity by regulating its accessibility to its coactivator. CGI-58 strongly associated with perilipin in the unstimulated (i.e., basal state). PKA activation rapidly phosphorylates perilipin and promotes dissociation of CGI-58 from perilipin – an event followed by ATGL activation [28]. In vitro data suggests that CGI-58 is less efficient in stimulating human than mouse ATGL [27]. In the absence of this factor, the lipase activity for ATGL is much lower than that of HSL in protein extracts of human adipose tissue [31].
9.3 Adrenergic Control of cAMP Production, Lipolysis and Lipid Mobilization
Catecholamines are important stimulators of NEFA release under conditions of stress and during exercise. Epinephrine and norepinephrine stimulate and/or inhibit lipolysis depending on their relative affinity for the b1/b2- and a2-adrenergic receptor subtypes [32], the relative number adrenergic receptors in the fat cell membrane, and their coupling efficiency to heterotrimeric G-proteins involved in signal transduction (Gs- and Gi-protein, respectively). Human and rat epididymal fat cell membranes contain the short and long forms of Gas (largely the long isoform), and three forms of Gai protein (ai1, ai2 and ai3). Both b35 and b36 subunits have also been identified, whereas Gc subunits are not known [4]. The pathways are summarized in Figure 9.1. Human adipocyte responsiveness to catecholamines differs according to the anatomical location of adipose tissue [33–35]. Decreased catecholamine-induced lipolysis has been reported in the adipocytes of obese men and women [36–39]; it was attributed to decreased expression of b2-adrenergic receptor, and increased expression of a2-adrenergic receptors and a2-adrenergic responsiveness. Lipolysis
9.3 Adrenergic Control of cAMP Production, Lipolysis and Lipid Mobilization
dysfunction could also affect downstream elements of the lipolytic cascade (i.e., expression level of Gs/Gi-proteins, modifications of the catalytic and regulatory components of PKA complex or expression level of lipases (i.e., HSL and ATGL) and their regulators (i.e., perilipins and CGI-58)) [4, 40]. Decreased catecholamineinduced lipolysis and low HSL expression constitute a possibly primary defect in familial combined hyperlipidemia [41] and obesity [25, 42]. Concerning the b-adrenergic lipolytic drive, human fat cell lipolysis is mainly regulated by b2- and b1-adrenergic receptor stimulation [43]. No evidence could be provided for b3-adrenergic receptor-dependent lipolysis when isoproterenol, norepinephrine, or epinephrine were used to stimulate human fat cells in vitro [43, 44]. The drug previously used (i.e., CGP12177, which possesses both agonist and antagonist properties at b-adrenergic receptors) to assess the presence of b3-adrenergic effects in human fat cells [45, 46] acts, in fact, via an atypical state of the b1-adrenoceptor when this compound is used at higher concentrations for fat cell stimulation [47, 48]. Confirmation of the lack of b3-adrenergic responsiveness in fat metabolism in humans has also been provided by in vivo studies [49–51]. A number of controversial results have been published concerning a polymorphism in codon 64 (Trp64Arg) of the b3-adrenergic receptor gene and the development of obesity and obesity-related disorders [52]. The subjects bearing the b3-adrenergic receptor variant, even the heterozygotes, had lower resting activity of the autonomic nervous system – a dysfunction that could be responsible for the lower resting metabolic rates described in some obese patients [53]. The studies performed until now have been unable to convincingly demonstrate a physiological contribution of a b3-adrenergic receptor to the regulation of lipolysis, lipid mobilization, and energy expenditure and lipid oxidation in humans. Concerning physiological regulations, sympathetic nerve fibers traveling in cutaneous nerve fascicles exert a regulatory influence on subcutaneous fat tissue in humans [54]. Profound unresponsiveness to neurally stimulated lipolysis has been described in the subcutaneous adipose tissue of obese subjects [55]. Reduced b2adrenergic lipolytic responsiveness has been reported in fat cells from subjects with isoproterenol resistance [56] and in obese subjects [37]. Increased antilipolytic responsiveness linked to a2-adrenergic receptor stimulation has also been found in subcutaneous adipocytes of the obese of both sexes [36, 38]. The lipolytic defects have been confirmed in in vivo studies [57–59]. Using in situ microdialysis, a specific impairment in the capacity of b2-adrenergic receptors agonists to promote lipolysis has been reported in the abdominal subcutaneous adipose tissue of obese adolescent girls [60]. It is suspected that a dysfunction of the b2-adrenergic pathway or of the b2adrenergic receptor density may play a role in the etiology or maintenance of a relatively increased fat mass and, consequently, obesity [61]. Further evidence for a putative role of b2-adrenergic receptors in the etiology of obesity is also provided by the discovery of three polymorphisms (the Gln27Glu, Arg16Gly variants and two polymorphic sites, T ! C substitution at 47 and T ! C substitution at 20, located in the 50 -leader cistron) of the b2-adrenergic receptor gene that are associated with obesity [62–65]. Interference for the b2-adrenergic receptor gene in the distribution of visceral adipose tissue, but not subcutaneous, was
j153
j 9 Signaling Pathways Controlling Lipolysis and Lipid Mobilization in Humans
154
proposed [66]. Increased body weight, body fat, and obesity have also been described in men bearing the Gln27Gln genotype [67]. However, obese individuals bearing the Gln27Gln b2-adrenergic receptor phenotype may benefit from physical activity to reduce their weight [68]. Some discrepancies, probably related to the poor delineation of obese phenotypes by the various investigators that have approached the problem, still persist [69, 70]. To conclude, these findings suggest that polymorphisms in the coding and noncoding sequences in the human b2-adrenergic receptor gene could be of major importance for obesity, energy expenditure, and b2-adrenergic receptordependent lipolytic function. The b1-adrenoceptor gene contains two nonsynonymous single nucleotide polymorphisms, Ser49Gly and Gly389Arg, which are both functional in human cells lines [71, 72]. Polymorphism of the b1-adrenoceptor gene influences long-term weight gain and the incidence of adult-onset overweight in women [73]; functional assays on lipolysis were not performed. To conclude, full badrenergic activation of human fat cell lipolysis usually requires synergistic activation of b1- and b2-adrenergic receptors [74]. A b2-adrenergic defect could be sufficient to alter the normal b-adrenergic responsiveness, even if b1-adrenergic effects are found to be preserved in obese subjects [61]. In addition any reduction of b2-adrenergic receptor-mediated lipolytic response will disturb the normal functional balance existing between a2- and b-adrenergic receptor-mediated effects in human fat cells. Thus, the reduction of the b-adrenergic receptor-dependent lipolytic responsiveness initiated by the physiological amines will be amplified, thus leading to human fat cells with very weak lipolytic responses. Concerning a2-adrenergic receptors, activation of a2-adrenergic receptors by epinephrine and norepinephrine impairs the b-adrenergic component of catecholamine-induced lipolysis [75, 76]. In human subcutaneous fat cells where a2-adrenergic receptors outnumber b-adrenergic receptors, the preferential recruitment of the a2-adrenergic receptors at the lowest catecholamine concentrations inhibits lipolysis [32, 34]. The strongest a2-adrenergic effect has been observed in the adipocytes from subcutaneous adipose tissue from men and women (Figure 9.2a); a2-adrenergic receptors are particularly expressed in subcutaneous adipocytes from obese subjects [36, 39]. Moderate weight loss leads to a higher adipose cell lipolytic efficiency that is associated with changes at receptor levels (mainly increased b2- and decreased a2-sensitivities) [77]. One of the major determinants of a2-adrenergic receptor expression is fat cell hypertrophy; a positive correlation exists between human fat cell diameter and a2-adrenergic receptor number while the inverse relationship is observed for b1/b2-adrenergic receptors. The higher the fat cell size, the lower the lipolytic responsiveness is (Figure 9.2b). It is a phenomenon that was also observed in fat cells of various animal models (golden hamster, rabbit) [78]. Interestingly, in animal models, strong fat cell size reduction induced by calorie restriction is associated with a reduction of a2-adrenergic receptor expression [79]. The mechanisms driving this cell-size-related regulation of fat cell adrenergic receptors expression are unknown. Utilization of the in situ microdialysis technique has allowed a better demonstration of the relative contribution of the b1/b2- and a2-adrenergic receptors in the control of lipid mobilization in vivo [49, 80, 81]. Administration of an a2-agonist
9.3 Adrenergic Control of cAMP Production, Lipolysis and Lipid Mobilization Receptor number (fmol/mg protein)
(a) 1200
2-adrenergic
1000
Number of 1/2 and 2-adrenergic receptors (per cell).
(b) 500000
receptors
1/2-adrenergic
j155
receptors
450000
***
400000
800
2-ARs
350000
r = 0.911
300000 600
**
visceral
250000
subcutaneous
r = 0.867
200000
400
150000
*
200
100000 1-
50000 0 omental
subcutaneous abdominal
femoral
Figure 9.2 Heterogeneity of human fat cell adrenergic receptor distribution: incidence of the anatomical location and of fat cell size on fat cell adrenergic receptor distribution. (a) Comparative study of the distribution of b1/b2and a2-adrenergic receptors in crude white fat cell membranes from omental, abdominal, and femoral fat deposits from women. The a2- and b1-/b2-adrenergic receptor numbers were determined from saturation binding studies on crude fat cell membranes using [3H]RX821002 and [3H]CGP12177, respectively. Bmax, the total number of binding sites, was determined from Scatchard analysis of the saturation data. The values are means standard errors (bars) of 10–17 separate experiments. P < 0.05; P < 0.01; P < 0.001; significantly different from
//
60
/
2-ARs
70 80 90 100 fat cell diameter (µm)
the corresponding values determined in omental fat cells (by Students paired t-test). (b) Relationships existing between b1/b2- and a2adrenergic receptor (AR) expression and mean fat cell diameter in human fat cells originating from omental and subcutaneous fat deposits. The a2- and b1-/b2-adrenergic receptor numbers were determined using saturation binding studies on intact fat cells with [3H]RX821002 and [3H]CGP12177, respectively. The a2-adrenergic receptor expression was positively correlated to the increment of fat cell diameter while an inverse correlation was found for the b1/b2-adrenergic receptors. A similar relationship has also been observed in hamster and rabbit white fat cells.
(clonidine) directly in the microdialysis probe has not been fully conclusive to attribute a physiological role to a2-adrenergic receptors due to potent vasoconstriction induced by clonidine [82]. Exercise-induced lipolysis is impaired in subcutaneous adipose tissue in obese men and women. The physiological stimulation of adipocyte a2-adrenergic receptors during exercise contributes to this impairment since the blunting of lipid mobilization was suppressed by local administration of an a2-adrenergic receptor antagonist [83] (Figure 9.3a and 9.3b). In heavily trained men, it was impossible to reveal any a2-adrenergic effect in the reduced subcutaneous fat deposits of such subjects [84] (Figure 9.3c). Sex-related differences in the lipid-mobilizing efficacy of physical exercise have been revealed in obese women.
110
j 9 Signaling Pathways Controlling Lipolysis and Lipid Mobilization in Humans
156
control probe
probe + phentolamine ( 1/
(a)
900
non-obese men
800 700
Epi Nepi R: 59 ± 21 192 ± 28 700 E: 160 ± 30 1059 ± 124 600
600
extracellular glycerol (µmol/l)
Epi R: 27 ± 4 E: 93 ± 18
trained
400
400
300
300
200
200
Exercise
100 -15 0
15 30 45
Exercise
100 60 75 90 105 120
0 -15 0
15 30
45 60
Time (min) 800 700 600
Nepi 161 ± 35 898 ± 72
500
500
0
2 antagonist)
(c)
(b) obese men
Epi Nepi R: 65 ± 23 178 ± 38 E: 202 ± 33 1027 ± 67
500
800 700
75 90 105 120 Time (min)
(d) obese women
Epi R: 12 ± 1 E: 42 ± 9
600
Nepi 178 ± 38 713 ± 93
500
400
400
300
300
200
200
Exercise
100 -15 0
15 30 45
Exercise
100
0 60 75 90 105 120
0
Time (min)
Figure 9.3 Demonstration of the a2adrenergic receptor-dependent modulation of lipid mobilization in human subcutaneous adipose tissue during exercise. Comparative study of exercise-induced lipid mobilization in subcutaneous adipose tissue of men and women. Time course of extracellular glycerol concentration changes in subcutaneous adipose tissue, calculated from dialysate glycerol levels, during 60-min cycle-ergometer exercise in lean (a), obese (b), and trained (c) men. Comparison was performed with changes occurring in subcutaneous adipose tissue, during 45 min cycle-ergometer exercise in obese women (d). The nonselective a1/a2-adrenergic receptor antagonist, phentolamine, was or was not added to the perfusion medium of the microdialysis probe. Data are means
0
15
30
45
60
75 90 105 Time (min)
standard errors from seven to 10 separate experiments. Physiological stimulation of adipocyte a2-adrenergic receptors strongly impairs exercise-induced lipid mobilization in subcutaneous adipose tissue in obese subjects (the effect is stronger in male than in female adipose tissue). The blunting of lipid mobilization induced by exercise-induced norepinephrine (Nepi)/epinephrine (Epi) release is completely suppressed by the local administration of a a1/a2-adrenergic receptor antagonist. Plasma levels of catecholamines are given at rest (R) and at the end of exercise (E). Epinephrine is suspected to be an important regulator in the control of lipid mobilization through activation of antilipolytic a2-adrenergic receptors in human subcutaneous adipose tissue during exercise.
The weak a2-adrenergic responsiveness observed in abdominal subcutaneous adipose tissue of obese women was also reduced after a moderate hypocalorific diet [85]. Gender differences in the adrenergic regulation of lipid mobilization have been reported in nonobese patients performing short submaximal exercise bouts (75% maximum O2 uptake, 30 min duration); however, the nature of the differences has not been interpreted by the authors [86]. Mechanisms remain still poorly understood.
9.4 Control of cAMP Production by Adenylyl Cyclase Inhibitors – Inhibition of Lipolysis
9.4 Control of cAMP Production by Adenylyl Cyclase Inhibitors – Inhibition of Lipolysis
Neuropeptides, paracrine factors, and autacoid agents (adenosine, prostaglandins, and their metabolites) originating from the adipocytes themselves, preadipocytes, endothelial cells, macrophages, and sympathetic nerves terminals act on human fat cells. Adenosine and prostaglandins are released by the adipocytes and various cells of the stroma vascular fraction of adipose tissue [87]. There are five different antilipolytic receptors negatively coupled to adenylyl cyclase in human fat cells: a2-adrenergic receptors (previously discussed), adenosine A1 receptors, EP3 prostaglandin E2 receptors, NPY/PYY receptors, and nicotinic acid receptors. The basal mechanisms underlying adenylyl cyclase inhibition and antilipolytic effects via inhibitory receptors seem to be similar for all the receptor classes. When the agonist interacts with the inhibitory receptor, activation of the Gi protein (i.e., the ai/bc subunits trimer) of a GTP-binding protein promotes dissociation of subunits, adenylyl cyclase inhibition and a decrease in intracellular cAMP. Adenosine and prostaglandins E2 and E1 exert potent antilipolytic effects in human fat cells. Concerning adenosine and prostaglandins, these compounds are probably metabolized very rapidly in vitro as well as in vivo [88, 89]. Nevertheless, substantial amounts of adenosine were found in the interstitial fluid of adipose tissue [90]. Endogenous inhibitory agents may therefore have a stronger role on the control of triacylglycerol hydrolysis than previously suspected. Gia2 subunit appears to be the major transducer of antilipolytic responses in adipose rodent tissue, it provides a tonic suppression of basal adenylyl cyclase activity in vitro. This action is assessed by enhancement of lipolysis induced by the pertussis toxin treatment of the adipocytes in vitro [91, 92] and in vivo when using Gia2specific antisense RNA [93]. Unrestrained fat cell adenylyl cyclase proceeds at increased rates. It is suggesting that a certain degree of inhibition might be necessary for fat cell adenylyl cyclase to be susceptible to stimulation. Under in vivo conditions, in the presence of endogenous ligands, Gi-dependent inhibitory pathways may exert some permanent inhibition since the pathways driven by prostaglandins, catecholamines (i.e., a2-adrenergic receptors) and adenosine are always activated at low concentrations of the agents [78, 94]. A convincing demonstration that such mechanisms operate in vivo in human adipose tissue remains to be established. Two peptides of nervous (NPY) and gut origin (PYY) exert antilipolytic effects in human isolated fat cells. NPY/PYY receptor stimulation, via Gi-protein coupling, inhibits adenylyl cyclase activity and cAMP production [95]. Differences exist in human NPY/PYY receptor distribution according to the anatomical location of adipose tissue; the highest level of expression was found in subcutaneous adipocytes [96]. The human fat cell NPY/PYY receptor is a NPY-Y1 receptor subtype that when stimulated sustains a strong antilipolytic effect. In addition, its stimulation is also associated with a positive action on leptin secretion by human fat cells [97]. NPY is expressed by sympathetic neurons both in vivo and ex vivo, and its inhibitory effect on lipolysis has been confirmed when neurons and fat cells are treated in coculture [98]. The specific circumstances under which sympathetic neurons release NPY to adipocytes in the periphery are unknown.
j157
j 9 Signaling Pathways Controlling Lipolysis and Lipid Mobilization in Humans
158
Nicotinic acid has been used in the treatment of dyslipidemia for many years. These benefits result from the ability of nicotinic acid to inhibit lipolysis in adipocytes and thereby reduce serum NEFA levels [99, 100]. Its effect on the inhibition of lipolysis via the activation of a Gi-protein-coupled receptor has been described in rodent adipocytes [91, 101]. Nicotinic acid and several of its derivatives exert potent antilipolytic effects in human fat cells (Lafontan et al., unpublished results). Nicotinic acid receptors were identified in rodent fat cell plasma membranes using the usual binding techniques with radiolabeled [3H]nicotinic acid [102]. A G-protein-coupled receptor that binds to nicotinic acid with the expected affinity was identified by three groups. The receptor, termed GPR109A (HM74A in humans and PUMA-G in mice), is coupled to Gi-proteins and is mainly expressed in adipocytes and immune cells [103–105]. The antilipolytic effect of nicotinic acid disappeared in mice invalidated for the PUMA-G gene. D-b-Hydroxybutyrate was the first endogenous ligand described for the PUMA-G receptor. It specifically activates the PUMA-G receptor at concentrations observed in serum during fasting in mice and its effect is abrogated in PUMA-G-deficient mice [106]. Such a result supports the concept that the nicotinic acid receptor mediates the antilipolytic effects of D-b-hydroxybutyrate during starvation. However, an antilipolytic effect of D-b-hydroxybutyrate and acetoacetate was not observed in human isolated fat cells at relevant physiological concentrations (Lafontan et al., unpublished results).
9.5 Insulin: A Major Antilipolytic Agent Controlling cAMP Degradation
Insulin plays a major role in the control of NEFA disposal. It regulates the rate of lipolysis and NEFA efflux (i.e., inhibits lipolysis), as well as fat storage (i.e., increases the rate of resynthesis of triacylglycerols from NEFA; the re-esterification effect) and glucose uptake by fat cell. Studies in the past 20 years have elucidated the main features of how insulin acts at the molecular level and this has been covered in a number of recent reviews [107]. Insulin is a major regulator of lipolysis; the supply of NEFAs to other tissues is rapidly and strongly inhibited by an elevation of the plasma insulin concentrations. The cellular mechanisms involved in the inhibition of lipolysis by insulin have been mainly delineated in rat fat cells; a similar mechanism is expected in human adipocytes. Insulin activates the cGMP-inhibited low-Km cAMP phosphodiesterase (PDE)-3B in rat fat cells. Insulin-induced activation of the PDE-3B is mediated via phosphorylation by the serine protein kinase Akt/protein kinase B (PKB), which is phosphorylated in response to insulin stimulation [108, 109]. PDE-3B appears to be associated with caveolae in adipocytes and this localization seems to be functionally important [110]. In fact, insulin induces formation of macromolecular complexes involved in activation of PDE-3B and its interaction with Akt/PKB. This recruitment of PDE-3B in macromolecular complexes may be critical for regulation of specific cAMP pools and signaling pathways by insulin (e.g., lipolysis) [111]. That PDE-3B is important in regulating cAMP signaling pathways, including lipolysis and insulin-induced antilipolysis, was confirmed by the invalidation of PDE-3B gene in
9.6 Natriuretic Peptides Control cGMP Production, Lipolysis, and Lipid Mobilization in Humans
mice [112]. A number of circulating factors (such as TNF-a, interleukins (ILs), insulin itself, fatty acids, and glycation products) have been shown to influence the effects of insulin at the target cell level, and could lead to hyperglycemia and type 2 diabetes upon deregulation of their action [113]. Moreover, alterations in the level of expression of proteins involved in insulin signaling will also alter insulin responses in human fat cells. A low insulin receptor substrate (IRS)-1 expression in human fat cells is a marker of insulin resistance and risk for type 2 diabetes, and is associated with evidence of early vascular complications [114]. Striking adipose location-related differences, modulated by obesity, have been found in fat cell responsiveness to insulin. Insulin-induced antilipolysis and activation of NEFA re-esterification are blunted in omental compared with subcutaneous fat cells. Various functional differences have been identified at the insulin receptor level and the postreceptor level of the insulin signaling cascade [115, 116]. Other partners of the insulin signaling cascade such as PDE-3B, responsible for the antilipolytic action of insulin in fat cells, and protein tyrosine phosphatases (PTPs), involved in the dephosphorylation of the insulin receptor, could also contribute to the modulation of insulin action. Endogenous PTP activity, including PTP-1B, is increased in omental adipose tissue and may contribute to the relative insulin resistance of this fat depot [117]. Increases in baseline systemic NEFA flux have been reported in upper-body obese women. They have been partly attributed to a decreased sensitivity to the antilipolytic effect of insulin, independent of fat cell size, and to increased lipolytic rates associated with subcutaneous fat cell hypertrophy [118]. Subcutaneous abdominal adipocytes are more resistant to the antilipolytic effect of insulin than gluteal adipocytes, independently of cell size [119]. The regional heterogeneity of insulinregulated NEFA release has been confirmed in vivo. Visceral adipose tissue is more resistant to insulin antilipolytic effects than leg and nonsplanchnic body fat [120]. Nevertheless, visceral fat may be a marker for, but not the source of, excess postprandial NEFA in obesity since the increased postprandial NEFA release observed in upper-body obese women and type 2 diabetics originates from the nonsplanchnic upper-body fat, not from visceral fat [121–123].
9.6 Natriuretic Peptides Control cGMP Production, Lipolysis, and Lipid Mobilization in Humans 9.6.1 Natriuretic Peptides
The natriuretic peptide family, identified for its natriuretic properties, is represented by ANP, BNP, and the C-type natriuretic peptide (CNP). ANP and BNP are essentially synthesized by atrial and ventricular cardiomyocytes, and regulate a variety of physiological events. They possess an important role in blood pressure regulation and volume homeostasis, and have natriuretic and vasodilating properties [124]. They
j159
j 9 Signaling Pathways Controlling Lipolysis and Lipid Mobilization in Humans
160
also influence sympathetic nervous system (SNS) activity and the renin–angiotensin system. Most of the effects are mediated by the stimulation of cGMP production by target cells [124, 125]. The functions of ANP are not simply restricted to blood pressure homeostasis, they also seem to play an important role in the immune system [126]. Production of ANP and BNP is stimulated in pathological conditions; plasma levels of these peptides are increased in subjects with left ventricular hypertrophy, asymptomatic ventricular dysfunction, and overt heart failure [124]. NPRs either present a guanylyl cyclase activity (NPR-A and NPR-B) or not (NPR-C). NPR-A and NPR-B are the active forms of the receptors since their stimulation activates the guanylyl cyclase function of the receptor protein and the production of the second messenger, cGMP. NPR-C, which has a short cytoplasmic domain without guanylyl cyclase activity, influences plasma natriuretic peptide levels, ANP half-life, and its systemic effects [127]. ANP receptors have been identified in various tissues, including rat fat cells. NPRA have been identified in rat fat cells [128, 129] and a mild increment of intracellular cGMP was reported in rat fat cells [130]. Human adipose tissue expresses NPR-A and NPR-C mRNAs [131]. NPR-C and NPR-A protein levels and receptor function have never been explored, and no biological response had yet been reported in human fat cells when our first studies were initiated. 9.6.2 Lipolytic Effect of Natriuretic Peptides
The original finding that was at the origin of numerous subsequent studies was the discovery of the lipolytic action of natriuretic peptides. Natriuretic peptides exert potent lipolytic effects similar to those induced by the b-adrenergic receptor agonist of reference, isoproterenol. The relative order of lipolytic potency of the peptides was ANP > BNP >> CNP (Figure 9.4a). The presence of a NPR-A receptor was revealed by the binding studies performed on human fat cell membranes using [125I]ANP as a radioligand [132]. Natriuretic peptides promoted a strong and sustained increment of intracellular cGMP in mature human adipocytes [133] as well as in adipocyte precursors differentiated into adipocytes [134]. The signal transduction pathway stimulated by ANP to promote lipolysis in human fat cells is strictly connected to an increase in intracellular cGMP concentrations. The nonhydrolyzable analog of cGMP, 8-bromo-cGMP, mimicked the lipolytic effects of ANP. Since PKA could be activated by cGMP, it was verified that ANP does not stimulate PKA activity and that inhibition of PKA by H-89 does not affect ANP-induced lipolysis. ANP-mediated lipolysis did not involve cross-talk between cGMP and PKA. It is a cGMP-dependent protein kinase (PKG), identified as cGMP-dependent kinasec (GK-I), which promotes perilipin and HSL phosphorylation, and which is at the origin of ANP-induced lipolysis. Inhibition of cGK-I by the cGMP analog 8-pCPT-cGMPS, inhibited HSL activation and lipolysis [134]. This result in isolated human fat cells confirms early data in a rat cell-free system where phosphorylation and activation of HSL by a purified cGMP-dependent protein kinase was demonstrated [135, 136]. Neither the
9.6 Natriuretic Peptides Control cGMP Production, Lipolysis, and Lipid Mobilization in Humans
Figure 9.4 In vitro and in vivo effects on natriuretic peptides on isolated fat cell lipolysis and lipid mobilization in humans. (a) Comparison of the lipolytic effects of natriuretic peptides in isolated human fat cells. Values are means standard error. An asterisk indicates significantly different from basal value. (Adapted from [132].) (b) Changes in extracellular glycerol concentration and in ethanol ratio (ethanol dialysate concentration/ ethanol perfusate levels 100), which reveals changes in local blood flow, during the infusion of human ANP (10 mmol/l) in a microdialysis probe implanted in human subcutaneous
adipose tissue (Adapted from [132].) (c) Effect of intravenous infusion of human ANP (50 ng/ min/kg during 60 min) on plasma NEFA and glycerol levels (Adapted from [140].). (d) Comparison of the mean changes in extracellular glycerol concentration values in abdominal subcutaneous adipose tissue during two successive exercise bouts performed at 35% (exercise 1) and 60% (exercise 2) of VO2max and during recovery. Control microdialysis probe was perfused with Krebs–Ringer buffer. For the study of local b-adrenergic receptor blockade, a microdialysis probe was supplemented with propranolol (100 mmol/l) (Adapted from [145].).
mitogen-activated protein kinases (MAPK) inhibition (extracellular signal-regulated kinase (ERK)) nor p38 MAPK was involved in the ANP-mediated HSL phosphorylation. It was observed that the lipolytic effect of natriuretic peptides is independent of control by insulin. Insulin treatment of human fat cells has no incidence on ANPinduced lipolytic response [132, 133, 137]. The occurrence of natriuretic peptideinduced lipolysis has primate fat cell specificity. Natriuretic peptides do not stimulate lipolysis in various other species (mice, rat, dog and rabbit) [138].
j161
j 9 Signaling Pathways Controlling Lipolysis and Lipid Mobilization in Humans
162
9.6.3 Induction of Lipid Mobilization by Administration of Pharmacological Doses of ANP
Infusion of human ANP in a microdialysis probe implanted in human subcutaneous adipose tissue promoted an increment in extracellular concentration of glycerol as well as vasodilatation of the vessels draining the fat deposit [132]. Both events contribute to a coordinated enhancement of lipid mobilization (Figure 9.4B). The lipid-mobilizing effect of an intravenous infusion of human ANP, as well as various metabolic and cardiovascular parameters were studied in young obese and normalweight subjects (Figure 9.4c). These in vivo studies showed that ANP is a potent lipidmobilizing hormone that acts independently of the activation of the SNS. Apparently, obesity did not modify the lipid-mobilizing effect of ANP in young obese subjects [139, 140]. Hemodynamic and metabolic response to physiologically relevant ANP concentrations was explored in healthy normal-weight young men. The increase in serum NEFA and glycerol concentrations were correlated with ANP plasma concentrations as well as glycerol increment in adipose tissue. Indirect calorimetry indicated an increase in lipid oxidation concomitantly with a decrease in carbohydrate oxidation, without changes in overall energy expenditure. ANP briskly stimulates lipid mobilization and oxidation at plasma concentrations that are usually encountered in conditions such as heart failure [141, 142]. 9.6.4 Contribution of ANP to the Physiological Control of Lipid Mobilization in Humans
Exercise-induced lipid mobilization was considered to mainly depend on SNS activation and catecholamine action in man. In addition, SNS-induced inhibition of insulin release also contributes to the lipid-mobilizing effect during exercise. A putative physiological contribution of ANP/BNP to exercise-induced lipid mobilization was hypothesized. During exercise, the SNS is activated and, concomitantly, ANP is released from the exercising heart. Strenuous endurance exercise is followed by increases in plasma BNP [143, 144]. Lipid mobilization assays were performed using in situ microdialysis in subcutaneous adipose tissue in healthy young men during two successive exercise bouts performed at 35 and 60% VO2max after placebo, local (i.e., in the microdialysis probe) or oral nonselective bantagonist treatment. In placebo-treated subjects, exercise promoted an increment in extracellular glycerol concentration. Infusion of propranolol (a nonselective bantagonist) in the microdialysis probe only partially reduced the extracellular glycerol concentration increase promoted by exercise (Figure 9.4d). It suggests a possible contribution of another lipid-mobilizing pathway. Indeed, oral b-adrenergic receptor blockade (i.e., tertatolol given per os 1 h before the beginning of exercise) did not prevent exercise-induced lipid mobilization in subcutaneous adipose tissue. Moreover, exercise-induced increase in plasma ANP was potently amplified by tertatolol administration. A positive correlation was found between extracellular glycerol concentration and plasma ANP levels but also between extracellular cGMP and extracellular glycerol concentration [145]. Since full
9.7 Other Lipolytic Pathways
blockade of fat-cell b-adrenergic receptors was verified, the existence of another partner was strengthened. The results demonstrate that exercise-induced lipid mobilization, resistant to local propranolol or oral tertatolol, is partly related to the action of ANP. Oral b-adrenergic receptor blockade promotes strong exercise-related ANP release by the heart, which explains the remaining lipid mobilization. ANP, concomitantly with the SNS, contributes to the control of lipid mobilization during exercise. Due to the lack of a suitable NPR-A receptor antagonist, usable in clinical studies, it is difficult to determine the relative contribution of both pathways to the physiological control of lipid mobilization. Putative contribution of other biological compounds (parathyroid hormone (PTH), growth hormone, and IL-6) known to exert lipolytic effects in human fat cells was excluded [145].
9.7 Other Lipolytic Pathways 9.7.1 Growth Hormone
Exposure to growth hormone leads to increased plasma NEFA, ketone bodies, insulin-like growth factor-1, insulin, and glucose. Growth hormone defects in humans are associated with reduced lean body mass and increased fat mass; both can be normalized by growth hormone treatments [146]. Growth hormonedeficient patients exhibit a reduction of lipolysis and plasma NEFA concentrations [147]. The physiological contribution of growth hormone to the control of human adipose tissue lipolysis and lipid mobilization has remained elusive, and is not yet entirely clear. Growth hormone receptors are not known in human fat cells; five human growth hormone receptor mRNA variants have been identified in fat cells [148]. In vitro studies have shown that growth hormone stimulates lipolysis in human adipocytes [149, 150]; the effect is delayed (2–3 h) when compared with that of catecholamines and the exact mechanism of action is not fully established. The transducing pathways are suspected to involve those used by catecholamines (i.e., cAMP- and PKA-dependent pathways). Growth hormone-dependent modifications of the interactions between adenylyl cyclase and Gia2 have been reported. Consequently, the growth hormone-related relief of Gi-dependent inhibition of cAMP production increases lipolysis [151, 152]. In rat adipocytes growth hormone increases lipolysis partly through the b-adrenergic system, including increases in both b1- and b3-adrenergic receptor function, and partly through enhanced adenylyl cyclase function, perhaps via a decrease in Gai protein expression, and increased expression of HSL [153]. Finally, in addition to its lipolytic effects, growth hormone produces a pronounced inhibition of adipose tissue lipoprotein lipase activity – the enzyme that plays the main role for hydrolyzing triglycerides in the vessels in the adipose tissue and thus for triglyceride accumulation in adipose cells.
j163
j 9 Signaling Pathways Controlling Lipolysis and Lipid Mobilization in Humans
164
Pulsatile and continuous growth hormone administration, leading to plasma concentration rises seen during exercise in humans, promote a significant increase in NEFA after 2–3 h, reflecting stimulation of lipolysis and ketogenesis [154, 155]. Small physiological growth hormone pulses increase interstitial glycerol concentrations in both femoral and abdominal adipose tissue [156]. Moreover, the normal nocturnal rise in plasma growth hormone concentrations also leads to site-specific regulation of lipolysis in adipose tissue [147, 157]. The lipolytic sensitivity to growth hormone shows increases during fasting [158]. The nocturnal mean peak of growth hormone preceded that of NEFA by 2 h; it is a lag-time that fits with that found after a growth hormone bolus administration [159]. Growth hormone-dependent stimulation of lipolysis probably represents a physiological adaptation to stress (maintenance of basal lipolysis during fasting and exercise) [160]. Growth hormone and cortisol are cosecreted during stress conditions. It is probable that both hormones are involved in the regulation of adipose tissue metabolism during fasting and stress. Acute lipolytic effects of cortisol have been reported [161, 162]. Growth hormone and cortisol stimulate systemic and regional lipolysis independently and in an additive manner when coadministered [163, 164]. A small synthetic peptide sequence of human growth hormone (AOD-9041) has been shown to increase human and rodent fat cell lipolysis in vitro. It is efficient on lipid mobilization after chronic oral administration in rodents; mechanisms of action remain to be clarified in humans [165]. To conclude, growth hormone, although it possesses some delayed lipolytic and lipid-mobilizing properties, can be considered as a weaker regulator of lipolysis than catecholamines and insulin. 9.7.2 IL-6
The cytokine IL-6 is produced during muscle contraction and released into the blood [166]. The subcutaneous adipose tissue was also shown to secrete IL-6 and this secretion was correlated with the body mass index of the subjects [167]. Circulating IL-6 levels might reflect, at least in part, adipose tissue IL-6 production [168] and it was proposed that locally secreted IL-6 could act on adipocytes by a paracrine/autocrine mechanism. Human adipocytes express both IL-6 and its receptor system consisting of the IL-6 receptor and the signal transducing protein gp130 [169]. IL-6 stimulates lipolysis in human adipocytes [170] and exerts antiinsulin actions. It was found that IL-6-treated adipocytes have reduced insulinstimulated lipogenesis and glucose transport, and fail to maintain their adipocyte phenotype (e.g., downregulation of various adipogenic markers). Likewise, expression of insulin receptor-b and IRS-1 is reduced as is insulin-induced activation of insulin receptor-b, Akt/PKB and ERK1/2. Expression of suppressor of cytokine signaling-3, a potential inhibitor of insulin signaling, is also induced by IL-6 [171, 172]. Recombinant human IL-6 infusion, leading to plasma IL-6 concentrations of about 140 pg/ml in healthy volunteers, resulted in an increment of plasma NEFA and glycerol concentrations, and an increased rate of appearance of NEFA and glycerol measured by isotope dilution techniques. The increase in lipolysis is
9.7 Other Lipolytic Pathways
observed after more than 6 h [173]. Plasma cortisol concentrations were increased by 50%, transient changes in epinephrine were also observed during IL-6 infusion, while putative concomitant changes in growth hormone levels were not determined. It could be premature to include IL-6 inside a physiological loop of lipolytic process regulation [174]. 9.7.3 TNF-a
TNF-a is a macrophage-secreted product that has been suggested to signal the loss of body mass through the decrease in adipose tissue and muscle. TNF-a promotes hydrolysis of intracellular triacylglycerols in rodent fat cells [175]. Stimulation of lipolysis by TNF-a is not direct, since it becomes apparent only after long-lasting exposure of human and rodent adipocytes to the cytokine [176]. TNF-a stimulates triglyceride hydrolysis by multiple intracellular interferences with insulin signaling, G-protein expression, and perilipin [8]. TNF-a mechanisms of action have been explored in rodent fat cells with altered expression of TNF-a receptors (i.e., tumor necrosis factor-a receptor TNF-R1 and TNF-R2). Experiments were performed on preadipocyte cell lines established from wild-type mice (TNF-R1 þ / þ ; TNF-R2 þ / þ ) and from mice lacking TNF-R1 (TNF-R1/), TNF-R2 (TNF-R2/), or both (TNFR1/; TNFR2/) to demonstrate the role of the different TNF-a receptors in the induction of the lipolytic effects. TNF-a-induced lipolysis as well as inhibition of insulin-stimulated glucose transport are predominantly mediated by TNF-R1 [177, 178]. One important effect of TNF-a is suppression of the effect of insulin through inactivation of IRS-1 (i.e., reduction of the amount of IRS-1 protein and inhibition of its tyrosine phosphorylation). The inactivating serine-phosphorylation of IRS-1 is mediated by p42/44 MAPKs activation, at least in 3T3-L1 adipocytes [179, 180]. In human fat cells, TNF-a activates the three mammalian MAPKs in a distinct time- and concentration-dependent manner. TNF-a-induced lipolysis is mediated by only p44/42 ERKs and Jun kinase, but not by p38 kinase [181]. Blunting the endogenous tonic inhibition of lipolysis through downregulation of three Gai-protein subtypes is another possible mechanism since the amounts of Gs-protein or b-subunits of G-protein complex remain unaffected [182]. The mechanism involves proteolytic degradation mediated through the proteasome pathway [183]. Reduction of Gai coupling will raise basal lipolysis and reduce the effect of inhibiting ligands (i.e., adenosine, prostaglandins). Nevertheless, in contrast to findings in rodent cells, Gai does not appear to be essential for TNF-a-induced lipolysis in human adipocytes [184]. Experiments in rodent and human fat cells have demonstrated that TNF-a could also activate lipolysis by activating perilipin phosphorylation and decreasing its levels at the lipid droplet surface. A rather complex mechanism involves: (i) activation of ERK pathway (i.e., p42/44 MAPKs and Jun kinase) which mediates reduction of perilipin expression and facilitate lipases access to the lipid droplet [181, 184–186]; and (ii) reduction of PDE-3B expression followed by an elevated cAMP concentration leading to a concomitant increase in PKA activity and perilipin hyperphosphorylation that enables the lipases to reach lipid droplet [187].
j165
j 9 Signaling Pathways Controlling Lipolysis and Lipid Mobilization in Humans
166
Although the influence of TNF-a on lipolysis is modified in obese rodents, the physiological and/or pathological importance of TNF-a signaling on lipolysis in humans remains rather debated [8]. 9.7.4 Other Lipolytic Peptides
PTH stimulates lipolysis in human fat cells [188–190]. The N-terminal 1–34 peptide portion of the hormone is responsible for adenylyl cyclase stimulation and cAMP production leading to stimulation of lipolysis. Furthermore, PTH stimulates lipid mobilization in vivo in man. Prolonged exposure to hypobaric hypoxia led to a potent reduction in lipid mobilization, through a decrease in the efficiency of b-adrenergic and PTH lipolytic pathways, as well as an increment in the a2-adrenergic receptormediated antilipolytic effects [150]. There appears to be no defect in the adenylate cyclase system in the fat cell in response to PTH in patients with pseudohypoparathyroidism. The effect of PTH appears at rather high PTH concentrations of the hormone which are clearly extraphysiological. There are no data concerning a physiological contribution of PTH in the control of lipid mobilization in humans. Lipolytic peptides (i.e., adrenocorticotropic hormone, a-melanocyte-stimulating hormone, lipotropin), which exert potent lipolytic effects in rodent fat cells via MC2 receptor stimulation, have no effect in human fat cells. Glucagon and glucagon-like peptide (GLP)-1, which also act in rodent fat cells, do not stimulate lipolysis in human isolated subcutaneous fat cells. Moreover, no significant effect of either GLP-1 or glucagon on either lipolysis rate or blood flow was detected in muscle or adipose tissue during local or experimental intravenous hyperglucagonemia [191, 192]. Leptin has been shown to increase glycerol release from mature adipocytes [193]. Nevertheless, leptin (within a concentration range of 25–250 ng/ml) has no direct lipolytic effect in human adipocytes either in children or adults [194]. Cachexia-inducing tumors release a lipid-mobilizing factor (LMF) that promotes release of glycerol when incubated with murine adipocytes. Induction of lipolysis by LMF was associated with an increase in intracellular cAMP levels. The serum and urine of cachectic cancer patients contain LMF, the activity of which is correlated with the extent of weight loss [195]. Zinc-a2-glycoprotein (ZAG), a protein of 43 kDa, acts as a LMF to stimulate lipolysis in adipocytes, leading to cachexia in mice implanted with ZAG-producing tumors. ZAG was detected in the major fat deposits of mice and in 3T3-L1 adipocytes. ZAG gene expression and protein were also found in human fat cells (visceral adipose tissue and subcutaneous adipose tissue). Murine and human ZAG share up to 100% identity in specific regions hypothesized to be important in lipid metabolism [196]. ZAG is a new adipose tissue protein factor that may be involved in the modulation of lipolysis in adipocytes [197]. Human adipocytes (i.e., originating from the SGBS human cell line) express and secrete ZAG, with ZAG expression being regulated particularly through TNF-a and the peroxisome proliferator-activated receptor-c nuclear receptor [198]. Nevertheless, its physiological role remains to be established in human fat cells and in human physiology.
9.8 Future Trends and Pharmacological Prospects
9.8 Future Trends and Pharmacological Prospects
To conclude, there are only two hormone systems, namely catecholamines and natriuretic peptides, that have acute stimulatory effects on lipolysis and fat mobilization in humans. Adipose tissue (e.g., fat cells and the vascular bed of adipose tissue) is a new and unsuspected target organ of natriuretic peptides. Two strictly independent pathways control cAMP and cGMP production, respectively. Induction of lipolysis and lipid mobilization must be now included in the numerous physiological actions of natriuretic peptides. Further fundamental and clinical studies will be required to answer the various questions raised by the discovery of the metabolic effects of natriuretic peptides. The effect of b-adrenergic antagonist treatment on natriuretic peptide release merits further study. Finally, all the drugs known to modulate natriuretic peptide-dependent pathways should be evaluated for their putative metabolic side-effects when given for the management of cardiovascular diseases. Deregulation of lipid metabolism has long been recognized as essential in the development of obesity and the metabolic syndrome. Lipolysis plays a pivotal role in controlling the quantity of triglycerides stored in fat depots and in determining plasma NEFA levels. Critical steps in this catabolic process constitute targets for strategies to fight against obesity and to improve the poor metabolic profile of patients with the metabolic syndrome. Activators of lipolysis could present a pharmacological interest to induce mobilization in fat deposits that are resistant to hormone-induced lipolysis. However, they must be associated with agents that stimulate the oxidation of fatty acids by skeletal muscle and energy expenditure. Concomitant stimulation of fat oxidation in skeletal muscle is an important alternative strategy. The blockade of a2adrenergic receptors has been considered for the enhancement of lipid mobilization. Administration of a a2-adrenergic receptor antagonist promotes SNS activation and blocks cell a2-adrenergic receptors in fat cells and other cells expressing this adrenergic receptor subtype. A strong lipid mobilization is induced by their blockade. Since the launch of nicotinic acid (niacin) as a lipid-lowering drug some time ago, the suppression of lipolysis to decrease free fatty acid levels has attracted much interest. The recent cloning of the receptor for nicotinic acid that is mainly expressed in adipose tissue has undoubtedly led to important screening efforts to identify agonists with fewer side-effects than niacin and its long-lasting form, acipimox. Inhibition of HSL is also attractive as the enzyme has little homology with other mammalian lipases and shows a rather limited tissue distribution. The effect of chronic treatment with these in rodent models of obesity and dyslipidemia is now awaited.
Acknowledgments
The author thanks all the past and present members of the laboratory (INSERM U317 and 586) for their contribution to research. Thanks go out more specifically to Drs. M.
j167
j 9 Signaling Pathways Controlling Lipolysis and Lipid Mobilization in Humans
168
Berlan, C. Carpene, P. Mauriege, J. Galitzky, P. Valet, J.-S. Saulnier-Blache, G. Tavernier, A. Bouloumie, I. Castan, D. Langin, C. Sengenes, C. Moro, F. Crampes, I. De Glisezinski, I. Harant, and V. Stich who contributed to the described studies. Studies in the authors laboratory are supported by INSERM French National Institute for Medical Research and funds from Projects of the Fifth and Sixth Framework Programs of European Commission. The author apologizes to many colleagues for not being able to cite all relevant references because of space limitations.
References 1 Cannon, B. and Nedergaard, J. (2004)
2
3
4
5
6
7
8
9
Brown adipose tissue: function and physiological significance. Physiol. Rev., 84, 277–359. Astrup, A., Bulow, J., Madsen, J., and Christensen, N.J. (1985) Contribution of BAT and skeletal muscle to thermogenesis induced by ephedrine in man. Am. J. Physiol. Endocrinol. Metab., 248, E507–E515. Frayn, K.N. (2002) Adipose tissue as a buffer for daily lipid flux. Diabetologia, 45, 1201–1210. Lafontan, M. and Berlan, M. (1993) Fat cell adrenergic receptors and the control of white and brown fat cell function. J. Lipid Res., 34, 1057–1091. Arner, P. (1999) Catecholamine-induced lipolysis in obesity. Int. J. Obes. Metab. Disord., 23 (Suppl. 1), 10–13. Langin, D., Lucas, S., and Lafontan, M. (2000) Millenium fat-cell lipolysis reveals unsuspected novel tracks. Horm. Metab. Res., 32, 443–452. Langin, D. and Lafontan, M. (2004) Lipolysis and lipid mobilization in human adipose tissue, in Handbook of Obesity: Etiology and Pathophysiology (eds G.A. Bray and C. Bouchard), Marcel Dekker, New York, pp. 515–532. Langin, D. and Arner, P. (2006) Importance of TNFalpha and neutral lipases in human adipose tissue lipolysis. Trends Endocrinol. Metab., 17, 314–320. Fredrikson, G., Tornqvist, H., and Belfrage, P. (1986) Hormone-sensitive lipase and monoacylglycerol lipase are both required for complete degradation
10
11
12
13
14
15
of adipocyte triacylglycerol. Biochim. Biophys. Acta, 876, 288–293. Holm, C. (2003) Molecular mechanisms regulating hormone-sensitive lipase and lipolysis. Biochem. Soc. Trans., 31, 1120–1124. Tansey, J.T., Sztalryd, C., Hlavin, E.M., Kimmel, A.R., and Londos, C. (2004) The central role of perilipin A in lipid metabolism and adipocyte lipolysis. IUBMB Life, 56, 379–385. Miyoshi, H., Souza, S.C., Zhang, H.H., Strissel, K.J., Christoffolete, M.A., Kovsan, J., Rudich, A. Kraemer, F.B. et al. (2006) Perilipin promotes hormonesensitive lipase-mediated adipocyte lipolysis via phosphorylation-dependent and -independent mechanisms. J. Biol. Chem., 281, 15837–15844. Miyoshi, H., Perfield, J.W. 2nd, Souza, S.C., Shen, W.J., Zhang, H.H., Stancheva, Z.S., Kraemer, F.B., Obin, M.S. et al. (2007) Control of adipose triglyceride lipase action by serine 517 of perilipin a globally regulates protein kinase a-stimulated lipolysis in adipocytes. J. Biol. Chem, 282, 996–1002. Marcinkiewicz, A., Gauthier, D., Garcia, A., and Brasaemle, D.L. (2006) The phosphorylation of serine 492 of perilipin a directs lipid droplet fragmentation and dispersion. J. Biol. Chem., 281, 11901–11909. Su, C.L., Sztalryd, C., Contreras, J.A., Holm, C., Kimmel, A.R., and Londos, C. (2003) Mutational analysis of the hormone-sensitive lipase translocation reaction in adipocytes. J. Biol. Chem., 278, 43615–43619.
References 16 Smith, A.J., Sanders, M.A., Thompson,
17
18
19
20
21
22
23
B.R., Londos, C., Kraemer, F.B., and Bernlohr, D.A. (2004) Physical association between the adipocyte fatty acid-binding protein and hormonesensitive lipase: a fluorescence resonance energy transfer analysis. J. Biol. Chem., 279, 52399–52405. Kishida, K., Kuriyama, H., Funahashi, T., Shimomura, I., Kihara, S., Ouchi, N., Nishida, M. Nishizawa, H. et al. (2000) Aquaporin adipose, a putative glycerol channel in adipocytes. J. Biol. Chem., 275, 20896–20902. Kondo, H., Shimomura, I., Kishida, K., Kuriyama, H., Makino, Y., Nishizawa, H., Matsuda, M. Maeda, N. et al. (2002) Human aquaporin adipose (AQPap) gene. Genomic structure, promoter analysis and functional mutation. Eur. J. Biochem., 269, 1814–1826. Fruhbeck, G., Catalan, V., GomezAmbrosi, J., and Rodriguez, A. (2006) Aquaporin-7 and glycerol permeability as novel obesity drug-target pathways. Trends Pharmacol. Sci., 27, 345–347. Jenkins, C.M., Mancuso, D.J., Yan, W., Sims, H.F., Gibson, B., and Gross, R.W. (2004) Identification, cloning, expression, and purification of three novel human calcium-independent phospholipase A2 family members possessing triacylglycerol lipase and acylglycerol transacylase activities. J. Biol. Chem., 279, 48968–48975. Villena, J.A., Roy, S., Sarkadi-Nagy, E., Kim, K.-H., and Sul, H.S. (2004) Desnutrin, an adipocyte gene encoding a novel patatin domain-containing protein, is induced by fasting and glucocorticoids: ectopic expression of desnutrin increases triglyceride hydrolysis. J. Biol. Chem., 279, 47066–47075. Zimmermann, R., Strauss, J.G., Haemmerle, G., Schoiswohl, G., BirnerGruenberger, R., Riederer, M., Lass, A. Neuberger, G. et al. (2004) Fat mobilization in adipose tissue is promoted by adipose triglyceride lipase. Science, 306, 1383–1386. Zechner, R., Strauss, J.G., Haemmerle, G., Lass, A., and Zimmermann, R. (2005)
24
25
26
27
28
29
30
31
Lipolysis: pathway under construction. Curr. Opin. Lipidol., 16, 333–340. Haemmerle, G., Lass, A., Zimmermann, R., Gorkiewicz, G., Meyer, C., Rozman, J., Heldmaier, G. Maier, R. et al. (2006) Defective lipolysis and altered energy metabolism in mice lacking adipose triglyceride lipase. Science, 312, 734–737. Langin, D., Dicker, A., Tavernier, G., Hoffstedt, J., Mairal, A., Ryden, M., Arner, E. Sicard, A. et al. (2005) Adipocyte lipases and defect of lipolysis in human obesity. Diabetes, 54, 3190–3197. Ryden, M., Jocken, J., van Harmelen, V., Dicker, A., Hoffstedt, J., Wiren, M., Blomqvist, L. Mairal, A. et al. (2007) Comparative studies of the role of hormone sensitive lipase and adipose triglyceride lipase in human fat cell lipolysis. Am. J. Physiol. Endocrinol. Metab., 292, E1847–E1855. Lass, A., Zimmermann, R., Haemmerle, G., Riederer, M., Schoiswohl, G., Schweiger, M., Kienesberger, P. Strauss, J.G. et al. (2006) Adipose triglyceride lipase-mediated lipolysis of cellular fat stores is activated by CGI-58 and defective in Chanarin–Dorfman syndrome. Cell Metab., 3, 309–319. Granneman, J.G., Moore, H.P., Granneman, R.L., Greenberg, A.S., Obin, M.S., and Zhu, Z. (2007) Analysis of lipolytic protein trafficking and interactions in adipocytes. J. Biol. Chem., 282, 5726–5735. Subramanian, V., Rothenberg, A., Gomez, C., Cohen, A.W., Garcia, A., Bhattacharyya, S., Shapiro, L. Dolios, G. et al. (2004) Perilipin A mediates the reversible binding of CGI-58 to lipid droplets in 3T3-L1 adipocytes. J. Biol. Chem., 279, 42062–42071. Yamaguchi, T., Omatsu, N., Matsushita, S., and Osumi, T. (2004) CGI-58 interacts with perilipin and is localized to lipid droplets. Possible involvement of CGI-58 mislocalization in Chanarin–Dorfman syndrome. J. Biol. Chem., 279, 30490–30497. Mairal, A., Langin, D., Arner, P., and Hoffstedt, J. (2006) Human adipose triglyceride lipase (PNPLA2) is not regulated by obesity and exhibits low
j169
j 9 Signaling Pathways Controlling Lipolysis and Lipid Mobilization in Humans
170
32
33
34
35
36
37
38
39
40
in vitro triglyceride hydrolase activity. Diabetologia, 49, 1629–1636. Lafontan, M. and Berlan, M. (1982) Characterization of physiological agonist selectivity of human fat cell alpha2adrenoceptors: adrenaline is the major stimulant of the alpha2-adrenoceptor. Eur. J. Pharmacol., 82, 107–111. Richelsen, B. (1986) Increased alpha2- but similar beta-adrenergic receptor activities in subcutaneous gluteal adipocytes from females compared with males. Eur. J. Clin. Invest., 16, 302–309. Mauriege, P., Galitzky, J., Berlan, M., and Lafontan, M. (1987) Heterogeneous distribution of beta- and alpha2adrenoceptor binding sites in human fat cells from various fat deposits: functional consequences. Eur. J. Clin. Invest., 17, 156–165. Wahrenberg, H., L€ onnqvist, F., and Arner, P. (1989) Mechanisms underlying regional differences in lipolysis in human adipose tissue. J. Clin. Invest., 84, 458–467. Mauriege, P., Despres, J.P., Prudhomme, D., Pouliot, M.C., Marcotte, M., Tremblay, A., and Bouchard, C. (1991) Regional variation in adipose tissue lipolysis in lean and obese men. J. Lipid Res., 32, 1625–1633. Reynisdottir, S., Ellerfeldt, K., Wahrenberg, H., Lithell, H., and Arner, P. (1994) Multiple lipolysis defects in the insulin resistance (metabolic) syndrome. J. Clin. Invest., 93, 2590–2599. Mauriege, P., Prudhomme, D., Lemieux, S., Tremblay, A., and Despres, J.-P. (1995) Regional differences in adipose tissue lipolysis from lean and obese women: existence of postreceptor alterations. Am. J. Physiol. Endocrinol. Metab., 269, E341–E350. Mauriege, P., Marette, A., Atgie, C., Bouchard, C., Theriault, G., Bukowiecki, L.K., Marceau, P. Biron, S. et al. (1995) Regional variation in adipose tissue metabolism of severely obese premenopausal women. J. Lipid Res., 36, 672–684. Lafontan, M. (2005) Fat cells: afferent and efferent messages define new
41
42
43
44
45
46
47
48
approaches to treat obesity. Annu. Rev. Pharmacol. Toxicol., 45, 119–146. Reynisdottir, S., Eriksson, M., Angelin, B., and Arner, P. (1995) Impaired activation of adipocyte lipolysis in familial combined hyperlipidemia. J. Clin. Invest., 95, 2161–2169. Large, V., Reynisdottir, S., Langin, D., Fredby, K., Klannemark, M., Holm, C., and Arner, P. (1999) Decreased expression and function of adipocyte hormone-sensitive lipase in subcutaneous fat cells of obese subjects. J. Lipid Res., 40, 2059–2065. Mauriege, P., Pergola, G.D., Berlan, M., and Lafontan, M. (1988) Human fat cell beta-adrenergic receptors: beta agonist-dependent lipolytic responses and characterization of beta-adrenergic binding sites on human fat cell membranes with highly selective beta1-antagonists. J. Lipid Res., 29, 587–601. Tavernier, G., Barbe, P., Galitzky, J., Berlan, M., Caput, D., Lafontan, M., and Langin, D. (1996) Expression of b3adrenoceptors with low lipolytic action in human subcutaneous fat cells. J. Lipid Res., 37, 87–97. L€ onnqvist, F., Krief, S., Strosberg, A.D., Nyberg, B., Emorine, L.J., and Arner, P. (1993) Evidence for a functional beta3adrenoceptor in man. Br. J. Pharmacol., 110, 929–936. L€ onnqvist, F., Th€ orne, A., Nilsell, K., Hoffstedt, J., and Arner, P. (1995) A pathogenic role of visceral fat b3adrenoceptors in obesity. J. Clin. Invest., 95, 1109–1116. Konkar, A.A., Zhai, Y., and Granneman, J.G. (2000) b1-adrenergic receptors mediate b3-adrenergic-independent effects of CGP12177. Mol. Pharmacol., 57, 252–258. Kaumann, A., Engelhardt, S., Hein, L., Molenaar, P., and Lohse, M. (2001) Abolition of (–)CGP12177-evoked cardiostimulation in double beta1/beta2adrenoceptor knock out mice. Obligatory role of beta1-adrenoceptors for putative beta4-adrenoceptor pharmacology. Naunyn Schmied. Arch. Pharmacol., 363, 87–93.
References 49 Barbe, P., Millet, L., Galitzky, J., Lafontan,
50
51
52
53
54
55
56
57
M., and Berlan, M. (1996) In situ assessment of the role of the b1-, b2- and b3-adrenoceptors in the control of lipolysis and nutritive blood flow in human subcutaneous adipose tissue. Br. J. Pharmacol., 117, 907–913. Schiffelers, S.L.H., Blaak, E.E., Saris, W.H.M., and Baak, M.A.v. (2000) In vivo b3-adrenergic stimulation of human thermogenesis and lipid utilization. Clin. Pharmacol. Therap., 67, 558–566. Redman, L.M., de Jonge, L., Fang, X., Gamlin, B., Recker, D., Greenway, F.L., Smith, S.R., and Ravussin, E. (2007) Lack of an effect of a novel beta3-adrenoceptor agonist, TAK-677, on energy metabolism in obese individuals: a double-blind, placebo-controlled randomized study. J. Clin. Endocrinol. Metab., 92, 527–531. Allison, D.B., Heo, M., Faith, M.S., and Pietrobelli, A. (1998) Meta-analysis of the association of the Trp64Arg polymorphism in the beta3 adrenergic receptor with body mass index. Int. J. Obes. Relat. Metab. Disord., 22, 559–566. Shihara, N., Yasuda, K., Moritani, T., Ue, H., Adachi, T., Tanaka, H., Tsuda, K., and Seino, Y. (1999) The association between Trp64Arg polymorphism of the beta3adrenergic receptor and autonomic nervous system activity. J. Clin. Endocrinol. Metab., 84, 1623–1627. Dodt, C., Lonnroth, P., Fehm, H.L., and Elam, M. (1999) Intraneural stimulation elicits an increase in subcutaneous interstitial glycerol levels in humans. J. Physiol., 521, 545–552. Dodt, C., Lonnroth, P., Fehm, H.L., and Elam, M. (2000) The subcutaneous lipolytic response to regional neural stimulation is reduced in obese women. Diabetes, 49, 1875–1879. L€onnqvist, F., Wahrenberg, H., Hellstrom, L., Reynisdottir, S., and Arner, P. (1992) Lipolytic catecholamine resistance due to decreased b2adrenoceptor expression in fat cells. J. Clin. Invest., 90, 2175–2186. Bougneres, P., Stunff, C.L., Pecqueur, C., Pinglier, E., Adnot, P., and Ricquier, D. (1997) In vivo resistance of lipolysis to epinephrine. A new feature of childhood
58
59
60
61
62
63
64
65
onset obesity. J. Clin. Invest., 99, 2568–2573. Horowitz, J.F. and Klein, S. (2000) Whole body and abdominal lipolytic sensitivity to epinephrine is suppressed in upper body obese women. Am. J. Physiol. Endocrinol. Metab., 278, E1144–E1152. Carel, J.C., Stunff, C.L., Condamine, L., Mallet, E., Chaussain, J.L., Adnot, P., Garabedian, M., and Bougneres, P. (1999) Resistance to the lipolytic action of epinephrine: a new feature of protein Gs deficiency. J. Clin. Endocrinol. Metab., 84, 4127–4131. Enoksson, S., Talbot, M., Rife, F., Tamborlane, W.V., Sherwin, R.S., and Caprio, S. (2000) Impaired in vivo stimulation of lipolysis in adipose tissue by selective b2-adrenergic agonist in obese adolescent girls. Diabetes, 49, 2149–2153. Schiffelers, S.L.H., Saris, W.H.M., Boomsma, F., and Baak, M.A.v. (2001) Beta1- and beta2-adrenoceptor-mediated thermogenesis and lipid utilization in obese and lean men. J. Clin. Endocrinol. Metab., 86, 2191–2199. Large, V., Hellstr€ om, L., Reynisdottir, S., L€ onnqvist, F., Eriksson, P., Lannfelt, L., and Arner, P. (1997) Human beta2adrenoceptor gene polymorphism are highly frequent in obesity and associated with altered adipocyte beta2adrenoceptor function. J. Clin. Invest., 100, 3005–3013. Ishiyama-Shigemoto, S., Yamada, K., Yuan, X., Ichikawa, F., and Nonaka, K. (1999) Association of polymorphisms in the beta2-adrenergic receptor gene with obesity, hypertriglyceridemia and diabetes mellitus. Diabetologia, 42, 98–101. Mori, Y., Kim-Motoyama, H., Ito, Y., Katakura, T., Yasuda, K., IshiyamaShigemoto, S., Yamada, K. Akanuma, Y. et al. (1999) The Gln27Glu beta2adrenergic receptor variant is associated with obesity due to subcutaneous fat accumulation. Biochem. Biophys. Res. Commun., 258, 138–140. Yamada, K., Ishiyama-Shigemoto, S., Ichikawa, F., Yuan, X., Koyanagi, A., Koyama, W., and Nonaka, K. (1999)
j171
j 9 Signaling Pathways Controlling Lipolysis and Lipid Mobilization in Humans
172
66
67
68
69
70
71
72
73
Polymorphism in the 50 -leader cistron of the beta2-adrenergic receptor gene associated with obesity and type 2 diabetes. J. Clin. Endocrinol. Metab., 84, 1754–1757. Lange, L.A., Norris, J.M., Langefeld, C.D., Nicklas, B.J., Wagenknecht, L.E., Saad, M.F., and Bowden, D.W. (2005) Association of adipose tissue deposition and beta-2 adrenergic receptor variants: the IRAS family study. Int. J. Obes., 29, 449–457. Meirhaeghe, A., Cottel, D., Helbecque, N., and Amouyel, P. (2000) Impact of polymorphisms in the human b2adrenoceptor gene on obesity in French population. Int. J. Obes. Relat. Metab. Disord., 24, 382–387. Meirhaeghe, A., Helbecque, N., Cottel, D., and Amouyel, P. (1999) b2adrenoceptor gene polymorphism, body weight and physical activity. Lancet, 353, 236. Hayakawa, T., Nagai, Y., Kahara, T., Yamashita, H., Takamura, T., Abe, T., Nomura, G., and Kobayashi, K. (2000) Gln27Glu and Arg16Gly polymorphisms of the beta2-adrenergic receptor gene are not associated with obesity in japanese men. Metabolism, 49, 1215–1218. Oberkofler, H., Esterbauer, H., Hell, E., Krempler, F., and Patsch, W. (2000) The Gln27Glu polymorphism in the beta2adrenergic receptor gene is not associated with morbid obesity in Austrian women. Int. J. Obes. Relat. Metab. Disord., 24, 388–390. Mason, D.A., Moore, J.D., Green, S.A., and Liggett, S.B. (1999) A gain of function polymorphism in a G-protein coupling domain of the human beta1-adrenergic receptor. J. Biol. Chem., 274, 12670–12674. Rathz, D.A., Brown, K.M., Kramer, L.A., and Liggett, S.B. (2002) Amino acid 49 polymorphism in the human beta-1 adrenergic receptor affect agonistpromoted trafficking. J. Cardiovasc. Pharmacol., 30, 155–160. Linne, Y., Dahlman, I., and Hoffstedt, J. (2005) beta1-Adrenoceptor gene polymorphism predicts long-term
74
75
76
77
78
79
80
81
82
83
changes in body weight. Int. J. Obes., 29, 458–462. Lafontan, M. (1994) Differential recruitment and differential regulation by physiological amines of fat cell beta-1, beta-2 and beta-3 adrenergic receptors expressed in native fat cells and in transfected cell lines. Cell. Signal., 6, 363–392. Lafontan, M. and Berlan, M. (1981) Alpha-adrenergic receptors and the regulation of lipolysis in adipose tissue. Trends Pharmacol. Sci., 2, 126–129. Lafontan, M. and Berlan, M. (1980) Evidence for the alpha2-nature of the alpha-adrenergic receptor inhibiting lipolysis in human fat cells. Eur. J. Pharmacol., 66, 87–93. Mauriege, P., Imbeault, P., Langin, D., Lacaille, M., Almeras, N., Tremblay, A., and Despres, J.P. (1999) Regional and gender variations in adipose tissue lipolysis in response to weight loss. J. Lipid Res., 40, 1559–1571. Lafontan, M. and Berlan, M. (1995) Fat cell a2-adrenoceptors: the regulation of fat cell function and lipolysis. Endocr. Rev., 16, 716–738. Carpene, C., Berlan, M., and Lafontan, M. (1983) Influence of development and reduction of fat stores on the antilipolytic alpha2-adrenoceptor in hamster adipocytes: comparison with adenosine and beta-adrenergic lipolytic responses. J. Lipid Res., 24, 766–774. Arner, P., Kriegholm, E., and Engfeldt, P. (1990) In situ studies of catecholamineinduced lipolysis in human adipose tissue using microdialysis. J. Pharmacol. Exp. Ther., 254, 284–288. Lafontan, M. and Arner, P. (1996) Application of in situ microdialysis to measure metabolic and vascular responses in adipose tissue. Trends Pharmacol. Sci., 17, 309–313. Galitzky, J., Lafontan, M., Nordenstr€ om, J., and Arner, P. (1993) Role of vascular alpha2-adrenoceptors in regulating lipid mobilization from human adipose tissue. J. Clin. Invest., 91, 1997–2003. Stich, V., de Glisezinski, I., Crampes, F., Hejnova, J., Cottet-Emard, J.-M., Galitzky, J., Lafontan, M. Riviere, D. et al.
References
84
85
86
87
88
89
90
91
(2000) Activation of alpha2-adrenergic receptors impairs exercise-induced lipolysis in SCATof obese subjects. Am. J. Physiol. Regul. Integr. Comp. Physiol., 279, R499–R504. de Glisezinski, I., Marion-Latard, F., Crampes, F., Berlan, M., Hejnova, J., Cottet-Emard, J.-M., Stich, V., and Riviere, D. (2001) Lack of alpha2adrenergic antilipolytic effect during exercise in subcutaneous adipose tissue of trained men. J. Appl. Physiol., 91, 1760–1765. Stich, V., Marion-Latard, F., Hejnova, J., Viguerie, N., Lefort, C., Suljkovicova, H., Langin, D. Lafontan, M. et al. (2002) Hypocaloric diet reduces exerciseinduced alpha2-adrenergic antilipolytic effect and alpha2-adrenergic receptor mRNA levels in adipose tissue of obese women. J. Clin. Endocrinol. Metab., 87, 1274–1281. Hellstr€om, L., Blaak, E., and HagstromToft, E. (1996) Gender differences in adrenergic regulation of lipid mobilization during exercise. Int. J. Sports Med., 17, 439–447. Fain, J.N. (2006) Release of interleukins and other inflammatory cytokines by human adipose tissue is enhanced in obesity and primarily due to the nonfat cells. Vitam. Horm., 74, 443–477. Kather, H. (1988) Purine accumulation in human fat cell suspensions. J. Biol. Chem., 263, 8803–8809. Kather, H. (1990) Pathways of purine metabolism in human adipocytes: further evidence against a role of adenosine as an endogenous regulator of human fat cell function. J. Clin. Invest., 265, 96–102. L€onnroth, P., Jansson, P.-A., Fredholm, B.B., and Smith, U. (1989) Microdialysis of intercellular adenosine concentration in subcutaneous adipose tissue in humans. Am. J. Physiol. Endocrinol. Metab., 256, E250–E255. Aktories, K., Schultz, G., and Jakobs, K.H. (1983) Islet-activating protein prevents nicotinic acid-induced GTPase stimulation and GTP but not GTP gamma S-induced adenylate cyclase
92
93
94
95
96
97
98
99
100
inhibition in rat adipocytes. FEBS Lett., 156, 88–92. Kather, H., Bieger, W., Michel, G., Aktories, K., and Jakobs, K.H. (1985) Human fat cell lipolysis is primarily regulated by inhibitory modulators acting through distinct mechanisms. J. Clin. Invest., 76, 1559–1565. Moxham, C.M., Hod, Y., and Malbon, C.C. (1993) Gi alpha 2 mediates the inhibitory regulation of adenylylcyclase in vivo: analysis in transgenic mice with Gi alpha 2 suppressed by inducible antisense RNA. Dev. Genet, 14, 266–273. Kather, H. and Simon, B. (1979) Biphasic effects of prostaglandin E2 on the human fat cell adenylate cyclase. J. Clin. Invest., 64, 609–612. Valet, P., Berlan, M., Beauville, M., Crampes, F., Montastruc, J.-L., and Lafontan, M. (1990) Neuropeptide Y and peptide YY inhibit lipolysis in human and dog fat cells through a pertussis toxinsensitive G protein. J. Clin. Invest., 85, 291–295. Castan, I., Valet, P., Larrouy, D., Voisin, T., Remaury, A., Daviaud, D., Laburthe, M., and Lafontan, M. (1993) Distribution of PYY receptors in human fat cells: an antilipolytic system alongside the a2adrenergic one. Am. J. Physiol. Endocrinol. Metab., 265, E74–E80. Serradeil-Le Gal, C., Lafontan, M., Raufaste, D., Marchand, J., Pouzet, B., Casellas, P., Pascal, M. Maffrand, J.-P. et al. (2000) Characterization of NPY receptors controlling lipolysis and leptin secretion in human adipocytes. FEBS Lett., 475, 150–156. Turtzo, L.C., Marx, R., and Lane, M.D. (2001) Cross-talk between sympathetic neurons and adipocytes in coculture. Proc. Natl. Acad. Sci. USA, 98, 12385–12390. Carlson, L.A., Havel, R.J., Ekelund, L.G., and Holmgren, A. (1963) Effect of nicotinic acid on the turnover rate and oxidation of the free fatty acids of plasma in man during exercise. Metabolism, 12, 837–845. Carlson, L.A. (1963) Studies on the effect of nicotinic acid on catecholamine
j173
j 9 Signaling Pathways Controlling Lipolysis and Lipid Mobilization in Humans
174
101
102
103
104
105
106
107
108
109
stimulated lipolysis in adipose tissue in vitro. Acta Med. Scand., 173, 719–722. Aktories, K., Schultz, G., and Jakobs, K.H. (1980) Regulation of adenylate cyclase activity in hamster adipocytes. Inhibition by prostaglandins, alpha-adrenergic agonists and nicotinic acid. Naunyn Schmiedebergs Arch. Pharmacol., 312, 167–173. Lorenzen, A., Stannek, C., Lang, H., Andrianov, V., Kalvinsh, I., and Schwabe, U. (2001) Characterization of a G proteincoupled receptor for nicotinic acid. Mol. Pharmacol., 59, 349–357. Soga, T., Kamohara, M., Takasaki, J., Matsumoto, S., Saito, T., Ohishi, T., Hiyama, H. Matsuo, A. et al. (2003) Molecular identification of nicotinic acid receptor. Biochem. Biophys. Res. Commun., 303, 364–369. Tunaru, S., Kero, J., Schaub, A., Wufka, C., Blaukat, A., Pfeffer, K., and Offermanns, S. (2003) PUMA-G and HM74 are receptors for nicotinic acid and mediate its anti-lipolytic effect. Nat. Med., 9, 352–355. Wise, A., Foord, S.M., Fraser, N.J., Barnes, A.A., Elshourbagy, N., Eilert, M., Ignar, D.M. Murdock, P.R. et al. (2003) Molecular identification of high and low affinity receptors for nicotinic acid. J. Biol. Chem., 278, 9869–9874. Taggart, A.K., Kero, J., Gan, X., Cai, T.Q., Cheng, K., Ippolito, M., Ren, N. Kaplan, R. et al. (2005) (D)-b-Hydroxybutyrate inhibits adipocyte lipolysis via the nicotinic acid receptor PUMA-G. J. Biol. Chem., 280, 26649–26652. Kido, Y., Nakae, J., and Accili, D. (2001) The insulin receptor and its cellular targets. J. Clin. Endocrinol. Metab., 86, 972–979. Degerman, E., Smith, C.J., Tornqvist, H., Vasta, V., Belfrage, P., and Manganiello, V.C. (1990) Evidence that insulin and isoprenaline activate the cGMP-inhibited low-Km cAMP phosphodiesterase in rat fat cells by phosphorylation. Proc. Natl. Acad. Sci. USA, 87, 533–537. Degerman, E., Belfrage, P., and Manganiello, V.C. (1997) Structure, localization, and regulation of cGMP-
110
111
112
113
114
115
116
117
inhibited phosphodiesterase (PDE 3). J. Biol. Chem., 272, 6823–6826. Nilsson, R., Ahmad, F., Sward, K., Andersson, U., Weston, M., Manganiello, V., and Degerman, E. (2006) Plasma membrane cyclic nucleotide phosphodiesterase 3B (PDE3B) is associated with caveolae in primary adipocytes. Cell. Signal., 18, 1713–1721. Ahmad, F., Lindh, R., Tang, Y., Weston, M., Degerman, E., and Manganiello, V.C. (2007) Insulin-induced formation of macromolecular complexes involved in activation of cyclic nucleotide phosphodiesterase 3B (PDE3B) and its interaction with PKB. Biochem. J., 404, 257–268. Choi, Y.H., Park, S., Hockman, S., Zmuda-Trzebiatowska, E., Svennelid, F., Haluzik, M., Gavrilova, O. Ahmad, F. et al. (2006) Alterations in regulation of energy homeostasis in cyclic nucleotide phosphodiesterase 3B-null mice. J. Clin. Invest., 116, 3240–3251. Pirola, L., Johnston, A.M., and Obberghen, E.V. (2004) Modulation of insulin action. Diabetologia, 47, 170–184. Jansson, P.A., Pellme, F., Hammarstedt, A., Sandqvist, M., Brekke, H., Caidahl, K., Forsberg, M. Volkmann, R. et al. (2003) A novel cellular marker of insulin resistance and early atherosclerosis in humans is related to impaired fat cell differentiation and low adiponectin. FASEB J., 17, 1434–1440. Lefebvre, A.-M., Laville, M., Vega, N., Riou, J.P., Gaal, L.v., Auwerx, J., and Vidal, H. (1998) Depot-specific differences in adipose tissue gene expression in lean and obese subjects. Diabetes, 47, 98–103. Zierath, J., Livingston, J., Thorne, A., Bolinder, J., Reynisdottir, S., Lonnqvist, F., and Arner, P. (1998) Regional difference in insulin inhibition of nonesterified fatty acid release from human adipocytes: relation to insulin receptor phosphorylation and intracellular signalling through the insulin receptor substrate-1 pathway. Diabetologia, 41, 1343–1354. Wu, X., Hoffstedt, J., Deeb, W., Singh, R., Sedkova, N., Zilbering, A., Zhu, L. Park,
References
118
119
120
121
122
123
124
125
126
127
P.K. et al. (2001) Depot-specific variation in protein-tyrosine phosphatase activities in human omental and subcutaneous adipose tissue: a potential contribution to differential insulin sensitivity. J. Clin. Endocrinol. Metab., 86, 5973–5980. Jensen, M., Haymond, M., Rizza, R., Cryer, P., and Miles, J. (1989) Influence of body fat distribution on free fatty acid metabolism in obesity. J. Clin. Invest., 83, 1168–1173. Johnson, J.A., Fried, S.K., Pi-Sunyer, F.X., and Albu, J.B. (2001) Impaired insulin action in subcutaneous adipocytes from women with visceral obesity. Am. J. Physiol. Endocrinol. Metab., 280, E40–E49. Meek, S.E., Nair, K.S., and Jensen, M.D. (1999) Insulin regulation of regional free fatty acid metabolism. Diabetes, 48, 10–14. Guo, Z., Hensrud, D.D., Johnson, C.M., and Jensen, M.D. (1999) Regional postprandial fatty acid metabolism in different obesity phenotypes. Diabetes, 48, 1586–1592. Basu, A., Basu, R., Shah, P., Vella, A., Rizza, R.A., and Jensen, M.D. (2001) Systemic and regional free fatty acid metabolism in type 2 diabetes. Am. J. Physiol. Endocrinol. Metab., 280, E1000–E1006. Nielsen, S., Guo, Z., Johnson, M., Hensrud, D.D., and Jensen, M.D. (2004) Splanchnic lipolysis in human obesity. J. Clin. Invest., 113, 1582–1588. Potter, L.R., Abbey-Hosch, S., and Dickey, D.M. (2006) Natriuretic peptides, their receptors, and cyclic guanosine monophosphate-dependent signaling functions. Endocr. Rev., 27, 47–72. Silberbach, M. and Roberts, C.T. (2001) Natriuretic peptide signalling. Molecular and cellular pathways to growth regulation. Cell. Signal., 13, 221–231. Kiemer, A.K. and Vollmar, A.M. (2001) The atrial natriuretic peptide regulates the production of inflammatory mediators in macrophages. Ann. Rheum. Dis., 60, 68–70. Anand-Srivastava, M.B., Palaparti, A., and Pion, J. (1997) Differential regulation of G-protein expression by vasoactive peptides. Mol. Cell. Biochem., 176, 21–27.
128 De Leon, H., Bonhomme, M.-C.,
129
130
131
132
133
134
135
136
Thibault, G., and Garcia, R. (1995) Localization of atrial natriuretic factor receptors in the mesenteric arterial bed. Comparison with angiotensin II and endothelin receptors. Circ. Res., 77, 64–72. G€ oke, R., G€ oke, B., Noll, B., Richter, G., Christoph-Fehmann, H., and Arnold, R. (1989) Receptors for atrial natriuretic peptide on isolated rat adipocytes. Biomed. Res., 10, 463–467. Jeandel, L., Okamura, H., Belles-Isles, M., Chabot, J.-G., Dihl, F., Morel, G., Kelly, P.A., and Heisler, S. (1988) Immunocytochemical localization, binding and effects of atrial natriuretic peptide in rat adipocytes. Mol. Cell. Endocrinol., 62, 69–78. Sarzani, R., Dessi-Fulgheri, P., Paci, V.M., Espinosa, E., and Rappelli, A. (1996) Expression of natriuretic peptide receptors in human adipose and other tissues. J. Endocrinol. Invest., 1996, 581–585. Sengenes, C., Berlan, M., Glisezinski, I.D., Lafontan, M., and Galitzky, J. (2000) Natriuretic peptides: a new lipolytic pathway in human adipocytes. FASEB J., 14, 1345–1351. Moro, C., Galitzky, J., Sengenes, C., Crampes, F., Lafontan, M., and Berlan, M. (2004) Functional and pharmacological characterization of the natriuretic peptide-dependent lipolytic pathway in human fat cells. J. Pharmacol. Exp. Ther., 308, 984–992. Sengenes, C., Bouloumie, A., Hauner, H., Berlan, M., Busse, R., and Lafontan, M. (2003) Involvement of a cGMPdependent pathway in natriuretic peptide-mediated hormone-sensitive lipase phosphorylation in human adipocytes. J. Biol. Chem., 278, 48617–48626. Khoo, J.C., Sperry, P.J., Gill, G.N., and Steinberg, D. (1977) Activation of hormone-sensitive lipase and phosphorylase kinase by purified cyclic GMP-dependent protein kinase. Proc. Natl. Acad. Sci. USA, 74, 4843–4847. Stralfors, P. and Belfrage, P. (1985) Phosphorylation of hormone-sensitive
j175
j 9 Signaling Pathways Controlling Lipolysis and Lipid Mobilization in Humans
176
137
138
139
140
141
142
143
144
lipase by cyclic GMP-dependent protein kinase. FEBS Lett., 180, 280–284. Moro, C., Polak, J., Richterova, B., Sengenes, C., Pelikanova, T., Galitzky, J., Stich, V. Lafontan, M. et al. (2005) Differential regulation of atrial natriuretic peptide- and adrenergic receptordependent lipolytic pathways in human adipose tissue. Metabolism, 54, 122–131. Sengenes, C., Zakaroff-Girard, A., Moulin, A., Berlan, M., Bouloumie, A., Lafontan, M., and Galitzky, J. (2002) Natriuretic peptide-dependent lipolysis in fat cells is a primate specificity. Am. J. Physiol. Regul. Integr. Comp. Physiol., 283, R257–R265. Sengenes, C., Stich, V., Berlan, M., Hejnova, J., Lafontan, M., Pariskova, Z., and Galitzky, J. (2002) Increased lipolysis in adipose tissue and lipid mobilization to natriuretic peptides during low-calorie diet in obese women. Int. J. Obesity, 26, 24–32. Galitzky, J., Sengenes, C., Thalamas, C., Marques, M.-A., Senard, J.-M., Lafontan, M., and Berlan, M. (2001) The lipid mobilizing effect of atrial natriuretic peptides is unrelated to sympathetic nervous system activation or obesity in young men. J. Lipid Res., 42, 536–544. Birkenfeld, A.L., Boschmann, M., Moro, C., Adams, F., Heusser, K., Franke, G., Berlan, M. Luft, F.C. et al. (2005) Lipid mobilization with physiological atrial natriuretic peptide concentrations in humans. J. Clin. Endocrinol. Metab., 90, 3622–3628. Birkenfeld, A.L., Boschmann, M., Moro, C., Adams, F., Heusser, K., Tank, J., Diedrich, A. Schroeder, C. et al. (2006) Beta-adrenergic and atrial natriuretic peptide interactions on human cardiovascular and metabolic regulation. J. Clin. Endocrinol. Metab., 91, 5069–5075. Ohba, H., Takada, H., Musha, H., Nagashima, J., Mori, N., Awaya, T., Omiya, K., and Maruyama, M. (2001) Effects of prolonged strenous exercise on plasma levels of brain atrial natriuretic peptide and brain natriuretic peptide in healphy men. Am. Heart J., 141, 751–758. K€oning, D., Schumacher, O., Heinrich, L., Schmid, A., Berg, A., and Dickhuth,
145
146
147
148
149
150
151
152
153
H.H. (2003) Myocardial stress after competitive exercise in professional road cyclists. Med. Sci. Sports Exerc., 35, 1679–1683. Moro, C., Crampes, F., Sengenes, C., de Glisezinski, I., Galitzky, J., Thalamas, C., Lafontan, M., and Berlan, M. (2004) Atrial natriuretic peptide contributes to the physiological control of lipid mobilization in humans. FASEB J., 18, 908–910. Jorgensen, J.O. (1991) Human growth hormone replacement therapy: pharmacological and clinical aspects. Endocr. Rev., 12, 189–207. Boyle, P.J., Avogaro, A., Smith, L., Bier, D.M., Pappu, A.S., Illingworth, D.R., and Cryer, P.E. (1992) Role of GH in regulating nocturnal rate of lipolysis and plasma mevalonate levels in normal and diabetic humans. Am. J. Physiol. Endocrinol. Metab., 263, E168–E172. Wei, Y., Rhani, Z., and Goodyer, C.G. (2006) Characterization of growth hormone receptor messenger ribonucleic acid variants in human adipocytes. J. Clin. Endocrinol. Metab., 91, 1901–1908. Harant, I., Beauville, M., Crampes, F., Riviere, D., Tauber, M.-T., Tauber, J.-P., and Garrigues, M. (1994) Response of fat cells to gowth hormone: effect of longterm treatment with recombinant human growth hormone in GH-deficient adults. J. Clin. Endocrinol. Metab., 78, 1392–1395. de Glisezinski, I., Crampes, F., Harant, I., Havlik, P., Gardette, B., Jammes, Y., Souberbielle, J.C. Richalet, J.P. et al. (1999) Decrease of subcutaneous adipose tissue lipolysis after exposure to hypoxia during a simulated ascent of Mt Everest. Pflugers Arch., 439, 134–140. Doris, R., Vernon, R.G., Houslay, M.D., and Kilgour, E. (1994) Growth hormone decreases the response to anti-lipolytic agonists and decreases the levels of Gi2 in rat adipocytes. Biochem. J., 297, 41–45. Yip, R.G.-C. and Goodman, H.M. (1999) Growth hormone and dexamethasone stimulate lipolysis and activate adenylyl cyclase in rat adipocytes by selectively shifting Gia2 to lower density membrane fractions. Endocrinology, 140, 1219–1227. Yang, S., Mulder, H., Holm, C., and Eden, S. (2004) Effects of growth hormone on
References
154
155
156
157
158
159
160
161
162
the function of beta-adrenoceptor subtypes in rat adipocytes. Obes. Res., 12, 330–339. Moller, N., Jorgensen, J.O.L., Schmitz, O., Moller, J.S., Christiansen, J.S., Alberti, K.G.M.M., and Orskov, H. (1990) Effect of growth hormone pulse on total and forearm substrate fluxes in humans. Am. J. Physiol. Endocrinol. Metab., 258, E86–E91. Moller, N., Schmitz, O., Porksen, J., Moller, J., and Jorgensen, J.O. (1992) Dose–response studies on the metabolic effects of a growth hormone pulse in humans. Metabolism, 41, 172–175. Gravholt, C., Schmitz, O., Simonsen, L., Bulow, J., Christiansen, J., and Moller, N. (1999) Effects of a physiological GH pulse on interstitial glycerol in abdominal and femoral adipose tissue. Am. J. Physiol. Endocrinol. Metab., 277, E848–E854. Samra, J.S., Clark, M.L., Humphreys, S.M., MacDonald, I.A., Bannister, P.A., Matthews, D.R., and Frayn, K.N. (1999) Suppression of the nocturnal rise in growth hormone reduces subsequent lipolysis in subcutaneous adipose tissue. Eur. J. Clin. Invest., 29, 1045–1052. Moller, N., Porksen, N., Ovesen, P., and Alberti, K.G.M.M. (1993) Evidence for increased sensitivity of fuel mobilization to growth hormone during short-term fasting in humans. Horm. Metab. Res., 25, 175–179. Rosenthal, M.J. and Woodside, W.F. (1988) Nocturnal regulation of free fatty acids in healthy young and elderly men. Metabolism, 37, 645–648. Moller, N., Gjedsted, J., Gormsen, L., Fuglsang, J., and Djurhuus, C. (2003) Effects of growth hormone on lipid metabolism in humans. Growth Horm. IGF Res., 13 (Suppl. A), S18–S21. Divertie, G.D., Jensen, M.D., and Miles, J.M. (1991) Stimulation of lipolysis in humans by physiological hypercortisolemia. Diabetes, 40, 1228–1232. Djurhuus, C.B., Gravholt, C.H., Nielsen, S., Mengel, A., Christiansen, J.S., Schmitz, O.E., and Moller, N. (2002) Effects of cortisol and lipolysis on regional interstitial glycerol levels in
163
164
165
166
167
168
169
170
humans. Am. J. Physiol. Endocrinol. Metab., 283, E172–E177. Ottoson, M., L€ onnroth, P., Bj€ orntorp, P., and Eden, S. (2000) Effects of cortisol and growth hormone on lipolysis in human adipose tissue. J. Clin. Endocrinol. Metab., 85, 799–803. Djuurhus, C.B., Gravholt, C.H., Nielsen, S., Pedersen, S.B., Moller, N., and Schmitz, O. (2003) Additive effects of cortisol and growth hormone on regional and systemic lipolysis in humans. Am. J. Physiol. Endocrinol. Metab., 286, E488–E494. Hefferman, M.A., Jiang, W.J., Thorburn, A.W., and Ng, F.M. (2000) Effects of oral administration of a synthetic fragment of human growth hormone on lipid metabolism. Am. J. Physiol. Endocrinol. Metab., 279, E501–507. Pedersen, B.K. and Fischer, C.P. (2007) Beneficial health effects of exercise – the role of IL-6 as a myokine. Trends Pharmacol. Sci., 28, 152–156. Mohamed-Ali, V., Goodrick, S., Rawesh, A., Katz, D.R., Miles, J.M., Yudkin, J.S., Klein, S., and Coppack, S.W. (1997) Subcutaneous adipose tissue releases interleukin-6 but not tumor necrosis factor-a, in vivo. J. Clin. Endocrinol. Metab., 82, 4196–4200. Bastard, J.-P., Jardel, C., Bruckert, E., Blondy, P., Capeau, J., Laville, M., Vidal, H., and Hainque, B. (2000) Elevated levels of interleukin-6 are reduced in serum and subcutaneous adipose tissue of obese women after weight loss. J. Clin. Endocrinol. Metab., 85, 3338–3342. Bastard, J.-P., Maachi, M., Nhieu, J.T.V., Jardel, C., Bruckert, E., Grimaldi, A., Robert, J.-J. Capeau, J. et al. (2002) Adipose tissue IL-6 content correlates with resistance to insulin activation of glucose uptake both in vivo and in vitro. J. Clin. Endocrinol. Metab., 87, 2084–2089. P€ath, G., Bornstein, S.R., Gurniak, M., Chrousos, G.P., Scherbaum, W.A., and Hauner, H. (2001) Human breast adipocytes express interleukin-6 (IL-6) and its receptor system: increased IL-6 production by beta-adrenergic activation
j177
j 9 Signaling Pathways Controlling Lipolysis and Lipid Mobilization in Humans
178
171
172
173
174
175
176
177
178
179
and effects of IL-6 on adipocyte function. J. Clin. Endocrinol. Metab., 86, 2281–2288. Lagathu, C., Bastard, J.-P., Auclair, M., Maachi, M., Capeau, J., and Caron, M. (2003) Chronic interleukin-6 (IL-6) treatment increased IL-6 secretion and induced insulin resistance in adipocyte: prevention by rosiglitazone. Biochem. Biophys. Res. Commun., 311, 372–379. Rotter, V., Nagaev, I., and Smith, U. (2003) Interleukin-6 (IL-6) induces insulin resistance in 3T3-L1 adipocytes and is, like IL-8 and tumor necrosis factor-a, overexpressed in human fat cells from insulin resistant subjects. J. Biol. Chem., 278, 45777–45784. van Hall, G., Steenberg, A., Sacchetti, M., Fisher, C., Keller, C., Schjerling, P., Hiscock, N. Moller, H. et al. (2003) Interleukin-6 stimulates lipolysis and fat oxidation in humans. J. Clin. Endocrinol. Metab., 88, 3005–3010. Jensen, M.D. (2003) Cytokine regulation of lipolysis in humans? J. Clin. Endocrinol. Metab., 88, 3003–3004. Kawakami, M., Murase, T., Igawa, H., Ishibashi, S., Mori, N., Takagu, F., and Shibata, S. (1987) Human recombinant TNF suppresses lipoprotein lipase activity and stimulates lipolysis in 3T3-L1 cells. J. Biochem., 101, 331–338. Hauner, H., Petruschke, T., Russ, M., R€ohrig, K., and Eckel, J. (1995) Effects of tumor necrosis factor alpha (TNFa) on glucose transport and lipid metabolism of newly differentiated human fat cells in culture. Diabetologia, 38, 764–771. Sethi, J., Xu, H., Uysal, K., Wiesbrock, S., Scheja, L., and Hotamisligil, G. (2000) Characterisation of receptor-specific TNFa functions in adipocyte cell lines lacking type 1 and 2 TNF receptors. FEBS Lett., 469, 77–82. Xu, H. and Hotamisligil, G.S. (2001) Signaling pathways utilized by tumor necrosis factor receptor-1 in adipocytes to suppress differentiation. FEBS Lett., 506, 97–102. Engelman, J.A., Berg, A.H., Lewis, R.Y., Lisanti, M.P., and Scherer, P.E. (2000) Tumor necrosis factor alpha-mediated insulin resistance, but not dedifferentiation, is abrogated by MEK1/
180
181
182
183
184
185
186
187
2 inhibitors in 3T3-L1 adipocytes. Mol Endocrinol., 14, 1557–1569. Fujishiro, M., Gotoh, Y., Katagiri, H., Sakoda, H., Ogihara, T., Anai, M., Onishi, Y. Ono, H. et al. (2003) Three mitogenactivated protein kinases inhibit insulin signaling by different mechanisms in 3T3-L1 adipocytes. Mol Endocrinol., 17, 487–497. Ryden, M., Dicker, A., Harmelen, V.V., Hauner, H., Brunnberg, M., Perbeck, L., L€ onnqvist, F., and Arner, P. (2002) Mapping of early signaling events in tumor necrosis-alpha-mediated lipolysis in human fat cells. J. Biol. Chem., 277, 1085–1091. Gasic, S. and Green, A. (1995) Gi Downregulation and heterologous desensitization in adipocytes after treatment with the a2-agonist UK14304. Biochem. Pharmacol., 49, 785–790. Botion, L.M., Brasier, A.R., Tian, B., Udupi, V., and Green, A. (2001) Inhibition of proteasome activity blocks the ability of TNF alpha to down-regulate Gi proteins and stimulate lipolysis. Endocrinology, 142, 5069–5075. Ryden, M., Arvidsson, E., Blomqvist, L., Perbeck, L., Dicker, A., and Arner, P. (2004) Targets for TNF-alpha-induced lipolysis in human adipocytes. Biochem. Biophys. Res. Commun., 318, 168–175. Souza, S.C., Vargas, L.M.d., Yamamoto, M.T., Lien, P., Franciosa, M.D., Moss, L.G., and Greenberg, A.S. (1998) Overexpression of perilipin A and B blocks the ability of tumor necrosis factora to increase lipolysis in 3T3-L1 adipocytes. J. Biol. Chem., 273, 24665–24669. Souza, S.C., Palmer, H.J., Kang, Y.-H., Yamamoto, M.T., Muliro, K.V., Paulson, K.E., and Greenberg, A.S. (2003) TNF-a induction of lipolysis is mediated through activation of the extracellular signal related kinase pathway in 3T3-L1 adipocytes. J. Cell. Biochem., 89, 1077–1086. Zhang, H.H., Halbleib, M., Ahmad, F., Manganiello, V.C., and Greenberg, A.S. (2002) Tumor necrosis factor-a stimulates lipolysis in differentiated
References
188
189
190
191
192
human adipocytes through activation of extracellular signal-related kinase and elevation of intracellular cAMP. Diabetes, 51, 2929–2935. Sinha, T.K., Thajchayapong, P., Queener, S.F., Allen, D.O., and Bell, N.H. (1976) On the lipolytic action of parathyroid hormone in man. Metabolism, 25, 251–260. Taniguchi, A., Kataoka, K., Kono, T., Oseko, F., Okuda, H., Nagata, I., and Imura, H. (1987) Parathyroid hormone-induced lipolysis in human adipose tissue. J. Lipid Res., 28, 490–494. Bousquet-Melou, A., Galitzky, J., Lafontan, M., and Berlan, M. (1995) Control of lipolysis in intra-abdominal fat cells of non-human primates: comparison with humans. J. Lipid Res., 36, 451–461. Bertin, E.P.A., Bolinder, J., and Hagstrom-Toft, E. (2001) Action of glucagon and glucagon-like peptide-1(7–36) amide on lipolysis in human subcutaneous adipose tissue and skelatl muscle in vivo. J. Clin. Endocrinol. Metab., 86, 1229–1234. Gravholt, C., Moller, N., Jensen, M., Christiansen, J., and Schmitz, O. (2001) Physiological levels of glucagon do not influence lipolysis in abdominal adipose tissue as assessed by microdialysis. J. Clin. Endocrinol. Metab., 86, 2085–2089.
193 Siegrest-Kaiser, C.A., Pauli, V., Juge-
194
195
196
197
198
Aubry, C.E., Boss, O., Pernin, A., Chin, W.W., Cusin, I. Rohner-Jeanrenaud, F. et al. (1997) Direct effects of leptin on brown and white adipose tissues. J. Clin. Invest., 100, 2858–2864. Eliman, A., Kamel, A., and Marcus, C. (2002) In vitro effects of leptin on human adipocyte metabolism. Horm. Res., 58, 88–93. Groundwater, M., Bulcavage, L., Barton, C., Adamson, C., Ferrier, I., and Tisdale, M. (1990) Alteration of serum and urinary lipolytic activity with weight loss in cachectic cancer patients. Br. J. Cancer, 62, 816–821. Sanchez, L.M., Chirino, A.J., and Bjorkman, P.J. (1999) Crystal structure of human ZAG, a fat-depleting factor related to MHC molecules. Science, 283, 1914–1919. Bing, C., Bao, Y., Sanders, P., Manieri, M., Cinti, S., Tisdale, M.J., and Trayhurn, P. (2004) Zinc-a2-glycoprotein, a lipid mobilizing factor, is expressed in adipocytes and is up-regulated in mice with cancer cachexia. Proc. Natl. Acad. Sci. USA, 101, 2500–2505. Bao, Y., Bing, C., Hunter, L., Jenkins, J.R., Wabitsch, M., and Trayhurn, P. (2005) Zinc-alpha2-glycoprotein, a lipid mobilizing factor, is expressed and secreted by human (SGBS) adipocytes. FEBS Lett., 579, 41–47.
j179
Part Three Endocrine Functions of Adipose Tissue
j183
10 Leptin Secretion and Action Robert V. Considine 10.1 Introduction
As discussed in several chapters in this book, adipose tissue is an active endocrine organ releasing a varied array of metabolites, hormones, cytokines, and other factors. Although the potential for adipose tissue to act in an endocrine manner to regulate energy intake was suggested by Kennedy over 65 years ago [1], it was the discovery of leptin synthesis and release [2] that focused and accelerated investigation into the endocrine function of adipose tissue. Shortly following the discovery of adipose tissue leptin synthesis, a number of laboratories demonstrated that recombinant leptin inhibited food intake and caused weight loss in mice (reviewed in detail in [3]). A receptor for leptin was found in the hypothalamus and a point mutation within the gene implicated as the defect resulting in obesity in db/db mice [4, 5]. Taken together, these observations, as well as numerous other related findings, have established a major role for leptin in regulation of body weight. Further, studies to understand the central neural pathways responsive to leptin have provided extensive insight into the hypothalamic regulation of energy intake and energy expenditure. Defects in leptin synthesis and signaling such as found in ob/ob and db/db mice are rarely the cause of obesity in humans [6]. In contrast, human obesity is characterized by elevated serum leptin levels (hyperleptinemia) and resistance to the appetitesuppressing effect of leptin. Evidence suggests that hyperleptinemia contributes to obesity-related hypertension and other comorbidities. This chapter reviews the synthesis of leptin and its actions in the central nervous system. The concept of leptin resistance is discussed, as is evidence for the contribution of selective leptin resistance to development of comorbidities in obesity. The use of leptin to induce weight loss or to ameliorate the metabolic abnormalities associated with lipodystrophy are also reviewed.
j 10 Leptin Secretion and Action
184
Figure 10.1 Serum leptin is determined by adiposity and is significantly reduced with weight loss. Serum leptin levels were measured in 10 women and 10 men before and 6 months after Roux-en-Y bariatric surgery. BMI was
significantly decreased 33.1 2.3% (56.3 to 36.1 kg/m2) in the men and 32.3 1.6% (46.4 1.0 to 8.9 2.8 kg/m2) in the women 6 months postsurgery.
10.2 Leptin Synthesis
Circulating leptin concentrations are highly positively correlated with adiposity, measured as body mass index (BMI), percent body fat, or fat mass (kg), in humans and also in rodent models [7]. As a consequence of the strong correlation between body fat and serum leptin, changes in adiposity result in changes in serum leptin. As shown in Figure 10.1, the reduction in fat mass following bariatric surgery is associated with a significant decrease in serum leptin. An increase in adipose tissue during weight gain results in greater serum leptin [8]. These observations provide support for the concept that leptin is a signal of the size of energy stores in the body. Despite the strong correlation between serum leptin and fat mass in general population studies there is a considerable degree of variation in serum leptin at any given fat mass. Factors that contribute to the variation in serum leptin are gender, differential distribution of adipose tissue into the visceral or subcutaneous depots, and insulin/glucose metabolism. 10.2.1 Gender and Body Fat Distribution Determine Serum Leptin
Women have significantly higher serum leptin concentrations than men with an equivalent amount of body fat [9]. One factor contributing to this difference is the deposition of body fat into different adipose tissue depots. Women have greater amounts of subcutaneous adipose tissue than men, who tend to have greater visceral
10.2 Leptin Synthesis
adipose tissue mass, particularly when obese. Leptin gene (LEP) expression and leptin secretion are greater from subcutaneous than visceral adipocytes (reviewed in [7]), thus more leptin is released into the blood from the greater subcutaneous adipose tissue mass in women. Gondal steroids also contribute to greater serum leptin in women. In vivo and in vitro studies have suggested that testosterone and estrogens can regulate leptin synthesis and release from adipose tissue independently of their effects to influence deposition of adipose tissue into the subcutaneous or visceral depots. In general, androgens reduce, and estrogens increase, leptin synthesis in adipose tissue [9]. A suppressive effect of testosterone on serum leptin is supported by studies of pubertal development in males, in whom serum leptin levels decrease as testosterone increases [10]. Further, administration of testosterone lowers serum leptin in hypogonadal men [11, 12] and in female-to-male transsexuals [13]. In vitro, exposure to dihydrotestosterone for 48 h decreases leptin secretion from visceral adipose tissue pieces [14, 15]. Evidence for a stimulatory effect of estrogen on serum leptin are observations that estrogen therapy (along with antiandrogens) increases leptin in male-to-female transsexuals [13] and that estradiol stimulates leptin secretion from visceral adipose tissue pieces in vitro [14, 15]. The mechanism(s) through which gonadal steroids directly regulate leptin synthesis and release from adipocytes remain to be fully elucidated. 10.2.2 Caloric Intake, Insulin, and Glucose Influence Serum Leptin
Serum leptin measured in the morning following an overnight fast tends to be fairly constant from day to day. However, over a 24-h period serum leptin exhibits a diurnal pattern with a peak at around 0200 h in both lean and obese individuals [16, 17]. If meal times are shifted by 6 h such that dinner is eaten at 2400 h instead of 1800 h, the peak in leptin is also shifted by 6 h. Further, complete day/night reversal results in peak leptin occurring at 1400 h [17]. These observations suggest that the leptin peak is entrained to food intake, and the requisite increase in insulin and glucose that accompanies eating. Additional evidence for insulin and glucose regulating serum leptin is provided by the finding that hyperinsulinemic/ euglycemic clamps of differing duration increase serum leptin [18, 19] and that feeding high fat/low carbohydrate meals, which result in smaller postprandial excursions in insulin and glucose than meals of standard carbohydrate content, reduce serum leptin [20]. Hexosamine (UDP-GlcNAc) biosynthesis in adipocytes has been suggested as a mechanism through which insulin and glucose regulate leptin synthesis. An increase in adipose tissue UDP-GlcNAc with infusion of glucosamine, uridine, or free fatty acids during a hyperinsulinemic/euglycemic clamp in rats was associated with an increase in serum leptin [21]. Transgenic mice with elevated adipose tissue hexosamine biosynthesis due to overexpression of the rate-limiting enzyme in UDP-GlcNAc biosynthesis have elevated Lep mRNA and serum leptin [22]. In obese humans subcutaneous adipose tissue UDP-GlcNAc is elevated 3.2-fold, and a
j185
j 10 Leptin Secretion and Action
186
significant positive correlation between BMI and adipose tissue UDP-GlcNAc has been reported [23]. Further, increasing UDP-GlcNAc synthesis in human subcutaneous adipocytes in vitro stimulates leptin release and reducing UDP-GlcNAc decreases leptin secretion [23]. As described above, serum leptin measured after an overnight fast is fairly constant from day to day. However, a rapid decrease in serum leptin levels with short-term fasting (24–72 h) has been observed in both animals [24] and humans [25–27]. Leptin levels rise again with refeeding, and the fall in leptin can be blocked by maintenance of blood sugar at approximately 90 mg/dl during the fasting period [25, 26]. The rapid fall in leptin with fasting is disproportionately greater than the small reduction in adipose tissue mass that occurs over the same time period. Thus, it has been suggested that the fall in leptin with fasting is a signal to the central nervous system that coordinates the hypothalamic neuroendocrine response to caloric deprivation [28]. Evidence that leptin coordinates the neuroendocrine response to fasting was originally derived through replacement experiments in rodents [24]. In 48-h fasted mice, thyroid and reproductive hormone levels are reduced, and glucocortiocoids increased. These neuroendocrine adaptations occur to promote survival by reducing energy expenditure and managing the stress of caloric deprivation. Preventing the starvation-induced fall in leptin, by administration of recombinant leptin to achieve levels similar to the fed state, substantially blunted the reduction in gonadal and thyroid hormones, and attenuated the increase in glucocorticoids. Chan et al. [27] have demonstrated that replacement of leptin during complete caloric restriction in men can prevent the fasting-induced reduction in testosterone and partially prevent the suppression of the hypothalamic–pituitary–thyroid axis. These observations establish a role for leptin in regulating hypothalamic–pituitary function in response to caloric restriction, in addition to leptins role as a marker of energy stores in the fed state. 10.2.3 Transcriptional Regulation of Leptin Synthesis in Adipocytes
LEP mRNA is greater in large adipocytes than in small adipocytes isolated from the same piece of adipose tissue and leptin secretion strongly correlates with fat cell volume [29–31]. Thus, elevated leptin levels in obese individuals result from both greater secretion from larger adipocytes and an increased number of adipocytes. Hexosamine biosynthesis may be one link between adipocyte size and leptin synthesis [23]. Many hormones and cytokines also regulate leptin synthesis when tested in isolation. However, the effects of tumor necrosis factor (TNF)-a and cortisol have been the best studied and appear to be relevant in vivo. TNF-a, which is elevated in the adipose tissue of obese subjects, inhibits leptin release from cultured rodent and human adipocytes [32, 33]. Cortisol stimulates leptin synthesis and secretion from adipocytes in vivo and in vitro (e.g., [34, 35]). Synthesis of cortisol by 11b-hydroxysteroid dehydrogenase in the adipose tissue itself [36] likely regulates leptin secretion in a paracrine manner.
10.4 Leptin Action in the Central Nervous System
10.3 Leptin Receptors
The leptin receptor is present in almost all tissues examined. The best-studied isoform, the hypothalamic leptin receptor Ob-Rb, is a class I cytokine receptor. Leptin binding to Ob-Rb promotes Janus kinase (JAK)-dependent signaling through signal transducer and activator of transcription (STAT) proteins, primarily STAT-3. This leptin receptor has also been observed to activate phosphoinositol-3-kinase and phosphodiesterase 3B signaling pathways in the hypothalamus, although the role of JAK and STAT proteins in this process is not fully understood [37–39]. Ob-Ra (originally termed the short leptin receptor) is the other major isoform of leptin receptor, which is derived by alternative splicing of the LEPR gene. The extracellular domains of Ob-Ra and Ob-Rb are identical; however, the intracellular domain of Ob-Ra is truncated and lacks the structural motifs to initiate JAK–STAT signaling. Ob-Ra is highly expressed in cerebral microvessels comprising the blood–brain barrier where it functions to transport leptin from the blood to the brain [40]. Expression of Ob-Rb mRNA is greatest in the hypothalamus and strong evidence supports the concept that this receptor isoform signals for leptin action within the central nervous system [41]. In contrast, expression of Ob-Ra is more readily detectable than is Ob-Rb in non-neural tissue. This significant difference in expression levels must be taken into consideration when interpreting effects of leptin elicited by direct interaction of the hormone with tissues and cells. However, based on observations in leptin receptor transfected cells, it appears that limited expression of Ob-Rb is sufficient to provide competent leptin signaling [42].
10.4 Leptin Action in the Central Nervous System
Within the hypothalamus Ob-Rb is highly expressed in the arcuate, paraventricular, ventromedial, and dorsomedial nuclei [41, 43]. Leptin signaling in the hypothalamus is primarily mediated by two leptin-responsive populations of neurons present in the arcuate nucleus (Figure 10.2). One group of neurons express pro-opiomelanocortin (POMC), which is processed to a-melanocyte-stimulating hormone (MSH), and cocaine- and amphetamine-regulated transcript (CART). a-MSH and CART inhibit food intake and promote weight loss in a leptin-responsive manner. The second population of neurons contain both neuropeptide Y (NPY) and agouti-related peptide (AGRP). NPY and AGRP stimulate feeding and are inhibited by leptin [43]. The leptin-responsive neurons present in the arcuate nucleus innervate other hypothalamic areas, including the paraventricular nucleus (PVN), perifornical area (PFA), and lateral hypothalamic area (LHA), which contain secondary neurons that express different neuropeptides that regulate food intake [44]. The presence of leptin receptors in the PVN, PFA, and LHA suggests that leptin may regulate food intake or other processes through mechanisms initiated independent of the arcuate
j187
j 10 Leptin Secretion and Action
188
Cerebral Cortex
PVN DMH
Parasympathetic VMH ARC
NPY AGRP
LHA
and Sympathetic
αMSH
PBN
+
LEPTIN
ME NTS
LEPTIN
Pituitary Stalk
LEPTIN
Figure 10.2 Schematic drawing of the hypothalamus and brainstem in sagittal section illustrating leptin signal pathways. Leptin enters the hypothalamus through the median eminence (ME), but can also access other areas of the brain via transport across the blood–brain barrier. In the arcuate nucleus (ARC) leptin activates neurons containing a-MSH and CART, which inhibit feeding. Leptin also binds to arcuate neurons expressing NPY and AGRP, and inhibits release of these orexigenic peptide neurotransmitters. Leptin-responsive neurons in the arcuate nucleus project to the PVN and the LHA for integration with other neural signals. The effects of leptin signaling in the
hypothalamus are then relayed to the body via parasympathetic and sympathetic neurons. Hypothalamic leptin receptors (black semicircle) are also present in the dorsomedial (DMH) and ventromedial (VMH) nuclei, PVN, and LHA. Leptin receptors have also been detected in hindbrain structures such as the NTS, which receives chemosensory and mechanosensory input from the gut about meal size. Leptin may regulate NTS activity to influence meal size via descending connections from the hypothalamus or by directly binding to its receptor in this nucleus. (Figure modified with permission from [41].)
nucleus. In support of this concept, POMC neuron-specific leptin receptor knockout mice exhibit only modest increases in body weight [45], suggesting that leptin receptors located on neurons other than arcuate POMC neurons are important in body weight homeostasis. Gastrointestinal signals (mechanosensory, chemosesory, and hormonal) are the principal determinants of meal size. These neural signals are first processed in the nucleus of the solitary tract (NTS) and parabrachial nucleus located in the dorsal medulla [46]. Recently, investigators have begun to focus in detail on the ability of leptin to regulate neuronal activity in the NTS. Reconstitution of viable leptin receptors in the arcuate nucleus of leptin receptor-deficient Koletsky rats suggests that leptin acts in the hypothalamus to regulate NTS activity via descending projections [47]. However, leptin receptors have been detected in the NTS and injection of leptin directly into this nucleus inhibits feeding [48], suggesting leptin may directly signal in the hindbrain. Leptin could access the NTS from the blood via the
10.5 Leptin Resistance in Obesity
fenestrated capillaries of the adjacent area postrema [49]. Further work is necessary to fully understand leptin signaling in the hindbrain. In addition to reducing food intake, leptin has also been shown to increase energy expenditure via hypothalamic mechanisms. Leptin-induced weight loss in ob/ob mice results from an increase in oxygen consumption, body temperature, and locomotor activity, in addition to the reduction in food intake [50]. There is little evidence that leptin alters locomotor activity or increases body temperature when administered to lean or obese mice in which leptin synthesis is not genetically blocked. However, leptin administration to lean and obese rodents does increase sympathetic nerve activity to thermogenic brown adipose tissue, as well as nonthermogenic tissues including the kidney and adrenals [51]. Leptin activation of the sympathetic nervous system likely has a pathologic role in obesity-related hypertension, as discussed in detail in Section 10.6.1.
10.5 Leptin Resistance in Obesity
Mutations in both leptin [2] and the leptin receptor [4, 5] result in obesity in rodent models. However, inactivating mutations in the human LEP or LEPR gene causing obesity are extremely rare and have been identified in only a handful of families [6]. Rather, serum leptin levels are elevated in obese individuals due to the greater amount of adipose tissue. Thus, the concept of leptin resistance, in analogy to insulin resistance, was proposed to explain the observation that elevated leptin levels did not reduce food intake or prevent body weight gain in obese humans [3]. Several molecular possibilities have been put forth to explain the mechanism of leptin resistance. In rodents, consumption of a high-fat diet decreases the weight loss response to peripherally injected leptin by impairing Ob-Ra-mediated transport of leptin across the blood–brain barrier [52, 53]. Although defective leptin transport occurs in this model, the extent to which this defect contributes to leptin resistance is not entirely clear considering that the arcuate nucleus is located very near the median eminence where Ob-Ra-facilitated leptin transport may not be necessary for leptin access. A second mechanism for leptin resistance involves suppressors of cytokine signaling (SOCS) – a group of early genes activated by the JAK–STAT signal transduction pathway that act in a negative feedback loop to limit cytokine signaling. SOCS-3 is a potent inhibitor of leptin receptor-initiated JAK–STAT signaling in cultured cell lines and SOCS-3 mRNA in the hypothalamus is increased by leptin treatment [54]. Agouti mice are resistant to the appetite curbing effects of central leptin administration and SOCS-3 mRNA is elevated in leptin-responsive arcuate neurons in these mice, suggesting that increased SOCS-3 expression is a cause of leptin resistance in these animals [54]. Of importance, it appears that leptin resistance can exhibit a distinct anatomic distribution. Defective leptin-stimulated STAT3 phosphorylation can be demonstrated in the arcuate nucleus at the same time that other hypothalamic and extrahypothalamic sites (see Figure 10.1) remain leptinsensitive [55]. The selective anatomic distribution of resistance to leptin signaling in
j189
j 10 Leptin Secretion and Action
190
the hypothalamus is of particular importance in understanding the effects of leptin on blood pressure. A third molecular mechanism for leptin resistance may involve the activity of protein tyrosine phosphatase (PTP)-1B. In Cos-7 cells expressing leptin receptor, coexpression of PTP-1B inhibits tyrosyl phosphorylation of JAK-2 and STAT-3. In contrast, fibroblasts engineered to express leptin receptor but lacking PTP-1B have enhanced leptin signaling [56]. PTP-1B knockout animals are resistant to obesity and exhibit enhanced leptin-induced hypothalamic STAT-3 phosphorylation [56, 57], suggesting that PTP1-B can regulate neuronal leptin signaling in vivo.
10.6 Metabolic Complications of Hyperleptinemia in Obesity
As discussed above, the concept of leptin resistance was originally proposed to explain the observation that elevated leptin did not reduce food intake or prevent body weight gain in obese humans. However, it is now recognized that resistance to leptin action may be primarily centered within the neuronal pathways regulating food intake and that other leptin-responsive processes remain intact in the obese state. Thus, hyperleptinemia resulting from leptin resistance within pathways regulating energy intake can have pathologic effects on other regulatory systems and contribute to the metabolic complications of obesity. 10.6.1 Leptin and Obesity-Related Hypertension
Leptin promotes weight loss in rodents via sympathetic activation of brown adipose tissue and oxidation of fatty acids. Leptin signaling in the central nervous system also increases the activity of renal, lumbar, hindlimb, and adrenal gland sympathetic nerves. Sympathoactivation with either intracerebroventricular or chronic intravenous leptin administration has been demonstrated to increase mean arterial blood pressure and heart rate in a number of rodent studies [51]. Furthermore, arterial blood pressure in leptin-deficient ob/ob mice, which is lower than in wild-type littermates, is substantially increased with leptin treatment. In contrast, obese hyperleptinemic agouti mice and transgenic skinny hepatic-leptin-overexpressing mice both have elevated blood pressure [58]. Although inhibition of food intake by leptin is impaired in obese agouti mice, the leptin-induced increase in renal sympathetic nerve activity is not different in agouti mice and their lean littermates [59, 60]. Finally, in high-fat-fed mice the effect of intraperitoneal or intracerebroventricular leptin to decrease food intake and body weight was impaired, but leptin-induced renal sympathetic nerve activity was preserved [61]. Taken together, these observations demonstrate that leptin regulates blood pressure via sympathetic activation and that hyperleptinemia in obesity can result in hypertension. Further, leptin regulation of blood pressure via stimulation of renal sympathetic nerve activity appears to be
10.6 Metabolic Complications of Hyperleptinemia in Obesity
intact in the presence of resistance to the weight reducing effects of the hormone, supporting the concept of selective central leptin resistance in obesity. Leptin regulates sympathetic nerve activity via a-MSH and the melanocortin-4 receptor (MC-4R). The MC-4R receptor antagonist SHU-9119 blocks both acute and chronic effects of leptin to stimulate renal sympathetic nerve activity and heart rate [62–65]. However, MC-4R antagonism has also been shown to block leptin effects on food intake and body weight [62, 66], implying that the same neural pathway mediates both the metabolic and sympathetic effects of leptin. How can such an observation be reconciled with the finding of leptin resistance in metabolic pathways but leptin sensitivity in sympathetic pathways? One possibility is that resistance to the metabolic effects of leptin is not mediated by melanocortin signaling. As discussed in Section 10.4, POMC neuron-specific leptin receptor knockout only results in mild obesity, implicating other neural pathways in leptin regulation of food intake, possibly where leptin resistance could be focused. Alternatively, it is possible that leptin engages MC-4R signaling for both metabolic and sympathetic effects, but that the anatomic location of the neurons mediating each response is different. With intracerebroventricular administration of SHU9119 into the third ventricle it is not possible to determine if antagonism of MC-4R function blocks the sympathetic or metabolic responses to leptin via the same hypothalamic nuclei. In support of the idea that other hypothalamic nuclei may be engaged by leptin, a recent study has shown that injection of leptin into the ventromedial and dorsomedial hypothalamus can increase renal sympathetic activity, arterial pressure, and heart rate [67]. These hypothalamic nuclei have previously been shown to express normal leptin sensitivity in the presence of leptin resistance in the arcuate nucleus [55]. Evidence against the hypothesis of separate nuclei for the metabolic and sympathetic effects of leptin is provided by a recent report demonstrating that injection of leptin directly into the arcuate nucleus of normal rats increased renal sympathetic nerve activity [68]. While illustrating the central role of the arcuate nucleus in the metabolic and sympathetic effects of leptin, this study did not directly address the contribution of other nuclei in mediating the sympathetic effects of leptin in obese leptin-resistant animals. Thus, the exact mechanism(s) that provide for selective leptin resistance and maintenance of leptin-derived sympathetic effects remain to be fully elucidated. 10.6.2 Other Possible Pathologic Effects of Leptin
Elevated leptin levels in obese humans have been suggested to increase risk of thrombosis, and to contribute to key aspects of atherogenesis. However, as recently reviewed [69], these consequences of hyperleptinemia are highly debated with many studies finding no effect of leptin on thrombosis and atherogenesis. Additional work, with careful attention to the concentration of leptin used, will be needed to determine if leptin has a role in the pathophysiology of these vascular complications in obesity.
j191
j 10 Leptin Secretion and Action
192
10.7 Leptin Therapy in Humans
Early observations that leptin treatment resulted in substantial weight loss in rodents suggested that the hormone might be useful in treating human obesity. However, the ability of leptin to mediate weight loss in obese, leptin-resistant humans has been modest. In contrast, leptin has been found to be a useful therapeutic in states of human leptin deficiency. 10.7.1 Leptin, Weight Loss, and Human Obesity
Two clinical trials have been conducted to test the therapeutic potential of recombinant leptin in treating common obesity. In the first trial daily leptin administration resulted in modest weight loss after 24 weeks of treatment in a group of lean and obese subjects [70]. Weight loss was highly variable by subject, but in general higher doses of recombinant leptin caused greater weight loss. In a second trial of obese men only, pegylated recombinant leptin caused a reduction in appetite, but no significant decrease in body weight with 12 weeks of therapy [71]. An important consideration in this second study is that serum leptin levels were only elevated at two timepoints over the 12-week treatment period, suggesting that weight loss was not achieved because the leptin dose was not high enough. However, taken together, these two studies suggest that leptin can stimulate weight loss in humans if a sufficient dose can be given that does not evoke significant side-effects. Structural analogs or modifications to the hormone may lead to an improved pharmacology with regard to weight loss in generalized obesity. 10.7.2 Congenital Leptin Deficiency
Defects in the LEP gene resulting in human obesity have been identified in five different kindreds. The first two cases to be identified, an 8-year-old girl weighing 86 kg and a 2-year-old boy weighing 29 kg, were cousins in a highly consanguineous Pakastani family [72]. The LEP gene in these children contained a homozygous frameshift mutation resulting from deletion of a single guanine nucleotide in codon 133, resulting in a truncated leptin protein that is not secreted [73]. This same mutation was subsequently found in four other individuals from three different unrelated families of Pakistani origin [74]. Leptin therapy in three of the children with congenital leptin deficiency has resulted in significant and sustained loss of body fat. Beneficial effects on appetite, hyperinsulinemia, hyperlipidemia, and immune cell number have also been observed. Leptin therapy also facilitated appropriately timed pubertal development [74]. Leptin deficiency has also been described in four members of a Turkish kindred [75, 76]. In this family a C ! Tsubstitution, changing arginine at position 105 to
10.7 Leptin Therapy in Humans
a tryptophan, impairs leptin secretion. All subjects were hyperphagic and severely obese. In addition, the three adults had hypothalamic hypogonadism. Leptin treatment in the three adults resulted in significant weight loss and, in the one subject with diabetes, an improvement in hyperinsulinemia [77]. Overall, these findings strongly support a role for leptin to reduce obesity and improve metabolism in individuals with congenital leptin deficiency. 10.7.3 Lipodystrophic Leptin Deficiency
Lipodystrophy, a partial or complete loss of adipose tissue, results in hyperphagia, insulin resistance, diabetes, hypertriglyceridemia, nonalcoholic hepatic steatosis, and low leptin levels [78]. Leptin replacement therapy in lipodystrophic animal models improved a number of the metabolic abnormalities resulting from the lack of adipose tissue [79, 80], supporting its use in humans. Leptin administration to lipodystrophic patients improves insulin resistance, lowers hemoglobin A1c, and decreases fasting serum triglycerides [81, 82]. Liver and muscle lipid content is significantly reduced with leptin treatment [82–84] as are semiquantitative scores of nonalcoholic steatohepatitis [85]. Animal studies suggest that leptin stimulates fatty acid oxidation in liver and muscle, thus improving insulin sensitivity of these tissues [86, 87]. Highly active antiretroviral therapy (HAART) for HIV-1 infection has been associated with insulin resistance, hyperlipidemia, and lipodystrophy [88]. Lee et al. hypothesized that the relative leptin deficiency in lipodystrophic HAARTtreated subjects might contribute to their insulin resistance and other metabolic abnormalities [89]. Leptin therapy in seven HIV þ men with HAART-induced lipoatrophy improved insulin resistance and high-density lipoprotein. Body weight and fat mass decreased with treatment due to a reduction in central trunk fat. Leptin may therefore be of use in treating the metabolic abnormalities associated with HAART treatment. 10.7.4 Hypothalamic Amenorrhea
Functional hypothalamic amenorrhea occurs when a relative energy deficit due to weight loss, excessive exercise, or eating disorders disrupts the secretion of hypothalamic gonadotropin-releasing hormone, resulting in the absence of menstrual cycles, low estrogen levels, and low or normal levels of gonadotropins [90]. Due to the limited amount of adipose tissue, leptin levels are low in women with hypothalamic amenorrhea [91]. In eight women with hypothalamic amenorrhea leptin treatment increased mean luteinizing hormone levels, luteinizing hormone pulse frequency, and estradiol, and improved a number of measures of ovarian function [92]. Leptin therapy also increased insulin-like growth factor-1, insulin-like growth factor-binding protein-3, bone alkaline phosphatase, and osteocalcin, suggesting that leptin had beneficial effects on bone metabolism in these subjects.
j193
j 10 Leptin Secretion and Action
194
10.8 Conclusions
Leptin is synthesized and released into the circulation in proportion to the amount of body fat, gender, and distribution of body fat into the subcutaneous or visceral depots. Elevated serum leptin in obesity results from the greater fat mass in the body and greater leptin synthesis in adipocytes of obese subjects. Adipocyte size, hexosamine biosynthesis mediated by insulin-stimulated glucose uptake, and elevated production of cortisol in adipose tissue all contribute to the increase in leptin synthesis by adipocytes in obesity. Leptin acts in the brain to regulate food intake and energy expenditure. Hypothalamic leptin signal pathways are the best understood at present, but intriguing work on leptin action in the hindbrain is now emerging. Resistance to leptin in the hypothalamus has been suggested to explain the observation that elevated leptin levels in obesity do not reduce food intake or body weight. However, leptin resistance in the central nervous system appears to be selective, with leptininduced activation of the sympathetic nervous system intact and contributing to hypertension in obese subjects. Recombinant leptin administration is an effective therapeutic for the metabolic complications of congenital or relative hypoleptinemia and leptin has some limited efficacy as an antiobesity agent in subjects with general obesity. Future work is needed to better understand the effect of leptin to regulate the activity of the NTS to modify meal size. Administration of leptin in combination with gut hormones (glucagon-like peptide-1, peptide YY, and amylin) may prove to be more effective in mediating weight loss than using leptin alone.
Acknowledgments
Work of the authors cited in this chapter was supported in part by grants from the NIH (DK51 140 and M01 RR00 750 (Indiana University General Clinical Research Center)), the American Diabetes Association, and the Showalter Trust.
References 1 Kennedy, G.C. (1953) The role of depot fat
4 Lee, G.H., Proenca, R., Montez, J.M.,
in the hypothalamic control of food intake in the rat. Proc. R. Soc. B, 140, 578–592. 2 Zhang, Y., Proenca, R., Maffei, R.M., Barone, M., Leopold, L., and Friedman, J.M. (1994) Positional cloning of the mouse obese gene and its human homologue. Nature, 372, 425–432. 3 Caro, J.F. and Considine, R.V. (2004) Leptin: from laboratory to clinic, in Handbook of Obesity: Clinical Applications, 2nd edn (eds G.A. Bray and C. Bouchard), Marcel Dekker, New York.
Carroll, K.M., Darvishzadeh, J.G., Lee, J.I., and Friedman, J.M. (1996) Abnormal splicing of the leptin receptor in diabetic mice. Nature, 379, 632–635. 5 Chen, H., Charlat, O., Tartaglia, L.A., Woolf, E.A., Weng, X., Ellis, S.J., Lakey, N.D., Culpepper, J., Moore, K.J., Breitbart, R.E., Duyk, G.M., Tepper, R.I., and Morgenstern, J.P. (1996) Evidence that the diabetes gene encodes the leptin receptor: identification of a mutation in the leptin
References
6
7
8
9
10
11
12
13
14
receptor gene in db/db mice. Cell, 84, 491–495. Farooqi, I.S. and ORahilly, S. (2005) Monogenic obesity in humans. Annu. Rev. Med., 56, 443–458. Bell, L.N. and Considine, R.V. (2006) Leptin and obesity, in Leptin (eds M.C. Henson and V.D. Castracane), Springer, New York. Kolaczynski, J.W., Ohannesian, J., Considine, R.V., Marco, C., and Caro, J.F. (1996) Response of leptin to short term and prolonged overfeeding in humans. J. Clin. Endocrinol. Metab., 81, 4162–4165. Rosenbaum, M. and Leibel, R.L. (1999) Clinical Review 107. Role of gonadal steroids in the sexual dimorphisms in body composition and circulating concentrations of leptin. J. Clin. Endocrinol. Metab., 84, 1784–1789. Mantzoros, C.S., Flier, J.S., and Rogol, A.D. (1997) A longitudinal assessment of hormonal and physical alterations during normal puberty in boys. V. Rising leptin levels may signal the onset of puberty. J. Clin. Endocrinol. Metab., 82, 1066–1070. Sih, R., Morley, J.E., Kaiser, F.E., Perry, H.M. III, Patrick, P., and Ross, C. (1997) Testosterone replacement in older hypogonadal men: a 12-month randomized controlled trial. J. Clin. Endocrinol. Metab., 82, 1661–1667. Jockenhovel, F., Blum, W.F., Vogel, E., Englaro, P., Muller-Wieland, D., Reinwein, D., Rascher, W., and Krone, W. (1997) Testosterone substitution normalizes elevated serum leptin levels in hypogonadal men. J. Clin. Endocrinol. Metab., 82, 2510–2513. Elbers, J.M., Asscheman, H., Seidell, J.C., Frolich, M., Meinders, A.E., and Gooren, L.J. (1997) Reversal of the sex difference in serum leptin levels upon cross-sex hormone administration in transsexuals. J. Clin. Endocrinol. Metab., 82, 3267–3270. Casabiell, X., Pineiro, V., Peino, R., Lage, M., Camina, J.P., Gallego, R., Vallejo, L.G., Dieguez, C., and Casanueva, F.F. (1998) Gender differences in both spontaneous and stimulated leptin secretion by human omental adipose tissue in vitro:
15
16
17
18
19
20
21
22
23
dexamethasone and estradiol stimulate leptin release in women, but not in men. J. Clin. Endocrinol. Metab., 83, 2149–2155. Pineiro, V., Casabiell, X., Peino, R., Lage, M., Camina, J.P., Menendez, C., Baltar, J., Dieguez, C., and Casanueva, F.F. (1999) Dihydrotestosterone, stanozol, androstenedione and dehydroepiandrosterone sulphate inhibit leptin secretion in female but not male samples of omental adipose tissue in vitro: lack of effect of testosterone. J. Endocrinol., 160, 425–432. Sinha, M.K., Ohannesian, J.P., Heiman, M.L., Kriauciunas, A., Stephens, T.W., Magosin, S., Marco, C., and Caro, J.F. (1996) Nocturnal rise of leptin in lean, obese, and non-insulin-dependent diabetes mellitus subjects. J. Clin. Invest., 97, 1344–1347. Schoeller, D.A., Cella, L.K., Sinha, M.K., and Caro, J.F. (1997) Entrainment of the diurnal rhythm of plasma leptin to meal timing. J. Clin. Invest., 100, 1882–1887. Utriainen, T., Malmstrom, R., Makimattila, S., and Yki-Jarvinen, H. (1996) Supraphysiological hyperinsulinemia increases plasma leptin concentrations after 4 h in normal subjects. Diabetes, 45, 1364–1366. Saad, M.F., Khan, A., Sharma, A., Michael, R., Road-Gabriel, M.G., Boyadjian, R., Jinagouda, S.D., Steil, G.M., and Kamdar, V. (1998) Physiological insulinemia acutely modulates plasma leptin. Diabetes, 47, 544–549. Havel, P.J., Townsend, R., Chaump, L., and Teff, K. (1999) High fat meals reduce 24 h circulating leptin concentration in women. Diabetes, 48, 334–341. Rossetti, L. (2000) Perspective: hexosamines and nutrient sensing. Endocrinology, 141, 1922–1925. McClain, D.A., Alexander, T., Cooksey, R.C., and Considine, R.V. (2000) Hexosamines stimulate leptin production in transgenic mice. Endocrinology, 141, 1999–2002. Considine, R.V., Cooksey, R.C., Williams, L.B., Fawcett, R.L., Zhang, P., Ambrosius, W.T., Whitfield, R.M., Jones, R.M., Inman, M., Huse, J., and McClain, D.A. (2000) Hexosamines regulate leptin production
j195
j 10 Leptin Secretion and Action
196
24
25
26
27
28
29
30
31
32
in human subcutaneous adipocytes. J. Clin. Endocrinol. Metab., 85, 3551–3556. Ahima, R.S., Prabakaran, D., Mantzoros, C., Qu, D., Lowell, B., Maratos-Flier, E., and Flier, J.S. (1996) Role of leptin in the neuroendocrine response to fasting. Nature, 382, 250–252. Kolaczynski, J.W., Considine, R.V., Ohannesian, J., Marco, C., Opentanova, I., Nyce, M.R., Myint, M., and Caro, J.F. (1996) Responses of leptin to short-term fasting and refeeding in humans: a link with ketogenesis but not ketones themselves. Diabetes, 45, 1511–1515. Boden, G., Chen, X., Mozzoli, M., and Ryan, I. (1996) Effect of fasting on serum leptin in normal human subjects. J. Clin. Endocrinol. Metab., 81, 3419–3423. Chan, J.L., Heist, K., DePaoli, A.M., Veldhuis, J.D., and Mantzoros, C.S. (2003) The role of falling leptin levels in the neuroendocrine and metabolic adaptation to short-term starvation in healthy men. J. Clin. Invest., 111, 1409–1421. Flier, J.S. (1998) Whats in a name? In search of leptins physiologic role. J. Clin. Endocrinol. Metab., 83, 1407–1413. Hamilton, B.S., Paglia, D., Kwan, A.Y.M., and Deitel, M. (1995) Increased obese mRNA expression in omental fat cells from massively obese humans. Nat. Med., 1, 953–956. Guo, K.Y., Halo, P., Leibel, R.L., and Zhang, Y. (2004) Effects of obesity on the relationship of leptin mRNA expression and adipocyte size in anatomically distinct fat depots in mice. Am. J. Physiol. Regul. Integr. Comp. Physiol., 287, R112–R119. Lonnqvist, F., Nordfors, L., Jansson, M., Thorne, A., Schalling, M., and Arner, P. (1997) Leptin secretion from adipose tissue of women. Relationship to plasma levels and gene expression. J. Clin. Invest., 99, 2398–2404. Medina, E.A., Stanhope, K.L., Mizuno, T.M., Mobbs, C.V., Gregoire, F., Hubbard, N.E., Erickson, K.L., and Havel, P.J. (1999) Effects of tumor necrosis factor alpha on leptin secretion and gene expression: relationship to changes of glucose metabolism in isolated rat adipocytes. Int. J. Obes. Relat. Metab. Disord., 23, 896–903.
33 Fawcett, R.L., Waechter, A.S., Williams,
34
35
36
37 38 39
40
41
42
43
L.B., Zhang, P., Louie, R., Jones, R.M., Inman, M., Huse, J., and Considine, R.V. (2000) TNFa inhibits leptin production in subcutaneous and omental adipocytes from morbidly obese humans. J. Clin. Endocrinol. Metab., 85, 530–535. Larsson, H. and Ahren, B. (1996) Shortterm dexamethasone treatment increases plasma leptin independently of changes in insulin sensitivity in healthy women. J. Clin. Endocrinol. Metab., 81, 4428–4432. Williams, L.B., Fawcett, R.L., Waechter, A.S., Zhang, P., Kogon, B.E., Jones, R.M., Inman, M., Huse, J., and Considine, R.V. (2000) Leptin production in adipocytes from morbidly obese subjects: stimulation by dexamethasone, inhibition with troglitazone and influence of gender. J. Clin. Endocrinol. Metab., 85, 2678–2684. Wake, D.J. and Walker, B.R. (2004) 11 betahydroxysteroid dehydrogenase type 1 in obesity and the metabolic syndrome. Mol. Cell. Endocrinol., 215, 45–54. Tartaglia, L.A. (1997) The leptin receptor. J. Biol. Chem., 272, 6093–6096. Ahima, R.S. and Flier, J.S. (2000) Leptin. Annu. Rev. Physiol., 62, 413–437. Leshan, R.L., Bjornholm, M., Munzberg, H., and Myers, M.G. Jr. (2006) Leptin receptor signaling and action in the central nervous system. Obesity, 14, 208S–212. Hileman, S.M., Pierroz, D.D., Masuzaki, H., Bjorbaek, C., El-Haschimi, K., Banks, W.A., and Flier, J.S. (2002) Characterizaton of short isoforms of the leptin receptor in rat cerebral microvessels and of brain uptake of leptin in mouse models of obesity. Endocrinology, 143, 775–783. Elmquist, J.K., Elias, C.F., and Saper, C.B. (1999) From lesions to leptin: hypothalamic control of food intake and body weight. Neuron, 22, 221–232. Bjorbaek, C. and Kahn, B.B. (2004) Leptin signaling in the central nervous system and the periphery. Recent Prog. Horm. Res., 59, 305–331. Elmquist, J.K., Coppari, R., Balthasar, N., Ichinose, M., and Lowell, B.B. (2005) Identifying hypothalamic pathways controlling food intake, body weight, and
References
44
45
46
47
48
49
50
51
52
53
glucose homeostasis. J. Comp. Neurol., 493, 63–71. Morton, G.J., Cummings, D.E., Baskin, D.G., Barsh, G.S., and Schwartz, M.W. (2006) Central nervous system control of food intake and body weight. Nature, 443, 289–295. Balthasar, N., Coppari, R., McMinn, J., Liu, S.M., Lee, C.E., Tang, V., Kenny, C.D., McGovern, R.A., Chua, S.C. Jr., Elmquist, J.K., and Lowell, B.B. (2004) Leptin receptor signaling in POMC neurons is required for normal body weight homeostasis. Neuron, 42, 983–991. Leibowitz, S.F. and Hoebel, B.G. (1994) Behavioral neuroscience and obesity, in Handbook of Obesity: Clinical Applications, 2nd edn (eds G.A. Bray and C. Bouchard), Marcel Dekker, New York. Morton, G.J., Blevins, J.E., Williams, D.L., Niswender, K.D., Gelling, R.W., Rhodes, C.J., Baskin, D.G., and Schwartz, M.W. (2005) Leptin action in the forebrain regulates the hindbrain response to satiety signals. J. Clin. Invest., 115, 703–710. Grill, H.J. (2006) Distributed neural control of energy balance: contributions from hindbrain and hypothalamus. Obesity, 14, 216S–221S. Fry, M., Hoyda, T.D., and Ferguson, A.V. (2007) Making sense of it: roles of the sensory circumventricular organs in feeding and regulation of energy homeostasis. Exp. Biol. Med., 232, 14–26. Pelleymounter, M.A., Cullen, M.J., Baker, M.B., Hecht, R., Winters, D., Boone, T., and Collins, F. (1995) Effects of the obese gene product on body weight regulation in ob/ob mice. Science, 269, 540–543. Rahmouni, K. and Haynes, W.G. (2004) Leptin and the cardiovascular system. Recent Prog. Horm. Res., 59, 225–244. Van Heek, M., Compton, D.S., France, C.F., Tedesco, R.P., Fawzi, A.B., Graziano, M.P., Sybertz, E.J., Strader, C.D., and Davis, H.R. Jr. (1997) Diet-induced obese mice develop peripheral, but not central, resistance to leptin. J. Clin. Invest., 99, 385–390. El-Haschimi, K., Pierroz, D.D., Hileman, S.M., Bjorbaek, C., and Flier, J.S. (2000) Two defects contribute to hypothalamic
54
55
56
57
58
59
60
61
62
leptin resistance in mice with dietinduced obesity. J. Clin. Invest., 105, 1827–1832. Bjorbaek, C., Elmquist, J.K., Frantz, J.D., Shoelson, S.E., and Flier, J.S. (1998) Identification of SOCS-3 as a potential mediator of central leptin resistance. Mol. Cell, 191, 619–625. Munzberg, H., Flier, J.S., and Bjorbaek, C. (2004) Region-specific leptin resistance within the hypothalamus of diet-induced obese mice. Endocrinology, 145, 4880–4889. Zabolotny, J.M., Bence-Hanulec, K.K., Stricker-Krongrad, A., Haj, F., Wang, Y., Minokoshi, Y., Kim, Y., Elmquist, J.K., Tartaglia, L.A., Kahn, B.B., and Neel, B.G. (2002) PTP1B regulates leptin signal transduction in vivo. Dev. Cell, 2, 489–495. Cheng, A., Uetani, N., Simoncic, P.D., Chaubey, V.P., Lee-Loy, A., McGlade, C.J., Kennedy, B.P., and Tremblay, M.L. (2002) Attenuation of leptin action and regulation of obesity by protein tyrosine phosphatase 1B. Dev. Cell, 2, 497–503. Aizawa-Abe, M., Ogawa, Y., Masuzaki, H., Ebihara, K., Satoh, N., Iwai, H., Matsuoka, N., Hayashi, T., Hosoda, K., Inoue, G., Yoshimasa, Y., and Nakao, K. (2000) Pathophysiological role of leptin in obesity-related hypertension. J. Clin. Invest., 105, 1243–1252. Correia, M.L., Haynes, W.G., Rahmouni, K., Morgan, D.A., Sivitz, W.I., and Mark, A.L. (2002) The concept of selective leptin resistance: evidence from agouti yellow obese mice. Diabetes, 51, 439–442. Rahmouni, K., Haynes, W.G., Morgan, D.A., and Mark, A.L. (2002) Selective resistance to central neural administration of leptin in agouti obese mice. Hypertension, 39, 486–490. Rahmouni, K., Morgan, D.A., Morgan, G.M., Mark, A.L., and Haynes, W.G. (2005) Role of selective leptin resistance in diet-induced obesity hypertension. Diabetes, 54, 2012–2018. Satoh, N., Ogawa, Y., Katsuura, G., Numata, Y., Masuzaki, H., Yoshimasa, Y., and Nakao, K. (1998) Satiety effect and sympathetic activation of leptin are mediated by hypothalamic melanocortin system. Neurosci. Lett., 249, 107–110.
j197
j 10 Leptin Secretion and Action
198
63 Haynes, W.G., Morgan, D.A., Djalali, A.,
64
65
66
67
68
69
70
71
72
Sivitz, W.I., and Mark, A.L. (1999) Interactions between the melanocortin system and leptin in control of sympathetic nerve traffic. Hypertension, 33, 542–547. da Silva, A.A., Kuo, J.J., and Hall, J.E. (2004) Role of hypothalamic melanocortin 3/4-receptors in mediating chronic cardiovascular, renal, and metabolic actions of leptin. Hypertension, 43, 1312–1317. Tallam, L.S., da Silva, A.A., and Hall, J.E. (2006) Melanocortin-4 receptor mediates chronic cardiovascular and metabolic actions of leptin. Hypertension, 48, 58–64. Seeley, R.J., Yagaloff, K.A., Fisher, S.L., Burn, P., Thiele, T.E., van Dijk, G., Baskin, D.G., and Schwartz, M.W. (1997) Melanocortin receptors in leptin effects. Nature, 390, 349. Marsh, A.J., Fontes, M.A., Killinger, S., Pawlak, D.B., Polson, J.W., and Dampney, R.A. (2003) Cardiovascular responses evoked by leptin acting on neurons in the ventromedial and dorsomedial hypothalamus. Hypertension, 42, 488–493. Rahmouni, K. and Morgan, D.A. (2007) Hypothalamic arcuate nucleus mediates the sympathetic and arterial pressure responses to leptin. Hypertension, 49, 647–652. Tune, J.D. and Considine, R.V. (2007) Effects of leptin on cardiovascular physiology. J. Am. Soc. Hypertens., 1, 231–241. Heymsfield, S.B., Greenberg, A.S., Fujioka, K., Dixon, R.M., Kusher, R., Hunt, T., Lubina, J.A., Patane, J., Self, B., Hunt, P., and McCamish, M. (1999) Recombinant leptin for weight loss in obese and lean adults. JAMA, 282, 1568–1575. Hukshorn, C.J., Saris, W.H.M., Westerterp-Plantenga, S., Farid, A.R., Smith, F.J., and Campfield, L.A. (2000) Weekly subcutaneous pegylated recombinant native human leptin (PEGOB) administration in obese men. J. Clin. Endocrinol. Metab., 85, 4003–4009. Montague, C.T., Farooqi, I.S., Whitehead, J.P., Soos, M.A., Rau, H., Wareham, N.J., Sewter, C.P., Digby, J.E., Mohammed,
73
74
75
76
77
78
79
S.N., Hurst, J.A., Cheetham, C.H., Earley, A.R., Barnett, A.H., Prins, J.B., and ORahilly, S. (1997) Congenital leptin deficiency is associated with severe earlyonset obesity in humans. Nature, 387, 903–908. Rau, H., Reaves, B.J., ORahilly, S., and Whitehead, J.P. (1999) Truncated human leptin (delta133) associated with extreme obesity undergoes proteasomal degradation after defective intracellular transport. Endocrinology, 140, 1718–1723. Farooqi, I.S., Matarese, G., Lord, G.M., Keogh, J.M., Lawrence, E., Agwu, C., Sanna, V., Jebb, S.A., Perna, F., Fontana, S., Lechler, R.I., DePaoli, A.M., and ORahilly, S. (2002) Beneficial effects of leptin on obesity, T cell hyporesponsiveness, and neuroendocrine/metabolic dysfunction of human congenital leptin deficiency. J. Clin. Invest., 110, 1093–1103. Strobel, A., Issad, T., Camoin, L., Ozata, M., and Strosberg, A.D. (1998) A leptin missense mutation associated with hypogonadism and morbid obesity. Nat. Genet., 18, 213–215. Ozata, M., Ozdemir, I.C., and Licinio, J. (2000) Human leptin deficiency caused by a missense mutation: multiple endocrine defects, decreased sympathetic tone, and immune system dysfunction indicate new targets for leptin action, greater central than peripheral resistance to the effects of leptin, and spontaneous correction of leptin-mediated defects. J. Clin. Endocrinol. Metab., 84, 3686–3695. Licinio, J., Caglayan, S., Ozata, M., Yildiz, B.O., de Miranda, P.B., OKirwan, F., Whitby, R., Liang, L., Cohen, P., Bhasin, S., Krauss, R.M., Veldhuis, J.D., Wagner, A.J., DePaoli, A.M., McCann, S.M., and Wong, M.L. (2004) Phenotypic effects of leptin replacement on morbid obesity, diabetes mellitus, hypogonadism, and behavior in leptin-deficient adults. Proc. Natl. Acad. Sci. USA, 101, 4531–4536. Garg, A. (2004) Acquired and inherited lipodystrophies. N. Engl. J. Med., 350, 1220–1234. Shimomura, I., Hammer, R.E., Ikemoto, S., Brown, M.S., and Goldstein, J.L. (1999) Leptin reverses insulin resistance and
References
80
81
82
83
84
85
diabetes mellitus in mice with congenital lipodystrophy. Nature, 401, 73–76. Ebihara, K., Ogawa, Y., Masuzaki, H., Shintani, M., Miyanaga, F., Aizawa-Abe, M., Hayashi, T., Hosoda, K., Inoue, G., Yoshimasa, Y., Gavrilova, O., Reitman, M.L., and Nakao, K. (2001) Transgenic overexpression of leptin rescues insulin resistance and diabetes in a mouse model of lipoatrophic diabetes. Diabetes, 50, 1440–1448. Oral, E.A., Simha, V., Ruiz, E., Andewelt, A., Premkumar, A., Snell, P., Wagner, A.J., DePaoli, A.M., Reitman, M.L., Taylor, S.I., Gorden, P., and Garg, A. (2002) Leptinreplacement therapy for lipodystrophy. N. Engl. J. Med., 346, 570–578. Ebihara, K., Kusakabe, T., Hirata, M., Masuzaki, H., Miyanaga, F., Kobayashi, N., Tanaka, T., Chusho, H., Miyazawa, T., Hayashi, T., Hosoda, K., Ogawa, Y., DePaoli, A.M., Fukushima, M., and Nakao, K. (2007) Efficacy and safety of leptin-replacement therapy and possible mechanisms of leptin actions in patients with generalized lipodystrophy. J. Clin. Endocrinol. Metab., 92, 532–541. Petersen, K.F., Oral, E.A., Dufour, S., Befroy, D., Ariyan, C., Yu, C., Cline, G.W., DePaoli, A.M., Taylor, S.I., Gorden, P., and Shulman, G.I. (2002) Leptin reverses insulin resistance and hepatic steatosis in patients with severe lipodystrophy. J. Clin. Invest., 109, 1345–13450. Simha, V., Szczepaniak, L.S., Wagner, A.J., DePaoli, A.M., and Garg, A. (2003) Effect of leptin replacement on intrahepatic and intramyocellular lipid content in patients with generalized lipodystrophy. Diabetes Care, 26, 30–35. Javor, E.D., Ghany, M.G., Cochran, E.K., Oral, E.A., DePaoli, A.M., Premkumar, A., Kleiner, D.E., and Gorden, P. (2005)
86
87
88
89
90
91
92
Leptin reverses nonalcoholic steatohepatitis in patients with severe lipodystrophy. Hepatology, 41, 753–760. Minokoshi, Y., Kim, Y.B., Peroni, O.D., Fryer, L.G., Muller, C., Carling, D., and Kahn, B.B. (2002) Leptin stimulates fattyacid oxidation by activating AMP-activated protein kinase. Nature, 415, 339–343. Lee, Y., Wang, M.Y., Kakuma, T., Wang, Z.W., Babcock, E., McCorkle, K., Higa, M., Zhou, Y.T., and Unger, R.H. (2001) Liporegulation in diet-induced obesity. The antisteatotic role of hyperleptinemia. J. Biol. Chem., 276, 5629–5635. Grinspoon, S. and Carr, A. (2005) Cardiovascular risk and body-fat abnormalities in HIV-infected adults. N. Engl. J. Med., 352, 48–62. Lee, J.H., Chan, J.L., Sourlas, E., Raptopoulos, V., and Mantzoros, C.S. (2006) Recombinant methionyl human leptin therapy in replacement doses improves insulin resistance and metabolic profile in patients with lipoatrophy and metabolic syndrome induced by the highly active antiretroviral therapy. J. Clin. Endocrinol. Metab., 91, 2605–2611. Santoro, N., Filicori, M., and Crowley, W.F. Jr. (1986) Hypogonadotropic disorders in men and women: diagnosis and therapy with pulsatile gonadotropin-releasing hormone. Endocrine Rev., 7, 11–23. Laughlin, G.A. and Yen, S.S. (1997) Hypoleptinemia in women athletes: absence of a diurnal rhythm with amenorrhea. J. Clin. Endocrinol. Metab., 82, 318–321. Welt, C.K., Chan, J.L., Bullen, J., Murphy, R., Smith, P., DePaoli, A.M., Karalis, A., and Mantzoros, C.S. (2004) Recombinant human leptin in women with hypothalamic amenorrhea. N. Engl. J. Med., 351, 987–997.
j199
j201
11 Adiponectin Jonathan P. Whitehead and Ayanthi A. Richards 11.1 Introduction
Adipocytes secrete a plethora of bioactive molecules collectively termed adipokines. Adiponectin is the most abundant of these and circulates at high concentrations, around 5–30 mg/ml in humans. It has an admirable range of properties, including insulin-sensitizing, anti-inflammatory, antiatherogenic, and anticancer, and is also cardioprotective. Unlike most other adipokines, circulating levels of adiponectin are reduced in obesity and associated diseases, making it an attractive therapeutic target [1]. In support of its therapeutic potential, administration of recombinant adiponectin ameliorates metabolic complications in mice [2, 3], whilst the beneficial effects of the insulin-sensitizing thiazolidinediones (TZDs) in humans are at least partly due to the improvement in adiponectin profiles [4]. Adiponectin, also termed Acrp30 (adipocyte complement-related protein of 30 kDa), ADIPOQ, apM1 (adipose most abundant gene transcript-1), or GBP28 (gelatin-binding protein of 28 kDa), was originally identified by four groups [5–8]. Its expression is largely restricted to adipocytes and is induced over 100-fold during adipocyte differentiation [5, 6]. The beneficial effects of adiponectin are mediated through the ubiquitously expressed adiponectin receptors, AdipoR1 and AdipoR2, which represent a new class of membrane receptor [9]. APPL1 (adaptor protein containing phosphotyrosine-binding protein, pleckstrin homology domains, and leucine zipper 1) has recently been identified as a key signaling molecule that transduces the adiponectin signal from its receptors to downstream effectors [10]. Of these, the intracellular energy sensor AMP-activated protein kinase (AMPK) is central to many of adiponectins effects [11, 12], whilst activation of the peroxisome proliferator-activated receptor (PPAR)-a transcription factor is also pivotal [13]. Numerous clinical and epidemiological studies have demonstrated a decrease in circulating adiponectin levels in chronic inflammatory states such as obesity [14], insulin-resistance [15], type 2 diabetes [16], hypertension [17], cardiovascular disease [18], and liver disease [19, 20] (Figure 11.1). Polymorphisms at the adiponectin locus are predictors of circulating adiponectin levels, insulin sensitivity, and
j 11 Adiponectin
202
Figure 11.1 Circulating adiponectin levels in various states. See text for details.
atherosclerosis [21], whilst rare mutations in the adiponectin gene, called ADIPOQ, can impair adiponectin secretion and cause type 2 diabetes [22]. Males have lower circulating adiponectin levels than females, an observation that has been linked to the increased risk of insulin resistance and atherosclerosis in men [23–26], and testosterone accounts for this sexual dimorphism, with elevated adiponectin levels in hypogonadal men being reduced upon testosterone supplementation [25–27]. Many, if not all, of these correlations have been confirmed in rodents, and the generation and characterization of adiponectin knockout mice has further established the importance of adiponectin in the etiology of the various disease states [28–33]. Adiponectin acts on multiple tissues and cell types to regulate numerous processes. It coordinates carbohydrate and lipid metabolism, primarily by its actions in liver and skeletal muscle, acting to decrease hepatic glucose output and increase peripheral glucose disposal, and increase fatty acid oxidation/decrease circulating fatty acids [3, 11, 12, 34]. Adiponectin acts on the endothelium to promote vasodilation [35] and has direct protective effects on the myocardium [36]. Recent evidence also supports an important role for adiponectin acting centrally in the brain [37]. At the molecular level adiponectin is no-less impressive, showing an array of modifications unparalleled by other adipokines. An overwhelming body of evidence has revealed that the resultant structural complexity is critical for both production and action of adiponectin, and gives rise to the variety of multimeric forms present in the circulation. In this chapter, we highlight current understanding of adiponectin structure and function, and its associations with health and disease.
11.2 Adiponectin Structure and Post-Translational Modifications
The adiponectin protein shares considerable homology with complement factor C1q and collagens, and consists of four domains (Figure 11.2): an N-terminal signal peptide that is cleaved upon entry into the endoplasmic reticulum; a variable region that shows greatest amino acid sequence divergence between species; a collagenous domain, so named because of its sequence and structural homology with collagen;
11.2 Adiponectin Structure and Post-Translational Modifications
Figure 11.2 Domain structure of human adiponectin. PTMs and highly conserved proline residues are detailed. The collagenous domain contains 22 G-X-Y or G-X-X collagen repeats involved in collagen triple-helix
formation. The globular domain exhibits a high degree of homology with subunits of C1q and TNF-a. aa, amino acid. See text for additional details.
and a C-terminal globular domain, involved in receptor binding. Synthesized as a single subunit, adiponectin undergoes extensive post-translation modifications (PTMs) during transit through the endoplasmic reticulum and Golgi. These PTMs are essential for multimerization, which occurs prior to secretion and results in formation of trimers, hexamers (collectively termed low-molecular-weight (LMW) multimers or sometimes referred to as LMW and medium-molecular-weight, respectively) and larger high-molecular-weight (HMW) multimers [22]. The structure of the various adiponectin multimers was elegantly illustrated by Lodishs group, using freeze-etch cryoelectron microscopy [38]. Adiponectin trimers are generated upon formation of a triple helix by noncovalent interactions within the collagenous domain and hydrophobic interactions between the globular heads [39]. Hydroxylation of multiple conserved proline residues in the collagenous domain appear to be involved in this process, since pharmacological inhibition of proline hydroxylation or expression in bacteria (which cannot perform these eukaryotic modifications) prevents trimer formation [40]. Numerous groups have demonstrated the importance of a conserved cysteine residue in the variable domain (Cys36 in human and Cys39 in mouse) that mediates the intertrimer disulfide bonds necessary for formation of hexamers and HMW multimers [22, 38, 41]. In addition, hydroxylation and subsequent glycosylation of four conserved lysine residues located within the collagenous domain are required for formation of the HMW multimers, since mutation of the glycosylated residues does not compromise trimer and hexamer formation, but abrogates formation of the HMW multimers [40, 42]. The presence of an a2–8-linked disialic acid moiety has also been reported although the site(s) and structural/functional significance of this modification are still to be determined [43, 44].
j203
j 11 Adiponectin
204
11.3 Significance and Bioactivity of Adiponectin Multimers
The multimeric nature of circulating adiponectin has been demonstrated by a variety of biochemical separation techniques including velocity sedimentation, size-exclusion chromatography, and semidenaturing sodium dodecylsulfate– polyacrylamide gel electrophoresis. These studies have revealed that circulating adiponectin exists as a mixture of the trimer, hexamer, and HMW multimers [22, 38, 41], and that the multimers do not undergo interconversion once secreted [41]. A small amount of a truncated C-terminal globular form of adiponectin has been detected in human serum following immunoprecipitation [45] and Kadowakis group demonstrated that leukocyte elastase, a protease secreted by monocytes, is capable of producing such truncated fragments [46]. Whilst the physiological significance of this truncated form remains unclear, as it has not been widely reported, a model that may account for the limited presence of such truncated forms of adiponectin was proposed by Scherer, based on a number of experimental observations [47]. Scherers group found that HMW multimers were cleared more rapidly than LMW oligomers following a metabolic challenge in mice. A recombinant form of adiponectin (C39S) that is incapable of forming oligomers larger than trimers and is sensitive to proteolytic cleavage following secretion was more biologically active than HMW adiponectin and subject to more rapid clearance. These and other observations that indicate an important role for HMW adiponectin in insulin sensitivity led them to propose that HMW adiponectin may be converted to a more biologically active form, through reduction and proteolytic cleavage [47]. Using the biochemical approaches mentioned above it has now been shown that decreases in total adiponectin observed in pathological states such as insulin resistance [48–50], the metabolic syndrome [51], hepatitis C genotype-3 infection [48] as well as testosterone-related decreases [25, 47] typically reflect a selective loss of HMW multimers and that effective therapeutic intervention is accompanied by an increase in the ratio of HMW to total adiponectin [47, 52–54]. Recently, several commercial enzyme-linked immunosorbent assays that facilitate measurement of the various multimers have been developed [55–57], making it possible to determine adiponectin profiles in a high-throughput manner. As a result, we have begun to see reports describing adiponectin profiles in larger cohorts, which further emphasizes the correlation between the decline in HMW adiponectin and cardiovascular disease [58, 59], insulin resistance, and the metabolic syndrome [60]. The above clinical and epidemiological observations are corroborated by direct investigations of the relative potencies/bioactivities of the LMW and HMW multimers in functional assays, in vitro and in vivo. Increasing evidence indicates that different adiponectin oligomers act on different target tissues and promote distinct biological actions. It is therefore important to take note of the source (bacterial or mammalian) and form (total, LMW or HMW) of recombinant adiponectin used in these functional investigations. In each of the following sections we present evidence supporting a role for the various adiponectin oligomers in key target tissues, followed
11.4 Adiponectin and Liver
by a brief description of relevant disease states with particular emphasis on metabolic dysregulation.
11.4 Adiponectin and Liver
A large body of evidence indicates that the HMW forms of adiponectin are the major effectors in liver. Scherer et al. first demonstrated that recombinant adiponectin produced from mammalian cells, which produce the HMW multimers, reduced hepatic glucose output in diabetic mice [3]. In contrast, bacterially produced adiponectin, which is unable to form the HMW multimers [40, 42, 61], was virtually inactive. Furthermore, purified HMW adiponectin, but not LMW, reduced blood glucose in adiponectin null mice [47]. Consistent with this, Xu et al. demonstrated that hepatic AMPK activation and alleviation of hyperglycemia in diabetic mice was directly proportional to the concentration of HMW multimers administered [42]. Finally, unlike wild-type adiponectin, a glycosylation-defective mutant that could form only trimer and hexamer [40, 42] failed to enhance insulin-mediated suppression of glucose output in isolated primary rat hepatocytes [62]. Scherers group also showed that the beneficial effects of TZDs are largely due to the increase in HMW adiponectin acting primarily on the liver in mice [47] and humans [54]. HMW adiponectin has also been proposed to be the most efficacious adiponectin multimer for alleviation of fatty liver disease in obese mice [63]. Administration of adiponectin purified from mammalian cells ameliorated both alcoholic and nonalcoholic fatty liver disease (NAFLD) [64]. It also reduced hepatic production of proinflammatory cytokines such as tumor necrosis factor (TNF)-a [64], due at least in part to a direct effect on the Kuppfer cells [65]. In the human HepG2 hepatoma cell line, adiponectin promoted the expression of apolipoprotein A-I and ABCAI (ATP-binding cassette transporter) [66], which may facilitate increased assembly of high-density lipoprotein (HDL), and so provide a potential mechanism for the observed correlation between HDL and adiponectin [67, 68], particularly HMW adiponectin [51, 58]. The above functional studies provide a consensus regarding adiponectin and liver function; however, clinical and epidemiological investigations have generated mixed results with respect to adiponectins association with chronic liver disease (CLD). While several studies reported that circulating adiponectin levels were reduced in humans with nonalcoholic steatohepatitis [19, 20] and NAFLD [69, 70], adiponectin levels have also been shown to be elevated in subjects with chronic cirrhosis, independent of etiology [71, 72], and with increasing inflammation [73]. Interestingly, adiponectin levels were no longer found to correlate with insulin sensitivity or body massindex (BMI) in patients with CLD [74]. High adiponectin levels have beendetected in bile from patients with biliary obstruction and bile duct ligation in mice promoted a rapid increase in circulating levels, suggesting that biliary excretion contributes to adiponectin clearance and this may contribute to adiponectin accumulation, at least in states of cholestatic liver disease [74]. Further investigation is warranted to understand the complex interactions between adiponectin and the etiology of CLD.
j205
j 11 Adiponectin
206
11.5 Adiponectin and Skeletal Muscle
Unlike the liver, the most physiologically relevant form(s) of adiponectin in skeletal muscle remain unclear. Lodishs group reported that bacterially produced globular adiponectin reduced circulating free fatty acids and glucose following a high fat meal or lipid injection [11, 45]. In vitro studies performed on isolated muscle strips and C2C12 myotubes showed that these effects were mediated by activation of AMPK, leading to increased fatty acid oxidation and glucose uptake. In contrast to globular adiponectin, full-length adiponectin produced in bacteria was relatively ineffective [11, 45]. Using similar forms of recombinant adiponectin, Kadowakis group found that chronic administration of globular adiponectin promoted partial restoration of insulin sensitivity in mouse models of obesity and lipoatrophy through increased expression of key molecules (CD36, acyl-CoA oxidase and uncoupling protein-2) and fatty acid oxidation in skeletal muscle. Once again, the relative efficacy of full-length adiponectin was limited [2]. Lodish et al. also found that different adiponectin oligomers, produced in mammalian cells, activated discrete signaling pathways in C2C12 myotubes and muscle strips [38, 45, 61]. HMW and hexameric adiponectin promoted activation of nuclear factor-kB (NF-kB), but the trimeric isoform did not. In contrast, trimeric adiponectin, but not HMW or hexameric forms, stimulated phosphorylation and activation of AMPK [38, 45, 61]. Additional support for the potential importance of LMW oligomers in mediating the metabolic effects of adiponectin in skeletal muscle came from Kadowaki et al., when they identified the adiponectin receptors (see Section 11.13). However, given that these studies employed adiponectin purified from bacterial systems the physiological relevance is unclear. A more recent study found that HMWadiponectin purified from human serum had the greatest binding affinity and most potent effect on AMPK activity in C2C12 myotubes, suggesting this may be the more physiologically relevant form [75]. There is reduced mitochondrial mass in skeletal muscle of mice lacking adiponectin and individuals with a family history of type 2 diabetes. Adiponectin has been shown to stimulate mitochondrial biogenesis in human myotubes, via AMPKdependent increases in PPAR-c coactivator-1a, providing a potential explanation [76]. Experimental evidence also suggests that adiponectin resistance may develop in skeletal muscle, at least in obesity, with compromised adiponectin signaling and action observed in isolated human skeletal muscle/cultured myotubes from obese subjects [77, 78] and obese mice [79].
11.6 Adiponectin and the Vasculature
All the adiponectin multimers are implicated in regulation of the endothelium and vasculature. Matsuzawa et al. demonstrated that adiponectin adheres to injured vascular endothelium [80] and also found that bacterially produced adiponectin blocked TNF-a-induced monocyte adhesion to endothelial cells, via inhibition of
11.7 Adiponectin and the Brain
induction of cell adhesion molecules and NF-kB activation [81, 82]. Several groups have subsequently shown that all forms of adiponectin are able to promote nitric oxide production, and suppress hyperglycemia-induced oxidative stress and inflammation in endothelial cells [35, 83, 84]. Thus, states of hypoadiponectinemia are associated with endothelial dysfunction [85], decreased endothelium-dependent vasodilation, and hypertension [17]. In normal tissues angiogenesis is a controlled process and this control is perturbed in many tumors. In this setting adiponectin has antiangiogenic activities, through inhibition of endothelial cell proliferation and migration and the promotion of endothelial cell apoptosis [86]. In contrast, injured vasculature is characterized by accelerated endothelial cell turnover and increased angiogenesis, especially in the context of ischemia. Adiponectin regulates the endothelial response to injury [87] by suppression of endothelial cell apoptosis [49] and stimulation of angiogenesis [88, 89]. The clinical relevance of the differing molecular weight multimers is again demonstrated by the more potent vascular protection afforded by the HMW multimers [49]. Adiponectin also attenuates smooth muscle proliferation and new intima formation in an oligomer-specific manner, and it binds to a number of growth factors [87, 90, 91] as well as a variety of circulating factors, including lipopolysaccharide (LPS) [92], albumin [56, 75], and cytokines such as monocyte chemoattractant protein (MCP)-1 [93]. Matsuzawas group demonstrated that adiponectin had direct effects on macrophages, with macrophage-to-foam cell progression, phagocytic activity, and LPS-induced TNF-a production all blocked by treatment with adiponectin [94, 95]. Walshs group have also recently shown that adiponectin protects against systemic inflammation by a mechanism involving macrophage-dependent clearance of early apoptotic cells through a receptor-dependent pathway involving calreticulin [96]. Collectively, these observations suggest that adiponectin is likely to provide important regulation by direct and indirect effects.
11.7 Adiponectin and the Brain
Several recent reports indicate an important role for LMW adiponectin in the brain. Although some studies concluded adiponectin did not cross the blood–brain barrier (BBB) [97, 98] this may be at least partly explained by the low levels of adiponectin found in the cerebrospinal fluid (CSF), which are below the levels predicted by the baseline permeability of the BBB/blood–cerebrospinal barrier [99]. Nevertheless, it has become apparent that LMW, but not HMW, forms of adiponectin are found in the CSF in humans [100, 101] and mice [37], although only at concentrations around 1000-fold lower than those in serum. Unlike serum adiponectin, levels in the CSF showed no gender differences or correlation with insulin resistance [37, 100], probably because the reduction in circulating levels reflects a selective loss of HMW adiponectin. Interestingly, Kadowakis group reported that both circulating and CSF levels of adiponectin were increased in mice after fasting and reduced upon
j207
j 11 Adiponectin
208
Figure 11.3 Major targets of adiponectin. FA, fatty acid; See text for details.
refeeding [37]. Importantly, they also showed that intracerebroventricular administration of adiponectin hexamer stimulated AMPK in the arcuate hypothalamus, via AdipoR1, increased food intake, and blocked leptins effects on these parameters. These observations prompted the intriguing proposal that adiponectin may have evolved as a starvation factor, serving to reduce energy expenditure and increase food intake during periods of fasting [37]. Such a suggestion had previously been proposed by Behre [102] and was also put forward by Scherer, who reported that a transgenic mouse line with elevated adiponectin levels grew morbidly obese, yet remained insulin sensitive [103]. It is unclear how observations made in fasted mice will translate to free-living humans, given the latters general reluctance to endure sustained periods of negative energy balance. Feeding does not typically alter adiponectin in humans [104, 105], although one study found that fasting increased circulating adiponectin levels [106], suggesting the regulatory mechanisms are likely to be conserved between species. Collectively (see Figure 11.3), these studies suggest that the HMW multimers are responsible for mediating the majority of adiponectins metabolic effects in peripheral tissues. In contrast, adiponectins central effects appear to be mediated by the LMW forms. Thus, understanding the processes governing the regulation of adiponectin multimer formation, secretion, and metabolism/clearance in both healthy and disease states is central to the identification of novel therapeutic targets and the development of adiponectin-based treatments.
11.8 Adiponectin Expression and Secretion
Expression of adiponectin occurs from an intermediate stage of adipogenesis onwards [5, 6] and it may act in an autocrine fashion to promote adipogenesis [107]. Adiponectin production is common to adipocytes in both white and brown adipose
11.9 Adiponectin Secretion
tissues [47, 108]. Studies of isolated human explants or adipocytes suggest adiponectin secretion from visceral or subcutaneous depots is comparable [109] although it may be subject to depot-specific regulation [110], and differences have been reported for cells derived from visceral and subcutaneous depots, following differentiation in vitro [111]. Given the overwhelming evidence demonstrating that expression and secretion of adiponectin, particularly HMW adiponectin, is compromised in a variety of disease states, the next section describes our current understanding of adiponectins secretory pathway, followed by a discussion of some of the factors that have been shown to regulate adiponectin expression/secretion.
11.9 Adiponectin Secretion
While expression of adiponectin is largely restricted to adipocytes, other mammalian cell types can efficiently produce the same complement of multimers following ectopic expression [40]. Thus, the basic cellular machinery for production and secretion of adiponectin multimers would seem to be conserved. However, the possibility that adipocyte-specific regulation of various steps in the synthesis, multimerization and secretion of adiponectin remains. The molecular details of adiponectins secretory journey through the adipocyte are still relatively poorly defined (Figure 11.4). Initial, pulse–chase experiments revealed that acute insulin treatment stimulated adiponectin secretion in a phosphoinositide-3-kinase-dependent manner [5, 112, 113]. Early comparisons of the intracellular distribution and secretion of adiponectin with other proteins suggested that adiponectin may enjoy a unique trafficking itinerary and/or be regulated by distinct mechanisms [5, 112]. Support for the latter comes from a recent report demonstrating significant biochemical overlap between adiponectin, adipsin, and transferrin receptors [114]. Important new insights into the molecular mechanisms facilitating transit of adiponectin through the secretory pathway are provided by two recent studies that demonstrate adiponectin is subject to thiol-mediated retention in the endoplasmic reticulum [115, 116]. Adiponectin binds directly to the resident endoplasmic reticulum chaperone, ERp44, via an intermolecular disulfide bond involving Cys36 (Cys39 in mouse) and this interaction is proposed to delay its secretion, facilitating PTMs and multimerization. The oxidoreductase Ero1-La is a preferred partner for ERp44, capable of using oxygen to generate disulfide bonds that it transfers to proteins such as ERp44 and protein disulfide isomerase, and displaces adiponectin from ERp44. Although ERp44 and Ero1-La are widely expressed, levels of both are increased during differentiation of adipocytes [115, 116]. Experimental approaches to manipulate ERp44 and/or Ero1-La provide evidence that both proteins play a key role in determining the secretion of adiponectin multimers. Scherers group found that increasing ERp44 levels increased the intracellular retention of adiponectin. Conversely, reducing ERp44 had the opposite effect [115]. Farmer et al. found that increasing Ero1-La increased adiponectin secretion and this was largely through an increase in the secretion of HMWadiponectin, whilst knockdown of Ero1-La reduced
j209
j 11 Adiponectin
210
Figure 11.4 Summary of adiponectin multimerization and the secretory pathway. PTMs, and trimer, hexamer, and HMW multimer formation occur in the endoplasmic reticulum (ER) and Golgi prior to secretion. The ERp44/Ero1-La balance regulates production and secretion of adiponectin in a multimer-
specific fashion, and expression of ERp44/Ero1La is affected by factors including nutrient/ metabolic status and TZDs. Other proteins implicated in adiponectin trafficking are also shown. SIRT1, sirtuin-1. See text for additional details.
adiponectin secretion [116]. Additional studies demonstrated that expression of both ERp44 and Ero1-La are regulated in response to various stimuli. Levels of both proteins are reduced in obesity and in males – two situations where levels of HMW adiponectin are decreased. Conversely, both proteins are induced in response to PPAR-c agonists, which preferentially increase secretion of HMW adiponectin [47]. Moreover, the NAD-dependent deacetylase sirtuin-1, which regulates PPAR-c, was shown to represent a direct link between expression of ERp44 and Ero1-La and nutrient status [116]. Finally, insulin reduces the interaction of ERp44 with adiponectin [115], providing a potential mechanism for the observed increase in adiponectin secretion in response to acute insulin. These findings establish a mechanism by which effectors may specifically alter parameters of adiponectin secretion in a multimer-specific fashion, without perturb-
11.10 Ectopic Adiponectin Expression
ing secretion of other proteins, through an effect on the retention mechanisms rather than an effect on vesicle trafficking per se. One such effector is testosterone. Matsuzawas group first demonstrated that testosterone inhibited adiponectin secretion [26] and Xu et al. went on to show that this was due to a selective inhibition of HMW multimer secretion [25]. Although the levels of ERp44 and Ero1-La were not determined in these studies, given the above, it is tempting to speculate that changes in the levels and/or functional status of these proteins affect retention and secretion of HMW adiponectin as described. Changes in this process of intracellular retention are also likely to be of particular relevance in scenarios that affect cellular redox potential. Moving through the secretory pathway, several groups have demonstrated that secretion of adiponectin is blocked by treatment with the ADP ribosylation factor (ARF)-guanine nucleotide exchange factor) inhibitor, Brefeldin A, demonstrating the absolute dependence of adiponectin secretion on ARF activity and transit through the Golgi [40, 114, 117]. Consistent with this, ARF6 and the small G-protein Rab11 have recently been reported to play a role in basal and insulin-stimulated adiponectin secretion from 3T3-L1 adipocytes [114], while adiponectin also shows some colocalization with ARF1 [117]. The vesicle SNARE (soluble N-ethyl maleimide-sensitive fusion protein attachment protein receptor), vps10 tail-interacting protein-1a (Vti1a), which is localized to the trans-Golgi network (TGN) in some cell types and associates with glucose transporter 4 (GLUT4) vesicles in adipocytes, has also been implicated in adiponectin secretion [118]. Knockdown of Vti-1a impaired both basal and insulin-stimulated adiponectin secretion, as well as insulin-stimulated glucose uptake, prompting the suggestion that Vti-1a may be involved in an early sorting step common to both adiponectin and GLUT4 [118]. The recently discovered Golgilocalizing c-adaptin ear homology ARF-binding protein (Golgi-localizing c-adaptin ear homology ADP ribosylation factor-binding protein GGA) family of adapter proteins are known to play a key role in the differential regulation of secretion from the TGN. They function by facilitating sorting and recruitment of specific cargo molecules into clathrin-coated exocytic vesicles in an ARF-GTPase-dependent manner. GGA1, but not GGA2 or GGA3, has recently been implicated in adiponectin secretion [117]. Adiponectin-containing vesicles were specifically precipitated by the cargo binding domain of GGA1 and a dominant negative GGA1 mutant inhibited adiponectin secretion whilst coexpression of wild-type GGA1 enhanced adiponectin secretion [117].
11.10 Ectopic Adiponectin Expression
Several reports indicate adiponectin can be expressed in a number of nonadipose cells, often in response to stress. Adiponectin mRNA was detected in mouse liver parenchyma cells following administration of carbon tetrachloride [119] and in human liver biopsies from patients with steatosis [120]. Adiponectin expression was also induced in skeletal muscle following treatment with inflammatory
j211
j 11 Adiponectin
212
cytokines, in both in vivo and in vitro settings, prompting the suggestion that the adiponectin response may represent a local anti-inflammatory mechanism and a means of increasing energy supply [121]. Expression of adiponectin has been detected in osteoblasts [122], which are derived from pluripotent precursor cells that can also give rise to adipocytes. Finally, regulated expression of adiponectin has been demonstrated in cytotrophoblast and syncytiotrophoblast cells in human placenta [123, 124], leading to the suggestion that adiponectin may play an important role in the regulation of energy metabolism at the materno-fetal interface.
11.11 Regulation of Expression and Secretion
Numerous investigators have sought to identify the mechanisms that contribute to changes in adiponectin expression and secretion. Early longitudinal studies, performed in rhesus monkeys, demonstrated that the reduction in circulating adiponectin levels paralleled the development of obesity and insulin resistance [125]. Importantly, the reduction in adiponectin levels occurred in the absence of any changes in adiponectin mRNA expression, strongly supporting the notion that the major effects are mediated at a post-transcriptional level, at least in this setting. Although in vitro studies demonstrate that acute insulin promotes adiponectin secretion, in vivo evidence from fat-specific insulin receptor knockout mice [126] and humans with severe loss of insulin receptor function [127, 128] or type 1 diabetes [129, 130] suggest that chronic insulin reduces circulating adiponectin levels. One possibility is that lack of insulin action leads to a reduction in reactive oxygen species (ROS) and that this accounts for the increase in adiponectin [128]. 11.11.1 Oxidative stress
Increased oxidative stress has been widely documented to contribute to the reduced levels of adiponectin via effects on transcription and secretion [131–134], and is implicated in multiple forms of insulin resistance [135]. In obese states, adipose tissue-specific changes in the balance of pro- and antioxidative enzymes results in increased levels of ROS within adipose tissue and increased systemic markers of oxidative stress [131]. This correlates with altered adipokine levels, including reduced adiponectin. Complementary studies in 3T3-L1 adipocytes showed that ROS levels were increased during differentiation and following treatment of cells with fatty acids. Treatment with NADPH oxidase inhibitors prevented the increase in ROS, indicating that NADPH oxidase is a major protagonist. Increased ROS were shown to directly reduce both PPAR-c and adiponectin mRNA expression and secretion, while increasing expression of other genes such as those for plasminogen activator inhibitor-1, interleukin (IL)-6, and MCP-1, and treatment with the antioxidant Nacetyl cysteine (NAC) reversed these effects [131]. Importantly, treatment of obese KKAy mice with the NADPH oxidase inhibitor apocynin for 3 weeks reduced both
11.11 Regulation of Expression and Secretion
systemic and adipose tissue ROS levels, without altering food intake or body weight, and increased mRNA expression and circulating levels of adiponectin suggesting such approaches may have therapeutic potential [131]. Similar effects have also been reported using angiotensin II type I receptor blockers. Treatment of obese mice with olmasartan reduced adipose ROS and NADPH oxidase levels, and increased circulating adiponectin levels, as well as improving other adipokine profiles [136]. In humans undergoing peritoneal dialysis, a 3-month treatment with candersartan reduced markers of oxidative stress and increased adiponectin levels [137]. Recent evidence indicates that induction of CCAAT/enhancer-binding protein (C/EBP) homologous protein (CCAAT/enhancer-binding protein homologous protein CHOP), which is an endoplasmic reticulum stress-induced protein, plays a key role in attenuation of adiponectin mRNA expression in the face of increasing ROS and endoplasmic reticulum stress [138, 139]. CHOP attenuates adiponectin promoter activity by direct antagonism of C/EBP-a binding. Increased suppressor of cytokine signaling-3 expression has also been implicated in the reduced expression of adiponectin observed in vitro [140] and in obese mouse models [141]. 11.11.2 Activators of PPARc – TZDs and Fish Oils
TZDs increase adiponectin levels via a combination of events occurring at the transcriptional [54] and post-transcriptional level [142]. TZDs such as pioglitazone reduce ROS [135], which may account for many of their beneficial effects, including increased adiponectin levels. The efficacy of TZDs in humans was shown to correlate more strongly with the increase in circulating levels of HMW adiponectin rather than changes in total adiponectin levels per se [47], and the TZD-induced increases in ERp44 and Ero-1La expression mentioned earlier [115] may contribute to the increase in HMW adiponectin. Fish oils and n-3 polyunsaturated fatty acids have also been shown to increase adiponectin levels in mice through PPAR-c activation, suggesting they may act via a similar mechanism [143, 144]. Studies from Scherers group, using adiponectin knockout mice, highlight the importance of adiponectin in the context of TZD-mediated improvements in metabolism, with obese, adiponectin knockout mice failing to respond to TZDs [32]. 11.11.3 Weight Loss
Improvements in insulin sensitivity following modest weight loss (8–9 kg) or exercise are not associated with changes in adiponectin levels [145] or multimer distribution [146]. However, more significant weight loss (10% or greater reduction in BMI) has been reported to increase adiponectin levels [52, 147–149], and promote a shift in the multimer distribution, with increased levels of HMW adiponectin and a concomitant reduction in LMW levels [49, 52]. A recent study suggests that the weight loss-induced increase in circulating adiponectin can occur in the absence of changes in adiponectin mRNA levels, consistent with an important role for
j213
j 11 Adiponectin
214
post-transcriptional mechanisms [150]. Changes in adiponectin do not appear to be involved in improved insulin sensitivity associated with exercise, in the absence of changes in fat mass [149]; however, emerging evidence suggests that changes in expression of the adiponectin receptors may play a role [151]. 11.11.4 Other Agents
The cannabinoid receptor subtype-1 antagonist rimonabant increases adiponectin expression and secretion in vivo and in 3T3-L1 adipocytes [152, 153], leading to the suggestion that rimonabant may mediate its effects at least partly by increasing adiponectin, independent of effects on appetite, although these data are not supported by work from all groups [154]. b-Adrenergic agonists (and cAMP) promote reduced expression and secretion of adiponectin, both in vivo and in vitro [155], whilst adiponectin itself has been reported to be involved in a negative feedback loop, with exogenous adiponectin reducing expression of adiponectin and AdipoR2, but not AdipoR1, both in vivo and in vitro [156]. In vitro systems have been widely employed to examine the effects of a variety of agents on adiponectin expression and secretion. Experiments in 3T3-L1 cells suggest that insulin, TNF-a, or dexamethasone, but not growth hormone, angiotensin II or tri-iodothyronine, reduce adiponectin mRNA expression [157], whilst growth hormone and prolactin suppress adiponectin expression from human adipose tissue [158]. As described, oxidative and endoplasmic reticulum stress reduce adiponectin expression [131, 159], whilst concomitantly increasing expression of proinflammatory cytokines [160]. Proinflammatory cytokines in turn increase oxidative stress and thereby decrease adiponectin expression producing a vicious cycle. Interestingly, recent evidence demonstrates this can occur without changes in multimer distribution [161]. Antioxidants such as NAC are able to restore adiponectin expression and secretion and also prevent other cytokine-induced effects such as activation of NF-kB [162]. In contrast to most cytokines, IL-15 increases adiponectin secretion [163] whilst the widely used antidiabetic drug metformin reduced adiponectin expression in 3T3-L1 adipocytes [164].
11.12 Adiponectin Clearance
Relatively little is known about how adiponectin is metabolized and cleared from the circulation. Once in the circulation, adiponectin oligomers are stable and do not undergo exchange from one form to another [41, 105]. Studies in mice and rabbits suggest the HMW multimers are cleared more rapidly than LMWoligomers [41, 105]. Recent investigations in humans are consistent with this and also highlight how changes in total adiponectin reflect changes in HMW multimers [165]. Adiponectin has been detected in urine from type 2 diabetic subjects and healthy males [166]. Urinary adiponectin levels, which are around three orders of magnitude lower than
11.13 Adiponectin Receptors and Downstream Effectors
serum levels, were significantly elevated in patients with macro-albuminuria and correlated with urinary albumin. These observations support a model where leakage of circulating adiponectin is largely responsible for the high urinary adiponectin [166]. Intriguingly serum adiponectin levels were also elevated in patients with macro-albuminuria, suggesting there may be a compensatory mechanism to assuage microvascular damage in the advanced stages of diabetic nephropathy by increased production of adiponectin. As in the case of CLD, where altered biliary clearance of adiponectin has been implicated [74], the relationship between adiponectin and chronic or end-stage kidney disease appears complex. Increased adiponectin levels have recently been associated with a range of positive and negative outcomes, presenting something of an epidemiological conundrum in this setting [167]. It is clear from the above that expression of the adiponectin gene is regulated by multiple factors. Once translated, the protein undergoes a series of PTMs as it passes through the secretory pathway and these are intimately involved in the adiponectin multimerization process. As with adiponectin expression, multimerization and secretion are subject to multiple levels of regulation. Although relatively little is known about mechanisms governing adiponectin clearance, studies suggest this may also be altered in pathophysiological states. Interventions at any or all of these steps represent attractive therapeutic opportunities. In the next section we describe the adiponectin receptors. Increasing evidence indicates that these are responsible for mediating the majority of adiponectins effects.
11.13 Adiponectin Receptors and Downstream Effectors
The adiponectin receptors, termed AdipoR1 and AdipoR2, were identified by expression cloning by Kadowaki et al. [9]. They share a high degree of homology and are conserved from yeast to humans [168]. Structural predictions for AdipoR1 and AdipoR2 identified both as members of a novel class of seven transmembrane domain proteins, termed progestin and AdipoQ receptors [169]. While they lack significant homology with other proteins they are distantly related to G-proteincoupled receptors (GPCRs); however, they exhibit reversed topology with an intracellular N-terminus and do not signal via classic GPCR pathways (G-proteins or calcium) [9]. A large body of evidence supports the hypothesis that these adiponectin receptors serve to transduce adiponectin signals. Typically, increasing AdipoR1 and/ or AdipoR2 expression increases adiponectin binding, signaling, and action [9]. Conversely, reducing receptor expression has reciprocal effects [9]. Until recently a lack of suitable antibodies has limited investigation of AdipoR1 and AdipoR2 proteins in relevant tissues, and most studies have combined measurement of mRNA levels with readouts of adiponectin action to infer relative significance and regulation of the two receptors [79, 122, 170–174]. Notable findings from these studies include the early observations that expression of AdipoR1/R2 is reduced by insulin [79]; AdipoR1 expression is reduced in adipose tissue from obese subjects [174]; TZDs do not change expression of AdipoR1/R2 [175]; fibrates increase
j215
j 11 Adiponectin
216
expression of AdipoR1/R2 in adipose tissue [176] but not skeletal muscle [177]; and feeding reduces expression of AdipoR1/R2 [79, 178]. Collectively these studies demonstrate that, like adiponectin, expression of the adiponectin receptors is subject to regulation in response to multiple factors. The characteristics of adiponectin binding to the two receptors have still to be rigorously examined. In the original study, Kadowakis group employed recombinant adiponectin (full-length or globular) purified from bacteria. Notwithstanding, differences were observed with AdipoR1-binding globular adiponectin with high affinity whilst AdipoR2 showed intermediate affinity for both globular and full-length adiponectin [9]. A more recent report using purified trimer, hexamer, and HMW adiponectin from human serum demonstrated that HMW adiponectin was the most potent activator of AMPK in C2C12 myotubes, which express high levels of AdipoR1 [75]. Kadowakis group also recently reported that manipulation of AdipoR1 and/or AdipoR2 in mice altered metabolism in a manner consistent with a central role for both receptors in adiponectin action [179]. The two receptors appeared to have specific downstream targets in liver, with AdipoR1 linked more closely to AMPK whereas AdipoR2 was linked more closely with PPAR-a, prompting speculation that functional differences may be accounted for by AdipoR1- or AdipoR2-specific intracellular binding proteins [179]. In an independent, study Linden et al. found that AdipoR1/ mice were obese, glucose-intolerant, and showed decreased energy expenditure consistent with a positive role for AdipoR1 in energy metabolism; however, AMPK activity was not altered [180]. Perhaps more unexpectedly, they found that AdipoR2/ mice displayed improved insulin sensitivity, exhibiting resistance to diet-induced obesity and increased energy expenditure [180]. Whilst the latter findings are difficult to rationalize in the context of the body of evidence in favor of a positive role for both AdipoR1 and AdipoR2 they are supported by another recent study from Reifel-Miller et al., who found that ablation of AdipoR2 reduced diet-induced weight gain, dyslipidemia, and insulin resistance [181]. Collectively, these studies emphasize the important metabolic role of AdipoR1 and AdipoR2, and also highlight the limitations of our current understanding and the need for additional investigations to further define the molecular details and physiological roles of these receptors.
11.14 Adiponectin Signaling
Adiponectin stimulates the activation of a number of intracellular kinases including AMPK, p38 mitogen-activated protein kinase (MAPK) and c-Jun N-terminal kinase (JNK) via AdipoR1 and AdipoR2 [182]. The signaling pathways are poorly defined, but Dong et al. recently identified APPL1 as a key transducer of the adiponectin signal [10]. APPL1 binds constitutively to both AdipoR1 and AdipoR2, and adiponectin increases this interaction [10]. The phosphotyrosine-binding domain of APPL1 is required for binding, although the receptors are not phosphorylated on
11.15 Conclusions
tyrosine residues [10], and binding presumably occurs via the conserved region of the cytoplasmic tail of the receptors. Adiponectin-stimulated phosphorylation of AMPK and p38 MAPK was increased in C2C12 cells overexpressing APPL1 and decreased in cells with reduced APPL1 [10]. APPL1 has recently been shown to interact directly with AKT2 in 3T3-L1 adipocytes, and it appears to act as a point of convergence between the insulin and adiponectin signaling cascades [10, 182, 183]. APPL1 is also required for the adiponectin-induced, AMPK-dependent phosphorylation and activation of endothelial nitric oxide synthetase in human endothelial cells [84]. Thus, APPL1 has already been implicated in adiponectin-stimulated glucose uptake, fatty acid oxidation [10], and nitric oxide-induced vasodilatation [84], and is likely to be involved in many more of adiponectins pleiotropic actions. Like APPL1, the energy sensor and metabolic regulator AMPK is implicated in most of adiponectins actions and is itself an attractive therapeutic target for obesityrelated diseases. It is a heterotrimer made up of a catalytic a-subunit, and regulatory b- and c-subunits, with distinct isoforms of each subunit (a1/a2, b1/b2 and c1/c2/ c3) present at varying levels in different tissues. Activation of AMPK is complex and can be promoted by a combination of events that include a decrease in the cellular AMP/ATP ratio [184], phosphorylation by upstream kinases, of which four have now been identified (LKB1 [185], calmodulin-dependent protein kinase kinases [186, 187], TAK1 [188], and ataxia telangiectasia mutated kinase [189]), and reduced accessibility to phosphatases [190]. As such, the molecular details by which adiponectin stimulates AMPK remain to be defined and it seems likely that different mechanisms will exist in different cell types. Adiponectin induces fatty acid oxidation in cultured muscle cells (C2C12) by sequential activation of an AMPK–p38 MAPK–PPAR-a pathway [191], whilst the AMPK–p38 MAPK axis also results in NF-kB-dependent, IL-6 production in human synovial fibroblasts [192], suggesting this may be a common pathway. Adiponectin activates JNK in a range of cancer cell lines [193], suppressing constitutive activation of signal transducer and activator of transcription-3, which may contribute to adiponectins anticancer effects [194], and in osteoblasts [195], where JNK activation was linked to proliferation. Interestingly, Goldstein et al. found that full-length and globular adiponectin reduced glucose-induced ROS in human endothelial cells via AMPK-independent, cAMP/protein kinase A (PKA)-dependent pathways [83] and have more recently demonstrated that both AMPK-dependent and cAMP/PKAdependent pathways are involved in adiponectins suppression of IkB activation induced by TNF-a or glucose in these cells [196]. These data highlight how multiple parallel signaling pathways may mediate adiponectins effects and future investigations should help to elaborate the molecular details in different cell types.
11.15 Conclusions
The association between hypoadiponectinemia and metabolic disease provides an ideal scenario for adiponectin therapy. Therapeutic approaches must give due
j217
j 11 Adiponectin
218
consideration to our evolving appreciation of the complexity of adiponectin biology and its pleiotropic actions. Hypoadiponectinemia is characterized by a preferential loss of HMWadiponectin, the major effector in peripheral tissues such as liver, whilst the LMW oligomers, which mediate adiponectins central actions, are relatively unchanged. Hence, strategies to selectively increase the circulating levels of HMW adiponectin appear desirable. This may be achieved by simple administration of recombinant HMW adiponectin or by alternative therapies such as the TZDs, which selectively increase the production and secretion of HMW adiponectin from adipocytes. Whilst emerging evidence suggests that adiponectin resistance may be a feature of obesity, findings to date, albeit mainly from animal studies, suggest that adiponectin treatment will be sufficient to ameliorate many of the complications. In conclusion, the prospect of adiponectin therapy or regulation of adiponectin multimer distribution by affecting production, secretion, clearance or action is an attractive one for the treatment of many facets of obesity-associated diseases. Continued basic and clinical research efforts are warranted to realize the maximum potential of adiponectin-based strategies.
References 1 Scherer, P.E. (2006) Adipose tissue: from
2
3
4
5
6
lipid storage compartment to endocrine organ. Diabetes, 55, 1537–1545. Yamauchi, T., Kamon, J., Waki, H., Terauchi, Y., Kubota, N., Hara, K., Mori, Y., Ide, T. et al. (2001) The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat. Med., 7, 941–946. Berg, A.H., Combs, T.P., Du, X., Brownlee, M., and Scherer, P.E. (2001) The adipocyte-secreted protein Acrp30 enhances hepatic insulin action. Nat. Med., 7, 947–953. Whitehead, J.P., Richards, A.A., Hickman, I.J., Macdonald, G.A., and Prins, J.B. (2006) Adiponectin – a key adipokine in the metabolic syndrome. Diabetes Obes. Metab., 8, 264–280. Scherer, P.E., Williams, S., Fogliano, M., Baldini, G., and Lodish, H.F. (1995) A novel serum protein similar to C1q, produced exclusively in adipocytes. J. Biol. Chem., 270, 26746–26749. Hu, E., Liang, P., and Spiegelman, B.M. (1996) AdipoQ is a novel adipose-specific gene dysregulated in obesity. J. Biol. Chem., 271, 10697–10703.
7 Maeda, K., Okubo, K., Shimomura, I.,
8
9
10
11
Funahashi, T., Matsuzawa, Y., and Matsubara, K. (1996) cDNA cloning and expression of a novel adipose specific collagen-like factor, apM1 (AdiPose Most abundant Gene transcript 1). Biochem. Biophys. Res. Commun., 221, 286–289. Nakano, Y., Tobe, T., Choi-Miura, N.H., Mazda, T., and Tomita, M. (1996) Isolation and characterization of GBP28, a novel gelatin-binding protein purified from human plasma. J. Biochem., 120, 803–812. Yamauchi, T., Kamon, J., Ito, Y., Tsuchida, A., Yokomizo, T., Kita, S., Sugiyama, T., Miyagishi, M. et al. (2003) Cloning of adiponectin receptors that mediate antidiabetic metabolic effects. Nature, 423, 762–769. Mao, X., Kikani, C.K., Riojas, R.A., Langlais, P., Wang, L., Ramos, F.J., Fang, Q., Christ-Roberts, C.Y. et al. (2006) APPL1 binds to adiponectin receptors and mediates adiponectin signalling and function. Nat. Cell. Biol., 8, 516–523. Tomas, E., Tsao, T.S., Saha, A.K., Murrey, H.E., Zhang Cc, C., Itani, S.I., Lodish, H.F., and Ruderman, N.B. (2002) Enhanced muscle fat oxidation and
References
12
13
14
15
16
17
18
19
glucose transport by ACRP30 globular domain: acetyl-CoA carboxylase inhibition and AMP-activated protein kinase activation. Proc. Natl. Acad. Sci. USA, 99, 16309–16313. Yamauchi, T., Kamon, J., Minokoshi, Y., Ito, Y., Waki, H., Uchida, S., Yamashita, S., Noda, M. et al. (2002) Adiponectin stimulates glucose utilization and fattyacid oxidation by activating AMPactivated protein kinase. Nat. Med., 8, 1288–1295. Yamauchi, T., Kamon, J., Waki, H., Imai, Y., Shimozawa, N., Hioki, K., Uchida, S., Ito, Y. et al. (2003) Globular adiponectin protected ob/ob mice from diabetes and ApoE-deficient mice from atherosclerosis. J. Biol. Chem., 278, 2461–2468. Arita, Y., Kihara, S., Ouchi, N., Takahashi, M., Maeda, K., Miyagawa, J., Hotta, K., Shimomura, I. et al. (1999) Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem. Biophys. Res. Commun., 257, 79–83. Weyer, C., Funahashi, T., Tanaka, S., Hotta, K., Matsuzawa, Y., Pratley, R.E., and Tataranni, P.A. (2001) Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. J. Clin. Endocrinol. Metab., 86, 1930–1935. Spranger, J., Kroke, A., Mohlig, M., Bergmann, M.M., Ristow, M., Boeing, H., and Pfeiffer, A.F. (2003) Adiponectin and protection against type 2 diabetes mellitus. Lancet, 361, 226–228. Iwashima, Y., Katsuya, T., Ishikawa, K., Ouchi, N., Ohishi, M., Sugimoto, K., Fu, Y., Motone, M. et al. (2004) Hypoadiponectinemia is an independent risk factor for hypertension. Hypertension, 43, 1318–1323. Kern, P.A., Di Gregorio, G.B., Lu, T., Rassouli, N., and Ranganathan, G. (2003) Adiponectin expression from human adipose tissue: relation to obesity, insulin resistance, and tumor necrosis factoralpha expression. Diabetes, 52, 1779–1785. Targher, G., Bertolini, L., Scala, L., Poli, F., Zenari, L., and Falezza, G. (2004) Decreased plasma adiponectin
20
21
22
23
24
25
26
27
concentrations are closely associated with nonalcoholic hepatic steatosis in obese individuals. Clin. Endocrinol., 61, 700–703. Hui, J.M., Hodge, A., Farrell, G.C., Kench, J.G., Kriketos, A., and George, J. (2004) Beyond insulin resistance in NASH: TNF-alpha or adiponectin? Hepatology, 40, 46–54. Menzaghi, C., Trischitta, V., and Doria, A. (2007) Genetic influences of adiponectin on insulin resistance, type 2 diabetes, and cardiovascular disease. Diabetes, 56, 1198–1209. Waki, H., Yamauchi, T., Kamon, J., Ito, Y., Uchida, S., Kita, S., Hara, K., Hada, Y. et al. (2003) Impaired multimerization of human adiponectin mutants associated with diabetes: molecular structure and multimer formation of adiponectin. J. Biol. Chem., 278, 40352–40363. Bottner, A., Kratzsch, J., Muller, G., Kapellen, T.M., Bluher, S., Keller, E., Bluher, M., and Kiess, W. (2004) Gender differences of adiponectin levels develop during the progression of puberty and are related to serum androgen levels. J. Clin. Endocrinol. Metab., 89, 4053–4061. Tsou, P.L., Jiang, Y.D., Chang, C.C., Wei, J.N., Sung, F.C., Lin, C.C., Chiang, C.C., Tai, T.Y. et al. (2004) Sex-related differences between adiponectin and insulin resistance in schoolchildren. Diabetes Care, 27, 308–313. Xu, A., Chan, K.W., Hoo, R.L., Wang, Y., Tan, K.C., Zhang, J., Chen, B., Lam, M.C. et al. (2005) Testosterone selectively reduces the high molecular weight form of adiponectin by inhibiting its secretion from adipocytes. J. Biol. Chem., 280, 18073–18080. Nishizawa, H., Shimomura, I., Kishida, K., Maeda, N., Kuriyama, H., Nagaretani, H., Matsuda, M., Kondo, H. et al. (2002) Androgens decrease plasma adiponectin, an insulin-sensitizing adipocyte-derived protein. Diabetes, 51, 2734–2741. Lanfranco, F., Zitzmann, M., Simoni, M., and Nieschlag, E. (2004) Serum adiponectin levels in hypogonadal males: influence of testosterone replacement therapy. Clin. Endocrinol., 60, 500–507.
j219
j 11 Adiponectin
220
28 Maeda, N., Shimomura, I., Kishida, K.,
29
30
31
32
33
34
35
36
Nishizawa, H., Matsuda, M., Nagaretani, H., Furuyama, N., Kondo, H. et al. (2002) Diet-induced insulin resistance in mice lacking adiponectin/ACRP30. Nat. Med., 8, 731–737. Ma, K., Cabrero, A., Saha, P.K., Kojima, H., Li, L., Chang, B.H., Paul, A., and Chan, L. (2002) Increased beta-oxidation but no insulin resistance or glucose intolerance in mice lacking adiponectin. J. Biol. Chem., 277, 34658–34661. Kubota, N., Terauchi, Y., Yamauchi, T., Kubota, T., Moroi, M., Matsui, J., Eto, K., Yamashita, T. et al. (2002) Disruption of adiponectin causes insulin resistance and neointimal formation. J. Biol. Chem., 277, 25863–25866. Liao, Y., Takashima, S., Maeda, N., Ouchi, N., Komamura, K., Shimomura, I., Hori, M., Matsuzawa, Y. et al. (2005) Exacerbation of heart failure in adiponectin-deficient mice due to impaired regulation of AMPK and glucose metabolism. Cardiovasc. Res., 67, 795–713. Nawrocki, A.R., Rajala, M.W., Tomas, E., Pajvani, U.B., Saha, A.K., Trumbauer, M.E., Pang, Z., Chen, A.S. et al. (2006) Mice lacking adiponectin show decreased hepatic insulin sensitivity and reduced responsiveness to peroxisome proliferator-activated receptor c agonists. J. Biol. Chem., 281, 2654–2660. Kato, H., Kashiwagi, H., Shiraga, M., Tadokoro, S., Kamae, T., Ujiie, H., Honda, S., Miyata, S. et al. (2006) Adiponectin acts as an endogenous antithrombotic factor. Arterioscler. Thromb. Vasc. Biol., 26, 224–230. Berg, A.H., Combs, T.P., and Scherer, P.E. (2002) ACRP30/adiponectin: an adipokine regulating glucose and lipid metabolism. Trends Endocrinol. Metab., 13, 84–89. Chen, H., Montagnani, M., Funahashi, T., Shimomura, I., and Quon, M.J. (2003) Adiponectin stimulates production of nitric oxide in vascular endothelial cells. J. Biol. Chem., 278, 45021–45026. Shibata, R., Ouchi, N., Ito, M., Kihara, S., Shiojima, I., Pimentel, D.R., Kumada, M., Sato, K. et al. (2004) Adiponectin-
37
38
39
40
41
42
43
mediated modulation of hypertrophic signals in the heart. Nat. Med., 10, 1384–1389. Kubota, N., Yano, W., Kubota, T., Yamauchi, T., Itoh, S., Kumagai, H., Kozono, H., Takamoto, I. et al. (2007) Adiponectin stimulates AMP-activated protein kinase in the hypothalamus and increases food intake. Cell Metab., 6, 55–68. Tsao, T.-S., Tomas, E., Murrey, H.E., Hug, C., Lee, D.H., Ruderman, N.B., Heuser, J.E., and Lodish, H.F. (2003) Role of disulfide bonds in Acrp30/adiponectin structure and signaling specificity: different oligomers activate different signal transduction pathways. J. Biol. Chem., 278, 50810–50817. Shapiro, L. and Scherer, P.E. (1998) The crystal structure of a complement-1q family protein suggests an evolutionary link to tumor necrosis factor. Curr. Biol., 8, 335–340. Richards, A.A., Stephens, T., Charlton, H.K., Jones, A., Macdonald, G.A., Prins, J.B., and Whitehead, J.P. (2006) Adiponectin multimerisation is dependent on conserved lysines in the collagenous domain: evidence for regulation of multimerisation by alterations in post-translational modifications. Mol. Endocrinol., 20, 1673–1687. Pajvani, U.B., Du, X., Combs, T.P., Berg, A.H., Rajala, M.W., Schulthess, T., Engel, J., Brownlee, M. et al. (2003) Structure–function studies of the adipocyte-secreted hormone Acrp30/ adiponectin. Implications for metabolic regulation and bioactivity. J. Biol. Chem., 278, 9073–9085. Wang, Y., Lam, K.S.L., Chan, L., Chan, K.W., Lam, J.B.B., Lam, M.C., Hoo, R.C.L., Mak, W.W.N. et al. (2006) Posttranslational modifications on the four conserved lysine residues within the collagenous domain of adiponectin are required for the formation of its highmolecular-weight oligomeric complex. J. Biol. Chem., 281, 16391–16400. Sato, C., Yasukawa, Z., Honda, N., Matsuda, T., and Kitajima, K. (2001) Identification and adipocyte
References
44
45
46
47
48
49
50
differentiation-dependent expression of the unique disialic acid residue in an adipose tissue-specific glycoprotein, adipo Q. J. Biol. Chem., 276, 28849–28856. Peake, P.W., Hughes, J.T., Shen, Y., and Charlesworth, J.A. (2007) Glycosylation of human adiponectin affects its conformation and stability. J. Mol. Endocrinol., 39, 45–52. Fruebis, J., Tsao, T.S., Javorschi, S., Ebbets-Reed, D., Erickson, M.R., Yen, F.T., Bihain, B.E., and Lodish, H.F. (2001) Proteolytic cleavage product of 30-kDa adipocyte complement-related protein increases fatty acid oxidation in muscle and causes weight loss in mice. Proc. Natl. Acad. Sci. USA, 98, 2005–2010. Waki, H., Yamauchi, T., Kamon, J., Kita, S., Ito, Y., Hada, Y., Uchida, S., Tsuchida, A. et al. (2004) Generation of globular fragment of adiponectin by leukocyte elastase secreted by monocytic cell line THP-1. Endocrinology, 146, 790–796. Pajvani, U.B., Hawkins, M., Combs, T.P., Rajala, M.W., Doebber, T., Berger, J.P., Wagner, J.A., Wu, M. et al. (2004) Complex distribution, not absolute amount of adiponectin, correlates with thiazolidinedione -mediated improvement in insulin sensitivity. J. Biol. Chem., 279, 12152–12162. Wang, A.Y.-H., Hickman, I.J., Richards, A.A., Whitehead, J.P., Prins, J.B., and MacDonald, G.A. (2005) High molecular weight adiponectin correlates with insulin sensitivity in patients with Hepatitis C Genotype 3 but not Genotype 1 infection. Am. J. Gasteroenterol., 100, 2717–2723. Kobayashi, H., Ouchi, N., Kihara, S., Walsh, K., Kumada, M., Abe, Y., Funahashi, T., and Matsuzawa, Y. (2004) Selective suppression of endothelial cell apoptosis by the high molecular weight form of adiponectin. Circ. Res., 94, e27–e31. Fisher, F.F., Trujillo, M.E., Hanif, W., Barnett, A.H., McTernan, P.G., Scherer, P.E., and Kumar, S. (2005) Serum high molecular weight complex of adiponectin correlates better with glucose tolerance
51
52
53
54
55
56
57
58
than total serum adiponectin in IndoAsian males. Diabetologia, 48, 1084–1087. Lara-Castro, C., Luo, N., Wallace, P., Klein, R.L., and Garvey, W.T. (2006) Adiponectin multimeric complexes and the metabolic syndrome trait cluster. Diabetes, 55, 249–259. Bobbert, T., Rochlitz, H., Wegewitz, U., Akpulat, S., Mai, K., Weickert, M.O., Mohlig, M., Pfeiffer, A.F.H. et al. (2005) Changes of adiponectin oligomer composition by moderate weight reduction. Diabetes, 54, 2712–2719. Hammarstedt, A., Sopasakis, V.R., Gogg, S., Jansson, P.A., and Smith, U. (2005) Improved insulin sensitivity and adipose tissue dysregulation after short-term treatment with pioglitazone in nondiabetic, insulin-resistant subjects. Diabetologia, 48, 96–104. Tonelli, J., Li, W., Kishore, P., Pajvani, U.B., Kwon, E., Weaver, C., Scherer, P.E., and Hawkins, M. (2004) Mechanisms of early insulin-sensitizing effects of thiazolidinediones in type 2 diabetes. Diabetes, 53, 1621–1629. Nakano, Y., Tajima, S., Yoshimi, A., Akiyama, H., Tsushima, M., Tanioka, T., Negoro, T., Tomita, M. et al. (2006) A novel enzyme-linked immunosorbent assay specific for high-molecular weight adiponectin. J. Lipid Res., 47, 1572–1582. Ebinuma, H., Miyazaki, O., Yago, H., Hara, K., Yamauchi, T., and Kadowaki, T. (2006) A novel ELISA system for selective measurement of human adiponectin multimers by using proteases. Clin. Chim. Acta, 372, 47–53. Sinha, M.K., Songer, T., Xiao, Q., Sloan, J.H., Wang, J., Ji, S., Alborn, W.E., Davis, R.A., Swarbrick, M.M. et al. (2007) Analytical validation and biological evaluation of a high molecular-weight adiponectin ELISA. Clin. Chem., 53, 2144–2151. Aso, Y., Yamamoto, R., Wakabayashi, S., Uchida, T., Takayanagi, K., Takebayashi, K., Okuno, T., Inoue, T. et al. (2006) Comparison of serum high-molecular weight (HMW) adiponectin with total adiponectin concentrations in type 2 diabetic patients with coronary artery disease using a novel enzyme-linked
j221
j 11 Adiponectin
222
59
60
61
62
63
64
65
66
immunosorbent assay to detect HMW adiponectin. Diabetes, 55, 1954–1960. Tsutamoto, T., Tanaka, T., Sakai, H., Ishikawa, C., Fujii, M., Yamamoto, T., and Horie, M. (2007) Total and high molecular weight adiponectin, haemodynamics, and mortality in patients with chronic heart failure. Eur. Heart J., 28, 1723–1730. Hara, K., Horikoshi, M., Yamauchi, T., Yago, H., Miyazaki, O., Ebinuma, H., Imai, Y., Nagai, R. et al. (2006) Measurement of the high-molecular weight form of adiponectin in plasma is useful for the prediction of insulin resistance and metabolic syndrome. Diabetes Care, 29, 1357–1362. Tsao, T.S., Murrey, H.E., Hug, C., Lee, D.H., and Lodish, H.F. (2002) Oligomerization state-dependent activation of NF-kappa B signaling pathway by adipocyte complementrelated protein of 30 kDa (Acrp30). J. Biol. Chem., 277, 29359–29362. Wang, Y., Xu, A., Knight, C., Xu, L.Y., and Cooper, G.J.S. (2002) Hydroxylation and glycosylation of the four conserved lysine residues in the collagenous domain of adiponectin. Potential role in the modulation of its insulin-sensitizing activity. J. Biol. Chem., 277, 19521–19529. Wang, Y., Lu, G., Wong, W.P., Vliegenthart, J.F., Gerwig, G.J., Lam, K.S., Cooper, G.J., and Xu, A. (2004) Proteomic and functional characterization of endogenous adiponectin purified from fetal bovine serum. Proteomics, 4, 3933–3942. Xu, A., Wang, Y., Keshaw, H., Xu, L.Y., Lam, K.S.L., and Cooper, G.J.S. (2003) The fat-derived hormone adiponectin alleviates alcoholic and nonalcoholic fatty liver diseases in mice. J. Clin. Invest., 112, 91–100. Park, P.-h., Thakur, V., Pritchard, M.T., McMullen, M.R., and Nagy, L.E. (2006) Regulation of Kupffer cell activity during chronic ethanol exposure: role of adiponectin. J. Gastroenterol. Hepatol., 21, S30–S33. Matsuura, F., Oku, H., Koseki, M., Sandoval, J.C., Yuasa-Kawase, M., Tsubakio-Yamamoto, K., Masuda, D.,
67
68
69
70
71
72
73
Maeda, N. et al. (2007) Adiponectin accelerates reverse cholesterol transport by increasing high density lipoprotein assembly in the liver. Biochem. Biophys. Res. Commun., 358, 1091–1095. Cnop, M., Havel, P.J., Utzschneider, K.M., Carr, D.B., Sinha, M.K., Boyko, E.J., Retzlaff, B.M., Knopp, R.H. et al. (2003) Relationship of adiponectin to body fat distribution, insulin sensitivity and plasma lipoproteins: evidence for independent roles of age and sex. Diabetologia, 46, 459–469. Tschritter, O., Fritsche, A., Thamer, C., Haap, M., Shirkavand, F., Rahe, S., Staiger, H., Maerker, E. et al. (2003) Plasma adiponectin concentrations predict insulin sensitivity of both glucose and lipid metabolism. Diabetes, 52, 239–243. Pagano, C., Soardo, G., Esposito, W., Fallo, F., Basan, L., Donnini, D., Federspil, G., Sechi, L.A. et al. (2005) Plasma adiponectin is decreased in nonalcoholic fatty liver disease. Eur. J. Endocrinol., 152, 113–118. Bugianesi, E., Pagotto, U., Manini, R., Vanni, E., Gastaldelli, A., de Iasio, R., Gentilcore, E., Natale, S. et al. (2005) Plasma adiponectin in nonalcoholic fatty liver is related to hepatic insulin resistance and hepatic fat content, not to liver disease severity. J. Clin. Endocrinol. Metab., 90, 3498–3504. Kaser, S., Moschen, A., Kaser, A., Ludwiczek, O., Ebenbichler, C.F., Vogel, W., Jaschke, W., Patsch, J.R., and Tilg, H. (2005) Circulating adiponectin reflects severity of liver disease but not insulin sensitivity in liver cirrhosis. J. Intern. Med., 258, 274–280. Hui, C.-K., Zhang, H.-Y., Lee, N.P., Chan, W., Yueng, Y.-H., Leung, K.-W., Lu, L., Leung, N. et al. (2007) Serum adiponectin is increased in advancing liver fibrosis and declines with reduction in fibrosis in chronic hepatitis B. J. Hepatol., 47, 191–202. Jonsson, J.R., Moschen, A.R., Hickman, I.J., Richardson, M.M., Kaser, S., Clouston, A.D., Powell, E.E., and Tilg, H. (2005) Adiponectin and its receptors in
References
74
75
76
77
78
79
80
81
patients with chronic hepatitis C. J. Hepatol., 43, 929–936. Tacke, F., Wustefeld, T., Horn, R., Luedde, T., Srinivas Rao, A., Manns, M.P., Trautwein, C., and Brabant, G. (2005) High adiponectin in chronic liver disease and cholestasis suggests biliary route of adiponectin excretion in vivo. J. Hepatol., 42, 666–673. Hada, Y., Yamauchi, T., Waki, H., Tsuchida, A., Hara, K., Yago, H., Miyazaki, O., Ebinuma, H. et al. (2007) Selective purification and characterization of adiponectin multimer species from human plasma. Biochem. Biophys. Res. Commun., 356, 487–493. Civitarese, A.E., Ukropcova, B., Carling, S., Hulver, M., Defronzo, R.A., Mandarino, L., Ravussin, E., and Smith, S.R. (2006) Role of adiponectin in human skeletal muscle bioenergetics. Cell Metab., 4, 75–87. Bruce, C.R., Mertz, V.A., Heigenhauser, G.J., and Dyck, D.J. (2005) The stimulatory effect of globular adiponectin on insulin-stimulated glucose uptake and fatty acid oxidation is impaired in skeletal muscle from obese subjects. Diabetes, 54, 3154–3160. Chen, M.B., McAinch, A.J., Macaulay, S.L., Castelli, L.A., OBrien, P.E., Dixon, J.B., Cameron-Smith, D., Kemp, B.E. et al. (2005) Impaired activation of AMPkinase and fatty acid oxidation by globular adiponectin in cultured human skeletal muscle of obese type 2 diabetics. J. Clin. Endocrinol. Metab., 90, 3665–3672. Tsuchida, A., Yamauchi, T., Ito, Y., Hada, Y., Maki, T., Takekawa, S., Kamon, J., Kobayashi, M. et al. (2004) Insulin/foxo1 pathway regulates expression levels of adiponectin receptors and adiponectin sensitivity. J. Biol. Chem., 279, 30817–30822. Okamoto, Y., Arita, Y., Nishida, M., Muraguchi, M., Ouchi, N., Takahashi, M., Igura, T., Inui, Y. et al. (2000) An adipocyte-derived plasma protein, adiponectin, adheres to injured vascular walls. Horm. Metab. Res., 32, 47–50. Ouchi, N., Kihara, S., Arita, Y., Maeda, K., Kuriyama, H., Okamoto, Y., Hotta, K., Nishida, M. et al. (1999) Novel modulator
82
83
84
85
86
87
88
89
for endothelial adhesion molecules: adipocyte-derived plasma protein adiponectin. Circulation, 100, 2473–2476. Ouchi, N., Kihara, S., Arita, Y., Okamoto, Y., Maeda, K., Kuriyama, H., Hotta, K., Nishida, M. et al. (2000) Adiponectin, an adipocyte-derived plasma protein, inhibits endothelial NF-kappaB signaling through a cAMP-dependent pathway. Circulation, 102, 1296–1301. Ouedraogo, R., Wu, X., Xu, S.-Q., Fuchsel, L., Motoshima, H., Mahadev, K., Hough, K., Scalia, R. et al. (2006) Adiponectin suppression of highglucose-induced reactive oxygen species in vascular endothelial cells: evidence for involvement of a cAMP signaling pathway. Diabetes, 55, 1840–1846. Cheng, K.K., Lam, K.S., Wang, Y., Yu, H., Carling, D., Wu, D., Wong, C., and Xu, A. (2007) Adiponectin-induced eNOS activation and nitric oxide production are mediated by APPL1 in endothelial cells. Diabetes, 56, 1387–1394. Shimabukuro, M., Higa, N., Asahi, T., Oshiro, Y., Takasu, N., Tagawa, T., Ueda, S., Shimomura, I. et al. (2003) Hypoadiponectinemia is closely linked to endothelial dysfunction in man. J. Clin. Endocrinol. Metab., 88, 3236–3240. Brakenhielm, E., Veitonmaki, N., Cao, R., Kihara, S., Matsuzawa, Y., Zhivotovsky, B., Funahashi, T., and Cao, Y. (2004) Adiponectin-induced antiangiogenesis and antitumor activity involve caspasemediated endothelial cell apoptosis. Proc. Natl. Acad. Sci. USA, 101, 2476–2481. Matsuda, M., Shimomura, I., Sata, M., Arita, Y., Nishida, M., Maeda, N., Kumada, M., Okamoto, Y. et al. (2002) Role of adiponectin in preventing vascular stenosis. The missing link of adipo-vascular axis. J. Biol. Chem., 277, 37487–37491. Shibata, R., Ouchi, N., Kihara, S., Sato, K., Funahashi, T., and Walsh, K. (2004) Adiponectin stimulates angiogenesis in response to tissue ischemia through stimulation of AMP-activated protein kinase signaling. J. Biol. Chem., 279, 28670–28674. Ouchi, N., Kobayashi, H., Kihara, S., Kumada, M., Sato, K., Inoue, T.,
j223
j 11 Adiponectin
224
90
91
92
93
94
95
96
Funahashi, T., and Walsh, K. (2004) Adiponectin stimulates angiogenesis by promoting cross-talk between AMPactivated protein kinase and Akt signaling in endothelial cells. J. Biol. Chem., 279, 1304–1309. Arita, Y., Kihara, S., Ouchi, N., Maeda, K., Kuriyama, H., Okamoto, Y., Kumada, M., Hotta, K. et al. (2002) Adipocyte-derived plasma protein adiponectin acts as a platelet-derived growth factor-BBbinding protein and regulates growth factor-induced common postreceptor signal in vascular smooth muscle cell. Circulation, 105, 2893–2898. Wang, Y., Lam, K.S., Xu, J.Y., Lu, G., Xu, L.Y., Cooper, G.J., and Xu, A. (2005) Adiponectin inhibits cell proliferation by interacting with several growth factors in an oligomerization dependent manner. J. Biol. Chem., 280, 18341–18347. Peake, P.W., Shen, Y., Campbell, L.V., and Charlesworth, J.A. (2006) Human adiponectin binds to bacterial lipopolysaccharide. Biochem. Biophys. Res. Commun., 341, 108–115. Masaie, H., Oritani, K., Yokota, T., Takahashi, I., Shirogane, T., Ujiie, H., Ichii, M., Saitoh, N. et al. (2007) Adiponectin binds to chemokines via the globular head and modulates interactions between chemokines and heparan sulfates. Exp. Hematol., 35, 947–956. Ouchi, N., Kihara, S., Arita, Y., Nishida, M., Matsuyama, A., Okamoto, Y., Ishigami, M., Kuriyama, H. et al. (2001) Adipocyte-derived plasma protein, adiponectin, suppresses lipid accumulation and class A scavenger receptor expression in human monocytederived macrophages. Circulation, 103, 1057–1063. Yokota, T., Oritani, K., Takahashi, I., Ishikawa, J., Matsuyama, A., Ouchi, N., Kihara, S., Funahashi, T. et al. (2000) Adiponectin, a new member of the family of soluble defense collagens, negatively regulates the growth of myelomonocytic progenitors and the functions of macrophages. Blood, 96, 1723–1732. Takemura, Y., Ouchi, N., Shibata, R., Aprahamian, T., Kirber, M.T., Summer,
97
98
99
100
101
102
103
104
R.S., Kihara, S., and Walsh, K. (2007) Adiponectin modulates inflammatory reactions via calreticulin receptordependent clearance of early apoptotic bodies. J. Clin. Invest., 117, 375–386. Spranger, J., Verma, S., Gohring, I., Bobbert, T., Seifert, J., Sindler, A.L., Pfeiffer, A., Hileman, S.M. et al. (2006) Adiponectin does not cross the blood–brain barrier but modifies cytokine expression of brain endothelial cells. Diabetes, 55, 141–147. Pan, W. and Kastin, A.J. (2007) Adipokines and the blood–brain barrier. Peptides, 28, 1317–1330. Neumeier, M., Weigert, J., Buettner, R., Wanninger, J., Schaffler, A., Muller, A.M., Killian, S., Sauerbruch, S. et al. (2007) Detection of adiponectin in cerebrospinal fluid in humans. Am. J. Physiol. Endocrinol. Metab., 293, E965–E969. Kos, K., Harte, A.L., da Silva, N.F., Tonchev, A., Chaldakov, G., James, S., Snead, D.R., Hoggart, B. et al. (2007) Adiponectin and resistin in human cerebrospinal fluid and expression of adiponectin receptors in the human hypothalamus. J. Clin. Endocrinol. Metab., 92, 1129–1136. Kusminski, C.M., McTernan, P.G., Schraw, T., Kos, K., OHare, J.P., Ahima, R., Kumar, S., and Scherer, P.E. (2007) Adiponectin complexes in human cerebrospinal fluid: distinct complex distribution from serum. Diabetologia, 50, 634–642. Behre, C.J. (2007) Adiponectin: saving the starved and the overfed. Med. Hypotheses, 69, 1290–1292. Kim, J.-Y., van de Wall, E., Laplante, M., Azzara, A., Trujillo, M.E., Hofmann, S.M., Schraw, T., Durand, J.L. et al. (2007) Obesity-associated improvements in metabolic profile through expansion of adipose tissue. J. Clin. Invest., 117, 2621–2637. Peake, P.W., Kriketos, A.D., Denyer, G.S., Campbell, L.V., and Charlesworth, J.A. (2003) The postprandial response of adiponectin to a high-fat meal in normal and insulin-resistant subjects. Int. J. Obes. Relat. Relat. Disord., 27, 657–662.
References 105 Peake, P.W., Kriketos, A.D., Campbell,
106
107
108
109
110
111
112
L.V., Shen, Y., and Charlesworth, J.A. (2005) The metabolism of isoforms of human adiponectin: studies in human subjects and in experimental animals. Eur. J. Endocrinol., 153, 409–417. Halberg, N., Henriksen, M., Soderhamn, N., Stallknecht, B., Ploug, T., Schjerling, P., and Dela, F. (2005) Effect of intermittent fasting and refeeding on insulin action in healthy men. J. Appl. Physiol., 99, 2128–2136. Fu, Y., Luo, N., Klein, R.L., and Garvey, W.T. (2005) Adiponectin promotes adipocyte differentiation, insulin sensitivity, and lipid accumulation. J. Lipid Res., 46, 1369–1379. Zhang, Y., Matheny, M., Zolotukhin, S., Tumer, N., and Scarpace, P.J. (2002) Regulation of adiponectin and leptin gene expression in white and brown adipose tissues: influence of beta3-adrenergic agonists, retinoic acid, leptin and fasting. Biochim. Biophys. Acta, 1584, 115–122. Fain, J.N., Madan, A.K., Hiler, M.L., Cheema, P., and Bahouth, S.W. (2004) Comparison of the release of adipokines by adipose tissue, adipose tissue matrix and adipocytes from visceral and subcutaneous abdominal adipose tissues of obese humans. Endocrinology, 145, 2273–2282. Motoshima, H., Wu, X., Sinha, M.K., Hardy, V.E., Rosato, E.L., Barbot, D.J., Rosato, F.E., and Goldstein, B.J. (2002) Differential regulation of adiponectin secretion from cultured human omental and subcutaneous adipocytes: effects of insulin and rosiglitazone. J. Clin. Endocrinol. Metab., 87, 5662–5667. Perrini, S., Laviola, L., Cignarelli, A., Melchiorre, M., De Stefano, F., Caccioppoli, C., Natalicchio, A., Orlando, M.R. et al. (2007) Fat depot-related differences in gene expression, adiponectin secretion, and insulin action and signalling in human adipocytes differentiated in vitro from precursor stromal cells. Diabetologia, 51, 155–164. Bogan, J.S. and Lodish, H.F. (1999) Two compartments for insulin-stimulated exocytosis in 3T3-L1 adipocytes defined
113
114
115
116
117
118
119
120
121
by endogenous ACRP30 and GLUT4. J. Cell Biol., 146, 609–620. Pereira, R.I. and Draznin, B. (2005) Inhibition of the phosphatidylinositol 30 kinase signaling pathway leads to decreased insulin-stimulated adiponectin secretion from 3T3-L1 adipocytes. Metabolism, 54, 1636–1643. Clarke, M., Ewart, M.A., Santy, L.C., Prekeris, R., and Gould, G.W. (2006) ACRP30 is secreted from 3T3-L1 adipocytes via a Rab11-dependent pathway. Biochem. Biophys. Res. Commun., 342, 1361–1367. Wang, Z.V., Schraw, T.D., Kim, J.-Y., Khan, T., Rajala, M.W., Follenzi, A., and Scherer, P.E. (2007) Secretion of the adipocyte-specific secretory protein adiponectin critically depends on thiolmediated protein retention. Mol. Cell. Biol., 27, 3716–3731. Qiang, L., Wang, H., and Farmer, S.R. (2007) Adiponectin secretion is regulated by SIRT1 and the endoplasmic reticulum oxidoreductase Ero1-La. Mol. Cell. Biol., 27, 4698–4707. Xie, L., Boyle, D., Sanford, D., Scherer, P.E., Pessin, J.E., and Mora, S. (2005) Intracellular trafficking and secretion of adiponectin is dependent on GGA coated vesicles. J. Biol. Chem., 281, 7253–7259. Bose, A., Guilherme, A., Huang, S., Hubbard, A.C., Lane, C.R., Soriano, N.A., and Czech, M.P. (2005) The v-SNARE Vti1a regulates insulin-stimulated glucose transport and Acrp30 secretion in 3T3-L1 adipocytes. J. Biol. Chem., 280, 36946–36951. Yoda-Murakami, M., Taniguchi, M., Takahashi, K., Kawamata, S., Saito, K., Choi-Miura, N.H., and Tomita, M. (2001) Change in expression of GBP28/ adiponectin in carbon tetrachlorideadministrated mouse liver. Biochem. Biophys. Res. Commun., 285, 372–377. Kaser, S., Moschen, A., Cayon, A., Kaser, A., Crespo, J., Pons-Romero, F., Ebenbichler, C.F., Patsch, J.R. et al. (2005) Adiponectin and its receptors in nonalcoholic steatohepatitis. Gut, 54, 117–121. Delaigle, A.M., Jonas, J.C., Bauche, I.B., Cornu, O., and Brichard, S.M. (2004)
j225
j 11 Adiponectin
226
122
123
124
125
126
127
128
129
Induction of adiponectin in skeletal muscle by inflammatory cytokines: in vivo and in vitro studies. Endocrinology, 145, 5589–5597. Berner, H.S., Lyngstadaas, S.P., Spahr, A., Monjo, M., Thommesen, L., Drevon, C.A., Syversen, U., and Reseland, J.E. (2004) Adiponectin and its receptors are expressed in bone-forming cells. Bone, 35, 842–849. Caminos, J.E., Nogueiras, R., Gallego, R., Bravo, S., Tovar, S., Garcia-Caballero, T., Casanueva, F.F., and Dieguez, C. (2005) Expression and regulation of adiponectin and receptor in human and rat placenta. J. Clin. Endocrinol. Metab., 90, 4276–4286. Chen, J., Tan, B., Karteris, E., Zervou, S., Digby, J., Hillhouse, E.W., Vatish, M., and Randeva, H.S. (2006) Secretion of adiponectin by human placenta: differential modulation of adiponectin and its receptors by cytokines. Diabetologia, 49, 1292–1302. Hotta, K., Funahashi, T., Bodkin, N.L., Ortmeyer, H.K., Arita, Y., Hansen, B.C., and Matsuzawa, Y. (2001) Circulating concentrations of the adipocyte protein adiponectin are decreased in parallel with reduced insulin sensitivity during the progression to type 2 diabetes in rhesus monkeys. Diabetes, 50, 1126–1133. Bluher, M., Michael, M.D., Peroni, O.D., Ueki, K., Carter, N., Kahn, B.B., and Kahn, C.R. (2002) Adipose tissue selective insulin receptor knockout protects against obesity and obesity-related glucose intolerance. Dev. Cell, 3, 25–38. Semple, R.K., Soos, M.A., Luan, J., Mitchell, C.S., Wilson, J.C., Gurnell, M., Cochran, E.K., Gorden, P. et al. (2006) Elevated plasma adiponectin in humans with genetically defective insulin receptors. J. Clin. Endocrinol. Metab., 91, 3219–3223. Semple, R.K., Halberg, N.H., Burling, K., Soos, M.A., Schraw, T., Luan, J.A., Cochran, E.K., Dunger, D.B. et al. (2007) Paradoxical elevation of high-molecular weight adiponectin in acquired extreme insulin resistance due to insulin receptor antibodies. Diabetes, 56, 1712–1717. Imagawa, A., Funahashi, T., Nakamura, T., Moriwaki, M., Tanaka, S., Nishizawa,
130
131
132
133
134
135
136
137
H., Sayama, K., Uno, S. et al. (2002) Elevated serum concentration of adiposederived factor, adiponectin, in patients with type 1 diabetes. Diabetes Care, 25, 1665–1666. Hadjadj, S., Aubert, R., Fumeron, F., Pean, F., Tichet, J., Roussel, R., and Marre, M. (2005) Increased plasma adiponectin concentrations are associated with microangiopathy in type 1 diabetic subjects. Diabetologia, 48, 1088–1092. Furukawa, S., Fujita, T., Shimabukuro, M., Iwaki, M., Yamada, Y., Nakajima, Y., Nakayama, O., Makishima, M. et al. (2004) Increased oxidative stress in obesity and its impact on metabolic syndrome. J. Clin. Invest., 114, 1752–1761. Hattori, S., Hattori, Y., and Kasai, K. (2005) Hypoadiponectinemia is caused by chronic blockade of nitric oxide synthesis in rats. Metabolism, 54, 482–487. Fujita, K., Nishizawa, H., Funahashi, T., Shimomura, I., and Shimabukuro, M. (2006) Systemic oxidative stress is associated with visceral fat accumulation and the metabolic syndrome. Circ. J., 70, 1437–1442. Katsuki, A., Suematsu, M., Gabazza, E.C., Murashima, S., Nakatani, K., Togashi, K., Yano, Y., Adachi, Y. et al. (2006) Increased oxidative stress is associated with decreased circulating levels of adiponectin in Japanese metabolically obese, normal-weight men with normal glucose tolerance. Diabetes Res. Clin. Pract., 73, 310–314. Houstis, N., Rosen, E.D., and Lander, E.S. (2006) Reactive oxygen species have a causal role in multiple forms of insulin resistance. Nature, 440, 944–948. Kurata, A., Nishizawa, H., Kihara, S., Maeda, N., Sonoda, M., Okada, T., Ohashi, K., Hibuse, T. et al. (2006) Blockade of angiotensin II type-1 receptor reduces oxidative stress in adipose tissue and ameliorates adipocytokine dysregulation. Kidney Int., 70, 1717–1724. Furuya, R., Odamaki, M., Kumagai, H., and Hishida, A. (2006) Impact of angiotensin II receptor blocker on plasma
References
138
139
140
141
142
143
144
levels of adiponectin and advanced oxidation protein products in peritoneal dialysis patients. Blood Purif., 24, 445–450. Hosogai, N., Fukuhara, A., Oshima, K., Miyata, Y., Tanaka, S., Segawa, K., Furukawa, S., Tochino, Y. et al. (2007) Adipose tissue hypoxia in obesity and its impact on adipocytokine dysregulation. Diabetes, 56, 901–911. Chevillotte, E., Giralt, M., Miroux, B., Ricquier, D., and Villarroya, F. (2007) Uncoupling protein-2 controls adiponectin gene expression in adipose tissue through the modulation of reactive oxygen species production. Diabetes, 56, 1042–1050. Nguyen, M.T.A., Satoh, H., Favelyukis, S., Babendure, J.L., Imamura, T., Sbodio, J.l., Zalevsky, J., Dahiyat, B.I. et al. (2005) JNK and TNF-a mediated free fatty acidinduced insulin resistance in 3T3-L1 adipocytes. J. Biol. Chem., 280, 35361–35371. Kanatani, Y., Usui, I., Ishizuka, K., Bukhari, A., Fujisaka, S., Urakaze, M., Haruta, T., Kishimoto, T. et al. (2007) Effects of pioglitazone on suppressor of cytokine signaling 3 expression: potential mechanisms for its effects on insulin sensitivity and adiponectin expression. Diabetes, 56, 795–803. Rasouli, N., Yao-Borengasser, A., Miles, L.M., Elbein, S.C., and Kern, P.A. (2006) Increased plasma adiponectin in response to pioglitazone does not result from increased gene expression. Am. J. Physiol. Endocrinol. Metab., 290, E42–E46. Neschen, S., Morino, K., Rossbacher, J.C., Pongratz, R.L., Cline, G.W., Sono, S., Gillum, M., and Shulman, G.I. (2006) Fish oil regulates adiponectin secretion by a peroxisome proliferator-activated receptor-c-dependent mechanism in mice. Diabetes, 55, 924–928. Todoric, J., Loffler, M., Huber, J., Bilban, M., Reimers, M., Kadl, A., Zeyda, M., Waldhausl, W. et al. (2006) Adipose tissue inflammation induced by high-fat diet in obese diabetic mice is prevented by n-3 polyunsaturated fatty acids. Diabetologia, 49, 2109–2119.
145 Abbasi, F., Lamendola, C., McLaughlin,
146
147
148
149
150
151
152
T., Hayden, J., Reaven, G.M., and Reaven, P.D. (2004) Plasma adiponectin concentrations do not increase in association with moderate weight loss in insulin-resistant, obese women. Metabolism, 53, 280–283. Abbasi, F., Chang, S.-A., Chu, J.W., Ciaraldi, T.P., Lamendola, C., McLaughlin, T., Reaven, G.M., and Reaven, P.D. (2006) Improvements in insulin resistance with weight loss, in contrast to rosiglitazone, are not associated with changes in plasma adiponectin or adiponectin multimeric complexes. Am. J. Physiol. Regul. Comp. Physiol., 290, R139–R144. Hotta, K., Funahashi, T., Arita, Y., Takahashi, M., Matsuda, M., Okamoto, Y., Iwahashi, H., Kuriyama, H. et al. (2000) Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. Arterioscler. Thromb. Vasc. Biol., 20, 1595–1599. Yang, W.S., Lee, W.J., Funahashi, T., Tanaka, S., Matsuzawa, Y., Chao, C.L., Chen, C.L., Tai, T.Y. et al. (2001) Weight reduction increases plasma levels of an adipose-derived anti-inflammatory protein, adiponectin. J. Clin. Endocrinol. Metab., 86, 3815–3819. Hulver, M.W., Zheng, D., Tanner, C.J., Houmard, J.A., Kraus, W.E., Slentz, C.A., Sinha, M.K., Pories, W.J. et al. (2002) Adiponectin is not altered with exercise training despite enhanced insulin action. Am. J. Physiol. Endocrinol. Metab., 283, E861–E865. Behre, C.J., Gummesson, A., Jernas, M., Lystig, T.C., Fagerberg, B., Carlsson, B., and Carlsson, L.M.S. (2007) Dissociation between adipose tissue expression and serum levels of adiponectin during and after diet-induced weight loss in obese subjects with and without the metabolic syndrome. Metabolism, 56, 1022–1028. Vu, V., Riddell, M.C., and Sweeney, G. (2007) Circulating adiponectin and adiponectin receptor expression in skeletal muscle: effects of exercise. Diabetes. Metab. Res. Rev., 23, 600–611. Bensaid, M., Gary-Bobo, M., Esclangon, A., Maffrand, J.P., Le Fur, G., Oury-Donat,
j227
j 11 Adiponectin
228
153
154
155
156
157
158
159
F., and Soubrie, P. (2003) The cannabinoid CB1 receptor antagonist SR141716 increases Acrp30 mRNA expression in adipose tissue of obese fa/fa rats and in cultured adipocyte cells. Mol. Pharmacol., 63, 908–914. Gary-Bobo, M., Elachouri, G., Gallas, J.F., Janiak, P., Marini, P., Ravinet-Trillou, C., Chabbert, M., Cruccioli, N. et al. (2007) Rimonabant reduces obesity-associated hepatic steatosis and features of metabolic syndrome in obese Zucker fa/ fa rats. Hepatology, 46, 122–129. Thornton-Jones, Z.D., Kennett, G.A., Benwell, K.R., Revell, D.F., Misra, A., Sellwood, D.M., Vickers, S.P., and Clifton, P.G. (2006) The cannabinoid CB1 receptor inverse agonist, rimonabant, modifies body weight and adiponectin function in diet-induced obese rats as a consequence of reduced food intake. Pharmacol. Biochem. Behav., 84, 353–359. Delporte, M.L., Funahashi, T., Takahashi, M., Matsuzawa, Y., and Brichard, S.M. (2002) Pre- and post-translational negative effect of beta-adrenoceptor agonists on adiponectin secretion: in vitro and in vivo studies. Biochem. J., 367, 677–685. Bauche, I.B., Ait El Mkadem, S., Rezsohazy, R., Funahashi, T., Maeda, N., Miranda, L.M., and Brichard, S.M. (2006) Adiponectin downregulates its own production and the expression of its AdipoR2 receptor in transgenic mice. Biochem. Biophys. Res. Commun., 345, 1414–1424. Fasshauer, M., Klein, J., Neumann, S., Eszlinger, M., and Paschke, R. (2002) Hormonal regulation of adiponectin gene expression in 3T3-L1 adipocytes. Biochem. Biophys. Res. Commun., 290, 1084–1089. Nilsson, L., Binart, N., Bohlooly, Y.M., Bramnert, M., Egecioglu, E., Kindblom, J., Kelly, P.A., Kopchick, J.J. et al. (2005) Prolactin and growth hormone regulate adiponectin secretion and receptor expression in adipose tissue. Biochem. Biophys. Res. Commun., 331, 1120–1126. Soares, A.F., Guichardant, M., Cozzone, D., Bernoud-Hubac, N., Bouzaidi-Tiali, N., Lagarde, M., and Geloen, A. (2005)
160
161
162
163
164
165
166
Effects of oxidative stress on adiponectin secretion and lactate production in 3T3L1 adipocytes. Free Radic. Biol. Med., 38, 882–889. Kamigaki, M., Sakaue, S., Tsujino, I., Ohira, H., Ikeda, D., Itoh, N., Ishimaru, S., Ohtsuka, Y. et al. (2006) Oxidative stress provokes atherogenic changes in adipokine gene expression in 3T3-L1 adipocytes. Biochem. Biophys. Res. Commun., 339, 624–632. Simons, P.J., van den Pangaart, P.S., Aerts, J.M.F.G., and Boon, L. (2007) Proinflammatory delipidizing cytokines reduce adiponectin secretion from human adipocytes without affecting adiponectin oligomerization. J. Endocrinol., 192, 289–299. Araki, S., Dobashi, K., Kubo, K., Yamamoto, Y., Asayama, K., and Shirahata, A. (2006) N-acetylcysteine attenuates TNF-alpha induced changes in secretion of interleukin-6, plasminogen activator inhibitor-1 and adiponectin from 3T3-L1 adipocytes. Life Sci., 79, 2405–2412. Quinn, L.S., Strait-Bodey, L., Anderson, B.G., Argiles, J.M., and Havel, P.J. (2005) Interleukin-15 stimulates adiponectin secretion by 3T3-L1 adipocytes: evidence for a skeletal muscle-to-fat signaling pathway. Cell. Biol. Int., 29, 449–457. Huypens, P., Quartier, E., Pipeleers, D., and Van de Casteele, M. (2005) Metformin reduces adiponectin protein expression and release in 3T3-L1 adipocytes involving activation of AMP activated protein kinase. Eur. J. Pharmacol., 518, 90–95. Basu, R., Pajvani, U.B., Rizza, R.A., and Scherer, P.E. (2007) Selective downregulation of the high molecular weight form (HMW) of adiponectin in hyperinsulinemia and in type 2 diabetes: differential regulation from non-diabetic subjects. Diabetes, 56, 2174–2177. Koshimura, J., Fujita, H., Narita, T., Shimotomai, T., Hosoba, M., Yoshioka, N., Kakei, M., Fujishima, H. et al. (2004) Urinary adiponectin excretion is increased in patients with overt diabetic nephropathy. Biochem. Biophys. Res. Commun., 316, 165–169.
References 167 Zoccali, C. and Mallamaci, F. (2007)
168
169
170
171
172
173
174
Adiponectin and renal disease progression: another epidemiologic conundrum? Kidney Int., 71, 1195–1197. Narasimhan, M.L., Coca, M.A., Jin, J., Yamauchi, T., Ito, Y., Kadowaki, T., Kim, K.K., Pardo, J.M. et al. (2005) Osmotin is a homolog of mammalian adiponectin and controls apoptosis in yeast through a homolog of mammalian adiponectin receptor. Mol. Cell, 17, 171–180. Tang, Y.T., Hu, T., Arterburn, M., Boyle, B., Bright, J.M., Emtage, P.C., and Funk, W.D. (2005) PAQR proteins: a novel membrane receptor family defined by an ancient 7-transmembrane pass motif. J. Mol. Evol., 61, 372–380. Chinetti, G., Zawadski, C., Fruchart, J.C., and Staels, B. (2004) Expression of adiponectin receptors in human macrophages and regulation by agonists of the nuclear receptors PPARa, PPARc, and LXR. Biochem. Biophys. Res. Commun., 314, 151–158. Staiger, H., Kaltenbach, S., Staiger, K., Stefan, N., Fritsche, A., Guirguis, A., Peterfi, C., Weisser, M. et al. (2004) Expression of adiponectin receptor mRNA in human skeletal muscle cells is related to in vivo parameters of glucose and lipid metabolism. Diabetes, 53, 2195–2201. Satoh, H., Nguyen, M.T.A., Trujillo, M., Imamura, T., Usui, I., Scherer, P.E., and Olefsky, J.M. (2005) Adenovirusmediated adiponectin expression augments skeletal muscle insulin sensitivity in male Wistar rats. Diabetes, 54, 1304–1313. Tan, G.D., Debard, C., Funahashi, T., Humphreys, S.M., Matsuzawa, Y., Frayn, K.N., Karpe, F., and Vidal, H. (2005) Changes in adiponectin receptor expression in muscle and adipose tissue of type 2 diabetic patients during rosiglitazone therapy. Diabetologia, V48, 1585–1589. Rasmussen, M.S., Lihn, A.S., Pedersen, S.B., Bruun, J.M., Rasmussen, M., and Richelsen, B. (2006) Adiponectin receptors in human adipose tissue: effects of obesity, weight loss, and fat depots. Obesity, 14, 28–35.
175 Li, W., Tonelli, J., Kishore, P., Owen, R.,
176
177
178
179
180
181
182
Goodman, E., Scherer, P.E., and Hawkins, M. (2007) Insulin-sensitizing effects of thiazolidinediones are not linked to adiponectin receptor expression in human fat or muscle. Am. J. Physiol. Endocrinol. Metab., 292, E1301–E1307. Tsuchida, A., Yamauchi, T., Takekawa, S., Hada, Y., Ito, Y., Maki, T., and Kadowaki, T. (2005) Peroxisome proliferatoractivated receptor (PPAR)a activation increases adiponectin receptors and reduces obesity-related inflammation in adipose tissue: comparison of activation of PPARa, PPARc, and their combination. Diabetes, 54, 3358–3370. Kaltenbach, S., Staiger, H., Weisser, M., Haas, C., Stumvoll, M., Machicao, F., and Haring, H.U. (2005) Adiponectin receptor gene expression in human skeletal muscle cells is not regulated by fibrates and thiazolidinediones. Int. J. Obes., 29, 760–765. Bluher, M., Fasshauer, M., Kralisch, S., Schon, M.R., Krohn, K., and Paschke, R. (2005) Regulation of adiponectin receptor R1 and R2 gene expression in adipocytes of C57BL/6 mice. Biochem. Biophys. Res. Commun., 329, 1127–1132. Yamauchi, T., Nio, Y., Maki, T., Kobayashi, M., Takazawa, T., Iwabu, M., OkadaIwabu, M., Kawamoto, S. et al. (2007) Targeted disruption of AdipoR1 and AdipoR2 causes abrogation of adiponectin binding and metabolic actions. Nat. Med., 13, 332–339. Bjursell, M., Ahnmark, A., Bohlooly-Y, M., William-Olsson, L., Rhedin, M., Peng, X.-R., Ploj, K., Gerdin, A.-K. et al. (2007) Opposing effects of adiponectin receptors 1 and 2 on energy metabolism. Diabetes, 56, 583–593. Liu, Y., Michael, M.D., Kash, S., Bensch, W.R., Monia, B.P., Murray, S.F., Otto, K.A., Syed, S.K. et al. (2007) Deficiency of adiponectin receptor 2 reduces dietinduced insulin resistance but promotes type 2 diabetes. Endocrinology, 148, 683–692. Mao, X., Hong, J.Y., and Dong, L.Q. (2006) The adiponectin signaling pathway as a novel pharmacological
j229
j 11 Adiponectin
230
183
184
185
186
187
188
189
target. Mini Rev. Med. Chem., 6, 1331–1340. Saito, T., Jones, C.C., Huang, S., Czech, M.P., and Pilch, P.F. (2007) The interaction of AKT with APPL1 is required for insulin-stimulated Glut4 translocation. J. Biol. Chem., 282, 32280–32287. Fryer, L.G., Parbu-Patel, A., and Carling, D. (2002) The anti-diabetic drugs rosiglitazone and metformin stimulate AMP-activated protein kinase through distinct signaling pathways. J. Biol. Chem., 277, 25226–25232. Hawley, S.A., Boudeau, J., Reid, J.L., Mustard, K.J., Udd, L., Makela, T.P., Alessi, D.R., and Hardie, D.G. (2003) Complexes between the LKB1 tumor suppressor, STRAD alpha/beta and MO25 alpha/beta are upstream kinases in the AMP-activated protein kinase cascade. J. Biol., 2, 28. Hawley, S.A., Pan, D.A., Mustard, K.J., Ross, L., Bain, J., Edelman, A.M., Frenguelli, B.G., and Hardie, D.G. (2005) Calmodulin-dependent protein kinase kinase-b is an alternative upstream kinase for AMP-activated protein kinase. Cell Metab., 2, 9–19. Hurley, R.L., Anderson, K.A., Franzone, J.M., Kemp, B.E., Means, A.R., and Witters, L.A. (2005) The Ca2 þ / calmodulin-dependent protein kinase kinases are AMP-activated protein kinase kinases. J. Biol. Chem., 280, 29060–29066. Goransson, O., McBride, A., Hawley, S.A., Ross, F.A., Shpiro, N., Foretz, M., Viollet, B., Hardie, D.G. et al. (2007) Mechanism of action of A-769662, a valuable tool for activation of AMPactivated protein kinase. J. Biol. Chem., 282, 32549–32560. Sun, Y., Connors, K.E., and Yang, D.Q. (2007) AICAR induces phosphorylation of AMPK in an ATM-dependent, LKB1independent manner. Mol. Cell. Biochem., 306, 239–245.
190 Sanders, M.J., Grondin, P.O., Hegarty,
191
192
193
194
195
196
B.D., Snowden, M.A., and Carling, D. (2007) Investigating the mechanism for AMP activation of the AMP-activated protein kinase cascade. Biochem. J., 403, 139–148. Yoon, M.J., Lee, G.Y., Chung, J.-J., Ahn, Y.H., Hong, S.H., and Kim, J.B. (2006) Adiponectin increases fatty acid oxidation in skeletal muscle cells by sequential activation of AMP-activated protein kinase, p38 mitogen-activated protein kinase, and peroxisome proliferatoractivated receptor a. Diabetes, 55, 2562–2570. Tang, C.-H., Chiu, Y.-C., Tan, T.-W., Yang, R.-S., and Fu, W.-M. (2007) Adiponectin enhances IL-6 production in human synovial fibroblast via an AdipoR1 receptor, AMPK, p38, and NF-kB pathway. J. Immunol., 179, 5483–5492. Miyazaki, T., Bub, J.D., Uzuki, M., and Iwamoto, Y. (2005) Adiponectin activates c-Jun NH2-terminal kinase and inhibits signal transducer and activator of transcription 3. Biochem. Biophys. Res. Commun., 333, 79–87. Kelesidis, I., Kelesidis, T., and Mantzoros, C.S. (2006) Adiponectin and cancer: a systematic review. Br. J. Cancer, 94, 1221–1225. Luo, X.H., Guo, L.J., Yuan, L.Q., Xie, H., Zhou, H.D., Wu, X.P., and Liao, E.Y. (2005) Adiponectin stimulates human osteoblasts proliferation and differentiation via the MAPK signaling pathway. Exp. Cell. Res., 309, 99–109. Wu, X., Mahadev, K., Fuchsel, L., Ouedraogo, R., Xu, S.-q., and Goldstein, B.J. (2007) Adiponectin suppresses IkB kinase activation induced by tumor necrosis factor-a or high glucose in endothelial cells: role of cAMP and AMP kinase signaling. Am. J. Physiol. Endocrinol. Metab., 293, E1836–E1844.
j231
12 Preadipocyte factor-1 and Adipose Tissue-Specific Secretory Factor/Resistin – Two Secreted Factors from Adipose Tissue: Role in Adipogenesis and Insulin Resistance Hei Sook Sul, Yuhui Wang, and Carolyn Hudak 12.1 Introduction
Although the principal mechanisms linking increased adiposity with insulin resistance are only partially understood, obesity is associated with major diseases such as diabetes and cardiovascular diseases. Adipose tissue development can be affected by genetic background, hormonal balance, diet, and physical activity. Adipose tissue mass can increase by increased fat cell size due to lipid accumulation as well as by increased number of fat cells arising from differentiation of preadipocytes into adipocytes. Peroxisome proliferator-activated receptor (PPAR)-c and CCAAT/ enhancer-binding protein (C/EBP) play critical roles in adipocyte differentiation [1–3]. Adipocyte differentiation and expression of these transcription factors can be regulated by various factors. In this regard, in addition to being the main site for energy storage in the body, adipose tissue has recently been appreciated as a major endocrine organ. Adipose tissue secretes a wide array of molecules that are involved in various physiological processes, including immune response, vascular function, and energy homeostasis, as well as growth and development of the adipose tissue itself. Among these factors are leptin, adiponectin, tumor necrosis factor (TNF)-a and other cytokines, including interleukin (IL)-6 and IL-8. In this chapter, we address the role of two secreted factors from adipose tissue – preadipocyte factor (Pref)-1 and adipose tissue-specific secretory factor (ADSF)/resistin. We discuss current knowledge on their role in the regulation of adipose tissue development, their signaling mechanisms, as well as their involvement in different pathological disorders such as obesity-related diabetes.
j 12 Preadipocyte factor-1 and Adipose Tissue-Specific Secretory Factor/Resistin
232
12.2 Pref-1 Structure
We originally cloned Pref-1 by differential screening of a 3T3-L1 cDNA library, by the criteria of preadipocyte-specific expression and absence in other tissues [4]. Pref-1 is expressed in multiple mouse embryonic tissues, such as liver, lung, tongue, pituitary, and developing vertebrae [4], and placenta, and detectable amounts of circulating Pref-1 are found in maternal serum in concentrations that correlate with the number of fetuses [5]. Dlk-1, the human homolog of Pref-1, also identified as fetal antigen (FA)-1 [6] by purification from fetal circulation, has been shown to be expressed in a wide array of human embryonic tissues [7]. However, after birth, expression of Pref-1 is rapidly abolished in most tissues and becomes restricted to certain cell types that include preadipocytes [4], thymic stromal cells [8] as well as some of the neuroendocrine type of cells, such as pancreatic islet b-cells [9], adrenal glands [10], and pituitary. Pref-1 is synthesized as a protein of 385 amino acids that contains a signal sequence at the N-terminus and a single membrane-spanning domain of amino acids 300–322 (Figure 12.1). The most striking structural feature of Pref-1 is the presence of six tandem epidermal growth factor (EGF)-like repeats in the extracellular domain that maintain both the conserved spacing of six cysteines for the formation of three disulfide bonds and other amino acids characteristic of the EGF-like repeat motif-containing proteins (Figure 12.1) [4]. The EGF-like motif was originally described for EGF and subsequently for other growth factors, which, by binding to EGF receptor, act as signals for cell proliferation and differentiation. However, Pref-1 does not contain the conserved amino acid residues that are required for EGF receptor binding. Rather, Pref-1 shares higher structural homology with another class of EGF-like repeat containing signaling proteins, the Notch/Delta/Serrate family that are involved in cell signaling and cell fate determination. Pref-1 however, lacks the DSL (Delta Serrate Lin12) domain that is conserved in all Notch ligands to mediate receptor–ligand interaction for Notch [11], indicating that Pref-1 would not act as a Notch ligand. In preadipocytes, multiple transmembrane forms of Pref-1, ranging from 50 to 60 kDa,arefound in thecell membrane due, inpart,to post-translational modifications
Figure 12.1 Domain structure of Pref-1 isoforms. S, signal sequence; Jm, juxtamembrane domain; Tm, transmembrane domain; Cy, cytoplasmic region; D and P, distal and proximal cleavage sites.
12.3 Pref-1 Inhibition of Adipocyte Differentiation
containing N-linked oligosaccharides as well as sialic acids. Moreover, there are four major alternative splicing products of Pref-1 (Pref-1A–D) (Figure 12.1) [12]. In addition to the largest full-length Pref-1 form, alternate splicing generates three major shorter forms of Pref-1, each containing in-frame deletions in the extracellular juxtamembrane region or EGF-like repeat domain (Figure 12.1). The relative abundance of the different spliced forms varies depending on the tissue or developmental stage investigated [13]. Pref-1 can be proteolytically cleaved at the extracellular domain at two sites to generate soluble forms of Pref-1 [13, 14]. Thus, the two larger alternate splicing forms of Pref-1, Pref-1A and -1B, are cleaved at a juxtamembrane as well as at a more N-terminal processing sites to generate a larger 50-kDa and a smaller 25-kDa soluble form. The smaller Pref-1C and -1D, due to the larger deletions that include the juxtamembrane processing site, are cleaved only at the N-terminal site to generate the smaller 25-kDa soluble form, but not the larger 50-kDa form. In this regard, FA-1, the protein in fetal circulation, likely corresponds to the larger soluble form of human Pref-1. Using various inhibitors and in vitro approaches, we found that one of the ADAM (a disintegrin and metalloproteinase) family members, TNF-a-converting enzyme (tumor necrosis factor-a-converting enzyme TACE, ADAM17), can cleave the Pref-1 at the juxtamembrane region to generate the large soluble form of Pref-1. We also found that both basal and stimulated cleavage was inhibited by the broad metalloproteinase inhibitor GM6001, suggesting that cleavage of membrane Pref-1 is dependent on a metalloproteinase. In addition, lentivirus-mediated overexpression of TACE increased Pref-1 cleavage to produce the large soluble form. Conversely, knockdown of TACE by transfecting small interfering RNA (siRNA) decreased the release of the large soluble form from the membrane form [15]. In addition, this cleavage was not detectable or was markedly decreased in cells bearing mutated TACE or in cells transfected with TACE siRNA. These data clearly demonstrate TACE mediated cleavage at the juxtamembrane and generation of the large 50-kDa soluble form of Pref-1. We also found that the release of the 50-kDa full extracellular domain was markedly enhanced by phorbol 12-myristate 13-acetate treatment in a dose- and time-dependent manner. This indicated that cleavage of Pref-1 is regulated by protein kinase C.
12.3 Pref-1 Inhibition of Adipocyte Differentiation
Pref-1 is highly expressed in 3T3-L1 preadipocytes, but decreases during differentiation and is absent in mature adipocytes [4, 16]. Pref-1 expression is downregulated specifically by the synthetic glucocorticoid dexamethasone – a component of the differentiation-inducing agents dexamethasone, methylisobutylxanthine, and insulin that are routinely used for adipocyte differentiation in vitro. Glucocorticoid receptors are present in preadipocytes, and glucocorticoids have been attributed to enhance adipocyte differentiation by increasing C/EBP-d and PPAR-c expression. We found a close correlation between dexamethasone-mediated downregulation of
j233
j 12 Preadipocyte factor-1 and Adipose Tissue-Specific Secretory Factor/Resistin
234
Pref-1 and efficacy of dexamethasone on differentiation of 3T3-L1 preadipocytes. Thus, dexamethasone may induce adipocyte differentiation partly by suppressing Pref-1 expression [17]. Using various in vitro approaches, we have shown the inhibitory role of Pref-1 in adipocyte differentiation. In 3T3-L1 cells, constitutive expression of Pref-1 by stable transfection markedly lowers the degree of adipocyte differentiation. Pref-1 prevents lipid accumulation and expression of various adipocyte markers, such as fatty acid synthase (FAS), stearoyl-CoA desaturase (SCD), aP2 (adipocyte-selective fatty acid-binding protein), PPAR-c, and C/EBP-a. Conversely, decreasing Pref-1 levels by transfection of antisense sequence greatly enhances adipogenesis [4, 17]. This suggests that Pref-1 acts at an early stage during the differentiation process to inhibit adipogenesis [14]. Overall, these studies demonstrate that Pref-1 expression inhibits adipocyte conversion of 3T3-L1 cells and that downregulation of Pref-1 is a necessary step in adipocyte differentiation. The human homolog of Pref-1, Dlk-1, inhibits 3T3-L1 differentiation, demonstrating that Pref-1 and Dlk-1 are functionally equivalent [18]. Since Pref-1 can generate a soluble form by cleavage of the extracellular domain, the above-described transfection of full-length Pref-1 cannot distinguish the effect of the membrane form of Pref-1 from soluble Pref-1 in regulating adipocyte differentiation. However, addition of the large soluble form expressed in COS cells as well as Pref-1 extracellular domain fused to glutathione-S-transferase expressed in Escherichia coli are effective at inhibiting adipocyte differentiation. In addition, unlike Pref1A and -1B, which generate a 50-kDa soluble Pref-1, Pref-1C and -1D, that still produce 25-kDa cleavage product but not the large 50-kDa soluble form, are not effective at inhibiting adipocyte differentiation. These observations clearly show the inhibitory effect of the large soluble 50-kDa protein but not the full-length membrane form on adipocyte differentiation. Furthermore, transfection of a noncleavable transmembrane form of Pref-1A, constructed by the deletion of the 22 amino acids containing the putative cleavage site at the juxtamembrane region, confirmed that the membrane form of Pref-1 cannot inhibit adipocyte differentiation. Since the smaller 25-kDa cleavage product is not effective at inhibiting adipocyte differentiation, the additional N-terminal cleavage may be a means to inactivate the biologically active 50kDa soluble Pref-1.
12.4 Mechanism for Pref-1 Function
We have used Pref-1 null mouse embryonic fibroblasts (MEFs) to examine the signaling pathways for Pref-1 inhibition of adipocyte differentiation. As predicted, the degree of adipose conversion is higher in Pref-1 null MEFs as compared to wildtype MEFs. Compared to the 50% differentiation of wild-type MEFs into adipocytes, 90% of Pref-1 null MEFs differentiated into adipocytes. Furthermore, infection of lentivirus containing the soluble form of Pref-1 into Pref-1 null MEFs decreased the degree of differentiation, confirming the inhibitory effect of Pref-1 on adipogenesis [15]. We recently demonstrated that the inhibitory effect of Pref-1 is mediated
12.5 In Vivo Effect of Pref-1 on Adipogenesis and Glucose/Insulin Homeostasis
through activation of the mitogen-activated protein kinase kinase (MEK)/extracellular signal-regulated kinase (ERK) pathway [19]. Addition of the large soluble Pref-1 increases the phosphorylation of ERK in a time- and dose-dependent manner. Both wild-type and Pref-1 null MEFs show a transient burst of ERK phosphorylation upon addition of adipogenic agents. Wild-type MEFs also show a low but significant second increase in ERK phosphorylation peaking at day 2 that parallels the expression level of Pref-1. This second increase in ERK phosphorylation is absent in Pref-1 null MEFs. Furthermore, a specific MEK inhibitor or siRNA-mediated ERK depletion prevented the second ERK phosphorylation and enhanced adipocyte conversion of wild-type MEFs. Furthermore, treatment of Pref-1 null MEFs with Pref-1 restores the second ERK phosphorylation, resulting in inhibition of adipocyte differentiation [19]. These studies show that Pref-1 inhibition of adipogenesis is by activation of ERK/MEK pathway during differentiation. Since the cleaved Pref-1 ectodomain containing six EGF-like repeats, which are presumably involved in protein–protein interaction, is biologically active, we predict that Pref-1 acts as a ligand for a yet to be identified EGFrepeat-containing receptor to activate ERK/MEK pathway to inhibit adipocyte differentiation. Identification of the Pref-1 receptor is critical for understanding the mode of Pref-1 action.
12.5 In Vivo Effect of Pref-1 on Adipogenesis and Glucose/Insulin Homeostasis
To determine the role of Pref-1 in vivo, we generated Pref-1 null mice [20] as well as transgenic mice overexpressing the large soluble form of Pref-1 in adipose tissue [21]. In Pref-1 null mice, both male and female mice weighed significantly less than wild-type mice at weaning. However, Pref-1 null mice gained body weight more rapidly. The weight of major fat depots (inguinal, retroperitoneal, and gonadal) was significantly higher in Pref-1 null mice, indicating that the accelerated body weight gain in Pref-1 null mice was due to an increase in adipose tissue mass. Histological analysis of fat depots revealed that adipocytes from Pref-1 null mice were bigger than those from wild-type littermates. Moreover, mRNA levels of various markers of adipocyte differentiation, including, C/EBP-a, SCD, FAS as well as ADSF/ resistin and other adipocyte-secreted factors were significantly higher in adipose tissue from Pref-1 null mice, indicating enhanced adipogenesis. Pref-1 null mice also showed enlarged fatty liver as well as increased circulating levels of triglycerides, cholesterol, and free fatty acids – characteristics usually associated with obesity. Thus, studies of Pref-1 null mice demonstrate that ablation of Pref-1 enhances adipogenesis in vivo and support the proposed role of Pref-1 as a negative regulator of adipogenesis [20]. Transgenic mice overexpressing the soluble form of Pref-1 as a human immunoglobulin-c constant region (hFc) fusion protein in adipose tissue were generated using the aP2 promoter. These transgenic mice showed a marked decrease in adipose tissue mass, and reduced expression of adipocyte markers and adipocyte secreted factors. With decreased adipose tissue development, as observed in lipodystrophy
j235
j 12 Preadipocyte factor-1 and Adipose Tissue-Specific Secretory Factor/Resistin
236
mouse models, these mice suffered from hypertriglyceridemia, decreased glucose tolerance, and lower insulin sensitivity [21]. Mice expressing the Pref-1–hFc exclusively in liver under the control of the albumin promoter also showed a decrease in adipose mass and adipocyte marker expression, suggesting an endocrine mode of action of Pref-1 [21]. Data from these in vivo studies with Pref-1 knockout and transgenic mice models are consistent with in vitro studies, strongly demonstrating the inhibitory effect of Pref-1 on adipogenesis. The results from Pref-1 null and Pref1-overexpressing transgenic mice also suggest that proper development of adipose tissue is critical for maintenance of glucose/insulin homeostasis. Pref-1 is encoded by the gene dlk1 and, along with dat, gtl2, peg11, antipeg11, and meg8, is located in an imprinted syntenic region of mouse chromosome 12, human chromosome 14, and sheep chromosome 18. Paternal monoallelic expression of the Pref-1 gene, due to differential methylation, is well documented [22–24]. Given the role of imprinted genes in fetal growth and development in general, and the expression of Pref-1 during embryonic development in a variety of tissues, Pref-1 undoubtedly has a function beyond the regulation of adipogenesis [22–26]. Pref-1 null mice, in addition to increased adiposity, display greater than 50% perinatal lethality, and surviving animals show growth retardation, skeletal malformation, and eyelid defects [20]. In addition, Pref-1 transgenic mice not only have reduced adiposity but also show skeletal defects [21]. Pref-1 null and transgenic mice show distinct defects similar to maternal uniparenteral disomy (UPD) syndrome UPD12 and paternal UPD12 in mice, respectively, and syntenic maternal and paternal UPD14 syndromes in humans. Calipyge sheep with a mutation in chromosome 18 show decreased adiposity with elevated Pref-1 levels. Taken together, these results strongly suggest that Pref-1 is involved not only in adipogenesis, but also in embryonic development, and that the observed UPD syndromes are at least partly due to altered Pref-1 expression levels. In this regard, as during adipocyte differentiation, Pref-1 may function as a soluble factor, maintaining proliferating cells in an undifferentiated state during mouse embryonic development.
12.6 ADSF/Resistin: Identification and Structure
ADSF/resistin was identified by three independent groups via different approaches. ADSF/resistin was identified in our laboratory as ADSF that inhibits adipocyte differentiation of 3T3-L1 cells [27]. This protein was also identified as an adipocytesecreted hormone whose expression is suppressed by the insulin-sensitizing PPAR-c agonists thiazolidinediones and was named resistin [28]. Steppan et al. reported that the circulating levels of resistin were high in genetically obese mice and mice treated with recombinant resistin had increased insulin resistance, while administration of antibody against resistin improved insulin sensitivity. Thus, these authors suggested resistin as a potential link between obesity and insulin resistance. Yet, Holcomb et al. originally identified the same protein, FIZZ3, as a member of the FIZZ (found in inflammatory zone) family of cysteine-rich secreted proteins. These authors
12.7 ADSF/Resistin Expression and Function
originally found FIZZ1 in bronchoalveolar lavage fluid from mice with ovalbumininduced pulmonary inflammation [29]. FIZZ2 was reported to have similar action to resistin in insulin resistance [30]. In this chapter, the protein is referred to as ADSF and/or resistin. ADSF/resistin is a 114-amino-acid polypeptide that has a unique cysteine repeat motif at the C-terminus [27]. It exists as both a monomer and homodimer, and it can form a hetero-oligomer with the two other members of this family [30–32]. This oligomerzation is mediated by disulfide bonds at cysteine residues [33]. A recent crystal structure study indicates that resistin circulates as two distinct assembly states, probably corresponding to hexamers as well as more bioactive trimers [34].
12.7 ADSF/Resistin Expression and Function
In rodents, ADSF/resistin mRNA is exclusively expressed in adipose tissue, including brown adipose tissue, and inguinal, gonadal, and retroperitoneal fat pads of white adipose tissue. ADSF/resistin mRNA is markedly increased at later stages of 3T3-L1 as well as primary rat preadipocyte differentiation into adipocytes [27]. In humans, however, resistin is abundantly expressed in peripheral monocytes and macrophages and, if expressed, at a very low level in adipocytes [35]. Treatment of 3T3-L1 cells with conditioned media from COS cells transfected with ADSF/resistin suppressed differentiation of these cells into adipocytes, demonstrating in vitro inhibition of adipogenesis by ADSF/resistin [27]. Similarly, another member of this protein family of FIZZ1 (also called resistin-related molecule-b) has also been shown to inhibit adipocyte differentiation of 3T3-L1 preadipocytes [31]. To examine ADSF/resistin function in adipogenesis in vivo, we generated transgenic mice overexpressing ADSF/resistin–hFc fusion protein, which functions in a dominant-negative manner [36]. The ADSF/resistin fusion protein not only forms homooligomers, but can also hetero-oligomerize with endogenous ADSF/resistin. The hFc domain probably blocks the interaction of ADSF/resistin with its putative interacting protein or receptor. These transgenic mice showed increased adiposity in a transgene dose-dependent manner, owing to enhanced adipocyte differentiation as well as adipocyte hypertrophy. Interestingly, although resistin null mice were reported to have normal adiposity, loss of resistin in ob/ob mice exacerbated obesity without changes in food intake – a phenotype consistent with the role of ADSF/resistin in inhibition of adipogenesis. In this regard, ADSF/resistin mRNA levels were reported to be at a lower level in adipose tissue of various genetically obese and diet-induced obesity mouse models [37]. However, the circulating ADSF/resistin level was reported to be higher in genetically obese and diet-induced obesity in mice. It is possible the half-life of circulating resistin may be affected in these mice. Regardless, the local concentration of ADSF/resistin in adipose tissue may be critical for its effect during the expansion of adipose tissue. ADSF/resistin mRNA levels are very low in fasting conditions or in streptozotocin-induced diabetes, but are increased drastically by refeeding or by insulin treatment [27], reflecting tightly controlled expression of
j237
j 12 Preadipocyte factor-1 and Adipose Tissue-Specific Secretory Factor/Resistin
238
ADSF/resistin by nutrition and hormones. Similar ADSF/resistin protein levels in the adipose tissue as well as in circulation by radioimmunoassay confirmed the changes in ADSF/resistin mRNA levels during fasting/feeding as well as by glucose and/or insulin [38, 39]. ADSF/resistin, therefore, could be an adipocyte sensor for the nutritional state of animals and function as a feedback regulator in adipogenesis. The physiological role of resistin and its involvement in obesity-associated insulin resistance has been an ongoing debate. As mentioned above, correlating with insulin resistance, circulating resistin levels are higher in genetic and diet-induced obesity mouse models [38, 39]. Administration of resistin impaired glucose tolerance in normal mice, while a neutralizing resistin antibody improved insulin sensitivity in diet-induced obese mouse models [28]. Furthermore, despite the development of obesity, transgenic mice overexpressing dominant-negative ADSF/resistin fed either a chow or high-fat diet showed enhanced glucose tolerance and insulin sensitivity compared to wild-type mice [36]. These mice also had increased leptin and adiponectin levels in circulation, probably because of increased adiposity and adipogenesis. The complex phenotype of enhanced insulin sensitivity with increased adiposity observed in these transgenic mice could be caused by the chronic effect of the impairment of inhibitory function of ADSF/resistin in adipocyte differentiation. A direct effect of this dominant-negative ADSF/resistin on glucose/insulin homeostasis, however, cannot be ruled out. On a chow diet, mice lacking resistin showed a normal glucose tolerance. However, on a high-fat diet, resistin-deficient mice had improved glucose tolerance, but fasting insulin levels or insulin tolerance were not altered in these mice. Loss of resistin also improved glucose homeostasis in leptindeficient ob/ob mice [40]. The primary target of resistin action appears to be the liver, causing hepatic insulin resistance, with secondary effects on skeletal muscles and adipose tissue [30]. Feeding mice a high-fat diet for 3 weeks brought about an 80% increase in plasma resistin levels accompanying an increase in hepatic glucose production. This hepatic insulin resistance was reversed by resistin antisense oligonucleotide that normalized plasma resistin levels [41]. Acute infusion of resistin reconstituted insulin resistance also. Whole-body insulin resistance involving impaired insulin signaling in skeletal muscle, liver, and adipose tissue, resulting in glucose intolerance and hyperinsulinemia was also reported upon adenovirus-mediated hyper-resistinemia in rats [42]. Contrary to the observed relationship between resistin and insulin resistance, no correlation between either resistin expression or serum levels with serum insulin or glucose levels was reported in obese and insulin-resistant mouse models [43]. These discrepancies may be due to the methodology of measurements or the potentially differing function of various multimeric forms of resistin. Similar to leptin, which has been well documented for its central role in peripheral glucose homeostasis, central infusion of resistin to cerebral ventricle or mediobasal hypothalamus showed an increase in glucose production, that was abrogated in neuropeptide Y null mice suggesting the central function of resistin [44, 45]. Impaired phosphorylation of Akt and AMP-activated protein kinase as well as induction of suppressor of cytokine signaling-3 in hepatic insulin resistance
12.8 Conclusions
by resistin have been reported. However, these changes may represent a consequence of insulin resistance. Identification of a potential membrane receptor that mediates resistin action would be necessary to better understand the underlying mechanism. The function of human resistin is even more complex not only with regard to adipogenesis, but also to the metabolic physiology [42, 46]. The biological role of human resistin in glucose metabolism is controversial at best. Several human studies have shown correlation of resistin levels with obesity and insulin resistance, while other studies found no association of resistin with insulin sensitivity or the metabolic syndrome [47–55]. However, it has been reported that resistin levels may be related to the degree of adiposity [56].
12.8 Conclusions
Both obesity and lipodystrophy are commonly associated with diverse pathologies, including diabetes and cardiovascular diseases. It has become evident that adipose tissue is an endocrine organ that secretes a wide variety of factors and dysfunction in secretion affects whole-body glucose homeostasis. Here, we have presented the current knowledge on the function of two adipocyte secreted proteins, Pref-1 and ADSF/resistin. Pref-1 is synthesized and released from preadipocytes in both rodents and humans. ADSF/resistin is secreted from adipocytes in rodents, while, in humans, it is produced from monocytes and macrophages. Although their signaling may differ, these two proteins inhibit adipocyte differentiation and directly or indirectly affect glucose/insulin homeostasis. The inhibitory role of Pref-1 on adipogenesis has been clearly demonstrated in vivo by the generation of Pref-1 null and Pref-1-overexpressing transgenic mice. Pref-1 null mice exhibit increased deposition of adipose tissue, with enlarged adipocytes with increased expression of adipocyte markers. Transgenic mice overexpressing Pref-1 show impaired adipose tissue development and lower insulin sensitivity. By a variety of in vitro approaches using 3T3-L1 cells and Pref-1 null MEFs, Pref-1 has been shown to be processed by TACE to generate a biologically active soluble form and the soluble form prevents differentiation into adipocytes through activation of MEK/ERK pathway. The role of ADSF/resistin in obesity-linked diabetes and cardiovascular diseases is, to date, an ongoing debate. Clearly, identification of the receptors through which Pref-1 and ADSF/resistin signaling occur is critical, and would represent a major advance in understanding the molecular mechanisms underlying the function of these adipose tissue secreted factors. Acknowledgments
The work from the authors laboratory was supported by NIH grants to H.S.S. We thank Nabila Aboulaich for her contribution in the initial draft of the review.
j239
j 12 Preadipocyte factor-1 and Adipose Tissue-Specific Secretory Factor/Resistin
240
References 1 Rosen, E.D. and Spiegelman, B.M. (2006)
2
3
4
5
6
7
8
9
Adipocytes as regulators of energy balance and glucose homeostasis. Nature, 444, 847–853. Rosen, E.D. and MacDougald, O.A. (2006) Adipocyte differentiation from the inside out. Nat. Rev. Mol. Cell. Biol., 7, 885–896. Gregoire, F.M., Smas, C.M., and Sul, H.S. (1998) Understanding adipocyte differentiation. Physiol. Rev., 78, 783–809. Smas, C.M. and Sul, H.S. (1993) Pref-1, a protein containing EGF-like repeats, inhibits adipocyte differentiation. Cell, 73, 725–734. Bachmann, E., Krogh, T.N., Hojrup, P., Skjodt, K., and Teisner, B. (1996) Mouse fetal antigen 1 (mFA1), the circulating gene product of mdlk, pref-1 and SCP-1: isolation, characterization and biology. J. Reprod. Fertil., 107, 279–285. Jensen, C.H., Krogh, T.N., Hojrup, P., Clausen, P.P., Skjodt, K., Larsson, L.I., Enghild, J.J., and Teisner, B. (1994) Protein structure of fetal antigen 1 (FA1). A novel circulating human epidermalgrowth-factor-like protein expressed in neuroendocrine tumors and its relation to the gene products of dlk and pG2. Eur. J. Biochem., 225, 83–92. Floridon, C., Jensen, C.H., Thorsen, P., Nielsen, O., Sunde, L., Westergaard, J.G., Thomsen, S.G., and Teisner, B. (2000) Does fetal antigen 1 (FA1) identify cells with regenerative, endocrine and neuroendocrine potentials? A study of FA1 in embryonic, fetal, and placental tissue and in maternal circulation. Differentiation, 66, 49–59. Kaneta, M., Osawa, M., Sudo, K., Nakauchi, H., Farr, A.G., and Takahama, Y. (2000) A role for Pref-1 and HES-1 in thymocyte development. J. Immunol., 164, 256–264. Carlsson, C., Tornehave, D., Lindberg, K., Galante, P., Billestrup, N., Michelsen, B., Larsson, L.I., and Nielsen, J.H. (1997) Growth hormone and prolactin stimulate the expression of rat preadipocyte factor1/delta-like protein in pancreatic islets: molecular cloning and expression pattern during development and growth of the
10
11
12
13
14
15
16
17
18
endocrine pancreas. Endocrinology, 138, 3940–3948. Halder, S.K., Takemori, H., Hatano, O., Nonaka, Y., Wada, A., and Okamoto, M. (1998) Cloning of a membrane-spanning protein with epidermal growth factor-like repeat motifs from adrenal glomerulosa cells. Endocrinology, 139, 3316–3328. Tax, F.E., Yeargers, J.J., and Thomas, J.H. (1994) Sequence of C. elegans lag-2 reveals a cell-signalling domain shared with Delta and Serrate of Drosophila. Nature, 368, 150–154. Smas, C.M., Green, D., and Sul, H.S. (1994) Structural characterization and alternate splicing of the gene encoding the preadipocyte EGF-like protein pref-1. Biochemistry, 33, 9257–9265. Mei, B., Zhao, L., Chen, L., and Sul, H.S. (2002) Only the large soluble form of preadipocyte factor-1 (Pref-1), but not the small soluble and membrane forms, inhibits adipocyte differentiation: role of alternative splicing. Biochem. J., 364, 137–144. Smas, C.M., Chen, L., and Sul, H.S. (1997) Cleavage of membrane-associated pref-1 generates a soluble inhibitor of adipocyte differentiation. Mol. Cell. Biol., 17, 977–988. Wang, Y., Kim, K.A., Kim, J.H., and Sul, H.S. (2006) Pref-1, a preadipocyte secreted factor that inhibits adipogenesis. J. Nutr., 136, 2953–2956. Smas, C.M., Kachinskas, D., Liu, C.M., Xie, X., Dircks, L.K., and Sul, H.S. (1998) Transcriptional control of the pref-1 gene in 3T3-L1 adipocyte differentiation. Sequence requirement for differentiationdependent suppression. J. Biol. Chem., 273, 31751–31758. Smas, C.M., Chen, L., Zhao, L., Latasa, M.J., and Sul, H.S. (1999) Transcriptional repression of pref-1 by glucocorticoids promotes 3T3-L1 adipocyte differentiation. J. Biol. Chem., 274, 12632–12641. Garces, C., Ruiz-Hidalgo, M.J., Bonvini, E., Goldstein, J., and Laborda, J. (1999) Adipocyte differentiation is modulated by secreted delta-like (dlk) variants and requires the expression of membrane-
References
19
20
21
22
23
24
25
26
associated dlk. Differentiation, 64, 103–114. Kim, K.A., Kim, J.H., Wang, Y., and Sul, H.S. (2007) Pref-1 (preadipocyte factor 1) activates the MEK/extracellular signalregulated kinase pathway to inhibit adipocyte differentiation. Mol. Cell. Biol., 27, 2294–2308. Moon, Y.S., Smas, C.M., Lee, K., Villena, J.A., Kim, K.H., Yun, E.J., and Sul, H.S. (2002) Mice lacking paternally expressed Pref-1/Dlk1 display growth retardation and accelerated adiposity. Mol. Cell. Biol., 22, 5585–5592. Lee, K., Villena, J.A., Moon, Y.S., Kim, K.H., Lee, S., Kang, C., and Sul, H.S. (2003) Inhibition of adipogenesis and development of glucose intolerance by soluble preadipocyte factor-1 (Pref-1). J. Clin. Invest., 111, 453–461. Schmidt, J.V., Matteson, P.G., Jones, B.K., Guan, X.J., and Tilghman, S.M. (2000) The Dlk1 and Gtl2 genes are linked and reciprocally imprinted. Genes Dev., 14, 1997–2002. Takada, S., Tevendale, M., Baker, J., Georgiades, P., Campbell, E., Freeman, T., Johnson, M.H., Paulsen, M., and Ferguson-Smith, A.C. (2000) Delta-like and gtl2 are reciprocally expressed, differentially methylated linked imprinted genes on mouse chromosome 12. Curr. Biol., 10, 1135–1138. Wylie, A.A., Murphy, S.K., Orton, T.C., and Jirtle, R.L. (2000) Novel imprinted DLK1/GTL2 domain on human chromosome 14 contains motifs that mimic those implicated in IGF2/H19 regulation. Genome Res., 10, 1711–1718. Jensen, C.H., Teisner, B., Hojrup, P., Rasmussen, H.B., Madsen, O.D., Nielsen, B., and Skjodt, K. (1993) Studies on the isolation, structural analysis and tissue localization of fetal antigen 1 and its relation to a human adrenal-specific cDNA, pG2. Hum. Reprod., 8, 635–641. Laborda, J., Sausville, E.A., Hoffman, T., and Notario, V. (1993) dlk, a putative mammalian homeotic gene differentially expressed in small cell lung carcinoma and neuroendocrine tumor cell line. J. Biol. Chem., 268, 3817–3820.
27 Kim, K.H., Lee, K., Moon, Y.S., and Sul,
28
29
30
31
32
33
34
35
H.S. (2001) A cysteine-rich adipose tissuespecific secretory factor inhibits adipocyte differentiation. J. Biol. Chem., 276, 11252–11256. Steppan, C.M., Bailey, S.T., Bhat, S., Brown, E.J., Banerjee, R.R., Wright, C.M., Patel, H.R., Ahima, R.S., and Lazar, M.A. (2001) The hormone resistin links obesity to diabetes. Nature, 409, 307–312. Holcomb, I.N., Kabakoff, R.C., Chan, B., Baker, T.W., Gurney, A., Henzel, W., Nelson, C., Lowman, H.B., Wright, B.D., Skelton, N.J., Frantz, G.D., Tumas, D.B., Peale, F.V. Jr., Shelton, D.L., and Hebert, C.C. (2000) FIZZ1, a novel cysteine-rich secreted protein associated with pulmonary inflammation, defines a new gene family. EMBO J., 19, 4046–4055. Rajala, M.W., Obici, S., Scherer, P.E., and Rossetti, L. (2003) Adipose-derived resistin and gut-derived resistin-like molecule-beta selectively impair insulin action on glucose production. J. Clin. Invest., 111, 225–230. Blagoev, B., Kratchmarova, I., Nielsen, M.M., Fernandez, M.M., Voldby, J., Andersen, J.S., Kristiansen, K., Pandey, A., and Mann, M. (2002) Inhibition of adipocyte differentiation by resistin-like molecule alpha. Biochemical characterization of its oligomeric nature. J. Biol. Chem., 277, 42011–42016. Chen, J., Wang, L., Boeg, Y.S., Xia, B., and Wang, J. (2002) Differential dimerization and association among resistin family proteins with implications for functional specificity. J. Endocrinol., 175, 499–504. Banerjee, R.R. and Lazar, M.A. (2001) Dimerization of resistin and resistin-like molecules is determined by a single cysteine. J. Biol. Chem., 276, 25970–25973. Patel, S.D., Rajala, M.W., Rossetti, L., Scherer, P.E., and Shapiro, L. (2004) Disulfide-dependent multimeric assembly of resistin family hormones. Science, 304, 1154–1158. Patel, L., Buckels, A.C., Kinghorn, I.J., Murdock, P.R., Holbrook, J.D., Plumpton, C., Macphee, C.H., and Smith, S.A. (2003) Resistin is expressed in human macrophages and directly regulated by
j241
j 12 Preadipocyte factor-1 and Adipose Tissue-Specific Secretory Factor/Resistin
242
36
37
38
39
40
41
42
43
PPAR gamma activators. Biochem. Biophys. Res. Commun., 300, 472–476. Kim, K.H., Zhao, L., Moon, Y., Kang, C., and Sul, H.S. (2004) Dominant inhibitory adipocyte-specific secretory factor (ADSF)/resistin enhances adipogenesis and improves insulin sensitivity. Proc. Natl. Acad. Sci. USA, 101, 6780–6785. Way, J.M., Gorgun, C.Z., Tong, Q., Uysal, K.T., Brown, K.K., Harrington, W.W., Oliver, W.R. Jr., Willson, T.M., Kliewer, S.A., and Hotamisligil, G.S. (2001) Adipose tissue resistin expression is severely suppressed in obesity and stimulated by peroxisome proliferatoractivated receptor gamma agonists. J. Biol. Chem., 276, 25651–25653. Rajala, M.W., Lin, Y., Ranalletta, M., Yang, X.M., Qian, H., Gingerich, R., Barzilai, N., and Scherer, P.E. (2002) Cell type-specific expression and coregulation of murine resistin and resistin-like molecule-alpha in adipose tissue. Mol. Endocrinol., 16, 1920–1930. Rajala, M.W., Qi, Y., Patel, H.R., Takahashi, N., Banerjee, R., Pajvani, U.B., Sinha, M.K., Gingerich, R.L., Scherer, P.E., and Ahima, R.S. (2004) Regulation of resistin expression and circulating levels in obesity, diabetes, and fasting. Diabetes, 53, 1671–1679. Qi, Y., Nie, Z., Lee, Y.S., Singhal, N.S., Scherer, P.E., Lazar, M.A., and Ahima, R.S. (2006) Loss of resistin improves glucose homeostasis in leptin deficiency. Diabetes, 55, 3083–3090. Muse, E.D., Obici, S., Bhanot, S., Monia, B.P., McKay, R.A., Rajala, M.W., Scherer, P.E., and Rossetti, L. (2004) Role of resistin in diet-induced hepatic insulin resistance. J. Clin. Invest., 114, 232–239. Satoh, H., Nguyen, M.T., Miles, P.D., Imamura, T., Usui, I., and Olefsky, J.M. (2004) Adenovirus-mediated chronic hyper-resistinemia leads to in vivo insulin resistance in normal rats. J. Clin. Invest., 114, 224–231. Lee, J.H., Bullen, J.W. Jr., Stoyneva, V.L., and Mantzoros, C.S. (2005) Circulating resistin in lean, obese, and insulinresistant mouse models: lack of association with insulinemia and
44
45
46
47
48
49
50
51
glycemia. Am. J. Physiol. Endocrinol. Metab. 288, E625–E632. Singhal, N.S., Lazar, M.A., and Ahima, R.S. (2007) Central resistin induces hepatic insulin resistance via neuropeptide Y. J. Neurosci., 27, 12924–12932. Muse, E.D., Lam, T.K., Scherer, P.E., and Rossetti, L. (2007) Hypothalamic resistin induces hepatic insulin resistance. J. Clin. Invest., 117, 1670–1678. Pravenec, M., Kazdova, L., Landa, V., Zidek, V., Mlejnek, P., Jansa, P., Wang, J., Qi, N., and Kurtz, T.W. (2003) Transgenic and recombinant resistin impair skeletal muscle glucose metabolism in the spontaneously hypertensive rat. J. Biol. Chem., 278, 45209–45215. Silha, J.V., Krsek, M., Skrha, J., Sucharda, P., Nyomba, B.L., and Murphy, L.J. (2004) Plasma resistin, leptin and adiponectin levels in non-diabetic and diabetic obese subjects. Diabet. Med., 21, 497–499. Silha, J.V. and Murphy, L.J. (2004) Serum resistin (FIZZ3) protein is increased in obese humans. J. Clin. Endocrinol. Metab., 89, 1977; author reply 1978–1977. Youn, B.S., Yu, K.Y., Park, H.J., Lee, N.S., Min, S.S., Youn, M.Y., Cho, Y.M., Park, Y.J., Kim, S.Y., Lee, H.K., and Park, K.S. (2004) Plasma resistin concentrations measured by enzyme-linked immunosorbent assay using a newly developed monoclonal antibody are elevated in individuals with type 2 diabetes mellitus. J. Clin. Endocrinol. Metab., 89, 150–156. Norata, G.D., Ongari, M., Garlaschelli, K., Raselli, S., Grigore, L., and Catapano, A.L. (2007) Plasma resistin levels correlate with determinants of the metabolic syndrome. Eur. J. Endocrinol., 156, 279–284. Lee, J.H., Chan, J.L., Yiannakouris, N., Kontogianni, M., Estrada, E., Seip, R., Orlova, C., and Mantzoros, C.S. (2003) Circulating resistin levels are not associated with obesity or insulin resistance in humans and are not regulated by fasting or leptin administration: cross-sectional and interventional studies in normal, insulinresistant, and diabetic subjects. J. Clin. Endocrinol. Metab., 88, 4848–4856.
References 52 Pfutzner, A., Langenfeld, M., Kunt, T.,
Lobig, M., and Forst, T. (2003) Evaluation of human resistin assays with serum from patients with type 2 diabetes and different degrees of insulin resistance. Clin. Lab., 49, 571–576. 53 Heilbronn, L.K., Rood, J., Janderova, L., Albu, J.B., Kelley, D.E., Ravussin, E., and Smith, S.R. (2004) Relationship between serum resistin concentrations and insulin resistance in nonobese, obese, and obese diabetic subjects. J. Clin. Endocrinol. Metab., 89, 1844–1848. 54 Utzschneider, K.M., Carr, D.B., Tong, J., Wallace, T.M., Hull, R.L., Zraika, S., Xiao, Q., Mistry, J.S., Retzlaff, B.M., Knopp, R.H., and Kahn, S.E. (2005) Resistin is not
associated with insulin sensitivity or the metabolic syndrome in humans. Diabetologia, 48, 2330–2333. 55 Iqbal, N., Seshadri, P., Stern, L., Loh, J., Kundu, S., Jafar, T., and Samaha, F.F. (2005) Serum resistin is not associated with obesity or insulin resistance in humans. Eur. Rev. Med. Pharmacol. Sci., 9, 161–165. 56 Pagano, C., Marin, O., Calcagno, A., Schiappelli, P., Pilon, C., Milan, G., Bertelli, M., Fanin, E., Andrighetto, G., Federspil, G., and Vettor, R. (2005) Increased serum resistin in adults with Prader–Willi syndrome is related to obesity and not to insulin resistance. J. Clin. Endocrinol. Metab., 90, 4335–4340.
j243
j245
13 Adipose Tissue and Blood Pressure Regulation Lisa A. Cassis and Sara B. Police 13.1 Introduction
The modern industrialized environment has contributed to an epidemic rise in the prevalence of obesity and obesity-associated disorders, including hypertension. Hypertension affects more than 65 million adult Americans [1]. The majority of patients with hypertension are overweight, with a recently reported odds ratio (95% confidence interval) of 1.73 and 3.39 for overweight and obesity, respectively, for independent association with hypertension [2]. A 10 kg greater body weight is associated with a 3.0 and 2.3 mmHg increase in systolic and diastolic pressure, respectively, increasing the risk of cardiovascular disease by 12% [3, 4]. Early reports in the Framingham Heart Study demonstrated that 78% of essential hypertension in men can be directly attributed to obesity [5]. Given the unabating epidemic of obesity in the United States, it is clear that obesity-related hypertension will increase in the future. Despite a strong association between obesity and hypertension, mechanisms linking the two diseases are not fully understood. Hemodynamic characteristics of obese hypertensive subjects include an increase in intravascular volume, increased cardiac output, endothelial dysfunction, and abnormal kidney function [6–15]. Candidate mediators contributing to these hemodynamic changes in obese hypertensives include activation of the sympathetic nervous system [16–18], the renin–angiotensin system (RAS) [19–21], elevated free fatty acids (for review, see [22]), oxidative stress [23–26], insulin resistance and hyperinsulinemia [27–30], and dysregulated production and function of various adipocyte-derived factors (Figure 13.1). For the purposes of this chapter, we focus on adipose tissue and its role in obesity-related hypertension. 13.2 Adipose Tissue Changes with Obesity: Relation to Blood Pressure Control
During positive energy balance, excess energy is stored in adipose tissue. This mechanism is important in normal physiology, where adipose tissue serves as an
j 13 Adipose Tissue and Blood Pressure Regulation
246
Obesity
Sympathetic Nervous System
ReninAngiotensin System
Free Fatty Acids
Insulin Resistance Hyperinsulinemia
Adipokines
Hypertension Figure 13.1 Mechanisms contributing to obesity-related hypertension. Obesity could increase blood pressure through multiple mechanisms, including stimulation of the sympathetic nervous system, activation of the
RAS, elevations in circulating concentrations of free fatty acids, insulin resistance and hyperinsulinemia, and elevated expression and release of various adipokines.
energy storage reservoir for the release of lipids during fasting that are oxidized as fuel for skeletal muscle. When energy intake exceeds energy expenditure, however, triglycerides accumulate in adipocytes, leading to adipocyte hypertrophy and hyperplasia. Enlargement of existing adipocytes with lipid is usually the first mechanism utilized to handle excess energy stores [31], followed by recruitment of precursor cells to healthy adipocytes that can contribute to additional lipid storage. Dysfunction of adipose tissue with obesity thus represents the combined mechanisms of markedly hypertrophied adipocytes and impaired adipogenesis. Depending on the anatomic location of adipose tissue, these mechanisms are differentially altered with obesity. For example, subcutaneous adipose tissue typically retains the ability to increase proliferation and differentiation of adipocytes to accommodate a positive energy balance, while hypertrophy of the more metabolically active visceral adipose tissue is closely associated with hypertension. The concept of the adipocyte as a simple energy storage site for lipid has evolved considerably, primarily as a result of the discovery of leptin production and secretion by adipocytes [32]. It is now widely recognized that adipocytes produce a variety of factors that are present in the circulation and that can act in an autocrine/paracrine manner to regulate energy homeostasis. The list of factors produced by adipocytes grows longer each year (Figure 13.2) and has spurred the terminology adipokine to describe a variety of factors that exhibit a proinflammatory phenotype. With adipocyte hypertrophy, the production of many of these adipocyte-derived factors is dysregulated. Mechanisms for changes in adipokine expression and secretion with adipocyte hypertrophy are not well defined, but have been suggested to include interactions between adipocytes and recruited macrophages, interactions with the extracellular matrix, and changes in cholesterol distribution from the cell
13.2 Adipose Tissue Changes with Obesity: Relation to Blood Pressure Control
Adipocytes
Adipocyte-derived factors
Leptin
Resistin
Adiponectin
TNFα
Angiotensinogen
Glucocorticoids
PAI1
IL6
MCP1
Visfatin
Figure 13.2 Adipocyte-derived factors. Adipocytes produced a variety of factors, termed adipokines due to their ability to promote inflammation. Adipocyte-derived factors can act in an autocrine or paracrine manner. IL6, interleukin-6.
membrane to the triacylglycerol droplet [33, 34]. The consequences of adipocyte hypertrophy on the expression of adipocyte-derived factors are pronounced, and many of these factors, as described below, can contribute to the control of blood pressure (Figure 13.3). 13.2.1 Adipocyte RAS in Obesity-Related Hypertension
We originally reported expression of angiotensinogen, the only known precursor to angiotensin II, in a variety of white and brown adipose tissues from rats [35, 36]. Follow-up studies in our laboratory examined mechanisms for processing of angiotensinogen to angiotensin II in adipocytes and adipose tissue, and demonstrated renin-like and angiotensin-converting enzyme (ACE) activity, and the release of angiotensin peptides from adipocytes [37–39]. Further studies in our laboratory demonstrated regulation of adipose angiotensinogen expression by nephrectomy [40, 41], angiotensin II [42, 43], diabetes [44], obesity [45–48], and cold acclimation [49, 50]. Additional research by a variety of investigators has demonstrated a complete RAS in rodent and human adipocytes (for reviews, see [51–54]). Evidence suggests that the adipocyte RAS may contribute to obesity-related hypertension. In mice with adipocyte-specific overexpression of angiotensinogen, adipocyte
j247
j 13 Adipose Tissue and Blood Pressure Regulation
248
Obesity
Adipocyte Leptin RAS
Adiponectin Insulin PAI-1
SNS Endothelial dysfunction
Free fatty Resistin acids
11-βHSD1
RAS Vascular reactivity
Hypertension Figure 13.3 The role of adipokines in obesity-related hypertension. Several different adipokines have the ability to modulate blood pressure through regulation of the sympathetic nervous system (SNS), the RAS, by causing endothelial dysfunction, or by enhancing vascular reactivity.
growth was increased [55]. Importantly, in mice overexpressing angiotensinogen in adipocytes, plasma angiotensinogen concentrations increased and were associated with elevated blood pressure. Unexpectedly, mice with deficiency of either AT1a or AT2 receptors exhibit resistance to diet-induced obesity [56, 57]. In mice overexpressing 11bhydroxysteroid dehydrogenase (HSD)-1 selectively in adipose tissue, visceral adiposity was associated with an increase in adipose angiotensinogen expression and the development of hypertension [58]. In mice with diet-induced obesity, angiotensinogen expression was increased in visceral adipose tissue, but not in subcutaneous adipose or nonadipose tissues, but blood pressure was not examined [59]. Results from our laboratory demonstrated a site-specific increase in angiotensinogen mRNA abundance in a visceral adipose tissue of rats with diet-induced obesity and hypertension [45]. Importantly, obese hypertensive rats exhibited pronounced elevations in systemic angiotensin II concentrations, which correlated positively to adipose angiotensinogen mRNA abundance and to blood pressure [45]. Administration of an AT1 receptor antagonist resulted in a greater reduction in blood pressure in diet-induced obese rats withhypertension comparedtoleancontrols [60]. Additionalstudies examinedmechanisms for regulation of adipose angiotensinogen, focusing on endocrine feedback regulation by the end-product peptide, angiotensin II. Results demonstrated that angiotensin II regulates adipose angiotensinogen mRNA abundance through the AT1a receptor and that in states of high systemic angiotensin II (i.e., obesity), angiotensin II regulation of adipose angiotensinogen expression increases [42]. In humans, angiotensinogen mRNA abundance in omental, but not in subcutaneous adipose tissue correlated positively to waist-to-hip ratios [61]. In obese and lean
13.2 Adipose Tissue Changes with Obesity: Relation to Blood Pressure Control
patients, angiotensinogen gene expression was greater in visceral compared to subcutaneous adipose tissue and was increased in adipose tissue from obese compared to lean subjects [62]. In contrast, other studies have revealed either a slight decrease or no change in angiotensinogen gene expression in adipose tissue from obese compared to lean patients [63–65]. Recent studies in obese menopausal women demonstrated lower angiotensinogen gene expression in adipose tissue; however, expression of angiotensinogen decreased in adipose tissue of obese patients with weight loss [66]. Importantly, reductions in angiotensinogen gene expression with weight loss in obese patients were associated with decreased circulating angiotensinogen concentrations and reductions in blood pressure. Clinical studies comparing obese to lean subjects demonstrated a positive correlation between body mass index (BMI) and plasma angiotensinogen concentrations [19–21, 67, 68]. Plasma renin activity has been reported to increase in obese hypertensives [69] and recent studies demonstrate that direct renin inhibition with Aliskiren results in a reduction in arterial hypertension in obese patients [70]. In addition, a positive correlation between plasma ACE activity and BMI was demonstrated [20], while weight loss in obese subjects resulted in a reduction in plasma ACE activity [71]. In the placebo-controlled TROPHY trial for the treatment of obese patients with hypertension, 66% of patients administered lisinopril exhibited a reduction in diastolic blood pressure below 90 mmHg, compared to 43% of patients administered hydrochlorothiazide.ain [7, 10, 72] Similar results were obtained in the Candesartan Role on Obesity and Sympathetic System study, where the AT1 receptor antagonist candesartan decreased blood pressure, muscle sympathetic nerve activity, and improved insulin sensitivity, while hydrochlorothiazide exhibited favorable effects on blood pressure, but not on the other parameters [73]. Collectively, these results support a role for the adipocyte RAS in human obesity-related hypertension. 13.2.2 Leptin in Obesity-Related Hypertension
Leptin, a peptide hormone secreted by adipocytes, regulates food intake and energy expenditure through effects on the central nervous system. In the brain, leptin binds to the long form of the leptin receptor and activates pro-opiomelanocortin (POMC)/cocaine- and amphetamine-related transcript neurons in the hypothalamus, while inhibiting the activity of neuropeptide Y/agouti-related protein neurons (for review, see [74]). These neurons project to the paraventricular nucleus and lateral hypothalamic area, and to sympathetic preganglionic neurons in the medulla and spinal cord [75]. In addition to stimulating sympathetic outflow to thermogenic tissues for the control of energy expenditure, leptin also increases sympathetic activity to cardiovascular-relevant organs, including the kidneys and adrenal gland [76–78]. These effects of leptin have been demonstrated to result in an increase in arterial blood pressure when leptin is administered chronically into the central nervous system [79]. However, while both central and peripheral administration of leptin both stimulate the sympathetic nervous system, only central leptin administration increases blood pressure [76, 78]. These results have suggested that peripheral
j249
j 13 Adipose Tissue and Blood Pressure Regulation
250
effects of leptin, including stimulation of nitric oxide, may counterbalance the central effects of leptin to stimulate the sympathetic nervous system, resulting in no change in arterial pressure when leptin is elevated peripherally. Many of the effects of leptin are mediated by a product of POMC processing, amelanocyte-stimulating hormone (MSH), which binds to melanocortin (MC)-4/5 receptors in the hypothalamus to elicit the metabolic effects of leptin [80, 81]. Administration of an MC-4/5 receptor antagonist to rats abolished the effects of chronic leptin administration to raise blood pressure [82]. Moreover, in mice with obesity from MC-4 receptor deficiency, intravenous leptin infusion did not increase blood pressure, suggesting that a functional MC-4 receptor is essential for the cardiovascular effects of leptin [83]. Circulating leptin levels are considered to be a marker of adiposity and plasma leptin concentrations are increased in obese compared to lean individuals [84]. The presence of obesity despite increased circulating concentrations of leptin has led to the hypothesis that obese humans are resistant to the metabolic actions of leptin [85]. However, in order for leptin to be considered a pivotal adipokine linking obesity to hypertension, the cardiovascular effects of leptin would need to be preserved in obese subjects with high circulating leptin concentrations. This hypothesis is supported by data from yellow obese agouti mice, which are resistant to the anorexigenic effects of leptin, but have an intact sympathetic excitatory response to leptin administration [86, 87]. Metabolic and cardiovascular effects of leptin have also been demonstrated to diverge based on the response of the baroreflex, where activation of the baroflex selectively inhibits leptin-induced renal sympathetic activation, but has no effect on sympathetic activation to brown adipose tissue [88, 89]. The mechanism for these diverging effects of leptin to increase sympathetic outflow for metabolic versus cardiovascular regulation involves differences in the neuronal pathways. For example, antagonists of the MC-4 receptor inhibit leptin-induced activation of renal sympathetic nerves, but have no effect on sympathetic activation to brown adipose tissue, while a corticotrophin-releasing factor receptor antagonist selectively inhibits leptin-induced sympathetic activation to brown adipose tissue [90]. If these data are extrapolated to obesity, it is conceivable that obese individuals have selective leptin resistance to the metabolic effects of leptin, while cardiovascular effects of leptin are maintained. However, this hypothesis has not been directly tested in human obesity. 13.2.3 Adiponectin in Obesity-Related Hypertension
Adiponectin was cloned independently by four groups in 1995 and 1996, and is expressed at the mRNA level predominantly in adipose tissue from experimental animals and humans [91–93]. Adipose tissue serves as the major source of circulating adiponectin, which is present in plasma at concentrations ranging from 3 to 30 mg/ml in adults [94]. Circulating adiponectin exists in two major oligomeric forms of a hexamer and a 400-kDa high-molecular-weight complex [95]. Unlike other adipokines, adiponectin levels in plasma are inversely correlated with BMI [96]. Moreover, the negative correlation of adiponectin with body weight becomes stronger when
13.2 Adipose Tissue Changes with Obesity: Relation to Blood Pressure Control
correlated to visceral, as compared to subcutaneous, adipose tissue [97]. Mechanisms for reductions in adipose expression of adiponectin with obesity are unknown; however, tumor necrosis factor (TNF)-a has been suggested as a contributor due to its ability to inhibit adiponectin promoter activity [98]. The significance of reductions in circulating adiponectin with obesity arise from its ability to act as an insulin sensitizer [99–102], and anti-inflammatory and antiatherogenic protein [103, 104]. Circulating levels of adiponectin have been reported to decrease in patients with hypertension [105] and hypoadiponectinemia has been demonstrated as an independent risk factor for hypertension in cross-sectional studies [106, 107]. Moreover, in recent studies prospectively examining the 5-year development of hypertension in a nondiabetic Chinese cohort, an inverse relationship between plasma adiponectin concentration and the future development of hypertension was defined [108]. Surprisingly, the predictive nature of plasma adiponectin concentrations with hypertension remained significant even after adjustment for BMI. These results suggest that adiponectin may play a role in the pathogenesis of essential hypertension, including obesity-related hypertension. Mechanisms potentially contributing to hypertension in patients with hypoadiponectinemia include increased plasma fatty acid concentrations and insulin resistance, endothelial dysfunction from loss of nitric oxide [109], dysregulated vascular smooth muscle growth with resulting vascular hypertrophy [110, 111], and loss of suppression of renal sympathetic nerve activity [112]. Interestingly, recent studies demonstrate that adenoviral delivery of adiponectin to obese KKAy mice decreased blood pressure, while adiponectin deficient mice exhibited hypertension, supporting an in vivo role for adiponectin in obesity-related hypertension [113]. 13.2.4 Insulin and Obesity-Related Hypertension
In addition to regulating glucose uptake into adipocytes, insulin increases lipid storage by promoting adipocyte differentiation, inhibiting lipolysis, and stimulating lipogenesis. With insulin resistance at hypertrophied adipocytes, lipolysis is increased and plasma levels of nonesterified fatty acids (NEFAs) rise. Elevations in NEFA have been demonstrated to increase sympathetic nerve activity, promote insulin resistance at skeletal muscle, cause endothelial dysfunction, increase oxidative stress in variety of cell types, and enhance vascular smooth muscle sensitivity to contractile agonists. In addition, insulin has direct effects through insulin receptors to regulate a variety of cardiovascular-relevant functions. At the vascular endothelium, insulin stimulates the production of nitric oxide [114] through insulin receptor tyrosine kinase-dependent phosphorylation of insulin receptor substrate-1 leading to Akt activation and phosphorylation of endothelial nitric oxide synthetase [115, 116]. At vascular smooth muscle, insulin decreases contractility associated with reductions in membrane RhoA [117], by inhibiting calcium influx and promoting calcium efflux [118]. In the heart, insulin regulates a variety of metabolic processes (glucose uptake, glycolysis, lipid metabolism, protein synthesis), enhances cardiac contractility [119–122], and through several insulin signaling pathways can contribute to
j251
j 13 Adipose Tissue and Blood Pressure Regulation
252
cardiac hypertrophy [118]. Moreover, a variety of studies demonstrate that physiological concentrations of insulin increase sympathetic nerve activity [123–125]. Given that insulin has opposing effects to increase vasodilation, but yet promote vasoconstriction, the net hemodynamic effect of insulin on blood pressure is minimal in healthy subjects. In states of insulin resistance, specific signaling pathways utilized by the insulin receptor are impaired, with decrements in phosphoinositide-3-kinase signaling and retained Ras/mitogen-activated protein kinase (MAPK)-dependent signaling effects of insulin [126, 127]. Interestingly, many of the prohypertensive effects of insulin occur through MAPK signaling, such that in states of hyperinsulinemia insulin may contribute to hypertension. 13.2.5 Plasminogen Activator Inhibitor-1 and Obesity-Related Hypertension
Plasminogen activator inhibitor (PAI)-1 is the major physiological inhibitor of tissuetype plasminogen activator and urokinase-type plasminogen activator, and as such inhibits fibrinolysis. PAI-1 concentrations in plasma are elevated in type 2 diabetes, even after correction for insulin levels [128, 129]. The source of elevated PAI-1 with obesity is controversial, since both adipocytes and stromal vascular cells (i.e., macrophages) express PAI-1 [130–132]. In addition, stromal vascular cells in visceral adipose tissue express considerably more (5-fold) PAI-1 compared to subcutaneous adipose tissue [133]. However, plasma concentrations of PAI-1 are more closely related to fat accumulation and PAI-1 expression in the liver than in adipose tissue, suggesting the liver serves as a major source of PAI-1 production [134]. Several different mechanisms have been suggested to contribute to elevated PAI-1 expression with obesity, including TNF [135, 136], transforming growth factor-b [137, 138], oxidative stress [139], free fatty acids [140], and angiotensin II [141–143]. In mice with PAI-1 deficiency, both diet-induced [144, 145] and genetic obesity [146] are decreased, suggesting that PAI-1 can contribute to the development of obesity. Moreover, pharmacologic inhibition of PAI-1 results in a reduction in weight gain and improved insulin sensitivity in mice [147, 148]. While obesity-induced increases in PAI-1 expression have been mechanistically linked to insulin resistance and atherosclerosis, there have been no studies directly examining the role of PAI-1 in obesity-related hypertension. 13.2.6 Free Fatty Acids and Obesity-Related Hypertension
The release of free fatty acids from abdominal adipocytes increases with central obesity [149, 150]. Free fatty acids are released from adipocytes following hormonesensitive lipase (HSL)-mediated hydrolysis of triacylglycerol, and represent the major secretory product of adipocytes [151]. The activity of HSL is stimulated by badrenergic agonists, and decreased by insulin. With insulin resistance, activity of HSL increases, with a resulting release of free fatty acids from adipocytes into the
13.2 Adipose Tissue Changes with Obesity: Relation to Blood Pressure Control
systemic circulation. A variety of studies, performed in animals and humans, demonstrate that infusion of Intralipid results in an increase in blood pressure (for review, see [22]). Elevations in circulating levels of free fatty acids can influence blood pressure through multiple mechanisms. Elevations in blood pressure following infusion of oleic acid to rats were blunted by an a1-adrenergic antagonist [152]. Conversely, infusion of Intralipid in hand veins of normotensive subjects resulted in a lower dose of phenylephrine required to produce 50% of the maximal vasoconstrictor response [153], suggesting that free fatty acids promote a-adrenergic responsiveness. These data suggest that enhancing the responsiveness to a1-adrenergic agonists may serve as a mechanism linking elevated fatty acids to hypertension. Free fatty acids reduce endothelium-dependent production of nitric oxide and studies have demonstrated that infusion of Intralipid to lean, healthy individuals results in a reduction in methacholine-induced relaxation [154]. Moreover, elevated free fatty acids have been suggested to serve as a mechanism for impaired vasodilator responses to insulin [155]. Another potential mechanism linking elevations in free fatty acids to hypertension with obesity includes an increase in oxidative stress; however, this mechanism has not been directly tested in humans. Free fatty acids exhibit mitogen actions on vascular smooth muscle, potentially related to activation of protein kinase C and potentiation of the responsiveness to other growth factors (insulin-like growth factor-1) [156–160]. Finally, free fatty acids have been reported to activate the RAS, as evidenced by increased expression of angiotensinogen in adipocytes [161], enhanced mitogenic responses to angiotensin II [157, 162], and stimulation of the production of aldosterone from rat adrenal cells [163]. Collectively, these results suggest that elevations in circulating concentrations of free fatty acids could contribute to obesityrelated hypertension through multiple mechanisms. 13.2.7 Resistin and Obesity-Related Hypertension
Resistin was identified by three independent groups [164–166] and is a predominantly adipocyte-derived protein that is detectable in the systemic circulation [164]. In rodent models of obesity resistin levels were elevated in serum [164], and some studies have shown elevations in resistin with human obesity and diabetes [167]. However, conflicting data has also been reported, showing either a reduction in serum resistin levels and decreased resistin mRNA expression in adipose tissue from genetically obese db/db mice [168], or no change [169]. Resistin has been suggested to play a role in the regulation of glucose homeostasis. Administration of resistin protein resulted in a reduction in insulin action in C57BL/6 mice [164] and SpragueDawley rats [170]. Interestingly, resistin has been demonstrated to increase the production of the proinflammatory cytokines endothelin-1 and monocyte chemotactic protein (MCP)-1 in endothelial cells [171, 172], and stimulate foam cell formation in macrophages [173, 174]. However, it is unclear whether these effects of resistin contribute to a role of this protein in the pathogenesis of obesity, atherosclerosis, or diabetes. In prehypertensive subjects with normal BMI, plasma levels of resistin were increased [175]. Moreover, in patients with essential
j253
j 13 Adipose Tissue and Blood Pressure Regulation
254
hypertension and type 2 diabetes mellitus, serum resistin levels were increased [176]. However, a role for resistin in the development of obesity-related hypertension in animal models or humans has not been defined. 13.2.8 11b-HSD-1 and Obesity-Related Hypertension
The effect of cortisol at target tissues is modulated by the tissue-specific enzyme 11bHSD-1. The type 1 form of 11b-HSD is expressed by adipocytes and facilitates the conversion of inactive cortisone to active cortisol. The type 2 form of 11b-HSD catalyzes the metabolism of cortisol locally to cortisone, minimizing the effects of glucocorticoids and allowing actions at the mineralocorticoid receptor. 11b-HSD-1 is expressed to a greater extent in omental than subcutaneous adipose tissue [177] and thus contributes to the differential effects of glucocorticoids on regional adipose depots. In adipocytes, by promoting the formation of active cortisol, 11b-HSD-1 promotes the differentiation of preadipocytes to adipocytes. Transgenic mice overexpressing 11b-HSD-1 in adipocytes exhibit elevated plasma corticosterone, visceral obesity, and several aspects of the metabolic syndrome, including hypertension [58]. Interestingly, hypertension in these mice was associated with activation of the RAS and blood pressure was decreased by an AT1 receptor antagonist. Conversely, inhibition of 11b-HSD-1 in obese rodents improves glucose tolerance, insulin sensitivity, and lipid profiles [178]. While a role of 11b-HSD-1 in hypertension has been demonstrated in several experimental models, the enzyme does not appear to be as clearly linked to hypertension in humans [179].
13.3 Regional Adipose Deposition and Blood Pressure Regulation
In 1956, Vague first described different patterns of fat distribution, coined android for upper-body obesity and gynoid for lower-body obesity [180]. As far back as 1956, android obesity was found to be more closely related to diabetes mellitus and coronary artery disease. It is generally well accepted that central adiposity (android obesity) is associated with greater cardiovascular risk than gynoid obesity. Subcutaneous fat comprises approximately 80% of total body fat [181], but is generally less metabolically active as compared to visceral adipose tissue [181, 182]. Both genetic and hormonal (sex hormones, corticosteroids, growth hormone, insulin, etc.) mechanisms may regulate the regional distribution of adipose tissue. With obesity, both subcutaneous and visceral adipose tissue increase in mass; however, the greater metabolic activity of visceral adipose tissue is more closely associated with metabolic disease. Using computed tomography to measure abdominal, thoracic and thigh fat, Hayashi et al. [183] demonstrated a significant odds ratio of hypertension with increasing quartiles of intra-abdominal fat, which remained after adjusting for total subcutaneous fat area or waist circumference in Japanese Americans with a high degree of abdominal fat given their BMI. In Dallas Heart Study participants,
13.3 Regional Adipose Deposition and Blood Pressure Regulation
dual-energy X-ray absorptiometry scanning assessment of fat in the trunk area correlated positively with systolic blood pressure [184]. Recent studies in participants from the Framingham Heart Study using multidetector computed tomography assessment of both subcutaneous and visceral adipose tissue demonstrated that visceral adipose tissue was more strongly associated with an adverse metabolic risk profile even after accounting for standard anthropometric indexes [185]. Mechanisms for these close associations of visceral adipose tissue to metabolic risk, including hypertension, are unknown, but are thought to relate to the greater metabolic activity of visceral adipose tissue which then drains into the portal circulation [186]. 13.3.1 Changes in Visceral Adipose Tissue in Obesity-Related Hypertension
With the exception of leptin and HSL, each of the adipokines described above is expressed in greater abundance in visceral compared to subcutaneous adipose tissue. For example, in young rats, mRNA abundance of approximately 20 genes, including HSL and angiotensinogen, was greater in perirenal visceral as compared to subcutaneous adipose tissue [187]. Similar results have been obtained using human adipose tissue [181, 188, 189]. Moreover, using the clamp technique to control delivery of nutrients to adipose tissue, glucose uptake was associated with an increased expression of resistin, adiponectin, leptin, PAI-1, and angiotensinogen in visceral, but not subcutaneous, fat [190]. However, only a few adipokines with regional variations in expression have been examined in the context of obesityrelated hypertension. We demonstrated a site-specific increase in mRNA abundance of angiotensinogen in rats with diet-induced obesity and hypertension [45]. Administration of an AT1 receptor antagonist to rats with diet-induced obesity hypertension resulted in normalization of blood pressure, supporting a role for the RAS in obesity-related hypertension [60]. In transgenic mice expressing 11bHSD-1 in adipose tissue, visceral obesity developed on normal mouse diet and was exacerbated by high-fat feeding [191]. Importantly, these mice developed hypertension which was associated with activation of the RAS [58]. To date, results support a role for increased expression and activity of specific adipokines in visceral adipose tissue as a potential link between obesity and hypertension. However, without methodologies to control the depot-specific expression of adipokines, it is difficult to directly define the role of regional expression of adipokines in obesity-related hypertension. 13.3.2 Potential Role for Perivascular Adipose Tissue in Obesity-Related Hypertension
Following our original observation that adipose tissue, including periaortic adipose tissue, expressed angiotensinogen as the precursor to angiotensin II, we examined the role of periaortic adipose tissue as a potential modulator of the contractile response to a variety of agonists [192]. The general consensus prior to this time was
j255
j 13 Adipose Tissue and Blood Pressure Regulation
256
that periarterial adipose tissue served primarily a mechanical, rather than a metabolic function [193, 194]. Our results demonstrated that in rat aortic rings with adherent periaortic adipose tissue, the contractile response to norepinephrine was reduced, supporting a role for periaortic adipose tissue as modulator of vascular responsiveness. Since this time, a variety of investigators have demonstrated that adipose tissue surrounding blood vessels serves a physiological and/or pathophysiologic role. In addition, alterations in the function of perivascular adipose tissue have been suggested to contribute to various diseases, including hypertension. In 2002, Lohn et al., [195] demonstrated that perivascular adipocytes secreted a factor, termed adventitial-derived relaxing factor (ADRF), which acts by a tyrosine kinasedependent mechanism to activate potassium channels in vascular smooth muscle. The release of ADRF resulted in attenuated vascular responses to angiotensin II, serotonin, and phenylephrine. Further studies focused on ADRF release from resistance arteries demonstrated hyperpolarization of vascular smooth muscle in rat mesenteric arteries by periadventitial fat [196], and that these effects were diminished in mesenteric arteries from spontaneously hypertensive rats [197]. Additional studies demonstrated that conditioned media from rat perivascular adipose tissue stimulates the proliferation of vascular smooth muscle cells and that with obesity, these effects are augmented [198]. Finally, recent studies in lipoatrophic A-ZIP/F1 transgenic mice demonstrated that enhanced contractile responses of blood vessels to agonists was associated with an absence of perivascular adipose tissue, potentially contributing to hypertension [199]. Interestingly, the mass of perivascular adipose tissue increased markedly along the length of the aorta when rats were fed a high-fat diet [200] and was suggested to contribute to obesity-associated atherosclerosis through stimulation of macrophage recruitment to adipose tissue [201]. Collectively, these results suggest that expanded mass of adipose tissue surrounding cardiovascular relevant organs, including blood vessels, may contribute to obesityrelated diseases, including hypertension. Future studies should address the pathophysiological relevance of periorgan adipose tissue in obesity-associated disease.
13.4 Conclusions
Adipose tissue is no longer a simple energy-storing site, but is capable of the production of a variety of factors that can influence blood pressure. Alterations in adipose production and release of proteins with obesity may contribute to obesityassociated diseases, including hypertension. Future areas for investigation include definition of the mechanisms for altered adipokine expression with obesity and the relative contribution of adipokines to obesity-related hypertension. The use of adipocyte-specific promoters to deplete adipokines in mice should facilitate our understanding of the role of these adipose-derived factors in obesity and obesityrelated hypertension.
References
References 1 Fields, L.E., Burt, V.L., Cutler, J.A.,
2
3
4
5
6
7
8 9
10
11
12
13
14 15 16
Hughes, J., Roccella, E.J., and Sorlie, P. (2004) Hypertension, 44, 398–404. Ong, K.L., Cheung, B.M., Man, Y.B., Lau, C.P., and Lam, K.S. (2007) Hypertension, 49, 69–75. Poirier, P., Giles, T.D., Bray, G.A., Hong, Y., Stern, J.S., Pi-Sunyer, F.X., and Eckel, R.H. (2006) Arterioscler. Thromb. Vasc. Biol., 26, 968–976. Stamler, R., Stamler, J., Riedlinger, W.F., Algera, G., and Roberts, R.H. (1978) JAMA, 240, 1607–1610. Garrison, R.J., Kannel, W.B., Stokes, J. 3rd, and Castelli, W.P. (1987) Prev. Med., 16, 235–251. Carroll, J.F., Huang, M., Hester, R.L., Cockrell, K., and Mizelle, H.L. (1995) Hypertension, 26, 465–470. Davy, K.P. and Hall, J.E. (2004) Am. J. Physiol. Regul. Integr. Comp. Physiol., 286, R803–R813. Hall, J.E. (1997) Am. J. Hypertens., 10, 49S–55. Messerli, F.H., Christie, B., DeCarvalho, J.G., Aristimuno, G.G., Suarez, D.H., Dreslinski, G.R., and Frohlich, E.D. (1981) Arch. Intern. Med., 141, 81–85. Reisin, E., Abel, R., Modan, M., Silverberg, D.S., Eliahou, H.E., and Modan, B. (1978) N. Engl. J. Med., 298, 1–6. Messerli, F.H., Christie, B., DeCarvalho, J.G., Aristimuno, G.G., Suarez, D.H., Dreslinski, G.R., and Frohlich, E.D. (1981) Arch. Intern. Med., 141, 81–85. Reisin, E., Abel, R., Modan, M., Silverberg, D.S., Eliahou, H.E., and Modan, B. (1978) N. Engl. J. Med., 298, 1–6. Carroll, J.F., Huang, M., Hester, R.L., Cockrell, K., and Mizelle, H.L. (1995) Hypertension, 26, 465–470. Hall, J.E. (1997) Am. J. Hypertens., 10, 49S–55. Davy, K.P. (2004) Curr. Hypertens. Rep., 6, 241–246. Esler, M., Straznicky, N., Eikelis, N., Masuo, K., Lambert, G., and Lambert, E. (2006) Hypertension, 48, 787–796.
17 Landsberg, L. and Young, J.B. (1978)
N. Engl. J. Med., 298, 1295–1301. 18 ODea, K., Esler, M., Leonard, P.,
19
20
21
22 23
24
25 26
27
28
29
30 31
Stockigt, J.R., and Nestel, P. (1982) Metabolism, 31, 896–899. Cooper, R., Forrester, T., Ogunbiyi, O., and Muffinda, J. (1998) J. Hypertens., 16, 571–575. Cooper, R., McFarlane-Anderson, N., Bennett, F.I., Wilks, R., Puras, A., Tewksbury, D., Ward, R., and Forrester, T. (1997) J. Hum. Hypertens., 11, 107–111. Umemura, S., Nyui, N., Tamura, K., Hibi, K., Yamaguchi, S., Nakamaru, M., Ishigami, T., Yabana, M., Kihara, M., Inoue, S., and Ishii, M. (1997) Am. J. Hypertens., 10, 629–633. Sarafidis, P.A. and Bakris, G.L. (2007) J. Hum. Hypertens., 21, 12–19. Ceriello, A. and Motz, E. (2004) Arterioscler. Thromb. Vasc. Biol., 24, 816–823. Keaney, J.F. Jr., Larson, M.G., Vasan, R.S., Wilson, P.W., Lipinska, I., Corey, D., Massaro, J.M., Sutherland, P., Vita, J.A., and Benjamin, E.J. (2003) Arterioscler. Thromb. Vasc. Biol., 23, 434–439. Olusi, S.O. (2002) Int. J. Obes. Relat. Metab. Disord., 26, 1159–1164. Furukawa, S., Fujita, T., Shimabukuro, M., Iwaki, M., Yamada, Y., Nakajima, Y., Nakayama, O., Makishima, M., Matsuda, M., and Shimomura, I. (2004) J. Clin. Invest., 114, 1752–1761. Modan, M., Halkin, H., Almog, S., Lusky, A., Eshkol, A., Shefi, M., Shitrit, A., and Fuchs, Z. (1985) J. Clin. Invest., 75, 809–817. Manicardi, V., Camellini, L., Bellodi, G., Coscelli, C., and Ferrannini, E. (1986) J. Clin. Endocrinol. Metab., 62, 1302–1304. Ferrannini, E., Buzzigoli, G., Bonadonna, R., Giorico, M.A., Oleggini, M., Graziadei, L., Pedrinelli, R., Brandi, L., and Bevilacqua, S. (1987) N. Engl. J. Med., 317, 350–357. Landsberg, L. (2006) Clin. Exp. Pharmacol. Physiol., 33, 863–867. Bays, H., Blonde, L., and Rosenson, R. (2006) Expert Rev. Cardiovasc. Ther., 4, 871–895.
j257
j 13 Adipose Tissue and Blood Pressure Regulation
258
32 Zhang, Y., Proenca, R., Maffei, M.,
33
34
35 36 37
38 39 40 41 42
43
44 45
46 47
48
49 50 51
Barone, M., Leopold, L., and Friedman, J.M. (1994) Nature, 372, 425–432. Le Lay, S., Krief, S., Farnier, C., Lefrere, I., Le Liepvre, X., Bazin, R., Ferre, P., and Dugail, I. (2001) J. Biol. Chem., 276, 16904–16910. Bergman, R.N., Kim, S.P., Hsu, I.R., Catalano, K.J., Chiu, J.D., Kabir, M., Richey, J.M., and Ader, M. (2007) Am. J. Med, 120, S3–S8; discussion S29–S32. Cassis, L.A., Lynch, K.R., and Peach, M.J. (1988) Circ. Res., 62, 1259–1262. Cassis, L.A., Lynch, K.R., and Peach, M.J. (1988) Circ. Res., 62, 1259–1262. Saye, J.A., Cassis, L.A., Sturgill, T.W., Lynch, K.R., and Peach, M.J. (1989) Am. J. Physiol. Cell Physiol., 256, C448–C451. Shenoy, U. and Cassis, L. (1997) Am. J. Physiol. Cell Physiol., 272, C989–999. Shenoy, U. and Cassis, L. (1997) Am. J. Physiol. Cell Physiol., 272, C989–C999. Cassis, L.A., Saye, J., and Peach, M.J. (1988) Hypertension, 11, 591–596. Cassis, L.A., Saye, J., and Peach, M.J. (1988) Hypertension, 11, 591–596. Lu, H., Boustany-Kari, C.M., Daugherty, A., and Cassis, L.A. (2007) Am. J. Physiol. Endocrinol. Metab., 292, E1280–E1287. Cassis, L.A., Rateri, D.L., Lu, H., and Daugherty, A. (2007) Arterioscler. Thromb. Vasc. Biol., 27, 380–386. Cassis, L.A. (1992) Am J. Physiol. Endocrinol. Metab., 262, E105–109. Boustany, C.M., Bharadwaj, K., Daugherty, A., Brown, D.R., Randall, D.C., and Cassis, L.A. (2004) Am. J. Physiol. Regul. Integr. Comp. Physiol., 287, R943–R949. Cassis, L.A. (1994) Am. J. Physiol. Endocrinol. Metab., 266, E453–E458. Cassis, L.A., Fettinger, M.J., Roe, A.L., Shenoy, U.R., and Howard, G. (1996) Adv. Exp. Med. Biol., 396, 39–47. Cassis, L.A., Fettinger, M.J., Roe, A.L., Shenoy, U.R., and Howard, G. (1996) Adv. Exp. Med. Biol., 396, 39–47. Cassis, L.A. (1993) Am. J. Physiol. Endocrinol. Metab., 265, E860–E865. Cassis, L.A. (1993) Am. J. Physiol. Endocrinol. Metab., 265, E860–E865. Cassis, L.A. (2000) Curr. Hypertens. Rep., 2, 132–138.
52 Engeli, S., Negrel, R., and Sharma, A.M.
(2000) Hypertension, 35, 1270–1277. 53 Cassis, L.A. (2000) Curr. Hypertens. Rep.,
2, 132–138.
54 Engeli, S., Negrel, R., and Sharma, A.M.
(2000) Hypertension, 35, 1270–1277. 55 Massiera, F., Bloch-Faure, M., Ceiler, D.,
56
57
58
59
60
61
62
63
64
Murakami, K., Fukamizu, A., Gasc, J.M., Quignard-Boulange, A., Negrel, R., Ailhaud, G., Seydoux, J., Meneton, P., and Teboul, M. (2001) FASEB J., 15, 2727–2729. Kouyama, R., Suganami, T., Nishida, J., Tanaka, M., Toyoda, T., Kiso, M., Chiwata, T., Miyamoto, Y., Yoshimasa, Y., Fukamizu, A., Horiuchi, M., Hirata, Y., and Ogawa, Y. (2005) Endocrinology, 146, 3481–3489. Tondu, A.L., Robichon, C., Yvan-Charvet, L., Donne, N., Le Liepvre, X., Hajduch, E., Ferre, P., Dugail, I., and Dagher, G. (2005) J. Biol. Chem., 280, 33536–33540. Masuzaki, H., Yamamoto, H., Kenyon, C.J., Elmquist, J.K., Morton, N.M., Paterson, J.M., Shinyama, H., Sharp, M.G., Fleming, S., Mullins, J.J., Seckl, J.R., and Flier, J.S. (2003) J. Clin. Invest., 112, 83–90. Rahmouni, K., Mark, A.L., Haynes, W.G., and Sigmund, C.D. (2004) Am. J. Physiol. Endocrinol. Metab., 286, E891–E895. Boustany, C.M., Brown, D.R., Randall, D.C., and Cassis, L.A. (2005) Am. J. Physiol. Regul. Integr. Comp. Physiol., 289, R181–R186. van Harmelen, V., Elizalde, M., Ariapart, P., Bergstedt-Lindqvist, S., Reynisdottir, S., Hoffstedt, J., Lundkvist, I., Bringman, S., and Arner, P. (2000) Int. J. Obes. Relat. Metab. Disord., 24, 673–678. Giacchetti, G., Faloia, E., Sardu, C., Camilloni, M.A., Mariniello, B., Gatti, C., Garrapa, G.G., Guerrieri, M., and Mantero, F. (2000) Int. J. Obes. Relat. Metab. Disord., 24 (Suppl. 2), S142–S143. Gorzelniak, K., Engeli, S., Janke, J., Luft, F.C., and Sharma, A.M. (2002) J. Hypertens., 20, 965–973. Giacchetti, G., Faloia, E., Mariniello, B., Sardu, C., Gatti, C., Camilloni, M.A., Guerrieri, M., and Mantero, F. (2002) Am. J. Hypertens., 15, 381–388.
References 65 Faloia, E., Gatti, C., Camilloni, M.A.,
66
67
68
69
70
71 72
73
74 75 76
77
78 79 80 81
Mariniello, B., Sardu, C., Garrapa, G.G., Mantero, F., and Giacchetti, G. (2002) J. Endocrinol. Invest., 25, 309–314. Engeli, S., Bohnke, J., Gorzelniak, K., Janke, J., Schling, P., Bader, M., Luft, F.C., and Sharma, A.M. (2005) Hypertension, 45, 356–362. Umemura, S., Nyui, N., Tamura, K., Hibi, K., Yamaguchi, S., Nakamaru, M., Ishigami, T., Yabana, M., Kihara, M., Inoue, S., and Ishii, M. (1997) Am. J. Hypertens., 10, 629–633. Cooper, R., McFarlane-Anderson, N., Bennett, F.I., Wilks, R., Puras, A., Tewksbury, D., Ward, R., and Forrester, T. (1997) J. Hum. Hypertens., 11, 107–111. Licata, G., Scaglione, R., Ganguzza, A., Corrao, S., Donatelli, M., Parrinello, G., Dichiara, M.A., Merlino, G., and Cecala, M.G. (1994) Am. J. Hypertens., 7, 314–320. Jordan, J., Engeli, S., Boye, S.W., Le Breton, S., and Keefe, D.L. (2007) Hypertension, 49, 1047–1055. Harp, J.B., Henry, S.A., and DiGirolamo, M. (2002) Obes. Res., 10, 985–990. Reisin, E., Weir, M.R., Falkner, B., Hutchinson, H.G., Anzalone, D.A., and Tuck, M.L. (1997) Hypertension, 30, 140–145. Grassi, G., Seravalle, G., DellOro, R., Trevano, F.Q., Bombelli, M., Scopelliti, F., Facchini, A., and Mancia, G. (2003) J. Hypertens., 21, 1761–1769. Haynes, W.G. (2005) Exp. Physiol., 90, 683–688. Elmquist, J.K., Elias, C.F., and Saper, C.B. (1999) Neuron, 22, 221–232. Haynes, W.G., Sivitz, W.I., Morgan, D.A., Walsh, S.A., and Mark, A.L. (1997) Hypertension, 30, 619–623. Mark, A.L., Shaffer, R.A., Correia, M.L., Morgan, D.A., Sigmund, C.D., and Haynes, W.G. (1999) J. Hypertens., 17, 1949–1953. Dunbar, J.C., Hu, Y., and Lu, H. (1997) Diabetes, 46, 2040–2043. Shek, E.W., Brands, M.W., and Hall, J.E. (1998) Hypertension, 31, 409–414. Hakansson, M.L. and Meister, B. (1998) Neuroendocrinology, 68, 420–427. Cowley, M.A., Smart, J.L., Rubinstein, M., Cerdan, M.G., Diano, S., Horvath,
82 83 84
85
86
87
88
89
90
91
92
93 94
95
96
T.L., Cone, R.D., and Low, M.J. (2001) Nature, 411, 480–484. da Silva, A.A., Kuo, J.J., and Hall, J.E. (2004) Hypertension, 43, 1312–1317. Tallam, L.S., da Silva, A.A., and Hall, J.E. (2006) Hypertension, 48, 58–64. Considine, R.V., Sinha, M.K., Heiman, M.L., Kriauciunas, A., Stephens, T.W., Nyce, M.R., Ohannesian, J.P., Marco, C.C., McKee, L.J., Bauer, T.L. et al. (1996) N. Engl. J. Med., 334, 292–295. Rahmouni, K., Correia, M.L., Haynes, W.G., and Mark, A.L. (2005) Hypertension, 45, 9–14. Correia, M.L., Haynes, W.G., Rahmouni, K., Morgan, D.A., Sivitz, W.I., and Mark, A.L. (2002) Diabetes, 51, 439–442. Mark, A.L., Correia, M.L., Rahmouni, K., and Haynes, W.G. (2002) J. Hypertens., 20, 1245–1250. Hausberg, M., Morgan, D.A., Chapleau, M.A., Sivitz, W.I., Mark, A.L., and Haynes, W.G. (2002) J. Hypertens., 20, 1633–1641. Hausberg, M., Morgan, D.A., Mitchell, J.L., Sivitz, W.I., Mark, A.L., and Haynes, W.G. (2002) Diabetes, 51, 2434–2440. Correia, M.L., Morgan, D.A., Mitchell, J.L., Sivitz, W.I., Mark, A.L., and Haynes, W.G. (2001) Hypertension, 38, 384–388. Maeda, K., Okubo, K., Shimomura, I., Funahashi, T., Matsuzawa, Y., and Matsubara, K. (1996) Biochem. Biophys. Res. Commun., 221, 286–289. Scherer, P.E., Williams, S., Fogliano, M., Baldini, G., and Lodish, H.F. (1995) J. Biol. Chem., 270, 26746–26749. Hu, E., Liang, P., and Spiegelman, B.M. (1996) J. Biol. Chem., 271, 10697–10703. Corbetta, S., Bulfamante, G., Cortelazzi, D., Barresi, V., Cetin, I., Mantovani, G., Bondioni, S., Beck-Peccoz, P., and Spada, A. (2005) J. Clin. Endocrinol. Metab., 90, 2397–2402. Nishida, M., Funahashi, T., and Shimomura, I. (2007) Med. Mol. Morphol., 40, 55–67. Arita, Y., Kihara, S., Ouchi, N., Takahashi, M., Maeda, K., Miyagawa, J., Hotta, K., Shimomura, I., Nakamura, T., Miyaoka, K., Kuriyama, H., Nishida, M., Yamashita, S., Okubo, K., Matsubara, K.,
j259
j 13 Adipose Tissue and Blood Pressure Regulation
260
97
98
99
100
101
102
103 104 105
106
107
108
Muraguchi, M., Ohmoto, Y., Funahashi, T., and Matsuzawa, Y. (1999) Biochem. Biophys. Res. Commun., 257, 79–83. Cnop, M., Havel, P.J., Utzschneider, K.M., Carr, D.B., Sinha, M.K., Boyko, E.J., Retzlaff, B.M., Knopp, R.H., Brunzell, J.D., and Kahn, S.E. (2003) Diabetologia, 46, 459–469. Maeda, N., Takahashi, M., Funahashi, T., Kihara, S., Nishizawa, H., Kishida, K., Nagaretani, H., Matsuda, M., Komuro, R., Ouchi, N., Kuriyama, H., Hotta, K., Nakamura, T., Shimomura, I., and Matsuzawa, Y. (2001) Diabetes, 50, 2094–2099. Stefan, N., Vozarova, B., Funahashi, T., Matsuzawa, Y., Weyer, C., Lindsay, R.S., Youngren, J.F., Havel, P.J., Pratley, R.E., Bogardus, C., and Tataranni, P.A. (2002) Diabetes, 51, 1884–1888. Berg, A.H., Combs, T.P., Du, X., Brownlee, M., and Scherer, P.E. (2001) Nat. Med., 7, 947–953. Combs, T.P., Berg, A.H., Obici, S., Scherer, P.E., and Rossetti, L. (2001) J. Clin. Invest., 108, 1875–1881. Yamauchi, T., Kamon, J., Minokoshi, Y., Ito, Y., Waki, H., Uchida, S., Yamashita, S., Noda, M., Kita, S., Ueki, K., Eto, K., Akanuma, Y., Froguel, P., Foufelle, F., Ferre, P., Carling, D., Kimura, S., Nagai, R., Kahn, B.B., and Kadowaki, T. (2002) Nat. Med., 8, 1288–1295. Lam, K.S. and Xu, A. (2005) Curr. Diabetes Rep., 5, 254–259. Lihn, A.S., Pedersen, S.B., and Richelsen, B. (2005) Obes. Rev., 6, 13–21. Adamczak, M., Wiecek, A., Funahashi, T., Chudek, J., Kokot, F., and Matsuzawa, Y. (2003) Am. J. Hypertens., 16, 72–75. Kazumi, T., Kawaguchi, A., Hirano, T., and Yoshino, G. (2003) Metabolism, 52, 1113–1116. Iwashima, Y., Katsuya, T., Ishikawa, K., Ouchi, N., Ohishi, M., Sugimoto, K., Fu, Y., Motone, M., Yamamoto, K., Matsuo, A., Ohashi, K., Kihara, S., Funahashi, T., Rakugi, H., Matsuzawa, Y., and Ogihara, T. (2004) Hypertension, 43, 1318–1323. Chow, W.S., Cheung, B.M., Tso, A.W., Xu, A., Wat, N.M., Fong, C.H., Ong, L.H., Tam, S., Tan, K.C., Janus, E.D., Lam, T.H.,
109
110
111 112
113
114 115
116
117 118
119 120 121 122
123
and Lam, K.S. (2007) Hypertension, 49, 1455–1461. Kobayashi, H., Ouchi, N., Kihara, S., Walsh, K., Kumada, M., Abe, Y., Funahashi, T., and Matsuzawa, Y. (2004) Circ. Res., 94, e27–31. Arita, Y., Kihara, S., Ouchi, N., Maeda, K., Kuriyama, H., Okamoto, Y., Kumada, M., Hotta, K., Nishida, M., Takahashi, M., Nakamura, T., Shimomura, I., Muraguchi, M., Ohmoto, Y., Funahashi, T., and Matsuzawa, Y. (2002) Circulation, 105, 2893–2898. Mahmud, A. and Feely, J. (2005) Am. J. Hypertens., 18, 1543–1548. Tanida, M., Shen, J., Horii, Y., Matsuda, M., Kihara, S., Funahashi, T., Shimomura, I., Sawai, H., Fukuda, Y., Matsuzawa, Y., and Nagai, K. (2007) Exp. Biol. Med., 232, 390–397. Ohashi, K., Kihara, S., Ouchi, N., Kumada, M., Fujita, K., Hiuge, A., Hibuse, T., Ryo, M., Nishizawa, H., Maeda, N., Maeda, K., Shibata, R., Walsh, K., Funahashi, T., and Shimomura, I. (2006) Hypertension, 47, 1108–1116. Zeng, G. and Quon, M.J. (1996) J. Clin. Invest., 98, 894–898. Montagnani, M., Chen, H., Barr, V.A., and Quon, M.J. (2001) J. Biol. Chem., 276, 30392–30398. Montagnani, M., Golovchenko, I., Kim, I., Koh, G.Y., Goalstone, M.L., Mundhekar, A.N., Johansen, M., Kucik, D.F., Quon, M.J., and Draznin, B. (2002) J. Biol. Chem., 277, 1794–1799. Begum, N., Sandu, O.A., and Duddy, N. (2002) Diabetes, 51, 2256–2263. Muniyappa, R. and Quon, M.J. (2007) Curr. Opin. Clin. Nutr. Metab. Care, 10, 523–530. Brownsey, R.W., Boone, A.N., and Allard, M.F. (1997) Cardiovasc. Res., 34, 3–24. Abel, E.D. (2004) Front. Biosci., 9, 201–215. Baron, A.D. (1994) Am. J. Physiol. Endocrinol. Metab., 267, E187–202. Aulbach, F., Simm, A., Maier, S., Langenfeld, H., Walter, U., Kersting, U., and Kirstein, M. (1999) Cardiovasc. Res., 42, 113–120. Anderson, E.A., Hoffman, R.P., Balon, T.W., Sinkey, C.A., and Mark, A.L. (1991) J. Clin. Invest., 87, 2246–2252.
References 124 Lembo, G., Napoli, R., Capaldo, B.,
125
126
127
128
129 130
131 132
133
134
135
136
137
138
Rendina, V., Iaccarino, G., Volpe, M., Trimarco, B., and Sacca, L. (1992) J. Clin. Invest., 90, 24–29. Rowe, J.W., Young, J.B., Minaker, K.L., Stevens, A.L., Pallotta, J., and Landsberg, L. (1981) Diabetes, 30, 219–225. Jiang, Z.Y., Lin, Y.W., Clemont, A., Feener, E.P., Hein, K.D., Igarashi, M., Yamauchi, T., White, M.F., and King, G.L. (1999) J. Clin. Invest., 104, 447–457. Cusi, K., Maezono, K., Osman, A., Pendergrass, M., Patti, M.E., Pratipanawatr, T., DeFronzo, R.A., Kahn, C.R., and Mandarino, L.J. (2000) J. Clin. Invest., 105, 311–320. Asplund-Carlson, A., Hamsten, A., Wiman, B., and Carlson, L.A. (1993) Diabetologia, 36, 817–825. Mavri, A., Alessi, M.C., and Juhan-Vague, I. (2004) J. Intern. Med., 255, 448–456. Seki, T., Miyasu, T., Noguchi, T., Hamasaki, A., Sasaki, R., Ozawa, Y., Okukita, K., Declerck, P.J., and Ariga, T. (2001) J. Cell. Physiol., 189, 72–78. Samad, F. and Loskutoff, D.J. (1996) Mol. Med., 2, 568–582. Bastelica, D., Morange, P., Berthet, B., Borghi, H., Lacroix, O., Grino, M., JuhanVague, I., and Alessi, M.C. (2002) Arterioscler. Thromb. Vasc. Biol., 22, 173–178. Van Gaal, L.F., Mertens, I.L., and De Block, C.E. (2006) Nature, 444, 875–880. Alessi, M.C., Bastelica, D., Mavri, A., Morange, P., Berthet, B., Grino, M., and Juhan-Vague, I. (2003) Arterioscler. Thromb. Vasc. Biol., 23, 1262–1268. Samad, F., Uysal, K.T., Wiesbrock, S.M., Pandey, M., Hotamisligil, G.S., and Loskutoff, D.J. (1999) Proc. Natl. Acad. Sci. USA, 96, 6902–6907. Pandey, M., Tuncman, G., Hotamisligil, G.S., and Samad, F. (2003) Am. J. Pathol., 162, 933–941. Alessi, M.C. and Juhan-Vague, I. (2006) Arterioscler. Thromb. Vasc. Biol., 26, 2200–2207. Mavri, A., Bastelica, D., Poggi, M., Morange, P., Peiretti, F., Verdier, M., Juhan-Vague, I., and Alessi, M.C. (2007) Thromb. Haemost., 97, 62–66.
139 Ferroni, P., Guagnano, M.T., Manigrasso,
140
141 142
143 144
145
146
147
148
149
150 151 152
153
154
M.R., Ciabattoni, G., and Davi, G. (2005) J. Thromb. Haemost., 3, 1086–1087. Nilsson, L., Banfi, C., Diczfalusy, U., Tremoli, E., Hamsten, A., and Eriksson, P. (1998) Arterioscler. Thromb. Vasc. Biol., 18, 1679–1685. Skurk, T., Lee, Y.M., and Hauner, H. (2001) Hypertension, 37, 1336–1340. Skurk, T., Lee, Y.M., Rohrig, K., and Hauner, H. (2001) Horm. Metab. Res., 33, 196–200. Skurk, T., Lee, Y.M., and Hauner, H. (2001) Hypertension, 37, 1336–1340. Ma, L.J., Mao, S.L., Taylor, K.L., Kanjanabuch, T., Guan, Y., Zhang, Y., Brown, N.J., Swift, L.L., McGuinness, O.P., Wasserman, D.H., Vaughan, D.E., and Fogo, A.B. (2004) Diabetes, 53, 336–346. De Taeye, B.M., Novitskaya, T., Gleaves, L., Covington, J.W., and Vaughan, D.E. (2006) J. Biol. Chem., 281, 32796–32805. Schafer, K., Fujisawa, K., Konstantinides, S., and Loskutoff, D.J. (2001) FASEB J., 15, 1840–1842. Crandall, D.L., Quinet, E.M., El Ayachi, S., Hreha, A.L., Leik, C.E., Savio, D.A., Juhan-Vague, I., and Alessi, M.C. (2006) Arterioscler. Thromb. Vasc. Biol., 26, 2209–2215. Lijnen, H.R., Alessi, M.C., Van Hoef, B., Collen, D., and Juhan-Vague, I. (2005) J. Thromb. Haemost., 3, 1174–1179. Jensen, M.D., Haymond, M.W., Rizza, R.A., Cryer, P.E., and Miles, J.M. (1989) J. Clin. Invest., 83, 1168–1173. Martin, M.L. and Jensen, M.D. (1991) J. Clin. Invest., 88, 609–613. Trayhurn, P., Bing, C., and Wood, I.S. (2006) J. Nutr., 136, 1935S–1939. Grekin, R.J., Dumont, C.J., Vollmer, A.P., Watts, S.W., and Webb, R.C. (1997) Am. J. Physiol. Regul. Integr. Comp. Physiol., 273, R324–R330. Stepniakowski, K.T., Goodfriend, T.L., and Egan, B.M. (1995) Hypertension, 25, 774–778. Steinberg, H.O., Tarshoby, M., Monestel, R., Hook, G., Cronin, J., Johnson, A., Bayazeed, B., and Baron, A.D. (1997) J. Clin. Invest., 100, 1230–1239.
j261
j 13 Adipose Tissue and Blood Pressure Regulation
262
155 Steinberg, H.O., Paradisi, G., Hook, G.,
170 Rajala, M.W., Obici, S., Scherer, P.E., and
Crowder, K., Cronin, J., and Baron, A.D. (2000) Diabetes, 49, 1231–1238. Lu, G., Morinelli, T.A., Meier, K.E., Rosenzweig, S.A., and Egan, B.M. (1996) Circ. Res., 79, 611–618. Lu, G., Meier, K.E., Jaffa, A.A., Rosenzweig, S.A., and Egan, B.M. (1998) Hypertension, 31, 978–985. Egan, B.M., Greene, E.L., and Goodfriend, T.L. (2001) Am. J. Hypertens., 14, 116S–125. Khan, W.A., Blobe, G., Halpern, A., Taylor, W., Wetsel, W.C., Burns, D., Loomis, C., and Hannun, Y.A. (1993) J. Biol. Chem., 268, 5063–5068. Askari, B., Carroll, M.A., Capparelli, M., Kramer, F., Gerrity, R.G., and Bornfeldt, K.E. (2002) J. Biol. Chem., 277, 36338–36344. Safonova, I., Aubert, J., Negrel, R., and Ailhaud, G. (1997) Biochem. J., 322, 235–239. Egan, B.M., Greene, E.L., and Goodfriend, T.L. (2001) Curr. Hypertens. Rep., 3, 107–116. Goodfriend, T.L., Ball, D.L., Egan, B.M., Campbell, W.B., and Nithipatikom, K. (2004) Hypertension, 43, 358–363. Steppan, C.M., Bailey, S.T., Bhat, S., Brown, E.J., Banerjee, R.R., Wright, C.M., Patel, H.R., Ahima, R.S., and Lazar, M.A. (2001) Nature, 409, 307–312. Kim, K.H., Lee, K., Moon, Y.S., and Sul, H.S. (2001) J. Biol. Chem., 276, 11252–11256. Holcomb, I.N., Kabakoff, R.C., Chan, B., Baker, T.W., Gurney, A., Henzel, W., Nelson, C., Lowman, H.B., Wright, B.D., Skelton, N.J., Frantz, G.D., Tumas, D.B., Peale, F.V. Jr., Shelton, D.L., and Hebert, C.C. (2000) EMBO J., 19, 4046–4055. Yannakoulia, M., Yiannakouris, N., Bluher, S., Matalas, A.L., Klimis-Zacas, D., and Mantzoros, C.S. (2003) J. Clin. Endocrinol. Metab., 88, 1730–1736. Rajala, M.W., Lin, Y., Ranalletta, M., Yang, X.M., Qian, H., Gingerich, R., Barzilai, N., and Scherer, P.E. (2002) Mol. Endocrinol., 16, 1920–1930. Makimura, H., Mizuno, T.M., Bergen, H., and Mobbs, C.V. (2002) Am. J. Physiol. Endocrinol. Metab., 283, E1266–E1271.
Rossetti, L. (2003) J. Clin. Invest., 111, 225–230. Verma, S., Li, S.H., Wang, C.H., Fedak, P.W., Li, R.K., Weisel, R.D., and Mickle, D.A. (2003) Circulation, 108, 736–740. Kawanami, D., Maemura, K., Takeda, N., Harada, T., Nojiri, T., Imai, Y., Manabe, I., Utsunomiya, K., and Nagai, R. (2004) Biochem. Biophys. Res. Commun., 314, 415–419. Xu, W., Yu, L., Zhou, W., and Luo, M. (2006) Biochem. Biophys. Res. Commun., 351, 376–382. Rae, C. and Graham, A. (2006) Diabetologia, 49, 1112–1114. Papadopoulos, D.P., Makris, T.K., Krespi, P.G., Poulakou, M., Stavroulakis, G., Hatzizacharias, A.N., Perrea, D., and Votteas, V.V. (2005) J. Clin. Hypertens., 7, 729–733. Zhang, J.L., Qin, Y.W., Zheng, X., Qiu, J.L., and Zou, D.J. (2003) Diabet. Med., 20, 828–831. Rahmouni, K., Haynes, W.G., and Mark, A.L. (2002) Curr. Hypertens. Rep., 4, 119–125. Alberts, P., Engblom, L., Edling, N., Forsgren, M., Klingstrom, G., Larsson, C., Ronquist-Nii, Y., Ohman, B., and Abrahmsen, L. (2002) Diabetologia, 45, 1528–1532. Ma, J., Graves, J., Bradbury, J.A., Zhao, Y., Swope, D.L., King, L., Qu, W., Clark, J., Myers, P., Walker, V., Lindzey, J., Korach, K.S., and Zeldin, D.C. (2004) Mol. Pharmacol., 65, 730–743. Vague, J. (1956) Mars. Chir., 8, 425–434. Arner, P. (2001) Ann. Med., 33, 542–546. Lewis, G.F., Carpentier, A., Adeli, K., and Giacca, A. (2002) Endocr. Rev., 23, 201–229. Hayashi, T., Boyko, E.J., Leonetti, D.L., McNeely, M.J., Newell-Morris, L., Kahn, S.E., and Fujimoto, W.Y. (2004) Ann. Intern. Med., 140, 992–1000. Jain, T., Peshock, R., McGuire, D.K., Willett, D., Yu, Z., Vega, G.L., Guerra, R., Hobbs, H.H., and Grundy, S.M. (2004) J. Am. Coll. Cardiol., 44, 1011–1017. Fox, C.S., Massaro, J.M., Hoffmann, U., Pou, K.M., Maurovich-Horvat, P., Liu,
156
157
158 159
160
161
162
163
164
165
166
167
168
169
171
172
173
174 175
176
177
178
179
180 181 182
183
184
185
References
186 187
188
189 190
191
192 193
194
C.Y., Vasan, R.S., Murabito, J.M., Meigs, J.B., Cupples, L.A., DAgostino, R.B. Sr., and ODonnell, C.J. (2007) Circulation, 116, 39–48. Bjorntorp, P. (1990) Arteriosclerosis, 10, 493–496. Atzmon, G., Yang, X.M., Muzumdar, R., Ma, X.H., Gabriely, I., and Barzilai, N. (2002) Horm. Metab. Res., 34, 622–628. Wajchenberg, B.L., Giannella-Neto, D., da Silva, M.E., and Santos, R.F. (2002) Horm. Metab. Res., 34, 616–621. Dusserre, E., Moulin, P., and Vidal, H. (2000) Biochim. Biophys. Acta, 1500, 88–96. Einstein, F.H., Atzmon, G., Yang, X.M., Ma, X.H., Rincon, M., Rudin, E., Muzumdar, R., and Barzilai, N. (2005) Diabetes, 54, 672–678. Masuzaki, H., Paterson, J., Shinyama, H., Morton, N.M., Mullins, J.J., Seckl, J.R., and Flier, J.S. (2001) Science, 294, 2166–2170. Soltis, E.E. and Cassis, L.A. (1991) Clin. Exp. Hypertens. A, 13, 277–296. Garg, A., Fleckenstein, J.L., Peshock, R.M., and Grundy, S.M. (1992) J. Clin. Endocrinol. Metab., 75, 358–361. Abate, N. and Garg, A. (1995) Prog. Lipid Res., 34, 53–70.
195 Lohn, M., Dubrovska, G., Lauterbach, B.,
196
197
198
199
200
201
Luft, F.C., Gollasch, M., and Sharma, A.M. (2002) FASEB J., 16, 1057–1063. Verlohren, S., Dubrovska, G., Tsang, S.Y., Essin, K., Luft, F.C., Huang, Y., and Gollasch, M. (2004) Hypertension, 44, 271–276. Galvez, B., de Castro, J., Herold, D., Dubrovska, G., Arribas, S., Gonzalez, M.C., Aranguez, I., Luft, F.C., Ramos, M.P., Gollasch, M., and Fernandez Alfonso, M.S. (2006) Arterioscler. Thromb. Vasc. Biol., 26, 1297–1302. Barandier, C., Montani, J.P., and Yang, Z. (2005) Am. J. Physiol. Heart Circ. Physiol., 289, H1807–H1813. Takemori, K., Gao, Y.J., Ding, L., Lu, C., Su, L.Y., An, W.S., Vinson, C., and Lee, R.M. (2007) Hypertension, 49, 365–372. Henrichot, E., Juge-Aubry, C.E., Pernin, A., Pache, J.C., Velebit, V., Dayer, J.M., Meda, P., Chizzolini, C., and Meier, C.A. (2005) Arterioscler. Thromb. Vasc. Biol., 25, 2594–2599. Weisberg, S.P., McCann, D., Desai, M., Rosenbaum, M., Leibel, R.L., and Ferrante, A.W. Jr. (2003) J. Clin. Invest., 112, 1796–1808.
j263
j265
14 Adipokines, Inflammation, and Obesity Karine Clement 14.1 Introduction
Links between the inflammation of adipose tissue and its potential role in systemic complications of obesity were proposed in 1993 by Hotamisligil et al. [1]. In a study first carried out in the mouse, this group showed that white adipose tissue (WAT) synthesizes a proinflammatory cytokine called tumor necrosis factor (TNF)-a, the expression of which was elevated in adipocytes of insulin-resistant and obese mice. The insulin sensitivity in the animals could be improved using TNF-a antibodies. These first observations underlined the existence of a tie between a proinflammatory cytokine, produced and secreted by adipose tissue, and the development of insulin resistance in rodents. However, the neutralization of TNF-a did not appear to be very effective in controlling insulin resistance in humans. Nevertheless, a novel field of research was opened linking inflammation and obesity domains that took on an even greater dimension after the discovery of the adipocyte hormone, leptin, in 1994. Leptin is a cytokine produced and secreted by WAT, which has not only an essential role in the control of energy metabolism via its role on hypothalamic pathways, but is also a key player in many metabolic activities in peripheral tissues (including the liver, pancreas, muscles and immune system) [2]. The discovery of leptin paved the way to the concept of adipocytokines or adipokines that was proposed to qualify the small proteins synthesized and secreted by adipose tissue. They are prone to circulate in the plasma and eventually to exert a systemic influence. In this context, they can interfere with the cross-talk between organs [3]. Among these proteins, a distinction has to be made between the molecules specifically or exclusively produced by adipose tissue depots and other molecules produced in abundance by tissues other than adipose tissue (like the liver). Within adipose tissue itself, one can still distinguish between adipokines produced specifically by adipocytes (like leptin, adiponectin, and serum amyloid A (SAA)), and those produced by other cell types of the nonadipocyte fraction. The identification in 2003 that macrophages accumulate in adipose tissue of obese subjects has made inflammatory cells major contributors to adipokine production in adipose tissue.
j 14 Adipokines, Inflammation, and Obesity
266
Excellent reviews have been published on this subject in the past few years, detailing particularly the roles and functions of adipokines [4, 5]. In this chapter, we cover certain aspects showing the contribution of adipose tissue in producing adipokines that may influence local and systemic biology.
14.2 Contribution of Adipose Tissue in Systemic Inflammation during Obesity
Obesity is characterized by the augmentation of adipose tissue mass; however, according to individual characteristics, adipose tissue depots are more or less abundant in certain regions of the organism; in the upper part of the body in android obesity, in the lower part of the body in gynoid obesity. The distribution of adipose mass in the upper part of the body confers an increased risk for obesity complications. The increase in fat mass, especially in the abdominal region, is usually associated with a moderate but chronic increase in circulating levels of inflammatory mediators. They include nonspecific markers like C-reactive protein (CRP) [6, 7], acute-phase inflammatory proteins, and proinflammatory cytokines. Adhesion and remodeling molecules of the extracellular matrix are part of these systemic changes since they can also exert, among many functions, pro- and anti-inflammatory, and prothrombotic effects [7–10] (Table 14.1). The liver and lymphoid organs are usual sites of production of these mediators. Recent developments have shown that adipose tissue secretes some of these active molecules and in this way might contribute to their systemic increase during the development of obesity (Table 14.1). These molecules represent a very heterogeneous panel of factors with diverse, complex, and sometimes redundant roles. They can participate in innate, adaptive immunity, growth, hematopoiesis, and metabolism, among others. The number of molecules known to be produced by adipose tissue is increasing regularly, especially because of the developments in the utilization of analytical systems exploring large-scale gene expression (DNA chips) or proteins secreted by the tissue depots [11, 12]. The most studied proteins, historically involved in interorgan cross-talk that connects weight homeostasis, insulin sensitivity, and many other key biological systems, remain leptin [13] and adiponectin [14]. In contrast to leptin, known as a proinflammatory mediator, adiponectin has compelling anti-inflammatory functions and is an insulin-sensitizer molecule. Other molecules like visfatin [15], resistin [16], or omentin [17] have also been described in adipose tissue of mice and humans. Mainly secreted by the visceral adipose tissue, they are suggested to contribute to the development of insulin resistance (resistin, visfatin) or, in contrast, to facilitate insulin action (omentin). Studies were mostly performed in cells or in rodents. Nonetheless, there is still a lot to be discovered regarding these adipokines in human adipose tissue biology, particularly their effective role in insulin sensitivity [18] since non-negligible differences might exist between humans and rodents. The potential role of the recently discovered molecules has recently been discussed in detail [19].
14.2 Contribution of Adipose Tissue in Systemic Inflammation during Obesity Modification of circulating inflammatory or adhesion markers during the course of obesity and weight loss brought about by diet.
Table 14.1
Name
Nonspecific markers CRP fibrinogen orosomucoid Acute phase of inflammation haptoglobin SAA Cytokines/ILs IL-6 IL-8 IL-18 IL-10 IL-1Ra TNF-a MCP-1 MCP-4 MIF Other adipokines leptin visfatin resistin adiponectin omentin Adhesion proteins/extracellular matrix remodeling/ prothrombotics MMP-9 ICAM VCAM hepatocyte growth factor PAI-1 cathepsin S
Systemic modification
Effect of weight loss
Visceral (vis) versus subcutaneous (sc)
increase increase increase
decrease decrease decrease
increase increase
decrease decrease
vis > sc sc > vis
increase increase increase increase increase increase increase increase increase
decrease decrease decrease decrease decrease decrease or 0 decrease ? decrease
discussed vis > sc vis > sc vis ¼ sc not clear vis ¼ sc vis > sc ? vis ¼ sc
increase increase diminution diminution diminution
decrease decrease augmentation or 0 increase ?
sc > vis vis > sc (discussed) vis > sc (discussed) vis > sc vis sc
increase increase increase increase increase increase
decrease decrease decrease ? decrease decrease
— — — vis > sc vis ¼ sc
The expression and secretion of a myriad of other adipokines belonging to different family classes have been identified in adipose tissue (Table 14.2, A and B). They include members of the cytokine family, such as interleukins IL-1, IL-1Ra [20–22], IL-8 [23–25], IL-18 [26], and IL-10 [27, 28], growth factors like transforming growth factor (TGF)-b [29], proteins secreted in the acute phase of inflammation (IL-6, plasminogen activator inhibitor (PAI)-1 [8], haptoglobin, SAA [30], or the chemokines (monocyte chemoattractant proteins (MCP)-1, -3, and -4), angiopoietin, metallothionein), macrophage inflammatory protein (MIP)-1a) [31], and complement factors [32]. Other active biomolecules like retinol-binding protein-4 tend to be synthesized by the
j267
j 14 Adipokines, Inflammation, and Obesity
268
Table 14.2 Cytokine families expressed or secreted by the human adipose tissue.
Cytokine
Identified in the human adipose tissue (example)
References
Chemokines
MCP-1/CCL2 MCP-3 MCP-4 RANTES/CCL5 MIP-1a IL-6 IL-8 IL-1Ra IL-10 IL-18 Interferon family (IP-10/CXCL10) TNF-a vascular endothelial growth factor isoforms TGF-b hepatocyte growth factor leptin
[99] [12] [62] [106]
ILs
Interferons TNF family Growth factors
Others
[107] [108] [109] [11] [48] [110] [1] [111] [43] [112] [2]
WATand to be linked with insulin resistance [33, 34], although its precise role has been debated [35]. Some molecules were originally found in rodents or in mouse adipocyte models [5], and others were identified while studying the gene expression profile of human adipose tissue. Using this technique, our group demonstrated, for example, that different isoforms of SAA, particularly the inducible forms SAA-1 and -2, can be produced by human adipose tissue. SAA was usually thought to be produced by the liver. SAA circulating levels increase in obese subjects, and correlate with adipose tissue and adipocyte size [30]. Proteins like the cysteine proteases of the cathepsins family also belong to the adipokine family since they are synthesized and secreted in excess by adipose tissue throughout obesity [36]. Obesity is therefore associated with a moderate but chronic increase of a cocktail of inflammatory factors and a decrease of production of some factors like adiponectin. The relative contribution of the different tissues (hepatic, the lymphoid system, subcutaneous and visceral adipose tissues, and eventually the muscle) in the delivery of adipokines to the systemic circulation is technically difficult to examine and even more so during the different phases of obesity development. Even though the expression of a large number of cytokines is found in adipose tissue and some may influence its local biology, this does not necessarily mean that these molecules are significantly secreted in the circulation to exert a major systemic role [37]. 14.3 Adipose Tissue Depots and Adipokine Production
Adipose tissue in the upper part of the body is a usual risk factor of type 2 diabetes, hypertension, dyslipidemia, and cardiovascular diseases [38]. Glucose intolerance is
14.4 Adipokines and Adipose Tissue Cell Types
significantly more common in subjects with abdominal obesity than in those with fat mass accumulation in the lower part of their body. Plasma triglyceride levels are also significantly more elevated in individuals with central obesity. By contrast, excess adipose tissue in the lower part of the body (i.e., gynoid obesity) is not associated with major metabolic consequences[39, 40]. Adipose tissue possesses anatomical specificities, particularly regarding adipocyte functions and roles (lipogenesis, lipolytic activity, and expression of developmental genes, hormonal response to insulin or to catecholamines, to sexual hormones, or to cortisol) as reviewed in [41]. The profile of adipokine secretion is part of these dissimilar characteristics between the subcutaneous and visceral tissues. Leptin is preferentially secreted by the subcutaneous adipose tissue [42], while the expression of adiponectin, PAI-1, IL-8, IL-1b, MCP-1, and TGF-b is higher in visceral fat. By contrast, there are controversial reports concerning IL-6 and TNF-a appears to be equally synthesized by the different sites [43–48]. Visfatin, resistin, and omentin were shown to be preferentially expressed in the visceral tissue in humans [31, 49], but this was recently debated for visfatin [50]. It is important to mention that in severe forms of obesity in which all adipose tissue stores increase in volume, the part played by the visceral or the very abundant subcutaneous adipose tissue in the systemic delivery of inflammatory mediators is still not well known. Nevertheless, the distinct profile of adipokine secretion between visceral and subcutaneous adipose tissues probably contributes to the increased risk of metabolic and cardiovascular complications, and to the development of other complications like hepatic steatosis and nonalcoholic steatosis in obese individuals. Finally, other adipose tissue depots in the so-called ectopic sites may contribute to the production of inflammatory mediators in the absence of obesity. In this regard, the local production of inflammatory molecules by epicardial adipose tissue and its proximity with coronary vessels could contribute to the development of coronary pathologies [51].
14.4 Adipokines and Adipose Tissue Cell Types
The adipose tissue is a heterogeneous tissue composed of several cell types – the mature adipocytes and many other cells (preadipocytes, fibroblasts, endothelial cells, histiocytes, and macrophages) grouped together in the stromal vascular fraction (SVF). The various cell types remain to be precisely characterized as well as the relative change in their phenotypes and proportional number in line with the accumulation in human adipose tissue depots. Owing to this heterogeneity, the cellular source of inflammatory factors secreted by adipose tissue has been discussed. In vitro studies showed primarily that isolated adipocytes can express inflammatory factors like TNF-a [52]. The acute-phase protein SAA is overexpressed and secreted in abundance by isolated adipocytes of obese subjects, as is leptin, whereas adipocyte secretion of adiponectin diminishes in insulin-resistant and obese individuals. SAA and leptin production by adipose tissue depends on adipocyte size [30, 53, 54]. Adipocyte size influences the expression of inflammatory mediators
j269
j 14 Adipokines, Inflammation, and Obesity
270
as demonstrated by fractionation studies of adipocytes coupled with studies of gene expression profiles [53]. Adipocyte size, for example, determines the secretion of adipokines like IL-6 and IL-8 secreted by the most hypertrophic adipocytes, but also of MCP-1 and granulocyte colony-stimulating factor [55]. The size of adipocytes may influence the metabolism and obesity complications since it was shown, for example, that adipocyte hypertrophy precedes the development of type 2 diabetes [56]. Nevertheless, an increasing number of studies agree that the principal production site of inflammatory mediators is cells of the SVF [57]. By separating mature adipocytes from the stromal fraction, we characterized functional expression profiles of the SVF showing an enrichment of functions related to immunity and inflammation while the adipocyte profile is mostly metabolic [58]. Studies published by North American and French groups prove that adipose tissue of obese subjects or animals is a site of major macrophage accumulation, which is proportional to the body mass index and adipocyte hypertrophy [31, 59, 60]. Macrophages of adipose tissue are undoubtedly a source of adipokine production, as described for visfatin and resistin [31]. Other cell types, such as endothelial cells, inflammatory cells (lymphocytes, natural killer (NK) cells), and preadipocytes, can also contribute to the production of adipokines, notably when exposed to a local inflammatory microenvironment. A study carried out in rodents shows the modification of NK cell populations and lymphocyte subpopulations in mice fed with a high-fat diet [61]. Markers of activated T cells have also been identified in adipose tissue of obese subjects [62]. Studies are underway to characterize cell phenotypes, their origin, and their secretory capacities in human, especially in the different fat depots. It was proposed that macrophages and mature adipocytes show close gene expression profiles. In addition, adipocytes could exert macrophage-like properties, especially when exposed to a proinflammatory environment [63, 64]. However, the transplantation of bone marrow into irradiated mice has established that the vast majority of macrophage infiltration in adipose tissue originates from the circulation. In obese subjects, these macrophages typically aggregate in crowns around the adipocytes [27]. Macrophages express activation markers, but are they in a pro- or anti-inflammatory state? The macrophage phenotypes could be pro- or anti-inflammatory depending on the degree of obesity and of its evolution, as suggested by studies in mice showing that weight gain is accompanied by transformation from a macrophagic M2 (anti-inflammatory) phenotype towards an M1 (proinflammatory) profile [65]. Consequently, secretion profiles of adipose tissue can change depending on the phenotype of the cell population infiltrating it during the different stages of obesity (installation, aggravation, maintenance, weight loss).
14.5 Adipokines, Macrophages, and the Biology of Adipocytes
Adipose tissue macrophages may contribute to maintaining the low-grade inflammatory state linked to obesity (Figure 14.1). The factors that induce the
14.5 Adipokines, Macrophages, and the Biology of Adipocytes
Figure 14.1 Typical aspect of macrophage infiltration in obese subjects. Note the distribution in rosettes of the macrophages, which are not seen on the nonobese, but which are more enhanced in the deep (omental)
tissue. A, adipocyte. The macrophages are stained with HAM56 antibody. These macrophages synthesize many cytokines locally. SC, subcutaneous.
infiltration and activation of macrophages in adipose tissue are probably multifactorial. The paracrine, autocrine, and endocrine signals as well as mechanical modifications (hypertrophy and adipocyte hyperplasia) could play a role in this phenomenon. 14.5.1 Chemoattraction
Many adipokines synthesized by adipose tissue are candidates to attract inflammatory cells. In vitro studies suggest that leptin itself at supraphysiologic levels induces adhesion proteins, hence facilitating the migration of monocytes [66]. Conversely, adiponectin inhibits this process, but only in models of aortic endothelial cells [67]. This potential action still needs to be demonstrated with adipose tissue cells. Very little is known about the role of selectins, integrins, and elements of adhesion to the extracellular matrix in the process of macrophage attraction in adipose tissue. Many adipokines could exert a stimulatory or inhibitory effect on the recruitment of macrophages into adipose tissue. The large-scale analysis of gene expression that can be done with DNA chips allows the identification of candidate genes. For example, we observed in human studies that the levels of expression of MCP-1, colony-stimulating factor-3 and of the urokinase plasminogen activator (CD87) increase significantly in adipose tissue of subjects with morbid obesity [27].
j271
j 14 Adipokines, Inflammation, and Obesity
272
MCP-1 (also known as CCL2) is a strong chemoattractant cytokine and it acts via its receptor CCR2. CCR2 can also link other molecules like MCP-3/CCL7. In a first study, CCR2 (CCR2/) gene knockout mice show a reduction of macrophage infiltration in adipose tissue and improvement of insulin sensitivity. This led to the suggestion that the CCR2 receptor and the MCP-1 cytokine are major players in macrophage accumulation within adipose tissue [68]. Meanwhile, recent contradictory data suggest that MCP-1 might not be such a crucial candidate since knockout mice for CCR2 that have the same level of macrophage infiltration as the wild-type gain more weight and are insulin-resistant [69]. Other candidate molecules and other mechanisms are on track to be explored. Local hypoxia could also play an important role in the attraction and retention of macrophages within adipose tissue. We have shown that hypoxia-inducible factor (HIF)-1a, a transcription factor normally induced by hypoxia, is overexpressed in subcutaneous adipose tissue of obese subjects and that this expression is decreased during weight reduction. Tissue hypoxia induces macrophage attraction in solid tumors as well as in atheromatosed plaques. These observations suggest that adipose tissue of obese subjects could be hypoxic in some areas and a local expression of chemokines could be induced. It should be noted that leptin, which possesses indirect chemoattractant properties, is itself a known factor of induction of the HIF-1 gene [70]. 14.5.2 Paracrine Cross-Talk in the Adipose Tissue via Adipokines
Does the macrophage accumulation in adipose tissue really have a detrimental role? In other words, could macrophage accumulation be related to an adaptation process associated with the augmentation of fat mass? In such circumstances, macrophage accumulation could be necessary for the upkeep of the tissue and perhaps aim to limit its expansion? A recent study has established that macrophagic aggregates within adipose tissue are localized around the dead adipocytes, suggesting that one of their functions is to clean up the debris of necrotic cells [71]. We have previously shown, using electron microscopy, that adipocytes surrounded by macrophages have indeed granules of lipofuscin in their cytoplasm, suggesting accelerated aging of the cells [27]. In addition to their role in cleaning up old and useless cells, the accumulation of macrophages may be also useful for the formation of new vessels, particularly at the site of inflammation and in ischemic zones when adipose tissue grows. Macrophages could also control fat mass growth and modify the biology of adipocytes and preadipocytes via the local production of adipokines. This is demonstrated by several studies. The specific effects of adipokines on different adipocyte functions (increased lipolysis, modifications of adipocyte secretion, and induction of adipocyte insulin resistance eventually overcome by thiazolinediones) have been shown for TNF-a and IL-6 [72]. However, the SVF cells produce cocktails of inflammatory molecules. The consequence of local inflammation on preadipocyte biology has thus been studied. In the presence of a medium derived from human
14.5 Adipokines, Macrophages, and the Biology of Adipocytes
Figure 14.2 Cross-talk between macrophages, preadipocytes, and adipocytes via the chemokines and adipokines.
macrophages, human preadipocytes show a drastic change in their phenotype, acquiring a proinflammatory phenotype by secreting significant amounts of IL-6 or IL-8; they grow [73], but differentiate badly [73, 74]. These cellular alterations are induced in cocultures without direct cellular contact, suggesting the key role of soluble factors (Figure 14.2). The mature adipocyte also endures profound modifications of its biology in coculture systems with activated macrophage medium. Other than the proinflammatory state, an increased lipolysis and a resistance to insulin are observed [75, 76]. TNF-a has been proposed to mediate these effects. From the molecular point of view, the nuclear factor-kappa B (NF-kB) pathway, implicated in the primary regulation of inflammatory responses, is induced in the preadipocyte [73] as in the adipocyte in the presence of medium from macrophages [77]. The NF-kB pathway is also brought into play in macrophages in contact with a medium from adipocytes. The Toll-like receptors (TLR-4) appear to be important actors that lead to the induction or suppression of genes orchestrating the inflammatory response. TLRs are a large family of receptors, including TLR-4, identified in the mid-1990s as a bacterial lipopolysaccharide receptor (endotoxin). Recent data have shown that free fatty acids produced by adipocytes after adrenergic stimulation are also strong inducers of TLR-4/NF-kB [77]. TLR-4 is hence expressed by the adipocytes and overexpressed during obesity [78]. Therefore, fatty acids produced in excess by the adipocytes, filled with triglycerides, and stimulated by the inflammatory medium, activate TLR-4, thus inducing these inflammatory changes. TLR-4 knockout mice are protected from these deleterious effects, especially from insulin resistance induced by lipid infusions [79].
j273
j 14 Adipokines, Inflammation, and Obesity
274
Based on these different studies, a dual effect of macrophages of adipose tissue could be expected: (i) a local beneficial effect in clearing out the old adipocytes, and in the control and in limiting the development of fat mass, and (ii) in a simultaneous manner, a deleterious systemic effect via the increase in the production and secretion of adipokines, easing the production and progression of complications of obesity and the induction of insulin resistance.
14.6 Adipokines and Complications of Obesity
Inflammatory molecules could be candidates to exert a molecular link between adipose tissue and the metabolic, cardiovascular, hepatic, thrombotic complications and certain cancer types occurring during the natural evolution of human obesity. A myriad of candidate adipokines are proposed to play this role. The potential influence of adipokines on the complications of obesity is the subject of regular updating reports [80, 81]. In the cardiovascular field, they can be considered as cardiovascular risk factors and even play a direct physiopathological role, eventually favoring the installation and aggravation of atherosclerosis. In terms of the relationship between abnormalities of cardiac function in obese subjects, the accumulation of visceral fat and low-grade inflammation has been suggested. Among the candidates secreted by adipose tissue, the increase in IL-6, IL-8, and MCP-1, and the decrease of adiponectin, are cited frequently. The studies of the physiopathological links between adipokines and cardiac function can be illustrated by the analysis of adiponectin effects in rodents. Adiponectin can indeed diminish the size of lesions observed in acute ischemic myocardial infarctus, exert angiogenic properties, and lower the atherogenesis plaque in genetically predisposed mice (apolipoprotein E/ invalidation) with an overexpression of adiponectin [82]. In the metabolic field, several chemokines known to be produced by adipose tissue, like RANTES (Regulated upon Activation of Normal T cells Expressed and Secreted), IL-1b, and IL-8, as well as factors of oxidative stress, are increased in diabetic or glucose-intolerant patients and the amelioration of glycemia by insulin therapy reduces circulating levels of these molecules [83, 84]. The increase in the levels of TNF-a, IL-6, IL-1b, IL-8, resistin, and many other factors produced by macrophage activation could contribute to the deterioration of insulin sensitivity. Nonetheless, the precise relationship between the importance of macrophage accumulation in adipose tissue depots, adipokine secretion, and modifications of insulin sensitivity also need to be addressed in humans. Macrophage accumulation is clearly more abundant in visceral tissue [58] than in subcutaneous tissue and this could explain some of the risks associated with the accumulation of intra-abdominal fat. Our group has shown, for example, a relationship between the increase of macrophages in visceral adipose tissue and hepatic fibroinflammation [58]. In a recent study, expression levels of MCP-1 and colonystimulating factor-1 genes and proteins were also associated with this macrophage accumulation in obese subjects [85]. Since the visceral adipose tissue is drained by the
14.7 Adipokines and Weight Loss
portal system, it cannot be excluded that some adipokines delivered by adipose tissue could contribute to the alteration of hepatic function observed in obese subjects, the mechanism of which needs to be investigated. The relationships between the newly identified adipokines, like cathepsin S and the SAA, and the complications of obesity are still to be evaluated in clinical studies. Furthermore, many differences may exist between humans and rodents, notably whether some of these molecules have specific actions in the development of obesity complications.
14.7 Adipokines and Weight Loss
Even modest weight reduction is well known to improve the metabolic and cardiovascular risks associated with human obesity. Measures of endothelial stress also improve after weight reduction in women [86–88]. In this context, many studies showed that a decrease in food intake, and sometimes an increase in exercise, reduce global systemic inflammation. A reduction of numerous inflammatory molecules and endothelial risk factors, and an increase of adiponectin have been observed during weight-loss programs, and sometime relates to the improvement of insulin sensitivity [89]. This has been described for CRP [90], IL-6 [91], IL-18 [92], IL1-Ra [22], PAI-1 [93], SAA [30, 94], cathepsin S [95], matrix metalloproteinase (MMP)-9 [96], adhesion molecules (intercellular adhesion molecule (ICAM) and vascular cell adhesion molecule (VCAM)) [88], tissue factor [97], macrophage inhibitory factor (MIF) [98], MCP-1 [99], soluble receptor factors of TNF receptor-1, and eotaxin, an inflammatory factor implicated in asthma – another complication of obesity [100]. Weight loss induced by gastric bypass also induces a reduction in the circulating levels of visfatin [101] and this has also been discussed for TNF-a [102, 103]. Exercise does not always have a major effect on the modification of these parameters [104]. The dynamics, amount of weight loss, and amelioration of insulin sensitivity can sometimes, but not always, modify these circulating parameters. We followed 60 obese patients during the course of weight loss induced by bariatric surgery leading to a reduction of 30% of initial weight. A significant decrease in CRP, SAA, orosomucoid protein, IL-6, TNF-a, and fibrinogen, and an increase in the level of circulating adiponectin was observed. After the surgery, the level of IL-6 decreased slowly while the level of SAA and/or CRP decreased very quickly. On the other hand, the variation of SAA was not associated with the rapid change in insulin sensitivity [105]. Are these systemic changes of inflammatory-related molecules associated with significant modifications of inflammatory gene expression in adipose tissue? We observed a significant modification in the expression of inflammatory genes in the subcutaneous adipose tissue of obese women following a hypocaloric diet [11]. The expression of 100 genes linked to inflammation processes was modified after 4 weeks (41% increased and 59% decreased). These genes belong to at least 12 functional
j275
j 14 Adipokines, Inflammation, and Obesity
276
families, including cytokines, interleukins, the complement factor cascade, and acute-phase proteins of inflammation, and of certain molecules playing a role in cellular adhesion and in the remodeling of the extracellular matrix. The improvement of the inflammatory profile is not only associated with decreased expression of the proinflammatory factors, but also with the increase in the expression of IL-10 or IL1Ra – molecules having anti-inflammatory properties. The modification of the inflammatory gene expression profile was very similar in subjects during bariatric surgery and was associated with a reduction of macrophage infiltration. In this study the protein expression of IL10 also increased, suggesting a possible M1/M2 (proinflammatory to anti-inflammatory) switch of macrophage phenotypes [27]. Overall, the improvement of the systemic inflammatory profile observed during weight loss is associated with modifications of adipose tissue profiles in inflammatory gene expression. The eventual consequence of this phenomenon on the local biology of adipose tissue remains to be identified.
14.8 Conclusions
The discoveries of a chronic low-grade inflammatory state in obesity and the infiltration of macrophages in adipose tissue have opened new perspectives in the search for the physiopathologic mechanisms that can explain the development of the complications linked with obesity, their evolution, and their persistence. A novel objective would be the identification of molecular mechanisms of adipose tissue with the goal of controlling the interaction between macrophages and adipocytes and other tissues. Eventually, other biomarkers must also be identified, produced specifically by adipose tissue during obesity, leading to comorbidities in the obese patient. Acknowledgments
The author would like to thank the Agence Nationale de la Recherche (Programs RIOMA and ObCat), lAssistance Publique Hôpitaux de Paris/Direction de la Recherche Clinique (PHRC, CRC), and lINSERM et lUniversite Pierre et Marie Curie Paris 6 (BQR Paris 6) and the European Commission (7th framework ADAPT) for project fundings related to inflammatory processes in obesity, and also Daniele Lacasa, Joan Tordjman, Raffaella Cancello, and Froogh Hajduch for their reading and contribution to the manuscript.
References 1 Hotamisligil, G.S., Shargill, N.S., and
2 Zhang, F., Chen, Y., Heiman, M., and
Spiegelman, B.M. (1993) Science, 259, 87–91.
Dimarchi, R. (2005) Vitam. Horm., 71, 345–372.
References 3 Trayhurn, P. and Wood, I.S. (2004) Br. J.
18 Sethi, J.K. and Vidal-Puig, A. (2005)
4
19 Stephens, J.M. and Vidal-Puig, A.J.
5 6
7
8
9 10 11
12
13 14 15
16
17
Nutr., 92, 347–355. Koerner, A., Kratzsch, J., and Kiess, W. (2005) Best Pract. Res. Clin. Endocrinol. Metab., 19, 525–546. Trujillo, M.E. and Scherer, P.E. (2006) Endocr. Rev., 27, 762–778. Visser, M., Bouter, L.M., McQuillan, G.M., Wener, M.H., and Harris, T.B. (1999) JAMA, 282, 2131–2135. Cook, D.G., Mendall, M.A., Whincup, P.H., Carey, I.M., Ballam, L., Morris, J.E., Miller, G.J., and Strachan, D.P. (2000) Atherosclerosis, 149, 139–150. Juhan-Vague, I., Alessi, M.C., Mavri, A., and Morange, P.E. (2003) J. Thromb. Haemost, 1, 1575–1579. Yudkin, J.S. (2003) Int. J. Obes. Relat. Metab. Disord., 27 (Suppl. 3), S25–S28. Wellen, K.E. and Hotamisligil, G.S. (2005) J. Clin. Invest., 115, 1111–1119. Clement, K., Viguerie, N., Poitou, C., Carette, C., Pelloux, V., Curat, C.A., Sicard, A., Rome, S., Benis, A., Zucker, J.D., Vidal, H., Laville, M., Barsh, G.S., Basdevant, A., Stich, V., Cancello, R., and Langin, D. (2004) FASEB. J., 18, 1657–1669. Hashimoto, I., Wada, J., Hida, A., Baba, M., Miyatake, N., Eguchi, J., Shikata, K., and Makino, H. (2006) Obesity, 14, 799–811. Ahima, R.S., Qi, Y., and Singhal, N.S. (2006) Prog. Brain Res., 153, 155–174. Matsuzawa, Y. (2006) FEBS Lett., 580, 2917–2921. Fukuhara, A., Matsuda, M., Nishizawa, M., Segawa, K., Tanaka, M., Kishimoto, K., Matsuki, Y., Murakami, M., Ichisaka, T., Murakami, H., Watanabe, E., Takagi, T., Akiyoshi, M., Ohtsubo, T., Kihara, S., Yamashita, S., Makishima, M., Funahashi, T., Yamanaka, S., Hiramatsu, R., Matsuzawa, Y., and Shimomura, I. (2005) Science, 307, 426–430. McTernan, P.G., Kusminski, C.M., and Kumar, S. (2006) Curr. Opin. Lipidol., 17, 170–175. Yang, R.Z., Lee, M.J., Hu, H., Pray, J., Wu, H.B., Hansen, B.C., Shuldiner, A.R., Fried, S.K., McLenithan, J.C., and Gong, D.W. (2006) Am. J. Physiol. Endocrinol. Metab., 290, E1253–E1261.
Trends. Mol. Med., 11, 344–347. (2006) Curr. Opin. Lipidol., 17, 128–131. 20 Somm, E., Cettour-Rose, P., Asensio, C.,
21
22
23
24
25
26
27
28
29
Charollais, A., Klein, M., TheanderCarrillo, C., Juge-Aubry, C.E., Dayer, J.M., Nicklin, M.J., Meda, P., RohnerJeanrenaud, F., and Meier, C.A. (2006) Diabetologia, 49, 387–393. Somm, E., Henrichot, E., Pernin, A., Juge-Aubry, C.E., Muzzin, P., Dayer, J.M., Nicklin, M.J., and Meier, C.A. (2005) Diabetes, 54, 3503–3509. Meier, C.A., Bobbioni, E., Gabay, C., Assimacopoulos-Jeannet, F., Golay, A., and Dayer, J.M. (2002) J. Clin. Endocrinol. Metab., 87, 1184–1188. Straczkowski, M., Kowalska, I., Nikolajuk, A., Dzienis-Straczkowska, S., Szelachowska, M., and Kinalska, I. (2003) Cardiovasc. Diabetol., 2, 5. Straczkowski, M., Dzienis-Straczkowska, S., Stepien, A., Kowalska, I., Szelachowska, M., and Kinalska, I. (2002) J. Clin. Endocrinol. Metab., 87, 4602–4606. Straczkowski, M., Kowalska, I., Nikolajuk, A., Otziomek, E., Adamska, A., Karolczuk-Zarachowicz, M., and Gorska, M. (2007) Int. J. Obes., 31, 221–225. Netea, M.G., Joosten, L.A., Lewis, E., Jensen, D.R., Voshol, P.J., Kullberg, B.J., Tack, C.J., van Krieken, H., Kim, S.H., Stalenhoef, A.F., van de Loo, F.A., Verschueren, I., Pulawa, L., Akira, S., Eckel, R.H., Dinarello, C.A., van den Berg, W., and van der Meer, J.W. (2006) Nat. Med., 12, 650–656. Cancello, R., Henegar, C., Viguerie, N., Taleb, S., Poitou, C., Rouault, C., Coupaye, M., Pelloux, V., Hugol, D., Bouillot, J.L., Bouloumie, A., Barbatelli, G., Cinti, S., Svensson, P.A., Barsh, G.S., Zucker, J.D., Basdevant, A., Langin, D., and Clement, K. (2005) Diabetes, 54, 2277–2286. Juge-Aubry, C.E., Somm, E., Pernin, A., Alizadeh, N., Giusti, V., Dayer, J.M., and Meier, C.A. (2005) Cytokine, 29, 270–274. Fain, J.N., Tichansky, D.S., and Madan, A.K. (2005) Metabolism, 54, 1546–1551.
j277
j 14 Adipokines, Inflammation, and Obesity
278
30 Poitou, C., Viguerie, N., Cancello, R., De
42 van Harmelen, V., Dicker, A., Ryden, M.,
Matteis, R., Cinti, S., Stich, V., Coussieu, C., Gauthier, E., Courtine, M., Zucker, J.D., Barsh, G.S., Saris, W., Bruneval, P., Basdevant, A., Langin, D., and Clement, K. (2005) Diabetologia, 48, 519–528. Curat, C.A., Wegner, V., Sengenes, C., Miranville, A., Tonus, C., Busse, R., and Bouloumie, A. (2006) Diabetologia, 49, 744–747. Guerre-Millo, M. (2006) J. Soc. Biol., 200, 37–43. Graham, T.E., Yang, Q., Bluher, M., Hammarstedt, A., Ciaraldi, T.P., Henry, R.R., Wason, C.J., Oberbach, A., Jansson, P.A., Smith, U., and Kahn, B.B. (2006) N. Engl. J. Med., 354, 2552–2563. Yang, Q., Graham, T.E., Mody, N., Preitner, F., Peroni, O.D., Zabolotny, J.M., Kotani, K., Quadro, L., and Kahn, B.B. (2005) Nature, 436, 356–362. Janke, J., Engeli, S., Boschmann, M., Adams, F., Bohnke, J., Luft, F.C., Sharma, A.M., and Jordan, J. (2006) Diabetes, 55, 2805–2810. Taleb, S., Lacasa, D., Bastard, J.P., Poitou, C., Cancello, R., Pelloux, V., Viguerie, N., Benis, A., Zucker, J.D., Bouillot, J.L., Coussieu, C., Basdevant, A., Langin, D., and Clement, K. (2005) FASEB J., 19, 1540–1542. Dahlman, I., Kaaman, M., Olsson, T., Tan, G.D., Bickerton, A.S., Wahlen, K., Andersson, J., Nordstrom, E.A., Blomqvist, L., Sjogren, A., Forsgren, M., Attersand, A., and Arner, P. (2005) J. Clin. Endocrinol. Metab., 90, 5834–5840. Despres, J.P. and Lemieux, I. (2006) Nature, 444, 881–887. Carey, V.J., Walters, E.E., Colditz, G.A., Solomon, C.G., Willett, W.C., Rosner, B.A., Speizer, F.E., and Manson, J.E. (1997) Am. J. Epidemiol., 145, 614–619. Kissebah, A.H., Vydelingum, N., Murray, R., Evans, D.J., Hartz, A.J., Kalkhoff, R.K., and Adams, P.W. (1982) J. Clin. Endocrinol. Metab., 54, 254–260. Lafontan, M. and Berlan, M. (2003) Trends. Pharmacol. Sci., 24, 276–283.
Hauner, H., Lonnqvist, F., Naslund, E., and Arner, P. (2002) Diabetes, 51, 2029–2036. Alessi, M.C., Bastelica, D., Morange, P., Berthet, B., Leduc, I., Verdier, M., Geel, O., and Juhan-Vague, I. (2000) Diabetes, 49, 1374–1380. Bruun, J.M., Lihn, A.S., Madan, A.K., Pedersen, S.B., Schiott, K.M., Fain, J.N., and Richelsen, B. (2004) Am. J. Physiol. Endocrinol. Metab., 286, E8–E13. Bastelica, D., Morange, P., Berthet, B., Borghi, H., Lacroix, O., Grino, M., JuhanVague, I., and Alessi, M.C. (2002) Arterioscler. Thromb. Vasc. Biol., 22, 173–178. Fain, J.N., Bahouth, S.W., and Madan, A.K. (2004) J. Lipid Res., 45, 536–542. Hauner, H. (2005) Proc. Nutr. Soc., 64, 163–169. Skurk, T., Kolb, H., Muller-Scholze, S., Rohrig, K., Hauner, H., and Herder, C. (2005) Eur. J. Endocrinol., 152, 863–868. de Souza Batista, C.M., Yang, R.Z., Lee, M.J., Glynn, N.M., Yu, D.Z., Pray, J., Ndubuizu, K., Patil, S., Schwartz, A., Kligman, M., Fried, S.K., Gong, D.W., Shuldiner, A.R., Pollin, T.I., and McLenithan, J.C. (2007) Diabetes, 56, 1655–1661. Arner, P. (2006) J. Clin. Endocrinol. Metab., 91, 28–30. Rabkin, S.W. (2007) Obes. Rev., 8, 253–261. Fain, J.N., Madan, A.K., Hiler, M.L., Cheema, P., and Bahouth, S.W. (2004) Endocrinology, 145, 2273–2282. Jernas, M., Palming, J., Sjoholm, K., Jennische, E., Svensson, P.A., Gabrielsson, B.G., Levin, M., Sjogren, A., Rudemo, M., Lystig, T.C., Carlsson, B., Carlsson, L.M., and Lonn, M. (2006) FASEB J., 20, 1540–1542. Yang, R.Z., Lee, M.J., Hu, H., Pollin, T.I., Ryan, A.S., Nicklas, B.J., Snitker, S., Horenstein, R.B., Hull, K., Goldberg, N.H., Goldberg, A.P., Shuldiner, A.R., Fried, S.K., and Gong, D.W. (2006) PLoS Med., 3, e287. Skurk, T., Alberti-Huber, C., Herder, C., and Hauner, H. (2007) J. Clin. Endocrinol. Metab., 92, 1023–1033.
31
32 33
34
35
36
37
38 39
40
41
43
44
45
46 47 48
49
50 51 52
53
54
55
References 56 Weyer, C., Foley, J.E., Bogardus, C.,
57 58
59
60
61
62
63
64
65 66
67 68
69
Tataranni, P.A., and Pratley, R.E. (2000) Diabetologia, 43, 1498–1506. Fain, J.N. (2006) Vitam. Horm., 74, 443–477. Cancello, R., Tordjman, J., Poitou, C., Guilhem, G., Bouillot, J.L., Hugol, D., Coussieu, C., Basdevant, A., Hen, A.B., Bedossa, P., Guerre-Millo, M., and Clement, K. (2006) Diabetes, 55, 1554–1561. Weisberg, S.P., McCann, D., Desai, M., Rosenbaum, M., Leibel, R.L., and Ferrante, A.W. Jr. (2003) J. Clin. Invest., 112, 1796–1808. Xu, H., Barnes, G.T., Yang, Q., Tan, G., Yang, D., Chou, C.J., Sole, J., Nichols, A., Ross, J.S., Tartaglia, L.A., and Chen, H. (2003) J. Clin. Invest., 112, 1821–1830. Caspar-Bauguil, S., Cousin, B., Andre, M., Nibbelink, M., Galinier, A., Periquet, B., Casteilla, L., and Penicaud, L. (2006) Exp. Cell. Res., 312, 2195–2202. Wu, H., Ghosh, S., Perrard, X.D., Feng, L., Garcia, G.E., Perrard, J.L., Sweeney, J.F., Peterson, L.E., Chan, L., Smith, C.W., and Ballantyne, C.M. (2007) Circulation, 115, 1029–1038. Cousin, B., Munoz, O., Andre, M., Fontanilles, A.M., Dani, C., Cousin, J.L., Laharrague, P., Casteilla, L., and Penicaud, L. (1999) FASEB J., 13, 305–312. Cousin, B., Andre, M., Casteilla, L., and Penicaud, L. (2001) J. Cell. Physiol., 186, 380–386. Lumeng, C.N., Bodzin, J.L., and Saltiel, A.R. (2007) J. Clin. Invest., 117, 175–184. Curat, C.A., Miranville, A., Sengenes, C., Diehl, M., Tonus, C., Busse, R., and Bouloumie, A. (2004) Diabetes, 53, 1285–1292. Guzik, T.J., Mangalat, D., and Korbut, R. (2006) J. Physiol. Pharmacol., 57, 505–528. Weisberg, S.P., Hunter, D., Huber, R., Lemieux, J., Slaymaker, S., Vaddi, K., Charo, I., Leibel, R.L., and Ferrante, A.W. Jr. (2006) J. Clin. Invest., 116, 115–124. Inouye, K.E., Shi, H., Howard, J.K., Daly, C.H., Lord, G.M., Rollins, B.J., and Flier, J.S. (2007) Diabetes, 56, 2241–2250.
70 Guerre-Millo, M., Grosfeld, A., and Issad,
T. (2002) Obes. Res. 10, 856, 857–858. 71 Cinti, S., Mitchell, G., Barbatelli, G.,
72
73
74
75
76
77
78
79
80 81 82
83
84
85
Murano, I., Ceresi, E., Faloia, E., Wang, S., Fortier, M., Greenberg, A.S., and Obin, M.S. (2005) J. Lipid Res., 46, 2347–2355. Lagathu, C., Bastard, J.P., Auclair, M., Maachi, M., Capeau, J., and Caron, M. (2003) Biochem. Biophys. Res. Commun., 311, 372–379. Lacasa, D., Taleb, S., Keophiphath, M., Miranville, A., and Clement, K. (2007) Endocrinology, 148, 868–877. Constant, V.A., Gagnon, A., Landry, A., and Sorisky, A. (2006) Diabetologia, 49, 1402–1411. Permana, P.A., Menge, C., and Reaven, P.D. (2006) Biochem. Biophys. Res. Commun., 341, 507–514. Suganami, T., Nishida, J., and Ogawa, Y. (2005) Arterioscler. Thromb. Vasc. Biol., 25, 2062–2068. Suganami, T., Tanimoto-Koyama, K., Nishida, J., Itoh, M., Yuan, X., Mizuarai, S., Kotani, H., Yamaoka, S., Miyake, K., Aoe, S., Kamei, Y., and Ogawa, Y. (2007) Arterioscler. Thromb. Vasc. Biol., 27, 84–91. Lin, Y., Lee, H., Berg, A.H., Lisanti, M.P., Shapiro, L., and Scherer, P.E. (2000) J. Biol. Chem., 275, 24255–24263. Shi, H., Kokoeva, M.V., Inouye, K., Tzameli, I., Yin, H., and Flier, J.S. (2006) J. Clin. Invest., 116, 3015–3025. Matsuzawa, Y. (2006) Nat. Clin. Pract. Cardiovasc. Med., 3, 35–42. Chen, H. (2006) Pharmacol. Res., 53, 469–477. Ouchi, N., Kihara, S., Funahashi, T., Matsuzawa, Y., and Walsh, K. (2003) Curr. Opin. Lipidol., 14, 561–566. Herder, C., Haastert, B., Muller-Scholze, S., Koenig, W., Thorand, B., Holle, R., Wichmann, H.E., Scherbaum, W.A., Martin, S., and Kolb, H. (2005) Diabetes, 54 (Suppl. 2), S11–S17. Stentz, F.B., Umpierrez, G.E., Cuervo, R., and Kitabchi, A.E. (2004) Diabetes, 53, 2079–2086. Harman-Boehm, I., Bluher, M., Redel, H., Sion-Vardy, N., Ovadia, S., Avinoach, E., Shai, I., Kloting, N., Stumvoll, M.,
j279
j 14 Adipokines, Inflammation, and Obesity
280
86 87 88
89
90 91
92
93
94
95
96
97
98
Bashan, N., and Rudich, A. (2007) J. Clin. Endocrinol. Metab., 92, 2240–2247. Berg, A.H. and Scherer, P.E. (2005) Circ. Res., 96, 939–949. Kopelman,P.(2007)Obes.Rev.,8(Suppl.1), 13–17. Ziccardi, P., Nappo, F., Giugliano, G., Esposito, K., Marfella, R., Cioffi, M., DAndrea, F., Molinari, A.M., and Giugliano, D. (2002) Circulation, 105, 804–809. Esposito, K., Pontillo, A., Di Palo, C., Giugliano, G., Masella, M., Marfella, R., and Giugliano, D. (2003) JAMA, 289, 1799–1804. Heilbronn, L.K. and Clifton, P.M. (2002) J. Nutr. Biochem., 13, 316–321. Bastard, J.P., Jardel, C., Bruckert, E., Blondy, P., Capeau, J., Laville, M., Vidal, H., and Hainque, B. (2000) J. Clin. Endocrinol. Metab., 85, 3338–3342. Esposito, K., Pontillo, A., Ciotola, M., Di Palo, C., Grella, E., Nicoletti, G., and Giugliano, D. (2002) J. Clin. Endocrinol. Metab., 87, 3864–3866. Bastard, J.P., Vidal, H., Jardel, C., Bruckert, E., Robin, D., Vallier, P., Blondy, P., Turpin, G., Forest, C., and Hainque, B. (2000) Int. J. Obes. Relat. Metab. Disord., 24, 70–74. Gomez-Ambrosi, J., Salvador, J., Rotellar, F., Silva, C., Catalan, V., Rodriguez, A., Jesus Gil, M., and Fruhbeck, G. (2006) Obes. Surg., 16, 262–269. Taleb, S., Cancello, R., Poitou, C., Rouault, C., Sellam, P., Levy, P., Bouillot, J.L., Coussieu, C., Basdevant, A., Guerre-Millo, M., Lacasa, D., and Clement, K. (2006) J. Clin. Endocrinol. Metab., 91, 1042–1047. Laimer, M., Kaser, S., Kranebitter, M., Sandhofer, A., Muhlmann, G., Schwelberger, H., Weiss, H., Patsch, J.R., and Ebenbichler, C.F. (2005) Int. J. Obes., 29, 498–501. Kopp, C.W., Kopp, H.P., Steiner, S., Kriwanek, S., Krzyzanowska, K., Bartok, A., Roka, R., Minar, E., and Schernthaner, G. (2003) Obes. Res., 11, 950–956. Church, T.S., Willis, M.S., Priest, E.L., Lamonte, M.J., Earnest, C.P., Wilkinson,
99
100
101
102
103
104
105
106
107
108
109
110
111
W.J., Wilson, D.A., and Giroir, B.P. (2005) Int. J. Obes., 29, 675–681. Christiansen, T., Richelsen, B., and Bruun, J.M. (2005) Int. J. Obes., 29, 146–150. Vasudevan, A.R., Wu, H., Xydakis, A.M., Jones, P.H., Smith, E.O., Sweeney, J.F., Corry, D.B., and Ballantyne, C.M. (2006) J. Clin. Endocrinol. Metab., 91, 256–261. Krzyzanowska, K., Mittermayer, F., Krugluger, W., Kopp, H.P., and Schernthaner, G. (2006) Obesity, 14, 1886–1889. Bastard, J.P., Hainque, B., Dusserre, E., Bruckert, E., Robin, D., Vallier, P., Perche, S., Robin, P., Turpin, G., Jardel, C., Laville, M., Forest, C., and Vidal, H. (1999) Diabetes. Metab. Res. Rev., 15, 92–98. Kopp, H.P., Kopp, C.W., Festa, A., Krzyzanowska, K., Kriwanek, S., Minar, E., Roka, R., and Schernthaner, G. (2003) Arterioscler. Thromb. Vasc. Biol., 23, 1042–1047. Nicklas, B.J., Ambrosius, W., Messier, S.P., Miller, G.D., Penninx, B.W., Loeser, R.F., Palla, S., Bleecker, E., and Pahor, M. (2004) Am. J. Clin. Nutr., 79, 544–551. Poitou, C., Coussieu, C., Rouault, C., Coupaye, M., Cancello, R., Bedel, J.F., Gouillon, M., Bouillot, J.L., Oppert, J.M., Basdevant, A., and Clement, K. (2006) Obesity, 14, 309–318. Gerhardt, C.C., Romero, I.A., Cancello, R., Camoin, L., and Strosberg, A.D. (2001) Mol. Cell. Endocrinol., 175, 81–92. Mohamed-Ali, V., Goodrick, S., Rawesh, A., Katz, D.R., Miles, J.M., Yudkin, J.S., Klein, S., and Coppack, S.W. (1997) J. Clin. Endocrinol. Metab., 82, 4196–4200. Bruun, J.M., Pedersen, S.B., and Richelsen, B. (2000) Horm. Metab. Res., 32, 537–541. Juge-Aubry, C.E., Somm, E., Giusti, V., Pernin, A., Chicheportiche, R., Verdumo, C., Rohner-Jeanrenaud, F., Burger, D., Dayer, J.M., and Meier, C.A. (2003) Diabetes, 52, 1104–1110. Herder, C., Hauner, H., Kempf, K., Kolb, H., and Skurk, T. (2007) Int. J. Obes., 31, 403–410. Rehman, J., Traktuev, D., Li, J., MerfeldClauss, S., Temm-Grove, C.J., Bovenkerk,
References J.E., Pell, C.L., Johnstone, B.H., Considine, R.V., and March, K.L. (2004) Circulation, 109, 1292–1298. 112 Bell, L.N., Ward, J.L., Degawa-Yamauchi, M., Bovenkerk, J.E., Jones, R., Cacucci,
B.M., Gupta, C.E., Sheridan, C., Sheridan, K., Shankar, S.S., Steinberg, H.O., March, K.L., and Considine, R.V. (2006) Am. J. Physiol. Endocrinol. Metab., 291, E843–E848.
j281
Part Four Adipose Tissue and Disease
j285
15 Depot-Specific Biology of Adipose Tissues: Links to Fat Distribution and Metabolic Risk Mi-Jeong Lee and Susan K. Fried 15.1 Introduction
An abdominal or so-called central pattern of fat distribution of body fat is tightly correlated with complications of obesity, such as insulin resistance, dyslipidemia, hypertension, hypercoagulation, and chronic inflammation. The clinical and epidemiological literature show strong associations of abdominal obesity (high waist circumference) with adverse health outcomes, while lower-body fat stores typical of females are protective [1–3]. Many clinical studies that used computerized tomography (CT) or magnetic resonance imaging (MRI) to distinguish visceral and subcutaneous abdominal depots point to a strong negative effect of visceral fat mass on metabolic risk [4], while other studies show independent associations with abdominal sc fat [2]. The production of metabolic products (fatty acids, glycerol, lactate), adipokines, and other proteins secreted from the adipocyte varies among fat depots and may link regional fat to metabolic risk [5]. Thus, increasing research attention has focused on the physiological, biochemical, and molecular determinants of regional differences in adipose tissue development, and the metabolic and endocrine functions of different adipose depots. Body fat is mainly stored within the adipocytes (fat cells) of adipose tissues that collectively define the adipose organ (i.e., a group of tissues that performs a specific function or group of functions, as defined in medical dictionaries) and includes numerous discrete anatomical depots [6]. Adipocytes are a highly specialized cell type that store energy in the form of triglyceride and releases it as required by the energy needs of other cells [6, 7]. The adipocyte is also an endocrine cell that secretes several hormones, most notably leptin and adiponectin, which modulate fuel metabolism, immunity, and reproduction [8]. Our objectives in this chapter are to summarize (i) the phenotypic characteristics of different fat depots (i.e., including morphological, physiologic, and metabolic characteristics), and (ii) the molecular underpinnings of depot differences in metabolic and endocrine function.
j 15 Depot-Specific Biology of Adipose Tissues: Links to Fat Distribution and Metabolic Risk
286
15.2 Adipose Depots: Definitions
Subcutaneous adipose tissue, located just under the skin, stores more than 85% of the total body fat. Different locations within the subcutaneous depot are morphologically (e.g., fat cell size and number) and functionally heterogeneous. The most commonly defined and studied subcutaneous depots are the abdominal, femoral, and gluteal. The fascia superficialis (Scarpas fascia), a layer of connective tissue visible on MRI or CT, demarcates deep from superficial subcutaneous fat [9]. The thickness of the deep subcutaneous layer is of particular interest, as it independently correlates with metabolic complications of obesity in both men and women. Intra-abdominal fat depots are associated with internal organs, and in humans are divided into intra- and retroperitoneal. Intraperitoneal depots are associated with digestive organs, and include the omental (hangs off the stomach), mesenteric (associated with the intestine), and epiploic (along the colon). These visceral fat depots are characterized by the presence of lymph nodes and milky spots, distinguishing them from other intra-abdominal depots such as the perirenal and retroperitoneal, as well as subcutaneous [10]. There are also numerous smaller depots such as epicardial that share an embryological origin with the other visceral depots and may subserve specialized functions [11, 12].
15.3 Physiological and Anatomical Differences among Depots may Drive Functional Heterogeneity 15.3.1 Depot Differences in Cellular Composition
Functional differences between depots appear to be related to the cellular composition as well as variations in blood flow [13] and innervation [14]. Possibly as a result of these physiological differences, as well as possible intrinsic differences in fat cells from different depots [15, 16], the average fat cell size and distribution varies among depots [17]. Adipocyte size is of importance because it is related to adipocyte metabolic and endocrine function (e.g., leptin production) [18, 19]. Triglyceride turnover is higher in larger adipocytes – basal lipolysis and triglyceride synthesis (fatty acid esterification) are both increased. As basal rates are higher, relative responses (fold change from basal) to the stimulatory effect of catecholamines on lipolysis and the insulin stimulation of glucose uptake and metabolism decline. In women, lower-body subcutaneous adipocytes tend to be larger than subcutaneous abdominal ones, which are in turn larger than omental adipocytes. Depot differences in adipocyte size are less apparent in men [20, 21]. In addition to adipocytes, adipose tissue is composed of fibroblasts, preadipocytes, stem cells, mast cells, endothelial cells, and pericytes, as well as immunocytes (neutrophils, dendritic cells, T cells, lymphocytes, macrophages). Omental adipose
15.3 Physiological and Anatomical Differences among Depots may Drive Functional Heterogeneity
tissue also includes mesothelial cells [22]. The number of stromal vascular cells per gram of adipose tissue is greater in omental compared to subcutaneous adipose tissue [23, 24]. Depending on the level of obesity, adipose tissue includes substantial numbers of resident macrophages, especially in the omental depot of humans. These are often found in crown-like structures surrounding dead adipocytes during periods of tissue remodeling [25]. The higher number of macrophages in omental compared to subcutaneous adipose tissue is likely the major source for the higher production of cytokines from this depot [26–28], but other stromal cells may also contribute [29]. 15.3.2 Definition of Visceral Fat Depots
The literature on human adipose tissues frequently defines visceral depots as portally draining, as this anatomical relationship is thought to drive the metabolic complications associated with visceral obesity [30, 31]. Thus, this definition would include only omental and mesenteric depots. The rationale for distinguishing these depots based on their anatomical location is that the metabolic (fatty acids, glycerol, lactate) and secretory products (e.g., adipokines) of these depots are predicted to be high within the portal vein, and thereby have a large impact on hepatic function, including hepatic glucose production and very-low-density lipoprotein triglyceride secretion (Figure 15.1). However, the experimental basis for this assumption is considered weak [32]. A recent study found only a higher concentration of interleukin (IL)-6 in
Figure 15.1 Consequences of portal drainage of visceral adipose tissue. It has been hypothesized that fatty acids and adipokines released from visceral adipose tissues (omental and mesenteric) may directly reach the liver in high concentrations via the portal vein. As a result, higher production of IL-6, and perhaps other adipokines, may promote hepatic
production of very-low-density lipoprotein (VLDL) and hypertriglyceridemia, and impair insulin sensitivity, contributing to hyperglycemia. In contrast, free fatty acids (FFAs) released from subcutaneous fat enter the systemic circulation where they reach muscle and can be oxidized, reducing concentrations reaching the liver.
j287
j 15 Depot-Specific Biology of Adipose Tissues: Links to Fat Distribution and Metabolic Risk
288
the portal compared to peripheral blood of humans [33], and other studies calculate no difference in portal free fatty acid concentrations [34]. Interestingly, there was a strong association of IL-6 and circulating C-reactive protein (CRP) – a marker of chronic inflammation that is produced mainly in the liver. Thus, it seems likely that the disproportionate influence of portally draining adipose tissues is related to their impact on hepatic metabolism, although the mediator(s) are as yet undefined. Pond [35] suggests that lymph node containing depots are functionally distinct and play a special role in immunity. As compared to subcutaneous depots, visceral depots within the peritoneal cavity of humans (omental, mesenteric) contain a greater abundance of milky spots where immunocytes accumulate and these undoubtedly contribute to the overexpression of immune-related proteins [36].
15.4 Heterogeneity in Adipocyte Function among Adipose Depots 15.4.1 Lipolysis
A number of studies conducted over the past 30 years indicated that omental adipocytes (as a typical visceral adipocyte) are more lipolytic compared to subcutaneous adipocytes and this idea has become ingrained in the literature [37–40]. Compared to abdominal subcutaneous adipocytes, omental adipocytes of women exhibit lower basal (spontaneous) lipolysis and higher incremental (as percentage or delta over baseline) responses to mixed adrenergic agonists, due mainly to the lower expression of antilipolytic a2-adrenergic receptors [40, 41]. However, maximally stimulated rates of lipolysis do not differ. In addition, omental adipocytes were reported to be less sensitive to the antilipolytic effect of insulin [42]. Most of these studies were carried out on a relatively small number of subjects who were not wellcharacterized with respect to level of visceral adiposity. Recently, Tchernof et al. analyzed the lipolytic function of omental compared to abdominal subcutaneous adipocytes of premenopausal women [21] and men [20] across a wide range of visceral adiposity. They found similarly sized adipocytes and no regional differences in basal lipolysis or in the absolute rates of b-adrenergic-stimulated lipolytic agonists in men, and this was consistent across subjects with low and high waist circumference. In their study of premenopausal women, they found smaller omental fat cells with lower basal lipolysis and no differences in rates of stimulated lipolysis, although due to the lower basal, the response to an adrenergic agonist was relatively increased (fold stimulation). Similarly, Reynisdottir et al. [43] found that the higher maximally stimulated lipolysis observed in abdominal subcutaneous rather than omental adipocytes is associated with higher hormone-sensitive lipase activity in subjects over a wide range of body mass index (BMI). However, the differences could be accounted for by the smaller size of omental adipocytes. These data agree with previous reports in morbidly obese subjects [44, 45].
15.4 Heterogeneity in Adipocyte Function among Adipose Depots
With regard to heterogeneity in lipolysis between femoral, gluteal, and abdominal subcutaneous depots, many but not all studies indicate that lower-body adipocytes are more responsive to the antilipolytic effects of a2-adrenergic agonists, resulting in lower lipolytic responses to mixed agonists that are consistently documented in in vitro studies [46]. A study of premenopausal women indicated that gluteal adipocytes were more sensitive to the antilipolytic effect of insulin, but that basal lipolysis did not differ [47]. However, our preliminary studies do not show this depot difference in postmenopausal women [48]. Thus, it is tempting to speculate that estrogen may differentially regulate adipocyte metabolism in gluteal/femoral compared to abdominal subcutaneous depots and the change in fat distribution after menopause [49]. Animal studies support the hypothesis that estrogen regulates regional adiposity [50, 51]. Further work on the mechanisms by which sex steroids regulate fat distribution are clearly needed. Fewstudies have addressed invivo factors that could affect adipocyte lipolytic activity. Differential sympathetic innervation of visceral depots may mediate the preferential mobilization of these depots under hypocaloric conditions [14], although this possibility has not been documented in humans. The rate of removal of lipolytic products can also affect the rate of lipolysis in vivo. Virtanen et al. [52] found that blood flow per kilogram of fat tended to be higher in omental than abdominal subcutaneous or perirenal depots of both lean and obese humans, but differences were not statistically significant with a relatively small sample size (10 in each group). In rats, mesenteric adipose tissue blood flow is around 5-fold greater than other depots [53, 54]. These physiologic factors merit further study as determinants of adipocyte function. Recent studies point to the importance of the lipid droplet-associated proteins and lipases in the regulation of adipocyte lipolysis, but their role in depot differences in adipocyte metabolism are not yet clear [55, 56]. Both Wang et al. [57] and Ryden et al. [58] found lower mRNA, but not protein expression, of perilipin in human omental compared to abdominal subcutaneous adipose tissue. This result suggests that depot differences in perilipin mass are unlikely to explain the lower basal lipolysis in omental fat and are consistent with the lack of depot difference in maximally stimulated lipolysis. The expression of intracellular fatty acid-binding protein (FABP)-4 (adipocyte lipid-binding protein (ALBP); aP2) at the mRNA and protein levels is higher in subcutaneous than omental adipose tissue of obese subjects, while FABP-5 (keratinocyte lipid-binding protein (KLBP)) was lower in subcutaneous adipose tissue [59]. Additionally, the ALBP: KLBP ratio was higher in subcutaneous compared to omental of both lean and obese. ALBP levels have been associated with insulin resistance and lipolytic rates by some [60, 61], but not all studies [62], thus further analysis of the roles of these proteins in regulating depotspecific alterations in fatty acid flux are warranted. 15.4.2 Triglyceride Deposition
A major mechanism regulating the rate of triglyceride synthesis and storage in adipocytes is the activity of the enzyme lipoprotein lipase (LPL). LPL hydrolyzes
j289
j 15 Depot-Specific Biology of Adipose Tissues: Links to Fat Distribution and Metabolic Risk
290
circulating triglycerides in chylomicra and very-low-density lipoproteins to fatty acids that can cross the endothelium, and be transported and esterified by adipocytes. Our early studies showed lower LPL activity per adipocyte in the omental depot of premenopausal severely obese subjects [63], and a recent study showed that this depot difference applies to women across a range of adiposity and fat distribution [21]. In contrast, LPL activity per fat cell is similar in omental and abdominal subcutaneous adipose tissue of severely obese men [63], while in nonobese or moderately obese subjects, omental fat cells are larger and LPL activity is higher (most markedly in men with intermediate waist circumference) [20]. Thus, in men, higher LPL may favor the preferential fat deposition in visceral depots [20]. Binding of the adipocyte secretory product acylation stimulation protein (ASP, C3a), which promotes triglyceride synthesis, is higher in subcutaneous than omental adipose tissue [64]. However, glucose transporter 4 (GLUT4) expression and glucose transport were also higher in the omental depot of severely obese women [65]. Higher glucose uptake would be expected to lead to higher rates of fatty acid esterification to match a hypothesized higher rate of lipolysis. However, in vivo studies do not support this hypothesis. A recent study by Jensens group [66] analyzed regional meal fatty acid uptake in obese premenopausal women. They found that in women visceral fat accounted for only approximately 5% of meal fat disposal irrespective of visceral fat mass, while with increasing thigh fat mass there was a proportional increase in meal fatty acid uptake. These results strongly suggest that mechanisms that regulate fat deposition play an important role in regulating regional fat mass. They are also consistent with the conclusion that in obese women, visceral fat is not hyperlipolytic in vivo, but further studies in men are required [66].
15.4.3 Glucose Uptake and Insulin Action
Our early studies showed that on a per fat cell basis, there were no differences in the in vitro glucose uptake and conversion to triglyceride among omental, mesenteric, and abdominal subcutaneous adipose tissues of men, but lower uptake in omental adipose tissue (with smaller adipocytes) of women [67]. Recent in vivo [52] and in vitro [68] studies could document no depot differences in glucose uptake or insulin action in visceral compared to abdominal subcutaneous adipose tissue, while others find evidence for insulin resistance in omental adipose tissue [42]. Surprisingly, considering the high levels of inflammatory cytokines and activation of mitogenactivated protein kinases (MAPKs) in omental adipose tissue, factors usually associated with insulin resistance, the insulin stimulation of Akt did not differ in omental and abdominal subcutaneous adipose tissue. Thus, we speculate that a unique function of the omental depot protects it from insulin resistance; high concentrations of the insulin-sensitizing visceral-specific adipokine omentin [69] being one possible mediator.
15.6 Search for Novel Adipokines with Depot-Specific Expression that Link Regional Adiposity
15.5 Regional Differences in Adipose Tissue Gene Expression and Protein Production: Relationship to the Metabolic Syndrome
It is becoming increasingly clear that adipocytes function to integrate nutrient sensing pathways, inflammation, and immunity [70]. Thus, a mechanism that probably evolved to promote survival and adapt to undernutrition may lead to chronic influence in the face of chronic overnutrition, with pathophysiological consequences on metabolism, ultimately leading to diabetes, stroke, atherogenesis, and premature death. In obese compared to lean, and most markedly in visceral compared to subcutaneous depots, levels of proinflammatory cytokines are elevated and levels of antiinflammatory cytokines such as adiponectin and IL-10 are diminished, as reviewed in several excellent recent papers [8, 71, 72]. Adipokines produced within adipose tissues have local paracrine and endocrine effects. Proinflammatory cytokines, especially tumor necrosis factor (TNF) and IL-6 [73, 74], can impair insulin action on target tissues, decreasing insulin effects on glucose uptake into skeletal muscle and hepatic glucose output, contributing to the development of insulin resistance and type 2 diabetes. Adipokines can also act in a paracrine fashion by interfering with insulin signaling in adipose tissue. Inflammatory cytokines increase expression levels of p38 MAPK, extracellular signal-regulated kinase, c-Jun kinase-1, and IkB kinase-b at the mRNA and protein (total and phosphorylation) levels in adipose tissue. Consistent with higher proinflammatory cytokine levels, these MAPKs levels were 1.5- to 2.5-fold higher in omental versus subcutaneous fat [68]. Increased MAPK activity is known to impair insulin signaling at the insulin receptor substrate level [75].
15.6 Search for Novel Adipokines with Depot-Specific Expression that Link Regional Adiposity to Metabolic Risk
To identify new factors that may explain the association between visceral adiposity and metabolic disease produced from excess visceral compared to subcutaneous adipose tissue, several groups have searched for genes or secretory protein products that are differentially expressed between visceral and subcutaneous. In addition to proinflammatory cytokines, visceral adipose tissues overexpress many molecules involved in innate immunity and the acute-phase response, including serum amyloid A (SAA), retinol-binding protein (RBP) and complement factors [76–78] (Table 15.1). Yang et al. recently identified omentin, a C-type lectin, as a visceral-specific adipokine that is secreted from visceral, but not subcutaneous, adipose tissue. Omentin increases insulin sensitivity in human adipocytes [69]. Furthermore, plasma levels and mRNA expression of omentin in visceral tissue are decreased in obese, insulin-resistant subjects as compared to nonobese [79]. Another visceral adipokine, visfatin (also known as pre-B cell colony-enhancing factor-1 and nicotinamide phosphoribosyltransferase) was initially identified as a visceral-specific adipokine [80]. However, subsequent studies showed similar expression levels between
j291
j 15 Depot-Specific Biology of Adipose Tissues: Links to Fat Distribution and Metabolic Risk
292
Table 15.1 Genes known to be differentially expressed between omental (om) and subcutaneous (sc) adipose tissues.
Gene
Adipose hormones/cytokines/chemokines leptin [120, 121] adiponectin [122] RBP4 [76, 77] angiotensinogen angiotensin II [121] TNF-a [123, 124] IL-6 [125] IL-8 [126] IP-10 [127] MCP-1 [128] macrophage inflammatory protein-1a a plasminogen activator inhibitor-1 [26] RANTESa GM-CSFa resistin [130] visfatin [80, 81] omentin [69, 131] TSP-1 [110] Growth factors VEGF [26] HGFa fibroblast growth factor-1 and -9 [132] Extracellular matrix VIM [113] SPARC (osteonectin) [113] ANXA5 [113] Adipogenesis/organogenesis C/EBP-d [112] frizzled 7 [112] NR2F1 [112] HoxA5 [112] HoxC8 [112] Tbox-15 [112] HoxA10 [112] HoxC6 [112] C/EBP-a [112] PPAR-c [113, 129] Metabolism FABP-4 [113] Perilipin [113] CD36 [113] GLUT4 [65] glycogen synthase [113]
Differential expression
Role
om < sc om sc om > sc om > sc
energy/immune and so on energy/anti-inflammatory ? blood pressure
om > sc om > sc om > sc om sc om > sc om > sc om > sc om > sc om > sc om > sc om sc om sc om > sc
proinflammatory proinflammatory proinflammatory anti-inflammatory chemotactic proinflammatory coagulation proinflammatory proinflammatory proinflammatory insulin signaling? insulin signaling? angiogenesis
om > sc om > sc om > sc
angiogenesis angiogenesis ?
om < sc om < sc om < sc
? ? ?
om > sc om > sc om > sc om > sc om > sc om > sc om < sc om < sc om < sc om < sc
adipogenesis adipogenesis organogenesis organogenesis organogenesis organogenesis organogenesis organogenesis adipogenesis adipogenesis
om < sc om < sc om < sc om > sc om < sc
lipid metabolism lipid metabolism lipid metabolism glucose metabolism glucose metabolism (continued)
15.7 Importance of Adipose Tissue Macrophages and other Immunocytes Table 15.1
(Continued)
Gene
Differential expression
Role
cholesteryl ester transfer protein [121] Complement factors C2 [36] C3a, ASP [36, 121] C4 [36] C7 [36] Factor B [36] adipsin (Factor D) [36] Others carboxypeptidase E [110]
om < sc
lipid metabolism
om > sc om > sc om > sc om > sc om > sc om < sc
immune immune/lipid metabolism immune immune immune immune
om > sc
prohormone processing
a
Our unpublished observation.
depots [81, 82]. Intracellularly, visfatin regulates NAD þ levels and therefore works with sirtuins to regulate cell survival after nutritional or environmental stress [83]. Visfatin is also secreted through a nonclassical pathway [84] and is found in the circulation. The role of omentin and visfatin in obesity-related diseases remains largely unknown, although correlations between serum levels of these proteins and obesity and insulin resistance markers have been noted [79, 81]. Both omentin and visfatin are expressed in stromal vascular fraction and the cell type(s) expressing these proteins have not yet been identified. Adipose tissue, specifically the adipocyte, has been identified as a major producer of circulating SAA [78, 85] in individuals without acute infection. SAA is an acutephase reactant that is an independent risk factor for coronary artery disease [86]. SAA is primarily associated with high-density lipoprotein (HDL) and may inhibit reverse cholesterol transport [87–89]. Thus, SAA has been suggested as a link between obesity and coronary artery diseases. Furthermore, SAA is known to activate the chemoattractic formyl peptide receptor like-1, which results in migration of blood monocytes and neutrophils [90]. Adipose tissue has also been identified as a site of expression of the inflammatory marker CRP [91] and other proteins, including resistin (expressed in monocytes) and fasting-induced adipose factor (peroxisome proliferator-activated receptor (PPAR)-c angiopoietin related, expressed in fat cells), but their importance is as yet unclear. However, portally derived proinflammatory cytokines such as IL-6 can induce hepatic CRP production.
15.7 Importance of Adipose Tissue Macrophages and other Immunocytes in Regional Adipose Tissue Dysfunction
Recent research has focused on the importance of macrophage accumulation within obese adipose tissue as a mediator of inflammation and adipose tissue remodel-
j293
j 15 Depot-Specific Biology of Adipose Tissues: Links to Fat Distribution and Metabolic Risk
294
ing [92]. Two inflammatory cytokines that have been implicated in monocyte/ macrophage chemotaxis and activation, monocyte chemoattractant proteins (MCP)-1 and granulocyte-macrophage colony-stimulating factor (GM-CSF)-1 are expressed at higher levels in omental versus subcutaneous, leading macrophage infiltration into visceral adipose tissue. The involvement of MCP-1 and its receptor CCR2 in macrophage infiltration into adipose tissue has been demonstrated [93]. Macrophage infiltration is increased in omental compared to subcutaneous in all groups including lean controls and this difference is exaggerated in viscerally obese [94]. Preferential macrophage infiltration into omental was mainly observed in a subgroup in whom obesity was associated with impaired glucose tolerance (IGT). Further, there was a stronger association of macrophage infiltration into omental versus subcutaneous with obesity comorbidities, IGT, triglyceride, HDL-cholesterol, and blood pressure. They also showed that significant association between age and percent omental macrophages. In flammatory cytokines produced by nonadipocytes such as TNF-a, IL-6, and MCP-1 can impair insulin signaling [73, 75], decrease glucose metabolic capacity, increase lipolysis, and alter adipokine production [95–100]. These effects are likely to mediate the association of macrophage infiltration with systemic insulin resistance and, ultimately, risk of type 2 diabetes. Although most studies to date have focused on macrophages, increasing evidence points to the importance of other immunocytes within adipose tissue. RANTES (Regulated upon Activation of Normal T cells Expressed and Secreted) and its receptor CCR5 were significantly increased in diet induced obese mouse and human obese adipose tissue [101]. Adipose conditioned medium, especially culture medium from adipose tissue of obese animals, induced T cell migration while monoclonal antibodies to block RANTES significantly reduced T cell chemotaxis, suggesting RANTES/CCR5 may be important in leukocyte infiltration. Systemic RANTES concentration was higher in individuals with IGT [102] compared to normal subjects, and RANTES levels are higher in visceral than subcutaneous adipose tissue (mRNA and secretion; [101] and our unpublished observation), providing yet another potential link of visceral adiposity to systemic inflammation. In addition to factors involved in inflammation and immunity, an ever-growing and wide-ranging list of proteins that regulate lipid and lipoprotein metabolism, coagulation, and blood pressure are synthesized within adipose tissue and released systemically [8]. Also, bioactive factors released by adipose tissue include fatty acids, monobutyrin [103], prostaglandins, and steroids are either synthesized de novo or converted in adipose tissue and released into the blood stream [8, 104]. Adipose tissue secretes a number of angiogenic factors, including, hepatic growth factor (HGF), leptin, and vascular endothelial growth factor (VEGF), and these act in an autocrine or paracrine manner in adipose tissue, but may also act as endocrine hormones. Adipogenesis is closely related to angiogenesis; adipose tissue growth occurs with weight gain and requires the formation of new capillaries. Interestingly, angiogenic inhibitors are known to decrease obesity and ameliorate metabolic profiles [105, 106]. HGF expression is increased in obesity [107] and in vitro, omental adipose tissue secretes more HGF than subcutaneous adipose tissue (our unpublished observation). HGF has angiogenic, mitogenic, and antiapoptotic effects.
15.8 Gene Expression Profiles are Providing New Insights on Regional Adipose Growth
Circulating levels of HGF are associated with metabolic syndrome, cardiovascular, and cancer risk [108, 109]. Adipose tissue also secretes angiogenesis inhibitors, adiponectin, and thrombospondin (TSP)-1. Expression levels of TSP-1 are higher in omental than subcutaneous adipose tissue [110]. It is evident that interactions between different cell types within tissue modulate depot function. Studies directed at better defining these networks are critical to understanding the depot-specific biology of adipose tissues.
15.8 Gene Expression Profiles are Providing New Insights on Regional Adipose Growth and Function
Characterization of differences in gene expression between human visceral and subcutaneous adipose tissue using microarrays provides strong evidence for genetic and developmental heterogeneity between depots. Genes involved in immunity and adipose tissue development are over-represented in the list of genes differentially expressed between visceral and subcutaneous adipose tissue [36, 111, 112]; 25% of 28 genes whose expression levels were higher in omental compared to subcutaneous were genes involved in innate immunity [36]. Complement components C2, C3, C4, C7, and factor B expression are higher in omental compared to subcutaneous adipose tissue, whereas expression levels of factor D (adipsin), C1QB, C1R, and C1S are similar between these depots. Vohl et al. [111] found that out of around 6000 genes expressed in adipose tissue, 409 transcripts corresponding to 347 encoded genes or expressed sequence tags were differentially expressed between omental and subcutaneous adipose tissue; 216 genes are expressed at higher levels in visceral, whereas 131 were expressed more abundantly in subcutaneous adipose tissue. Genes involved in cell differentiation and adipogenesis/organogenesis, such as CCAAT/enhancer-binding protein (C/ EBP)-d, Frizzled 7 (Wnt signaling), and NR2F1, are more abundant in omental adipose tissue, while homeo box gene, HoxA10 and HoxC6, C/EBP-a, and adipsin levels were higher in subcutaneous adipose tissue. Gesta et al. [112] conducted an analysis of adipose tissue gene expression in men and women of widely varying BMIs. They found clear depot differences in expression of developmental genes involved in anteroposterior or dorsoventral patterning in adipocytes from intra-abdominal and subcutaneous depots of mice and humans. Similar differences were found in a stromal fraction of the tissue that includes preadipocytes. The differences in gene expression pattern persist even after in vitro differentiation, suggesting the differences are independent of extrinsic factors. Kirklands group also demonstrated that gene expression profiles of preadipocytes/differentiated adipocytes are also different between depots [113]. Taken together, these findings suggest that different adipocyte precursors are responsible for a specific adipose depot development, and may participate later in the functional differences observed between intra-abdominal and subcutaneous adipose depots. Epididymal adipose tissue of rodents shows a human visceral-type pattern of gene expression as revealed by analysis of gene expression [112]. Developmental
j295
j 15 Depot-Specific Biology of Adipose Tissues: Links to Fat Distribution and Metabolic Risk
296
genes, most strikingly Nr2f1, Thbd, HoxA5, and HoxC8, were more highly expressed in both mouse epididymal and human omental adipose tissue, and applied to both fat cell and stromal fractions. Both these depots show a lower capacity for growth through fat cell number (preadipocyte recruitment) compared to subcutaneous adipose tissue and they both may exhibit higher rates of adipocyte death/tissue remodeling as reflected in an increased number of macrophages forming crown-like structures around necrotic/apoptotic adipocytes under the stress of obesity or high-fat feeding [25, 114]. This result was somewhat unexpected because the epididymal depot, unlike typical human visceral depots, it is not portally draining or rich in lymph nodes or milky spots. Humans do not have a large epididymal fat pad as do rodents, but like the omental depot of humans, this depot lies over the intestine in vivo, where it may serve some sort of immune defense function, as does the omental depot.
15.9 Depot Differences in Cell Proliferation and Differentiation Capacity
Given the association of excess intra-abdominal fat and metabolic disorders, it is important to know how the deposition of intra-abdominal versus subcutaneous adipose tissue is regulated. Accumulation of adipose tissue depends in part on the balance of new adipocyte formation, hypertrophy of existing adipocytes, and cell death. To understand the potential depot differences in new preadipocyte recruitment and differentiation, the isolated stromal vascular cellular fraction taken from different adipose depots (subcutaneous, omental, or mesenteric origin) has been used for in vitro studies. Several studies showed that there is no depot difference in preadipocyte differentiation and similar proliferative rates between omental versus subcutaneous stromal vascular cells [23, 24], while others show higher proliferation/ differentiation capacity in subcutaneous [16, 115]. Varying culture conditions, differentiation protocols used, subject characteristics (age, BMI, fat distribution), and contamination of other cell types during culture could explain discrepancies. Differences in innervation, vascularity, and overall cellular composition of each depot might be also relevant in vivo. Convincing studies using clonally derived preadipocytes strongly suggest that compared to omental preadipocytes, subcutaneous preadipocytes show greater replication potential and differentiation capacity [16, 115]. To avoid contamination of other cells and to detect intrinsic or cell autonomous differences in preadipocytes from different depots, Tchkonia et al. compared clonally derived cells from subcutaneous, mesenteric, and omental adipose tissue, and showed regional differences are still evident [16]. Expression levels of the adipogenic transcription factor C/EBP-a are higher in subcutaneous than omental cells, and subcutaneous preadipocytes proliferate more rapidly and differentiate to a greater extent. Furthermore, these differences persist for 40 population doublings in the human telomerase reverse transcriptase-expressing strains derived from a single cell from each depots [116]. Consistent with this observation, omental preadipocytes have longer telomeres than
15.10 Conclusions and Future Directions
subcutaneous preadipocytes [116], suggesting subcutaneous preadipocytes have a longer replication history. Further, there is a negative correlation between age and proliferation of subcutaneous stromal cells, but not of omental cells [23]. The greater capacity of subcutaneous preadipocytes to proliferate may underlie the great growth capacity of these tissues in response to overnutrition or treatment with PPAR-c agonists during therapy for diabetes. Upon differentiation in vitro, genes that associated with adipocyte maturation are more highly expressed in cultures derived from subcutaneous than omental depots (e.g., GLUT4, leptin, FABP-4) [113]. This fuller differentiation in subcutaneous depots may have been mediated by higher expression of the key adipocyte transcription factors C/EBP-a and PPAR-c [113]. Expression profiles of mesenteric preadipocytes are much more like subcutaneous than omental preadipocytes [113], and mesenteric preadipocytes replicate and differentiate faster than omental preadipocytes [16, 116]. These apparently intrinsic differences in adipocytes from different depots may mediate the depot differences in metabolic and endocrine function that were described earlier. Adipocyte cell number also depends on rates of cell loss as well as a recruitment of preadipocytes and differentiation into adipocytes. It is shown that human omental preadipocytes are more susceptible to apoptotic stimuli (serum deprivation or TNF) than subcutaneous preadipocytes [116, 117], suggesting the intrinsic differences in apoptosis between preadipocytes from two depots.
15.10 Conclusions and Future Directions
The mechanisms linking regional adiposity to metabolic complications are rapidly being elucidated, but there remain many key gaps in our knowledge. Many studies have measured expression and secretion of numerous pro- and anti-inflammatory cytokines in obese adipose tissues. As different cytokines can work additively, synergistically, or antagonistically, it will be important to understand how the balance of these factors affects regional adipose and systemic metabolism through paracrine and endocrine interactions. A number of new studies point to evidence for as-yet unindentified depot- and sexspecific factors. A recent study showed that removing similar and relatively small quantities of gonadal fat improved glucose tolerance in lean male and female mice, while with diet-induced obesity, only removal of parametrial fat in females was effective [118]. Kahns group [119] also showed that transplantation of epididymal fat adversely affected glucose homeostasis, while inguinal (subcutaneous) fat improved it. Changes in the levels of the known key adipokines were not explanatory, so further work with these models will be important. Most studies of regional differences in adipose function only sample fat from subjects at their usual weight and this may limit our ability to detect differential sensitivity or responsiveness among fat depots. For example, we recently demonstrated that culture with the glucocorticoid analog dexamethasone plus insulin
j297
j 15 Depot-Specific Biology of Adipose Tissues: Links to Fat Distribution and Metabolic Risk
298
(compared to insulin alone) increased 11b-hydroxysteroid dehydrogenase activity in the omental but not subcutaneous depot of obese subjects [133]. It seems likely that sampling of adipose tissues of men and women in response to stresses (e.g., over- or underfeeding or hormone administration) is likely to reveal important depot-specific responses. Research on the regulation of regional adipose tissue growth is receiving more attention as the molecular details of adipogenesis in cell culture models are being unraveled. Differences in the mass of different fat deposits may be more closely related to adipocyte number than size, particularly in the obese. Thus, further understanding of the mechanisms regulating preadipocyte recruitment and differentiation will be important in understanding sex- and age-related differences in fat distribution. Also, with better phenotyping and genome-wide associations, analysis of the genetic determinants of fat distribution will likely yield important insights into mechanisms. In summary, the mechanisms underlying the regulation of regional adiposity and the disproportionate effects of enlargements in visceral fat depots on health of men and women remain enigmatic. Our knowledge of physiologically important variations in the secretome of the adipose depots is rapidly emerging. Further research on the local and systemic consequences of these mediators holds promise for understanding the mechanisms linking adiposity to health and disease.
References 1 St-Pierre, J., Lemieux, I., Perron, P.,
Brisson, D., Santure, M., Vohl, M.C., Despres, J.P., and Gaudet, D. (2007) Relation of the hypertriglyceridemic waist phenotype to earlier manifestations of coronary artery disease in patients with glucose intolerance and type 2 diabetes mellitus. Am. J. Cardiol., 99, 369–373. 2 Vega, G.L., Asam-Huet, B., Peshock, R., Willett, D., Shah, B., and Grundy, S.M. (2006) Influence of body fat content and distribution on variation in metabolic risk. J. Clin. Endocrinol. Metab., 91, 4459–4466. 3 Snijder, M.B., Visser, M., Dekker, J.M., Goodpaster, B.H., Harris, T.B., Kritchevsky, S.B., De, R.N., Kanaya, A.M., Newman, A.B., Tylavsky, F.A., and Seidell, J.C. (2005) Low subcutaneous thigh fat is a risk factor for unfavourable glucose and lipid levels, independently of high abdominal fat. The Health ABC Study. Diabetologia, 48, 301–308.
4 Despres, J.P. and Lemieux, I. (2006)
5
6
7
8
9
Abdominal obesity and metabolic syndrome. Nature, 444, 881–887. Greenberg, A.S. and Obin, M.S. (2006) Obesity and the role of adipose tissue in inflammation and metabolism. Am. J. Clin. Nutr., 83, 461S–465. Cinti, S. (2005) The adipose organ. Prostaglandins Leukot. Essent. Fatty Acids, 73, 9–15. Fried, S.K. and Ross, R.J.R. (2005) The biology of visceral adipose tissue, in Handbook of Obesity: Clinical Applications, 2nd edn (eds G.A. Bray and C. Bouchard), Marcel Dekker, New York. Trujillo, M.E. and Scherer, P.E. (2006) Adipose tissue-derived factors: impact on health and disease. Endocr. Rev., 27, 762–778. Smith, S.R., Lovejoy, J.C., Greenway, F., Ryan, D., deJonge, L., de la, B.J., Volafova, J., and Bray, G.A. (2001) Contributions of total body fat, abdominal subcutaneous adipose tissue compartments, and visceral adipose tissue to the metabolic
References
10
11
12
13
14
15
16
17
18
complications of obesity. Metabolism, 50, 425–435. Litbarg, N.O., Gudehithlu, K.P., Sethupathi, P., Arruda, J.A., Dunea, G., and Singh, A.K. (2007) Activated omentum becomes rich in factors that promote healing and tissue regeneration. Cell Tissue Res., 328, 487–497. Sacks, H.S. and Fain, J.N. (2007) Human epicardial adipose tissue: a review. Am. Heart J., 153, 907–917. Cinti, S. (2001) The adipose organ: morphological perspectives of adipose tissues. Proc. Nutr. Soc., 60, 319–328. Crandall, D.L. and DiGirolamo, M. (1990) Hemodynamic and metabolic correlates in adipose tissue: pathophysiologic considerations. FASEB J., 4, 141–147. Bartness, T.J. and Song, C.K. (2007) Thematic review series: adipocyte biology. Sympathetic and sensory innervation of white adipose tissue. J. Lipid Res., 48, 1655–1672. Tchkonia, T., Tchoukalova, Y.D., Giorgadze, N., Pirtskhalava, T., Karagiannides, I., Forse, R.A., Koo, A., Stevenson, M., Chinnappan, D., Cartwright, A., Jensen, M.D., and Kirkland, J.L. (2005) Abundance of two human preadipocyte subtypes with distinct capacities for replication, adipogenesis, and apoptosis varies among fat depots. Am. J. Physiol. Endocrinol. Metab., 288, E267–E277. Tchkonia, T., Giorgadze, N., Pirtskhalava, T., Tchoukalova, Y., Karagiannides, I., Forse, R.A., DePonte, M., Stevenson, M., Guo, W., Han, J., Waloga, G., Lash, T.L., Jensen, M.D., and Kirkland, J.L. (2002) Fat depot origin affects adipogenesis in primary cultured and cloned human preadipocytes. Am. J. Physiol. Regul. Integr. Comp. Physiol., 282, R1286–R1296. Votruba, S.B. and Jensen, M.D. (2007) Sex differences in abdominal, gluteal, and thigh LPL activity. Am. J. Physiol. Endocrinol. Metab., 292, E1823–E1828. van Harmelen, V., Reynisdottir, S., Eriksson, P., Thorne, A., Hoffstedt, J., Lonnqvist, F., and Arner, P. (1998) Leptin secretion from subcutaneous and visceral adipose tissue in women. Diabetes, 47, 913–917.
19 Skurk, T., berti-Huber, C., Herder, C., and
20
21
22
23
24
25
26
27
Hauner, H. (2007) Relationship between adipocyte size and adipokine expression and secretion. J. Clin. Endocrinol. Metab., 92, 1023–1033. Boivin, A., Brochu, G., Marceau, S., Marceau, P., Hould, F.S., and Tchernof, A. (2007) Regional differences in adipose tissue metabolism in obese men. Metabolism, 56, 533–540. Tchernof, A., Belanger, C., Morisset, A.S., Richard, C., Mailloux, J., Laberge, P., and Dupont, P. (2006) Regional differences in adipose tissue metabolism in women: minor effect of obesity and body fat distribution. Diabetes, 55, 1353–1360. Darimont, C., Avanti, O., Blancher, F., Wagniere, S., Mansourian, R., Zbinden, I., Leone-Vautravers, P., Fuerholz, A., Giusti, V., and Mace, K. (2008) Contribution of mesothelial cells in the expression of inflammatory-related factors in omental adipose tissue of obese subjects. Int. J. Obes., 32, 112–120. van Harmelen, V., Rohrig, K., and Hauner, H., (2004) Comparison of proliferation and differentiation capacity of human adipocyte precursor cells from the omental and subcutaneous adipose tissue depot of obese subjects. Metabolism, 53, 632–637. Shahparaki, A., Grunder, L., and Sorisky, A. (2002) Comparison of human abdominal subcutaneous versus omental preadipocyte differentiation in primary culture. Metabolism, 51, 1211–1215. Cinti, S., Mitchell, G., Barbatelli, G., Murano, I., Ceresi, E., Faloia, E., Wang, S., Fortier, M., Greenberg, A.S., and Obin, M.S. (2005) Adipocyte death defines macrophage localization and function in adipose tissue of obese mice and humans. J. Lipid Res., 46, 2347–2355. Fain, J.N., Madan, A.K., Hiler, M.L., Cheema, P., and Bahouth, S.W. (2004) Comparison of the release of adipokines by adipose tissue, adipose tissue matrix, and adipocytes from visceral and subcutaneous abdominal adipose tissues of obese humans. Endocrinology, 145, 2273–2282. Zeyda, M., Farmer, D., Todoric, J., Aszmann, O., Speiser, M., Gyori, G.,
j299
j 15 Depot-Specific Biology of Adipose Tissues: Links to Fat Distribution and Metabolic Risk
300
28
29
30
31
32
33
34
35
36
37
38
Zlabinger, G.J., and Stulnig, T.M. (2007) Human adipose tissue macrophages are of an anti-inflammatory phenotype but capable of excessive pro-inflammatory mediator production. Int. J. Obes., 31, 1420–1428. Lumeng, C.N., Bodzin, J.L., and Saltiel, A.R. (2007) Obesity induces a phenotypic switch in adipose tissue macrophage polarization. J. Clin. Invest, 117, 175–184. Harkins, J.M., Moustaid-Moussa, N., Chung, Y.J., Penner, K.M., Pestka, J.J., North, C.M., and Claycombe, K.J. (2004) Expression of interleukin-6 is greater in preadipocytes than in adipocytes of 3T3L1 cells and C57BL/6J and ob/ob mice. J. Nutr., 134, 2673–2677. Bjorntorp, P. (1990) Portal adipose tissue as a generator of risk factors for cardiovascular disease and diabetes. Arteriosclerosis, 10, 493–496. Klein, S. (2004) The case of visceral fat: argument for the defense. J. Clin. Invest., 113, 1530–1532. Frayn, K.N. (2000) Visceral fat and insulin resistance–causative or correlative? Br. J. Nutr., 83 (Suppl. 1), S71–S77. Fontana, L., Eagon, J.C., Trujillo, M.E., Scherer, P.E., and Klein, S. (2007) Visceral fat adipokine secretion is associated with systemic inflammation in obese humans. Diabetes, 56, 1010–1013. Nielsen, S., Guo, Z., Johnson, C.M., Hensrud, D.D., and Jensen, M.D. (2004) Splanchnic lipolysis in human obesity. J. Clin. Invest., 113, 1582–1588. Pond, C.M. (2005) Adipose tissue and the immune system. Prostaglandins Leukot. Essent. Fatty Acids, 73, 17–30. Gabrielsson, B.G., Johansson, J.M., Lonn, M., Jernas, M., Olbers, T., Peltonen, M., Larsson, I., Lonn, L., Sjostrom, L., Carlsson, B., and Carlsson, L.M. (2003) High expression of complement components in omental adipose tissue in obese men. Obes. Res., 11, 699–708. Arner, P. (1995) Differences in lipolysis between human subcutaneous and omental adipose tissues. Ann. Med., 27, 435–438. Bergman, R.N., Kim, S.P., Hsu, I.R., Catalano, K.J., Chiu, J.D., Kabir, M.,
39
40
41
42
43
44
45
46
47
Richey, J.M., and Ader, M. (2007) Abdominal obesity: role in the pathophysiology of metabolic disease and cardiovascular risk. Am. J. Med., 120, S3–S8. Jensen, M.D. (2006) Is visceral fat involved in the pathogenesis of the metabolic syndrome? Human model. Obesity, 14 (Suppl. 1), 20S–24. Leibel, R.L., Edens, N.K., and Fried, S.K. (1989) Physiologic basis for the control of body fat distribution in humans. Annu. Rev. Nutr., 9, 417–443. Lonnqvist, F., Thorne, A., Large, V., and Arner, P. (1997) Sex differences in visceral fat lipolysis and metabolic complications of obesity. Arterioscler. Thromb. Vasc. Biol., 17, 1472–1480. Zierath, J.R., Livingston, J.N., Thorne, A., Bolinder, J., Reynisdottir, S., Lonnqvist, F., and Arner, P. (1998) Regional difference in insulin inhibition of nonesterified fatty acid release from human adipocytes: relation to insulin receptor phosphorylation and intracellular signalling through the insulin receptor substrate-1 pathway. Diabetologia, 41, 1343–1354. Reynisdottir, S., Dauzats, M., Thorne, A., and Langin, D. (1997) Comparison of hormone-sensitive lipase activity in visceral and subcutaneous human adipose tissue. J. Clin. Endocrinol. Metab., 82, 4162–4166. Fried, S.K., Leibel, R.L., Edens, N.K., and Kral, J.G. (1993) Lipolysis in intraabdominal adipose tissues of obese women and men. Obes. Res., 1, 443–448. Rebuffe-Scrive, M., Anderson, B., Olbe, L., and Bjorntorp, P. (1990) Metabolism of adipose tissue in intraabdominal depots in severely obese men and women. Metabolism, 39, 1021–1025. Leibel, R.L., Edens, N.K., and Fried, S.K. (1989) Physiologic basis for the control of body fat distribution in humans. Annu. Rev. Nutr., 9, 417–443. Johnson, J.A., Fried, S.K., Pi-Sunyer, F.X., and Albu, J.B. (2001) Impaired insulin action in subcutaneous adipocytes from women with visceral obesity. Am. J. Physiol. Endocrinol. Metab., 280, E40–E49.
References 48 Tittelbach, T.J., Blumenthal, J.R., Ryan,
49
50
51
52
53
54
55
A.S., Goldberg, A.P., and Fried, S.K. (2006) Minimal alterations in lipolysis and sensitivity to the antilipolytic effect of insulin in adipocytes of insulin resistant post-menopausal women. Diabetes, 55, A318. Gower, B.A., Munoz, J., Desmond, R., Hilario-Hailey, T., and Jiao, X. (2006) Changes in intra-abdominal fat in early postmenopausal women: effects of hormone use. Obesity, 14, 1046–1055. Dieudonne, M.N., Pecquery, R., Leneveu, M.C., and Giudicelli, Y. (2000) Opposite effects of androgens and estrogens on adipogenesis in rat preadipocytes: evidence for sex and site-related specificities and possible involvement of insulin-like growth factor 1 receptor and peroxisome proliferator-activated receptor gamma2. Endocrinology, 141, 649–656. Giudicelli, Y., Dieudonne, M.N., Lacasa, D., Pasquier, Y.N., and Pecquery, R. (1993) Modulation by sex hormones of the membranous transducing system regulating fatty acid mobilization in adipose tissue. Prostaglandins Leukot. Essent. Fatty Acids, 48, 91–100. Virtanen, K.A., Lonnroth, P., Parkkola, R., Peltoniemi, P., Asola, M., Viljanen, T., Tolvanen, T., Knuuti, J., Ronnemaa, T., Huupponen, R., and Nuutila, P. (2002) Glucose uptake and perfusion in subcutaneous and visceral adipose tissue during insulin stimulation in nonobese and obese humans. J. Clin. Endocrinol. Metab., 87, 3902–3910. Crandall, D.L., Goldstein, B.M., Huggins, F., and Cervoni, P. (1984) Adipocyte blood flow: influence of age, anatomic location, and dietary manipulation. Am. J. Physiol. Regul. Integr. Comp. Physiol., 247, R46–R51. West, D.B., Prinz, W.A., and Greenwood, M.R. (1989) Regional changes in adipose tissue blood flow and metabolism in rats after a meal. Am. J. Physiol. Regul. Integr. Comp. Physiol., 257, R711–R716. Tansey, J.T., Sztalryd, C., Hlavin, E.M., Kimmel, A.R., and Londos, C. (2004) The central role of perilipin a in lipid metabolism and adipocyte lipolysis. IUBMB Life, 56, 379–385.
56 Arner, P. and Langin, D. (2007) The role
57
58
59
60
61
62
63
64
of neutral lipases in human adipose tissue lipolysis. Curr. Opin. Lipidol., 18, 246–250. Wang, Y., Sullivan, S., Trujillo, M., Lee, M.J., Schneider, S.H., Brolin, R.E., Kang, Y.H., Werber, Y., Greenberg, A.S., and Fried, S.K. (2003) Perilipin expression in human adipose tissues: effects of severe obesity, gender, and depot. Obes. Res., 11, 930–936. Arvidsson, E., Blomqvist, L., and Ryden, M. (2004) Depot-specific differences in perilipin mRNA but not protein expression in obesity. J. Intern. Med., 255, 595–601. Fisher, R.M., Eriksson, P., Hoffstedt, J., Hotamisligil, G.S., Thorne, A., Ryden, M., Hamsten, A., and Arner, P. (2001) Fatty acid binding protein expression in different adipose tissue depots from lean and obese individuals. Diabetologia, 44, 1268–1273. Hertzel, A.V., Smith, L.A., Berg, A.H., Cline, G.W., Shulman, G.I., Scherer, P.E., and Bernlohr, D.A. (2006) Lipid metabolism and adipokine levels in fatty acid-binding protein null and transgenic mice. Am. J. Physiol. Endocrinol. Metab., 290, E814–E823. Baar, R.A., Dingfelder, C.S., Smith, L.A., Bernlohr, D.A., Wu, C., Lange, A.J., and Parks, E.J. (2005) Investigation of in vivo fatty acid metabolism in AFABP/aP2/ mice. Am. J. Physiol. Endocrinol. Metab., 288, E187–E193. Shaughnessy, S., Smith, E.R., Kodukula, S., Storch, J., and Fried, S.K. (2000) Adipocyte metabolism in adipocyte fatty acid binding protein knockout mice (aP2/) after short-term high-fat feeding: functional compensation by the keratinocyte [correction of keritinocyte] fatty acid binding protein. Diabetes, 49, 904–911. Fried, S.K. and Kral, J.G. (1987) Adipose tissue of morbidly obese patients: clinical implications of distribution, morphology, and metabolism. Gastroenterol. Clin. North Am., 16, 207–213. Saleh, J., Christou, N., and Cianflone, K. (1999) Regional specificity of ASP
j301
j 15 Depot-Specific Biology of Adipose Tissues: Links to Fat Distribution and Metabolic Risk
302
65
66
67
68
69
70
71
72
73
binding in human adipose tissue. Am. J. Physiol. Endocrinol. Metab., 276, E815–E821. Marette, A., Mauriege, P., Marcotte, B., Atgie, C., Bouchard, C., Theriault, G., Bukowiecki, L.J., Marceau, P., Biron, S., Nadeau, A., and Despres, J.P. (1997) Regional variation in adipose tissue insulin action and GLUT4 glucose transporter expression in severely obese premenopausal women. Diabetologia, 40, 590–598. Votruba, S.B., Mattison, R.S., Dumesic, D.A., Koutsari, C., and Jensen, M.D. (2007) Meal fatty acid uptake in visceral fat in women. Diabetes, 56, 2589–2597. Edens, N.K., Fried, S.K., Kral, J.G., Hirsch, J., and Leibel, R.L. (1993) In vitro lipid synthesis in human adipose tissue from three abdominal sites. Am. J. Physiol. Endocrinol. Metab., 265, E374–E379. Bashan, N., Dorfman, K., Tarnovscki, T., Harman-Boehm, I., Liberty, I.F., Bluher, M., Ovadia, S., Maymon-Zilberstein, T., Potashnik, R., Stumvoll, M., Avinoach, E., and Rudich, A. (2007) Mitogenactivated protein kinases, inhibitorykappaB kinase, and insulin signaling in human omental versus subcutaneous adipose tissue in obesity. Endocrinology, 148, 2955–2962. Yang, R.Z., Lee, M.J., Hu, H., Pray, J., Wu, H.B., Hansen, B.C., Shuldiner, A.R., Fried, S.K., McLenithan, J.C., and Gong, D.W. (2006) Identification of omentin as a novel depot-specific adipokine in human adipose tissue: possible role in modulating insulin action. Am. J. Physiol. Endocrinol. Metab., 290, E1253–E1261. Hotamisligil, G.S. (2006) Inflammation and metabolic disorders. Nature, 444, 860–867. Tilg, H. and Moschen, A.R. (2006) Adipocytokines: mediators linking adipose tissue, inflammation and immunity. Nat. Rev. Immunol., 6, 772–783. Rondinone, C.M. (2006) Adipocytederived hormones, cytokines, and mediators. Endocrine, 29, 81–90. Hotamisligil, G.S., Shargill, N.S., and Spiegelman, B.M. (1993) Adipose
74
75
76
77
78
79
80
expression of tumor necrosis factoralpha: direct role in obesity-linked insulin resistance. Science, 259, 87–91. Senn, J.J., Klover, P.J., Nowak, I.A., and Mooney, R.A. (2002) Interleukin-6 induces cellular insulin resistance in hepatocytes. Diabetes, 51, 3391–3399. Tuncman, G., Hirosumi, J., Solinas, G., Chang, L., Karin, M., and Hotamisligil, G.S. (2006) Functional in vivo interactions between JNK1 and JNK2 isoforms in obesity and insulin resistance. Proc. Natl. Acad. Sci. USA, 103, 10741–10746. Kloting, N., Graham, T.E., Berndt, J., Kralisch, S., Kovacs, P., Wason, C.J., Fasshauer, M., Schon, M.R., Stumvoll, M., Bluher, M., and Kahn, B.B. (2007) Serum retinol-binding protein is more highly expressed in visceral than in subcutaneous adipose tissue and is a marker of intra-abdominal fat mass. Cell Metab., 6, 79–87. Yao-Borengasser, A., Varma, V., Bodles, A.M., Rasouli, N., Phanavanh, B., Lee, M.J., Starks, T., Kern, L.M., Spencer, H.J. III, Rashidi, A.A., McGehee, R.E. Jr., Fried, S.K., and Kern, P.A. (2007) Retinol binding protein 4 expression in humans: relationship to insulin resistance, inflammation, and response to pioglitazone. J. Clin. Endocrinol. Metab., 92, 2590–2597. Sjoholm, K., Palming, J., Olofsson, L.E., Gummesson, A., Svensson, P.A., Lystig, T.C., Jennische, E., Brandberg, J., Torgerson, J.S., Carlsson, B., and Carlsson, L.M. (2005) A microarray search for genes predominantly expressed in human omental adipocytes: adipose tissue as a major production site of serum amyloid A. J. Clin. Endocrinol. Metab., 90, 2233–2239. de Souza Batista, C.M., Yang, R.Z., Lee, M.J., Glynn, N.M., Yu, D.Z., Pray, J., Ndubuizu, K., Patil, S., Schwartz, A., Kligman, M., Fried, S.K., Gong, D.W., Shuldiner, A.R., Pollin, T.I., and McLenithan, J.C. (2007) Omentin plasma levels and gene expression are decreased in obesity. Diabetes, 56, 1655–1661. Fukuhara, A., Matsuda, M., Nishizawa, M., Segawa, K., Tanaka, M., Kishimoto,
References
81
82
83
84
85
86
K., Matsuki, Y., Murakami, M., Ichisaka, T., Murakami, H., Watanabe, E., Takagi, T., Akiyoshi, M., Ohtsubo, T., Kihara, S., Yamashita, S., Makishima, M., Funahashi, T., Yamanaka, S., Hiramatsu, R., Matsuzawa, Y., and Shimomura, I. (2005) Visfatin: a protein secreted by visceral fat that mimics the effects of insulin. Science, 307, 426–430. Berndt, J., Kloting, N., Kralisch, S., Kovacs, P., Fasshauer, M., Schon, M.R., Stumvoll, M., and Bluher, M. (2005) Plasma visfatin concentrations and fat depot-specific mRNA expression in humans. Diabetes, 54, 2911–2916. Varma, V., Yao-Borengasser, A., Rasouli, N., Bodles, A.M., Phanavanh, B., Lee, M.J., Starks, T., Kern, L.M., Spencer, H.J. III, McGehee, R.E. Jr., Fried, S.K., and Kern, P.A. (2007) Human visfatin expression: relationship to insulin sensitivity, intramyocellular lipids, and inflammation. J. Clin. Endocrinol. Metab., 92, 666–672. Yang, H., Yang, T., Baur, J.A., Perez, E., Matsui, T., Carmona, J.J., Lamming, D.W., Souza-Pinto, N.C., Bohr, V.A., Rosenzweig, A., de, C.R., Sauve, A.A., and Sinclair, D.A. (2007) Nutrientsensitive mitochondrial NAD þ levels dictate cell survival. Cell, 130, 1095–1107. Tanaka, M., Nozaki, M., Fukuhara, A., Segawa, K., Aoki, N., Matsuda, M., Komuro, R., and Shimomura, I. (2007) Visfatin is released from 3T3-L1 adipocytes via a non-classical pathway. Biochem. Biophys. Res. Commun., 359, 194–201. Yang, R.Z., Lee, M.J., Hu, H., Pollin, T.I., Ryan, A.S., Nicklas, B.J., Snitker, S., Horenstein, R.B., Hull, K., Goldberg, N.H., Goldberg, A.P., Shuldiner, A.R., Fried, S.K., and Gong, D.W. (2006) Acutephase serum amyloid A: an inflammatory adipokine and potential link between obesity and its metabolic complications. PLoS Med., 3, e287. Johnson, B.D., Kip, K.E., Marroquin, O.C., Ridker, P.M., Kelsey, S.F., Shaw, L.J., Pepine, C.J., Sharaf, B., Bairey Merz, C.N., Sopko, G., Olson, M.B., and Reis, S.E. (2004) Serum amyloid A as a predictor of coronary artery disease and
87
88
89
90
91
92
93
94
cardiovascular outcome in women: the National Heart, Lung, and Blood Institute-Sponsored Womens Ischemia Syndrome Evaluation (WISE). Circulation, 109, 726–732. van der Westhuyzen, D.R., Cai, L., de Beer, M.C., and de Beer, F.C. (2005) Serum amyloid A promotes cholesterol efflux mediated by scavenger receptor BI. J. Biol. Chem., 280, 35890–35895. Cai, L., de Beer, M.C., de Beer, F.C., and van der Westhuyzen, D.R. (2005) Serum amyloid A is a ligand for scavenger receptor class B type I and inhibits high density lipoprotein binding and selective lipid uptake. J. Biol. Chem., 280, 2954–2961. Marsche, G., Frank, S., Raynes, J.G., Kozarsky, K.F., Sattler, W., and Malle, E. (2007) The lipidation status of acutephase protein serum amyloid A determines cholesterol mobilization via scavenger receptor class B, type I. Biochem. J., 402, 117–124. Han, C.Y., Subramanian, S., Chan, C.K., Omer, M., Chiba, T., Wight, T.N., and Chait, A. (2007) Adipocyte-derived serum amyloid A3 and hyaluronan play a role in monocyte recruitment and adhesion. Diabetes, 56, 2260–2273. Memoli, B., Procino, A., Calabro, P., Esposito, P., Grandaliano, G., Pertosa, G., Del Prete, M.A., Andreucci, M., Dilillo, S., Ferulano, G., Cillo, C., Savastano, S., Colao, A., and Guida, B. (2007) Inflammation may modulate interleukin 6 and C-reactive protein gene expression in the adipose tissue: the role of IL-6 cell membrane receptor. Am. J. Physiol. Endocrinol. Metab., 293, E1030–E1035. Gordon, S. (2007) Macrophage heterogeneity and tissue lipids. J. Clin. Invest, 117, 89–93. Weisberg, S.P., Hunter, D., Huber, R., Lemieux, J., Slaymaker, S., Vaddi, K., Charo, I., Leibel, R.L., and Ferrante, A.W. Jr. (2006) CCR2 modulates inflammatory and metabolic effects of high-fat feeding. J. Clin. Invest., 116, 115–124. Harman-Boehm, I., Bluher, M., Redel, H., Sion-Vardy, N., Ovadia, S., Avinoach, E., Shai, I., Kloting, N., Stumvoll, M., Bashan, N., and Rudich, A. (2007)
j303
j 15 Depot-Specific Biology of Adipose Tissues: Links to Fat Distribution and Metabolic Risk
304
95
96
97
98
99
100
101
102
Macrophage infiltration into omental versus subcutaneous fat across different populations: effect of regional adiposity and the comorbidities of obesity. J. Clin. Endocrinol. Metab., 92, 2240–2247. Ryden, M., Arvidsson, E., Blomqvist, L., Perbeck, L., Dicker, A., and Arner, P. (2004) Targets for TNF-alpha-induced lipolysis in human adipocytes. Biochem. Biophys. Res. Commun., 318, 168–175. Trujillo, M.E., Lee, M.J., Sullivan, S., Feng, J., Schneider, S.H., Greenberg, A.S., and Fried, S.K. (2006) Tumor necrosis factor alpha and glucocorticoid synergistically increase leptin production in human adipose tissue: role for p38 mitogen-activated protein kinase. J. Clin. Endocrinol. Metab., 91, 1484–1490. Trujillo, M.E., Sullivan, S., Harten, I., Schneider, S.H., Greenberg, A.S., and Fried, S.K. (2004) Interleukin-6 regulates human adipose tissue lipid metabolism and leptin production in vitro. J. Clin. Endocrinol. Metab., 89, 5577–5582. Fain, J.N. and Madan, A.K. (2005) Regulation of monocyte chemoattractant protein 1 (MCP-1) release by explants of human visceral adipose tissue. Int. J. Obes., 29, 1299–1307. Zhang, H.H., Halbleib, M., Ahmad, F., Manganiello, V.C., and Greenberg, A.S. (2002) Tumor necrosis factor-alpha stimulates lipolysis in differentiated human adipocytes through activation of extracellular signal-related kinase and elevation of intracellular cAMP. Diabetes, 51, 2929–2935. Sartipy, P. and Loskutoff, D.J. (2003) Monocyte chemoattractant protein 1 in obesity and insulin resistance. Proc. Natl. Acad. Sci. USA, 100, 7265–7270. Wu, H., Ghosh, S., Perrard, X.D., Feng, L., Garcia, G.E., Perrard, J.L., Sweeney, J.F., Peterson, L.E., Chan, L., Smith, C.W., and Ballantyne, C.M. (2007) T-cell accumulation and regulated on activation, normal T cell expressed and secreted upregulation in adipose tissue in obesity. Circulation, 115, 1029–1038. Herder, C., Haastert, B., Muller-Scholze, S., Koenig, W., Thorand, B., Holle, R., Wichmann, H.E., Scherbaum, W.A., Martin, S., and Kolb, H. (2005)
103
104
105
106
107
108
109
Association of systemic chemokine concentrations with impaired glucose tolerance and type 2 diabetes: results from the Cooperative Health Research in the Region of Augsburg Survey S4 (KORA S4). Diabetes, 54 (Suppl. 2), S11–S17. Wilkison, W.O., Choy, L., and Spiegelman, B.M. (1991) Biosynthetic regulation of monobutyrin, an adipocytesecreted lipid with angiogenic activity. J. Biol. Chem., 266, 16886–16891. Quinkler, M., Bujalska, I.J., Tomlinson, J.W., Smith, D.M., and Stewart, P.M. (2006) Depot-specific prostaglandin synthesis in human adipose tissue: a novel possible mechanism of adipogenesis. Gene, 380, 137–143. Brakenhielm, E., Cao, R., Gao, B., Angelin, B., Cannon, B., Parini, P., and Cao, Y. (2004) Angiogenesis inhibitor, TNP-470, prevents diet-induced and genetic obesity in mice. Circ. Res., 94, 1579–1588. Voros, G., Maquoi, E., Demeulemeester, D., Clerx, N., Collen, D., and Lijnen, H.R. (2005) Modulation of angiogenesis during adipose tissue development in murine models of obesity. Endocrinology, 146, 4545–4554. Bell, L.N., Ward, J.L., gawa-Yamauchi, M., Bovenkerk, J.E., Jones, R., Cacucci, B.M., Gupta, C.E., Sheridan, C., Sheridan, K., Shankar, S.S., Steinberg, H.O., March, K.L., and Considine, R.V. (2006) Adipose tissue production of hepatocyte growth factor contributes to elevated serum HGF in obesity. Am. J. Physiol. Endocrinol. Metab., 291, E843–E848. Saiki, A., Watanabe, F., Murano, T., Miyashita, Y., and Shirai, K. (2006) Hepatocyte growth factor secreted by cultured adipocytes promotes tube formation of vascular endothelial cells in vitro. Int. J. Obes., 30, 1676–1684. Nakagami, H., Morishita, R., Yamamoto, K., Taniyama, Y., Aoki, M., Matsumoto, K., Nakamura, T., Kaneda, Y., Horiuchi, M., and Ogihara, T. (2001) Mitogenic and antiapoptotic actions of hepatocyte growth factor through ERK, STAT3, and AKT in endothelial cells. Hypertension, 37, 581–586.
References 110 Ramis, J.M., Franssen-van Hal, N.L.,
111
112
113
114
115
116
117
Kramer, E., Llado, I., Bouillaud, F., Palou, A., and Keijer, J. (2002) Carboxypeptidase E and thrombospondin-1 are differently expressed in subcutaneous and visceral fat of obese subjects. Cell. Mol. Life Sci., 59, 1960–1971. Vohl, M.C., Sladek, R., Robitaille, J., Gurd, S., Marceau, P., Richard, D., Hudson, T.J., and Tchernof, A. (2004) A survey of genes differentially expressed in subcutaneous and visceral adipose tissue in men. Obes. Res., 12, 1217–1222. Gesta, S., Bluher, M., Yamamoto, Y., Norris, A.W., Berndt, J., Kralisch, S., Boucher, J., Lewis, C., and Kahn, C.R. (2006) Evidence for a role of developmental genes in the origin of obesity and body fat distribution. Proc. Natl. Acad. Sci. USA, 103, 6676–6681. Tchkonia, T., Lenburg, M., Thomou, T., Giorgadze, N., Frampton, G., Pirtskhalava, T., Cartwright, A., Cartwright, M., Flanagan, J., Karagiannides, I., Gerry, N., Forse, R.A., Tchoukalova, Y., Jensen, M.D., Pothoulakis, C., and Kirkland, J.L. (2007) Identification of depot-specific human fat cell progenitors through distinct expression profiles and developmental gene patterns. Am. J. Physiol. Endocrinol. Metab., 292, E298–E307. Nayer, A. and Shoelson, S. (2007) Differential distribution of adipositis induced by high-fat diet in abdominal fat depots. Diabetes, 56, A71. Hauner, H., Wabitsch, M., and Pfeiffer, E.F. (1988) Differentiation of adipocyte precursor cells from obese and nonobese adult women and from different adipose tissue sites. Horm. Metab Res. Suppl, 19, 35–39. Tchkonia, T., Giorgadze, N., Pirtskhalava, T., Thomou, T., DePonte, M., Koo, A., Forse, R.A., Chinnappan, D., MartinRuiz, C., von, Z.T., and Kirkland, J.L. (2006) Fat depot-specific characteristics are retained in strains derived from single human preadipocytes. Diabetes., 55, 2571–2578. Niesler, C.U., Siddle, K., and Prins, J.B. (1998) Human preadipocytes display a
118
119
120
121
122
123
124
125
depot-specific susceptibility to apoptosis. Diabetes, 47, 1365–1368. Shi, H., Strader, A., Woods, S.C., and Seeley, R.J. (2007) The effect of fat removal on glucose tolerance is depot specific in male and female mice. Am. J. Physiol. Endocrinol. Metab., 293, E1012–E1020. Tran, T.T., Yamamoto, Y., Gesta, S., and Kahn, C.R. (2007) Beneficial effects of subcutaneous fat transplantation on metabolism. Cell Metab. 7, 410–420. Russell, C.D., Petersen, R.N., Rao, S.P., Ricci, M.R., Prasad, A., Zhang, Y., Brolin, R.E., and Fried, S.K. (1998) Leptin expression in adipose tissue from obese humans: depot-specific regulation by insulin and dexamethasone. Am. J. Physiol. Endocrinol. Metab., 275, E507–E515. Dusserre, E., Moulin, P., and Vidal, H. (2000) Differences in mRNA expression of the proteins secreted by the adipocytes in human subcutaneous and visceral adipose tissues. Biochim. Biophys. Acta, 1500, 88–96. Fisher, F.M., McTernan, P.G., Valsamakis, G., Chetty, R., Harte, A.L., Anwar, A.J., Starcynski, J., Crocker, J., Barnett, A.H., McTernan, C.L., and Kumar, S. (2002) Differences in adiponectin protein expression: effect of fat depots and type 2 diabetic status. Horm. Metab. Res., 34, 650–654. Hube, F., Birgel, M., Lee, Y.M., and Hauner, H. (1999) Expression pattern of tumour necrosis factor receptors in subcutaneous and omental human adipose tissue: role of obesity and noninsulin-dependent diabetes mellitus. Eur. J. Clin. Invest., 29, 672–678. Alessi, M.C., Bastelica, D., Morange, P., Berthet, B., Leduc, I., Verdier, M., Geel, O., and Juhan-Vague, I. (2000) Plasminogen activator inhibitor 1, transforming growth factor-beta1, and BMI are closely associated in human adipose tissue during morbid obesity. Diabetes, 49, 1374–1380. Fried, S.K., Bunkin, D.A., and Greenberg, A.S. (1998) Omental and subcutaneous adipose tissues of obese subjects release interleukin-6: depot difference and
j305
j 15 Depot-Specific Biology of Adipose Tissues: Links to Fat Distribution and Metabolic Risk
306
126
127
128
129
regulation by glucocorticoid. J. Clin. Endocrinol. Metab., 83, 847–850. Bruun, J.M., Lihn, A.S., Madan, A.K., Pedersen, S.B., Schiott, K.M., Fain, J.N., and Richelsen, B. (2004) Higher production of IL-8 in visceral vs. subcutaneous adipose tissue. Implication of nonadipose cells in adipose tissue. Am. J. Physiol. Endocrinol. Metab., 286, E8–E13. Herder, C., Hauner, H., Kempf, K., Kolb, H., and Skurk, T. (2007) Constitutive and regulated expression and secretion of interferon-gamma-inducible protein 10 (IP-10/CXCL10) in human adipocytes. Int. J. Obes., 31, 403–410. Bruun, J.M., Lihn, A.S., Pedersen, S.B., and Richelsen, B. (2005) Monocyte chemoattractant protein-1 release is higher in visceral than subcutaneous human adipose tissue (AT): implication of macrophages resident in the AT. J. Clin. Endocrinol. Metab., 90, 2282–2289. Tchkonia, T., Lenburg, M., Thomou, T., Giorgadze, N., Frampton, G., Pirtskhalava, T., Cartwright, A., Cartwright, M., Flanagan, J., Karagiannides, I., Gerry, N., Forse, R.A., Tchoukalova, Y., Jensen, M.D., Pothoulakis, C., and Kirkland, J.L. (2006) Identification of depot-specific human fat
130
131
132
133
cell progenitors through distinct expression profiles and developmental gene patterns. Am. J. Physiol. Endocrinol. Metab., 292, 298–307. Fain, J.N., Cheema, P.S., Bahouth, S.W., and Lloyd, H.M. (2003) Resistin release by human adipose tissue explants in primary culture. Biochem. Biophys. Res. Commun., 300, 674–678. Schaffler, A., Neumeier, M., Herfarth, H., Furst, A., Scholmerich, J., and Buchler, C. (2005) Genomic structure of human omentin, a new adipocytokine expressed in omental adipose tissue. Biochim. Biophys. Acta, 1732, 96–102. Gabrielsson, B.G., Johansson, J.M., Jennische, E., Jernas, M., Itoh, Y., Peltonen, M., Olbers, T., Lonn, L., Lonroth, H., Sjostrom, L., Carlsson, B., Carlsson, L.M., and Lonn, M. (2002) Depot-specific expression of fibroblast growth factors in human adipose tissue. Obes. Res., 10, 608–616. Lee, M.J., Fried, S.K., Mundt, S.S, Wang, Y., Sullivan, S., Stefanni, A., Daugherty, B.L, and Hermanovski-Vosatka, A. (2008) Depot-specific regulation of the conversion of cortisone to cortisol in human adipose tissue. Obesity, 16, 1178–1185.
j307
16 Viral Induction of Obesity and Adipogenesis Magdalena Pasarica, Rohan N. Dhurandhar, Nazar Mashtalir, and Nikhil V. Dhurandhar 16.1 Introduction
The World Health Organization has declared that the world is experiencing an obesity epidemic. As this epidemic continues unabated, infectobesity (obesity of infectious origin) has been receiving increasing attention in recent years [1–3]. In the last two decades, 10 obesity-promoting microbes have been reported [4–19]. During this period, the prevalence of obesity has increased by 30% in the United States. Several developed and developing countries echo this trend [20, 21]. Even in the best hands, obesity treatment yields merely marginal and transient weight loss. Considering our dismal record in fighting this epidemic, new information about every aspect of obesity, from its etiology to its treatment, is urgently needed to devise new and more effective strategies. An accurate understanding of the varied etiological factors of obesity may point the way to treatments directed specifically towards the cause and, consequently, its successful management. This chapter presents information about a relatively novel and unusual cause of obesity – obesity of infectious origin. A multitude of factors contribute to the etiology of obesity [22] and a proportion of obesity may be caused by infections. If infection by certain pathogens promotes human obesity, recognizing and acknowledging their role is the first important step in dealing with the infection and its pathogenesis. The adipogenic pathogens reported to date include human and nonhuman viruses, scrapie agents, bacteria, and gut microflora and parasites. This chapter describes various adipogenic pathogens reported since the first of such reports in 1982 [23], their natural hosts, signs and symptoms, and pathogenesis (Table 16.1). Data for this chapter were identified by searches of MEDLINE and references from relevant articles. Numerous articles were first identified by using search terms infectobesity, obesity and infection, viruses and obesity, fat and virus, and infection and weight gain. Search was further refined by using search terms pertinent to the adipogenic pathogens reported in the literature. English and French language publications were searched. Publications including original articles, reviews, and editorials describing causation, association, and/or mechanism of
Adipogenic pathogens.
Pathogen
Animal model, age, and sex
Effect of infection on body weight
Effect of infection on biochemical parameters
Potential mechanism of action
Association with human obesity
CDV [23, 29, 32, 34, 37–39, 127–131]
Swiss albino mice, male and female, 4–5 weeks old
obesity developed 6–10 weeks postinfection and reaches a plateau after 16–20 weeks mean weight of infected obese animals was nearly twice compared to the uninfected group
" insulin
alters hypothalamic integrity
association with human multiple sclerosis
no significant change in glucose
# leptin long receptor and " leptin
association with obesity not yet reported
" leptin levels # MCH, neuropeptide Y # catecholamine # neuropeptides
# MCH # neuropeptides
RAV-7 [7, 8, 44, 46, 132]
10-day-old embryos of white Leghorn chickens
stunting – 2 weeks posthatching
anemia
" visceral fat – 3 weeks of age
hyperlipidemia immune suppression
# catecholamine " cytokine production changes in lipid metabolism # thyroxine
not reported
j 16 Viral Induction of Obesity and Adipogenesis
308
Table 16.1
BDV [16, 50, 54, 59, 133]
SMAM-1 [10, 14, 75]
Ad-36 [4, 12, 13, 15, 79–81]
4-week-old Lewis rats
3-week-old white Leghorn broilers
chickens, mice, male rhesus monkeys and marmosets, rats
" body weight – 14 days postinoculation
stunting
" visceral fat 3 weeks postinoculation " body weight
" amylase " insulin # glucose # thyroxine " triglycerides
moderate " blood glucose # cholesterol
possible hypothalamic damage due to inflammatory lesions and viral replication
transmission of BDV from animals to humans is possible; increase BDV seroprevalence in psychiatric and neurological disorders; association with obesity not yet reported
impaired liver function
yes; seropositive obese subjects heavier versus seronegative obese counterparts
# triglycerides
impaired lipogenesis glucagon deficiency
# cholesterol
" replication
(continued)
16.1 Introduction
yes; greater prevalence of seropositivity in obese versus nonobese subjects; seropositive subjects were heavier than seronegative counterparts
j309
Ad-37 [4, 89]
Animal model, age, and sex
3-week-old white Leghorn chickens
3-week-old female CD1 mice
Effect of infection on body weight
Effect of infection on biochemical parameters
Potential mechanism of action
" visceral, epididymal-inguinal, retroperitoneal fat onset 4 weeks in chickens, 6–7 months postinoculation in rodents and mammals
# triglycerides
" differentiation
" insulin sensitivity
" lipid accumulation in preadipocytes
# leptin expression and secretion # corticosterone and norepinephrine # triglycerides
" insulin sensitivity
no difference in body weight " visceral fat onset 4 weeks postinoculation " body weight
179% " whole-body adiposity
—
# leptin secretion and expression in fat cells " adipocyte differentiation " triglyceride accumulation
increased preadipocyte differentiation – hypothesized anti-inflammatory response determined by infection – hypothesized
Association with human obesity
not reported
not reported
j 16 Viral Induction of Obesity and Adipogenesis
(Continued)
Pathogen
Ad-5 [18]
310
Table 16.1
C. pneumoniae [9, 92, 134–136]
humans
Microbiota [5, 19, 100, 137]
8- to 10-week-old germ-free male B6/ NMRI mice
onset 22–23 weeks postinoculation significantly higher BMI
association with coronary heart disease
no difference in body weight
insulin resistance, " glucose, " insulin
57% " whole-body fat
" metabolic rate with no alteration in tissue high-energy phosphate stores 2.3-fold " hepatic triglyceride content " expression of de novo fatty acid synthesis pathway (acetyl-CoA carboxylase-1 and fatty acid synthase)) # expression FIAF
69% " epididymal fat 7% # lean mass
onset after 14 days of colonization
mechanism unknown; preponderance of seropositivity in obese subjects is not a result of obesity " processing of polysaccharides
" inefficient metabolism
association with increased BMI
obesity correlates with abundance of Firmicutes in the gut flora weight loss decreases Firmicutes
" hepatic triglyceride production " FIAF, " incorporation of triglycerides into adipocytes by LPL
(continued)
16.1 Introduction
" leptin, " LPL activity in epididymal fat and heart
j311
(Continued)
Pathogen
Animal model, age, and sex
Effect of infection on body weight
Effect of infection on biochemical parameters
Potential mechanism of action
Association with human obesity
Gut parasites [101, 102]
adult male dragonflies (L. pulchella)
26% more thoracic lipid
no change in hemolyph lipid content
mechanism unknown; decline in flight-muscle power related to changes in parasite size, maturity, and length of infection
not reported
brain function alteration
not reported
Scrapie agents [17, 107, 109, 110, 117, 138]
6- to 9-week-old female mice SJL, C57NL, A2G, SAMP8, SAMR1, AKR, 22L
" body weight due to fat accumulation
12 weeks postinfection
Reproduced with permission from [139].
" hemolyph carbohydrate levels " insulin resistance " chronic p38 mitogen-activated protein kinase activation # flight-muscle power output " blood glucose
# GLUT1 density in certain brain areas
# GLUT1 density, # glucose tolerance " adrenal weight disturbs hypothalamic–pituitary–adrenal axis
j 16 Viral Induction of Obesity and Adipogenesis
312
Table 16.1
16.2 Viruses
microorganisms with obesity, and/or weight gain in animals and humans were reviewed.
16.2 Viruses 16.2.1 Canine Distemper Virus
Canine distemper virus (CDV) was the first obesity-promoting pathogen reported [23]. It is a lymphotropic and neurotropic negative-stranded RNA virus from the genus morbillivirus and paramyxovirus subgroup [24–26]. CDV causes a frequently fatal neurodegenerative disease in dogs and a wide range of mammals [23, 27–30]. The virus is antigenically related to the measles virus [31] and although CDV may be associated with other human diseases [29], it is not considered a human pathogen. CDV induced obesity in 26% of Swiss Albino mice after intracerebral viral inoculation and in 16% of animals after an intraperitoneal inoculation [23]. These results have since been reconfirmed [32–34]. CDV increased fat cell number and size, and body and fat pad weights in mice surviving the infection [23]. CDV inoculation by the intranasal, footpad, or subcutaneous route did not produce obesity, and vaccination with CDV surface antigens partially protected against acute encephalitis and obesity [35, 36]. In another study, the CDV-infected obese group showed 6 times greater insulin levels without differences in glucose levels compared to control animals [34]. Reduced catecholamine levels [23], decrease in hypothalamic expression of longform leptin receptor and the consequent leptin resistance [37], and downregulation of melanin-concentration hormone (MCH) precursor mRNA (ppMCH) are considered to contribute to CDV-induced obesity. Leptin, an adipokine, modulates food intake and energy metabolism, and MCH is a potent anorectic peptide involved in the hypothalamic regulation of feeding behavior. These findings suggest a role for food intake disregulation in CDV-infected animals. The food intake of CDV-infected animals was greater, but did not attain statistical significance [23]. The additional energy intake, however small, over several weeks may eventually contribute to biologically significant weight gain. Recently, Verlaeten et al. [38] suggested that CDV alters hypothalamic integrity and subsequently modifies the homeostasis of the brain – a condition known to lead to obesity. Although viral products are expressed at high levels in the acute stages of infection, surprisingly, by the time the obesity develops, CDV is no longer detectable in the hypothalamus [32, 39]. Therefore, Bernard et al. [37] speculated that the initial impact of CDV on the hypothalamus initiates changes that continue to promote obesity months after the acute infection, suggesting a hit-and-run effect similar to that described by Oldstone et al. [40]. No association of CDV with human obesity has been reported.
j313
j 16 Viral Induction of Obesity and Adipogenesis
314
16.2.2 Rous-Associated Virus-7
Rous-associated virus (RAV)-7 was reported to cause obesity as well as stunting and hyperlipidemia in chickens [8]. It is an avian leucosis retrovirus and the most common avian retrovirus associated with neoplastic disease in domesticated poultry [41]. RAV-7 belongs to subgroup C of the five subgroups of the virus based on envelope glycoproteins, A–F [42]. It shows the least antigenic cross-reactivity among the other subgroup C viruses [43] and shows similar pathogenesis, but also produce obesity [44]. RAV-7-induced obesity is characterized by stunting, fat deposition around crop and abdominal fat pads, and hyperlipidemia [8]. While there was no evidence of neoplastic transformation, stunted growth was the most impressive effect of RAV-7. Obesity was observed in birds infected as 10-day-old embryos, but not when inoculated as 1-day-old hatched chickens [8]. Difference in food intake was observed as early as 3 weeks postinfection, when stunting and obesity developed [7]. Fifty days after hatching, the RAV-7-infected chickens weighed 194 g compared to 515 g in the control group. The infected chickens developed fatty, yellow-colored livers, hepatomegaly, anemia, immune suppression, and striking hyperlipidemia. Serum triglyceride levels in the infected group were 1500 mg/dl compared with a range of 68.2–90.5 mg/dl in uninfected chickens. Pancreatic damage was indicated by histological changes, increased serum amylase levels, and reduced serum glucose and glucagon levels. Glucagon levels dipped 20 and 30 days posthatching, and as expected in poultry [45], the drop was accompanied with higher mortality. Insulin levels, on the other hand, remained at, or even above, normal. RAV-7-induced thyroiditis, and marked reductions in T3 and T4 levels [46], which may explain the adiposity and hyperlipidemia [46, 47]. The virally induced syndrome was ameliorated by thyroid hormone replacement [46], demonstrating the role of hypothyroidism in development of RAV-7-induced adiposity. 16.2.3 Borna Disease Virus
Borna disease virus (BDV) is an enveloped, nonsegmented, negative-stranded RNA virus belonging to the Mononegavirales order [48]. Although it can produce a strong immune response and can be fatal, it can persist in the nervous system with no major symptoms [49]. It causes encephalopathy in a broad range of animals, like horses, sheep, cattle, cats, and dogs [50]. Experimental infection with BDV has been reported in chicken, mice, rat, rabbit, hamster and rhesus monkey models [51, 52]. Infected rats show behavior changes and learning deficits [50]. In 1991, Gosztonyi et al. [53] described an obesity syndrome induced by BDV in rats. The induction of obesity was dependent on the age and genetic characteristics of the animals and the virus strain [16, 53]. Weanling or adult rats developed acute encephalitis 1–4 months postinfection. Two months later, surviving animals developed marked obesity. Obese rats had massive visceral fat deposition, with increased
16.2 Viruses
triglycerides and hyperplasia of islets of Langerhans, and a moderate increase in blood glucose [16]. It is believed that BDV-induced obesity may be due to inflammatory lesions and viral antigen expression in brain, especially in the hypothalamus, which is known to regulate body weight and food intake [54]. BDV received considerable attention when de la Torre demonstrated that it can infect the human brain, by detecting a BDV-specific antigen in four autopsied human brains [55]. Ludwig et al. [50] have since postulated that a cross-species transmission of BDV from animals to humans could occur. Although its pathogenesis is not yet clear, BDV as a pathogen once thought to only infect animals, indeed infects humans as well. BDV incidence in humans is reported worldwide: in the United Kingdom [56], Japan [57], China [58], Germany [59], and in the United States [60]. Seroprevalence in humans varies from 0 and 48% and viral prevalence from 0 to 82% [61]. Common human mental disorders like depression and schizophrenia are associated with the prevalence of BDV-specific antibodies [57–59, 62–64] and the presence of BDV RNA in the peripheral blood [65]. Chen et al. [62] provided some evidence for a possible human-to-human transmission of BDV infection by showing that the family members of psychiatric patients and mental health workers had a higher prevalence of BDVantibodies than the control population. However, Ferszt et al. [63] postulated that the higher prevalence of BDV antibodies in depressive patients may be a nonspecific aspect of immunosuppression. An association between obesity and mental depression is well documented [66–68], and some recent reports show that depression can predict weight gain [66, 69]. Although an association between BDV and human obesity has not been established, the role of BDV in depressed obese humans appears worth investigating. 16.2.4 Adenoviruses
Adenoviruses are nonenveloped DNA viruses with icosahedral symmetry and a diameter of 65–80 nm [70]. They were first isolated in 1953 by investigators trying to establish cell lines from the adenoidal tissue of children after tonsillectomies [71]. In nature, adenoviruses are widespread; infecting birds, mammals and humans. In humans, adenoviruses are frequently associated with acute upper respiratory tract infections, enteritis, or conjunctivitis. The presence of serum antibodies to various adenoviruses is common in the general population [72]. Adenoviral DNA has been detected in adult human lymphocytes and the number of these lymphocytes increases in correlation with the age of the person [73]. There are six major subgroups (A–F) among the 50 human adenoviruses maintained by the American Type Culture Collection. Each subgroup has a number of specific serotypes. The following is a brief description of four adenoviruses reported to cause obesity in animal models. 16.2.4.1 SMAM-1 The avian adenovirus SMAM-1 was discovered during a poultry epidemic in the early 1980s [74]. It is serologically related to the CELO (chick embryo lethal orphan) avian
j315
j 16 Viral Induction of Obesity and Adipogenesis
316
adenovirus. SMAM-1 causes adiposity in chickens. The peculiar features of its syndrome include increased adiposity and relative hypolipidemia. Chickens intranasally inoculated with SMAM-1 and their uninfected cagemates showed significantly greater adiposity, particularly in visceral fat depots (compared to separately housed control animals) [10, 14]. The development of adiposity in the uninfected cagemates of infected chickens adiposity suggested a horizontal transmission of the virus. Interestingly, the virally induced adiposity was accompanied by paradoxically lower serum cholesterol and triglycerides levels. The food intake of the chickens could not explain the adiposity [10, 14]. Subsequently, in 1997, Dhurandhar et al. [75] reported an association between SMAM-1 seropositivity and human obesity. Thus, it was the first virus reported to be associated with human obesity. Twenty percent of obese subjects screened had antibodies to SMAM-1. Seropositive subjects had a significantly greater body weight (95.1 2.1 versus 80.1 0.6 kg; P < 0.02), but 15% lower serum cholesterol and 60% lower serum triglycerides [75]. Avian adenoviruses, being serologically different from their human counterparts, have been thought to be incapable of infecting across species [76, 77]. Humans showing antibodies to an avian adenovirus challenges that view. It is also possible that the subjects of this study had antibodies to a human adenovirus that had cross-reacted with SMAM-1. Prevalence of SMAM-1 seropositivity in general population has not been reported. 16.2.4.2 Ad-36 Ad-36 was first isolated in 1978 in Germany from the feces of a 6-year-old girl with diabetes and enteritis [78]. Ad-36 infection was thought to be rare, but recent work indicates that 11–30% of the individuals screened in the United States are seropositive for Ad-36 antibodies [4]. In separate experiments, chicken, mice, rats, and marmosets (nonhuman primates) inoculated with human adenovirus Ad-36 developed a syndrome of increased adipose tissue, and paradoxically low levels of serum cholesterol and triglycerides [12, 13, 15, 79], without a significant change in food intake. The adipogenic effect was most pronounced in visceral fat depots. The amount of Ad-36 DNA present in visceral fat correlated with the amount of total visceral fat in the infected animals [12] (r ¼ 0.41, P < 0.03). When obesity was defined as body fat greater than or equal to the 85th percentile of that in the control group, 64–72% of the Ad-36-infected animals were considered obese versus only 18% in the uninfected controls Sections of the brain and hypothalamus of inoculated animals did not show any overt histopathological changes [13]. Subsequently, the avian adenovirus CELO, and two other human adenoviruses, Ad-2 and Ad-31, were shown to be nonadipogenic in animal models [4, 13]. Thus, the potential to promote obesity is not common to all adenoviruses. Post hoc screening of stored plasma samples from adult male rhesus monkeys housed at the Regional Primate Research Center in Wisconsin showed natural infection of animals with Ad-36 as indicated by development of neutralizing antibodies [15]. This spontaneous appearance of Ad-36 antibodies was followed by significant gain in weight and reduction in serum cholesterol in the year following
16.2 Viruses
the seroconversion compared to the year preceding it. This association with seroconversion is suggestive of the adipogenic consequence of natural Ad-36 infection. Interestingly, the human adenovirus Ad-36 appears to infect across a wide range of nonhuman hosts including chicken, mice, rats, marmosets, and rhesus monkeys [12, 13, 15, 79]. Although it showed causation or association with adiposity in these models, its effect on body weight of the host varied with the species (Table 16.1). Ad36-infected rats and mice showed 7% greater body weight compared to the uninfected controls, whereas infected chickens did not show greater body weight. The difference in body weights was greater for marmosets and rhesus monkeys (12 and 15%, respectively), but was the highest for humans (20%). The adipogenic mechanism of Ad-36 is unclear, but several in vitro and in vivo studies provide some insight about its molecular effects on adipose tissue metabolism. Recent studies show that Ad-36 has effects similar to those of thiazolidinediones (TZDs) – a class of antidiabetic drugs. Like TZDs, Ad-36 increases fat cell replication [80], differentiation [81], lipid accumulation [81], and insulin sensitivity [81, 82], and reduces leptin secretion and expression [82]. These effects were not observed with Ad-2 – a nonadipogenic human adenovirus. When infected, 3T3-L1 preadipocytes (mouse embryo-derived preadipocytes) and human primary preadipocytes show increased differentiation to adipocytes [81]. Ad-36 enhances lipid accumulation induced by differentiation inducers (Figure 16.1) and also induces it spontaneously even in the absence of inducers (Figure 16.2). Figure 16.2 shows that only Ad-36-infected human primary adipose tissue-derived stem cells (hASCs), as evident from the presence of viral proteins and bulging nucleus, show adipose differentiation-related protein (ADRP) – an early marker of adipose differentiation program and lipid presence [83]. The cells were not exposed to adipocyte inducers. Hence, as expected, the uninfected cells remained undifferentiated. After viral
Figure 16.1 Lipid accumulation in 3T3-L1 preadipocytes infected with Ad-36 in the presence of a cocktail of methylisobutylxanthine, dexamethasone, and insulin (MDI). (a) Mock infected. (b) Ad-36 infected. Confluent 3T3-L1 preadipocytes were infected with Ad-36, or mock
infected, and differentiation was induced by exposure to MDI. Cells were stained with lipidspecific fluorescent dye BODIPY (493/503). The figure shows a much greater number of lipidbearing cells in the Ad-36-infected group. (Reprinted with permission from [81].)
j317
j 16 Viral Induction of Obesity and Adipogenesis
318
Figure 16.2 Cells from the stromal vascular fraction of human adipose tissue were infected with Ad-36 with a multiplicity of infection of 3.8. Cells were fixed on day 9 postinfection in 4% paraformaldehyde and processed for immunofluorescence. Slides were mounted in ProLong Gold antifade reagent with DAPI (blue) (Invitrogen). Lipid droplets were identified using mouse monoclonal anti-ADRP antibodies (Research Diagnostics Inc.). AD-36 viral
particles were identified using anti-Ad-36 rabbit polyclonal antibodies. Secondary antibodies were anti-mouse Alexafluor 488 (green) (Invitrogen) and anti-rabbit Alexafluor 594 (red) (Invitrogen), respectively. (a) Cell nuclei stained with DAPI. (b) ADRP indicating lipid accumulation. (c) Viral proteins in and around a cell nucleus. (d) Overlay slide shows ADRP only in the cell that is infected with Ad-36, but not in the surrounding cells without virus.
inoculation, not all cells in a plate get infected with Ad-36 immediately. The experiment described in Figure 16.2 provided an excellent opportunity to compare onset of lipogenesis in uninfected and infected cells in the same plate. These data show that within the infected group of hASCs, lipogenesis is initiated as a direct consequence of Ad-36 infection. Although multiple pathways may explain the adipogenic effect of Ad-36, its prodifferentiation effect on preadipocytes appears to be a promising explanation. Association with Human Obesity Recently, prevalence of Ad-36 antibodies in 360 obese (body mass index (BMI) 30 kg/m2) and 142 non-obese (BMI < 30 kg/m2) subjects from Wisconsin, Florida, and New York was reported. Antibodies were more prevalent in obese subjects (30%) than in nonobese subjects (11%). The effect of Ad36 seropositivity on the risk of obesity was highly significant, and independent of age, sex, and the data collection site [4]. Interestingly, seropositive subjects, both obese and nonobese, had significantly greater BMI compared to their respective seronegative counterparts. Similarly, between human twins – who are generally believed to have
16.2 Viruses
similar body weight and fatness – Ad-36-seropositive twins had significantly greater body fat and BMI compared to their antibody-negative cotwins [4]. Globally speaking, the prevalence of Ad-36 antibodies in the human population appears to vary geographically. Only 5% of subjects screened in Denmark had antibodies to Ad-36 [84]. Ad-36 is a human virus that causes adiposity in several animal models and shows association with human obesity. This makes Ad-36 perhaps a leading candidate pathogen for determining its causative role in human obesity. Ethically, it is impossible to infect humans with the virus, which precludes an unequivocal demonstration of its causative role in human obesity. Therefore, such evidence must come from indirect approaches, such as determining the viral mechanism of action using tissue culture and animal models, and then applying that information to humans. 16.2.4.3 Ad-5 Ad-5 is a human adenovirus that causes respiratory tract infections in humans [85]. Recently, So et al. [18] showed that Ad-5 infection induces adiposity in mice, independent of their food intake. The infected group had a 2.8-fold increase in percentage of body fat measured by in vivo magnetic resonance spectroscopy. About 67% of the infected animals developed obesity against only 17% in the control group. This incidence of obesity was very similar to the 64–72% rate of obesity development observed for Ad-36 [12]. Although the authors suggested that increased preadipocyte differentiation (as in the case of Ad-36) may be responsible for the increase observed in body fat, no data to support this specific mechanism are available. Ad-5 is extensively used for gene therapy [86], because as a vector it is safe, efficient, and can accommodate large antigens encoding structure [87]. Although replicationdeficient virus is used as a vector, adipogenic potential of a replication deficient Ad-5 have not been reported. Such verification would greatly benefit researchers using Ad5 vectors to avoid potentially confounding adipogenic effects of the virus. 16.2.4.4 Ad-37 The human Ad-37 was discovered by de Jong in 1981 [88]. It causes keratoconjunctivitis and genitourinary tract infections in humans [88]. Whigham et al. [89] showed that Ad-37 causes adiposity in chickens, by an unknown mechanism. The visceral fat pads of infected chickens were 3 times heavier than those of the uninfected control group. Unlike Ad-36, it did not reduce serum cholesterol levels. Food intake could not explain the adiposity. 16.2.4.5 Adipogenic Potential of other Adenoviruses The adipogenic potential is not common to all adenoviruses. Thus far, reports show that human adenoviruses Ad-5, Ad-36, and Ad-37 are adipogenic, and Ad-2 and Ad-31 and avian adenovirus CELO are nonadipogenic [4, 13, 18, 89]. Unlike Ad-36, Ad-2 and Ad-31 did not show association with human obesity; the antibody prevalence between obese and nonobese subjects was similar (76 versus 81% for Ad-2 and 70 versus 80% for Ad-31). In contrast to the findings with Ad-36, BMIs and serum lipids were
j319
j 16 Viral Induction of Obesity and Adipogenesis
320
virtually identical for Ad-2 or Ad-31 regardless of the respective antibody status [4]. These findings are important – the almost equal distribution of seropositivity of Ad-2 and 31 between obese and nonobese subjects alike suggests that the greater prevalence of Ad-36 antibodies in obese subjects is most likely a cause, not result, of obesity. The adipogenic potential of the other serotypes is unknown. More information about the mode of action and elucidating viral mechanisms of adipogenesis may help in screening other serotypes for their adipogenic effects. Such a screening is important for the adenovirus class of viruses due to their high presence in the population and the use as vectors in research. 16.3 Chlamydia pneumoniae
Chlamydia are eubacteria that cause infection at some time in life for almost all humans [90]. It results in 10% of community acquired pneumonia, and 5% of bronchitis and sinusitis cases [91]. Chlamydia (Chlamydophila) pneumoniae is also the first bacteria reported to be associated with increased BMI in humans. Some studies have reported an association between C. pneumoniae infection and increased BMI [9, 92], while others have not found any relation [93–95]. Subjects positive for immunoglobulin G to C. pneumoniae had a significantly higher mean BMI compared to the seronegative subjects [9]. Ekesbo [92] reported that a group of subjects with a combined serology for C. pneumoniae and Helicobacter pylori had significantly higher BMI compared to the control group (27.3 versus 25.8 kg/m2). Greater age, lower socioeconomic status, and greater fasting levels of insulin also characterized the antibody-positive subjects. The authors of the study suggested that obesity might be a marker not only for lower social class but also for greater than normal susceptibility to such infections [92]. Obesity is associated with impaired immunity [96] and, as suggested by Ekesbo et al. [92], might be the indicator for increased susceptibility to H. pylori and C. pneumoniae infection [92]. However, Dart et al. [9] found no preponderance of antibodies to other types of Chlamydia (Chlamydia trachomatis and Chlamydia pssittaci) in the same subject population that showed an association of BMI with C. pneumoniae antibodies. This indicated that an increased BMI did not necessarily predispose subjects to catch a C. pneumoniae infection. Considering its widespread prevalence, to further determine the role of C. pneumoniae in obesity, experiments with animal models designed to investigate the adipogenic potential of C. pneumoniae as well as human sero-epidemeological data are needed. 16.4 Gut Microbiota
Gut microbiota is the collection of microorganisms that grow in the intestines. It is mostly composed of anaerobic bacteria, which are essential for processing dietary
16.5 Gut Parasites
polysaccharides. These bacteria act in symbiosis with the gut – consuming and distributing energy by processing nutrients otherwise inaccessible to humans [6]. Moreover, they fortify the mucosal barrier and stimulate angiogenesis [97–99]. Introduction of normal gut microbiota into the guts of 8- to 10-week-old germ-free mice caused insulin resistance, a 57% increase in total body fat with a 61% increase in epididymal fat, and a 7% decrease in lean mass [5] of the germ-free recipients. Serum lipid profiles did not change after microbial colonization. The age at intervention or the duration of colonization of the microbiota did not increase the effect on adipose tissue. Microbiota colonization resulted in a 27% decrease in metabolic rate of the animals and upregulation of the de novo fatty acid synthesis pathway, which may explain the observed weight gain without increased food intake. Microbial colonization of the gut suppressed fasting-induced adipocyte factor (FIAF), which is an inhibitor of lipoprotein lipase. Thus, suppression of FIAF was required to promote triglyceride deposition in adipocytes. Effects, if any, of gut microbiota on human body weight gain are unknown. However, the findings of Backhed et al. [5] demonstrate the ability of some nonpathogenic microbes to alter body composition and metabolism in a proadipogenic manner. In 2006, Turnbaugh et al. [19] demonstrated that the microbiota of the distal gut of genetically obese (ob/ob) mice have an increased ability to harvest energy from the diet. When the microbiota of these genetically obese mice were transmitted to colonize the gut of germ-free mice, the newly infected mice had a significantly increased level of total body fat than their germ-free counterparts colonized with microbiota from genetically lean mice. Moreover, the obese microbiota had a relative abundance of the Firmicutes versus the Bacteroidetes division of bacteria and the reverse was true with microbiota of the lean mice. In a companion publication, the same group [100] also reported that obese human subjects had a lesser proportion of Bacteroidetes than lean subjects. Weight loss on a low calorie diet increased the proportion of Bacteroidetes – a lean-type microbiota. This, according to the authors, suggests possibilities for microbe-based therapeutic intervention for obesity. Although these studies collectively suggest a novel role for gut microbiota in regulation of adipose tissue mass, the accompanying Editorial cautions about statistically significant, but biologically small gains in body fat of the mice receiving obese microflora [19]. Furthermore, it is inexplicable why the gut flora of obese subjects after weight loss change to those of lean subjects. It appears counterintuitive to see the change of the gut flora upon weight loss to less-efficient harvester of energy. Further research is required to answer these questions.
16.5 Gut Parasites
Dragonflies (Libellula pulchella) infected with a common, noninvasive gregarine gut parasite (Apicomplexa: Eugregarinorida) showed symptoms similar to the human metabolic syndrome [19]. Infected dragonflies developed significantly higher thoracic lipid accumulation, an inability to oxidize fatty acids in muscle tissue, 2-fold
j321
j 16 Viral Induction of Obesity and Adipogenesis
322
higher hemolyph carbohydrate concentrations than uninfected insects, increased insulin resistance, and elevated markers of a chronic inflammatory state. To isolate the effects of the gregarine parasite itself, healthy dragonflies were fed water with small amounts of excretory-secretory products (ESP s) from live gregarines. Two days of exposure to gregarine ESP s caused an elevation in hemolyph carbohydrate concentrations compared with control dragonflies (receiving regular water), comparable to the difference between healthy and gregarine infected dragonflies. This indicated that factors secreted by the parasites in the midgut in infected insects were responsible for the changes in hemolyph glucose concentrations [101]. The sister taxon of gregarine parasites, Cryptosporidium, shows similar symptoms in AIDS-infected humans. HIV-seropositive males with AIDS-defining diagnoses of Cryptosporidium infections had reduced resting energy expenditure and fat oxidation, and increased carbohydrate oxidation and nonprotein respiratory quotient in comparison with subjects with other AIDS-defining diagnoses (microsporidiosis, Pneumocystis carinii pneumonia, cytomegalovirus enteritis, and Mycobacterium avium-intracellulare) [102]. While the specific relation of cryptosporidiosis and obesity is not clear, it is of relevance that a parasite analogous to gregarine can result in similar metabolic changes in humans.
16.6 Scrapie Agents
Scrapie is a neurodegenerative disease with a long incubation period, known to occur in sheep and goats, and it can also infect mice and other small rodents [103]. Although the main manifestation of scrapie infections is abnormal behavior and motor dysfunction, certain scrapie strains induce obesity in experimentally infected mice. Weight increase in scrapie-infected animals was observed as a preclinical manifestation as early as 1968 by Pattison [104], and was followed by observations by Outram and Markovits in 1972 and 1981, respectively [105, 106]. The weight increase was due to fat accumulation and not edema [106, 107]. Regardless of the mouse strain, the scrapie strain ME7 injected in the hypothalamus induced obesity 12 weeks postinfection [17, 107–109]. This effect was also observed for the 22L [17, 107], but not for 139A [17, 107–109] or 22A scrapie strains [107]. Weight gain in ME7-infected mice paralleled increased food consumption [109]. The weight gain appeared 67 days postinfection and continued throughout the preclinical phase of the disease [109]. Unexpectedly, there was also an increase in food consumption in nonadipogenic scrapie strain 139A-infected mice, which did not become obese, suggesting possibly separate mechanisms for the increases in food consumption and weight [109]. Involvement of the brain is strongly implicated in scrapie-induced obesity. Kim et al. [17] speculated that scrapie-induced obesity is related to changes in central nervous system and neuroendocrine dysfunction. Role of brain function alterations was further supported by the findings of Vorbrodt et al. [110], who reported a decrease in glucose transporter 1 (GLUT1) density in certain brain regions, and reduced
16.7 Interaction of Pathogens and Adipose Tissue
glucose tolerance and hyperglycemia in ME7-infected mice. Glucose is of critical importance for normal functioning of the nervous system and impaired glucose transport may lead to impaired brain function. The authors recommend further studies to elucidate the regional difference in GLUT1 expression and the effect on brain function [110]. In addition to the role of higher centers, a role for a hypothalamic–pituitary–adrenal axis-mediated mechanism for scrapie-induced obesity has been suggested [109]. The adrenals in scrapie-induced obese mice were significantly larger than controls [109] and adrenalectomy performed before ME7 injection prevented weight gain in mice, which supports the hypothesis. A role, if any, of scrapie agents in human obesity has not been reported.
16.7 Interaction of Pathogens and Adipose Tissue
Although a causative role of certain infections in obesity is a relatively novel concept, the involvement of adipose tissue with modulators and mediators of immune response is well documented. For instance, Cousin et al. [111] showed that preadipocytes function like macrophages, and possess phagocytic and microbicidal activity. Leptin, an adipocyte-secreted hormone involved in body weight regulation, also enhances the proliferation and activation of human circulating T lymphocytes and stimulates cytokine production [112]. In addition, adipocytes themselves secrete various cytokines [113, 114], and, in turn, preadipocytes and adipocytes are subject to cytokine-directed modulations [115, 116]. Combs et al. [117] showed that adipocytes provide a chronic reservoir for Trypanosoma cruzi parasites, which attracts influx of macrophages to adipose tissue and also modulates adipokine secretion. With such an extensive interaction between the immune system and adipose tissue, the expansion of the latter in response to particular infections is certainly conceivable. For instance, macrophage colony-stimulating factor (M-CSF), which promotes the production of macrophages, is also secreted by adipocytes and, when overexpressed in vivo, induces significant adipose tissue hyperplasia [118]. It is unknown if obesity promoting pathogens stimulate M-CSF production leading to the growth of adipose tissue. M-CSF is an example of a proinflammatory cytokine. The relationship of infections with inflammation is well known. A recent body of evidence shows an association of obesity with cytokines and markers of inflammation. Elevated levels of interleukin6 [119] and C-reactive proteins (CRPs) [120] are observed in obese individuals. Interestingly, Duncan et al. [121] showed that markers of inflammation can predict weight gain in middle-aged adults. It remains to be determined if inflammation is a cause or effect of obesity, and whether a pathogenic infection leads to inflammation and consequent increase in adiposity. Recently, Fernandez-Real et al. [122] showed that in healthy middle-aged men, burden of infection was positively correlated with fat mass. Total seropositivity for herpes simplex virus 1 and 2, C. pneumoniae, and enteroviruses contributed to 9% of fat mass variance, independent of age and CRP. The authors concluded that either the subjects with greater fat mass were more
j323
j 16 Viral Induction of Obesity and Adipogenesis
324
susceptible to contracting multiple infections, or the exposure to multiple infections increases fat mass [122]. In a closely related study, the same team of researchers also showed that in healthy middle-aged men, the burden of infection due to these same pathogens was independently and negatively related to insulin sensitivity [123]. The authors hypothesized that exposure to multiple infections may cause a chronic lowgrade inflammation and result in insulin resistance.
16.8 Adipogenic Pathogens and Humans
Although some of the aforementioned adipogenic pathogens are conventionally considered to be nonhuman pathogens, the possible use of a human host by these pathogens cannot be ruled out. Such was the case with BDV, which was originally considered to be a virus of horses and sheep, but now shows clear evidence of human infections [16, 50, 55, 61]. Similarly, humans show antibodies to SMAM-1, the adipogenic avian adenovirus [75]. Moreover, human adenovirus Ad-36 is not fastidious about a host species, and infects chickens, mice, nonhuman primates, rats, and hamsters [12–14, 79]. A change of host by pathogens has been well documented. For instance, CDV changed the host to infect feline species and considerably reduced the lion population in the Serengeti [124]. Therefore, nonhuman adipogenic pathogens cannot be guaranteed to be nonpathogenic for humans. Although several pathogens have been unequivocally shown to cause obesity in animal models, determining their contribution to human obesity is of great significance – and a challenge. Unlike animal models, humans cannot be experimentally infected with these pathogens due to ethical reasons. This limitation precludes any direct demonstration of a cause-and-effect relationship between a pathogen and adiposity, and the evidence of such must be only indirect and circumstantial. The insidious onset of obesity makes it difficult to link to a particular episode of infection experienced in the past. Moreover, if an adipogenic pathogen uses a hit-and-run mechanism to induce obesity, it may be undetectable in the body by the time the adiposity is noticed. Weight of mounting indirect evidence will be required to convincingly establish such a relationship. Using animal and tissue culture models to elucidate the adipogenic mechanism of a pathogen may help considerably in understanding its role in human obesity.
16.9 Conclusions
The rapid increase in obesity, its comorbidities, and associated healthcare costs have prompted a search for better approaches for its prevention and management [125]. Such efforts may be facilitated by better understanding the etiology of obesity. Of its many etiological factors [22], the viral etiology of obesity was first reported in 1982 [23], followed by several reports of adipogenic pathogens. Some of these
References
pathogens are associated with human obesity [4, 9, 126], but their causative role in human obesity has not been established. In addition to treatment, prevention could be a long-term goal of researchers investigating infectobesity. Vaccines against adipogenic pathogens could be expected to provide protection specifically against obesity due to specific pathogens. In summary, infectobesity (obesity of infectious origin) would be a novel, yet significant concept, if it is shown to be relevant to humans. An adequate understanding of infectobesity is needed if we are to understand the implications of adipogenic pathogens and, thereof, treatment for the better management of obesity. A new perspective on the infectious etiology of obesity may stimulate additional research to assess the contribution of hitherto unknown pathogens in human obesity and possibly to prevent or treat obesity of infectious origins.
Acknowledgments
This work was partly supported by NIH grant 1R01 DK066164-01 awarded to N.V.D.
References 1 Astrup, A., Lundsgaard, C., and Stock,
2
3
4
5
6
7
M.J. (1998) Is obesity contagious? Int. J. Obes. Relat. Metab. Disord., 22, 375–376. Powledge, T.M. (2004) Is obesity an infectious disease? Lancet Infect. Dis., 4, 599. Rossner, S. (2005) Can obesity be an infectious disease? Lakartidningen, 102, 1896–1898. Atkinson, R.L., Dhurandhar, N.V., Allison, D.B., Bowen, R.L., Israel, B.A. Albu, J.B. et al. (2005) Human adenovirus-36 is associated with increased body weight and paradoxical reduction of serum lipids. Int. J. Obes. Relat. Metab. Disord., 29, 281–286. Backhed, F., Ding, H., Wang, T., Hooper, L.V., Koh, G.Y. Nagy, A. et al. (2004) The gut microbiota as an environmental factor that regulates fat storage. Proc. Natl. Acad. Sci. USA, 101, 15718–15723. Backhed, F., Ley, R.E., Sonnenburg, J.L., Peterson, D.A., and Gordon, J.I. (2005) Host–bacterial mutualism in the human intestine. Science, 307, 1915–1920. Carter, J.K., Garlich, J.D., Donaldson, W.E., and Smith, R.E. (1983) Influence of diet on a retrovirus-induced obesity and
8
9
10
11
12
stunting syndrome. Avian Dis., 27, 317–322. Carter, J.K., Ow, C.L., and Smith, R.E. (1983) Rous-associated virus type 7 induces a syndrome in chickens characterized by stunting and obesity. Infect Immun., 39, 410–422. Dart, A.M., Martin, J.L., and Kay, S. (2002) Association between past infection with Chlamydia pneumoniae and body mass index, low-density lipoprotein particle size and fasting insulin. Int. J. Obes. Relat. Metab. Disord., 26, 464–468. Dhurandhar, N., Kulkarni, P., Ajinkya, S., and Sherikar, A. (1990) Avian adenovirus leading to pathognomonic obesity in chicken. J. Bom. Vet. College, 2, 131–132. Dhurandhar, N.V. (2004) Contribution of pathogens in human obesity. Drug News Perspect., 17, 307–313. Dhurandhar, N.V., Israel, B.A., Kolesar, J.M., Mayhew, G., Cook, M.E., and Atkinson, R.L. (2001) Transmissibility of adenovirus-induced adiposity in a chicken model. Int. J. Obes. Relat. Metab. Disord., 25, 990–996.
j325
j 16 Viral Induction of Obesity and Adipogenesis
326
13 Dhurandhar, N.V., Israel, B.A., Kolesar,
14
15
16
17
18
19
20
21
22
23
24
J.M., Mayhew, G.F., Cook, M.E., and Atkinson, R.L. (2000) Increased adiposity in animals due to a human virus. Int. J. Obes. Relat. Metab. Disord., 24, 989–996. Dhurandhar, N.V., Kulkarni, P., Ajinkya, S.M., and Sherikar, A. (1992) Effect of adenovirus infection on adiposity in chicken. Vet. Microbiol., 31, 101–107. Dhurandhar, N.V., Whigham, L.D., Abbott, D.H., Schultz-Darken, N.J., Israel, B.A. Bradley, S.M. et al. (2002) Human adenovirus Ad-36 promotes weight gain in male rhesus and marmoset monkeys. J. Nutr., 132, 3155–3160. Gosztonyi, G. and Ludwig, H. (1995) Borna disease – neuropathology and pathogenesis. Curr. Top. Microbiol. Immunol., 190, 39–73. Kim, Y.S., Carp, R.I., Callahan, S.M., and Wisniewski, H.M. (1987) Scrapieinduced obesity in mice. J. Infect. Dis., 156, 402–405. So, P.W., Herlihy, A.H., and Bell, J.D. (2005) Adiposity induced by adenovirus 5 inoculation. Int. J. Obes. Relat. Metab. Disord., 29, 603–606. Turnbaugh, P.J., Ley, R.E., Mahowald, M.A., Magrini, V., Mardis, E.R., and Gordon, J.I. (2006) An obesity-associated gut microbiome with increased capacity for energy harvest. Nature, 444, 1027–1031. James, P.T., Leach, R., Kalamara, E., and Shayeghi, M. (2001) The worldwide obesity epidemic. Obes. Res., 9 (Suppl. 4), 228S–233S. Mokdad, A.H., Ford, E.S., Bowman, B.A., Dietz, W.H., Vinicor, F. Bales, V.S. et al. (2003) Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001. JAMA, 289, 76–79. Sclafani, A. (1984) Animal models of obesity: classification and characterization. Int. J. Obes., 8, 491–508. Lyons, M.J., Faust, I.M., Hemmes, R.B., Buskirk, D.R., Hirsch, J., and Zabriskie, J.B. (1982) A virally induced obesity syndrome in mice. Science, 216, 82–85. Rozenblatt, S., Eizenberg, O., Ben-Levy, R., Lavie, V., and Bellini, W.J. (1985)
25
26
27
28
29
30
31
32
33
34
Sequence homology within the morbilliviruses. J. Virol., 53, 684–690. Vandevelde, M. and Zurbriggen, A. (1995) The neurobiology of canine distemper virus infection. Vet. Microbiol., 44, 271–280. Yamanouchi, K. (1980) Comparative aspects of pathogenicity of measles, canine distemper, and rinderpest viruses. Jpn. J. Med. Sci. Biol., 33, 41–66. Leisewitz, A.L., Carter, A., van Vuuren, M., and van Blerk, L. (2001) Canine distemper infections, with special reference to South Africa, with a review of the literature. J. S. Afr. Vet. Assoc., 72, 127–136. Raine, C.S. (1976) On the development of CNS lesions in natural canine distemper encephalomyelitis. J. Neurol. Sci., 30, 13–28. Summers, B.A. and Appel, M.J. (1994) Aspects of canine distemper virus and measles virus encephalomyelitis. Neuropathol. Appl. Neurobiol., 20, 525–534. Vandevelde, M. and Kristensen, B. (1977) Observations on the distribution of canine distemper virus in the central nervous system of dogs with demyelinating encephalitis. Acta Neuropathol., 40, 233–236. Hall, W.W., Lamb, R.A., and Choppin, P.W. (1980) The polypeptides of canine distemper virus: synthesis in infected cells and relatedness to the polypeptides of other morbilliviruses. Virology, 100, 433–449. Bernard, A., Fevre-Montange, M., Bencsik, A., Giraudon, P., Wild, T.F. Confavreux, C. et al. (1993) Brain structures selectively targeted by canine distemper virus in a mouse model infection. J. Neuropathol. Exp. Neurol., 52, 471–480. Bernard, A., Fevre-Montange, M., Giraudon, P., Hardin, H., Wild, T.F., and Belin, M.F. (1991) Demonstration of viral proteins and RNA in hypothalamus of mice infected by canine distemper virus. C. R. Acad. Sci. III, 313, 545–551. Bernard, A., Zwingelstein, G., Meister, R., and Wild, T.F. (1988) Hyperinsulinemia induced by canine
References
35
36
37
38
39
40
41
42
43
44
distemper virus infection of mice and its correlation with the appearance of obesity. Comp. Biochem. Physiol. B, 91, 691–696. Sixt, N., Cardoso, A., Vallier, A., Fayolle, J., Buckland, R., and Wild, T.F. (1998) Canine distemper virus DNA vaccination induces humoral and cellular immunity and protects against a lethal intracerebral challenge. J. Virol., 72, 8472–8476. Wild, T.F., Bernard, A., Spehner, D., Villeval, D., and Drillien, R. (1993) Vaccination of mice against canine distemper virus-induced encephalitis with vaccinia virus recombinants encoding measles or canine distemper virus antigens. Vaccine, 11, 438–444. Bernard, A., Cohen, R., Khuth, S.T., Vedrine, B., Verlaeten, O. Akaoka, H. et al. (1999) Alteration of the leptin network in late morbid obesity induced in mice by brain infection with canine distemper virus. J. Virol., 73, 7317–7327. Verlaeten, O., Griffond, B., Khuth, S.T., Giraudon, P., Akaoka, H. Belin, M.F. et al. (2001) Down regulation of melanin concentrating hormone in virally induced obesity. Mol. Cell. Endocrinol., 181, 207–219. Nagashima, K., Zabriskie, J.B., and Lyons, M.J. (1992) Virus-induced obesity in mice: association with a hypothalamic lesion. J. Neuropathol. Exp. Neurol., 51, 101–109. Oldstone, M.B., Sinha, Y.N., Blount, P., Tishon, A., Rodriguez, M. von Wedel, R. et al. (1982) Virus-induced alterations in homeostasis: alteration in differentiated functions of infected cells in vivo. Science, 218, 1125–1127. Fadly, A.M. (1997) Avian retroviruses. Vet. Clin North Am. Food Anim. Pract., 13, 71–85. Vogt, P.K. and Hu, S.S. (1977) The genetic structure of RNA tumor viruses. Annu. Rev. Genet, 11, 203–238. Duff, R.G. and Vogt, P.K. (1969) Characteristics of two new avian tumor virus subgroups. Virology, 39, 18–30. Carter, J.K. and Smith, R.E. (1984) Specificity of avian leukosis virusinduced hyperlipidemia. J. Virol., 50, 301–308.
45 Mikami, S.I. and Ono, K. (1962)
46
47
48
49
50
51
52
53
54
Glucagon deficiency induced by extirpation of alpha islets of the fowl pancreas. Endocrinology, 71, 464–473. Carter, J.K. and Smith, R.E. (1983) Rapid induction of hypothyroidism by an avian leukosis virus. Infect Immun., 40, 795–805. Hoch, F.L. (1974) Metabolic effects of thyroid hormones, Handbook of Physiology, Section 7: Endocrinology (eds M.A. Greer and D.H. Solomon), American Physiological Society, Washington, DC, pp. 391–441. Kishi, M., Tomonanaga, K., Lai, P., and De la Torre, J.C. (2002) Borna disease virus molecular virology, in Borna Disease Virus and its Role in Neurobehavioral Disease (ed. K.M. Carbone), ASM Press, Washington, DC, pp. 23–44. Pletnikov, M., Gonzales-Dunia, D., and Stitz, L. (2002) Experimental infection: pathogenesis of neurobehavioral disease, in Borna Disease Virus and its Role in Neurobehavioral Disease (ed. K.M. Carbone), ASM Press, Washington, DC, pp. 125–178. Ludwig, H. and Bode, L. (2000) Borna disease virus: new aspects on infection, disease, diagnosis and epidemiology. Rev. Sci. Tech., 19, 259–288. Ludwig, H., Bode, L., and Gosztonyi, G. (1988) Borna disease: a persistent virus infection of the central nervous system. Prog. Med. Virol., 35, 107–151. Richt, J.A., VandeWoude, S., Zink, M.C., Clements, J.E., Herzog, S. Stitz, L. et al. (1992) Infection with Borna disease virus: molecular and immunobiological characterization of the agent. Clin. Infect Dis., 14, 1240–1250. Gosztonyi, G., Kao, M., Bode, L., and Ludwig, H. (1991) Obesity syndrome in experimental infection of rats with Borna disease virus. Clin. Neuropathol., 10, 33–34. Herden, C., Herzog, S., Richt, J.A., Nesseler, A., Christ, M. Failing, K. et al. (2000) Distribution of Borna disease virus in the brain of rats infected with an obesity-inducing virus strain. Brain Pathol., 10, 39–48.
j327
j 16 Viral Induction of Obesity and Adipogenesis
328
55 De La Torre, J.C., Gonzalez-Dunia, D.,
56
57
58
59
60
61
62
63
Cubitt, B., Mallory, M., Mueller-Lantzsch, N. Grasser, F.A. et al. (1996) Detection of borna disease virus antigen and RNA in human autopsy brain samples from neuropsychiatric patients. Virology, 223, 272–282. Thomas, D.R., Chalmers, R.M., Crook, B., Stagg, S., Thomas, H.V. Lewis, G. et al. (2005) Borna disease virus and mental health: a cross-sectional study. Q. J. Med., 98, 247–254. Terayama, H., Nishino, Y., Kishi, M., Ikuta, K., Itoh, M., and Iwahashi, K. (2003) Detection of anti-Borna Disease Virus (BDV) antibodies from patients with schizophrenia and mood disorders in Japan. Psychiatry Res., 120, 201–206. Yang, A.Y., Zhang, F.M., Li, J.H., Li, G.M., Ma, P.L. Gu, H.X. et al. (2003) Detection of Borna disease virus-p24 specific antibody in the sera of schizophrenic patients of China by means of Westernblot. Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi, 17, 85–87. Bechter, K., Herzog, S., Fleischer, B., Schuttler, R., and Rott, R. (1987) Findings with nuclear magnetic resonance tomography in psychiatric patients with and without serum antibodies to the virus of Borna disease. Nervenarzt, 58, 617–624. Kao, M., Hamir, A.N., Rupprecht, C.E., Fu, Z.F., Shankar, V. Koprowski, H. et al. (1993) Detection of antibodies against Borna disease virus in sera and cerebrospinal fluid of horses in the USA. Vet. Rec., 132, 241–244. Chalmers, R.M., Thomas, D.R., and Salmon, R.L. (2005) Borna disease virus and the evidence for human pathogenicity: a systematic review. Q. J. Med., 98, 255–274. Chen, C.H., Chiu, Y.L., Wei, F.C., Koong, F.J., Liu, H.C. Shaw, C.K. et al. (1999) High seroprevalence of Borna virus infection in schizophrenic patients, family members and mental health workers in Taiwan. Mol. Psychiatry, 4, 33–38. Ferszt, R., Severus, E., Bode, L., Brehm, M., Kuhl, K.P. Berzewski, H. et al. (1999)
64
65
66
67
68
69
70
71
72
73
Activated Borna disease virus in affective disorders. Pharmacopsychiatry, 32, 93–98. Richt, J.A., Pfeuffer, I., Christ, M., Frese, K., Bechter, K., and Herzog, S. (1997) Borna disease virus infection in animals and humans. Emerg. Infect Dis., 3, 343–352. Chen, C.H., Chiu, Y.L., Shaw, C.K., Tsai, M.T., Hwang, A.L., and Hsiao, K.J. (1999) Detection of Borna disease virus RNA from peripheral blood cells in schizophrenic patients and mental health workers. Mol. Psychiatry, 4, 566–571. Franko, D.L., Striegel-Moore, R.H., Thompson, D., Schreiber, G.B., and Daniels, S.R. (2005) Does adolescent depression predict obesity in black and white young adult women? Psychol. Med., 35, 1505–1513. Lee, E.S., Kim, Y.H., Beck, S.H., Lee, S., and Oh, S.W. (2005) Depressive mood and abdominal fat distribution in overweight premenopausal women. Obes. Res., 13, 320–325. Sjoberg, R.L., Nilsson, K.W., and Leppert, J. (2005) Obesity, shame, and depression in school-aged children: a population-based study. Pediatrics, 116, e389–e392. Hasler, G., Pine, D.S., Kleinbaum, D.G., Gamma, A., Luckenbaugh, D. Ajdacic, V. et al. (2005) Depressive symptoms during childhood and adult obesity: the Zurich Cohort Study. Mol. Psychiatry, 10, 842–850. Pereira, H.G., Huebner, R.J., Ginsberg, H.S., and Van Der Veen, J. (1963) A short description of the adenovirus group. Virology, 20, 613–620. Rowe, W.P., Huebner, R.J., Gilmore, L.K., Parrott, R.H., and Ward, T.G. (1953) Isolation of a cytopathogenic agent from human adenoids undergoing spontaneous degeneration in tissue culture. Proc. Soc. Exp. Biol. Med., 84, 570–573. Foy, H.M. and Grayston, J.T. (1976) Adenoviruses, in Viral infections of Humans: Epidemiology and Control (ed. S. Evans Alfred), Plenum Medical, New York, pp. 53–70. Horvath, J., Palkonyay, L., and Weber, J. (1986) Group C adenovirus DNA
References
74
75
76
77
78
79
80
81
82
83
84
sequences in human lymphoid cells. J. Virol., 59, 189–192. Ajinkya, S. (1985) ICAR: Final Technical Report, Red and Blue Cross Publishing, Bombay, pp. 13–43. Dhurandhar, N.V., Augustus, A.S., and Atkinson, R.L. (1997) Evidence of an association of a virus with obesity in humans. FASEB J., 3, A230. Asch, B.B., McCormick, K.J., and Trentin, J.J. (1979) Unusual features of the oncogenicity of chicken embryo lethal orphan (CELO) virus in hamsters. Prog. Exp. Tumor Res., 23, 56–88. McFerran, J.B., Adair, B., and Connor, T.J. (1975) Adenoviral antigens (CELO, QBV, GAL). Am. J. Vet. Res., 36, 527–529. Wigand, R., Gelderblom, H., and Wadell, G. (1980) New human adenovirus (candidate adenovirus 36), a novel member of subgroup D. Arch. Virol., 64, 225–233. Pasarica, M., Shin, A.C., Yu, M., Ou Yang, H.M., Rathod, M. Jen, K.L. et al. (2006) Human adenovirus 36 induces adiposity, increases insulin sensitivity, and alters hypothalamic monoamines in rats. Obesity, 14, 1905–1913. Pasarica, M., Holland, T., and Dhurandhar, N. (2005) Enhanced cell cycle activation by adenovirus 36 contributes to increased lipid accumulation in 3T3-L1 cells. FASEB J., 19, A67. Vangipuram, S.D., Sheele, J., Atkinson, R.L., Holland, T.C., and Dhurandhar, N.V. (2004) A human adenovirus enhances preadipocyte differentiation. Obes. Res., 12, 770–777. Vangipuram, S.D., Yu, M., Tian, J., Stanhope, K.L., Pasarica, M. Havel, P.J. et al. (2007) Adipogenic human adenovirus-36 reduces leptin expression and secretion and increases glucose uptake by fat cells. Int. J. Obes., 31, 87–96. Gao, J. and Serrero, G. (1999) Adipose differentiation related protein (ADRP) expressed in transfected COS-7 cells selectively stimulates long chain fatty acid uptake. J. Biol. Chem., 274, 16825–16830. Raben, A., Haulrik, N., Dhurandhar, N., Atkinson, R., and Astrup, A. (2001) Minor role of human adenovirus 36 in the
85
86
87
88
89
90
91
92
93
94
obesity epidemic in Denmark. Int. J. Obes., 25 (Suppl. 2), S46. Horwitz, M. (1996) Adenoviruses, in Fields Virology, 3rd edn (eds B. Fields, D. Knipe and P. Howley), Lippincott-Raven, Philadelphia, PA, pp. 2149–2171. Kanerva, A. and Hemminki, A. (2005) Adenoviruses for treatment of cancer. Ann. Med., 37, 33–43. Wu, Q., Xia, D., Carlsen, S., and Xiang, J. (2005) Adenovirus-mediated transgeneengineered dendritic cell vaccine of cancer. Curr. Gene Ther., 5, 237–247. de Jong, J.C., Wigand, R., Wadell, G., Keller, D., Muzerie, C.J. Wermenbol, A.G. et al. (1981) Adenovirus 37: identification and characterization of a medically important new adenovirus type of subgroup D. J. Med. Virol., 7, 105–118. Whigham, L.D., Israel, B.A., and Atkinson, R.L. (2006) Adipogenic potential of multiple human adenoviruses in vivo and in vitro in animals. Am. J. Physiol. Regul. Integr. Comp. Physiol., 290, R190–R194. Hogan, R.J., Mathews, S.A., Mukhopadhyay, S., Summersgill, J.T., and Timms, P. (2004) Chlamydial persistence: beyond the biphasic paradigm. Infect Immun., 72, 1843–1855. Kuo, C.C., Jackson, L.A., Campbell, L.A., and Grayston, J.T. (1995) Chlamydia pneumoniae (TWAR). Clin. Microbiol. Rev., 8, 451–461. Ekesbo, R., Nilsson, P.M., Lindholm, L.H., Persson, K., and Wadstrom, T. (2000) Combined seropositivity for H. pylori and C. pneumoniae is associated with age, obesity and social factors. J. Cardiovasc. Risk, 7, 191–195. Blanc, P., Corsi, A.M., Gabbuti, A., Peduzzi, C., Meacci, F. Olivieri, F. et al. (2004) Chlamydia pneumoniae seropositivity and cardiovascular risk factors: the InCHIANTI Study. J. Am. Geriatr Soc., 52, 1626–1631. Falck, G., Gnarpe, J., Hansson, L.O., Svardsudd, K., and Gnarpe, H. (2002) Comparison of individuals with and without specific IgA antibodies to Chlamydia pneumoniae: respiratory
j329
j 16 Viral Induction of Obesity and Adipogenesis
330
95
96
97
98
99
100
101
102
103
104
morbidity and the metabolic syndrome. Chest, 122, 1587–1593. Muller, J., Moller, D.S., Kjaer, M., Nyvad, O., Larsen, N.A., and Pedersen, E.B. (2003) Chlamydia pneumoniae DNA in peripheral blood mononuclear cells in healthy control subjects and patients with diabetes mellitus, acute coronary syndrome, stroke, and arterial hypertension. Scand. J. Infect Dis., 35, 704–712. Tanaka, S., Inoue, S., Isoda, F., Waseda, M., Ishihara, M. Yamakawa, T. et al. (1993) Impaired immunity in obesity: suppressed but reversible lymphocyte responsiveness. Int. J. Obes. Relat. Metab. Disord., 17, 631–636. Hooper, L.V., Stappenbeck, T.S., Hong, C.V., and Gordon, J.I. (2003) Angiogenins: a new class of microbicidal proteins involved in innate immunity. Nat. Immunol., 4, 269–273. Hooper, L.V., Wong, M.H., Thelin, A., Hansson, L., Falk, P.G., and Gordon, J.I. (2001) Molecular analysis of commensal host–microbial relationships in the intestine. Science, 291, 881–884. Stappenbeck, T.S., Hooper, L.V., and Gordon, J.I. (2002) Developmental regulation of intestinal angiogenesis by indigenous microbes via Paneth cells. Proc. Natl. Acad. Sci. USA, 99, 15451–15455. Ley, R.E., Backhed, F., Turnbaugh, P., Lozupone, C.A., Knight, R.D., and Gordon, J.I. (2005) Obesity alters gut microbial ecology. Proc. Natl. Acad Sci. USA, 102, 11070–11075. Schilder, R.J. and Marden, J.H. (2006) Metabolic syndrome and obesity in an insect. Proc. Natl. Acad. Sci. USA, 103, 18805–18809. Sharpstone, D., Phelan, M., and Gazzard, B. (2000) Differential metabolic response in AIDS-related chronic protozoal diarrhoea. HIV Med., 1, 102–106. Hunter, G.D. (1972) Scrapie: a prototype slow infection. J. Infect Dis., 125, 427–440. Pattison, I.H. and Jones, K.M. (1968) Modification of a strain of mouse-adapted scrapie by passage through rats. Res. Vet. Sci., 9, 408–410.
105 Markovits, P., Dormont, D., Delpech, B.,
106
107
108
109
110
111
112
113
114
Court, L., and Latarjet, R. (1981) [Trials of in vitro propagation of the scrapie agent in mouse nerve cells]. C. R. Seances Acad. Sci. III, 293, 413–417. Outram, G.W. (1972) Changes in drinking and feeding habits of mice with experimental scrapie. J. Comp. Pathol., 82, 415–427. Carp, R.I., Callahan, S.M., Sersen, E.A., and Moretz, R.C. (1984) Preclinical changes in weight of scrapie-infected mice as a function of scrapie agent–mouse strain combination. Intervirology, 21, 61–69. Carp, R.I., Meeker, H., Sersen, E., and Kozlowski, P. (1998) Analysis of the incubation periods, induction of obesity and histopathological changes in senescence-prone and senescenceresistant mice infected with various scrapie strains. J. Gen. Virol., 79, 2863–2869. Kim, Y.S., Carp, R.I., Callahan, S.M., and Wisniewski, H.M. (1988) Adrenal involvement in scrapie-induced obesity. Proc. Soc. Exp. Biol. Med., 189, 21–27. Vorbrodt, A.W., Dobrogowska, D.H., Tarnawski, M., Meeker, H.C., and Carp, R.I. (2001) Quantitative immunogold study of glucose transporter (GLUT-1) in five brain regions of scrapie-infected mice showing obesity and reduced glucose tolerance. Acta Neuropathol., 102, 278–284. Cousin, B., Munoz, O., Andre, M., Fontanilles, A.M., Dani, C. Cousin, J.L. et al. (1999) A role for preadipocytes as macrophage-like cells. FASEB J., 13, 305–312. Martin-Romero, C., Santos-Alvarez, J., Goberna, R., and Sanchez-Margalet, V. (2000) Human leptin enhances activation and proliferation of human circulating T lymphocytes. Cell. Immunol., 199, 15–24. Fried, S.K., Bunkin, D.A., and Greenberg, A.S. (1998) Omental and subcutaneous adipose tissues of obese subjects release interleukin-6: depot difference and regulation by glucocorticoid. J. Clin. Endocrinol. Metab., 83, 847–850. Sewter, C.P., Digby, J.E., Blows, F., Prins, J., and ORahilly, S. (1999) Regulation of
References
115
116
117
118
119
120
121
122
123
tumour necrosis factor-alpha release from human adipose tissue in vitro. J. Endocrinol., 163, 33–38. Gregoire, F., De Broux, N., Hauser, N., Heremans, H., Van Damme, J., and Remacle, C. (1992) Interferon-gamma and interleukin-1 beta inhibit adipoconversion in cultured rodent preadipocytes. J. Cell. Physiol., 151, 300–309. Kras, K.M., Hausman, D.B., and Martin, R.J. (2000) Tumor necrosis factor-alpha stimulates cell proliferation in adipose tissue-derived stromal-vascular cell culture: promotion of adipose tissue expansion by paracrine growth factors. Obes. Res., 8, 186–193. Combs, T.P. Nagajyothi, Mukherjee, S., de Almeida, C.J., Jelicks, L.A., Schubert, W. et al. (2005) The adipocyte as an important target cell for Trypanosoma cruzi infection. J. Biol. Chem, 280, 24085–24094. Levine, J.A., Jensen, M.D., Eberhardt, N.L., and OBrien, T. (1998) Adipocyte macrophage colony-stimulating factor is a mediator of adipose tissue growth. J. Clin. Invest, 101, 1557–1564. Roytblat, L., Rachinsky, M., Fisher, A., Greemberg, L., Shapira, Y. Douvdevani, A. et al. (2000) Raised interleukin-6 levels in obese patients. Obes. Res., 8, 673–675. Visser, M., Bouter, L.M., McQuillan, G.M., Wener, M.H., and Harris, T.B. (1999) Elevated C-reactive protein levels in overweight and obese adults. JAMA, 282, 2131–2135. Duncan, B.B., Schmidt, M.I., Chambless, L.E., Folsom, A.R., Carpenter, M., and Heiss, G. (2000) Fibrinogen, other putative markers of inflammation, and weight gain in middle-aged adults – the ARIC study. Atherosclerosis Risk in Communities. Obes. Res., 8, 279–286. Fernandez-Real, J.M., Ferri, M.J., Vendrell, J., and Ricart, W. (2007) Burden of infection and fat mass in healthy middle-aged men. Obesity, 15, 245–252. Fernandez-Real, J.M., Lopez-Bermejo, A., Vendrell, J., Ferri, M.J., Recasens, M., and Ricart, W. (2006) Burden of infection and insulin resistance in healthy middle-aged men. Diabetes Care, 29, 1058–1064.
124 Morell, V. (1996) New virus variant killed
Serengeti cats. Science, 271, 596. 125 World Health Organization (2000)
126
127
128
129
130
131
132
133
Obesity: Preventing and Managing the Global Epidemic. Report of a WHO Consultation. Technical Report Series 894, WHO, Geneva. Dhurandhar, N.V., Kulkarni, P.R., Ajinkya, S.M., Sherikar, A.A., and Atkinson, R.L. (1997) Association of adenovirus infection with human obesity. Obes. Res., 5, 464–469. Anderton, P., Wild, T.F., and Zwingelstein, G. (1983) Measles-viruspersistent infection in BGM cells. Modification of the incorporation of [3H] arachidonic acid and [14C]stearic acid into lipids. Biochem. J., 214, 665–670. Anderton, P., Wild, T.F., and Zwingelstein, G. (1983) Accumulation of radiolabelled fatty acids in the neutral lipid fraction of measles virus persistently infected BGM cells. Biochem. Biophys. Res. Commun., 112, 29–34. Bencsik, A., Malcus, C., Akaoka, H., Giraudon, P., Belin, M.F., and Bernard, A. (1996) Selective induction of cytokines in mouse brain infected with canine distemper virus: structural, cellular and temporal expression. J. Neuroimmunol., 65, 1–9. Griffond, B., Verlaeten, O., Belin, M.F., Risold, P.Y., and Bernard, A. (2004) Specific alteration of the expression of selected hypothalamic neuropeptides during acute and late mouse brain infection using a morbillivirus: relevance to the late-onset obesity? Brain Res., 1022, 173–181. Wild, T.F., Bernard, A., Malak, N.A., Brichon, G., and Zwinglestein, G. (1986) Imprints of virus infection: can paramyxoviruses permanently modify triacylglycerol metabolism? Lipids, 21, 608–611. Caligiuri, G., Rottenberg, M., Nicoletti, A., Wigzell, H., and Hansson, G.K. (2001) Chlamydia pneumoniae infection does not induce or modify atherosclerosis in mice. Circulation, 103, 2834–2838. Amsterdam, J.D., Winokur, A., Dyson, W., Herzog, S., Gonzalez, F. Rott, R. et al. (1985) Borna disease virus. A possible
j331
j 16 Viral Induction of Obesity and Adipogenesis
332
etiologic factor in human affective disorders? Arch. Gen. Psychiatry, 42, 1093–1096. 134 Danesh, J., Collins, R., and Peto, R. (1997) Chronic infections and coronary heart disease: is there a link? Lancet, 350, 430–436. 135 Kuo, C.C., Shor, A., Campbell, L.A., Fukushi, H., Patton, D.L., and Grayston, J.T. (1993) Demonstration of Chlamydia pneumoniae in atherosclerotic lesions of coronary arteries. J. Infect. Dis., 167, 841–849. 136 Saikku, P., Leinonen, M., Mattila, K., Ekman, M.R., Nieminen, M.S. Makela,
P.H. et al. (1988) Serological evidence of an association of a novel Chlamydia, TWAR, with chronic coronary heart disease and acute myocardial infarction. Lancet, ii, 983–986. 137 Bajzer, M. and Seeley, R.J. (2006) Physiology: obesity and gut flora. Nature, 444, 1009–1010. 138 Carp, R.I. and Kim, Y.S. (1989) Callahan SM. Scrapie-induced alterations in glucose tolerance in mice. J. Gen. Virol., 70, 827–835. 139 Pasarica, M. and Dhurandhar, N.V. (2007) Infectobesity: obesity of infectious origin. Adv. Food Nutr. Res., 52, 61–102.
j333
17 Adipose Tissue Cachexia Michael John Tisdale 17.1 Introduction
Patients with cancer cachexia show a progressive loss of body weight due to selective depletion of skeletal muscle and stores of adipose tissue. Studies on the body composition of cachectic cancer patients show that even in severe wasting a considerable proportion of body fat is retained (the maximum fat loss observed was 50%) and loss of body weight was predominantly due to loss of skeletal muscle, while nonmuscle tissue, including the visceral fraction, did not change [1]. However, body fat is lost more rapidly than lean tissue in progressive cancer cachexia [2]. Plasma levels of unesterified fatty acids have been shown to be higher in patients with neoplastic disease [3], and cancer patients with weight loss have increased glycerol and fatty acid turnover compared with normal subjects or cancer patients without weight loss [4]. Fasting levels of plasma glycerol have also been shown to be higher in weight-losing cancer patients compared with weight-stable individuals, providing evidence for an increase in lipolysis [5]. Studies in nude mice show that depletion of carcass lipid is a function of tumor type and not tumor burden, suggesting that tumors produce substances that induce lipid depletion in cachexia [6]. This would explain why glucose administration in normal individuals suppresses lipid mobilization, while in patients with malignant diseases there is impaired suppression and continued oxidation of fatty acids [7].
17.2 Changes in Adipose Tissue in Cachexia
Most of these studies have been carried out in mice with cachexia, where there is extensive loss of white adipose tissue (WAT). Such tissue contains shrunken adipocytes, which are heterogeneous in size, and there is increased fibrosis [8]. The small adipocytes show severe delipidation and modifications in cell membrane conformation. The mitochondria differ from typical WATmitochondria, are electron
j 17 Adipose Tissue Cachexia
334
Table 17.1 Changes in mRNA and protein levels of adipogenic transcription factors and other proteins in cachexia.
Decreases
Increases
C/EBP-a and -b PPAR-c SREBP-1c acetyl-CoA carboxylase glycerol-3-phosphate acyl transferase GLUT4 leptin inhibitory GTP-binding protein (Gai) UCP-2 stimulatory GTP-binding protein (Gas)
dense, and have increased cristae. There are major reductions in both mRNA and protein levels of adipogenic transcription factors including CCAAT/enhancer-binding protein (C/EBP)-a and -b, peroxisome proliferator-activated receptor (PPAR)-c, and sterol regulatory element-binding protein (SREBP)-1c. Levels of mRNA for acetyl-CoA carboxylase, stearoyl-CoA desaturase-1, and glycerol-3-phosphatase acyl transferase, targets of SREBP-1c, also fell, as did glucose transporter 4 (GLUT4) and leptin (Table 17.1). Levels of uncoupling protein (UCP)-2 increased. These changes point to an impairment not only in the lipid storage capacity of adipocytes in cancer cachexia, but also the ability to differentiate. Adipocyte differentiation is controlled by a myriad of transcription factors that are activated in a sequential manner [9]. Initially, C/EBP-b and -d are transiently activated, and these then activate the expression of PPAR-c, which in turn stimulates C/EBP-a expression, which synergizes with PPARc in controlling terminal differentiation. Differentiation is enhanced by SREBP-1c, which activates transcription of PPAR-c [10]. C/EBP-a deficiency in mice leads to greatly reduced body fat, and adipocytes lacking C/EBP-a accumulate less lipid, cannot induce PPAR-c expression, and there is also a complete absence of insulinstimulated glucose transport [11]. Thus, the decreased expression of adipogenic transcription factors in cancer cachexia would disrupt recruitment and maintenance of the adipocyte phenotype. The decrease in GLUT4 mRNA would suggest an altered glucose metabolism and adipose tissue of cachectic mice has been shown to use glucose at only one-third of the rate of noncachectic animals [12]. Glucose consumption by the brain is also decreased in response to the increased glucose utilization by the tumor and the brain adapts to use ketone bodies derived from fat metabolism, as in starvation. There is evidence that adipocytes from cachetic mice as well as humans with cancer cachexia have an increased response to lipolytic stimuli [13]. Patients with weight loss show an increased sensitivity to adrenaline compared with weight-stable subjects, and also show increased plasma and urinary catecholamines, elevated heart rate, and increased oxidation of fatty acids [5]. The effect has been attributed to an enhanced stimulation of adenylyl cyclase, due to an increased expression of the stimulatory GTP-binding protein (Gas) and a decrease in the inhibitory form (Gai) [13]. Similar changes were noted in both mice and humans with cachexia. The changes in
17.3 Energy Expenditure in Cancer Patients
G-protein expression were induced in WAT from normal mice by a tumor-produced lipid-mobilizing factor (LMF) (see Section 17.7), suggesting that such factors not only directly stimulate lipolysis, but also sensitizes adipocytes to other lipolytic stimuli. There may be changes in lipid metabolism in cancer patients, even when there is no overt cachexia. Thus, in the sera of patients with gynecological cancer, not generally considered to be associated with cachexia, there is an elevated lipolysis promoting activity, which increased the level of hormone-sensitive lipase (HSL) in normal adipocytes [14]. The increased mobilization and use of fat in cancer patients may be due to the increased metabolic demands of the tumor. Fat constitutes 90% of the energy reserves in birds and mammals, because of the high calorific value of lipid (39.1 kJ/g), compared with carbohydrate (15.4–17.5 kJ/g). Also, in contrast to carbohydrate, triacylglycerols can be stored with very little associated water.
17.3 Energy Expenditure in Cancer Patients
In normal subjects, the basal metabolic rate (BMR) decreases in response to a decrease in food intake (e.g., in chronic starvation). Thus, in cachectic cancer patients with a reduced food intake, the BMR would be expected to be also reduced. However, a number of studies have reported that cancer patients have an increased resting energy expenditure (REE) compared with either weight-losing or weight-stable controls [15]. The major determinant of an increased energy expenditure appears to be the type of tumor [16]. Thus, while patients with pancreatic [17] and lung cancer [16] showed an increase in REE, compared with healthy controls, patients with gastric and colorectal cancer showed no such elevation in REE [16]. Although REE has been shown to be increased in patients with pancreatic cancer, both the total energy expenditure (TEE) and physical activity level (PAL) have been shown to be reduced [18], reflecting the patients lack of ability to move to any significant extent, and a poor quality of life. Also in patients with pancreatic cancer the REE was significantly greater in patients with an acute-phase response [17], possibly reflecting an increased metabolic demand on the liver for the synthesis of acute-phase proteins, as well as for reactions due to proinflammatory cytokines. There are also increased metabolic demands due to futile cycling in cancer patients. Warburg was the first to observe that tumors have an increased demand for glucose for energy production. This is probably due to the tumor microenvironment, where oxygen levels are low and insufficient for mitochondrial oxidative phosphorylation to operate effectively. In this case tumors switch to an anaerobic conversion of glucose to lactate, which is highly energy inefficient yielding only 2 mol ATP/mol glucose consumed, compared with 38 mol ATP in the presence of oxygen [19]. The lactate is released from the tumor and transported to the liver where it is converted back into glucose (Cori cycle). This is also an energy consuming process requiring 6 mol ATP to convert 2 mol lactate back into glucose. The Cori cycle has been calculated to account for an additional loss of energy in the order of 300 kcal/ day [20]. Other substrates also contribute to the increased gluconeogenesis seen in
j335
j 17 Adipose Tissue Cachexia
336
cancer patients including glycerol, which is released from adipose tissue during lipolysis, and some amino acids, which are released from skeletal muscle due to an increase in protein degradation. Weight-losing cancer patients show a 40% increase in hepatic glucose production compared with controls, in contrast with patients with anorexia nervosa who show reduced levels [21]. There are also other metabolic changes leading to an increased energy utilization in cachexia. Thus, cachectic mice show an elevation of the triacylglycerol/fatty acid substrate cycle [22]. In the process of lipolysis one molecule of triacylglycerol is hydrolyzed to three molecules of nonesterified fatty acids (NEFAs) and one molecule of glycerol. However, in mice bearing a cachexia-inducing tumor a high proportion of the NEFA is immediately re-esterified, contributing to an increased energy demand. Energy may also be lost as heat through uncoupling of respiration from phosphorylation of ADP. The UCPs achieve this by facilitating proton leakage across the inner mitochondrial membrane. In mice, the major UCP involved in thermoregulation is UCP-1 found in BAT, although adult humans have been reported to have little, if any, BAT. However, a single study [23] that examined samples of periadrenal tissue by light microscopy revealed the presence of BAT in 80% of the samples from cachectic cancer patients, compared with 13% in age-matched controls. In humans another uncoupling protein, UCP-3, found in skeletal muscle is likely to play an equivalent role to UCP-1 in energy balance and lipid metabolism. In transgenic mice overexpressing UCP-3 in skeletal muscle there was a large reduction in adipose tissue mass, accompanied by a reduction in body weight, even though they were hyperphagic [24]. Cancer patients with weight loss have been reported to have a 5-fold increase in the levels of mRNA for UCP-3 in skeletal muscle compared with controls and cancer patients that had not lost weight [25]. This increase in UCP-3 would be expected to enhance energy expenditure, and may account for nightly sweating [19]. In experimental mice bearing a cachexia-inducing tumor levels of mRNA for UCP-1 in BAT and UCP-3 in skeletal muscle were also significantly increased [26]. The higher rate of energy expenditure in such animals was shown by a 2-fold increase in oxidation of infused lipid to CO2, in comparison with animals bearing a tumor of the same type, which did not induce cachexia, as well as non-tumor-bearing controls [27].
17.4 Factors Governing Adipose Tissue Mass
The mass of adipose tissue is governed by the rate of synthesis of triacylglycerol from exogenous and endogenous NEFAs, and the rate of hydrolysis back to NEFAs and glycerol. Synthesis of NEFAs can arise from excess carbohydrate in the diet and they are also transported from the liver to adipose tissue as triglyceride-rich lipoproteins, such as chylomicrons and very-low-density lipoprotein. The enzyme lipoprotein lipase (LPL) is responsible for the movement of fatty acids from the blood into the adipocytes by hydrolyzing the triglyceride-rich lipoproteins, so making them available for triacylglycerol synthesis. Leptin is a neuropeptide secreted from adipocytes that modulates food intake and energy balance through its actions at specific
17.5 Mechanism of Loss of Adipose Tissue in Cachexia
receptors in the hypothalamus. Cytokines such as tumor necrosis factor (TNF)-a and interleukin (IL)-1 and -6 increase ob gene expression and leptin secretion and decrease food intake resulting in a decrease in adipose mass [28]. Leptin causes loss of fat without a rise in NEFAs or ketones. It does this by decreasing expression of fatty acid synthase, while increasing PPAR-a and the enzymes of fatty acid oxidation, and stimulates release of glycerol without a proportional release of NEFAs [29]. Lipolysis is regulated by a number of hormonal and paracrine and/or autocrine signals. The key rate-limiting step in this reaction is the hydrolysis of triacylglycerol by the enzyme HSL. Another enzyme, adipose triglyceride lipase (ATGL), removes the first fatty acid from the triacylglycerol molecule generating NEFA and a diacylglycerol, while HSL degrades diacylglycerol into monoacylglycerol and NEFA. Thus, ATGL and HSL act coordinately in hydrolyzing triacylglycerol stores, and are responsible for more than 95% of the triacylglycerol hydrolase activity present in WAT [30]. HSL is activated by phosphorylation through protein kinase A (PKA), which in turn is activated by cAMP. Hormone production of cAMP is stimulated as a consequence of G-protein-coupled receptors acting through adenylyl cyclase. G-protein-coupled receptors can also activate mitogen-activated protein kinase (MAPK) and extracellular signal-regulated kinase (ERK) pathways. Activated ERK also increases lipolysis by phosphorylating HSL at Ser600 – one of the sites phosphorylated by PKA [31]. TNF-a has been shown to stimulate lipolysis in human adipocytes through stimulation of MAPK and ERK [32]. However, it also decreased the expression of cAMP phosphodiesterase by 50%, suggesting a mechanism by which it could increase cAMP. In contrast to HSL, ATGL is not a target for PKAmediated phosphorylation, but is regulated by an activator protein known as a/bhydrolase domain containing-5, also known as comparative gene identification (CGI)-58. CGI-58 is bound to perilipin A, which protects triacylglycerol stores from lipolysis. After lipolytic stimulation CGI-58 is released from perilipin A and becomes available for binding to ATGL, causing an increase in triacylglycerol hydrolysis.
17.5 Mechanism of Loss of Adipose Tissue in Cachexia
The primary mechanism for the depletion of triacylglycerol in adipose tissue appears to arise from an increase in HSL [33]. Although some studies have reported a decrease in plasma LPL in patients with cancer cachexia [34], other studies [33] have reported no change in either the total LPL or the relative level of mRNA for LPL in adipose tissue of cancer patients compared with controls. Lipogenesis from glucose in WATwas increased 6-fold in the tumor-bearing state, but this was not related to the development of cachexia [35]. Most studies report an increase in serum levels of triacylglycerol and NEFA, despite evidence of an increased lipid utilization, since the rate of removal of infused lipids from the blood is increased in cachectic cancer patients [36]. The increased lipolysis in cachectic cancer patients has been suggested to arise in part from an increased b-adrenoreceptor activity [37]. Thus oral administration of the specific b1 receptor blocker atenolol, as well as the nonspecific b1/b2-
j337
j 17 Adipose Tissue Cachexia
338
adrenoreceptor blocker propanolol, was found to significantly reduce REE, wholebody oxygen uptake, and CO2 production in weight-losing cancer patients. Such patients also show an increased sensitivity to adrenaline, and have increased plasma and urinary catecholamines, elevated heart rate, and increased fat oxidation [5]. These results suggest that stimulation of HSL in the adipocytes of cachectic cancer patients may be mediated through a b-adrenoreceptor. In rats with experimentally induced cachexia, anorexia is not related to changes in leptin, since both serum leptin levels and leptin mRNA in adipose tissue decreased prior to a drop in food intake [38]. In both mice and humans, leptin levels are generally proportional to the body fat content and decrease with loss of adipose mass. However, in weight-losing patients undergoing surgery for colorectal cancer omental WAT leptin mRNA levels were found to be decreased, while subcutaneous WAT showed higher levels of leptin mRNA than the same tissue of weight-stable patients [39].
17.6 Requirements of Tumor-Bearing Animals for Lipids
As already discussed, the energy demands in the tumor-bearing state are increased, resulting in an increased oxidation of lipids to CO2. It is unlikely that the tumor oxidizes lipid to any great extent, because of the low oxygen tension, but there may be a need for NEFAs, primarily polyunsaturated fatty acids (PUFAs), as growth signals to promote tumor growth. The subcutaneous adipose tissue of patients with ovarian and endometrial tumors contains a lower concentration of linoleic acid than that found in cancer-free subjects, suggesting selective loss of this PUFAs in the cancerbearing state [40]. Linoleic acid has been shown to stimulate tumor growth, both in vitro and in vivo, when the level exceeded 3.8% of the total calorie intake [41]. The stimulatory effect was attenuated by inhibitors of both cyclooxygenase and lipoxygenase (LOX). Arachidonic acid has also been shown to stimulate tumor growth [41] and malignant prostatic tissue has been found to contain lower levels of this PUFAs than benign tissue, which may be due to an increase in metabolism [42]. The critical metabolic pathway seems to occur by transformation through the 12- or 15-LOX to 12 (S)- or 15(S)-hydroxyeicosatetraneoic acids (HETEs), since LOX inhibitors induce apoptotic death in tumor cells, which can be partially inhibited by exogenous 12(S)- or 15(S)-HETEs [43]. The LOX inhibitor CV-6504 has been shown to have profound antitumor activity against murine tumors, which are generally refractory to cytotoxic agents [44].
17.7 Fat-Mobilizing Substances in Cancer Cachexia
The tumor and the hosts need for increased lipid utilization would favor those tumors capable of mobilizing triacylglycerol from adipose tissue. The first report
17.7 Fat-Mobilizing Substances in Cancer Cachexia
indicating that nonviable preparations of Krebs-2 carcinoma were able to induce fat depletion in vivo, in a manner similar to that of viable preparations, came in 1962 [45]. This suggested that tumor metabolism alone was not responsible for the atrophy of adipose tissue. Since then substances capable of inducing lipolysis in adipose tissue have been found to be produced by the murine tumors, Ehrlich ascites carcinoma [46], a thymic lymphoma [47], sarcoma 180 [48], MAC16 adenocarcinoma [49], and rabbit VX2 carcinoma [50]. Such LMFs are not confined to animal tumors. A LMF has been isolated from human A375 melanoma cells [51], in the ascites fluid of patients with hepatoma [52], in the sera and ascites fluid of patients with ovarian cancer [14], and in the serum and urine of cancer patients with weight loss [53]. A linear relationship was obtained between LMF activity and weight loss. In addition, LMF activity was reduced in cancer patients responding to therapy, suggesting a tumor origin [54]. It is not clear whether the LMFs from the different sources are the same material or a group of related substances, since the isolated materials differ in molecular weight. All, however, have been shown to have an overall negative charge – a unique feature of LMFs, since the natural lipolytic hormones such as adrenaline and glucagon all have positive charges. The best-characterized LMF is that produced by the MAC16 tumor, which appears to be identical with a LMF isolated from the urine of cachectic cancer patients [55]. Both materials have an apparent Mr of 43 kDa and sequence analysis showed them to be identical to a known protein, zinc a2-glycoprotein (ZAG), the function of which was previously unknown. Expression of ZAG in mouse tumors was found to correlate with the depletion of carcass lipids when they were transplanted into mice. Pure ZAG was found to stimulate lipolysis at the same concentrations as LMF, through stimulation of adenylate cyclase in a GTP-dependent process [55]. Both LMF [55] and ZAG [56] produced weight loss when administered to obese or ex-breeder mice, without a reduction in food and water intake. Loss of body weight was entirely due to loss of adipose tissue with no effect on lean body mass. There was a 3-fold increase in oxygen consumption by interscapular BAT, suggesting an increase in thermogenesis [55]. This was accompanied by an increase in expression of UCP-1. The increase in plasma NEFA may contribute to the increased expression of UCP-1 in BAT. However, in vitro experiments showed that ZAG induced a concentration-dependent increase in the expression of UCP-1 in primary cultures of BAT [57]. In addition, there were increases of between 2.5- and 3.5-fold in the expression of UCP-3 and UCP-2 in murine myotubes. These results confirm that ZAG is not only capable of stimulating lipolysis through activation of HSL, but also increases the utilization of the released NEFA through an increased level of UCPs in BAT and skeletal muscle. Evidence has been presented that both LMF [58] and ZAG [56] induce lipolysis in adipocytes through interaction with a b3-adrenoreceptor. This observation correlates with the clinical observation that lipolysis occurs through a b-adrenoreceptor [57]. Induction of UCP-3 in skeletal muscle occurs through a MAPK pathway rather than through a b3-adrenoreceptor [57]. Other studies have also shown that chronic treatment of mice with a specific b3-adrenoreceptor agonist markedly increased the expression of UCP-1 in BAT [59]. b-Agonists are known to stimulate skeletal muscle hypertrophy in animals, and studies with both LMF [55] and ZAG [56] show a
j339
j 17 Adipose Tissue Cachexia
340
tendency to increase lean body mass despite the loss of adipose tissue. LMF has been shown to stimulate protein synthesis in murine myotubes in vitro through an increase in intracellular cAMP, since it was attenuated by inhibition of adenylate cyclase and by an antagonist of the b3-adrenoreceptor [60]. There was also a decrease in protein catabolism mediated through the ubiquitin–proteasome proteolytic pathway. LMF was shown to increase the energy utilization of mice [61], producing a significant increase in oxidation of both glucose and triolein to CO2. Thus, the increased oxidation of lipid in cachectic cancer patients probably arises from the production of LMF. Although ZAG was known to be produced by the liver and cachexia-inducing tumors, recent evidence [62] suggests that it is also expressed in WATand BAT. There was a 10-fold increase in mRNA levels of ZAG in WATof mice with cachexia, that had lost 61% of their fat mass. ZAG mRNA levels in BATwere also increased 3-fold, while liver ZAG mRNA was increased 2-fold in comparison with non-tumor-bearing controls. In contrast, leptin mRNA was suppressed 33-fold, while adiponectin mRNA levels remained unchanged. Expression of ZAG mRNA levels in 3T3-L1 adipocytes was enhanced 3.3-fold with a b3-adrenoreceptor agonist and 55-fold with the synthetic glucocorticoid dexamethasone. Further studies have shown ZAG to increase its own expression through a b3-adrenoreceptor-mediated pathway [63]. Upregulation of ZAG expression during cachexia is probably due to increased cortisol production, since in a murine cachexia model the increase in ZAG expression in WAT could be blocked by the glucocorticoid receptor antagonist RU38 486 [63]. ZAG was also shown to upregulate its own expression, and this was attenuated by the b3-adrenoreceptor antagonist SR59 230A, suggesting that it was mediated through a b3-adrenoreceptor. Eicosapentaenoic acid (EPA), which has been shown to preserve adipose tissue in cachectic mice, caused downregulation of ZAG expression through interference with glucocorticoid signaling [64]. EPA has also been shown to attenuate lipolysis in WAT, by preventing stimulation of adenylyl cyclase, through an inhibitory guanine nucleotide-binding protein [65]. In home-living cachectic patients, with advanced pancreatic cancer, receiving an energy- and protein-dense oral supplement containing EPA, there was an increase in TEE and PAL [18]. The increased PAL may reflect an improved quality of life, but this most likely arises from an ability of EPA to preserve lean body mass. Patients receiving megestrol acetate gain weight through an increase in adipose tissue and water, but there is no effect on fat-free mass [66]. As a result, such patients show no improvement in the Karnofsky index – a measure of the activity level. This suggests that agents only attenuating the increased lipolysis may not be sufficient for the treatment of cancer cachexia.
17.8 Conclusion
Mobilization of triacylglycerol from adipose tissue in the cachectic state is indicative of the increased energy demands imposed by the tumor. The ability of tumors to produce LMF may be a general phenomenon and not restricted to those where gross
17.8 Conclusion
loss of adipose tissue is evident. LMF caused upregulation of UCP-2 in tumor cells, which is thought to be involved in the detoxification of free radicals and reduced the growth-inhibitory effect of free radical generators [67]. During the past 15 years evidence has been provided that in addition to its lipid storage capacity, WAT is capable of releasing a growing number of products into the blood stream. It now seems that in addition to production of LMF by certain tumors, WAT is a key player in this process, producing a specific LMF, ZAG, which in turn is able to stimulate
Figure 17.1 Interactions between tumor, WAT, BAT, skeletal muscle, and liver in the cachetic state. TG-LP, triglyceride-rich lipoprotein; AR, adrenoreceptor; other abbreviations are given in the text [69].
j341
j 17 Adipose Tissue Cachexia
342
lipolysis. It thus joins a growing list of adipokines that signal changes in the mass of WAT and energy status to other organs that control fuel usage. These also include TNF-a and IL-1b and -6, which are potent inhibitors of LPL, while TNF-a also suppresses key enzymes that contribute to lipogenesis and opposes the recruitment/ differentiation of mature adipocytes [68]. The interaction between these factors is not known, but the combined effect is likely to lead to extensive depletion of ZAG in WAT in the cachectic state. An overview of this process is provided in Figure 17.1 [69].
References 1 Yasumura, S., Cortes, E., and Vartsky, D.
2
3
4
5
6
7
8
(1981) Compartmental body composition of cancer patients by measurement of total body nitrogen, potassium and water. Metabolism, 30, 222–229. Fouladium, M., Korner, U., Bosaeus, I., Daneryd, P., Hyltander, A., and Lundholm, K.G. (2005) Body composition and time course changes in regional distribution of fat and lean tissue in unselected cancer patients in palliative care – correlations with food intake, metabolism, exercise capacity and hormones. Cancer, 103, 2189–2198. Mueller, P.S. and Watkin, M.D. (1961) Plasma unesterified fatty acid concentrations in neoplastic disease. J. Lab. Clin. Med., 57, 95–108. Shaw, J.H. and Wolfe, R.R. (1987) Fatty acid and glycerol kinetics in septic patients and in patients with gastrointestinal cancer. Ann. Surg., 205, 368–372. Drott, C., Persson, H., and Lundholm, K. (1989) Cardiovascular and metabolic response to adrenaline infusion in weightlosing patients with and without cancer. Clin. Physiol., 9, 427–439. Hollander, D.M., Ebert, E.C., Roberts, A.L., and Devereux, D.F. (1986) Effects of tumor type and burden on carcass lipid depletion in mice. Surgery, 100, 292–296. Edmondson, J.H. (1966) Fatty acid mobilization and glucose metabolism in patients with cancer. Cancer, 19, 277–282. Bing, C., Russell, S., Becket, E., Pope, M., Tisdale, M.J., Trayhurn, P., and Jenkins, J.K. (2006) Adipose atrophy in cancer cachexia: morphologic and molecular analysis of adipose tissue in tumourbearing mice. Br. J. Cancer, 95, 1028–1037.
9 Mandrup, S. and Lane, M.D. (1997)
10
11
12
13
14
15
Regulating adipogenesis. J. Biol. Chem., 272, 5367–5370. Fajas, L., Schoonjanz, K., Gelman, L., Kim, J.B., Najib, I., Martin, G., Fruchart, J.C., and Briggs, M. et al. (1999) Regulation of peroxisome proliferator-activated receptor gamma expression by adipocyte differentiation and determination fatcor 1/sterol regulatory element binding protein 1. Implication for adipocyte differentiation and metabolism. Mol. Cell. Biol., 19, 5495–5503. Wu, Z., Rosen, E.D., Brun, R., Hauser, S., Adelmant, G., Troy, A.E., McKeon, C., and Darlington, G.J. et al. (1999) Crossregulation of C/EBP alpha and PPAR gamma controls the transcriptional pathway of adipogenesis and insulin sensitivity. Mol. Cell, 3, 151–158. Mulligan, H.D. and Tisdale, M.J. (1991) Metabolic substrate utilisation by tumor and host tissues in cancer cachexia. Biochem. J., 277, 321–326. Islam-Ali, B., Khan, S., Price, S.A., and Tisdale, M.J. (2001) Modulation of adipocyte G-protein expression in cancer cachexia by a lipid-mobilizing factor (LMF). Br. J. Cancer, 85, 758–763. Gercel-Taylor, C., Doering, D.L., Kraemer, F.B., and Taylor, D.D. (1996) Aberrations in normal systemic lipid metabolism in ovarian cancer patients. Gynecol. Oncol., 66, 35–41. Hyltander, A., Drott, C., K€ orner, U., Sandstrom, R., and Lundholm, K. (1991) Elevated energy expenditure in cancer patients with solid tumors. Eur. J. Cancer, 27, 9–15.
References 16 Fredrix, E.W.H.M., Soeters, P.B., Wouters,
17
18
19
20
21
22
23
24
25
E.F.M., Deerenberg, I.M., von Meyerfeldt, M.F., and Saris, W.H.M. (1990) Energy balance in relation to cancer cachexia. Clin. Nutr., 9, 319–324. Falconer, J.S., Fearon, K.C.H., Plester, C.E., Ross, J.A., and Carter, D.C. (1994) Cytokines, the acute-phase response and resting energy expenditure in cachectic patients with pancreatic cancer. Ann. Surg., 219, 325–331. Moses, A.G.W., Slater, C., Preston, T., Barber, M.D., and Fearon, K.C.H. (2004) Reduced total energy expenditure and physical activity in cachectic patients with pancreatic cancer can be modulated by an energy and protein dense oral supplement enriched with n-3 fatty acids. Br. J. Cancer, 90, 991–1002. Bongaerts, G.P.A., van Halteren, H.K., Verhagen, C.A.M., and Wagener, D.J.Th. (2006) Cancer cachexia demonstrates the energetic impact of gluconeogenesis in human metabolism. Med. Hypothesis, 67, 1213–1222. Eden, E., Edstr€ om, S., Bennegard, K., Schersten, T., and Lundholm, K. (1984) Glucose flux in relation to energy expenditure in malnourished patients with and without cancer during periods of fasting and feeding. Cancer Res., 44, 1718–1724. Tayek, J.A. (1992) A review of cancer cachexia and abnormal glucose metabolism in humans with cancer. J. Am. Coll. Nutr., 11, 445–450. Beck, S.A. and Tisdale, M.J. (2004) Effect of cancer cachexia on triacylglycerol/fatty acid substrate cycling in white adipose tissue. Lipids, 39, 1187–1189. Shellock, F.G., Riedinger, M.S., and Fishbein, M.C. (1986) Brown adipose tissue in cancer patients. Possible cause of cancer-induced cachexia. J. Cancer Res. Clin. Oncol., 111, 82–85. Clapham, J.C., Arch, J.R.S., Chapman, H., Haynes, A., Lister, C., Moore, G.B.T., Piercy, V. et al. (2000) Mice overexpressing human uncoupling protein-3 in skeletal muscle are hyperphagic and lean. Nature, 406, 415–418. Collins, P., Bing, C., McColloch, P., and Williams, G. (2002) Muscle UCP-3 mRNA
26
27
28
29
30
31
32
33
34
levels are elevated in weight loss associated with gastrointestinal adenocarcinoma in humans. Br. J. Cancer, 86, 372–375. Bing, C., Brown, M., King, P., Collins, P., Tisdale, M.J., and Williams, G. (2000) Increased gene expression of brown fat uncoupling protein (UCP)1 and skeletal muscle UCP2 and UCP3 in MAC16induced cancer cachexia. Cancer Res., 60, 2405–2410. Mulligan, H.D., Beck, S.A., and Tisdale, M.J. (1992) Lipid metabolism in cancer cachexia. Br. J. Cancer, 66, 57–61. Grunfeld, C., Zhao, C., Fuller, J., Pollock, A., Moser, A., Friedman, J., and Feingold, K.R. (1996) Endotoxin and cytokines induce expression of leptin, the ob gene product in hamsters. J. Clin. Invest., 92, 2152–2157. Wang, M.-Y., Lee, Y., and Unger, R.H. (1999) Novel form of lipolysis induced by leptin. J. Biol. Chem., 274, 17541–17544. Schweiger, M., Schreiber, R., Haemmerle, G., Lass, A., Fledelius, C., Jacobren, P., Torngvist, H., Zechner, R., and Zimmerman, R. (2006) Adipose triglyceride lipase and hormone-sensitive lipase are the major enzymes in adipose tissue triacylglycerol catabolism. J. Biol. Chem., 281, 40236–40241. Greenberg, A.S., Shen, W.-J., Muliro, K., Patel, S., Souza, S.G., Rother, A.R., and Kramer, F.B. (2001) Stimulation of lipolysis and hormone-sensitive lipase via the extracellular signal-regulated kinase pathway. J. Biol. Chem., 276, 45456–45461. Zhang, H.H., Halbleib, M., Ahmad, F., Manganiello, V.C., and Greenberg, A.S. (2002) Tumour necrosis factor-a stimulates lipolysis in differentiated human adipocytes through activation of extracellular signal-related kinase and elevation of intracellular cyclic AMP. Diabetes, 51, 2929–2935. Thompson, M.P., Cooper, S.T., Parry, B.R., and Tuckey, J.A. (1993) Increased expression of the mRNA for hormonesensitive lipase in adipose tissue of cancer patients. Biochim. Biophys. Acta, 1180, 236–242. Vlassara, H., Spiegel, R.J., Doval, D.S., and Cerami, A. (1986) Reduced plasma
j343
j 17 Adipose Tissue Cachexia
344
35
36
37
38
39
40
41
42
43
44
lipoprotein lipase activity in patients with malignancy – associated weight loss. Horm. Metabol. Res., 18, 698–703. Mulligan, H.D. and Tisdale, M.J. (1991) Lipogenesis in tumor and host tissues in mice bearing colonic adenocarcinomas. Br. J. Cancer, 63, 719–722. Waterhouse, C. and Nye, W.H.R. (1961) Metabolic effects of infused triglycerides. Metabolism, 10, 403–408. Hyltander, A., Daneryd, P., Sandstrom, R., Korner, U., and Lundholm, K. (2000) Betaadrenoreceptor activity and resting energy metabolism in weight losing cancer patients. Eur. J. Cancer, 36, 330–334. Lopez-Soriano, J., Carbo, N., Tessitore, L., Lopez-Soriano, F.J., and Argiles, J.M. (1999) Leptin and tumor growth in rats. Int. J. Cancer, 81, 726–729. Moses, A.G., Dowidar, N., Holloway, B., Waddell, I., Fearon, K.C.H., and Ross, J.A. (2001) Leptin and its relation to weight loss, ob gene expression and the acutephase response in surgical patients. Br. J. Surg., 88, 588–593. Yam, D., Ben-Hur, H., Fink, A., Dagani, R., Shani, A., and Eliraz, A. et al. (1994) Insulin and glucose status, tissue and plasma lipids in patients with tumors of the ovary or endometrium: possible dietary implications. Br. J. Cancer, 70, 1186–1187. Hussey, H.J. and Tisdale, M.J. (1994) Effect of polyunsaturated fatty acids on the growth of murine colon adenocarcinomas in vitro and in vivo. Br. J. Cancer, 70, 6–10. Chaudry, A., McClinton, S., Moffat, L.E.F., and Wakle, K.W.J. (1991) Essential fatty acid distribution in the plasma and tissue phospholipids of patients with benign and malignant prostate diseases. Br. J. Cancer, 64, 1157–1160. Tang, D.G., Chen, Y.O., and Honn, K.V. (1996) Arachidonate lipoxygenases as essential regulators of cell survival and apoptosis. Proc. Natl. Acad. Sci. USA, 93, 5241–5246. Hussey, H.J., Bibby, M.C., and Tisdale, M.J. (1996) Novel antitumour activity of 2,3,5-trimethyl-6-(3-pyridylmethyl)1,4benzoquinone (CV-6504) against established murine adenocarcinomas (MAC). Br. J. Cancer, 73, 1187–1192.
45 Costa, G. and Holland, J.F. (1962) Effects
46
47
48
49
50
51
52
53
54
55
of Krebs-2 carcinoma on the lipid metabolism of male Swiss mice. Cancer Res., 22, 1081–1083. Balint, Z. (1991) Lipolytic activity in adipose tissue of mice bearing Ehrlich ascites carcinoma. Cancer Biochem. Biophys., 12, 45–52. Kitada, S., Hays, E.F., and Mead, J.F. (1980) A lipid mobilizing factor in serum of tumor-bearing mice. Lipids, 15, 168–174. Masuno, H., Yamasaki, N., and Okuda, H. (1981) Purification and characterization of a lipolytic factor (toxohormone L) from cell-free fluid of ascites sarcoma 180. Cancer Res., 41, 284–288. Beck, S.A. and Tisdale, M.J. (1987) Production of lipolytic and proteolytic factors by a murine tumor-producing cachexia in the host. Cancer Res., 47, 5919–5923. Ishiko, O., Yasui, T., Hirai, K., Honda, K., Sumi, T., Nishimura, S., and Ogita, S. (1999) Lipolytic activity of anemiainducing substance from tumor-bearing rabbits. Nutr. Cancer, 3, 201–205. Taylor, D.D., Gercel-Taylor, C., Jenis, L.G., and Deverux, D.F. (1992) Identification of a human tumor-derived lipolysispromoting factor. Cancer Res., 52, 829–834. Masuno, H., Yoshimura, H., Ogawa, N., and Okuda, H. (1984) Isolation of a lipolytic factor (toxohormone-L) from ascites fluid of patients with hepatoma and its effect on feeding behavior. Eur. J. Cancer Clin. Oncol., 20, 1177–1185. Groundwater, P., Beck, S.A., Barton, C., Adamson, C., Ferrier, I.N., and Tisdale, M.J. (1990) Alterations of serum and urinary lipolytic activity with weight loss in cachectic cancer patients. Br. J. Cancer, 62, 816–821. Beck, S.A., Groundwater, P., Barton, C., and Tisdale, M.J. (1990) Alterations in serum lipolytic activity of cancer patients with response to therapy. Br. J. Cancer, 62, 822–825. Todorov, P.T., McDevitt, T.M., Meyer, D.J., Ueyama, H., Okhubo, I., and Tisdale, M.J. (1998) Purification and characterization of a tumor lipid- mobilizing factor. Cancer Res., 58, 2353–2358.
References 56 Russell, S.T., Zimmerman, T.P., Domin,
57
58
59
60
61
62
B.A., and Tisdale, M.J. (2004) Induction of lipolysis in vitro and loss of body fat in vivo by zinc-a2-glycoprotein. Biochem. Biophys. Acta, 1636, 59–68. Sanders, P.M. and Tisdale, M.J. (2004) Effect of zinc-a2-glycoprotein (ZAG) on expression of uncoupling proteins in skeletal muscle and adipose tissue. Cancer Lett., 212, 71–81. Russell, S.T., Hirai, K., and Tisdale, M.J. (2002) Role of b3-adrenergic receptors in the action of a tumor lipid mobilizing factor. Br. J. Cancer, 86, 424–428. Yoshitomi, H., Yanazaki, K., Abe, S., and Tanaka, I. (1998) Differential regulation of mouse uncoupling proteins among brain adipose tissue, white adipose tissue and skeletal muscle in chronic b3-adrenergic receptor agonist treatment. Biochem. Biophys. Res. Commun., 253, 85–91. Islam-Ali, B.S. and Tisdale, M.J. (2001) Effect of a tumor-produced lipidmobilizing factor on protein synthesis and degradation. Br. J. Cancer, 84, 1648–1655. Russell, S.T. and Tisdale, M.J. (2001) Effect of a tumor-derived lipid-mobilizing factor on glucose and lipid metabolism in vivo. Br. J. Cancer, 87, 580–584. Bing, C., Bao, Y., Jenkins, J., Sanders, P., Manieri, M., Clint, S., Tisdale, M.J., and Trayhurn, P. (2004) Zinc-a2-glycoprotein, a lipid mobilizing factor, is expressed in adipocytes, and is up-regulated in mice with cancer cachexia. Proc. Natl. Acad. Sci. USA, 101, 2500–2505.
63 Russell, S.T. and Tisdale, M.J. (2005) The
64
65
66
67
68
69
role of glucocorticoids in the induction of zinc-a2-glycoprotein expression in adipose tissue in cancer cachexia. Br. J. Cancer, 92, 876–881. Russell, S.T. and Tisdale, M.J. (2005) Effect of eicosapentaenoic acid (EPA) on expression of a lipid mobilizing factor in adipose tissue in cancer cachexia. Prostaglandins Leukot. Essent. Fatty Acids, 72, 409–414. Price, S.A. and Tisdale, M.J. (1998) Mechanism of inhibition of a tumor lipidmobilizing factor by eicosapentaenoic acid. Cancer Res., 58, 4827–4831. Loprinzi, C.L., Schaid, D.J., Dose, A.M., Burnham, N.L., and Jensen, M.D. (1993) Body composition changes in patients who gain weight while receiving megestrol acetate. J. Clin. Oncol., 11, 152–154. Sanders, P.M. and Tisdale, M.J. (2004) Role of lipid mobilizing factor (LMF) in protecting tumor cells from oxidative damage. Br. J. Cancer, 90, 1274–1278. Zhang, B., Berger, J., Hu, E., Szalkowski, D., White-Carrington, S., Spiegelman, B.M., and Muller, D.E. (1996) Negative regulation of peroxisome proliferator-activated receptor-c gene expression contributes to the antiadipogeneic effects of tumor necrosis factor-a. Mol. Endocrinol., 10, 1457–1466. Tisdale, H.J. (2009) Zinc a-2-glycoprotein in cachexia and obesity. Curr. Opin. Support. Pall. Care, 3, 288–293.
j345
j347
18 Obesity and Diabetes: Lipotoxicity Christopher J. Lelliott, Matej Orešic, and Antonio J. Vidal-Puig 18.1 Introduction
Probably the most important emergent health crisis is the increase in prevalence of obesity. Obesity causes mechanical and psychological disorders, but more importantly it causes severe metabolic complications. No one doubts that the development of obesity requires a chronic state of positive energy balance. However, it is intuitively less clear why expansion of adipose tissue should be associated with insulin resistance, diabetes, dyslipidemia, fatty liver, and/or cardiovascular complications, collectively known as the metabolic syndrome [1, 2]. Current research on the pathogenesis of obesity has predominately focused on aspects related to food intake and energy expenditure as major determinants of energy balance. It has been incorrectly assumed that while there is a state of positive energy balance the adipose tissue would simply expand to meet storage demands. However, it is clear that the current epidemic of obesity poses unprecedented stress on the adipose tissue to reach previously unknown levels of expansion. The processes of adipogenesis and adipocyte growth are complex, and require the coordinated sequential activation of specific genetic pathways. Disturbance of specific components of these pathways, or of their sequential activation, results in defective adipose tissue development or function. This compromises not only the lipid buffer capacity of the adipose tissue, but also results in changes in synthesis and secretion of specific adipokines with important roles controlling insulin sensitivity. In this chapter, we review the evidence supporting the hypothesis that the link between obesity and these metabolic complications may be related to organ-specific toxic effects induced by excess of nutrients in the form of reactive lipid species. The concept of lipotoxicity describes a situation where ectopic deposition of reactive lipid species in organs different from adipose tissue induces a toxic reaction leading to insulin resistance, oxidative stress, endothelium reticulum stress, and ultimately dysfunction and cellular death. In this context, the most commonly studied tissues undergoing lipotoxicity include skeletal muscle, heart, liver, and pancreas. In the
j 18 Obesity and Diabetes: Lipotoxicity
348
context of obesity we consider exhausted capacity for adipose tissue expandability as an important determinant leading to lipid leakage into other organs.
18.2 White Adipose Tissue at the Center of Lipid Homeostasis and Delivery
White adipose tissue (WAT) senses and responds to the nutritional condition of the organism. In the postprandial condition, adipocytes are stimulated by insulin to take up glucose and fatty acids from the circulation, and to store them as triacylglycerol. Insulin also inhibits the release of fatty acids (lipolysis) from the fat cell [3]. Conversely, the reduction of circulating insulin together with stimulation from other peripheral factors, such as catecholamines, induces the release of fatty acids from the adipocyte for delivery to other tissues. Whilst this regulation is tightly controlled, in the obese patient as adipose tissue expands it becomes progressively resistant to the action of insulin. Under these conditions insulin-stimulated glucose and fatty acid uptake is impaired, and lipolysis is incompletely suppressed. Thus, fatty acids remain in the circulation longer and are now available to the rest of the body. In fact, the amount of stored fat may not be the main determinant of insulin resistance. It is not uncommon to identify morbid obese individuals that maintain their insulin sensitivity. The converse is also true – there are patients that could be considered inappropriately too insulin-resistant for their degree of obesity. Therefore, the question is to determine the key difference between these two scenarios. Our hypothesis is that intrinsic differences in the degree of adipose tissue expandability and functionality may account for the different susceptibility to obesity associated metabolic complications.
18.3 Insulin Resistance in Adipocytes Disrupts the Balance between Lipid Storage and Secretion
The adipocyte is a cell specifically adapted for the storage and release of energy in the form of lipids. Impaired insulin action in the adipocyte results in reduced postprandial uptake of circulating lipids and glucose, together with an incomplete shut-off of lipolysis. The net result is a delay in the clearance of circulating lipids and glucose after a meal and continued exposure of other peripheral tissues to these elevated substrates. The pathology of lipotoxicity is thought to arise from the ectopic deposition of lipids into these tissues that are not adapted to safely handling or storing large amounts of lipid molecules.
18.4 Scenarios that may Result in Ectopic Fat Deposition
We consider that there are a number of different scenarios that could result in lipotoxicity in peripheral tissues, as shown in Figure 18.1.
18.4 Scenarios that may Result in Ectopic Fat Deposition
Figure 18.1 Defects in adipose tissue expansion pattern drives the development of lipotoxicity in peripheral tissues. The adipose tissue must adapt to be able to handle increased amounts of energy delivered to it. The balance of existing adipocyte expansion and the recruitment of new adipocytes determines the metabolic outcome for peripheral tissues and the whole organism. Adipose tissue expansion that is the result of new adipocyte recruitment, hyperplasty, allows the adipose tissue to store more lipids, without detrimental effects on insulin sensitivity or cytokine output (top right). Adipose tissue expansion due mostly to the
enlargement of existing adipocytes adversely affects insulin responses to substrate storage and to the inhibition of lipolysis. In addition, the cytokine output pattern from the adipose tissue is deranged. Thus, lipids are available in circulation for uptake by peripheral tissues not capable of handling them in large amounts. The combination of ectopic lipid deposition with a detrimental hormonal pattern results in lipotoxicity (bottom left). If adipose tissue storage capacity is below storage demands, as in lipodystrophies, the excess lipids are also ectopically deposited in peripheral tissues (bottom right).
18.4.1 Altered Plasticity of the Adipose Tissue: A Shift in Expansion Towards Hypertrophy
Efficient expansion of the adipose tissue in response to overnutrition requires a titrated process that requires a tight balance between adipocyte enlargement, hypertrophy, and recruitment of new preadipocytes – hyperplasty. This process requires close contact between mature adipocytes and preadipocytes to communicate when a specific maximum threshold of adipocyte growth has been reached and differentiation of new storage units is required. Changes in the mechanisms controlling this balance may result in delayed recruitment of new adipocytes or hypertrophic adipose tissue, whereas early recruitment of preadipocytes may lead to a hyperplastic state [4]. Based on our research, our interpretation is that hypertrophic
j349
j 18 Obesity and Diabetes: Lipotoxicity
350
adipose tissue reflects a failure of new preadipocytes to differentiate, resulting in overstretched mature adipocytes attempting to store the excess of nutrients [5, 6]. Current thinking suggests that a critical difference between the two types of adipose is due to the size of the adipocyte. Typically hypertrophic adipocytes are associated with altered gene expression, insulin resistance (impaired glucose and fatty acid accumulation, incomplete suppression of lipolysis) [7, 8], and worsened adipokine profile [9]. The adipocyte is known to produce at least 20 factors (known as adipokines) that are able to influence diverse aspects of metabolic homeostasis. Hypertrophic adipocytes have an altered pattern of adipokines that overall has a negative affect on peripheral metabolism (Table 18.1) [4, 9], which promotes lipid deposition, but not the mechanisms to dispose of the lipids. Considering that adipose tissue is associated in significant amounts with skeletal muscle, heart, and liver, a paracrine effect of these adipokines on other peripheral tissues must be considered. The specific reason why an enlarged adipocyte has a worse profile is unclear, although a number of hypotheses have been proposed. These include changes in membrane mechanical stress due to expansion of the adipocyte, distorted properties of lipids and cholesterol in the plasma membrane or lipid droplets, and changes in the interaction of the adipocyte with the extracellular matrix. In contrast, hyperplastic adipose tissue, with increased proliferation of smaller adipocytes with an improved metabolic profile, may be beneficial, as seen with treatment with certain thiazolidinedione-class peroxisome proliferator-activated receptor (PPAR)-c agonists [10]. Hyperplastic adipose tissue may be particularly beneficial since it has an increased amount of total membrane and therefore an increased buffer capacity to store lipids. 18.4.2 Impaired Fat Deposition Capacity in Adipose Tissue
Lipotoxicity in peripheral tissues may develop since adipocytes may be unable to store the huge amount of lipid as demanded and so they remain in circulation, available for deposition in other tissues. Hypertrophic, insulin-resistant adipocytes have an altered balance of lipolysis and storage and would contribute to a higher maintenance of fatty acids in the circulation. There are extreme examples showing that defects in proteins needed for lipid deposition – such humans with defective LPL enzyme activity suffer from chylomicronemia and hypertriglyceridemia [11]. However, we think that in the current obesogenic climate, metabolic disturbances are more likely due to subtle genetic defects that previously did not cause metabolic problems, but now produce an adipose tissue with an inappropriately limited maximal expansion insufficient for the modern-day storage demands. In this context, adipose tissue may be incapable of expanding sufficiently by recruitment and differentiation of preadipocytes, or by apoptosis of existing adipocytes. The range of conditions, known as lipodystrophies where bodily adipose tissue is less than necessary, provides a dramatic illustration of whole body metabolism with insufficient adipose storage. Various forms of lipodystrophy are associated with
Table 18.1
Summary of known adipose tissue-generated hormones that may impact upon the development of insulin resistance and lipotoxicity Circulating levels in obesity
Central effect
Effect on adipocyte glucose/fatty acid flux
Liver
Metabolic actions on muscle
b-Cell survival/insulin production
Net effect of change in obesity for development of lipotoxicity
Leptin
elevated, but leptin resistance may occur
anorexigenic
antiadipogenic in vitro, promotes lipolysis
increases insulin sensitivity and b-oxidation via AMPK
enhances insulin sensitivity in muscle and b-oxidation via AMPK; decreases IMCL
inhibits insulin release; possibly antiapoptotic
Adiponectin
reduced
orexigenic
promotes lipogenesis in vitro
increases insulin sensitivity and b-oxidation via AMPK
increases b-oxidation via AMPK
may be beneficial for insulin secretion in insulin-resistant models
TNF-a
elevated
anorexigenic
antiadipogenic, lipolytic, inhibits glucose uptake
insulin resistance, although no effect in healthy humans infused with TNF-a; stimulates fatty acid and triacylglycerol biosynthesis
reduced insulinstimulated glucose uptake via multiple pathways; inhibits AMPK and promotes diacylglycerol and ceramide formation
IL-6
elevated
anorexigenic
insulin resistance, lipolytic
insulin resistance, in part by inhibition of insulin signaling via SOCS-3; stimulates fatty acid and cholesterol biosynthesis
in obesity, thought to reduce glucose uptake, but IL-6 is elevated in exercise and related here to enhanced insulin sensitivity
in vitro, impairs glucose-stimulated insulin secretion, proapoptotic; unclear role in vivo since transgenic expression of TNF-a in pancreas results in insulitis, not diabetes islet-specific transgenic expression of IL-6 in pancreas results in b-cell hyperplasia and insulitis
redirection of lipids from adipose to nonadipose for oxidative disposal –although some evidence it may be proinflammatory redirection of lipids from adipose to nonadipose, but reduced oxidative capacity results in lipotoxicity redirection of lipids from adipose to nonadipose, but reduced oxidative capacity results in lipotoxicity
redirection of lipids from adipose to nonadipose; may result in lipotoxicity
j351
(Continued)
18.4 Scenarios that may Result in Ectopic Fat Deposition
Adipokine
(Continued)
Adipokine
Circulating levels in obesity
Central effect
Effect on adipocyte glucose/fatty acid flux
Liver
Metabolic actions on muscle
b-Cell survival/insulin production
Net effect of change in obesity for development of lipotoxicity
Resistin
elevated
inhibits glucose uptake
Reduced insulin sensitivity, increased hepatic glucose output
reduced glucose uptake, fatty acid metabolism
Retinol binding protein-4
elevated
evidence for anorexigenic effect with intracerebroventricular administration unknown
reduced insulin sensitivity
elevated
unknown
increases gluconeogenesis, reduces insulin sensitivity; promotes lipid accumulation reduces glucose output, independent of insulin, in hepatocytes
redirection of lipids from adipose to nonadipose, but reduced oxidative capacity results in lipotoxicity to be fully determined, but appears to be prolipotoxic
Pre-B cell colonyenhancing factor
promotes insulin resistance, but not defects in glucose uptake in cell cultures promotes lipogenesis, glucose uptake
impaired glucosestimulated insulin secretion in vitro, but at low concentrations may be a survival factor unknown
may be upregulated in obesity to enhance metabolic status and prevent lipotoxicity
Omentin-1
reduced
unknown
not known
not clear, although omentin is expressed predominantly in omental adipose tissue
increased insulin sensitivity, glucose uptake
may be a b-cell survival factor since circulating visfatin is increased with progressive b-cell deterioration unknown
AMPK, AMP-activated protein kinase.
enhances glucose uptake
unclear but may be beneficial
j 18 Obesity and Diabetes: Lipotoxicity
352
Table 18.1
18.4 Scenarios that may Result in Ectopic Fat Deposition
a number of mutations in genes including PPARG, LMNA/C, BCSL, and AGPAT2, as well as with the use of antiretroviral therapy for HIV [12]. In all of these disorders, the lipodystrophy is associated with glucose intolerance, insulin resistance, and dyslipidemia. Whilst the mechanisms behind the loss of adipose tissue are diverse, a diminished ability of the adipose tissue to deposit lipids means that excess glucose and lipids remain in circulation, and accumulate in other peripheral tissues. In addition, the lack of adipose tissue means a reduced output of protective adipokines such as leptin and adiponectin, which would normally contribute to normal metabolic homeostasis. Interestingly, in mouse models for lipodystrophy where mice are genetically modified to lack adipose tissue, the metabolic disorders can be recovered by transplantation of normal adipose tissue [13], which demonstrates that defects in adipose tissue storage capacity and adipokine output are a primary source for the development of lipotoxicity in other peripheral tissues. With respect to obesity and insulin resistance, we consider that there are strong parallels with lipodystrophy. In our opinion, obesity-associated metabolic effects may occur when there is a mismatch between adipose tissue expandability and adipose tissue storage requirements. In short, metabolic problems associated to obesity may occur when the obese patient cannot become more obese because their adipose tissue has reached its maximal expansion. 18.4.3 Inappropriate Balance of Substrate Uptake and Oxidative Capacity in Peripheral Tissue
When the adipose tissue fails to correctly store lipids, circulating fuel is finally deposited in other peripheral tissues such as skeletal muscle, pancreas and liver. These tissues are not passive in the handling of excess lipids, but attempt to adapt to the incoming fuel load. Even relatively short periods of high-fat feeding increases the amount of fatty acid clearance and oxidation into muscle [14, 15]. Disposal of fatty acids by oxidation would be considered the best alternative when dealing with lipids in a tissue that is unable to store safely large amounts of them (Figure 18.2). However, prolonged exposure of muscle to excess of fatty acids results in a diminished fatty acid oxidation capability, elevated reactive lipid deposition, insulin resistance and impaired glucose uptake. The accumulation of lipids in nonadipose peripheral tissues may also be a consequence of a primary defect in this peripheral tissue. For example studies with healthy relatives of type 2 diabetic sufferers have revealed that oxidative metabolism gene expression and mitochondrial function in the skeletal muscle of this group appears lower than in subjects without a family history of type 2 diabetes [16–19]. This suggests a genetic predisposition to lower skeletal muscle oxidative capacity, which is required when the tissue is threatened with lipotoxicity. A second factor that would contribute to increased peripheral lipid deposition is the uptake capacity of the tissue. Using lipoprotein lipase (LPL) as an example, it has been suggested that the relative level of LPL activity, and thus fatty acid supply, between different tissues could be an important determinant for the peripheral
j353
j 18 Obesity and Diabetes: Lipotoxicity
354
Figure 18.2 Ectopic fat deposition may be enhanced by a mismatch in uptake and disposal rates. The accumulation of lipids in a tissue can be thought of as a balance between lipid uptake capacity and oxidation. In situations where excess lipids can be more rapidly oxidized for disposal than accumulated by the tissue, insulin sensitivity can be maintained since toxic lipid products are unable to be built up and
metabolized further (bottom left). If, however, oxidative capacity is lower than the rate of lipid intake, a build-up of lipid occurs and the resulting pools of lipid may be subject to the generation of lipotoxic products (bottom right). Familial studies may show that a lack of peripheral tissue oxidative capacity may predispose to insulin resistance and type 2 diabetes.
localization of lipid deposition [20]. An increased activity in WAT versus the muscle would be protective for muscle lipotoxicity, at the expense of increased adipose tissue expansion. Conversely, a predisposition towards a higher flux of substrates to the muscle by elevated LPL expression may also result in increased muscle lipid deposition and, consequently, lipotoxicity. The role of substrate flux has been tested using transgenic mice. Overexpression of LPL in skeletal muscle results in an elevation in muscle triacylglycerol content with concomitant decrease in insulinstimulated glucose uptake [21]. Similarly, hepatic overexpression of LPL also raises liver triacylglycerol content and blunts insulins ability to suppress glucose output [21]. Interestingly, levels of muscle LPL are increased by exercise training, together with increases in carnitine palmitoyl transferase (CPT)-1, PPAR-c coactivator (peroxisome proliferator-activated receptor-c coactivatorPGC)-1a, and mitochondrial number and activity [22, 23], thus suggesting that the balance between lipid uptake and oxidative capacity reflects the outcome of insulin sensitivity. The converse situation states that impaired fatty acid uptake in the muscle is beneficial to muscle insulin sensitivity. Mice lacking fatty acid transporter CD36/fatty acid
18.5 Mechanisms Contributing to the Lipotoxicity in the Peripheral Organs
translocase (FAT) on a chow diet are more insulin-sensitive than wild-type and are partially protected from a high-fat diet [24], with insulin-sensitive muscles despite hypertriglyceridemia.
18.5 Mechanisms Contributing to the Lipotoxicity in the Peripheral Organs 18.5.1 Lipotoxicity in Skeletal Muscle
Obesity is associated with insulin resistance in skeletal muscle and reduces its insulin-stimulated glucose uptake capacity. In addition, oxidative capacity is decreased in skeletal muscle from insulin-resistant humans, offering a mechanism for further weight gain. Importantly, the development of insulin resistance in muscle is associated with an accumulation of intramyocellular lipids (IMCL). Of note, increased IMCL levels are found in lean, glucose-tolerant offspring of parents who both have type 2 diabetes, when compared to those with no family history of type 2 diabetes [25]. Also, its oxidative capacity appears to be impaired in obese and type 2 diabetes sufferers related to markedly reduced mitochondrial size, even when related to fiber type [26]. In addition, there is a deficiency of sarcolemmal-located mitochondria in the skeletal muscle in both obese and type 2 diabetes sufferers [27]. This is potentially relevant to insulin resistance since these mitochondria are thought to provide energy for processes occurring at the cell surface, such as ion transport, glucose uptake, and signal transduction. An apparent paradox exists here since well-trained humans, despite being insulin-sensitive, also have significant stores of IMCL [25], and endurance training elevates IMCL content [28]. Here, the IMCL presumably acts as a readily accessible store of fatty acids for oxidation. This suggests that more important than the accumulation of fat is the type of fat accumulated. We have shown that accumulation of triacylglycerols in peripheral organs in the context of overnutrition may be a physiological protective adaptation that allows the storage of fatty acids as safe triacylglycerols [5]. Conversely, accumulation of nutrients as reactive lipid species is a more direct pathogenic mechanism linking overnutrition and insulin resistance. 18.5.1.1 Randle Hypothesis and its Successors The original hypothesis for why excess fatty acids in skeletal muscle causes insulin resistance was proposed by Randle in 1963 [29]. The essence of the hypothesis is that glucose and fatty acid oxidation are in competition with each other, and that glucose uptake and utilization is limited in tissues where fatty acid oxidation can be used for cellular energy requirements. Thus, an overload of fatty acids to a tissue such as muscle will impair glucose utilization – an event that has been shown both in vitro and in vivo. At the molecular level, the interplay of glucose and fatty acid metabolism is well established, since both glucose and fatty acid synthetic and oxidation pathways share a number of molecules from one pathway that are able to
j355
j 18 Obesity and Diabetes: Lipotoxicity
356
feed in to or cross-regulate reactions and processes in the alternative pathway (Figure 18.3). At the pathway level, Randle hypothesized that there are a number of key points for cross- and counter-regulation between the glucose and fatty acid oxidation pathways, so fatty acid overload results in a build-up of glucose-6-phosphate, which inhibits hexokinase and generates an increase in intracellular glucose to prevent glucose uptake. Since then, the hypothesis has identified signaling molecules as alternate effectors of fatty acid-induced insulin resistance. A number of studies using in vivo imaging techniques have suggested that in humans, increased plasma free fatty acid concentrations result in decreased glucose-6-phosphate levels that precede a drop in muscle glycogen synthesis – a finding also seen in type 2 diabetic humans [30–32]. From this, impaired glucose transport and therefore disposal has been highlighted as the primary defect in insulin resistance in skeletal muscle [33]. In addition, elevated plasma free fatty acid concentration causes a decrease of glucose concentrations, suggesting a direct inhibition in glucose transport and a loss of insulinstimulated phosphoinositide-3-kinase (PI3K) activity [34]. Thus, the hypothesis has emerged that triggers of insulin resistance, including free fatty acids, affect the very earliest steps of glucose disposal and the insulin signaling pathway required to control this. 18.5.2 Molecular Mechanisms for the Generation of Muscle Lipotoxicity
Fatty acids enter the cell via a variety of mechanisms including flip-flop diffusion across the plasma membrane in combination with transport mediated by the CD36/FAT transporters. Upon entry into the cell, fatty acids are rapidly converted to fatty acyl-CoA derivatives by acyl-CoA synthases and fatty acid transporter protein, and transported by fatty acid-binding proteins. From here, fatty acyl-CoAs then either enter the mitochondria for b-oxidation or are converted to stored triacylglycerols via diacylglycerol intermediates. Here, the adipose tissue plays an important role in the supply of lipids to other peripheral tissues in times of fasting. The conversion of the muscle from a glucose-oxidative fed state to a fatty acid-oxidative fasting state requires that the adipose tissue is able to deliver or retain fatty acids at the appropriate times. The idea of metabolic flexibility has been proposed as a central hypothesis by which the muscle, or other important metabolic tissues, is able to adapt to changing energy demand with alternate fuel supplies [35]. In the context of insulin resistance, this metabolic flexibility is impaired or inflexible due to inappropriate fuel supply from the adipose tissue and incomplete switching between metabolic pathways. Thus, with time, ectopic deposition of reactive lipid species occurs due to the inequality between fatty acid supply and utilization. 18.5.2.1 Type of Lipids is More Important than the Amount of Fat Deposited Following the finding that free fatty acids and reactive lipid species can interfere directly with insulin signaling, there has been much speculation about which molecule or molecules are responsible for this. The most-studied candidates include
18.5 Mechanisms Contributing to the Lipotoxicity in the Peripheral Organs
Figure 18.3 Randle hypothesis and interplay of glucose and fatty acid metabolism. In the original Randle hypothesis, it was thought that exposure of tissues to high levels of fatty acid, such as palmitate, would cause a switch in metabolism towards a preferential oxidation of the fatty acid. b-Oxidation of fatty acid would elevate acetyl-CoA/CoA and NADH/NAD þ ratios, which would inactivate pyruvate dehydrogenase (PDH). Citrate levels would increase and in turn inactivate phosphofructokinase (PFK)-1. A build-up of PFK substrate fructose 6-phosphate then inactivates hexokinase (HK) and in turn blocks glucose
uptake. Interestingly, fatty acid metabolism and glucose metabolism are coordinately regulated and intricately connected by common intermediated. Citrate can be diverted from the mitochondria and converted to acetyl-CoA for channeling into de novo fatty acid synthesis, via acetyl-CoA carboxylase (ACC) and fatty acid synthase (FAS). Flux through this pathway increases the concentration of malonyl-CoA, a potent inhibitor of CPT-1. Thus, glucose and fatty acid metabolism are able to regulate each other to switch between different sets of metabolic pathways.
j357
j 18 Obesity and Diabetes: Lipotoxicity
358
fatty acids or fatty acyl-CoA derivatives themselves, or alternatively metabolites deriving from fatty acids, including triacylglycerols, diacylglycerols, sphingolipids, and ceramides. It has been argued that elevated triacylglycerols in muscle of insulinresistant humans is merely a marker for more deleterious lipid species derived from fatty acids [36]. The type of fatty acids that are most consistently linked to metabolically deleterious consequences in humans and rodents are saturated fatty acids. In many insulin and metabolically related systems, such as insulin signaling and glucose utilization, saturated fatty acids show a greater impairment of the given system than unsaturated fatty acids. Unsaturated fatty acids are preferably oxidized and disposed of, suggesting that saturated fatty acids are more likely to accumulate. Finally, unsaturated fatty acids are thought to be metabolized to ligands for a number of transcription factors that have a beneficial metabolic effect, such as PPAR-a, so a diet proportionally rich in saturated fatty acids will essentially dilute out these lipids making them less detectable by the lipid sensor mechanisms. 18.5.2.2 Diacylglycerols and Insulin Resistance Current evidence suggests that saturated fatty acids and their derivatives play the roles in stimulating insulin resistance and lipotoxicity in the muscle to varying degrees (Figure 18.4). Long-chain fatty acyl-CoA accumulation, either by an increase in exogenous delivery or decreased mitochondrial oxidative capacity, may be converted to diacylglycerol moieties. Notably in both, diacylglycerol and long-chain fatty acyl-CoA levels are increased in insulin-resistant muscle [37, 38]. Diacylglycerols may also accumulate in hyperglycemia conditions via de novo synthesis from phosphatidic acid and through an elevated turnover of phosphatidylcholine. Diacylglycerols are cofactors of conventional and novel protein kinase C (PKC) isoforms. In addition, diacylglycerol-mediated PKC activation appears to be augmented by nonesterified fatty acids and CoA derivatives, enhancing the effect of an elevated fatty acid influx. The bulk of current data suggests that novel PKCs PKCe and PKCq are more likely to be involved in insulin signaling inhibition in skeletal muscle and liver [39]. Diacylglycerol-activated PKC phosphorylates insulin receptor substrate (IRS)-1 on serine residues that impede activating tyrosine phosphorylations by an activated insulin receptor. Since insulin signaling is impaired at the level of IRS-1, the activities of other critical signaling pathways downstream of IRS-1 such as the PI3K/Akt pathway are also blunted. This may be especially important in the muscle since both insulin-stimulated glucose uptake and glycogen synthesis is controlled via the IRS/PI3K/Akt pathway, and so diacylglycerols will impede muscle glucose disposal. 18.5.2.3 Ceramides and Insulin Resistance Evidence is accumulating for ceramide (and its derivatives) being a key mediator of fatty acid-mediated insulin resistance (Figure 18.3). Ceramide generation occurs both via the hydrolysis of sphingomyelin as a second messenger or de novo synthesis occurs via a four-enzyme pathway. This pathway is largely dependent on the supply of long-chain saturated fatty acids, with the key rate-limiting step serine-palmitoyl transferase providing the fatty acid chain specificity for the first assembled fatty
18.5 Mechanisms Contributing to the Lipotoxicity in the Peripheral Organs
Figure 18.4 Accumulation of lipid species interferes with molecular processes and cell metabolism. Fatty acid uptake via flip-flop mechanisms or protein-based translocation results in the generation of a number of lipid species. Among those known to be involved in the development of lipotoxicity include fatty acid-CoAs themselves, diacylglycerols (diacylglycerols), which in turn are converted to triacylglycerols, and ceramides, generated by the serine palmitoyltransferase pathway, for which saturated fatty acids are a prerequisite. Fatty acid-CoAs, diacylglycerols and ceramides are able to interfere with various components of the insulin signaling pathway via intermediatory protein kinases such as PKCs (to catalyze inhibitory serine phosphorylations) and protein
phosphatases like PP2A. Inhibition of the insulin signaling pathway results in an insulin resistance, with blockade of glucose uptake and disposal in tissues such as muscle. Ceramides are also thought to impact directly on mitochondrial function by inhibition of the ETC that induces ROS and may trigger apoptosis via cytochrome c (CytC) export. Fatty acids, via ceramides, also activate pathways that alter nuclear gene expression such as the JNK/c-Jun and IkB/NFkB pathways. These pathways are also shared in inflammatory responses, and enhance the link between obesity and low-grade chronic inflammation. Finally, genetic factors may alter metabolic capabilities that predispose to insulin resistance.
j359
j 18 Obesity and Diabetes: Lipotoxicity
360
acid moiety [40]. Due to this requirement of saturated fatty acids, there is an obvious link between saturated lipid oversupply to the muscle and generation of ceramide. The putative role for ceramides in the development of peripheral insulin resistance has been proposed based on a number of lines of evidence. These include an increase in ceramide levels in tissue from insulin-resistant rodents and humans, the ability exogenously applied palmitate and ceramide to induce insulin resistance in cell culture, and that pharmacological inhibition of ceramide synthesis improves metabolic status in both cell culture and diabetic rat models [38, 40–42]. The mechanism by which ceramides are able to inhibit insulin signaling is at present unclear, but ceramide treatments are known to inhibit several of the signal transduction components downstream of the insulin receptor [40, 43]. There are reports that ceramideinducing inhibitory serine phosphorylations of IRS-1, inhibition of PI3K activity and blockade of Akt/protein kinase B (PKB) action, probably via a combination of dephosphorylation by protein phosphatase 2A (PP2A) and inhibitory phosphorylation by atypical (diacylglycerol-independent) PKCz. Of these, the action on Akt/PKB has the most supportive data. There is also evidence for ceramides activating c-Jun N-terminal kinase (JNK) and IkB kinase (IKK)-b pathways. Both of these signaling pathways have been implicated in the development of insulin resistance from the perspective of inflammation, which may impact upon muscle metabolism both at the levels of signaling components such as IRS-1 and via the transcriptional activity of c-Jun and nuclear factor-kB. However, the full details of these pathways are still to be elucidated. Consistent with the mitochondrial dysfunction seen in the insulinresistant subjects, ceramides appear to also have direct effects on mitochondria, especially since many of the enzymes required for ceramide synthesis are localized here, in addition to the endoplasmic reticulum [40]. Ceramide analogs inhibit the electron transport chain (ETC) at complex III and promote reactive oxygen species (ROS) generation – an additional deleterious factor [44, 45]. There is also some evidence that ceramides may also trigger apoptosis by increasing mitochondrial permeability to cytochrome c via Bcl-2 proteins.
18.6 Impaired Oxidation as a Trigger for Lipotoxicity
Whilst increased flux of lipids into nonadipose tissue organs is one possible way for intracellular lipids to accumulate, there is also increasing evidence that impaired disposal of these lipids is also a key factor. Increased oxidation of accumulated lipids by the mitochondria is seen as one mechanism by which skeletal muscle insulin resistance could be reversed pharmacologically. Indeed various studies have shown that in obese or insulin-resistant rodents and humans, mitochondrial oxidative capacity is reduced at both gene expression and functional levels [17–19]. This reduction in mitochondrial activity has also been suggested as a primary mechanism that predisposes certain individuals to the development of insulin resistance and obesity since offspring of subjects with type 2 diabetes show a reduction in
18.6 Impaired Oxidation as a Trigger for Lipotoxicity
mitochondrial enzymes or in key transcriptional regulators of mitochondrial action, such as PGC-1. This implies that in pre-insulin-resistant states, the oxidative capacity of mitochondria is already compromised and less able to cope when insulted with increased lipid loads. Accumulated lipids may additionally become deleterious through the generation of ROS. This can occur through the deposition and conversion of lipid moieties to reactive peroxides or through the generation of mitochondrial ROS via impaired ETC activity. Both PGC-1a and -1b are important regulators of mitochondrial activity [46, 47]. In addition, PGC-1a is essential for the generation of an adequate ROS defense system [48], so in insulin-resistant states where PGC-1 action is inhibited, the double-whammy of reduced oxidative capacity and increased ROS production occurs. 18.6.1 Adipocytokines Proinflammatory Activity Contributes to Lipotoxicty in Skeletal Muscle
Hypertrophic adipose tissue not only has a dysregulation of lipid storage which contributes to elevated nonesterified fatty acid levels and lipotoxicity, but also has an altered pattern of adipokine output that impacts on whole-body energy homeostasis. The typical pattern of adipokines and related inflammatory markers release from hypertrophic adipose tissue is thought to have a dual effect on other nonadipose tissue peripheral tissues. (i) The pattern of cytokines points towards a reduced insulin sensitivity, decreased glucose disposal, and inhibition of insulin-suppressed glucose output. (ii) Peripheral oxidation capacity is reduced, by decreased adiponectin and increased tumor necrosis factor (TNF)-a. This results in an increase in intracellular lipids and the associated hazards concerning lipotoxicity. It is worth noting that adipocytes are not the only cell type in adipose tissue that produce cytokines or other factors that can impact on peripheral metabolism. 18.6.1.1 Adipose Tissue Macrophages as Key Players for Lipotoxicity Adipocytes are not the only contributors to the cytokine profile of the WAT. Many proinflammatory cytokines, such as interleukin (IL)-6, IL-1 and CCL2, and antiinflammatory cytokines, such as adiponectin, have been identified and shown to be dysregulated in WAT from obese subjects [49, 50]. Accumulating evidence shows that activated macrophages occurring in the WAT from obese rodents and humans can contribute to secretion of adipokines [51, 52] and adipocyte turnover, especially in obese tissue. As yet, it is not clear whether these activated macrophages are recruited from the circulation during the induction of obesogenic development or lie dormant in the tissue awaiting activation by engorged adipocytes [53]. Nonetheless, they appear to play an important part of a cycle of cytokine release that results in an unfavorable pattern of adipokines released from the adipocyte. 18.6.1.2 Signaling Effector Pathways in Lipotoxicty Inflammatory signals and lipids share some similar pathways that are known to mediate insulin resistance. Inflammatory cytokines such as TNF-a and IL-6 are
j361
j 18 Obesity and Diabetes: Lipotoxicity
362
known to increase IRS-1 serine phosphorylation and increase suppressor of cytokine signaling (SOCS)-3 expression. Serine kinases known to perform this phosphorylation include JNK, IKK, and PKCq. These pathways terminate at transcription factors such as AP-1 and c-Jun, which may also adversely impact on metabolic status. Both JNK and IKK are known players in a wide range of immune responses, and are also increased in liver and adipose in obese states [4, 49, 54–56]. In addition, in vivo and in vitro manipulation of these pathways, either by genetic modification or pharmacological intervention, can improve (with inhibition of pathway) or worsen (with activation of pathway) the metabolic state of the tissue or organism [55]. JNK1 appears to be the more important of the JNK isoforms in the context of metabolic dysregulation and insulin resistance. PKCq, which is activated by diacylglycerols, links lipid infiltration and inflammatory signal transduction pathways through IKK, and so may also mediate IRS-1 serine phosphorylation-mediated insulin resistance via this mechanism. 18.6.2 Lipotoxicity and Insulin Resistance Affecting Liver Metabolism
It has been demonstrated that there is a clear link between abdominal fat expansion and the risk of developing the metabolic syndrome. Omental adipose tissue has greater uptake of fatty acids, higher sensitivity to catecholamine-stimulated lipolysis, and is less sensitive to inhibition of lipolysis by insulin than the subcutaneous adipose tissue. The liver directly receives the first pass of both fatty acids (from higher basal and stimulated lipolysis in this adipose tissue) and cytokines produced by the visceral adipose tissue, which may be especially lipotoxic with hypertrophic adipose tissue. Expansion of the visceral adipose tissue with its enhanced lipid leakage facilitates the development of fatty liver. The specific reasons for why the mesenteric adipose tissue is more prolipotoxic to the liver are unclear, but a number of hypotheses have been postulated. These include (i) bacterial-induced inflammation from the intestine, (ii) more readily expanded adipocytes due to the relative hyperavailability/overload of the nutrients from the gut, and (iii) enhanced inflammatory profile of the mesenteric fat due to adipocyte insulin resistance, altered cytokine profile, macrophage infiltration, anoxia, and consequently apoptosis of adipocytes. 18.6.2.1 Hepatic Lipotoxicity A potential mechanism linking insulin resistance and hepatic steatosis involves dysregulation of IRS proteins and sterol regulatory element-binding protein (SREBP)-1 – the key transcription factor for de novo lipogenesis and triacylglycerol synthesis. SREBP-1 is activated both by saturated fatty acids and by proinflammatory signals, as well as in mice with insulin resistance [57]. In liver, the IRS proteins are linked to different aspects of metabolism. IRS-1 is primarily concerned with glucose homeostasis and control of glucose output, whereas IRS-2 is involved with lipid metabolism [58]. IRS-2 and SREBP-1 appear to be reciprocally regulated [59, 60]. Yet, IRS-2 expression is repressed in conditions of hyperinsulinemia, thereby allowing
18.8 New Analytical and Computational Methods
SREBP-1 action and, hence, de novo lipogenesis to occur. The flux via de novo lipogenesis increases the intermediate malonyl-CoA. Since malonyl-CoA is a potent inhibitor of CPT-1 [61], the oxidative capacity of the liver becomes limited, facilitating hepatic lipid accumulation from de novo generated lipids and exogenously derived lipids from the adipose tissue.
18.7 Pancreatic b-Cell as a Target for Lipotoxicity
The transition from an insulin resistant to a diabetic state is marked by the failure of the insulin-producing b-cell to provide enough insulin to stimulate other tissues to contribute to glucose and fatty acid disposal. In metabolically healthy individuals, postprandial hyperglycemia is matched by a temporary hyperinsulinemia to enable peripheral substrate disposal. However, with time, as insulins effectiveness at stimulating glucose disposal decreases due to peripheral insulin resistance, insulin output increases until a point when the b-cells fail and insulin secretion no longer matches the requirements for substrate disposal. Fatty acids have been implicated in the development of the failing b-cell. Acute fatty acid treatment of b-cells actually stimulates insulin secretion, whereas chronic treatment inhibits insulin output. Treatment of isolated islets from humans and rodent models with palmitate prevents proliferation and triggers apoptosis [62, 63]. The combination of glucose and fatty acids, as occurring in a hyperglycemic, hyperlipidemic subject, may be additionally deleterious since glucose oxidation is preferred to b-oxidation and causes the accumulation of long-chain acyl-CoA units in the cell. It remains unclear whether fatty acids themselves or a specific metabolite are the main deleterious species. However, similar to the situation in muscle, it is likely that a combination of fatty acid derivatives including diacylglycerol or ceramide are likely to be involved [40]. In addition, deleterious contributions of fatty acids to mitochondrial function via enhanced uncoupling protein action, direct effects on the ion channels required for insulin secretion and on insulin synthesis and glucose metabolism have been proposed. It is also interesting to note that chronic high levels of glucose also trigger b-cell apoptosis, so it is likely that the combination of high circulating glucose and free fatty acids is especially deleterious for b-cells. As shown in Table 18.1, b-cell function is likely to be impaired by hypertrophic WAT adipokine output.
18.8 New Analytical and Computational Methods to Identify Lipotoxicity-Related Metabolic Networks
Given the impossibility of measuring the levels of all metabolites in a biological sample simultaneously with a single analytical platform, it was previously difficult to identify a particular lipid species as being responsible for the metabolic abnormalities.
j363
j 18 Obesity and Diabetes: Lipotoxicity
364
The reason for this is that metabolites are chemically diverse and can cover a dynamic range of over 10 orders of magnitude in concentration, so a single extraction and detection method for all metabolites from biological matrices is unfeasible. Additionally, the complexity of biological samples may also affect the efficiency and reliability of detection, such as with ion suppression effects in mass spectrometrybased approaches. Multiple analytical platforms coupled to different extraction methods for specific groups of metabolites are commonly applied in parallel to cover broad ranges of metabolites. Analytical technologies based on gas chromatography coupled to mass spectrometry (MS), liquid chromatography/MS), capillary